[
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000890-25/FR",
        "title": "Treatment of Coronavirus SARS-Cov2 Respiratory Infections with Hydroxychloroquine - FR",
        "timestamp": "2020-03-05"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000841-15/DE",
        "title": "A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants with Severe COVID-19 - DE",
        "timestamp": "2020-03-18"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000841-15/ES",
        "title": "A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants with Severe COVID-19 - ES",
        "timestamp": "2020-03-18"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000841-15/IT",
        "title": "A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants with Severe COVID-19 - IT",
        "timestamp": "2020-03-18"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000841-15/NL",
        "title": "A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants with Severe COVID-19 - NL",
        "timestamp": "2020-03-18"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000841-15/GB",
        "title": "A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants with Severe COVID-19 - GB",
        "timestamp": "2020-03-18"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000841-15/SE",
        "title": "A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants with Severe COVID-19 - SE",
        "timestamp": "2020-03-18"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000842-32/DE",
        "title": "A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants with Moderate  COVID-19 Compared to Standard of Care Treatment - DE",
        "timestamp": "2020-03-18"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000842-32/ES",
        "title": "A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants with Moderate  COVID-19 Compared to Standard of Care Treatment - ES",
        "timestamp": "2020-03-18"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000842-32/IT",
        "title": "A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants with Moderate  COVID-19 Compared to Standard of Care Treatment - IT",
        "timestamp": "2020-03-18"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000842-32/NL",
        "title": "A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants with Moderate  COVID-19 Compared to Standard of Care Treatment - NL",
        "timestamp": "2020-03-18"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000842-32/GB",
        "title": "A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants with Moderate  COVID-19 Compared to Standard of Care Treatment - GB",
        "timestamp": "2020-03-18"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000842-32/SE",
        "title": "A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants with Moderate  COVID-19 Compared to Standard of Care Treatment - SE",
        "timestamp": "2020-03-18"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001010-38/NO",
        "title": "NORWEGIAN CORONAVIRUS DISEASE 2019 (NO COVID-19) STUDY: AN OPEN LABELED RANDOMIZED CONTROLLED PRAGMATIC TRIAL TO EVALUATE THE ANTIVIRAL EFFECT OF CHLOROQUINE IN ADULT PATIENTS WITH SARS-COV-2 INFEC... - NO",
        "timestamp": "2020-03-23"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001162-12/DE",
        "title": "An adaptive phase 2/3, randomized, double-blind, placebo-controlled, study assessing efficacy and safety of sarilumab for hospitalized patients with COVID-19 - DE",
        "timestamp": "2020-03-23"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001023-14/GB",
        "title": "A randomised double-blind placebo-controlled trial to determine the safety and efficacy of inhaled SNG001 (IFNβ-1a for nebulisation) for the treatment of patients with confirmed SARS-CoV-2 infection - GB",
        "timestamp": "2020-03-17"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000919-69/NL",
        "title": "Reducing health care workers absenteeism in SARS-CoV-2 pandemic by enhanced trained immune responses through Bacillus Calmette-Guérin vaccination, a randomized controlled trial. - NL",
        "timestamp": "2020-03-17"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-004863-35/FI",
        "title": "A prospective phase II study to assess the minimal residual disease after ixazomib plus lenalidomide plus dexamethasone (IRd) treatment for newly diagnosed transplant eligible patients - FI",
        "timestamp": "2016-08-01"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-004863-35/SE",
        "title": "A prospective phase II study to assess the minimal residual disease after ixazomib plus lenalidomide plus dexamethasone (IRd) treatment for newly diagnosed transplant eligible patients - SE",
        "timestamp": "2016-08-01"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-004863-35/LT",
        "title": "A prospective phase II study to assess the minimal residual disease after ixazomib plus lenalidomide plus dexamethasone (IRd) treatment for newly diagnosed transplant eligible patients - LT",
        "timestamp": "2016-08-01"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001254-22/BE",
        "title": "A prospective, randomized, open-label, interventional study to investigate the efficacy of sargramostim (Leukine®) in improving oxygenation and short- and long-term outcome of COVID-19 patients wit... - BE",
        "timestamp": "2020-03-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000919-69/NL",
        "title": "Reducing health care workers absenteeism in SARS-CoV-2 pandemic by enhanced trained immune responses through Bacillus Calmette-Guérin vaccination, a randomized controlled trial. - NL",
        "timestamp": "2020-03-17"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001010-38/NO",
        "title": "NORWEGIAN CORONAVIRUS DISEASE 2019 (NO COVID-19) STUDY: AN OPEN LABELED RANDOMIZED CONTROLLED PRAGMATIC TRIAL TO EVALUATE THE ANTIVIRAL EFFECT OF CHLOROQUINE IN ADULT PATIENTS WITH SARS-COV-2 INFEC... - NO",
        "timestamp": "2020-03-23"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001023-14/GB",
        "title": "A randomised double-blind placebo-controlled trial to determine the safety and efficacy of inhaled SNG001 (IFNβ-1a for nebulisation) for the treatment of patients with confirmed SARS-CoV-2 infection - GB",
        "timestamp": "2020-03-17"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000936-23/FR",
        "title": "Multi-centre, adaptive, randomized trial of the safety and efficacy of treatments of COVID-19 in hospitalized adults - FR",
        "timestamp": "2020-03-09"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001113-21/GB",
        "title": "Randomised Evaluation of COVID-19 Therapy (RECOVERY) - GB",
        "timestamp": "2020-03-17"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000841-15/DE",
        "title": "A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants with Severe COVID-19 - DE",
        "timestamp": "2020-03-18"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000841-15/ES",
        "title": "A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants with Severe COVID-19 - ES",
        "timestamp": "2020-03-18"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000841-15/IT",
        "title": "A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants with Severe COVID-19 - IT",
        "timestamp": "2020-03-18"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000841-15/NL",
        "title": "A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants with Severe COVID-19 - NL",
        "timestamp": "2020-03-18"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000841-15/GB",
        "title": "A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants with Severe COVID-19 - GB",
        "timestamp": "2020-03-18"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000841-15/SE",
        "title": "A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants with Severe COVID-19 - SE",
        "timestamp": "2020-03-18"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000842-32/DE",
        "title": "A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants with Moderate  COVID-19 Compared to Standard of Care Treatment - DE",
        "timestamp": "2020-03-18"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000842-32/ES",
        "title": "A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants with Moderate  COVID-19 Compared to Standard of Care Treatment - ES",
        "timestamp": "2020-03-18"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000842-32/IT",
        "title": "A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants with Moderate  COVID-19 Compared to Standard of Care Treatment - IT",
        "timestamp": "2020-03-18"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000842-32/NL",
        "title": "A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants with Moderate  COVID-19 Compared to Standard of Care Treatment - NL",
        "timestamp": "2020-03-18"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000842-32/GB",
        "title": "A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants with Moderate  COVID-19 Compared to Standard of Care Treatment - GB",
        "timestamp": "2020-03-18"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000842-32/SE",
        "title": "A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants with Moderate  COVID-19 Compared to Standard of Care Treatment - SE",
        "timestamp": "2020-03-18"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001052-18/DK",
        "title": "A Multicenter, Adaptive, Randomised Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Adults - Version for European U... - DK",
        "timestamp": "2020-03-25"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001110-38/IT",
        "title": "Multicenter study on the efficacy and tolerability of tocilizumab in the treatment of patients with COVID-19 pneumonia - IT",
        "timestamp": "2020-03-18"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-004863-35/FI",
        "title": "A prospective phase II study to assess the minimal residual disease after ixazomib plus lenalidomide plus dexamethasone (IRd) treatment for newly diagnosed transplant eligible patients - FI",
        "timestamp": "2016-08-01"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-004863-35/SE",
        "title": "A prospective phase II study to assess the minimal residual disease after ixazomib plus lenalidomide plus dexamethasone (IRd) treatment for newly diagnosed transplant eligible patients - SE",
        "timestamp": "2016-08-01"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-004863-35/LT",
        "title": "A prospective phase II study to assess the minimal residual disease after ixazomib plus lenalidomide plus dexamethasone (IRd) treatment for newly diagnosed transplant eligible patients - LT",
        "timestamp": "2016-08-01"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000841-15/DE",
        "title": "A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants with Severe COVID-19 - DE",
        "timestamp": "2020-03-18"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000841-15/ES",
        "title": "A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants with Severe COVID-19 - ES",
        "timestamp": "2020-03-18"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000841-15/IT",
        "title": "A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants with Severe COVID-19 - IT",
        "timestamp": "2020-03-18"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000841-15/NL",
        "title": "A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants with Severe COVID-19 - NL",
        "timestamp": "2020-03-18"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000841-15/GB",
        "title": "A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants with Severe COVID-19 - GB",
        "timestamp": "2020-03-18"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000841-15/SE",
        "title": "A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants with Severe COVID-19 - SE",
        "timestamp": "2020-03-18"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000842-32/DE",
        "title": "A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants with Moderate  COVID-19 Compared to Standard of Care Treatment - DE",
        "timestamp": "2020-03-18"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000842-32/ES",
        "title": "A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants with Moderate  COVID-19 Compared to Standard of Care Treatment - ES",
        "timestamp": "2020-03-18"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000842-32/IT",
        "title": "A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants with Moderate  COVID-19 Compared to Standard of Care Treatment - IT",
        "timestamp": "2020-03-18"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000842-32/NL",
        "title": "A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants with Moderate  COVID-19 Compared to Standard of Care Treatment - NL",
        "timestamp": "2020-03-18"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000842-32/GB",
        "title": "A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants with Moderate  COVID-19 Compared to Standard of Care Treatment - GB",
        "timestamp": "2020-03-18"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000842-32/SE",
        "title": "A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants with Moderate  COVID-19 Compared to Standard of Care Treatment - SE",
        "timestamp": "2020-03-18"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000936-23/FR",
        "title": "Multi-centre, adaptive, randomized trial of the safety and efficacy of treatments of COVID-19 in hospitalized adults - FR",
        "timestamp": "2020-03-09"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001052-18/DK",
        "title": "A Multicenter, Adaptive, Randomised Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Adults - Version for European U... - DK",
        "timestamp": "2020-03-25"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-004905-27/GB",
        "title": "Pharmacokinetic Interactions between Ciprofloxacin and Chloroquine / Proguanil Prophylaxis - GB",
        "timestamp": "2008-02-01"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001010-38/NO",
        "title": "NORWEGIAN CORONAVIRUS DISEASE 2019 (NO COVID-19) STUDY: AN OPEN LABELED RANDOMIZED CONTROLLED PRAGMATIC TRIAL TO EVALUATE THE ANTIVIRAL EFFECT OF CHLOROQUINE IN ADULT PATIENTS WITH SARS-COV-2 INFEC... - NO",
        "timestamp": "2020-03-23"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-000322-21/NL",
        "title": "Controlled human malaria infection after immunization with cryopreserved Plasmodium falciparum sporozoites under chloroquine prophylaxis - NL",
        "timestamp": "2012-05-29"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-000322-21/results",
        "title": "Controlled human malaria infection after immunization with cryopreserved Plasmodium falciparum sporozoites under chloroquine prophylaxis - View results",
        "timestamp": "2012-05-29"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-004906-14/3rd",
        "title": "An Open Label, Non-Comparative Study To Evaluate Parasitological Clearance Rates and Pharmacokinetics of Azithromycin and Chloroquine Following Administration of a Fixed Dose Combination of Azithro... - Outside EU/EEA",
        "timestamp": "2015-04-07"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-004906-14/results",
        "title": "An Open Label, Non-Comparative Study To Evaluate Parasitological Clearance Rates and Pharmacokinetics of Azithromycin and Chloroquine Following Administration of a Fixed Dose Combination of Azithro... - View results",
        "timestamp": "2015-04-07"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-012223-29/BE",
        "title": "A phase II, open, single centre, exploratory study to evaluate the safety and immunogenicity of one booster dose of a GSK Biologicals’ Hepatitis B vaccine Engerix™-B or a of GSK Biologicals’ HIV ca... - BE",
        "timestamp": "2009-09-01"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-012223-29/results",
        "title": "A phase II, open, single centre, exploratory study to evaluate the safety and immunogenicity of one booster dose of a GSK Biologicals’ Hepatitis B vaccine Engerix™-B or a of GSK Biologicals’ HIV ca... - View results",
        "timestamp": "2009-09-01"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-014772-22/NL",
        "title": "Chloroquine as an anti-autophagy drug in small cell lung cancer (SCLC) patients: A phase I trial to be followed by a phase II trial. - NL",
        "timestamp": "2010-04-29"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-004163-21/3rd",
        "title": "Phase 2/3, Open-Label, Comparative Trial Of Azithromycin Plus Chloroquine Versus Artemether-Lumefantrine For The Treatment Of Uncomplicated Plasmodium Falciparum Malaria In Children In Africa - Outside EU/EEA",
        "timestamp": "2015-04-06"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-004163-21/results",
        "title": "Phase 2/3, Open-Label, Comparative Trial Of Azithromycin Plus Chloroquine Versus Artemether-Lumefantrine For The Treatment Of Uncomplicated Plasmodium Falciparum Malaria In Children In Africa - View results",
        "timestamp": "2015-04-06"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-004952-80/3rd",
        "title": "Phase 3, Open-Label, Randomized, Comparative Study to Evaluate Azithromycin plus Chloroquine and Sulfadoxine plus Pyrimethamine Combinations for Intermittent Preventive Treatment of Falciparum Mala... - Outside EU/EEA",
        "timestamp": "2015-04-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-004952-80/results",
        "title": "Phase 3, Open-Label, Randomized, Comparative Study to Evaluate Azithromycin plus Chloroquine and Sulfadoxine plus Pyrimethamine Combinations for Intermittent Preventive Treatment of Falciparum Mala... - View results",
        "timestamp": "2015-04-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-003246-93/HU",
        "title": "A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 Study Characterizing the Pharmacokinetics, Pharmacodynamics, and Safety of Anifrolumab following subcutaneous administration in ... - HU",
        "timestamp": "2016-12-06"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-003246-93/PL",
        "title": "A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 Study Characterizing the Pharmacokinetics, Pharmacodynamics, and Safety of Anifrolumab following subcutaneous administration in ... - PL",
        "timestamp": "2016-12-06"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-003246-93/results",
        "title": "A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 Study Characterizing the Pharmacokinetics, Pharmacodynamics, and Safety of Anifrolumab following subcutaneous administration in ... - View results",
        "timestamp": "2016-12-06"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-000610-11/BE",
        "title": "A randomised, double blind, placebo-controlled, multiple dose, phase 2b, 24 week trial followed by an open label extension of NNC0109-0012, an anti-IL-20 biologic, in patients with active rheumatoi... - BE",
        "timestamp": "2013-02-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-000610-11/HU",
        "title": "A randomised, double blind, placebo-controlled, multiple dose, phase 2b, 24 week trial followed by an open label extension of NNC0109-0012, an anti-IL-20 biologic, in patients with active rheumatoi... - HU",
        "timestamp": "2013-02-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-000610-11/CZ",
        "title": "A randomised, double blind, placebo-controlled, multiple dose, phase 2b, 24 week trial followed by an open label extension of NNC0109-0012, an anti-IL-20 biologic, in patients with active rheumatoi... - CZ",
        "timestamp": "2013-02-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-000610-11/DE",
        "title": "A randomised, double blind, placebo-controlled, multiple dose, phase 2b, 24 week trial followed by an open label extension of NNC0109-0012, an anti-IL-20 biologic, in patients with active rheumatoi... - DE",
        "timestamp": "2013-02-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-000610-11/ES",
        "title": "A randomised, double blind, placebo-controlled, multiple dose, phase 2b, 24 week trial followed by an open label extension of NNC0109-0012, an anti-IL-20 biologic, in patients with active rheumatoi... - ES",
        "timestamp": "2013-02-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-000610-11/IT",
        "title": "A randomised, double blind, placebo-controlled, multiple dose, phase 2b, 24 week trial followed by an open label extension of NNC0109-0012, an anti-IL-20 biologic, in patients with active rheumatoi... - IT",
        "timestamp": "2013-02-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-000610-11/results",
        "title": "A randomised, double blind, placebo-controlled, multiple dose, phase 2b, 24 week trial followed by an open label extension of NNC0109-0012, an anti-IL-20 biologic, in patients with active rheumatoi... - View results",
        "timestamp": "2013-02-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003876-38/DE",
        "title": "A randomized, double- blind, controlled, parallel-group, multicenter study to assess the safety and immunogenicity of transitioning to GP2013 or re-treatment with Rituxan® or MabThera® in patients ... - DE",
        "timestamp": "2015-07-21"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003876-38/HU",
        "title": "A randomized, double- blind, controlled, parallel-group, multicenter study to assess the safety and immunogenicity of transitioning to GP2013 or re-treatment with Rituxan® or MabThera® in patients ... - HU",
        "timestamp": "2015-07-21"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003876-38/PL",
        "title": "A randomized, double- blind, controlled, parallel-group, multicenter study to assess the safety and immunogenicity of transitioning to GP2013 or re-treatment with Rituxan® or MabThera® in patients ... - PL",
        "timestamp": "2015-07-21"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003876-38/results",
        "title": "A randomized, double- blind, controlled, parallel-group, multicenter study to assess the safety and immunogenicity of transitioning to GP2013 or re-treatment with Rituxan® or MabThera® in patients ... - View results",
        "timestamp": "2015-07-21"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-002622-23/NL",
        "title": "Safety and Efficacy of BI 695500 in patients with moderately to severely active rheumatoid arthritis: an open-label extension trial - NL",
        "timestamp": "2014-06-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-002622-23/PT",
        "title": "Safety and Efficacy of BI 695500 in patients with moderately to severely active rheumatoid arthritis: an open-label extension trial - PT",
        "timestamp": "2014-06-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-002622-23/BG",
        "title": "Safety and Efficacy of BI 695500 in patients with moderately to severely active rheumatoid arthritis: an open-label extension trial - BG",
        "timestamp": "2014-06-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-002622-23/BE",
        "title": "Safety and Efficacy of BI 695500 in patients with moderately to severely active rheumatoid arthritis: an open-label extension trial - BE",
        "timestamp": "2014-06-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-002622-23/DE",
        "title": "Safety and Efficacy of BI 695500 in patients with moderately to severely active rheumatoid arthritis: an open-label extension trial - DE",
        "timestamp": "2014-06-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-002622-23/HU",
        "title": "Safety and Efficacy of BI 695500 in patients with moderately to severely active rheumatoid arthritis: an open-label extension trial - HU",
        "timestamp": "2014-06-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-002622-23/ES",
        "title": "Safety and Efficacy of BI 695500 in patients with moderately to severely active rheumatoid arthritis: an open-label extension trial - ES",
        "timestamp": "2014-06-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-002622-23/GR",
        "title": "Safety and Efficacy of BI 695500 in patients with moderately to severely active rheumatoid arthritis: an open-label extension trial - GR",
        "timestamp": "2014-06-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-002622-23/results",
        "title": "Safety and Efficacy of BI 695500 in patients with moderately to severely active rheumatoid arthritis: an open-label extension trial - View results",
        "timestamp": "2014-06-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-004523-36/DE",
        "title": "Safety and protective efficacy of a simplified Plasmodium falciparum sporozoite Chemoprophylaxis Vaccine (PfSPZ-CVac) regimen in healthy malaria-naïve adults in Germany - DE",
        "timestamp": "2019-04-17"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-003011-12/GB",
        "title": "Prospective Randomised Double-Blind Placebo Controlled Study Assessing the Efficacy of Tocilizumab with Synovial Analysis in Patients with Rheumatoid Arthritis - GB",
        "timestamp": "2009-03-30"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-003011-12/results",
        "title": "Prospective Randomised Double-Blind Placebo Controlled Study Assessing the Efficacy of Tocilizumab with Synovial Analysis in Patients with Rheumatoid Arthritis - View results",
        "timestamp": "2009-03-30"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-000659-42/SE",
        "title": "HYDROXYCHLOROQUINE FOR PREVENTION OF ABNORMAL GLUCOSE\nTOLERANCE AND DIABETES IN INDIVIDUALS AT-RISK FOR TYPE 1\nDIABETES MELLITUS - SE",
        "timestamp": "2019-03-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-000659-42/GB",
        "title": "HYDROXYCHLOROQUINE FOR PREVENTION OF ABNORMAL GLUCOSE\nTOLERANCE AND DIABETES IN INDIVIDUALS AT-RISK FOR TYPE 1\nDIABETES MELLITUS - GB",
        "timestamp": "2019-03-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-011206-42/CZ",
        "title": "A Randomized, Double Blind, Placebo Controlled, Dose Ranging, Parallel Group, Phase 2 Study of INCB028050 Compared to Background Therapy in Patients with Active Rheumatoid Arthritis with Inadequate... - CZ",
        "timestamp": "2009-08-18"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-011206-42/results",
        "title": "A Randomized, Double Blind, Placebo Controlled, Dose Ranging, Parallel Group, Phase 2 Study of INCB028050 Compared to Background Therapy in Patients with Active Rheumatoid Arthritis with Inadequate... - View results",
        "timestamp": "2009-08-18"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-003332-13/SK",
        "title": "A Phase 3, Randomized, Double-Blind Study Comparing ABT-494 to Placebo in Subjects with Moderately to Severely Active Rheumatoid Arthritis Who are on a Stable Dose of Conventional Synthetic Disease... - SK",
        "timestamp": "2016-01-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-003332-13/ES",
        "title": "A Phase 3, Randomized, Double-Blind Study Comparing ABT-494 to Placebo in Subjects with Moderately to Severely Active Rheumatoid Arthritis Who are on a Stable Dose of Conventional Synthetic Disease... - ES",
        "timestamp": "2016-01-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-003332-13/BG",
        "title": "A Phase 3, Randomized, Double-Blind Study Comparing ABT-494 to Placebo in Subjects with Moderately to Severely Active Rheumatoid Arthritis Who are on a Stable Dose of Conventional Synthetic Disease... - BG",
        "timestamp": "2016-01-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-003332-13/CZ",
        "title": "A Phase 3, Randomized, Double-Blind Study Comparing ABT-494 to Placebo in Subjects with Moderately to Severely Active Rheumatoid Arthritis Who are on a Stable Dose of Conventional Synthetic Disease... - CZ",
        "timestamp": "2016-01-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-003332-13/DK",
        "title": "A Phase 3, Randomized, Double-Blind Study Comparing ABT-494 to Placebo in Subjects with Moderately to Severely Active Rheumatoid Arthritis Who are on a Stable Dose of Conventional Synthetic Disease... - DK",
        "timestamp": "2016-01-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-003332-13/BE",
        "title": "A Phase 3, Randomized, Double-Blind Study Comparing ABT-494 to Placebo in Subjects with Moderately to Severely Active Rheumatoid Arthritis Who are on a Stable Dose of Conventional Synthetic Disease... - BE",
        "timestamp": "2016-01-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-003332-13/IE",
        "title": "A Phase 3, Randomized, Double-Blind Study Comparing ABT-494 to Placebo in Subjects with Moderately to Severely Active Rheumatoid Arthritis Who are on a Stable Dose of Conventional Synthetic Disease... - IE",
        "timestamp": "2016-01-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-003332-13/PT",
        "title": "A Phase 3, Randomized, Double-Blind Study Comparing ABT-494 to Placebo in Subjects with Moderately to Severely Active Rheumatoid Arthritis Who are on a Stable Dose of Conventional Synthetic Disease... - PT",
        "timestamp": "2016-01-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-003332-13/GB",
        "title": "A Phase 3, Randomized, Double-Blind Study Comparing ABT-494 to Placebo in Subjects with Moderately to Severely Active Rheumatoid Arthritis Who are on a Stable Dose of Conventional Synthetic Disease... - GB",
        "timestamp": "2016-01-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-003332-13/PL",
        "title": "A Phase 3, Randomized, Double-Blind Study Comparing ABT-494 to Placebo in Subjects with Moderately to Severely Active Rheumatoid Arthritis Who are on a Stable Dose of Conventional Synthetic Disease... - PL",
        "timestamp": "2016-01-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-003332-13/LV",
        "title": "A Phase 3, Randomized, Double-Blind Study Comparing ABT-494 to Placebo in Subjects with Moderately to Severely Active Rheumatoid Arthritis Who are on a Stable Dose of Conventional Synthetic Disease... - LV",
        "timestamp": "2016-01-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-003332-13/FI",
        "title": "A Phase 3, Randomized, Double-Blind Study Comparing ABT-494 to Placebo in Subjects with Moderately to Severely Active Rheumatoid Arthritis Who are on a Stable Dose of Conventional Synthetic Disease... - FI",
        "timestamp": "2016-01-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-003332-13/NO",
        "title": "A Phase 3, Randomized, Double-Blind Study Comparing ABT-494 to Placebo in Subjects with Moderately to Severely Active Rheumatoid Arthritis Who are on a Stable Dose of Conventional Synthetic Disease... - NO",
        "timestamp": "2016-01-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-003332-13/LT",
        "title": "A Phase 3, Randomized, Double-Blind Study Comparing ABT-494 to Placebo in Subjects with Moderately to Severely Active Rheumatoid Arthritis Who are on a Stable Dose of Conventional Synthetic Disease... - LT",
        "timestamp": "2016-01-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-003332-13/HU",
        "title": "A Phase 3, Randomized, Double-Blind Study Comparing ABT-494 to Placebo in Subjects with Moderately to Severely Active Rheumatoid Arthritis Who are on a Stable Dose of Conventional Synthetic Disease... - HU",
        "timestamp": "2016-01-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-003332-13/GR",
        "title": "A Phase 3, Randomized, Double-Blind Study Comparing ABT-494 to Placebo in Subjects with Moderately to Severely Active Rheumatoid Arthritis Who are on a Stable Dose of Conventional Synthetic Disease... - GR",
        "timestamp": "2016-01-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-003332-13/AT",
        "title": "A Phase 3, Randomized, Double-Blind Study Comparing ABT-494 to Placebo in Subjects with Moderately to Severely Active Rheumatoid Arthritis Who are on a Stable Dose of Conventional Synthetic Disease... - AT",
        "timestamp": "2016-01-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-003332-13/HR",
        "title": "A Phase 3, Randomized, Double-Blind Study Comparing ABT-494 to Placebo in Subjects with Moderately to Severely Active Rheumatoid Arthritis Who are on a Stable Dose of Conventional Synthetic Disease... - HR",
        "timestamp": "2016-01-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-003332-13/IT",
        "title": "A Phase 3, Randomized, Double-Blind Study Comparing ABT-494 to Placebo in Subjects with Moderately to Severely Active Rheumatoid Arthritis Who are on a Stable Dose of Conventional Synthetic Disease... - IT",
        "timestamp": "2016-01-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-002306-31/HU",
        "title": "A Phase 2, Multicenter, Double-Blind, Parallel Group Long Term Extension Study in Rheumatoid Arthritis Subjects Who Have Completed a Preceding Phase 2 Randomized Controlled Trial with ABBV-105 Give... - HU",
        "timestamp": "2019-03-08"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-002306-31/GB",
        "title": "A Phase 2, Multicenter, Double-Blind, Parallel Group Long Term Extension Study in Rheumatoid Arthritis Subjects Who Have Completed a Preceding Phase 2 Randomized Controlled Trial with ABBV-105 Give... - GB",
        "timestamp": "2019-03-08"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-002306-31/ES",
        "title": "A Phase 2, Multicenter, Double-Blind, Parallel Group Long Term Extension Study in Rheumatoid Arthritis Subjects Who Have Completed a Preceding Phase 2 Randomized Controlled Trial with ABBV-105 Give... - ES",
        "timestamp": "2019-03-08"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-004645-16/DE",
        "title": "A Multi-Center, Open-Label Trial to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of Subcutaneously Administered Belimumab, a Human Monoclonal Anti-BLyS Antibody, Plus Standard Therap... - DE",
        "timestamp": None
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-004645-16/NL",
        "title": "A Multi-Center, Open-Label Trial to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of Subcutaneously Administered Belimumab, a Human Monoclonal Anti-BLyS Antibody, Plus Standard Therap... - NL",
        "timestamp": None
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-004645-16/ES",
        "title": "A Multi-Center, Open-Label Trial to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of Subcutaneously Administered Belimumab, a Human Monoclonal Anti-BLyS Antibody, Plus Standard Therap... - ES",
        "timestamp": None
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-000328-16/DE",
        "title": "A Phase 2 Dose Ranging Study to Evaluate the Efficacy and Safety of AMG 570 in Subjects With Active Systemic Lupus Erythematosus (SLE) With Inadequate Response to Standard of Care (SOC) Therapy - DE",
        "timestamp": "2019-09-17"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-000328-16/HU",
        "title": "A Phase 2 Dose Ranging Study to Evaluate the Efficacy and Safety of AMG 570 in Subjects With Active Systemic Lupus Erythematosus (SLE) With Inadequate Response to Standard of Care (SOC) Therapy - HU",
        "timestamp": "2019-09-17"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-000328-16/FR",
        "title": "A Phase 2 Dose Ranging Study to Evaluate the Efficacy and Safety of AMG 570 in Subjects With Active Systemic Lupus Erythematosus (SLE) With Inadequate Response to Standard of Care (SOC) Therapy - FR",
        "timestamp": "2019-09-17"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-004905-27/GB",
        "title": "Pharmacokinetic Interactions between Ciprofloxacin and Chloroquine / Proguanil Prophylaxis - GB",
        "timestamp": "2008-02-01"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001010-38/NO",
        "title": "NORWEGIAN CORONAVIRUS DISEASE 2019 (NO COVID-19) STUDY: AN OPEN LABELED RANDOMIZED CONTROLLED PRAGMATIC TRIAL TO EVALUATE THE ANTIVIRAL EFFECT OF CHLOROQUINE IN ADULT PATIENTS WITH SARS-COV-2 INFEC... - NO",
        "timestamp": "2020-03-23"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-000322-21/NL",
        "title": "Controlled human malaria infection after immunization with cryopreserved Plasmodium falciparum sporozoites under chloroquine prophylaxis - NL",
        "timestamp": "2012-05-29"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-000322-21/results",
        "title": "Controlled human malaria infection after immunization with cryopreserved Plasmodium falciparum sporozoites under chloroquine prophylaxis - View results",
        "timestamp": "2012-05-29"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-004906-14/3rd",
        "title": "An Open Label, Non-Comparative Study To Evaluate Parasitological Clearance Rates and Pharmacokinetics of Azithromycin and Chloroquine Following Administration of a Fixed Dose Combination of Azithro... - Outside EU/EEA",
        "timestamp": "2015-04-07"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-004906-14/results",
        "title": "An Open Label, Non-Comparative Study To Evaluate Parasitological Clearance Rates and Pharmacokinetics of Azithromycin and Chloroquine Following Administration of a Fixed Dose Combination of Azithro... - View results",
        "timestamp": "2015-04-07"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-012223-29/BE",
        "title": "A phase II, open, single centre, exploratory study to evaluate the safety and immunogenicity of one booster dose of a GSK Biologicals’ Hepatitis B vaccine Engerix™-B or a of GSK Biologicals’ HIV ca... - BE",
        "timestamp": "2009-09-01"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-012223-29/results",
        "title": "A phase II, open, single centre, exploratory study to evaluate the safety and immunogenicity of one booster dose of a GSK Biologicals’ Hepatitis B vaccine Engerix™-B or a of GSK Biologicals’ HIV ca... - View results",
        "timestamp": "2009-09-01"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-014772-22/NL",
        "title": "Chloroquine as an anti-autophagy drug in small cell lung cancer (SCLC) patients: A phase I trial to be followed by a phase II trial. - NL",
        "timestamp": "2010-04-29"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-004163-21/3rd",
        "title": "Phase 2/3, Open-Label, Comparative Trial Of Azithromycin Plus Chloroquine Versus Artemether-Lumefantrine For The Treatment Of Uncomplicated Plasmodium Falciparum Malaria In Children In Africa - Outside EU/EEA",
        "timestamp": "2015-04-06"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-004163-21/results",
        "title": "Phase 2/3, Open-Label, Comparative Trial Of Azithromycin Plus Chloroquine Versus Artemether-Lumefantrine For The Treatment Of Uncomplicated Plasmodium Falciparum Malaria In Children In Africa - View results",
        "timestamp": "2015-04-06"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-004952-80/3rd",
        "title": "Phase 3, Open-Label, Randomized, Comparative Study to Evaluate Azithromycin plus Chloroquine and Sulfadoxine plus Pyrimethamine Combinations for Intermittent Preventive Treatment of Falciparum Mala... - Outside EU/EEA",
        "timestamp": "2015-04-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-004952-80/results",
        "title": "Phase 3, Open-Label, Randomized, Comparative Study to Evaluate Azithromycin plus Chloroquine and Sulfadoxine plus Pyrimethamine Combinations for Intermittent Preventive Treatment of Falciparum Mala... - View results",
        "timestamp": "2015-04-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-003246-93/HU",
        "title": "A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 Study Characterizing the Pharmacokinetics, Pharmacodynamics, and Safety of Anifrolumab following subcutaneous administration in ... - HU",
        "timestamp": "2016-12-06"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-003246-93/PL",
        "title": "A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 Study Characterizing the Pharmacokinetics, Pharmacodynamics, and Safety of Anifrolumab following subcutaneous administration in ... - PL",
        "timestamp": "2016-12-06"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-003246-93/results",
        "title": "A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 Study Characterizing the Pharmacokinetics, Pharmacodynamics, and Safety of Anifrolumab following subcutaneous administration in ... - View results",
        "timestamp": "2016-12-06"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-000610-11/BE",
        "title": "A randomised, double blind, placebo-controlled, multiple dose, phase 2b, 24 week trial followed by an open label extension of NNC0109-0012, an anti-IL-20 biologic, in patients with active rheumatoi... - BE",
        "timestamp": "2013-02-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-000610-11/HU",
        "title": "A randomised, double blind, placebo-controlled, multiple dose, phase 2b, 24 week trial followed by an open label extension of NNC0109-0012, an anti-IL-20 biologic, in patients with active rheumatoi... - HU",
        "timestamp": "2013-02-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-000610-11/CZ",
        "title": "A randomised, double blind, placebo-controlled, multiple dose, phase 2b, 24 week trial followed by an open label extension of NNC0109-0012, an anti-IL-20 biologic, in patients with active rheumatoi... - CZ",
        "timestamp": "2013-02-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-000610-11/DE",
        "title": "A randomised, double blind, placebo-controlled, multiple dose, phase 2b, 24 week trial followed by an open label extension of NNC0109-0012, an anti-IL-20 biologic, in patients with active rheumatoi... - DE",
        "timestamp": "2013-02-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-000610-11/ES",
        "title": "A randomised, double blind, placebo-controlled, multiple dose, phase 2b, 24 week trial followed by an open label extension of NNC0109-0012, an anti-IL-20 biologic, in patients with active rheumatoi... - ES",
        "timestamp": "2013-02-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-000610-11/IT",
        "title": "A randomised, double blind, placebo-controlled, multiple dose, phase 2b, 24 week trial followed by an open label extension of NNC0109-0012, an anti-IL-20 biologic, in patients with active rheumatoi... - IT",
        "timestamp": "2013-02-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-000610-11/results",
        "title": "A randomised, double blind, placebo-controlled, multiple dose, phase 2b, 24 week trial followed by an open label extension of NNC0109-0012, an anti-IL-20 biologic, in patients with active rheumatoi... - View results",
        "timestamp": "2013-02-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003876-38/DE",
        "title": "A randomized, double- blind, controlled, parallel-group, multicenter study to assess the safety and immunogenicity of transitioning to GP2013 or re-treatment with Rituxan® or MabThera® in patients ... - DE",
        "timestamp": "2015-07-21"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003876-38/HU",
        "title": "A randomized, double- blind, controlled, parallel-group, multicenter study to assess the safety and immunogenicity of transitioning to GP2013 or re-treatment with Rituxan® or MabThera® in patients ... - HU",
        "timestamp": "2015-07-21"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003876-38/PL",
        "title": "A randomized, double- blind, controlled, parallel-group, multicenter study to assess the safety and immunogenicity of transitioning to GP2013 or re-treatment with Rituxan® or MabThera® in patients ... - PL",
        "timestamp": "2015-07-21"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003876-38/results",
        "title": "A randomized, double- blind, controlled, parallel-group, multicenter study to assess the safety and immunogenicity of transitioning to GP2013 or re-treatment with Rituxan® or MabThera® in patients ... - View results",
        "timestamp": "2015-07-21"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-002622-23/NL",
        "title": "Safety and Efficacy of BI 695500 in patients with moderately to severely active rheumatoid arthritis: an open-label extension trial - NL",
        "timestamp": "2014-06-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-002622-23/PT",
        "title": "Safety and Efficacy of BI 695500 in patients with moderately to severely active rheumatoid arthritis: an open-label extension trial - PT",
        "timestamp": "2014-06-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-002622-23/BG",
        "title": "Safety and Efficacy of BI 695500 in patients with moderately to severely active rheumatoid arthritis: an open-label extension trial - BG",
        "timestamp": "2014-06-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-002622-23/BE",
        "title": "Safety and Efficacy of BI 695500 in patients with moderately to severely active rheumatoid arthritis: an open-label extension trial - BE",
        "timestamp": "2014-06-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-002622-23/DE",
        "title": "Safety and Efficacy of BI 695500 in patients with moderately to severely active rheumatoid arthritis: an open-label extension trial - DE",
        "timestamp": "2014-06-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-002622-23/HU",
        "title": "Safety and Efficacy of BI 695500 in patients with moderately to severely active rheumatoid arthritis: an open-label extension trial - HU",
        "timestamp": "2014-06-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-002622-23/ES",
        "title": "Safety and Efficacy of BI 695500 in patients with moderately to severely active rheumatoid arthritis: an open-label extension trial - ES",
        "timestamp": "2014-06-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-002622-23/GR",
        "title": "Safety and Efficacy of BI 695500 in patients with moderately to severely active rheumatoid arthritis: an open-label extension trial - GR",
        "timestamp": "2014-06-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-002622-23/results",
        "title": "Safety and Efficacy of BI 695500 in patients with moderately to severely active rheumatoid arthritis: an open-label extension trial - View results",
        "timestamp": "2014-06-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-004523-36/DE",
        "title": "Safety and protective efficacy of a simplified Plasmodium falciparum sporozoite Chemoprophylaxis Vaccine (PfSPZ-CVac) regimen in healthy malaria-naïve adults in Germany - DE",
        "timestamp": "2019-04-17"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-003011-12/GB",
        "title": "Prospective Randomised Double-Blind Placebo Controlled Study Assessing the Efficacy of Tocilizumab with Synovial Analysis in Patients with Rheumatoid Arthritis - GB",
        "timestamp": "2009-03-30"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-003011-12/results",
        "title": "Prospective Randomised Double-Blind Placebo Controlled Study Assessing the Efficacy of Tocilizumab with Synovial Analysis in Patients with Rheumatoid Arthritis - View results",
        "timestamp": "2009-03-30"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-000659-42/SE",
        "title": "HYDROXYCHLOROQUINE FOR PREVENTION OF ABNORMAL GLUCOSE\nTOLERANCE AND DIABETES IN INDIVIDUALS AT-RISK FOR TYPE 1\nDIABETES MELLITUS - SE",
        "timestamp": "2019-03-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-000659-42/GB",
        "title": "HYDROXYCHLOROQUINE FOR PREVENTION OF ABNORMAL GLUCOSE\nTOLERANCE AND DIABETES IN INDIVIDUALS AT-RISK FOR TYPE 1\nDIABETES MELLITUS - GB",
        "timestamp": "2019-03-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-011206-42/CZ",
        "title": "A Randomized, Double Blind, Placebo Controlled, Dose Ranging, Parallel Group, Phase 2 Study of INCB028050 Compared to Background Therapy in Patients with Active Rheumatoid Arthritis with Inadequate... - CZ",
        "timestamp": "2009-08-18"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-011206-42/results",
        "title": "A Randomized, Double Blind, Placebo Controlled, Dose Ranging, Parallel Group, Phase 2 Study of INCB028050 Compared to Background Therapy in Patients with Active Rheumatoid Arthritis with Inadequate... - View results",
        "timestamp": "2009-08-18"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-003332-13/SK",
        "title": "A Phase 3, Randomized, Double-Blind Study Comparing ABT-494 to Placebo in Subjects with Moderately to Severely Active Rheumatoid Arthritis Who are on a Stable Dose of Conventional Synthetic Disease... - SK",
        "timestamp": "2016-01-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-003332-13/ES",
        "title": "A Phase 3, Randomized, Double-Blind Study Comparing ABT-494 to Placebo in Subjects with Moderately to Severely Active Rheumatoid Arthritis Who are on a Stable Dose of Conventional Synthetic Disease... - ES",
        "timestamp": "2016-01-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-003332-13/BG",
        "title": "A Phase 3, Randomized, Double-Blind Study Comparing ABT-494 to Placebo in Subjects with Moderately to Severely Active Rheumatoid Arthritis Who are on a Stable Dose of Conventional Synthetic Disease... - BG",
        "timestamp": "2016-01-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-003332-13/CZ",
        "title": "A Phase 3, Randomized, Double-Blind Study Comparing ABT-494 to Placebo in Subjects with Moderately to Severely Active Rheumatoid Arthritis Who are on a Stable Dose of Conventional Synthetic Disease... - CZ",
        "timestamp": "2016-01-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-003332-13/DK",
        "title": "A Phase 3, Randomized, Double-Blind Study Comparing ABT-494 to Placebo in Subjects with Moderately to Severely Active Rheumatoid Arthritis Who are on a Stable Dose of Conventional Synthetic Disease... - DK",
        "timestamp": "2016-01-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-003332-13/BE",
        "title": "A Phase 3, Randomized, Double-Blind Study Comparing ABT-494 to Placebo in Subjects with Moderately to Severely Active Rheumatoid Arthritis Who are on a Stable Dose of Conventional Synthetic Disease... - BE",
        "timestamp": "2016-01-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-003332-13/IE",
        "title": "A Phase 3, Randomized, Double-Blind Study Comparing ABT-494 to Placebo in Subjects with Moderately to Severely Active Rheumatoid Arthritis Who are on a Stable Dose of Conventional Synthetic Disease... - IE",
        "timestamp": "2016-01-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-003332-13/PT",
        "title": "A Phase 3, Randomized, Double-Blind Study Comparing ABT-494 to Placebo in Subjects with Moderately to Severely Active Rheumatoid Arthritis Who are on a Stable Dose of Conventional Synthetic Disease... - PT",
        "timestamp": "2016-01-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-003332-13/GB",
        "title": "A Phase 3, Randomized, Double-Blind Study Comparing ABT-494 to Placebo in Subjects with Moderately to Severely Active Rheumatoid Arthritis Who are on a Stable Dose of Conventional Synthetic Disease... - GB",
        "timestamp": "2016-01-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-003332-13/PL",
        "title": "A Phase 3, Randomized, Double-Blind Study Comparing ABT-494 to Placebo in Subjects with Moderately to Severely Active Rheumatoid Arthritis Who are on a Stable Dose of Conventional Synthetic Disease... - PL",
        "timestamp": "2016-01-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-003332-13/LV",
        "title": "A Phase 3, Randomized, Double-Blind Study Comparing ABT-494 to Placebo in Subjects with Moderately to Severely Active Rheumatoid Arthritis Who are on a Stable Dose of Conventional Synthetic Disease... - LV",
        "timestamp": "2016-01-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-003332-13/FI",
        "title": "A Phase 3, Randomized, Double-Blind Study Comparing ABT-494 to Placebo in Subjects with Moderately to Severely Active Rheumatoid Arthritis Who are on a Stable Dose of Conventional Synthetic Disease... - FI",
        "timestamp": "2016-01-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-003332-13/NO",
        "title": "A Phase 3, Randomized, Double-Blind Study Comparing ABT-494 to Placebo in Subjects with Moderately to Severely Active Rheumatoid Arthritis Who are on a Stable Dose of Conventional Synthetic Disease... - NO",
        "timestamp": "2016-01-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-003332-13/LT",
        "title": "A Phase 3, Randomized, Double-Blind Study Comparing ABT-494 to Placebo in Subjects with Moderately to Severely Active Rheumatoid Arthritis Who are on a Stable Dose of Conventional Synthetic Disease... - LT",
        "timestamp": "2016-01-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-003332-13/HU",
        "title": "A Phase 3, Randomized, Double-Blind Study Comparing ABT-494 to Placebo in Subjects with Moderately to Severely Active Rheumatoid Arthritis Who are on a Stable Dose of Conventional Synthetic Disease... - HU",
        "timestamp": "2016-01-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-003332-13/GR",
        "title": "A Phase 3, Randomized, Double-Blind Study Comparing ABT-494 to Placebo in Subjects with Moderately to Severely Active Rheumatoid Arthritis Who are on a Stable Dose of Conventional Synthetic Disease... - GR",
        "timestamp": "2016-01-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-003332-13/AT",
        "title": "A Phase 3, Randomized, Double-Blind Study Comparing ABT-494 to Placebo in Subjects with Moderately to Severely Active Rheumatoid Arthritis Who are on a Stable Dose of Conventional Synthetic Disease... - AT",
        "timestamp": "2016-01-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-003332-13/HR",
        "title": "A Phase 3, Randomized, Double-Blind Study Comparing ABT-494 to Placebo in Subjects with Moderately to Severely Active Rheumatoid Arthritis Who are on a Stable Dose of Conventional Synthetic Disease... - HR",
        "timestamp": "2016-01-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-003332-13/IT",
        "title": "A Phase 3, Randomized, Double-Blind Study Comparing ABT-494 to Placebo in Subjects with Moderately to Severely Active Rheumatoid Arthritis Who are on a Stable Dose of Conventional Synthetic Disease... - IT",
        "timestamp": "2016-01-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-002306-31/HU",
        "title": "A Phase 2, Multicenter, Double-Blind, Parallel Group Long Term Extension Study in Rheumatoid Arthritis Subjects Who Have Completed a Preceding Phase 2 Randomized Controlled Trial with ABBV-105 Give... - HU",
        "timestamp": "2019-03-08"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-002306-31/GB",
        "title": "A Phase 2, Multicenter, Double-Blind, Parallel Group Long Term Extension Study in Rheumatoid Arthritis Subjects Who Have Completed a Preceding Phase 2 Randomized Controlled Trial with ABBV-105 Give... - GB",
        "timestamp": "2019-03-08"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-002306-31/ES",
        "title": "A Phase 2, Multicenter, Double-Blind, Parallel Group Long Term Extension Study in Rheumatoid Arthritis Subjects Who Have Completed a Preceding Phase 2 Randomized Controlled Trial with ABBV-105 Give... - ES",
        "timestamp": "2019-03-08"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-004645-16/DE",
        "title": "A Multi-Center, Open-Label Trial to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of Subcutaneously Administered Belimumab, a Human Monoclonal Anti-BLyS Antibody, Plus Standard Therap... - DE",
        "timestamp": None
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-004645-16/NL",
        "title": "A Multi-Center, Open-Label Trial to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of Subcutaneously Administered Belimumab, a Human Monoclonal Anti-BLyS Antibody, Plus Standard Therap... - NL",
        "timestamp": None
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-004645-16/ES",
        "title": "A Multi-Center, Open-Label Trial to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of Subcutaneously Administered Belimumab, a Human Monoclonal Anti-BLyS Antibody, Plus Standard Therap... - ES",
        "timestamp": None
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-000328-16/DE",
        "title": "A Phase 2 Dose Ranging Study to Evaluate the Efficacy and Safety of AMG 570 in Subjects With Active Systemic Lupus Erythematosus (SLE) With Inadequate Response to Standard of Care (SOC) Therapy - DE",
        "timestamp": "2019-09-17"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-000328-16/HU",
        "title": "A Phase 2 Dose Ranging Study to Evaluate the Efficacy and Safety of AMG 570 in Subjects With Active Systemic Lupus Erythematosus (SLE) With Inadequate Response to Standard of Care (SOC) Therapy - HU",
        "timestamp": "2019-09-17"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-000328-16/FR",
        "title": "A Phase 2 Dose Ranging Study to Evaluate the Efficacy and Safety of AMG 570 in Subjects With Active Systemic Lupus Erythematosus (SLE) With Inadequate Response to Standard of Care (SOC) Therapy - FR",
        "timestamp": "2019-09-17"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-003495-38/IE",
        "title": "A randomized, double-blind, placebo-controlled study to determine the efficacy and safety of 5 dose regimens of RO4402257 in patients with active rheumatoid arthritis (RA) on stable methotrexate (M... - IE",
        "timestamp": "2005-11-17"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-003495-38/ES",
        "title": "A randomized, double-blind, placebo-controlled study to determine the efficacy and safety of 5 dose regimens of RO4402257 in patients with active rheumatoid arthritis (RA) on stable methotrexate (M... - ES",
        "timestamp": "2005-11-17"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-003495-38/DE",
        "title": "A randomized, double-blind, placebo-controlled study to determine the efficacy and safety of 5 dose regimens of RO4402257 in patients with active rheumatoid arthritis (RA) on stable methotrexate (M... - DE",
        "timestamp": "2005-11-17"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-003495-38/GB",
        "title": "A randomized, double-blind, placebo-controlled study to determine the efficacy and safety of 5 dose regimens of RO4402257 in patients with active rheumatoid arthritis (RA) on stable methotrexate (M... - GB",
        "timestamp": "2005-11-17"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-003495-38/EE",
        "title": "A randomized, double-blind, placebo-controlled study to determine the efficacy and safety of 5 dose regimens of RO4402257 in patients with active rheumatoid arthritis (RA) on stable methotrexate (M... - EE",
        "timestamp": "2005-11-17"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-003495-38/GR",
        "title": "A randomized, double-blind, placebo-controlled study to determine the efficacy and safety of 5 dose regimens of RO4402257 in patients with active rheumatoid arthritis (RA) on stable methotrexate (M... - GR",
        "timestamp": "2005-11-17"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-003495-38/results",
        "title": "A randomized, double-blind, placebo-controlled study to determine the efficacy and safety of 5 dose regimens of RO4402257 in patients with active rheumatoid arthritis (RA) on stable methotrexate (M... - View results",
        "timestamp": "2005-11-17"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-003780-65/IT",
        "title": "A Phase IIb, Randomized, Multi-Center, Double-Blind, Dose-Ranging Study to Evaluate the Efficacy and Safety of Clazakizumab in Subjects with Moderate to Severe Active Rheumatoid Arthritis who have ... - IT",
        "timestamp": "2014-03-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-003780-65/HU",
        "title": "A Phase IIb, Randomized, Multi-Center, Double-Blind, Dose-Ranging Study to Evaluate the Efficacy and Safety of Clazakizumab in Subjects with Moderate to Severe Active Rheumatoid Arthritis who have ... - HU",
        "timestamp": "2014-03-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-003780-65/results",
        "title": "A Phase IIb, Randomized, Multi-Center, Double-Blind, Dose-Ranging Study to Evaluate the Efficacy and Safety of Clazakizumab in Subjects with Moderate to Severe Active Rheumatoid Arthritis who have ... - View results",
        "timestamp": "2014-03-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-019689-10/DE",
        "title": "A multi-center, double-blind, placebo-controlled, proof-of-concept study to evaluate the efficacy and tolerability of KRP203 in patients with active subacute cutaneous lupus erythematosus - DE",
        "timestamp": "2010-09-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-019689-10/IT",
        "title": "A multi-center, double-blind, placebo-controlled, proof-of-concept study to evaluate the efficacy and tolerability of KRP203 in patients with active subacute cutaneous lupus erythematosus - IT",
        "timestamp": "2010-09-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-019689-10/GR",
        "title": "A multi-center, double-blind, placebo-controlled, proof-of-concept study to evaluate the efficacy and tolerability of KRP203 in patients with active subacute cutaneous lupus erythematosus - GR",
        "timestamp": "2010-09-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-019689-10/results",
        "title": "A multi-center, double-blind, placebo-controlled, proof-of-concept study to evaluate the efficacy and tolerability of KRP203 in patients with active subacute cutaneous lupus erythematosus - View results",
        "timestamp": "2010-09-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-005026-37/GB",
        "title": "A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients with Systemic Lupus Erythematosus - GB",
        "timestamp": "2019-03-27"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-005026-37/AT",
        "title": "A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients with Systemic Lupus Erythematosus - AT",
        "timestamp": "2019-03-27"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-005026-37/BE",
        "title": "A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients with Systemic Lupus Erythematosus - BE",
        "timestamp": "2019-03-27"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-005026-37/HU",
        "title": "A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients with Systemic Lupus Erythematosus - HU",
        "timestamp": "2019-03-27"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-005026-37/CZ",
        "title": "A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients with Systemic Lupus Erythematosus - CZ",
        "timestamp": "2019-03-27"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-005026-37/GR",
        "title": "A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients with Systemic Lupus Erythematosus - GR",
        "timestamp": "2019-03-27"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-005026-37/NL",
        "title": "A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients with Systemic Lupus Erythematosus - NL",
        "timestamp": "2019-03-27"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-005026-37/HR",
        "title": "A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients with Systemic Lupus Erythematosus - HR",
        "timestamp": "2019-03-27"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-003335-35/DE",
        "title": "A Phase 3, Randomized, Double-Blind Study Comparing Upadacitinib (ABT-494) to Placebo on Stable Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs) in Subjects with Moderately ... - DE",
        "timestamp": "2016-05-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-003335-35/BE",
        "title": "A Phase 3, Randomized, Double-Blind Study Comparing Upadacitinib (ABT-494) to Placebo on Stable Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs) in Subjects with Moderately ... - BE",
        "timestamp": "2016-05-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-003335-35/IE",
        "title": "A Phase 3, Randomized, Double-Blind Study Comparing Upadacitinib (ABT-494) to Placebo on Stable Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs) in Subjects with Moderately ... - IE",
        "timestamp": "2016-05-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-003335-35/ES",
        "title": "A Phase 3, Randomized, Double-Blind Study Comparing Upadacitinib (ABT-494) to Placebo on Stable Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs) in Subjects with Moderately ... - ES",
        "timestamp": "2016-05-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-003335-35/DK",
        "title": "A Phase 3, Randomized, Double-Blind Study Comparing Upadacitinib (ABT-494) to Placebo on Stable Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs) in Subjects with Moderately ... - DK",
        "timestamp": "2016-05-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-003335-35/CZ",
        "title": "A Phase 3, Randomized, Double-Blind Study Comparing Upadacitinib (ABT-494) to Placebo on Stable Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs) in Subjects with Moderately ... - CZ",
        "timestamp": "2016-05-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-003335-35/SE",
        "title": "A Phase 3, Randomized, Double-Blind Study Comparing Upadacitinib (ABT-494) to Placebo on Stable Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs) in Subjects with Moderately ... - SE",
        "timestamp": "2016-05-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-003335-35/GB",
        "title": "A Phase 3, Randomized, Double-Blind Study Comparing Upadacitinib (ABT-494) to Placebo on Stable Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs) in Subjects with Moderately ... - GB",
        "timestamp": "2016-05-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-003335-35/HU",
        "title": "A Phase 3, Randomized, Double-Blind Study Comparing Upadacitinib (ABT-494) to Placebo on Stable Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs) in Subjects with Moderately ... - HU",
        "timestamp": "2016-05-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-003335-35/SK",
        "title": "A Phase 3, Randomized, Double-Blind Study Comparing Upadacitinib (ABT-494) to Placebo on Stable Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs) in Subjects with Moderately ... - SK",
        "timestamp": "2016-05-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-003335-35/PT",
        "title": "A Phase 3, Randomized, Double-Blind Study Comparing Upadacitinib (ABT-494) to Placebo on Stable Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs) in Subjects with Moderately ... - PT",
        "timestamp": "2016-05-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-003335-35/LV",
        "title": "A Phase 3, Randomized, Double-Blind Study Comparing Upadacitinib (ABT-494) to Placebo on Stable Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs) in Subjects with Moderately ... - LV",
        "timestamp": "2016-05-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-003335-35/AT",
        "title": "A Phase 3, Randomized, Double-Blind Study Comparing Upadacitinib (ABT-494) to Placebo on Stable Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs) in Subjects with Moderately ... - AT",
        "timestamp": "2016-05-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-003335-35/FI",
        "title": "A Phase 3, Randomized, Double-Blind Study Comparing Upadacitinib (ABT-494) to Placebo on Stable Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs) in Subjects with Moderately ... - FI",
        "timestamp": "2016-05-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-003335-35/GR",
        "title": "A Phase 3, Randomized, Double-Blind Study Comparing Upadacitinib (ABT-494) to Placebo on Stable Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs) in Subjects with Moderately ... - GR",
        "timestamp": "2016-05-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-003335-35/BG",
        "title": "A Phase 3, Randomized, Double-Blind Study Comparing Upadacitinib (ABT-494) to Placebo on Stable Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs) in Subjects with Moderately ... - BG",
        "timestamp": "2016-05-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-003335-35/SI",
        "title": "A Phase 3, Randomized, Double-Blind Study Comparing Upadacitinib (ABT-494) to Placebo on Stable Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs) in Subjects with Moderately ... - SI",
        "timestamp": "2016-05-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-003335-35/IT",
        "title": "A Phase 3, Randomized, Double-Blind Study Comparing Upadacitinib (ABT-494) to Placebo on Stable Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs) in Subjects with Moderately ... - IT",
        "timestamp": "2016-05-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-000933-37/HU",
        "title": "A Phase 3, Randomized, Active-Controlled, Double Blind Study Comparing ABT-494 to Abatacept in Subjects with Moderately to Severely Active Rheumatoid Arthritis with Inadequate Response or Intoleran... - HU",
        "timestamp": "2016-11-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-000933-37/DE",
        "title": "A Phase 3, Randomized, Active-Controlled, Double Blind Study Comparing ABT-494 to Abatacept in Subjects with Moderately to Severely Active Rheumatoid Arthritis with Inadequate Response or Intoleran... - DE",
        "timestamp": "2016-11-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-000933-37/LV",
        "title": "A Phase 3, Randomized, Active-Controlled, Double Blind Study Comparing ABT-494 to Abatacept in Subjects with Moderately to Severely Active Rheumatoid Arthritis with Inadequate Response or Intoleran... - LV",
        "timestamp": "2016-11-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-000933-37/PT",
        "title": "A Phase 3, Randomized, Active-Controlled, Double Blind Study Comparing ABT-494 to Abatacept in Subjects with Moderately to Severely Active Rheumatoid Arthritis with Inadequate Response or Intoleran... - PT",
        "timestamp": "2016-11-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-000933-37/SE",
        "title": "A Phase 3, Randomized, Active-Controlled, Double Blind Study Comparing ABT-494 to Abatacept in Subjects with Moderately to Severely Active Rheumatoid Arthritis with Inadequate Response or Intoleran... - SE",
        "timestamp": "2016-11-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-000933-37/ES",
        "title": "A Phase 3, Randomized, Active-Controlled, Double Blind Study Comparing ABT-494 to Abatacept in Subjects with Moderately to Severely Active Rheumatoid Arthritis with Inadequate Response or Intoleran... - ES",
        "timestamp": "2016-11-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-000933-37/CZ",
        "title": "A Phase 3, Randomized, Active-Controlled, Double Blind Study Comparing ABT-494 to Abatacept in Subjects with Moderately to Severely Active Rheumatoid Arthritis with Inadequate Response or Intoleran... - CZ",
        "timestamp": "2016-11-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-000933-37/BE",
        "title": "A Phase 3, Randomized, Active-Controlled, Double Blind Study Comparing ABT-494 to Abatacept in Subjects with Moderately to Severely Active Rheumatoid Arthritis with Inadequate Response or Intoleran... - BE",
        "timestamp": "2016-11-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-000933-37/NL",
        "title": "A Phase 3, Randomized, Active-Controlled, Double Blind Study Comparing ABT-494 to Abatacept in Subjects with Moderately to Severely Active Rheumatoid Arthritis with Inadequate Response or Intoleran... - NL",
        "timestamp": "2016-11-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-000933-37/SK",
        "title": "A Phase 3, Randomized, Active-Controlled, Double Blind Study Comparing ABT-494 to Abatacept in Subjects with Moderately to Severely Active Rheumatoid Arthritis with Inadequate Response or Intoleran... - SK",
        "timestamp": "2016-11-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-000933-37/BG",
        "title": "A Phase 3, Randomized, Active-Controlled, Double Blind Study Comparing ABT-494 to Abatacept in Subjects with Moderately to Severely Active Rheumatoid Arthritis with Inadequate Response or Intoleran... - BG",
        "timestamp": "2016-11-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-006603-20/HU",
        "title": "A Phase 2, 2-Part, Multicenter, Randomized, Double-blind,\nParallel-group, Placebo-controlled, Proof-of-concept, dose-finding\nStudy Evaluating the Efficacy and Safety of CNTO 136\nAdministered Subcut... - HU",
        "timestamp": "2009-07-29"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-006603-20/results",
        "title": "A Phase 2, 2-Part, Multicenter, Randomized, Double-blind,\nParallel-group, Placebo-controlled, Proof-of-concept, dose-finding\nStudy Evaluating the Efficacy and Safety of CNTO 136\nAdministered Subcut... - View results",
        "timestamp": "2009-07-29"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-002564-40/DE",
        "title": "A Phase 1b/2a Study to Evaluate the Safety and Efficacy of AMG 592 in Subjects With Active Systemic Lupus Erythematosus With Inadequate Response to Standard of Care Therapy. - DE",
        "timestamp": "2018-04-10"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-014373-41/GB",
        "title": "A randomised Phase II trial of Imatinib (IM) versus Hydroxychloroquine (HCQ) and Imatinib (IM) for patients with Chronic Myeloid Leukaemia (CML) in Cytogenetic Response (CyR) with residual disease ... - GB",
        "timestamp": "2010-02-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-014373-41/DE",
        "title": "A randomised Phase II trial of Imatinib (IM) versus Hydroxychloroquine (HCQ) and Imatinib (IM) for patients with Chronic Myeloid Leukaemia (CML) in Cytogenetic Response (CyR) with residual disease ... - DE",
        "timestamp": "2010-02-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-014373-41/FR",
        "title": "A randomised Phase II trial of Imatinib (IM) versus Hydroxychloroquine (HCQ) and Imatinib (IM) for patients with Chronic Myeloid Leukaemia (CML) in Cytogenetic Response (CyR) with residual disease ... - FR",
        "timestamp": "2010-02-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-014373-41/results",
        "title": "A randomised Phase II trial of Imatinib (IM) versus Hydroxychloroquine (HCQ) and Imatinib (IM) for patients with Chronic Myeloid Leukaemia (CML) in Cytogenetic Response (CyR) with residual disease ... - View results",
        "timestamp": "2010-02-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-006129-29/DE",
        "title": "A multicentre, randomized, double-blind, placebo-controlled study to evaluate the safety, preliminary clinical activity and immunogenicity of multiple doses of MOR103 administered intravenously to ... - DE",
        "timestamp": "2009-11-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-006129-29/NL",
        "title": "A multicentre, randomized, double-blind, placebo-controlled study to evaluate the safety, preliminary clinical activity and immunogenicity of multiple doses of MOR103 administered intravenously to ... - NL",
        "timestamp": "2009-11-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-006129-29/BG",
        "title": "A multicentre, randomized, double-blind, placebo-controlled study to evaluate the safety, preliminary clinical activity and immunogenicity of multiple doses of MOR103 administered intravenously to ... - BG",
        "timestamp": "2009-11-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-006129-29/PL",
        "title": "A multicentre, randomized, double-blind, placebo-controlled study to evaluate the safety, preliminary clinical activity and immunogenicity of multiple doses of MOR103 administered intravenously to ... - PL",
        "timestamp": "2009-11-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-003771-37/HU",
        "title": "A double-blind, randomized, placebo controlled, dose escalation, multi-center phase I/II trial of HuMax-CD20, a fully human monoclonal anti-CD20 antibody, in patients with active rheumatoid arthrit... - HU",
        "timestamp": "2006-03-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-003771-37/results",
        "title": "A double-blind, randomized, placebo controlled, dose escalation, multi-center phase I/II trial of HuMax-CD20, a fully human monoclonal anti-CD20 antibody, in patients with active rheumatoid arthrit... - View results",
        "timestamp": "2006-03-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-003051-35/DE",
        "title": "Efficacy of BELImumab for therapy-resistant SKIN manifestations in patients with lupus erythematosus (LE): A phase III, multicenter, randomized, double-blind, placebo-controlled, 24-week trial (BEL... - DE",
        "timestamp": "2018-10-09"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-003933-14/LV",
        "title": "A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Effect of Filgotinib on Semen Parameters in Adult Males with active Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosin... - LV",
        "timestamp": "2019-05-27"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-003933-14/EE",
        "title": "A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Effect of Filgotinib on Semen Parameters in Adult Males with active Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosin... - EE",
        "timestamp": "2019-05-27"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-003933-14/BG",
        "title": "A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Effect of Filgotinib on Semen Parameters in Adult Males with active Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosin... - BG",
        "timestamp": "2019-05-27"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-003933-14/ES",
        "title": "A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Effect of Filgotinib on Semen Parameters in Adult Males with active Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosin... - ES",
        "timestamp": "2019-05-27"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-004284-30/DE",
        "title": "Effectiveness of Canakinumab for first line steroid free treatment in systemic onset juvenile idiopathic arthritis / juvenile Still’s disease - DE",
        "timestamp": "2020-02-13"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-001808-11/GB",
        "title": "A Phase 2b, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy, safety, and tolerability of cenerimod in subjects with moderate to severe syste... - GB",
        "timestamp": "2018-12-17"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-001808-11/ES",
        "title": "A Phase 2b, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy, safety, and tolerability of cenerimod in subjects with moderate to severe syste... - ES",
        "timestamp": "2018-12-17"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-001808-11/HU",
        "title": "A Phase 2b, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy, safety, and tolerability of cenerimod in subjects with moderate to severe syste... - HU",
        "timestamp": "2018-12-17"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-001808-11/BG",
        "title": "A Phase 2b, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy, safety, and tolerability of cenerimod in subjects with moderate to severe syste... - BG",
        "timestamp": "2018-12-17"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-000867-26/GB",
        "title": "A 52-week, phase 3, multicentre, randomised, double blind, efficacy and safety study, comparing GSK3196165 with placebo and with tofacitinib in combination with conventional synthetic DMARDs, in pa... - GB",
        "timestamp": "2019-12-10"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-000867-26/DE",
        "title": "A 52-week, phase 3, multicentre, randomised, double blind, efficacy and safety study, comparing GSK3196165 with placebo and with tofacitinib in combination with conventional synthetic DMARDs, in pa... - DE",
        "timestamp": "2019-12-10"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-000867-26/ES",
        "title": "A 52-week, phase 3, multicentre, randomised, double blind, efficacy and safety study, comparing GSK3196165 with placebo and with tofacitinib in combination with conventional synthetic DMARDs, in pa... - ES",
        "timestamp": "2019-12-10"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-000867-26/PL",
        "title": "A 52-week, phase 3, multicentre, randomised, double blind, efficacy and safety study, comparing GSK3196165 with placebo and with tofacitinib in combination with conventional synthetic DMARDs, in pa... - PL",
        "timestamp": "2019-12-10"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-000867-26/BG",
        "title": "A 52-week, phase 3, multicentre, randomised, double blind, efficacy and safety study, comparing GSK3196165 with placebo and with tofacitinib in combination with conventional synthetic DMARDs, in pa... - BG",
        "timestamp": "2019-12-10"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-000867-26/EE",
        "title": "A 52-week, phase 3, multicentre, randomised, double blind, efficacy and safety study, comparing GSK3196165 with placebo and with tofacitinib in combination with conventional synthetic DMARDs, in pa... - EE",
        "timestamp": "2019-12-10"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-000867-26/HU",
        "title": "A 52-week, phase 3, multicentre, randomised, double blind, efficacy and safety study, comparing GSK3196165 with placebo and with tofacitinib in combination with conventional synthetic DMARDs, in pa... - HU",
        "timestamp": "2019-12-10"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-001114-26/DE",
        "title": "A Phase 4 Trial Assessing the ImPact of Residual Inflammation Detected via Imaging TEchniques, Drug Levels and Patient Characteristics on the Outcome of Dose TaperIng of Adalimumab in Clinical Remi... - DE",
        "timestamp": "2014-11-10"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-001114-26/IE",
        "title": "A Phase 4 Trial Assessing the ImPact of Residual Inflammation Detected via Imaging TEchniques, Drug Levels and Patient Characteristics on the Outcome of Dose TaperIng of Adalimumab in Clinical Remi... - IE",
        "timestamp": "2014-11-10"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-001114-26/GB",
        "title": "A Phase 4 Trial Assessing the ImPact of Residual Inflammation Detected via Imaging TEchniques, Drug Levels and Patient Characteristics on the Outcome of Dose TaperIng of Adalimumab in Clinical Remi... - GB",
        "timestamp": "2014-11-10"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-001114-26/SE",
        "title": "A Phase 4 Trial Assessing the ImPact of Residual Inflammation Detected via Imaging TEchniques, Drug Levels and Patient Characteristics on the Outcome of Dose TaperIng of Adalimumab in Clinical Remi... - SE",
        "timestamp": "2014-11-10"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-001114-26/ES",
        "title": "A Phase 4 Trial Assessing the ImPact of Residual Inflammation Detected via Imaging TEchniques, Drug Levels and Patient Characteristics on the Outcome of Dose TaperIng of Adalimumab in Clinical Remi... - ES",
        "timestamp": "2014-11-10"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-001114-26/HU",
        "title": "A Phase 4 Trial Assessing the ImPact of Residual Inflammation Detected via Imaging TEchniques, Drug Levels and Patient Characteristics on the Outcome of Dose TaperIng of Adalimumab in Clinical Remi... - HU",
        "timestamp": "2014-11-10"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-001114-26/IT",
        "title": "A Phase 4 Trial Assessing the ImPact of Residual Inflammation Detected via Imaging TEchniques, Drug Levels and Patient Characteristics on the Outcome of Dose TaperIng of Adalimumab in Clinical Remi... - IT",
        "timestamp": "2014-11-10"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-001114-26/NL",
        "title": "A Phase 4 Trial Assessing the ImPact of Residual Inflammation Detected via Imaging TEchniques, Drug Levels and Patient Characteristics on the Outcome of Dose TaperIng of Adalimumab in Clinical Remi... - NL",
        "timestamp": "2014-11-10"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-001114-26/AT",
        "title": "A Phase 4 Trial Assessing the ImPact of Residual Inflammation Detected via Imaging TEchniques, Drug Levels and Patient Characteristics on the Outcome of Dose TaperIng of Adalimumab in Clinical Remi... - AT",
        "timestamp": "2014-11-10"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-001114-26/GR",
        "title": "A Phase 4 Trial Assessing the ImPact of Residual Inflammation Detected via Imaging TEchniques, Drug Levels and Patient Characteristics on the Outcome of Dose TaperIng of Adalimumab in Clinical Remi... - GR",
        "timestamp": "2014-11-10"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-001114-26/results",
        "title": "A Phase 4 Trial Assessing the ImPact of Residual Inflammation Detected via Imaging TEchniques, Drug Levels and Patient Characteristics on the Outcome of Dose TaperIng of Adalimumab in Clinical Remi... - View results",
        "timestamp": "2014-11-10"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-003637-14/EE",
        "title": "A randomized, double-blind, placebo-controlled, multicenter, Phase II study to assess the efficacy and safety of filgotinib administered for 16 weeks to subjects with moderately to severely active ... - EE",
        "timestamp": "2017-01-26"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-003637-14/ES",
        "title": "A randomized, double-blind, placebo-controlled, multicenter, Phase II study to assess the efficacy and safety of filgotinib administered for 16 weeks to subjects with moderately to severely active ... - ES",
        "timestamp": "2017-01-26"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-003637-14/CZ",
        "title": "A randomized, double-blind, placebo-controlled, multicenter, Phase II study to assess the efficacy and safety of filgotinib administered for 16 weeks to subjects with moderately to severely active ... - CZ",
        "timestamp": "2017-01-26"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-003637-14/BE",
        "title": "A randomized, double-blind, placebo-controlled, multicenter, Phase II study to assess the efficacy and safety of filgotinib administered for 16 weeks to subjects with moderately to severely active ... - BE",
        "timestamp": "2017-01-26"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-003637-14/BG",
        "title": "A randomized, double-blind, placebo-controlled, multicenter, Phase II study to assess the efficacy and safety of filgotinib administered for 16 weeks to subjects with moderately to severely active ... - BG",
        "timestamp": "2017-01-26"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-003637-14/results",
        "title": "A randomized, double-blind, placebo-controlled, multicenter, Phase II study to assess the efficacy and safety of filgotinib administered for 16 weeks to subjects with moderately to severely active ... - View results",
        "timestamp": "2017-01-26"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-003984-72/LV",
        "title": "A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Investigate the Safety and Efficacy of ABT-494 with Background Methotrexate (MTX) in Subjects with Active Rheumatoid Arthritis (RA) ... - LV",
        "timestamp": "2014-05-30"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-003984-72/HU",
        "title": "A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Investigate the Safety and Efficacy of ABT-494 with Background Methotrexate (MTX) in Subjects with Active Rheumatoid Arthritis (RA) ... - HU",
        "timestamp": "2014-05-30"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-003984-72/CZ",
        "title": "A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Investigate the Safety and Efficacy of ABT-494 with Background Methotrexate (MTX) in Subjects with Active Rheumatoid Arthritis (RA) ... - CZ",
        "timestamp": "2014-05-30"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-003984-72/SK",
        "title": "A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Investigate the Safety and Efficacy of ABT-494 with Background Methotrexate (MTX) in Subjects with Active Rheumatoid Arthritis (RA) ... - SK",
        "timestamp": "2014-05-30"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-003984-72/ES",
        "title": "A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Investigate the Safety and Efficacy of ABT-494 with Background Methotrexate (MTX) in Subjects with Active Rheumatoid Arthritis (RA) ... - ES",
        "timestamp": "2014-05-30"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-003984-72/results",
        "title": "A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Investigate the Safety and Efficacy of ABT-494 with Background Methotrexate (MTX) in Subjects with Active Rheumatoid Arthritis (RA) ... - View results",
        "timestamp": "2014-05-30"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-022243-38/LT",
        "title": "A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study of CNTO 136 (sirukumab), a Human Anti-IL-6 Monoclonal Antibody, Administered Subcutaneously, in Subjects with Activ... - LT",
        "timestamp": "2012-07-11"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-022243-38/DE",
        "title": "A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study of CNTO 136 (sirukumab), a Human Anti-IL-6 Monoclonal Antibody, Administered Subcutaneously, in Subjects with Activ... - DE",
        "timestamp": "2012-07-11"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-022243-38/GB",
        "title": "A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study of CNTO 136 (sirukumab), a Human Anti-IL-6 Monoclonal Antibody, Administered Subcutaneously, in Subjects with Activ... - GB",
        "timestamp": "2012-07-11"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-022243-38/AT",
        "title": "A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study of CNTO 136 (sirukumab), a Human Anti-IL-6 Monoclonal Antibody, Administered Subcutaneously, in Subjects with Activ... - AT",
        "timestamp": "2012-07-11"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-022243-38/ES",
        "title": "A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study of CNTO 136 (sirukumab), a Human Anti-IL-6 Monoclonal Antibody, Administered Subcutaneously, in Subjects with Activ... - ES",
        "timestamp": "2012-07-11"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-022243-38/PT",
        "title": "A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study of CNTO 136 (sirukumab), a Human Anti-IL-6 Monoclonal Antibody, Administered Subcutaneously, in Subjects with Activ... - PT",
        "timestamp": "2012-07-11"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-022243-38/BE",
        "title": "A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study of CNTO 136 (sirukumab), a Human Anti-IL-6 Monoclonal Antibody, Administered Subcutaneously, in Subjects with Activ... - BE",
        "timestamp": "2012-07-11"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-022243-38/IT",
        "title": "A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study of CNTO 136 (sirukumab), a Human Anti-IL-6 Monoclonal Antibody, Administered Subcutaneously, in Subjects with Activ... - IT",
        "timestamp": "2012-07-11"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-022243-38/NL",
        "title": "A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study of CNTO 136 (sirukumab), a Human Anti-IL-6 Monoclonal Antibody, Administered Subcutaneously, in Subjects with Activ... - NL",
        "timestamp": "2012-07-11"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-022243-38/results",
        "title": "A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study of CNTO 136 (sirukumab), a Human Anti-IL-6 Monoclonal Antibody, Administered Subcutaneously, in Subjects with Activ... - View results",
        "timestamp": "2012-07-11"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-005525-11/DE",
        "title": "A randomized, placebo controlled, double-blind, parallel group study to compare the safety and reduction in disease activity with the combination of rituximab (MabThera) and tocilizumab (Actemra) v... - DE",
        "timestamp": "2009-04-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-005525-11/ES",
        "title": "A randomized, placebo controlled, double-blind, parallel group study to compare the safety and reduction in disease activity with the combination of rituximab (MabThera) and tocilizumab (Actemra) v... - ES",
        "timestamp": "2009-04-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-005525-11/NL",
        "title": "A randomized, placebo controlled, double-blind, parallel group study to compare the safety and reduction in disease activity with the combination of rituximab (MabThera) and tocilizumab (Actemra) v... - NL",
        "timestamp": "2009-04-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-005525-11/GB",
        "title": "A randomized, placebo controlled, double-blind, parallel group study to compare the safety and reduction in disease activity with the combination of rituximab (MabThera) and tocilizumab (Actemra) v... - GB",
        "timestamp": "2009-04-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-005525-11/FR",
        "title": "A randomized, placebo controlled, double-blind, parallel group study to compare the safety and reduction in disease activity with the combination of rituximab (MabThera) and tocilizumab (Actemra) v... - FR",
        "timestamp": "2009-04-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-005525-11/GR",
        "title": "A randomized, placebo controlled, double-blind, parallel group study to compare the safety and reduction in disease activity with the combination of rituximab (MabThera) and tocilizumab (Actemra) v... - GR",
        "timestamp": "2009-04-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-023782-22/ES",
        "title": "A PHASE 2, RANDOMIZED, DOUBLE-BLIND ASSESSMENT OF EFFICACY AND SAFETY OF PF-04171327(1, 5, 10, 15 MG DOSE, DAILY) COMPARED TO 5 MG AND 10 MG PREDNISONE DAILY AND PLACEBO DAILY IN SUBJECTS WITH RHEU... - ES",
        "timestamp": "2011-12-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-023782-22/CZ",
        "title": "A PHASE 2, RANDOMIZED, DOUBLE-BLIND ASSESSMENT OF EFFICACY AND SAFETY OF PF-04171327(1, 5, 10, 15 MG DOSE, DAILY) COMPARED TO 5 MG AND 10 MG PREDNISONE DAILY AND PLACEBO DAILY IN SUBJECTS WITH RHEU... - CZ",
        "timestamp": "2011-12-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-023782-22/DE",
        "title": "A PHASE 2, RANDOMIZED, DOUBLE-BLIND ASSESSMENT OF EFFICACY AND SAFETY OF PF-04171327(1, 5, 10, 15 MG DOSE, DAILY) COMPARED TO 5 MG AND 10 MG PREDNISONE DAILY AND PLACEBO DAILY IN SUBJECTS WITH RHEU... - DE",
        "timestamp": "2011-12-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-023782-22/HU",
        "title": "A PHASE 2, RANDOMIZED, DOUBLE-BLIND ASSESSMENT OF EFFICACY AND SAFETY OF PF-04171327(1, 5, 10, 15 MG DOSE, DAILY) COMPARED TO 5 MG AND 10 MG PREDNISONE DAILY AND PLACEBO DAILY IN SUBJECTS WITH RHEU... - HU",
        "timestamp": "2011-12-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-023782-22/SK",
        "title": "A PHASE 2, RANDOMIZED, DOUBLE-BLIND ASSESSMENT OF EFFICACY AND SAFETY OF PF-04171327(1, 5, 10, 15 MG DOSE, DAILY) COMPARED TO 5 MG AND 10 MG PREDNISONE DAILY AND PLACEBO DAILY IN SUBJECTS WITH RHEU... - SK",
        "timestamp": "2011-12-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-023782-22/BG",
        "title": "A PHASE 2, RANDOMIZED, DOUBLE-BLIND ASSESSMENT OF EFFICACY AND SAFETY OF PF-04171327(1, 5, 10, 15 MG DOSE, DAILY) COMPARED TO 5 MG AND 10 MG PREDNISONE DAILY AND PLACEBO DAILY IN SUBJECTS WITH RHEU... - BG",
        "timestamp": "2011-12-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-023782-22/results",
        "title": "A PHASE 2, RANDOMIZED, DOUBLE-BLIND ASSESSMENT OF EFFICACY AND SAFETY OF PF-04171327(1, 5, 10, 15 MG DOSE, DAILY) COMPARED TO 5 MG AND 10 MG PREDNISONE DAILY AND PLACEBO DAILY IN SUBJECTS WITH RHEU... - View results",
        "timestamp": "2011-12-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-000868-18/GB",
        "title": "A 24-week, phase 3, multicentre, randomised, double-blind, efficacy and safety study, comparing GSK3196165 with placebo and with sarilumab, in combination with conventional synthetic DMARDs, in par... - GB",
        "timestamp": "2019-12-02"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-000868-18/PL",
        "title": "A 24-week, phase 3, multicentre, randomised, double-blind, efficacy and safety study, comparing GSK3196165 with placebo and with sarilumab, in combination with conventional synthetic DMARDs, in par... - PL",
        "timestamp": "2019-12-02"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-000868-18/LT",
        "title": "A 24-week, phase 3, multicentre, randomised, double-blind, efficacy and safety study, comparing GSK3196165 with placebo and with sarilumab, in combination with conventional synthetic DMARDs, in par... - LT",
        "timestamp": "2019-12-02"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-000868-18/ES",
        "title": "A 24-week, phase 3, multicentre, randomised, double-blind, efficacy and safety study, comparing GSK3196165 with placebo and with sarilumab, in combination with conventional synthetic DMARDs, in par... - ES",
        "timestamp": "2019-12-02"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-000868-18/CZ",
        "title": "A 24-week, phase 3, multicentre, randomised, double-blind, efficacy and safety study, comparing GSK3196165 with placebo and with sarilumab, in combination with conventional synthetic DMARDs, in par... - CZ",
        "timestamp": "2019-12-02"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-000868-18/HU",
        "title": "A 24-week, phase 3, multicentre, randomised, double-blind, efficacy and safety study, comparing GSK3196165 with placebo and with sarilumab, in combination with conventional synthetic DMARDs, in par... - HU",
        "timestamp": "2019-12-02"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-004175-12/HU",
        "title": "A PHASE 2B, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTICENTER, DOSE RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY PROFILE OF PF-06700841 IN PARTICIPANTS WITH ACTIVE SYSTEMIC LUPUS ERYTH... - HU",
        "timestamp": "2019-09-23"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-004175-12/BG",
        "title": "A PHASE 2B, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTICENTER, DOSE RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY PROFILE OF PF-06700841 IN PARTICIPANTS WITH ACTIVE SYSTEMIC LUPUS ERYTH... - BG",
        "timestamp": "2019-09-23"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-004175-12/PT",
        "title": "A PHASE 2B, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTICENTER, DOSE RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY PROFILE OF PF-06700841 IN PARTICIPANTS WITH ACTIVE SYSTEMIC LUPUS ERYTH... - PT",
        "timestamp": "2019-09-23"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-004175-12/DE",
        "title": "A PHASE 2B, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTICENTER, DOSE RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY PROFILE OF PF-06700841 IN PARTICIPANTS WITH ACTIVE SYSTEMIC LUPUS ERYTH... - DE",
        "timestamp": "2019-09-23"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-004175-12/PL",
        "title": "A PHASE 2B, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTICENTER, DOSE RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY PROFILE OF PF-06700841 IN PARTICIPANTS WITH ACTIVE SYSTEMIC LUPUS ERYTH... - PL",
        "timestamp": "2019-09-23"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-004175-12/ES",
        "title": "A PHASE 2B, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTICENTER, DOSE RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY PROFILE OF PF-06700841 IN PARTICIPANTS WITH ACTIVE SYSTEMIC LUPUS ERYTH... - ES",
        "timestamp": "2019-09-23"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020744-35/GB",
        "title": "A Phase III, Multi-Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study of Two Dosing Regimens of Fostamatinib Disodium in Rheumatoid Arthritis Patients with an  Inadequate Re... - GB",
        "timestamp": "2010-10-26"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020744-35/DE",
        "title": "A Phase III, Multi-Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study of Two Dosing Regimens of Fostamatinib Disodium in Rheumatoid Arthritis Patients with an  Inadequate Re... - DE",
        "timestamp": "2010-10-26"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020744-35/LV",
        "title": "A Phase III, Multi-Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study of Two Dosing Regimens of Fostamatinib Disodium in Rheumatoid Arthritis Patients with an  Inadequate Re... - LV",
        "timestamp": "2010-10-26"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020744-35/LT",
        "title": "A Phase III, Multi-Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study of Two Dosing Regimens of Fostamatinib Disodium in Rheumatoid Arthritis Patients with an  Inadequate Re... - LT",
        "timestamp": "2010-10-26"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020744-35/CZ",
        "title": "A Phase III, Multi-Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study of Two Dosing Regimens of Fostamatinib Disodium in Rheumatoid Arthritis Patients with an  Inadequate Re... - CZ",
        "timestamp": "2010-10-26"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020744-35/PT",
        "title": "A Phase III, Multi-Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study of Two Dosing Regimens of Fostamatinib Disodium in Rheumatoid Arthritis Patients with an  Inadequate Re... - PT",
        "timestamp": "2010-10-26"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020744-35/ES",
        "title": "A Phase III, Multi-Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study of Two Dosing Regimens of Fostamatinib Disodium in Rheumatoid Arthritis Patients with an  Inadequate Re... - ES",
        "timestamp": "2010-10-26"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020744-35/IT",
        "title": "A Phase III, Multi-Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study of Two Dosing Regimens of Fostamatinib Disodium in Rheumatoid Arthritis Patients with an  Inadequate Re... - IT",
        "timestamp": "2010-10-26"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020744-35/results",
        "title": "A Phase III, Multi-Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study of Two Dosing Regimens of Fostamatinib Disodium in Rheumatoid Arthritis Patients with an  Inadequate Re... - View results",
        "timestamp": "2010-10-26"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-022242-24/LT",
        "title": "A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study of CNTO 136 (sirukumab), a Human Anti-IL-6 Monoclonal Antibody, Administered Subcutaneously, in Subjects with Activ... - LT",
        "timestamp": "2012-07-11"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-022242-24/BG",
        "title": "A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study of CNTO 136 (sirukumab), a Human Anti-IL-6 Monoclonal Antibody, Administered Subcutaneously, in Subjects with Activ... - BG",
        "timestamp": "2012-07-11"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-022242-24/results",
        "title": "A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study of CNTO 136 (sirukumab), a Human Anti-IL-6 Monoclonal Antibody, Administered Subcutaneously, in Subjects with Activ... - View results",
        "timestamp": "2012-07-11"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-007859-14/HU",
        "title": "A 12-WEEK, PHASE 2, RANDOMIZED, DOUBLE-BLIND, MULTICENTER, PLACEBO CONTROLLED STUDY TO INVESTIGATE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF ARRY-438162, ADMINISTERED ORALLY DAILY IN PATIENTS WI... - HU",
        "timestamp": "2008-05-22"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-007859-14/PL",
        "title": "A 12-WEEK, PHASE 2, RANDOMIZED, DOUBLE-BLIND, MULTICENTER, PLACEBO CONTROLLED STUDY TO INVESTIGATE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF ARRY-438162, ADMINISTERED ORALLY DAILY IN PATIENTS WI... - PL",
        "timestamp": "2008-05-22"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-007859-14/results",
        "title": "A 12-WEEK, PHASE 2, RANDOMIZED, DOUBLE-BLIND, MULTICENTER, PLACEBO CONTROLLED STUDY TO INVESTIGATE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF ARRY-438162, ADMINISTERED ORALLY DAILY IN PATIENTS WI... - View results",
        "timestamp": "2008-05-22"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-000305-23/BG",
        "title": "A Randomized Double-Blind Phase 1b/2 Combined Staggered Multiple Dose Escalation Study of BOS161721 in Systemic Lupus Erythematosus (SLE) Patients on a Background of Limited Standard of Care - BG",
        "timestamp": "2019-03-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-000305-23/HU",
        "title": "A Randomized Double-Blind Phase 1b/2 Combined Staggered Multiple Dose Escalation Study of BOS161721 in Systemic Lupus Erythematosus (SLE) Patients on a Background of Limited Standard of Care - HU",
        "timestamp": "2019-03-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-003140-39/BG",
        "title": "A Multicenter, Randomized, Double-blind, PlacebO-controlled, Parallel-group Study to EValuate the Efficacy and Safety of JTE-051 Administered for 12 Weeks to Subjects with Active Rheumatoid Arthrit... - BG",
        "timestamp": "2016-12-05"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-003140-39/PL",
        "title": "A Multicenter, Randomized, Double-blind, PlacebO-controlled, Parallel-group Study to EValuate the Efficacy and Safety of JTE-051 Administered for 12 Weeks to Subjects with Active Rheumatoid Arthrit... - PL",
        "timestamp": "2016-12-05"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-003140-39/results",
        "title": "A Multicenter, Randomized, Double-blind, PlacebO-controlled, Parallel-group Study to EValuate the Efficacy and Safety of JTE-051 Administered for 12 Weeks to Subjects with Active Rheumatoid Arthrit... - View results",
        "timestamp": "2016-12-05"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-004187-56/DE",
        "title": "International cooperative Phase III trial of the HIT-HGG study group for the treatment of high grade glioma, diffuse intrinsic pontine glioma, and gliomatosis cerebri in children and adolescents < ... - DE",
        "timestamp": "2017-04-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-002846-36/DE",
        "title": "A PHASE 2A, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO COMPARE 3 DOSE LEVELS OF CP 690,550 VERSUS PLACEBO,  ADMINISTERED ORALLY TWICE DAILY (BID) FOR 6 WEEKS, IN THE TREATME... - DE",
        "timestamp": "2005-06-14"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-002846-36/IT",
        "title": "A PHASE 2A, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO COMPARE 3 DOSE LEVELS OF CP 690,550 VERSUS PLACEBO,  ADMINISTERED ORALLY TWICE DAILY (BID) FOR 6 WEEKS, IN THE TREATME... - IT",
        "timestamp": "2005-06-14"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-002846-36/SK",
        "title": "A PHASE 2A, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO COMPARE 3 DOSE LEVELS OF CP 690,550 VERSUS PLACEBO,  ADMINISTERED ORALLY TWICE DAILY (BID) FOR 6 WEEKS, IN THE TREATME... - SK",
        "timestamp": "2005-06-14"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-002846-36/AT",
        "title": "A PHASE 2A, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO COMPARE 3 DOSE LEVELS OF CP 690,550 VERSUS PLACEBO,  ADMINISTERED ORALLY TWICE DAILY (BID) FOR 6 WEEKS, IN THE TREATME... - AT",
        "timestamp": "2005-06-14"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-002846-36/ES",
        "title": "A PHASE 2A, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO COMPARE 3 DOSE LEVELS OF CP 690,550 VERSUS PLACEBO,  ADMINISTERED ORALLY TWICE DAILY (BID) FOR 6 WEEKS, IN THE TREATME... - ES",
        "timestamp": "2005-06-14"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-002846-36/results",
        "title": "A PHASE 2A, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO COMPARE 3 DOSE LEVELS OF CP 690,550 VERSUS PLACEBO,  ADMINISTERED ORALLY TWICE DAILY (BID) FOR 6 WEEKS, IN THE TREATME... - View results",
        "timestamp": "2005-06-14"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-015978-35/FR",
        "title": "Etude ouverte de phase 2 de 52 semaines visant à établir l'efficacité et la tolérance du Belimumab (HGS1006, LymphoStat-B), un anticorps monoclonal humanisé anti-BLys (BAFF), chez des patients att... - FR",
        "timestamp": "2009-11-30"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020423-51/DE",
        "title": "Remission Induction by Etanercept in Enthesitis related Arthritis JIA-Patients (juvenile undifferentiated Spondylarthropathy) - DE",
        "timestamp": "2011-02-17"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003724-20/HU",
        "title": "A Phase 2, Double-Blind, Parallel, Placebo-Controlled, Randomized Study to Evaluate Multiple Dose Levels of IPI- 145 with Background Methotrexate in Subjects with Active Rheumatoid Arthritis and an... - HU",
        "timestamp": "2013-02-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003724-20/DE",
        "title": "A Phase 2, Double-Blind, Parallel, Placebo-Controlled, Randomized Study to Evaluate Multiple Dose Levels of IPI- 145 with Background Methotrexate in Subjects with Active Rheumatoid Arthritis and an... - DE",
        "timestamp": "2013-02-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003724-20/BG",
        "title": "A Phase 2, Double-Blind, Parallel, Placebo-Controlled, Randomized Study to Evaluate Multiple Dose Levels of IPI- 145 with Background Methotrexate in Subjects with Active Rheumatoid Arthritis and an... - BG",
        "timestamp": "2013-02-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003724-20/RO",
        "title": "A Phase 2, Double-Blind, Parallel, Placebo-Controlled, Randomized Study to Evaluate Multiple Dose Levels of IPI- 145 with Background Methotrexate in Subjects with Active Rheumatoid Arthritis and an... - RO",
        "timestamp": "2013-02-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003724-20/results",
        "title": "A Phase 2, Double-Blind, Parallel, Placebo-Controlled, Randomized Study to Evaluate Multiple Dose Levels of IPI- 145 with Background Methotrexate in Subjects with Active Rheumatoid Arthritis and an... - View results",
        "timestamp": "2013-02-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-006527-13/BG",
        "title": "A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Finding Study of the Safety and Efficacy of Daily CF101 Administered Orally, When Added to Weekly Methotre... - BG",
        "timestamp": "2008-06-18"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-006527-13/results",
        "title": "A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Finding Study of the Safety and Efficacy of Daily CF101 Administered Orally, When Added to Weekly Methotre... - View results",
        "timestamp": "2008-06-18"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-000743-34/BE",
        "title": "A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Dose Study of R935788 in Patients with Rheumatoid Arthritis Who Have Failed at Least One Biologic - BE",
        "timestamp": "2008-06-18"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-000743-34/FR",
        "title": "A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Dose Study of R935788 in Patients with Rheumatoid Arthritis Who Have Failed at Least One Biologic - FR",
        "timestamp": "2008-06-18"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-000743-34/DE",
        "title": "A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Dose Study of R935788 in Patients with Rheumatoid Arthritis Who Have Failed at Least One Biologic - DE",
        "timestamp": "2008-06-18"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-000743-34/IT",
        "title": "A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Dose Study of R935788 in Patients with Rheumatoid Arthritis Who Have Failed at Least One Biologic - IT",
        "timestamp": "2008-06-18"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-002024-40/ES",
        "title": "A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BMS-817399 in Adults with Active, Moderate to Severe Rheumato... - ES",
        "timestamp": "2012-02-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-002024-40/results",
        "title": "A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BMS-817399 in Adults with Active, Moderate to Severe Rheumato... - View results",
        "timestamp": "2012-02-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-005027-25/ES",
        "title": "A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3\nStudy of Baricitinib in Patients with Systemic Lupus Erythematosus - ES",
        "timestamp": "2018-09-21"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-002132-26/GB",
        "title": "A randomized placebo-controlled, multicenter, blinded Phase I/II study of the safety of escalating single intravenous doses of ocrelizumab (Ro 496-4913, PRO70769, rhuMAb 2H7) in patients with moder... - GB",
        "timestamp": "2008-02-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-002132-26/ES",
        "title": "A randomized placebo-controlled, multicenter, blinded Phase I/II study of the safety of escalating single intravenous doses of ocrelizumab (Ro 496-4913, PRO70769, rhuMAb 2H7) in patients with moder... - ES",
        "timestamp": "2008-02-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-002132-26/results",
        "title": "A randomized placebo-controlled, multicenter, blinded Phase I/II study of the safety of escalating single intravenous doses of ocrelizumab (Ro 496-4913, PRO70769, rhuMAb 2H7) in patients with moder... - View results",
        "timestamp": "2008-02-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-000170-20/FR",
        "title": "A Randomized, Parallel Group, Double-Blind, Placebo Controlled Study to Evaluate the\nClinical Efficacy and Safety of BMS-582949 Given Orally to Subjects with Rheumatoid\nArthritis Having an Inadequa... - FR",
        "timestamp": "2008-06-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-000170-20/CZ",
        "title": "A Randomized, Parallel Group, Double-Blind, Placebo Controlled Study to Evaluate the\nClinical Efficacy and Safety of BMS-582949 Given Orally to Subjects with Rheumatoid\nArthritis Having an Inadequa... - CZ",
        "timestamp": "2008-06-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-000170-20/ES",
        "title": "A Randomized, Parallel Group, Double-Blind, Placebo Controlled Study to Evaluate the\nClinical Efficacy and Safety of BMS-582949 Given Orally to Subjects with Rheumatoid\nArthritis Having an Inadequa... - ES",
        "timestamp": "2008-06-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-000170-20/results",
        "title": "A Randomized, Parallel Group, Double-Blind, Placebo Controlled Study to Evaluate the\nClinical Efficacy and Safety of BMS-582949 Given Orally to Subjects with Rheumatoid\nArthritis Having an Inadequa... - View results",
        "timestamp": "2008-06-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-006070-73/DE",
        "title": "A Multi-Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study of the Effect of Fostamatinib 100 mg Twice Daily on 24-hour Ambulatory Blood Pressure in Patients with Rheumatoid ... - DE",
        "timestamp": "2012-08-28"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-006070-73/CZ",
        "title": "A Multi-Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study of the Effect of Fostamatinib 100 mg Twice Daily on 24-hour Ambulatory Blood Pressure in Patients with Rheumatoid ... - CZ",
        "timestamp": "2012-08-28"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-006070-73/BG",
        "title": "A Multi-Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study of the Effect of Fostamatinib 100 mg Twice Daily on 24-hour Ambulatory Blood Pressure in Patients with Rheumatoid ... - BG",
        "timestamp": "2012-08-28"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-006070-73/results",
        "title": "A Multi-Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study of the Effect of Fostamatinib 100 mg Twice Daily on 24-hour Ambulatory Blood Pressure in Patients with Rheumatoid ... - View results",
        "timestamp": "2012-08-28"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-004808-19/GB",
        "title": "A multi-center, randomized, double-blind, placebo-controlled, parallel group study to assess the safety, tolerability, pharmacokinetics and preliminary efficacy of CFZ533 in patients with primary S... - GB",
        "timestamp": "2014-07-23"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-004808-19/HU",
        "title": "A multi-center, randomized, double-blind, placebo-controlled, parallel group study to assess the safety, tolerability, pharmacokinetics and preliminary efficacy of CFZ533 in patients with primary S... - HU",
        "timestamp": "2014-07-23"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-004808-19/DE",
        "title": "A multi-center, randomized, double-blind, placebo-controlled, parallel group study to assess the safety, tolerability, pharmacokinetics and preliminary efficacy of CFZ533 in patients with primary S... - DE",
        "timestamp": "2014-07-23"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-004808-19/results",
        "title": "A multi-center, randomized, double-blind, placebo-controlled, parallel group study to assess the safety, tolerability, pharmacokinetics and preliminary efficacy of CFZ533 in patients with primary S... - View results",
        "timestamp": "2014-07-23"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-003050-32/DE",
        "title": "A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-\r\nControlled, 104-Week Study to Evaluate the Efficacy and Safety of Belimumab\r\nAdministered in Combination with Rituximab to Adult Subject... - DE",
        "timestamp": "2018-01-09"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-003050-32/NL",
        "title": "A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-\r\nControlled, 104-Week Study to Evaluate the Efficacy and Safety of Belimumab\r\nAdministered in Combination with Rituximab to Adult Subject... - NL",
        "timestamp": "2018-01-09"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-003050-32/ES",
        "title": "A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-\r\nControlled, 104-Week Study to Evaluate the Efficacy and Safety of Belimumab\r\nAdministered in Combination with Rituximab to Adult Subject... - ES",
        "timestamp": "2018-01-09"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-007788-17/CZ",
        "title": "PHASE 3, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF THE EFFICACY AND SAFETY OF 2 DOSES OF CP 690,550 MONOTHERAPY IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS - CZ",
        "timestamp": "2009-05-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-007788-17/DE",
        "title": "PHASE 3, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF THE EFFICACY AND SAFETY OF 2 DOSES OF CP 690,550 MONOTHERAPY IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS - DE",
        "timestamp": "2009-05-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-007788-17/BG",
        "title": "PHASE 3, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF THE EFFICACY AND SAFETY OF 2 DOSES OF CP 690,550 MONOTHERAPY IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS - BG",
        "timestamp": "2009-05-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-007788-17/results",
        "title": "PHASE 3, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF THE EFFICACY AND SAFETY OF 2 DOSES OF CP 690,550 MONOTHERAPY IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS - View results",
        "timestamp": "2009-05-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-001203-79/HU",
        "title": "A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of BMS-986165 in Subjects with Systemic Lupus Erythematosus - HU",
        "timestamp": "2017-12-04"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-001203-79/PL",
        "title": "A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of BMS-986165 in Subjects with Systemic Lupus Erythematosus - PL",
        "timestamp": "2017-12-04"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-001203-79/ES",
        "title": "A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of BMS-986165 in Subjects with Systemic Lupus Erythematosus - ES",
        "timestamp": "2017-12-04"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-001417-32/DE",
        "title": "A Multicenter, Randomized, Double-blind, Parallel Group Study of CNTO 136 (sirukumab) Administered Subcutaneously as Monotherapy Compared With Adalimumab Monotherapy, in Subjects with Active Rheuma... - DE",
        "timestamp": "2014-06-02"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-001417-32/HU",
        "title": "A Multicenter, Randomized, Double-blind, Parallel Group Study of CNTO 136 (sirukumab) Administered Subcutaneously as Monotherapy Compared With Adalimumab Monotherapy, in Subjects with Active Rheuma... - HU",
        "timestamp": "2014-06-02"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-001417-32/LT",
        "title": "A Multicenter, Randomized, Double-blind, Parallel Group Study of CNTO 136 (sirukumab) Administered Subcutaneously as Monotherapy Compared With Adalimumab Monotherapy, in Subjects with Active Rheuma... - LT",
        "timestamp": "2014-06-02"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-001417-32/ES",
        "title": "A Multicenter, Randomized, Double-blind, Parallel Group Study of CNTO 136 (sirukumab) Administered Subcutaneously as Monotherapy Compared With Adalimumab Monotherapy, in Subjects with Active Rheuma... - ES",
        "timestamp": "2014-06-02"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-001417-32/BG",
        "title": "A Multicenter, Randomized, Double-blind, Parallel Group Study of CNTO 136 (sirukumab) Administered Subcutaneously as Monotherapy Compared With Adalimumab Monotherapy, in Subjects with Active Rheuma... - BG",
        "timestamp": "2014-06-02"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-001417-32/results",
        "title": "A Multicenter, Randomized, Double-blind, Parallel Group Study of CNTO 136 (sirukumab) Administered Subcutaneously as Monotherapy Compared With Adalimumab Monotherapy, in Subjects with Active Rheuma... - View results",
        "timestamp": "2014-06-02"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-004574-17/ES",
        "title": "A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLEBLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-220 IN SUBJECTS WITH ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS - ES",
        "timestamp": "2017-06-08"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-004574-17/HU",
        "title": "A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLEBLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-220 IN SUBJECTS WITH ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS - HU",
        "timestamp": "2017-06-08"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-004574-17/DE",
        "title": "A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLEBLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-220 IN SUBJECTS WITH ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS - DE",
        "timestamp": "2017-06-08"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-004574-17/BE",
        "title": "A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLEBLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-220 IN SUBJECTS WITH ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS - BE",
        "timestamp": "2017-06-08"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-004574-17/FR",
        "title": "A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLEBLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-220 IN SUBJECTS WITH ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS - FR",
        "timestamp": "2017-06-08"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-006018-15/BE",
        "title": "A Phase 2b, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Dose-Finding, Multi-Center Study to Evaluate the Safety and Efficacy of ASP015K in Moderate to Severe Rheumatoid Arthritis ... - BE",
        "timestamp": "2012-07-28"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-006018-15/CZ",
        "title": "A Phase 2b, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Dose-Finding, Multi-Center Study to Evaluate the Safety and Efficacy of ASP015K in Moderate to Severe Rheumatoid Arthritis ... - CZ",
        "timestamp": "2012-07-28"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-006018-15/PL",
        "title": "A Phase 2b, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Dose-Finding, Multi-Center Study to Evaluate the Safety and Efficacy of ASP015K in Moderate to Severe Rheumatoid Arthritis ... - PL",
        "timestamp": "2012-07-28"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-006018-15/HU",
        "title": "A Phase 2b, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Dose-Finding, Multi-Center Study to Evaluate the Safety and Efficacy of ASP015K in Moderate to Severe Rheumatoid Arthritis ... - HU",
        "timestamp": "2012-07-28"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-006018-15/BG",
        "title": "A Phase 2b, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Dose-Finding, Multi-Center Study to Evaluate the Safety and Efficacy of ASP015K in Moderate to Severe Rheumatoid Arthritis ... - BG",
        "timestamp": "2012-07-28"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-006018-15/results",
        "title": "A Phase 2b, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Dose-Finding, Multi-Center Study to Evaluate the Safety and Efficacy of ASP015K in Moderate to Severe Rheumatoid Arthritis ... - View results",
        "timestamp": "2012-07-28"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-005036-24/SE",
        "title": "A PHASE 2B, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, MULTICENTER STUDY TO COMPARE 6 DOSE REGIMENS OF CP 690,550 VS. PLACEBO, EACH COMBINED WITH METHOTREXATE, ADMINISTERED FOR 6 MONTHS IN THE T... - SE",
        "timestamp": "2007-05-04"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-005036-24/SK",
        "title": "A PHASE 2B, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, MULTICENTER STUDY TO COMPARE 6 DOSE REGIMENS OF CP 690,550 VS. PLACEBO, EACH COMBINED WITH METHOTREXATE, ADMINISTERED FOR 6 MONTHS IN THE T... - SK",
        "timestamp": "2007-05-04"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-005036-24/CZ",
        "title": "A PHASE 2B, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, MULTICENTER STUDY TO COMPARE 6 DOSE REGIMENS OF CP 690,550 VS. PLACEBO, EACH COMBINED WITH METHOTREXATE, ADMINISTERED FOR 6 MONTHS IN THE T... - CZ",
        "timestamp": "2007-05-04"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-005036-24/HU",
        "title": "A PHASE 2B, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, MULTICENTER STUDY TO COMPARE 6 DOSE REGIMENS OF CP 690,550 VS. PLACEBO, EACH COMBINED WITH METHOTREXATE, ADMINISTERED FOR 6 MONTHS IN THE T... - HU",
        "timestamp": "2007-05-04"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-005036-24/BG",
        "title": "A PHASE 2B, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, MULTICENTER STUDY TO COMPARE 6 DOSE REGIMENS OF CP 690,550 VS. PLACEBO, EACH COMBINED WITH METHOTREXATE, ADMINISTERED FOR 6 MONTHS IN THE T... - BG",
        "timestamp": "2007-05-04"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-005036-24/results",
        "title": "A PHASE 2B, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, MULTICENTER STUDY TO COMPARE 6 DOSE REGIMENS OF CP 690,550 VS. PLACEBO, EACH COMBINED WITH METHOTREXATE, ADMINISTERED FOR 6 MONTHS IN THE T... - View results",
        "timestamp": "2007-05-04"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-005028-11/GB",
        "title": "A Phase 3, Double-Blind, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients with Systemic Lupus Erythematosus (SLE) - GB",
        "timestamp": "2019-10-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-005028-11/CZ",
        "title": "A Phase 3, Double-Blind, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients with Systemic Lupus Erythematosus (SLE) - CZ",
        "timestamp": "2019-10-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-005028-11/AT",
        "title": "A Phase 3, Double-Blind, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients with Systemic Lupus Erythematosus (SLE) - AT",
        "timestamp": "2019-10-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-005028-11/HU",
        "title": "A Phase 3, Double-Blind, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients with Systemic Lupus Erythematosus (SLE) - HU",
        "timestamp": "2019-10-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-005028-11/PL",
        "title": "A Phase 3, Double-Blind, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients with Systemic Lupus Erythematosus (SLE) - PL",
        "timestamp": "2019-10-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-005028-11/ES",
        "title": "A Phase 3, Double-Blind, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients with Systemic Lupus Erythematosus (SLE) - ES",
        "timestamp": "2019-10-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-005177-21/GB",
        "title": "A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled 76 week Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-BLyS Ant... - GB",
        "timestamp": "2007-05-29"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-005177-21/BE",
        "title": "A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled 76 week Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-BLyS Ant... - BE",
        "timestamp": "2007-05-29"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-005177-21/DE",
        "title": "A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled 76 week Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-BLyS Ant... - DE",
        "timestamp": "2007-05-29"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-005177-21/AT",
        "title": "A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled 76 week Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-BLyS Ant... - AT",
        "timestamp": "2007-05-29"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-005177-21/CZ",
        "title": "A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled 76 week Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-BLyS Ant... - CZ",
        "timestamp": "2007-05-29"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-005177-21/ES",
        "title": "A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled 76 week Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-BLyS Ant... - ES",
        "timestamp": "2007-05-29"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-005177-21/SK",
        "title": "A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled 76 week Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-BLyS Ant... - SK",
        "timestamp": "2007-05-29"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-005177-21/SE",
        "title": "A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled 76 week Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-BLyS Ant... - SE",
        "timestamp": "2007-05-29"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-005177-21/NL",
        "title": "A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled 76 week Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-BLyS Ant... - NL",
        "timestamp": "2007-05-29"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-005177-21/IT",
        "title": "A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled 76 week Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-BLyS Ant... - IT",
        "timestamp": "2007-05-29"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-005177-21/FR",
        "title": "A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled 76 week Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-BLyS Ant... - FR",
        "timestamp": "2007-05-29"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-005177-21/results",
        "title": "A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled 76 week Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-BLyS Ant... - View results",
        "timestamp": "2007-05-29"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-012520-84/HU",
        "title": "A 2-Part Open-label Study to Assess the Clinical Benefit and Long-term Safety of Etanercept in Children and Adolescents With Extended Oligoarticular Juvenile Idiopathic Arthritis, Enthesitis-Relate... - HU",
        "timestamp": "2009-08-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-012520-84/DE",
        "title": "A 2-Part Open-label Study to Assess the Clinical Benefit and Long-term Safety of Etanercept in Children and Adolescents With Extended Oligoarticular Juvenile Idiopathic Arthritis, Enthesitis-Relate... - DE",
        "timestamp": "2009-08-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-012520-84/BE",
        "title": "A 2-Part Open-label Study to Assess the Clinical Benefit and Long-term Safety of Etanercept in Children and Adolescents With Extended Oligoarticular Juvenile Idiopathic Arthritis, Enthesitis-Relate... - BE",
        "timestamp": "2009-08-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-012520-84/CZ",
        "title": "A 2-Part Open-label Study to Assess the Clinical Benefit and Long-term Safety of Etanercept in Children and Adolescents With Extended Oligoarticular Juvenile Idiopathic Arthritis, Enthesitis-Relate... - CZ",
        "timestamp": "2009-08-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-012520-84/FR",
        "title": "A 2-Part Open-label Study to Assess the Clinical Benefit and Long-term Safety of Etanercept in Children and Adolescents With Extended Oligoarticular Juvenile Idiopathic Arthritis, Enthesitis-Relate... - FR",
        "timestamp": "2009-08-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-012520-84/SI",
        "title": "A 2-Part Open-label Study to Assess the Clinical Benefit and Long-term Safety of Etanercept in Children and Adolescents With Extended Oligoarticular Juvenile Idiopathic Arthritis, Enthesitis-Relate... - SI",
        "timestamp": "2009-08-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-012520-84/ES",
        "title": "A 2-Part Open-label Study to Assess the Clinical Benefit and Long-term Safety of Etanercept in Children and Adolescents With Extended Oligoarticular Juvenile Idiopathic Arthritis, Enthesitis-Relate... - ES",
        "timestamp": "2009-08-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-012520-84/SE",
        "title": "A 2-Part Open-label Study to Assess the Clinical Benefit and Long-term Safety of Etanercept in Children and Adolescents With Extended Oligoarticular Juvenile Idiopathic Arthritis, Enthesitis-Relate... - SE",
        "timestamp": "2009-08-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-012520-84/SK",
        "title": "A 2-Part Open-label Study to Assess the Clinical Benefit and Long-term Safety of Etanercept in Children and Adolescents With Extended Oligoarticular Juvenile Idiopathic Arthritis, Enthesitis-Relate... - SK",
        "timestamp": "2009-08-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-012520-84/LT",
        "title": "A 2-Part Open-label Study to Assess the Clinical Benefit and Long-term Safety of Etanercept in Children and Adolescents With Extended Oligoarticular Juvenile Idiopathic Arthritis, Enthesitis-Relate... - LT",
        "timestamp": "2009-08-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-012520-84/NL",
        "title": "A 2-Part Open-label Study to Assess the Clinical Benefit and Long-term Safety of Etanercept in Children and Adolescents With Extended Oligoarticular Juvenile Idiopathic Arthritis, Enthesitis-Relate... - NL",
        "timestamp": "2009-08-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-012520-84/LV",
        "title": "A 2-Part Open-label Study to Assess the Clinical Benefit and Long-term Safety of Etanercept in Children and Adolescents With Extended Oligoarticular Juvenile Idiopathic Arthritis, Enthesitis-Relate... - LV",
        "timestamp": "2009-08-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-012520-84/GR",
        "title": "A 2-Part Open-label Study to Assess the Clinical Benefit and Long-term Safety of Etanercept in Children and Adolescents With Extended Oligoarticular Juvenile Idiopathic Arthritis, Enthesitis-Relate... - GR",
        "timestamp": "2009-08-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-012520-84/DK",
        "title": "A 2-Part Open-label Study to Assess the Clinical Benefit and Long-term Safety of Etanercept in Children and Adolescents With Extended Oligoarticular Juvenile Idiopathic Arthritis, Enthesitis-Relate... - DK",
        "timestamp": "2009-08-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-012520-84/IT",
        "title": "A 2-Part Open-label Study to Assess the Clinical Benefit and Long-term Safety of Etanercept in Children and Adolescents With Extended Oligoarticular Juvenile Idiopathic Arthritis, Enthesitis-Relate... - IT",
        "timestamp": "2009-08-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-012520-84/3rd",
        "title": "A 2-Part Open-label Study to Assess the Clinical Benefit and Long-term Safety of Etanercept in Children and Adolescents With Extended Oligoarticular Juvenile Idiopathic Arthritis, Enthesitis-Relate... - Outside EU/EEA",
        "timestamp": "2009-08-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-012520-84/results",
        "title": "A 2-Part Open-label Study to Assess the Clinical Benefit and Long-term Safety of Etanercept in Children and Adolescents With Extended Oligoarticular Juvenile Idiopathic Arthritis, Enthesitis-Relate... - View results",
        "timestamp": "2009-08-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-010714-30/DE",
        "title": "A Phase 2, Multicenter, Randomized, Double blind, Parallel group, Placebo controlled Study Evaluating the Safety and Efficacy of Treatment with Ustekinumab or Golimumab in Subjects with Chronic Sar... - DE",
        "timestamp": "2009-10-23"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-010714-30/BE",
        "title": "A Phase 2, Multicenter, Randomized, Double blind, Parallel group, Placebo controlled Study Evaluating the Safety and Efficacy of Treatment with Ustekinumab or Golimumab in Subjects with Chronic Sar... - BE",
        "timestamp": "2009-10-23"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-010714-30/GB",
        "title": "A Phase 2, Multicenter, Randomized, Double blind, Parallel group, Placebo controlled Study Evaluating the Safety and Efficacy of Treatment with Ustekinumab or Golimumab in Subjects with Chronic Sar... - GB",
        "timestamp": "2009-10-23"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-010714-30/DK",
        "title": "A Phase 2, Multicenter, Randomized, Double blind, Parallel group, Placebo controlled Study Evaluating the Safety and Efficacy of Treatment with Ustekinumab or Golimumab in Subjects with Chronic Sar... - DK",
        "timestamp": "2009-10-23"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-010714-30/FR",
        "title": "A Phase 2, Multicenter, Randomized, Double blind, Parallel group, Placebo controlled Study Evaluating the Safety and Efficacy of Treatment with Ustekinumab or Golimumab in Subjects with Chronic Sar... - FR",
        "timestamp": "2009-10-23"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-010714-30/IT",
        "title": "A Phase 2, Multicenter, Randomized, Double blind, Parallel group, Placebo controlled Study Evaluating the Safety and Efficacy of Treatment with Ustekinumab or Golimumab in Subjects with Chronic Sar... - IT",
        "timestamp": "2009-10-23"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-010714-30/NL",
        "title": "A Phase 2, Multicenter, Randomized, Double blind, Parallel group, Placebo controlled Study Evaluating the Safety and Efficacy of Treatment with Ustekinumab or Golimumab in Subjects with Chronic Sar... - NL",
        "timestamp": "2009-10-23"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-010714-30/results",
        "title": "A Phase 2, Multicenter, Randomized, Double blind, Parallel group, Placebo controlled Study Evaluating the Safety and Efficacy of Treatment with Ustekinumab or Golimumab in Subjects with Chronic Sar... - View results",
        "timestamp": "2009-10-23"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-014296-40/DE",
        "title": "PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE SAFETY AND EFFICACY OF 2 DOSES OF CP-690,550 IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS ON BACKGROUND METHOTREXATE WITH INADEQUA... - DE",
        "timestamp": "2009-11-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-014296-40/ES",
        "title": "PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE SAFETY AND EFFICACY OF 2 DOSES OF CP-690,550 IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS ON BACKGROUND METHOTREXATE WITH INADEQUA... - ES",
        "timestamp": "2009-11-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-014296-40/IE",
        "title": "PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE SAFETY AND EFFICACY OF 2 DOSES OF CP-690,550 IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS ON BACKGROUND METHOTREXATE WITH INADEQUA... - IE",
        "timestamp": "2009-11-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-014296-40/BE",
        "title": "PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE SAFETY AND EFFICACY OF 2 DOSES OF CP-690,550 IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS ON BACKGROUND METHOTREXATE WITH INADEQUA... - BE",
        "timestamp": "2009-11-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-014296-40/FR",
        "title": "PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE SAFETY AND EFFICACY OF 2 DOSES OF CP-690,550 IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS ON BACKGROUND METHOTREXATE WITH INADEQUA... - FR",
        "timestamp": "2009-11-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-014296-40/AT",
        "title": "PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE SAFETY AND EFFICACY OF 2 DOSES OF CP-690,550 IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS ON BACKGROUND METHOTREXATE WITH INADEQUA... - AT",
        "timestamp": "2009-11-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-014296-40/IT",
        "title": "PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE SAFETY AND EFFICACY OF 2 DOSES OF CP-690,550 IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS ON BACKGROUND METHOTREXATE WITH INADEQUA... - IT",
        "timestamp": "2009-11-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-014296-40/GB",
        "title": "PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE SAFETY AND EFFICACY OF 2 DOSES OF CP-690,550 IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS ON BACKGROUND METHOTREXATE WITH INADEQUA... - GB",
        "timestamp": "2009-11-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-014296-40/results",
        "title": "PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE SAFETY AND EFFICACY OF 2 DOSES OF CP-690,550 IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS ON BACKGROUND METHOTREXATE WITH INADEQUA... - View results",
        "timestamp": "2009-11-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-000368-88/GB",
        "title": "A Multi-center, Randomized Parallel Group, Placebo-Controlled Double-Blind Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of Belimumab, a Human Monoclonal Anti-BLyS Antibody, Plus Sta... - GB",
        "timestamp": "2012-06-13"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-000368-88/ES",
        "title": "A Multi-center, Randomized Parallel Group, Placebo-Controlled Double-Blind Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of Belimumab, a Human Monoclonal Anti-BLyS Antibody, Plus Sta... - ES",
        "timestamp": "2012-06-13"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-000368-88/PL",
        "title": "A Multi-center, Randomized Parallel Group, Placebo-Controlled Double-Blind Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of Belimumab, a Human Monoclonal Anti-BLyS Antibody, Plus Sta... - PL",
        "timestamp": "2012-06-13"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-000368-88/NL",
        "title": "A Multi-center, Randomized Parallel Group, Placebo-Controlled Double-Blind Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of Belimumab, a Human Monoclonal Anti-BLyS Antibody, Plus Sta... - NL",
        "timestamp": "2012-06-13"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-000368-88/IT",
        "title": "A Multi-center, Randomized Parallel Group, Placebo-Controlled Double-Blind Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of Belimumab, a Human Monoclonal Anti-BLyS Antibody, Plus Sta... - IT",
        "timestamp": "2012-06-13"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-000368-88/3rd",
        "title": "A Multi-center, Randomized Parallel Group, Placebo-Controlled Double-Blind Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of Belimumab, a Human Monoclonal Anti-BLyS Antibody, Plus Sta... - Outside EU/EEA",
        "timestamp": "2012-06-13"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-000368-88/results",
        "title": "A Multi-center, Randomized Parallel Group, Placebo-Controlled Double-Blind Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of Belimumab, a Human Monoclonal Anti-BLyS Antibody, Plus Sta... - View results",
        "timestamp": "2012-06-13"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-004633-96/GB",
        "title": "A Multicentre, Randomised, Double-blind, Placebo-controlled, Phase 3 Study Evaluating the Efficacy and Safety of Two Doses of Anifrolumab in Adult Subjects with Active Systemic Lupus Erythematosus - GB",
        "timestamp": "2015-07-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-004633-96/DE",
        "title": "A Multicentre, Randomised, Double-blind, Placebo-controlled, Phase 3 Study Evaluating the Efficacy and Safety of Two Doses of Anifrolumab in Adult Subjects with Active Systemic Lupus Erythematosus - DE",
        "timestamp": "2015-07-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-004633-96/HU",
        "title": "A Multicentre, Randomised, Double-blind, Placebo-controlled, Phase 3 Study Evaluating the Efficacy and Safety of Two Doses of Anifrolumab in Adult Subjects with Active Systemic Lupus Erythematosus - HU",
        "timestamp": "2015-07-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-004633-96/PL",
        "title": "A Multicentre, Randomised, Double-blind, Placebo-controlled, Phase 3 Study Evaluating the Efficacy and Safety of Two Doses of Anifrolumab in Adult Subjects with Active Systemic Lupus Erythematosus - PL",
        "timestamp": "2015-07-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-004633-96/RO",
        "title": "A Multicentre, Randomised, Double-blind, Placebo-controlled, Phase 3 Study Evaluating the Efficacy and Safety of Two Doses of Anifrolumab in Adult Subjects with Active Systemic Lupus Erythematosus - RO",
        "timestamp": "2015-07-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-004633-96/IT",
        "title": "A Multicentre, Randomised, Double-blind, Placebo-controlled, Phase 3 Study Evaluating the Efficacy and Safety of Two Doses of Anifrolumab in Adult Subjects with Active Systemic Lupus Erythematosus - IT",
        "timestamp": "2015-07-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-004633-96/results",
        "title": "A Multicentre, Randomised, Double-blind, Placebo-controlled, Phase 3 Study Evaluating the Efficacy and Safety of Two Doses of Anifrolumab in Adult Subjects with Active Systemic Lupus Erythematosus - View results",
        "timestamp": "2015-07-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-004915-22/HU",
        "title": "A LONG-TERM, OPEN-LABEL FOLLOW-UP STUDY OF CP-690,550 FOR TREATMENT OF JUVENILE IDIOPATHIC ARTHRITIS (JIA) - HU",
        "timestamp": "2012-08-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-004915-22/PL",
        "title": "A LONG-TERM, OPEN-LABEL FOLLOW-UP STUDY OF CP-690,550 FOR TREATMENT OF JUVENILE IDIOPATHIC ARTHRITIS (JIA) - PL",
        "timestamp": "2012-08-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-004915-22/DE",
        "title": "A LONG-TERM, OPEN-LABEL FOLLOW-UP STUDY OF CP-690,550 FOR TREATMENT OF JUVENILE IDIOPATHIC ARTHRITIS (JIA) - DE",
        "timestamp": "2012-08-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-004915-22/SK",
        "title": "A LONG-TERM, OPEN-LABEL FOLLOW-UP STUDY OF CP-690,550 FOR TREATMENT OF JUVENILE IDIOPATHIC ARTHRITIS (JIA) - SK",
        "timestamp": "2012-08-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-004915-22/IT",
        "title": "A LONG-TERM, OPEN-LABEL FOLLOW-UP STUDY OF CP-690,550 FOR TREATMENT OF JUVENILE IDIOPATHIC ARTHRITIS (JIA) - IT",
        "timestamp": "2012-08-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-004915-22/ES",
        "title": "A LONG-TERM, OPEN-LABEL FOLLOW-UP STUDY OF CP-690,550 FOR TREATMENT OF JUVENILE IDIOPATHIC ARTHRITIS (JIA) - ES",
        "timestamp": "2012-08-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-004915-22/GB",
        "title": "A LONG-TERM, OPEN-LABEL FOLLOW-UP STUDY OF CP-690,550 FOR TREATMENT OF JUVENILE IDIOPATHIC ARTHRITIS (JIA) - GB",
        "timestamp": "2012-08-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-004915-22/BE",
        "title": "A LONG-TERM, OPEN-LABEL FOLLOW-UP STUDY OF CP-690,550 FOR TREATMENT OF JUVENILE IDIOPATHIC ARTHRITIS (JIA) - BE",
        "timestamp": "2012-08-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-004632-19/LT",
        "title": "A Multicentre, Randomised, Double-blind, Placebo-controlled, Phase 3 Study Evaluating the Efficacy and Safety of Anifrolumab in Adult Subjects with Active Systemic Lupus Erythematosus - LT",
        "timestamp": "2015-08-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-004632-19/BE",
        "title": "A Multicentre, Randomised, Double-blind, Placebo-controlled, Phase 3 Study Evaluating the Efficacy and Safety of Anifrolumab in Adult Subjects with Active Systemic Lupus Erythematosus - BE",
        "timestamp": "2015-08-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-004632-19/ES",
        "title": "A Multicentre, Randomised, Double-blind, Placebo-controlled, Phase 3 Study Evaluating the Efficacy and Safety of Anifrolumab in Adult Subjects with Active Systemic Lupus Erythematosus - ES",
        "timestamp": "2015-08-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-004632-19/CZ",
        "title": "A Multicentre, Randomised, Double-blind, Placebo-controlled, Phase 3 Study Evaluating the Efficacy and Safety of Anifrolumab in Adult Subjects with Active Systemic Lupus Erythematosus - CZ",
        "timestamp": "2015-08-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-004632-19/DE",
        "title": "A Multicentre, Randomised, Double-blind, Placebo-controlled, Phase 3 Study Evaluating the Efficacy and Safety of Anifrolumab in Adult Subjects with Active Systemic Lupus Erythematosus - DE",
        "timestamp": "2015-08-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-004632-19/BG",
        "title": "A Multicentre, Randomised, Double-blind, Placebo-controlled, Phase 3 Study Evaluating the Efficacy and Safety of Anifrolumab in Adult Subjects with Active Systemic Lupus Erythematosus - BG",
        "timestamp": "2015-08-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-004632-19/results",
        "title": "A Multicentre, Randomised, Double-blind, Placebo-controlled, Phase 3 Study Evaluating the Efficacy and Safety of Anifrolumab in Adult Subjects with Active Systemic Lupus Erythematosus - View results",
        "timestamp": "2015-08-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-006020-20/HU",
        "title": "A Phase 2b, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Dose-Finding, Multi-Center Study to Evaluate the Safety and Efficacy of ASP015K in Moderate to Severe Rheumatoid Arthritis ... - HU",
        "timestamp": "2012-09-07"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-006020-20/CZ",
        "title": "A Phase 2b, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Dose-Finding, Multi-Center Study to Evaluate the Safety and Efficacy of ASP015K in Moderate to Severe Rheumatoid Arthritis ... - CZ",
        "timestamp": "2012-09-07"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-006020-20/PL",
        "title": "A Phase 2b, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Dose-Finding, Multi-Center Study to Evaluate the Safety and Efficacy of ASP015K in Moderate to Severe Rheumatoid Arthritis ... - PL",
        "timestamp": "2012-09-07"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-006020-20/BG",
        "title": "A Phase 2b, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Dose-Finding, Multi-Center Study to Evaluate the Safety and Efficacy of ASP015K in Moderate to Severe Rheumatoid Arthritis ... - BG",
        "timestamp": "2012-09-07"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-006020-20/results",
        "title": "A Phase 2b, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Dose-Finding, Multi-Center Study to Evaluate the Safety and Efficacy of ASP015K in Moderate to Severe Rheumatoid Arthritis ... - View results",
        "timestamp": "2012-09-07"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-000327-25/ES",
        "title": "\"ESTUDIO DE FASE 2A ALEATORIZADO, DOBLE CIEGO, CONTROLADO CON PLACEBO Y DE GRUPOS PARALELOS DE CE-224,535, UN ANTAGONISTA DEL RECEPTOR P2X7, EN EL TRATAMIENTO DE LOS SIGNOS Y SÍNTOMAS DE LA ARTRITI... - ES",
        "timestamp": "2008-05-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-000327-25/CZ",
        "title": "\"ESTUDIO DE FASE 2A ALEATORIZADO, DOBLE CIEGO, CONTROLADO CON PLACEBO Y DE GRUPOS PARALELOS DE CE-224,535, UN ANTAGONISTA DEL RECEPTOR P2X7, EN EL TRATAMIENTO DE LOS SIGNOS Y SÍNTOMAS DE LA ARTRITI... - CZ",
        "timestamp": "2008-05-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-000327-25/PL",
        "title": "\"ESTUDIO DE FASE 2A ALEATORIZADO, DOBLE CIEGO, CONTROLADO CON PLACEBO Y DE GRUPOS PARALELOS DE CE-224,535, UN ANTAGONISTA DEL RECEPTOR P2X7, EN EL TRATAMIENTO DE LOS SIGNOS Y SÍNTOMAS DE LA ARTRITI... - PL",
        "timestamp": "2008-05-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-000327-25/results",
        "title": "\"ESTUDIO DE FASE 2A ALEATORIZADO, DOBLE CIEGO, CONTROLADO CON PLACEBO Y DE GRUPOS PARALELOS DE CE-224,535, UN ANTAGONISTA DEL RECEPTOR P2X7, EN EL TRATAMIENTO DE LOS SIGNOS Y SÍNTOMAS DE LA ARTRITI... - View results",
        "timestamp": "2008-05-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-003083-30/BE",
        "title": "The effect of hydroxychloroquine sulphate on hedonic food intake, appetite-related sensations and gastrointestinal hormone release in healthy female subjects - BE",
        "timestamp": "2019-01-31"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-001625-96/BE",
        "title": "The effect of hydroxychloroquine sulphate on hedonic food intake, appetite-related sensations and gastrointestinal hormone release in overweight female subject - BE",
        "timestamp": "2019-01-31"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-019684-11/NL",
        "title": "Pharmacological Treatment in Osteoarthritis - NL",
        "timestamp": "2010-06-09"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-007056-18/GB",
        "title": "The Discoid Lupus Research Project - GB",
        "timestamp": "2007-03-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-007056-18/results",
        "title": "The Discoid Lupus Research Project - View results",
        "timestamp": "2007-03-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-012499-28/IT",
        "title": "Efficacy of the treatment with hydroxychloroquine in non responders HIV-infected HAART-treated patients - IT",
        "timestamp": "2009-08-07"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-000233-73/FI",
        "title": "HYDROXYCHLOROQUINE IN ACUTE CORONARY SYNDROME:  PREVENTION OF RECURRENT CARDIOVASCULAR EVENTS - FI",
        "timestamp": "2016-01-05"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-004300-38/GB",
        "title": "HERO:Hydroxychloroquine Effectiveness in Reducing Symptoms of hand OA, a randomised, double-blind, placebo-controlled trial - GB",
        "timestamp": "2012-06-22"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-001330-97/FR",
        "title": "Prévention des Fausses Couches Spontanées Répétées par Hydroxychloroquine. \r\nEssai thérapeutique multicentrique, randomisé, en double insu, contre placebo. - FR",
        "timestamp": "2016-11-18"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-003260-20/NL",
        "title": "CHAMP: Children with Arthritis: Monotherapy or Polytherapy. A multicentre, single-blinded, randomized treat to target, one-year follow-up clinical trial in patients with recent onset Juvenile Idiop... - NL",
        "timestamp": "2016-05-04"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-002256-25/GB",
        "title": "HYPATIA: A prospective randomised controlled trial of HYdroxychloroquine to improve Pregnancy outcome in women with AnTIphospholipid Antibodies - GB",
        "timestamp": "2018-03-09"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-002256-25/DK",
        "title": "HYPATIA: A prospective randomised controlled trial of HYdroxychloroquine to improve Pregnancy outcome in women with AnTIphospholipid Antibodies - DK",
        "timestamp": "2018-03-09"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-000659-42/SE",
        "title": "HYDROXYCHLOROQUINE FOR PREVENTION OF ABNORMAL GLUCOSE\nTOLERANCE AND DIABETES IN INDIVIDUALS AT-RISK FOR TYPE 1\nDIABETES MELLITUS - SE",
        "timestamp": "2019-03-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-000659-42/GB",
        "title": "HYDROXYCHLOROQUINE FOR PREVENTION OF ABNORMAL GLUCOSE\nTOLERANCE AND DIABETES IN INDIVIDUALS AT-RISK FOR TYPE 1\nDIABETES MELLITUS - GB",
        "timestamp": "2019-03-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-001340-39/IT",
        "title": "Hydroxychloroquine as Steroid-Sparing Agent in pulmonary Sarcoidosis (HySSAS). A multicenter, prospectic, controlled, randomized trial. - IT",
        "timestamp": "2008-06-30"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-001268-40/GB",
        "title": "Hydroxychloroquine in ANCA Vasculitis Evaluation - A Multicentre, Randomised, Double-blind, Placebo-controlled Trial - GB",
        "timestamp": "2020-01-23"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-002006-30/GB",
        "title": "Triple therapy in early active rheumatoid arthritis - GB",
        "timestamp": "2004-11-17"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-002006-30/results",
        "title": "Triple therapy in early active rheumatoid arthritis - View results",
        "timestamp": "2004-11-17"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-004903-20/NL",
        "title": "Hydroxychloroquine as an anti-autophagy and chromatin modulating drug in combination with erlotinib in non-small cell lung cancer (NSCLC) patients: a single-center single arm open-label phase II trial - NL",
        "timestamp": "2012-05-09"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-000549-13/SK",
        "title": "A 12-Week, Double-Blind, Randomized, Parallel Group, Placebo-Controlled Study of Two Doses of VX-702 in Subjects with Moderate to Severe Rheumatoid Arthritis - SK",
        "timestamp": "2005-05-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-000549-13/CZ",
        "title": "A 12-Week, Double-Blind, Randomized, Parallel Group, Placebo-Controlled Study of Two Doses of VX-702 in Subjects with Moderate to Severe Rheumatoid Arthritis - CZ",
        "timestamp": "2005-05-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-000549-13/results",
        "title": "A 12-Week, Double-Blind, Randomized, Parallel Group, Placebo-Controlled Study of Two Doses of VX-702 in Subjects with Moderate to Severe Rheumatoid Arthritis - View results",
        "timestamp": "2005-05-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000890-25/FR",
        "title": "Treatment of Coronavirus SARS-Cov2 Respiratory Infections with Hydroxychloroquine - FR",
        "timestamp": "2020-03-05"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-000091-41/GB",
        "title": "A randomised phase 2 trial investigating the additional benefit of hydroxychloroquine(HCQ) to short  course radiotherapy (SCRT) in patients aged 70 years and older with high grade gliomas (HGG) - GB",
        "timestamp": "2012-10-22"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-003714-40/DE",
        "title": "Hydroxychloroquine in pediatric ILD START randomized controlled in parallel-group, then switch placebo to active drug, and STOP randomized controlled in parallel-group\r\nto evaluate the efficacy and... - DE",
        "timestamp": "2015-01-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-003714-40/GB",
        "title": "Hydroxychloroquine in pediatric ILD START randomized controlled in parallel-group, then switch placebo to active drug, and STOP randomized controlled in parallel-group\r\nto evaluate the efficacy and... - GB",
        "timestamp": "2015-01-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-003714-40/AT",
        "title": "Hydroxychloroquine in pediatric ILD START randomized controlled in parallel-group, then switch placebo to active drug, and STOP randomized controlled in parallel-group\r\nto evaluate the efficacy and... - AT",
        "timestamp": "2015-01-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-003714-40/ES",
        "title": "Hydroxychloroquine in pediatric ILD START randomized controlled in parallel-group, then switch placebo to active drug, and STOP randomized controlled in parallel-group\r\nto evaluate the efficacy and... - ES",
        "timestamp": "2015-01-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-001399-13/FR",
        "title": "MEK and Autophagy Inhibition in Metastatic/Locally Advanced, Unresectable NRAS Melanoma: A Phase Ib/II Trial of Trametinib plus Hydroxychloroquine in Patients with NRAS Melanoma. CHLORO TRAM MEL - FR",
        "timestamp": None
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-003083-30/BE",
        "title": "The effect of hydroxychloroquine sulphate on hedonic food intake, appetite-related sensations and gastrointestinal hormone release in healthy female subjects - BE",
        "timestamp": "2019-01-31"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-001625-96/BE",
        "title": "The effect of hydroxychloroquine sulphate on hedonic food intake, appetite-related sensations and gastrointestinal hormone release in overweight female subject - BE",
        "timestamp": "2019-01-31"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-019684-11/NL",
        "title": "Pharmacological Treatment in Osteoarthritis - NL",
        "timestamp": "2010-06-09"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-007056-18/GB",
        "title": "The Discoid Lupus Research Project - GB",
        "timestamp": "2007-03-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-007056-18/results",
        "title": "The Discoid Lupus Research Project - View results",
        "timestamp": "2007-03-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-012499-28/IT",
        "title": "Efficacy of the treatment with hydroxychloroquine in non responders HIV-infected HAART-treated patients - IT",
        "timestamp": "2009-08-07"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-000233-73/FI",
        "title": "HYDROXYCHLOROQUINE IN ACUTE CORONARY SYNDROME:  PREVENTION OF RECURRENT CARDIOVASCULAR EVENTS - FI",
        "timestamp": "2016-01-05"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-004300-38/GB",
        "title": "HERO:Hydroxychloroquine Effectiveness in Reducing Symptoms of hand OA, a randomised, double-blind, placebo-controlled trial - GB",
        "timestamp": "2012-06-22"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-001330-97/FR",
        "title": "Prévention des Fausses Couches Spontanées Répétées par Hydroxychloroquine. \r\nEssai thérapeutique multicentrique, randomisé, en double insu, contre placebo. - FR",
        "timestamp": "2016-11-18"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-003260-20/NL",
        "title": "CHAMP: Children with Arthritis: Monotherapy or Polytherapy. A multicentre, single-blinded, randomized treat to target, one-year follow-up clinical trial in patients with recent onset Juvenile Idiop... - NL",
        "timestamp": "2016-05-04"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-002256-25/GB",
        "title": "HYPATIA: A prospective randomised controlled trial of HYdroxychloroquine to improve Pregnancy outcome in women with AnTIphospholipid Antibodies - GB",
        "timestamp": "2018-03-09"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-002256-25/DK",
        "title": "HYPATIA: A prospective randomised controlled trial of HYdroxychloroquine to improve Pregnancy outcome in women with AnTIphospholipid Antibodies - DK",
        "timestamp": "2018-03-09"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-000659-42/SE",
        "title": "HYDROXYCHLOROQUINE FOR PREVENTION OF ABNORMAL GLUCOSE\nTOLERANCE AND DIABETES IN INDIVIDUALS AT-RISK FOR TYPE 1\nDIABETES MELLITUS - SE",
        "timestamp": "2019-03-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-000659-42/GB",
        "title": "HYDROXYCHLOROQUINE FOR PREVENTION OF ABNORMAL GLUCOSE\nTOLERANCE AND DIABETES IN INDIVIDUALS AT-RISK FOR TYPE 1\nDIABETES MELLITUS - GB",
        "timestamp": "2019-03-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-001340-39/IT",
        "title": "Hydroxychloroquine as Steroid-Sparing Agent in pulmonary Sarcoidosis (HySSAS). A multicenter, prospectic, controlled, randomized trial. - IT",
        "timestamp": "2008-06-30"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-001268-40/GB",
        "title": "Hydroxychloroquine in ANCA Vasculitis Evaluation - A Multicentre, Randomised, Double-blind, Placebo-controlled Trial - GB",
        "timestamp": "2020-01-23"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-002006-30/GB",
        "title": "Triple therapy in early active rheumatoid arthritis - GB",
        "timestamp": "2004-11-17"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-002006-30/results",
        "title": "Triple therapy in early active rheumatoid arthritis - View results",
        "timestamp": "2004-11-17"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-004903-20/NL",
        "title": "Hydroxychloroquine as an anti-autophagy and chromatin modulating drug in combination with erlotinib in non-small cell lung cancer (NSCLC) patients: a single-center single arm open-label phase II trial - NL",
        "timestamp": "2012-05-09"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-000549-13/SK",
        "title": "A 12-Week, Double-Blind, Randomized, Parallel Group, Placebo-Controlled Study of Two Doses of VX-702 in Subjects with Moderate to Severe Rheumatoid Arthritis - SK",
        "timestamp": "2005-05-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-000549-13/CZ",
        "title": "A 12-Week, Double-Blind, Randomized, Parallel Group, Placebo-Controlled Study of Two Doses of VX-702 in Subjects with Moderate to Severe Rheumatoid Arthritis - CZ",
        "timestamp": "2005-05-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-000549-13/results",
        "title": "A 12-Week, Double-Blind, Randomized, Parallel Group, Placebo-Controlled Study of Two Doses of VX-702 in Subjects with Moderate to Severe Rheumatoid Arthritis - View results",
        "timestamp": "2005-05-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000890-25/FR",
        "title": "Treatment of Coronavirus SARS-Cov2 Respiratory Infections with Hydroxychloroquine - FR",
        "timestamp": "2020-03-05"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-000091-41/GB",
        "title": "A randomised phase 2 trial investigating the additional benefit of hydroxychloroquine(HCQ) to short  course radiotherapy (SCRT) in patients aged 70 years and older with high grade gliomas (HGG) - GB",
        "timestamp": "2012-10-22"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-003714-40/DE",
        "title": "Hydroxychloroquine in pediatric ILD START randomized controlled in parallel-group, then switch placebo to active drug, and STOP randomized controlled in parallel-group\r\nto evaluate the efficacy and... - DE",
        "timestamp": "2015-01-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-003714-40/GB",
        "title": "Hydroxychloroquine in pediatric ILD START randomized controlled in parallel-group, then switch placebo to active drug, and STOP randomized controlled in parallel-group\r\nto evaluate the efficacy and... - GB",
        "timestamp": "2015-01-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-003714-40/AT",
        "title": "Hydroxychloroquine in pediatric ILD START randomized controlled in parallel-group, then switch placebo to active drug, and STOP randomized controlled in parallel-group\r\nto evaluate the efficacy and... - AT",
        "timestamp": "2015-01-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-003714-40/ES",
        "title": "Hydroxychloroquine in pediatric ILD START randomized controlled in parallel-group, then switch placebo to active drug, and STOP randomized controlled in parallel-group\r\nto evaluate the efficacy and... - ES",
        "timestamp": "2015-01-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-001399-13/FR",
        "title": "MEK and Autophagy Inhibition in Metastatic/Locally Advanced, Unresectable NRAS Melanoma: A Phase Ib/II Trial of Trametinib plus Hydroxychloroquine in Patients with NRAS Melanoma. CHLORO TRAM MEL - FR",
        "timestamp": None
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-006350-87/IT",
        "title": "HydrOxychloRoqUine and Sorafenib in  locally advanced or Metastatic  Hepatocellular Carcinoma as First line therapy: a multi-center phase II trial - IT",
        "timestamp": "2012-03-06"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-005418-45/SE",
        "title": "Improved cardiovascular risk factors and inflammatory markers in Rheumatoid Arthritis and Systemic Lupus Erythematosus? New aspects of Hydroxychloroquine – an interventional study (HCQCVDRASLE) - SE",
        "timestamp": "2015-05-04"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-005418-45/results",
        "title": "Improved cardiovascular risk factors and inflammatory markers in Rheumatoid Arthritis and Systemic Lupus Erythematosus? New aspects of Hydroxychloroquine – an interventional study (HCQCVDRASLE) - View results",
        "timestamp": "2015-05-04"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-004170-15/GB",
        "title": "A multicentre, randomised trial comparing combination gemcitabine/carboplatin and hydroxychloroquine versus carboplatin/etoposide therapy alone in small cell lung cancer (SCLC) - GB",
        "timestamp": "2016-11-17"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-004981-24/DK",
        "title": "Hydroxychloroquin (Plaquenil) treatment of recurrent pregnancy loss –  a randomized, double blinded, placebo controlled study - DK",
        "timestamp": "2017-04-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-004543-20/ES",
        "title": "EFFECTS OF ABATACEPT ON THE PROGRESSION TO RHEUMATOID ARTHRITIS  IN PATIENTS WITH PALINDROMIC RHEUMATISM (PALABA). - ES",
        "timestamp": "2019-01-22"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-006186-16/NL",
        "title": "IMPROVED: Induction therapy with Methotrexate and Prednisone in Rheumatoid Or Very Early arthritic Disease\n\nA randomized clinical trial in patients with recent-onset arthritis to compare the effica... - NL",
        "timestamp": "2007-01-30"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-005057-36/GB",
        "title": "Evaluation of the efficacy of hydroxychloroquine in decreasing immune activation in asymptomatic HIV-infected patients (HCQ-01) - GB",
        "timestamp": "2008-02-22"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-005057-36/results",
        "title": "Evaluation of the efficacy of hydroxychloroquine in decreasing immune activation in asymptomatic HIV-infected patients (HCQ-01) - View results",
        "timestamp": "2008-02-22"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001113-21/GB",
        "title": "Randomised Evaluation of COVID-19 Therapy (RECOVERY) - GB",
        "timestamp": "2020-03-17"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-022842-26/NL",
        "title": "Autophagy inhibition using hydrochloroquine in breast cancer patients: a pilot study - NL",
        "timestamp": "2010-11-25"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-001190-28/GB",
        "title": "Randomised controlled trial of tumour-necrosis-factor inhibitors against combination intensive therapy with conventional disease modifying anti-rheumatic drugs in established rheumatoid arthritis - GB",
        "timestamp": "2007-05-09"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-001190-28/results",
        "title": "Randomised controlled trial of tumour-necrosis-factor inhibitors against combination intensive therapy with conventional disease modifying anti-rheumatic drugs in established rheumatoid arthritis - View results",
        "timestamp": "2007-05-09"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-001688-74/GB",
        "title": "A prospective, randomized, double-blind, placebo controlled trial evaluating the effects of Mycophenolate Mofetil (MMF) on 'surrogate markers' for atherosclerosis in female patients with systemic l... - GB",
        "timestamp": "2005-09-22"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-001688-74/results",
        "title": "A prospective, randomized, double-blind, placebo controlled trial evaluating the effects of Mycophenolate Mofetil (MMF) on 'surrogate markers' for atherosclerosis in female patients with systemic l... - View results",
        "timestamp": "2005-09-22"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-001689-16/DE",
        "title": "Prospective randomized, double-blind, and placebo-controlled clinical trial with hydroxychloroquine (HCQ) in patients with erosive-inflammatory osteoarthritis (OA) of the finger joints (acronym: OA... - DE",
        "timestamp": "2013-06-06"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-001137-99/GB",
        "title": "CHANGE TO:\nA PILOT RANDOMISED STUDY TO COMPARE COMBINATION ANTIBIOTIC THERAPY (CIPROFLOXACIN AND DOXYCYCLINE) WITH STANDARD THERAPY (BUDESONIDE) IN THE TREATMENT OF ACTIVE CROHN'S DISEASE - GB",
        "timestamp": "2009-04-28"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-000547-32/GB",
        "title": "A Randomised Controlled Trial of Adjunctive Systemic Therapy for Vulval Erosive Lichen Planus - GB",
        "timestamp": "2014-04-02"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-000547-32/results",
        "title": "A Randomised Controlled Trial of Adjunctive Systemic Therapy for Vulval Erosive Lichen Planus - View results",
        "timestamp": "2014-04-02"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-001977-82/GB",
        "title": "A randomised, double-blind, placebo-controlled, parallel group study to investigate the safety, tolerability, pharmacokinetics and effect on synovial thickness and vascularity of 28 days repeat dos... - GB",
        "timestamp": "2005-09-09"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-001977-82/results",
        "title": "A randomised, double-blind, placebo-controlled, parallel group study to investigate the safety, tolerability, pharmacokinetics and effect on synovial thickness and vascularity of 28 days repeat dos... - View results",
        "timestamp": "2005-09-09"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-000482-35/GB",
        "title": "A randomised, double-blind, placebo-controlled, parallel group study to investigate the anti-inflammatory and metabolic effects of rosiglitazone XR, 8mg once daily, in subjects with rheumatoid arth... - GB",
        "timestamp": "2004-10-11"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-000482-35/LT",
        "title": "A randomised, double-blind, placebo-controlled, parallel group study to investigate the anti-inflammatory and metabolic effects of rosiglitazone XR, 8mg once daily, in subjects with rheumatoid arth... - LT",
        "timestamp": "2004-10-11"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-000482-35/results",
        "title": "A randomised, double-blind, placebo-controlled, parallel group study to investigate the anti-inflammatory and metabolic effects of rosiglitazone XR, 8mg once daily, in subjects with rheumatoid arth... - View results",
        "timestamp": "2004-10-11"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-003246-93/HU",
        "title": "A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 Study Characterizing the Pharmacokinetics, Pharmacodynamics, and Safety of Anifrolumab following subcutaneous administration in ... - HU",
        "timestamp": "2016-12-06"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-003246-93/PL",
        "title": "A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 Study Characterizing the Pharmacokinetics, Pharmacodynamics, and Safety of Anifrolumab following subcutaneous administration in ... - PL",
        "timestamp": "2016-12-06"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-003246-93/results",
        "title": "A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 Study Characterizing the Pharmacokinetics, Pharmacodynamics, and Safety of Anifrolumab following subcutaneous administration in ... - View results",
        "timestamp": "2016-12-06"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-003877-91/DE",
        "title": "Sequential B cell/T cell therapy to re-induce humoral immune tolerance in ACPA-positive Rheumatoid Arthritis (TOLERA): a prospective randomized controlled open-label single-centre clinical trial in... - DE",
        "timestamp": "2019-06-13"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-003658-26/NL",
        "title": "Treat-to-target strategy for early RA patients in usual clinical practice:\nThe COBRA Cohort Study - NL",
        "timestamp": "2013-11-13"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-014373-41/GB",
        "title": "A randomised Phase II trial of Imatinib (IM) versus Hydroxychloroquine (HCQ) and Imatinib (IM) for patients with Chronic Myeloid Leukaemia (CML) in Cytogenetic Response (CyR) with residual disease ... - GB",
        "timestamp": "2010-02-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-014373-41/DE",
        "title": "A randomised Phase II trial of Imatinib (IM) versus Hydroxychloroquine (HCQ) and Imatinib (IM) for patients with Chronic Myeloid Leukaemia (CML) in Cytogenetic Response (CyR) with residual disease ... - DE",
        "timestamp": "2010-02-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-014373-41/FR",
        "title": "A randomised Phase II trial of Imatinib (IM) versus Hydroxychloroquine (HCQ) and Imatinib (IM) for patients with Chronic Myeloid Leukaemia (CML) in Cytogenetic Response (CyR) with residual disease ... - FR",
        "timestamp": "2010-02-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-014373-41/results",
        "title": "A randomised Phase II trial of Imatinib (IM) versus Hydroxychloroquine (HCQ) and Imatinib (IM) for patients with Chronic Myeloid Leukaemia (CML) in Cytogenetic Response (CyR) with residual disease ... - View results",
        "timestamp": "2010-02-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-000610-11/BE",
        "title": "A randomised, double blind, placebo-controlled, multiple dose, phase 2b, 24 week trial followed by an open label extension of NNC0109-0012, an anti-IL-20 biologic, in patients with active rheumatoi... - BE",
        "timestamp": "2013-02-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-000610-11/HU",
        "title": "A randomised, double blind, placebo-controlled, multiple dose, phase 2b, 24 week trial followed by an open label extension of NNC0109-0012, an anti-IL-20 biologic, in patients with active rheumatoi... - HU",
        "timestamp": "2013-02-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-000610-11/CZ",
        "title": "A randomised, double blind, placebo-controlled, multiple dose, phase 2b, 24 week trial followed by an open label extension of NNC0109-0012, an anti-IL-20 biologic, in patients with active rheumatoi... - CZ",
        "timestamp": "2013-02-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-000610-11/DE",
        "title": "A randomised, double blind, placebo-controlled, multiple dose, phase 2b, 24 week trial followed by an open label extension of NNC0109-0012, an anti-IL-20 biologic, in patients with active rheumatoi... - DE",
        "timestamp": "2013-02-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-000610-11/ES",
        "title": "A randomised, double blind, placebo-controlled, multiple dose, phase 2b, 24 week trial followed by an open label extension of NNC0109-0012, an anti-IL-20 biologic, in patients with active rheumatoi... - ES",
        "timestamp": "2013-02-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-000610-11/IT",
        "title": "A randomised, double blind, placebo-controlled, multiple dose, phase 2b, 24 week trial followed by an open label extension of NNC0109-0012, an anti-IL-20 biologic, in patients with active rheumatoi... - IT",
        "timestamp": "2013-02-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-000610-11/results",
        "title": "A randomised, double blind, placebo-controlled, multiple dose, phase 2b, 24 week trial followed by an open label extension of NNC0109-0012, an anti-IL-20 biologic, in patients with active rheumatoi... - View results",
        "timestamp": "2013-02-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-015740-42/DE",
        "title": "A PHASE 3, MULTICENTER, RANDOMIZED, OPEN, PROSPECTIVE, CONTROLLED, PARALLEL-GROUP STUDY OF REDUCTION OF THERAPY IN PATIENTS WITH RHEUMATOID ARTHRITIS IN ONGOING REMISSION\r\nRETRO – REduction of Ther... - DE",
        "timestamp": "2010-05-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-002969-37/SE",
        "title": "A randomised, placebo-controlled, parallel group single dose study of GW856553 in patients with active RA to investigate the CRP dose response relationship. - SE",
        "timestamp": "2005-10-14"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-002969-37/ES",
        "title": "A randomised, placebo-controlled, parallel group single dose study of GW856553 in patients with active RA to investigate the CRP dose response relationship. - ES",
        "timestamp": "2005-10-14"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-002969-37/DE",
        "title": "A randomised, placebo-controlled, parallel group single dose study of GW856553 in patients with active RA to investigate the CRP dose response relationship. - DE",
        "timestamp": "2005-10-14"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-002969-37/results",
        "title": "A randomised, placebo-controlled, parallel group single dose study of GW856553 in patients with active RA to investigate the CRP dose response relationship. - View results",
        "timestamp": "2005-10-14"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003876-38/DE",
        "title": "A randomized, double- blind, controlled, parallel-group, multicenter study to assess the safety and immunogenicity of transitioning to GP2013 or re-treatment with Rituxan® or MabThera® in patients ... - DE",
        "timestamp": "2015-07-21"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003876-38/HU",
        "title": "A randomized, double- blind, controlled, parallel-group, multicenter study to assess the safety and immunogenicity of transitioning to GP2013 or re-treatment with Rituxan® or MabThera® in patients ... - HU",
        "timestamp": "2015-07-21"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003876-38/PL",
        "title": "A randomized, double- blind, controlled, parallel-group, multicenter study to assess the safety and immunogenicity of transitioning to GP2013 or re-treatment with Rituxan® or MabThera® in patients ... - PL",
        "timestamp": "2015-07-21"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003876-38/results",
        "title": "A randomized, double- blind, controlled, parallel-group, multicenter study to assess the safety and immunogenicity of transitioning to GP2013 or re-treatment with Rituxan® or MabThera® in patients ... - View results",
        "timestamp": "2015-07-21"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-003140-12/NL",
        "title": "Optimizing DMARD-therapy for primary Sjogren's Syndrome - Leflunomide and Hydroxychloroquine combination therapy for patients with primary Sjogren's Syndrome - NL",
        "timestamp": "2015-09-21"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-000431-14/DK",
        "title": "A Multicenter, Randomized, Double-Blind, Placebo Controlled Study Evaluating the Safety and Efficacy of Upadacitinib in Subjects with Active Ankylosing Spondylitis - DK",
        "timestamp": "2017-09-25"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-000431-14/DE",
        "title": "A Multicenter, Randomized, Double-Blind, Placebo Controlled Study Evaluating the Safety and Efficacy of Upadacitinib in Subjects with Active Ankylosing Spondylitis - DE",
        "timestamp": "2017-09-25"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-000431-14/FI",
        "title": "A Multicenter, Randomized, Double-Blind, Placebo Controlled Study Evaluating the Safety and Efficacy of Upadacitinib in Subjects with Active Ankylosing Spondylitis - FI",
        "timestamp": "2017-09-25"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-000431-14/CZ",
        "title": "A Multicenter, Randomized, Double-Blind, Placebo Controlled Study Evaluating the Safety and Efficacy of Upadacitinib in Subjects with Active Ankylosing Spondylitis - CZ",
        "timestamp": "2017-09-25"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-000431-14/GB",
        "title": "A Multicenter, Randomized, Double-Blind, Placebo Controlled Study Evaluating the Safety and Efficacy of Upadacitinib in Subjects with Active Ankylosing Spondylitis - GB",
        "timestamp": "2017-09-25"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-000431-14/ES",
        "title": "A Multicenter, Randomized, Double-Blind, Placebo Controlled Study Evaluating the Safety and Efficacy of Upadacitinib in Subjects with Active Ankylosing Spondylitis - ES",
        "timestamp": "2017-09-25"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-000431-14/PT",
        "title": "A Multicenter, Randomized, Double-Blind, Placebo Controlled Study Evaluating the Safety and Efficacy of Upadacitinib in Subjects with Active Ankylosing Spondylitis - PT",
        "timestamp": "2017-09-25"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-000431-14/NL",
        "title": "A Multicenter, Randomized, Double-Blind, Placebo Controlled Study Evaluating the Safety and Efficacy of Upadacitinib in Subjects with Active Ankylosing Spondylitis - NL",
        "timestamp": "2017-09-25"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-000431-14/BE",
        "title": "A Multicenter, Randomized, Double-Blind, Placebo Controlled Study Evaluating the Safety and Efficacy of Upadacitinib in Subjects with Active Ankylosing Spondylitis - BE",
        "timestamp": "2017-09-25"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-000431-14/HU",
        "title": "A Multicenter, Randomized, Double-Blind, Placebo Controlled Study Evaluating the Safety and Efficacy of Upadacitinib in Subjects with Active Ankylosing Spondylitis - HU",
        "timestamp": "2017-09-25"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-000431-14/PL",
        "title": "A Multicenter, Randomized, Double-Blind, Placebo Controlled Study Evaluating the Safety and Efficacy of Upadacitinib in Subjects with Active Ankylosing Spondylitis - PL",
        "timestamp": "2017-09-25"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-000431-14/SE",
        "title": "A Multicenter, Randomized, Double-Blind, Placebo Controlled Study Evaluating the Safety and Efficacy of Upadacitinib in Subjects with Active Ankylosing Spondylitis - SE",
        "timestamp": "2017-09-25"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-000431-14/HR",
        "title": "A Multicenter, Randomized, Double-Blind, Placebo Controlled Study Evaluating the Safety and Efficacy of Upadacitinib in Subjects with Active Ankylosing Spondylitis - HR",
        "timestamp": "2017-09-25"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005672-42/GB",
        "title": "A Phase 3/4, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 52-Week Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006) in Adult Subjects of Black Race With Systemic Lupus... - GB",
        "timestamp": "2013-06-11"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005672-42/results",
        "title": "A Phase 3/4, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 52-Week Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006) in Adult Subjects of Black Race With Systemic Lupus... - View results",
        "timestamp": "2013-06-11"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020063-21/DE",
        "title": "“A 20-week open-label study to assess the efficacy and safety of single doses of Ilaris® (Canakinumab, ACZ885) in patients with active, refractory urticarial vasculitis” - DE",
        "timestamp": "2010-06-15"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-003828-23/DE",
        "title": "A pilot open-label study to assess the efficacy and safety of tocilizumab (TCZ) in patients with active Schnitzler’s syndrome (SchS) - DE",
        "timestamp": "2017-04-11"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-002622-23/NL",
        "title": "Safety and Efficacy of BI 695500 in patients with moderately to severely active rheumatoid arthritis: an open-label extension trial - NL",
        "timestamp": "2014-06-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-002622-23/PT",
        "title": "Safety and Efficacy of BI 695500 in patients with moderately to severely active rheumatoid arthritis: an open-label extension trial - PT",
        "timestamp": "2014-06-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-002622-23/BG",
        "title": "Safety and Efficacy of BI 695500 in patients with moderately to severely active rheumatoid arthritis: an open-label extension trial - BG",
        "timestamp": "2014-06-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-002622-23/BE",
        "title": "Safety and Efficacy of BI 695500 in patients with moderately to severely active rheumatoid arthritis: an open-label extension trial - BE",
        "timestamp": "2014-06-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-002622-23/DE",
        "title": "Safety and Efficacy of BI 695500 in patients with moderately to severely active rheumatoid arthritis: an open-label extension trial - DE",
        "timestamp": "2014-06-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-002622-23/HU",
        "title": "Safety and Efficacy of BI 695500 in patients with moderately to severely active rheumatoid arthritis: an open-label extension trial - HU",
        "timestamp": "2014-06-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-002622-23/ES",
        "title": "Safety and Efficacy of BI 695500 in patients with moderately to severely active rheumatoid arthritis: an open-label extension trial - ES",
        "timestamp": "2014-06-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-002622-23/GR",
        "title": "Safety and Efficacy of BI 695500 in patients with moderately to severely active rheumatoid arthritis: an open-label extension trial - GR",
        "timestamp": "2014-06-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-002622-23/results",
        "title": "Safety and Efficacy of BI 695500 in patients with moderately to severely active rheumatoid arthritis: an open-label extension trial - View results",
        "timestamp": "2014-06-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-003011-12/GB",
        "title": "Prospective Randomised Double-Blind Placebo Controlled Study Assessing the Efficacy of Tocilizumab with Synovial Analysis in Patients with Rheumatoid Arthritis - GB",
        "timestamp": "2009-03-30"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-003011-12/results",
        "title": "Prospective Randomised Double-Blind Placebo Controlled Study Assessing the Efficacy of Tocilizumab with Synovial Analysis in Patients with Rheumatoid Arthritis - View results",
        "timestamp": "2009-03-30"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-013482-26/FR",
        "title": "« Rotation ou Changement de biothérapie dans la polyarthrite rhumatoïde en cas d’échec à un anti-TNF » - FR",
        "timestamp": "2009-09-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-003230-93/HU",
        "title": "A randomized, placebo-controlled, patient and investigator blinded study investigating the safety, tolerability, pharmacokinetics and preliminary efficacy of multiple doses of CFZ533 in patients wi... - HU",
        "timestamp": "2018-05-09"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-003230-93/DE",
        "title": "A randomized, placebo-controlled, patient and investigator blinded study investigating the safety, tolerability, pharmacokinetics and preliminary efficacy of multiple doses of CFZ533 in patients wi... - DE",
        "timestamp": "2018-05-09"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-004468-23/GB",
        "title": "Comparison of abatacept with tumor necrosis factor inhibitors in the treatment of rheumatoid arthritis pain: A phase IV trial - GB",
        "timestamp": "2020-02-10"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-023910-30/GB",
        "title": "A Prospective, Single-centre, Randomised Study Evaluating the Clinical, Imaging and Immunological Depth of Remission Achieved by Very Early versus Delayed Etanercept in patients with Rheumatoid Art... - GB",
        "timestamp": "2011-03-23"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-011206-42/CZ",
        "title": "A Randomized, Double Blind, Placebo Controlled, Dose Ranging, Parallel Group, Phase 2 Study of INCB028050 Compared to Background Therapy in Patients with Active Rheumatoid Arthritis with Inadequate... - CZ",
        "timestamp": "2009-08-18"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-011206-42/results",
        "title": "A Randomized, Double Blind, Placebo Controlled, Dose Ranging, Parallel Group, Phase 2 Study of INCB028050 Compared to Background Therapy in Patients with Active Rheumatoid Arthritis with Inadequate... - View results",
        "timestamp": "2009-08-18"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-004187-56/DE",
        "title": "International cooperative Phase III trial of the HIT-HGG study group for the treatment of high grade glioma, diffuse intrinsic pontine glioma, and gliomatosis cerebri in children and adolescents < ... - DE",
        "timestamp": "2017-04-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-005115-29/GB",
        "title": "A randomised, placebo-controlled, parallel group single dose study of SB681323 in patients with active RA to investigate the CRP dose response relationship - GB",
        "timestamp": "2005-06-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-005115-29/DE",
        "title": "A randomised, placebo-controlled, parallel group single dose study of SB681323 in patients with active RA to investigate the CRP dose response relationship - DE",
        "timestamp": "2005-06-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-005115-29/results",
        "title": "A randomised, placebo-controlled, parallel group single dose study of SB681323 in patients with active RA to investigate the CRP dose response relationship - View results",
        "timestamp": "2005-06-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-003065-95/DE",
        "title": "A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE\r\nEFFICACY AND SAFETY OF BIMEKIZUMAB IN SUBJECTS WITH ACTIVE ANKYLOSING SPONDYLITIS - DE",
        "timestamp": "2019-06-11"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-003065-95/HU",
        "title": "A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE\r\nEFFICACY AND SAFETY OF BIMEKIZUMAB IN SUBJECTS WITH ACTIVE ANKYLOSING SPONDYLITIS - HU",
        "timestamp": "2019-06-11"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-003065-95/GB",
        "title": "A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE\r\nEFFICACY AND SAFETY OF BIMEKIZUMAB IN SUBJECTS WITH ACTIVE ANKYLOSING SPONDYLITIS - GB",
        "timestamp": "2019-06-11"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-003065-95/BG",
        "title": "A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE\r\nEFFICACY AND SAFETY OF BIMEKIZUMAB IN SUBJECTS WITH ACTIVE ANKYLOSING SPONDYLITIS - BG",
        "timestamp": "2019-06-11"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-003065-95/FR",
        "title": "A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE\r\nEFFICACY AND SAFETY OF BIMEKIZUMAB IN SUBJECTS WITH ACTIVE ANKYLOSING SPONDYLITIS - FR",
        "timestamp": "2019-06-11"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-003065-95/ES",
        "title": "A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE\r\nEFFICACY AND SAFETY OF BIMEKIZUMAB IN SUBJECTS WITH ACTIVE ANKYLOSING SPONDYLITIS - ES",
        "timestamp": "2019-06-11"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-003065-95/CZ",
        "title": "A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE\r\nEFFICACY AND SAFETY OF BIMEKIZUMAB IN SUBJECTS WITH ACTIVE ANKYLOSING SPONDYLITIS - CZ",
        "timestamp": "2019-06-11"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-003065-95/NL",
        "title": "A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE\r\nEFFICACY AND SAFETY OF BIMEKIZUMAB IN SUBJECTS WITH ACTIVE ANKYLOSING SPONDYLITIS - NL",
        "timestamp": "2019-06-11"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-003405-94/HU",
        "title": "A multicenter, randomized, double-blind, placebo-controlled, dose-finding clinical trial inpatients with active psoriatic arthritis to investigate efficacy, tolerability, safety,\npharmacokinetics a... - HU",
        "timestamp": "2020-01-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-003405-94/ES",
        "title": "A multicenter, randomized, double-blind, placebo-controlled, dose-finding clinical trial inpatients with active psoriatic arthritis to investigate efficacy, tolerability, safety,\npharmacokinetics a... - ES",
        "timestamp": "2020-01-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003057-29/CZ",
        "title": "A RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLINDED, ASCENDING MULTIPLE DOSE STUDY OF THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF XMAB®5871 IN PATIENTS WITH RHEUMATOID ARTHRITIS - CZ",
        "timestamp": "2013-04-02"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003057-29/SK",
        "title": "A RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLINDED, ASCENDING MULTIPLE DOSE STUDY OF THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF XMAB®5871 IN PATIENTS WITH RHEUMATOID ARTHRITIS - SK",
        "timestamp": "2013-04-02"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003057-29/HU",
        "title": "A RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLINDED, ASCENDING MULTIPLE DOSE STUDY OF THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF XMAB®5871 IN PATIENTS WITH RHEUMATOID ARTHRITIS - HU",
        "timestamp": "2013-04-02"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003057-29/results",
        "title": "A RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLINDED, ASCENDING MULTIPLE DOSE STUDY OF THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF XMAB®5871 IN PATIENTS WITH RHEUMATOID ARTHRITIS - View results",
        "timestamp": "2013-04-02"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-004171-36/CZ",
        "title": "A Randomized, Double-blind, Parallel Group, Multicenter Trial to Compare the Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of SAIT101 to MabThera® in Subjects with Severe Rheumatoid Arthr... - CZ",
        "timestamp": "2012-02-15"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-004171-36/GB",
        "title": "A Randomized, Double-blind, Parallel Group, Multicenter Trial to Compare the Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of SAIT101 to MabThera® in Subjects with Severe Rheumatoid Arthr... - GB",
        "timestamp": "2012-02-15"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-004171-36/HU",
        "title": "A Randomized, Double-blind, Parallel Group, Multicenter Trial to Compare the Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of SAIT101 to MabThera® in Subjects with Severe Rheumatoid Arthr... - HU",
        "timestamp": "2012-02-15"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-004171-36/ES",
        "title": "A Randomized, Double-blind, Parallel Group, Multicenter Trial to Compare the Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of SAIT101 to MabThera® in Subjects with Severe Rheumatoid Arthr... - ES",
        "timestamp": "2012-02-15"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-004171-36/PL",
        "title": "A Randomized, Double-blind, Parallel Group, Multicenter Trial to Compare the Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of SAIT101 to MabThera® in Subjects with Severe Rheumatoid Arthr... - PL",
        "timestamp": "2012-02-15"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-003064-13/DE",
        "title": "A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE\r\nEFFICACY AND SAFETY OF BIMEKIZUMAB IN SUBJECTS WITH ACTIVE NONRADIOGRAPHIC AXIAL SPONDYLOARTHRITIS - DE",
        "timestamp": "2019-06-11"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-003064-13/CZ",
        "title": "A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE\r\nEFFICACY AND SAFETY OF BIMEKIZUMAB IN SUBJECTS WITH ACTIVE NONRADIOGRAPHIC AXIAL SPONDYLOARTHRITIS - CZ",
        "timestamp": "2019-06-11"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-003064-13/FR",
        "title": "A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE\r\nEFFICACY AND SAFETY OF BIMEKIZUMAB IN SUBJECTS WITH ACTIVE NONRADIOGRAPHIC AXIAL SPONDYLOARTHRITIS - FR",
        "timestamp": "2019-06-11"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-003064-13/HU",
        "title": "A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE\r\nEFFICACY AND SAFETY OF BIMEKIZUMAB IN SUBJECTS WITH ACTIVE NONRADIOGRAPHIC AXIAL SPONDYLOARTHRITIS - HU",
        "timestamp": "2019-06-11"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-003064-13/GB",
        "title": "A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE\r\nEFFICACY AND SAFETY OF BIMEKIZUMAB IN SUBJECTS WITH ACTIVE NONRADIOGRAPHIC AXIAL SPONDYLOARTHRITIS - GB",
        "timestamp": "2019-06-11"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-003064-13/BG",
        "title": "A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE\r\nEFFICACY AND SAFETY OF BIMEKIZUMAB IN SUBJECTS WITH ACTIVE NONRADIOGRAPHIC AXIAL SPONDYLOARTHRITIS - BG",
        "timestamp": "2019-06-11"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-003064-13/NL",
        "title": "A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE\r\nEFFICACY AND SAFETY OF BIMEKIZUMAB IN SUBJECTS WITH ACTIVE NONRADIOGRAPHIC AXIAL SPONDYLOARTHRITIS - NL",
        "timestamp": "2019-06-11"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-006917-25/DE",
        "title": "A Phase II, Randomized Multi-Center, Double-Blind Study of Tranilast with Concomitant Methotrexate (MTX) Compared to MTX Alone in Patients with Active Rheumatoid Arthritis (RA). - DE",
        "timestamp": "2009-04-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-006917-25/PL",
        "title": "A Phase II, Randomized Multi-Center, Double-Blind Study of Tranilast with Concomitant Methotrexate (MTX) Compared to MTX Alone in Patients with Active Rheumatoid Arthritis (RA). - PL",
        "timestamp": "2009-04-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-006917-25/CZ",
        "title": "A Phase II, Randomized Multi-Center, Double-Blind Study of Tranilast with Concomitant Methotrexate (MTX) Compared to MTX Alone in Patients with Active Rheumatoid Arthritis (RA). - CZ",
        "timestamp": "2009-04-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-006917-25/GB",
        "title": "A Phase II, Randomized Multi-Center, Double-Blind Study of Tranilast with Concomitant Methotrexate (MTX) Compared to MTX Alone in Patients with Active Rheumatoid Arthritis (RA). - GB",
        "timestamp": "2009-04-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-006917-25/BG",
        "title": "A Phase II, Randomized Multi-Center, Double-Blind Study of Tranilast with Concomitant Methotrexate (MTX) Compared to MTX Alone in Patients with Active Rheumatoid Arthritis (RA). - BG",
        "timestamp": "2009-04-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-003332-13/SK",
        "title": "A Phase 3, Randomized, Double-Blind Study Comparing ABT-494 to Placebo in Subjects with Moderately to Severely Active Rheumatoid Arthritis Who are on a Stable Dose of Conventional Synthetic Disease... - SK",
        "timestamp": "2016-01-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-003332-13/ES",
        "title": "A Phase 3, Randomized, Double-Blind Study Comparing ABT-494 to Placebo in Subjects with Moderately to Severely Active Rheumatoid Arthritis Who are on a Stable Dose of Conventional Synthetic Disease... - ES",
        "timestamp": "2016-01-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-003332-13/BG",
        "title": "A Phase 3, Randomized, Double-Blind Study Comparing ABT-494 to Placebo in Subjects with Moderately to Severely Active Rheumatoid Arthritis Who are on a Stable Dose of Conventional Synthetic Disease... - BG",
        "timestamp": "2016-01-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-003332-13/CZ",
        "title": "A Phase 3, Randomized, Double-Blind Study Comparing ABT-494 to Placebo in Subjects with Moderately to Severely Active Rheumatoid Arthritis Who are on a Stable Dose of Conventional Synthetic Disease... - CZ",
        "timestamp": "2016-01-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-003332-13/DK",
        "title": "A Phase 3, Randomized, Double-Blind Study Comparing ABT-494 to Placebo in Subjects with Moderately to Severely Active Rheumatoid Arthritis Who are on a Stable Dose of Conventional Synthetic Disease... - DK",
        "timestamp": "2016-01-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-003332-13/BE",
        "title": "A Phase 3, Randomized, Double-Blind Study Comparing ABT-494 to Placebo in Subjects with Moderately to Severely Active Rheumatoid Arthritis Who are on a Stable Dose of Conventional Synthetic Disease... - BE",
        "timestamp": "2016-01-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-003332-13/IE",
        "title": "A Phase 3, Randomized, Double-Blind Study Comparing ABT-494 to Placebo in Subjects with Moderately to Severely Active Rheumatoid Arthritis Who are on a Stable Dose of Conventional Synthetic Disease... - IE",
        "timestamp": "2016-01-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-003332-13/PT",
        "title": "A Phase 3, Randomized, Double-Blind Study Comparing ABT-494 to Placebo in Subjects with Moderately to Severely Active Rheumatoid Arthritis Who are on a Stable Dose of Conventional Synthetic Disease... - PT",
        "timestamp": "2016-01-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-003332-13/GB",
        "title": "A Phase 3, Randomized, Double-Blind Study Comparing ABT-494 to Placebo in Subjects with Moderately to Severely Active Rheumatoid Arthritis Who are on a Stable Dose of Conventional Synthetic Disease... - GB",
        "timestamp": "2016-01-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-003332-13/PL",
        "title": "A Phase 3, Randomized, Double-Blind Study Comparing ABT-494 to Placebo in Subjects with Moderately to Severely Active Rheumatoid Arthritis Who are on a Stable Dose of Conventional Synthetic Disease... - PL",
        "timestamp": "2016-01-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-003332-13/LV",
        "title": "A Phase 3, Randomized, Double-Blind Study Comparing ABT-494 to Placebo in Subjects with Moderately to Severely Active Rheumatoid Arthritis Who are on a Stable Dose of Conventional Synthetic Disease... - LV",
        "timestamp": "2016-01-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-003332-13/FI",
        "title": "A Phase 3, Randomized, Double-Blind Study Comparing ABT-494 to Placebo in Subjects with Moderately to Severely Active Rheumatoid Arthritis Who are on a Stable Dose of Conventional Synthetic Disease... - FI",
        "timestamp": "2016-01-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-003332-13/NO",
        "title": "A Phase 3, Randomized, Double-Blind Study Comparing ABT-494 to Placebo in Subjects with Moderately to Severely Active Rheumatoid Arthritis Who are on a Stable Dose of Conventional Synthetic Disease... - NO",
        "timestamp": "2016-01-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-003332-13/LT",
        "title": "A Phase 3, Randomized, Double-Blind Study Comparing ABT-494 to Placebo in Subjects with Moderately to Severely Active Rheumatoid Arthritis Who are on a Stable Dose of Conventional Synthetic Disease... - LT",
        "timestamp": "2016-01-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-003332-13/HU",
        "title": "A Phase 3, Randomized, Double-Blind Study Comparing ABT-494 to Placebo in Subjects with Moderately to Severely Active Rheumatoid Arthritis Who are on a Stable Dose of Conventional Synthetic Disease... - HU",
        "timestamp": "2016-01-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-003332-13/GR",
        "title": "A Phase 3, Randomized, Double-Blind Study Comparing ABT-494 to Placebo in Subjects with Moderately to Severely Active Rheumatoid Arthritis Who are on a Stable Dose of Conventional Synthetic Disease... - GR",
        "timestamp": "2016-01-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-003332-13/AT",
        "title": "A Phase 3, Randomized, Double-Blind Study Comparing ABT-494 to Placebo in Subjects with Moderately to Severely Active Rheumatoid Arthritis Who are on a Stable Dose of Conventional Synthetic Disease... - AT",
        "timestamp": "2016-01-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-003332-13/HR",
        "title": "A Phase 3, Randomized, Double-Blind Study Comparing ABT-494 to Placebo in Subjects with Moderately to Severely Active Rheumatoid Arthritis Who are on a Stable Dose of Conventional Synthetic Disease... - HR",
        "timestamp": "2016-01-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-003332-13/IT",
        "title": "A Phase 3, Randomized, Double-Blind Study Comparing ABT-494 to Placebo in Subjects with Moderately to Severely Active Rheumatoid Arthritis Who are on a Stable Dose of Conventional Synthetic Disease... - IT",
        "timestamp": "2016-01-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003536-23/CZ",
        "title": "A Randomized, Double-Blind, Double-Dummy Study Assessing The Safety and Tolerability of Sarilumab and Tocilizumab In Patients With Rheumatoid Arthritis Who Are Inadequate Responders to or Intoleran... - CZ",
        "timestamp": "2013-02-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003536-23/BE",
        "title": "A Randomized, Double-Blind, Double-Dummy Study Assessing The Safety and Tolerability of Sarilumab and Tocilizumab In Patients With Rheumatoid Arthritis Who Are Inadequate Responders to or Intoleran... - BE",
        "timestamp": "2013-02-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003536-23/HU",
        "title": "A Randomized, Double-Blind, Double-Dummy Study Assessing The Safety and Tolerability of Sarilumab and Tocilizumab In Patients With Rheumatoid Arthritis Who Are Inadequate Responders to or Intoleran... - HU",
        "timestamp": "2013-02-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003536-23/ES",
        "title": "A Randomized, Double-Blind, Double-Dummy Study Assessing The Safety and Tolerability of Sarilumab and Tocilizumab In Patients With Rheumatoid Arthritis Who Are Inadequate Responders to or Intoleran... - ES",
        "timestamp": "2013-02-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003536-23/IT",
        "title": "A Randomized, Double-Blind, Double-Dummy Study Assessing The Safety and Tolerability of Sarilumab and Tocilizumab In Patients With Rheumatoid Arthritis Who Are Inadequate Responders to or Intoleran... - IT",
        "timestamp": "2013-02-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003536-23/SE",
        "title": "A Randomized, Double-Blind, Double-Dummy Study Assessing The Safety and Tolerability of Sarilumab and Tocilizumab In Patients With Rheumatoid Arthritis Who Are Inadequate Responders to or Intoleran... - SE",
        "timestamp": "2013-02-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003536-23/EE",
        "title": "A Randomized, Double-Blind, Double-Dummy Study Assessing The Safety and Tolerability of Sarilumab and Tocilizumab In Patients With Rheumatoid Arthritis Who Are Inadequate Responders to or Intoleran... - EE",
        "timestamp": "2013-02-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003536-23/NO",
        "title": "A Randomized, Double-Blind, Double-Dummy Study Assessing The Safety and Tolerability of Sarilumab and Tocilizumab In Patients With Rheumatoid Arthritis Who Are Inadequate Responders to or Intoleran... - NO",
        "timestamp": "2013-02-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003536-23/FI",
        "title": "A Randomized, Double-Blind, Double-Dummy Study Assessing The Safety and Tolerability of Sarilumab and Tocilizumab In Patients With Rheumatoid Arthritis Who Are Inadequate Responders to or Intoleran... - FI",
        "timestamp": "2013-02-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003536-23/NL",
        "title": "A Randomized, Double-Blind, Double-Dummy Study Assessing The Safety and Tolerability of Sarilumab and Tocilizumab In Patients With Rheumatoid Arthritis Who Are Inadequate Responders to or Intoleran... - NL",
        "timestamp": "2013-02-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003536-23/GB",
        "title": "A Randomized, Double-Blind, Double-Dummy Study Assessing The Safety and Tolerability of Sarilumab and Tocilizumab In Patients With Rheumatoid Arthritis Who Are Inadequate Responders to or Intoleran... - GB",
        "timestamp": "2013-02-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003536-23/PL",
        "title": "A Randomized, Double-Blind, Double-Dummy Study Assessing The Safety and Tolerability of Sarilumab and Tocilizumab In Patients With Rheumatoid Arthritis Who Are Inadequate Responders to or Intoleran... - PL",
        "timestamp": "2013-02-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003536-23/results",
        "title": "A Randomized, Double-Blind, Double-Dummy Study Assessing The Safety and Tolerability of Sarilumab and Tocilizumab In Patients With Rheumatoid Arthritis Who Are Inadequate Responders to or Intoleran... - View results",
        "timestamp": "2013-02-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-000436-28/PL",
        "title": "A PHASE II, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTI-CENTER, RANDOMIZED WITHDRAWAL DESIGN TRIAL USING ADAPTIVE RANDOMIZATION COMPARING Z102 WITH PLACEBO IN PATIENTS WITH MODERATE TO SEVERE RHEUMATOI... - PL",
        "timestamp": "2011-12-07"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-000436-28/HU",
        "title": "A PHASE II, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTI-CENTER, RANDOMIZED WITHDRAWAL DESIGN TRIAL USING ADAPTIVE RANDOMIZATION COMPARING Z102 WITH PLACEBO IN PATIENTS WITH MODERATE TO SEVERE RHEUMATOI... - HU",
        "timestamp": "2011-12-07"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-000436-28/BG",
        "title": "A PHASE II, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTI-CENTER, RANDOMIZED WITHDRAWAL DESIGN TRIAL USING ADAPTIVE RANDOMIZATION COMPARING Z102 WITH PLACEBO IN PATIENTS WITH MODERATE TO SEVERE RHEUMATOI... - BG",
        "timestamp": "2011-12-07"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-001220-38/GB",
        "title": "A multicenter, 12 week, randomized, double-blind, placebo-controlled biomarker study of secukinumab (AIN457) in rheumatoid arthritis patients followed by an open label extension - GB",
        "timestamp": "2011-07-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-001220-38/DE",
        "title": "A multicenter, 12 week, randomized, double-blind, placebo-controlled biomarker study of secukinumab (AIN457) in rheumatoid arthritis patients followed by an open label extension - DE",
        "timestamp": "2011-07-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-001220-38/BE",
        "title": "A multicenter, 12 week, randomized, double-blind, placebo-controlled biomarker study of secukinumab (AIN457) in rheumatoid arthritis patients followed by an open label extension - BE",
        "timestamp": "2011-07-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-001220-38/results",
        "title": "A multicenter, 12 week, randomized, double-blind, placebo-controlled biomarker study of secukinumab (AIN457) in rheumatoid arthritis patients followed by an open label extension - View results",
        "timestamp": "2011-07-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-000305-23/BG",
        "title": "A Randomized Double-Blind Phase 1b/2 Combined Staggered Multiple Dose Escalation Study of BOS161721 in Systemic Lupus Erythematosus (SLE) Patients on a Background of Limited Standard of Care - BG",
        "timestamp": "2019-03-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-000305-23/HU",
        "title": "A Randomized Double-Blind Phase 1b/2 Combined Staggered Multiple Dose Escalation Study of BOS161721 in Systemic Lupus Erythematosus (SLE) Patients on a Background of Limited Standard of Care - HU",
        "timestamp": "2019-03-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-010939-40/NL",
        "title": "PLEASE Persistent Lyme Empiric Antibiotic Study Europe. A prospective, randomised study comparing two prolonged oral antibiotic strategies after initial intravenous ceftriaxone therapy for patients... - NL",
        "timestamp": "2010-04-29"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-002306-31/HU",
        "title": "A Phase 2, Multicenter, Double-Blind, Parallel Group Long Term Extension Study in Rheumatoid Arthritis Subjects Who Have Completed a Preceding Phase 2 Randomized Controlled Trial with ABBV-105 Give... - HU",
        "timestamp": "2019-03-08"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-002306-31/GB",
        "title": "A Phase 2, Multicenter, Double-Blind, Parallel Group Long Term Extension Study in Rheumatoid Arthritis Subjects Who Have Completed a Preceding Phase 2 Randomized Controlled Trial with ABBV-105 Give... - GB",
        "timestamp": "2019-03-08"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-002306-31/ES",
        "title": "A Phase 2, Multicenter, Double-Blind, Parallel Group Long Term Extension Study in Rheumatoid Arthritis Subjects Who Have Completed a Preceding Phase 2 Randomized Controlled Trial with ABBV-105 Give... - ES",
        "timestamp": "2019-03-08"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-004645-16/DE",
        "title": "A Multi-Center, Open-Label Trial to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of Subcutaneously Administered Belimumab, a Human Monoclonal Anti-BLyS Antibody, Plus Standard Therap... - DE",
        "timestamp": None
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-004645-16/NL",
        "title": "A Multi-Center, Open-Label Trial to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of Subcutaneously Administered Belimumab, a Human Monoclonal Anti-BLyS Antibody, Plus Standard Therap... - NL",
        "timestamp": None
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-004645-16/ES",
        "title": "A Multi-Center, Open-Label Trial to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of Subcutaneously Administered Belimumab, a Human Monoclonal Anti-BLyS Antibody, Plus Standard Therap... - ES",
        "timestamp": None
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-000328-16/DE",
        "title": "A Phase 2 Dose Ranging Study to Evaluate the Efficacy and Safety of AMG 570 in Subjects With Active Systemic Lupus Erythematosus (SLE) With Inadequate Response to Standard of Care (SOC) Therapy - DE",
        "timestamp": "2019-09-17"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-000328-16/HU",
        "title": "A Phase 2 Dose Ranging Study to Evaluate the Efficacy and Safety of AMG 570 in Subjects With Active Systemic Lupus Erythematosus (SLE) With Inadequate Response to Standard of Care (SOC) Therapy - HU",
        "timestamp": "2019-09-17"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-000328-16/FR",
        "title": "A Phase 2 Dose Ranging Study to Evaluate the Efficacy and Safety of AMG 570 in Subjects With Active Systemic Lupus Erythematosus (SLE) With Inadequate Response to Standard of Care (SOC) Therapy - FR",
        "timestamp": "2019-09-17"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-004293-10/CZ",
        "title": "A Randomized, Placebo-Controlled, Double-blind, Multicenter Study to Assess the Efficacy and Safety of Multiple Doses of BMS-986165 in Subjects with Active Psoriatic Arthritis (PsA) - CZ",
        "timestamp": "2019-07-22"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-004293-10/HU",
        "title": "A Randomized, Placebo-Controlled, Double-blind, Multicenter Study to Assess the Efficacy and Safety of Multiple Doses of BMS-986165 in Subjects with Active Psoriatic Arthritis (PsA) - HU",
        "timestamp": "2019-07-22"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-004293-10/ES",
        "title": "A Randomized, Placebo-Controlled, Double-blind, Multicenter Study to Assess the Efficacy and Safety of Multiple Doses of BMS-986165 in Subjects with Active Psoriatic Arthritis (PsA) - ES",
        "timestamp": "2019-07-22"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-002804-29/DE",
        "title": "A MULTICENTER, PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF BIMEKIZUMAB IN THE TREATMENT OF SUBJECTS WITH ACTIVE PSORIATIC ARTHRITIS - DE",
        "timestamp": "2019-06-26"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-002804-29/GB",
        "title": "A MULTICENTER, PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF BIMEKIZUMAB IN THE TREATMENT OF SUBJECTS WITH ACTIVE PSORIATIC ARTHRITIS - GB",
        "timestamp": "2019-06-26"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-002804-29/CZ",
        "title": "A MULTICENTER, PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF BIMEKIZUMAB IN THE TREATMENT OF SUBJECTS WITH ACTIVE PSORIATIC ARTHRITIS - CZ",
        "timestamp": "2019-06-26"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-001944-36/ES",
        "title": "A Phase 1b/2a Study to Evaluate the Safety and Efficacy of AMG 592 in Subjects with Active Rheumatoid Arthritis With Inadequate Response to Standard of Care Therapy - ES",
        "timestamp": "2018-05-21"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-001944-36/PL",
        "title": "A Phase 1b/2a Study to Evaluate the Safety and Efficacy of AMG 592 in Subjects with Active Rheumatoid Arthritis With Inadequate Response to Standard of Care Therapy - PL",
        "timestamp": "2018-05-21"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-001944-36/BG",
        "title": "A Phase 1b/2a Study to Evaluate the Safety and Efficacy of AMG 592 in Subjects with Active Rheumatoid Arthritis With Inadequate Response to Standard of Care Therapy - BG",
        "timestamp": "2018-05-21"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-003495-38/IE",
        "title": "A randomized, double-blind, placebo-controlled study to determine the efficacy and safety of 5 dose regimens of RO4402257 in patients with active rheumatoid arthritis (RA) on stable methotrexate (M... - IE",
        "timestamp": "2005-11-17"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-003495-38/ES",
        "title": "A randomized, double-blind, placebo-controlled study to determine the efficacy and safety of 5 dose regimens of RO4402257 in patients with active rheumatoid arthritis (RA) on stable methotrexate (M... - ES",
        "timestamp": "2005-11-17"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-003495-38/DE",
        "title": "A randomized, double-blind, placebo-controlled study to determine the efficacy and safety of 5 dose regimens of RO4402257 in patients with active rheumatoid arthritis (RA) on stable methotrexate (M... - DE",
        "timestamp": "2005-11-17"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-003495-38/GB",
        "title": "A randomized, double-blind, placebo-controlled study to determine the efficacy and safety of 5 dose regimens of RO4402257 in patients with active rheumatoid arthritis (RA) on stable methotrexate (M... - GB",
        "timestamp": "2005-11-17"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-003495-38/EE",
        "title": "A randomized, double-blind, placebo-controlled study to determine the efficacy and safety of 5 dose regimens of RO4402257 in patients with active rheumatoid arthritis (RA) on stable methotrexate (M... - EE",
        "timestamp": "2005-11-17"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-003495-38/GR",
        "title": "A randomized, double-blind, placebo-controlled study to determine the efficacy and safety of 5 dose regimens of RO4402257 in patients with active rheumatoid arthritis (RA) on stable methotrexate (M... - GR",
        "timestamp": "2005-11-17"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-003495-38/results",
        "title": "A randomized, double-blind, placebo-controlled study to determine the efficacy and safety of 5 dose regimens of RO4402257 in patients with active rheumatoid arthritis (RA) on stable methotrexate (M... - View results",
        "timestamp": "2005-11-17"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-002219-26/SE",
        "title": "A randomised, parallel group, placebo-controlled, double blind study to assess the safety and tolerability of SB-681323 at 7.5mg daily dose for 28 days and its effect on the levels of serum C-react... - SE",
        "timestamp": "2005-09-08"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-002219-26/NO",
        "title": "A randomised, parallel group, placebo-controlled, double blind study to assess the safety and tolerability of SB-681323 at 7.5mg daily dose for 28 days and its effect on the levels of serum C-react... - NO",
        "timestamp": "2005-09-08"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-002219-26/DE",
        "title": "A randomised, parallel group, placebo-controlled, double blind study to assess the safety and tolerability of SB-681323 at 7.5mg daily dose for 28 days and its effect on the levels of serum C-react... - DE",
        "timestamp": "2005-09-08"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-002219-26/DK",
        "title": "A randomised, parallel group, placebo-controlled, double blind study to assess the safety and tolerability of SB-681323 at 7.5mg daily dose for 28 days and its effect on the levels of serum C-react... - DK",
        "timestamp": "2005-09-08"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-002219-26/ES",
        "title": "A randomised, parallel group, placebo-controlled, double blind study to assess the safety and tolerability of SB-681323 at 7.5mg daily dose for 28 days and its effect on the levels of serum C-react... - ES",
        "timestamp": "2005-09-08"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-002219-26/GB",
        "title": "A randomised, parallel group, placebo-controlled, double blind study to assess the safety and tolerability of SB-681323 at 7.5mg daily dose for 28 days and its effect on the levels of serum C-react... - GB",
        "timestamp": "2005-09-08"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-002219-26/HU",
        "title": "A randomised, parallel group, placebo-controlled, double blind study to assess the safety and tolerability of SB-681323 at 7.5mg daily dose for 28 days and its effect on the levels of serum C-react... - HU",
        "timestamp": "2005-09-08"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-002219-26/IT",
        "title": "A randomised, parallel group, placebo-controlled, double blind study to assess the safety and tolerability of SB-681323 at 7.5mg daily dose for 28 days and its effect on the levels of serum C-react... - IT",
        "timestamp": "2005-09-08"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-002219-26/results",
        "title": "A randomised, parallel group, placebo-controlled, double blind study to assess the safety and tolerability of SB-681323 at 7.5mg daily dose for 28 days and its effect on the levels of serum C-react... - View results",
        "timestamp": "2005-09-08"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-003558-15/DE",
        "title": "A Phase 2 Study to Investigate the Safety, Tolerability and Efficacy of ABT-122 in Subjects with Active Psoriatic Arthritis Who Have an Inadequate Response to Methotrexate - DE",
        "timestamp": "2015-07-14"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-003558-15/LV",
        "title": "A Phase 2 Study to Investigate the Safety, Tolerability and Efficacy of ABT-122 in Subjects with Active Psoriatic Arthritis Who Have an Inadequate Response to Methotrexate - LV",
        "timestamp": "2015-07-14"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-003558-15/HU",
        "title": "A Phase 2 Study to Investigate the Safety, Tolerability and Efficacy of ABT-122 in Subjects with Active Psoriatic Arthritis Who Have an Inadequate Response to Methotrexate - HU",
        "timestamp": "2015-07-14"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-003558-15/CZ",
        "title": "A Phase 2 Study to Investigate the Safety, Tolerability and Efficacy of ABT-122 in Subjects with Active Psoriatic Arthritis Who Have an Inadequate Response to Methotrexate - CZ",
        "timestamp": "2015-07-14"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-003558-15/ES",
        "title": "A Phase 2 Study to Investigate the Safety, Tolerability and Efficacy of ABT-122 in Subjects with Active Psoriatic Arthritis Who Have an Inadequate Response to Methotrexate - ES",
        "timestamp": "2015-07-14"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-003558-15/BG",
        "title": "A Phase 2 Study to Investigate the Safety, Tolerability and Efficacy of ABT-122 in Subjects with Active Psoriatic Arthritis Who Have an Inadequate Response to Methotrexate - BG",
        "timestamp": "2015-07-14"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-003558-15/results",
        "title": "A Phase 2 Study to Investigate the Safety, Tolerability and Efficacy of ABT-122 in Subjects with Active Psoriatic Arthritis Who Have an Inadequate Response to Methotrexate - View results",
        "timestamp": "2015-07-14"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-001742-16/GB",
        "title": "A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, a Fully Human Anti-TNFalfa Monoclonal Antibody, Administered Subcutaneously in Subjects with Active Rheumatoid Arthri... - GB",
        "timestamp": "2006-05-26"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-001742-16/NL",
        "title": "A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, a Fully Human Anti-TNFalfa Monoclonal Antibody, Administered Subcutaneously in Subjects with Active Rheumatoid Arthri... - NL",
        "timestamp": "2006-05-26"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-001742-16/DE",
        "title": "A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, a Fully Human Anti-TNFalfa Monoclonal Antibody, Administered Subcutaneously in Subjects with Active Rheumatoid Arthri... - DE",
        "timestamp": "2006-05-26"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-001742-16/AT",
        "title": "A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, a Fully Human Anti-TNFalfa Monoclonal Antibody, Administered Subcutaneously in Subjects with Active Rheumatoid Arthri... - AT",
        "timestamp": "2006-05-26"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-001742-16/FI",
        "title": "A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, a Fully Human Anti-TNFalfa Monoclonal Antibody, Administered Subcutaneously in Subjects with Active Rheumatoid Arthri... - FI",
        "timestamp": "2006-05-26"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-001742-16/ES",
        "title": "A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, a Fully Human Anti-TNFalfa Monoclonal Antibody, Administered Subcutaneously in Subjects with Active Rheumatoid Arthri... - ES",
        "timestamp": "2006-05-26"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-001742-16/results",
        "title": "A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, a Fully Human Anti-TNFalfa Monoclonal Antibody, Administered Subcutaneously in Subjects with Active Rheumatoid Arthri... - View results",
        "timestamp": "2006-05-26"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-002322-20/DE",
        "title": "A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, ACTIVE REFERENCE (ADALIMUMAB) STUDY EVALUATING THE EFFICACY AND SAFETY OF BIMEKIZUMAB IN THE TREATMENT OF SUBJECTS WITH ACTIVE ... - DE",
        "timestamp": "2019-06-26"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-002322-20/GB",
        "title": "A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, ACTIVE REFERENCE (ADALIMUMAB) STUDY EVALUATING THE EFFICACY AND SAFETY OF BIMEKIZUMAB IN THE TREATMENT OF SUBJECTS WITH ACTIVE ... - GB",
        "timestamp": "2019-06-26"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-002322-20/FR",
        "title": "A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, ACTIVE REFERENCE (ADALIMUMAB) STUDY EVALUATING THE EFFICACY AND SAFETY OF BIMEKIZUMAB IN THE TREATMENT OF SUBJECTS WITH ACTIVE ... - FR",
        "timestamp": "2019-06-26"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-002322-20/HU",
        "title": "A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, ACTIVE REFERENCE (ADALIMUMAB) STUDY EVALUATING THE EFFICACY AND SAFETY OF BIMEKIZUMAB IN THE TREATMENT OF SUBJECTS WITH ACTIVE ... - HU",
        "timestamp": "2019-06-26"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-002322-20/ES",
        "title": "A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, ACTIVE REFERENCE (ADALIMUMAB) STUDY EVALUATING THE EFFICACY AND SAFETY OF BIMEKIZUMAB IN THE TREATMENT OF SUBJECTS WITH ACTIVE ... - ES",
        "timestamp": "2019-06-26"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-002322-20/CZ",
        "title": "A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, ACTIVE REFERENCE (ADALIMUMAB) STUDY EVALUATING THE EFFICACY AND SAFETY OF BIMEKIZUMAB IN THE TREATMENT OF SUBJECTS WITH ACTIVE ... - CZ",
        "timestamp": "2019-06-26"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-002392-41/HU",
        "title": "A PHASE II, DOUBLE-BLIND, CONTROLLED, MULTI-CENTER, RANDOMIZED, LONG TERM SAFETY TRIAL OF Z102 AND PREDNISONE (5 MG OR 7.5 MG) IN PATIENTS WITH MODERATE TO SEVERE RHEUMATOID ARTHRITIS - HU",
        "timestamp": "2012-03-28"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-002392-41/BG",
        "title": "A PHASE II, DOUBLE-BLIND, CONTROLLED, MULTI-CENTER, RANDOMIZED, LONG TERM SAFETY TRIAL OF Z102 AND PREDNISONE (5 MG OR 7.5 MG) IN PATIENTS WITH MODERATE TO SEVERE RHEUMATOID ARTHRITIS - BG",
        "timestamp": "2012-03-28"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-003780-65/IT",
        "title": "A Phase IIb, Randomized, Multi-Center, Double-Blind, Dose-Ranging Study to Evaluate the Efficacy and Safety of Clazakizumab in Subjects with Moderate to Severe Active Rheumatoid Arthritis who have ... - IT",
        "timestamp": "2014-03-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-003780-65/HU",
        "title": "A Phase IIb, Randomized, Multi-Center, Double-Blind, Dose-Ranging Study to Evaluate the Efficacy and Safety of Clazakizumab in Subjects with Moderate to Severe Active Rheumatoid Arthritis who have ... - HU",
        "timestamp": "2014-03-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-003780-65/results",
        "title": "A Phase IIb, Randomized, Multi-Center, Double-Blind, Dose-Ranging Study to Evaluate the Efficacy and Safety of Clazakizumab in Subjects with Moderate to Severe Active Rheumatoid Arthritis who have ... - View results",
        "timestamp": "2014-03-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-016068-35/BE",
        "title": "A randomized double blind-placebo controlled dose ranging study to evaluate the efficacy and safety of SAR153191 in patients with Ankylosing Spondylitis (AS) - BE",
        "timestamp": "2010-02-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-016068-35/DE",
        "title": "A randomized double blind-placebo controlled dose ranging study to evaluate the efficacy and safety of SAR153191 in patients with Ankylosing Spondylitis (AS) - DE",
        "timestamp": "2010-02-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-016068-35/FR",
        "title": "A randomized double blind-placebo controlled dose ranging study to evaluate the efficacy and safety of SAR153191 in patients with Ankylosing Spondylitis (AS) - FR",
        "timestamp": "2010-02-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-016068-35/HU",
        "title": "A randomized double blind-placebo controlled dose ranging study to evaluate the efficacy and safety of SAR153191 in patients with Ankylosing Spondylitis (AS) - HU",
        "timestamp": "2010-02-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-016068-35/ES",
        "title": "A randomized double blind-placebo controlled dose ranging study to evaluate the efficacy and safety of SAR153191 in patients with Ankylosing Spondylitis (AS) - ES",
        "timestamp": "2010-02-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-016068-35/LT",
        "title": "A randomized double blind-placebo controlled dose ranging study to evaluate the efficacy and safety of SAR153191 in patients with Ankylosing Spondylitis (AS) - LT",
        "timestamp": "2010-02-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-016068-35/AT",
        "title": "A randomized double blind-placebo controlled dose ranging study to evaluate the efficacy and safety of SAR153191 in patients with Ankylosing Spondylitis (AS) - AT",
        "timestamp": "2010-02-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-016068-35/CZ",
        "title": "A randomized double blind-placebo controlled dose ranging study to evaluate the efficacy and safety of SAR153191 in patients with Ankylosing Spondylitis (AS) - CZ",
        "timestamp": "2010-02-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-016068-35/NL",
        "title": "A randomized double blind-placebo controlled dose ranging study to evaluate the efficacy and safety of SAR153191 in patients with Ankylosing Spondylitis (AS) - NL",
        "timestamp": "2010-02-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-016068-35/results",
        "title": "A randomized double blind-placebo controlled dose ranging study to evaluate the efficacy and safety of SAR153191 in patients with Ankylosing Spondylitis (AS) - View results",
        "timestamp": "2010-02-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-019689-10/DE",
        "title": "A multi-center, double-blind, placebo-controlled, proof-of-concept study to evaluate the efficacy and tolerability of KRP203 in patients with active subacute cutaneous lupus erythematosus - DE",
        "timestamp": "2010-09-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-019689-10/IT",
        "title": "A multi-center, double-blind, placebo-controlled, proof-of-concept study to evaluate the efficacy and tolerability of KRP203 in patients with active subacute cutaneous lupus erythematosus - IT",
        "timestamp": "2010-09-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-019689-10/GR",
        "title": "A multi-center, double-blind, placebo-controlled, proof-of-concept study to evaluate the efficacy and tolerability of KRP203 in patients with active subacute cutaneous lupus erythematosus - GR",
        "timestamp": "2010-09-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-019689-10/results",
        "title": "A multi-center, double-blind, placebo-controlled, proof-of-concept study to evaluate the efficacy and tolerability of KRP203 in patients with active subacute cutaneous lupus erythematosus - View results",
        "timestamp": "2010-09-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-005026-37/GB",
        "title": "A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients with Systemic Lupus Erythematosus - GB",
        "timestamp": "2019-03-27"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-005026-37/AT",
        "title": "A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients with Systemic Lupus Erythematosus - AT",
        "timestamp": "2019-03-27"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-005026-37/BE",
        "title": "A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients with Systemic Lupus Erythematosus - BE",
        "timestamp": "2019-03-27"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-005026-37/HU",
        "title": "A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients with Systemic Lupus Erythematosus - HU",
        "timestamp": "2019-03-27"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-005026-37/CZ",
        "title": "A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients with Systemic Lupus Erythematosus - CZ",
        "timestamp": "2019-03-27"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-005026-37/GR",
        "title": "A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients with Systemic Lupus Erythematosus - GR",
        "timestamp": "2019-03-27"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-005026-37/NL",
        "title": "A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients with Systemic Lupus Erythematosus - NL",
        "timestamp": "2019-03-27"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-005026-37/HR",
        "title": "A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients with Systemic Lupus Erythematosus - HR",
        "timestamp": "2019-03-27"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-003335-35/DE",
        "title": "A Phase 3, Randomized, Double-Blind Study Comparing Upadacitinib (ABT-494) to Placebo on Stable Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs) in Subjects with Moderately ... - DE",
        "timestamp": "2016-05-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-003335-35/BE",
        "title": "A Phase 3, Randomized, Double-Blind Study Comparing Upadacitinib (ABT-494) to Placebo on Stable Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs) in Subjects with Moderately ... - BE",
        "timestamp": "2016-05-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-003335-35/IE",
        "title": "A Phase 3, Randomized, Double-Blind Study Comparing Upadacitinib (ABT-494) to Placebo on Stable Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs) in Subjects with Moderately ... - IE",
        "timestamp": "2016-05-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-003335-35/ES",
        "title": "A Phase 3, Randomized, Double-Blind Study Comparing Upadacitinib (ABT-494) to Placebo on Stable Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs) in Subjects with Moderately ... - ES",
        "timestamp": "2016-05-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-003335-35/DK",
        "title": "A Phase 3, Randomized, Double-Blind Study Comparing Upadacitinib (ABT-494) to Placebo on Stable Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs) in Subjects with Moderately ... - DK",
        "timestamp": "2016-05-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-003335-35/CZ",
        "title": "A Phase 3, Randomized, Double-Blind Study Comparing Upadacitinib (ABT-494) to Placebo on Stable Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs) in Subjects with Moderately ... - CZ",
        "timestamp": "2016-05-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-003335-35/SE",
        "title": "A Phase 3, Randomized, Double-Blind Study Comparing Upadacitinib (ABT-494) to Placebo on Stable Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs) in Subjects with Moderately ... - SE",
        "timestamp": "2016-05-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-003335-35/GB",
        "title": "A Phase 3, Randomized, Double-Blind Study Comparing Upadacitinib (ABT-494) to Placebo on Stable Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs) in Subjects with Moderately ... - GB",
        "timestamp": "2016-05-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-003335-35/HU",
        "title": "A Phase 3, Randomized, Double-Blind Study Comparing Upadacitinib (ABT-494) to Placebo on Stable Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs) in Subjects with Moderately ... - HU",
        "timestamp": "2016-05-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-003335-35/SK",
        "title": "A Phase 3, Randomized, Double-Blind Study Comparing Upadacitinib (ABT-494) to Placebo on Stable Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs) in Subjects with Moderately ... - SK",
        "timestamp": "2016-05-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-003335-35/PT",
        "title": "A Phase 3, Randomized, Double-Blind Study Comparing Upadacitinib (ABT-494) to Placebo on Stable Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs) in Subjects with Moderately ... - PT",
        "timestamp": "2016-05-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-003335-35/LV",
        "title": "A Phase 3, Randomized, Double-Blind Study Comparing Upadacitinib (ABT-494) to Placebo on Stable Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs) in Subjects with Moderately ... - LV",
        "timestamp": "2016-05-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-003335-35/AT",
        "title": "A Phase 3, Randomized, Double-Blind Study Comparing Upadacitinib (ABT-494) to Placebo on Stable Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs) in Subjects with Moderately ... - AT",
        "timestamp": "2016-05-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-003335-35/FI",
        "title": "A Phase 3, Randomized, Double-Blind Study Comparing Upadacitinib (ABT-494) to Placebo on Stable Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs) in Subjects with Moderately ... - FI",
        "timestamp": "2016-05-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-003335-35/GR",
        "title": "A Phase 3, Randomized, Double-Blind Study Comparing Upadacitinib (ABT-494) to Placebo on Stable Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs) in Subjects with Moderately ... - GR",
        "timestamp": "2016-05-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-003335-35/BG",
        "title": "A Phase 3, Randomized, Double-Blind Study Comparing Upadacitinib (ABT-494) to Placebo on Stable Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs) in Subjects with Moderately ... - BG",
        "timestamp": "2016-05-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-003335-35/SI",
        "title": "A Phase 3, Randomized, Double-Blind Study Comparing Upadacitinib (ABT-494) to Placebo on Stable Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs) in Subjects with Moderately ... - SI",
        "timestamp": "2016-05-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-003335-35/IT",
        "title": "A Phase 3, Randomized, Double-Blind Study Comparing Upadacitinib (ABT-494) to Placebo on Stable Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs) in Subjects with Moderately ... - IT",
        "timestamp": "2016-05-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-003084-37/CZ",
        "title": "A phase I/II study to evaluate safety and efficacy of DCVAC/LuCa added to standard first line chemotherapy with carboplatin and paclitaxel +/- immune enhancers (interferon-α and hydroxychloroquine)... - CZ",
        "timestamp": "2014-10-15"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-003084-37/SK",
        "title": "A phase I/II study to evaluate safety and efficacy of DCVAC/LuCa added to standard first line chemotherapy with carboplatin and paclitaxel +/- immune enhancers (interferon-α and hydroxychloroquine)... - SK",
        "timestamp": "2014-10-15"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-000933-37/HU",
        "title": "A Phase 3, Randomized, Active-Controlled, Double Blind Study Comparing ABT-494 to Abatacept in Subjects with Moderately to Severely Active Rheumatoid Arthritis with Inadequate Response or Intoleran... - HU",
        "timestamp": "2016-11-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-000933-37/DE",
        "title": "A Phase 3, Randomized, Active-Controlled, Double Blind Study Comparing ABT-494 to Abatacept in Subjects with Moderately to Severely Active Rheumatoid Arthritis with Inadequate Response or Intoleran... - DE",
        "timestamp": "2016-11-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-000933-37/LV",
        "title": "A Phase 3, Randomized, Active-Controlled, Double Blind Study Comparing ABT-494 to Abatacept in Subjects with Moderately to Severely Active Rheumatoid Arthritis with Inadequate Response or Intoleran... - LV",
        "timestamp": "2016-11-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-000933-37/PT",
        "title": "A Phase 3, Randomized, Active-Controlled, Double Blind Study Comparing ABT-494 to Abatacept in Subjects with Moderately to Severely Active Rheumatoid Arthritis with Inadequate Response or Intoleran... - PT",
        "timestamp": "2016-11-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-000933-37/SE",
        "title": "A Phase 3, Randomized, Active-Controlled, Double Blind Study Comparing ABT-494 to Abatacept in Subjects with Moderately to Severely Active Rheumatoid Arthritis with Inadequate Response or Intoleran... - SE",
        "timestamp": "2016-11-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-000933-37/ES",
        "title": "A Phase 3, Randomized, Active-Controlled, Double Blind Study Comparing ABT-494 to Abatacept in Subjects with Moderately to Severely Active Rheumatoid Arthritis with Inadequate Response or Intoleran... - ES",
        "timestamp": "2016-11-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-000933-37/CZ",
        "title": "A Phase 3, Randomized, Active-Controlled, Double Blind Study Comparing ABT-494 to Abatacept in Subjects with Moderately to Severely Active Rheumatoid Arthritis with Inadequate Response or Intoleran... - CZ",
        "timestamp": "2016-11-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-000933-37/BE",
        "title": "A Phase 3, Randomized, Active-Controlled, Double Blind Study Comparing ABT-494 to Abatacept in Subjects with Moderately to Severely Active Rheumatoid Arthritis with Inadequate Response or Intoleran... - BE",
        "timestamp": "2016-11-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-000933-37/NL",
        "title": "A Phase 3, Randomized, Active-Controlled, Double Blind Study Comparing ABT-494 to Abatacept in Subjects with Moderately to Severely Active Rheumatoid Arthritis with Inadequate Response or Intoleran... - NL",
        "timestamp": "2016-11-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-000933-37/SK",
        "title": "A Phase 3, Randomized, Active-Controlled, Double Blind Study Comparing ABT-494 to Abatacept in Subjects with Moderately to Severely Active Rheumatoid Arthritis with Inadequate Response or Intoleran... - SK",
        "timestamp": "2016-11-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-000933-37/BG",
        "title": "A Phase 3, Randomized, Active-Controlled, Double Blind Study Comparing ABT-494 to Abatacept in Subjects with Moderately to Severely Active Rheumatoid Arthritis with Inadequate Response or Intoleran... - BG",
        "timestamp": "2016-11-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005667-25/HU",
        "title": "A Randomized, Double-Blind, Placebo-Controlled 52-Week Study\r\nto Assess Adverse Events of Special Interest in Adults with Active, Autoantibody-Positive Systemic Lupus Erythematosus Receiving Belimumab - HU",
        "timestamp": "2013-01-22"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005667-25/LT",
        "title": "A Randomized, Double-Blind, Placebo-Controlled 52-Week Study\r\nto Assess Adverse Events of Special Interest in Adults with Active, Autoantibody-Positive Systemic Lupus Erythematosus Receiving Belimumab - LT",
        "timestamp": "2013-01-22"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005667-25/CZ",
        "title": "A Randomized, Double-Blind, Placebo-Controlled 52-Week Study\r\nto Assess Adverse Events of Special Interest in Adults with Active, Autoantibody-Positive Systemic Lupus Erythematosus Receiving Belimumab - CZ",
        "timestamp": "2013-01-22"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005667-25/EE",
        "title": "A Randomized, Double-Blind, Placebo-Controlled 52-Week Study\r\nto Assess Adverse Events of Special Interest in Adults with Active, Autoantibody-Positive Systemic Lupus Erythematosus Receiving Belimumab - EE",
        "timestamp": "2013-01-22"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005667-25/ES",
        "title": "A Randomized, Double-Blind, Placebo-Controlled 52-Week Study\r\nto Assess Adverse Events of Special Interest in Adults with Active, Autoantibody-Positive Systemic Lupus Erythematosus Receiving Belimumab - ES",
        "timestamp": "2013-01-22"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005667-25/IT",
        "title": "A Randomized, Double-Blind, Placebo-Controlled 52-Week Study\r\nto Assess Adverse Events of Special Interest in Adults with Active, Autoantibody-Positive Systemic Lupus Erythematosus Receiving Belimumab - IT",
        "timestamp": "2013-01-22"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005667-25/PT",
        "title": "A Randomized, Double-Blind, Placebo-Controlled 52-Week Study\r\nto Assess Adverse Events of Special Interest in Adults with Active, Autoantibody-Positive Systemic Lupus Erythematosus Receiving Belimumab - PT",
        "timestamp": "2013-01-22"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005667-25/BG",
        "title": "A Randomized, Double-Blind, Placebo-Controlled 52-Week Study\r\nto Assess Adverse Events of Special Interest in Adults with Active, Autoantibody-Positive Systemic Lupus Erythematosus Receiving Belimumab - BG",
        "timestamp": "2013-01-22"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005667-25/SK",
        "title": "A Randomized, Double-Blind, Placebo-Controlled 52-Week Study\r\nto Assess Adverse Events of Special Interest in Adults with Active, Autoantibody-Positive Systemic Lupus Erythematosus Receiving Belimumab - SK",
        "timestamp": "2013-01-22"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005667-25/PL",
        "title": "A Randomized, Double-Blind, Placebo-Controlled 52-Week Study\r\nto Assess Adverse Events of Special Interest in Adults with Active, Autoantibody-Positive Systemic Lupus Erythematosus Receiving Belimumab - PL",
        "timestamp": "2013-01-22"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005667-25/RO",
        "title": "A Randomized, Double-Blind, Placebo-Controlled 52-Week Study\r\nto Assess Adverse Events of Special Interest in Adults with Active, Autoantibody-Positive Systemic Lupus Erythematosus Receiving Belimumab - RO",
        "timestamp": "2013-01-22"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005667-25/results",
        "title": "A Randomized, Double-Blind, Placebo-Controlled 52-Week Study\r\nto Assess Adverse Events of Special Interest in Adults with Active, Autoantibody-Positive Systemic Lupus Erythematosus Receiving Belimumab - View results",
        "timestamp": "2013-01-22"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-006603-20/HU",
        "title": "A Phase 2, 2-Part, Multicenter, Randomized, Double-blind,\nParallel-group, Placebo-controlled, Proof-of-concept, dose-finding\nStudy Evaluating the Efficacy and Safety of CNTO 136\nAdministered Subcut... - HU",
        "timestamp": "2009-07-29"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-006603-20/results",
        "title": "A Phase 2, 2-Part, Multicenter, Randomized, Double-blind,\nParallel-group, Placebo-controlled, Proof-of-concept, dose-finding\nStudy Evaluating the Efficacy and Safety of CNTO 136\nAdministered Subcut... - View results",
        "timestamp": "2009-07-29"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-007018-12/ES",
        "title": "“Estudio prospectivo, abierto, aleatorizado y cruzado sobre el efecto de la Hidroxicloroquina, 200mg al día, en factores inflamatorios y metabólicos relacionados con la enfermedad cardiovascular en... - ES",
        "timestamp": "2008-06-23"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-005389-51/FR",
        "title": "Safety and Efficacy of tocilizuMAb versus placebo in Polymyalgia rHeumatica with glucocORticoid dEpendence SEMAPHORE - FR",
        "timestamp": "2017-10-06"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-000957-37/CZ",
        "title": "A Multicenter, Phase 2A, Randomized, Investigator-Blind, Subject-Blind, Parallel-Group Study to Evaluate the Efficacy and Safety of Bimekizumab and Certolizumab Pegol in Subjects with Active Ankylo... - CZ",
        "timestamp": "2017-09-25"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-000957-37/DE",
        "title": "A Multicenter, Phase 2A, Randomized, Investigator-Blind, Subject-Blind, Parallel-Group Study to Evaluate the Efficacy and Safety of Bimekizumab and Certolizumab Pegol in Subjects with Active Ankylo... - DE",
        "timestamp": "2017-09-25"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-000957-37/GR",
        "title": "A Multicenter, Phase 2A, Randomized, Investigator-Blind, Subject-Blind, Parallel-Group Study to Evaluate the Efficacy and Safety of Bimekizumab and Certolizumab Pegol in Subjects with Active Ankylo... - GR",
        "timestamp": "2017-09-25"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-000957-37/NL",
        "title": "A Multicenter, Phase 2A, Randomized, Investigator-Blind, Subject-Blind, Parallel-Group Study to Evaluate the Efficacy and Safety of Bimekizumab and Certolizumab Pegol in Subjects with Active Ankylo... - NL",
        "timestamp": "2017-09-25"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-003025-93/FR",
        "title": "Etude de la réduction des poussées de lupus érythémateux systémique par adaptation de la posologie de l'hydroxychloroquine à sa concentration sanguine. Etude randomisée multicentrique nationale. - FR",
        "timestamp": "2007-01-23"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-007637-39/DE",
        "title": "Effects of NSAIDs on RAdiographic Damage in AS (ENRADAS) \n– a prospective randomised controlled trial - Amendment 2 - DE",
        "timestamp": "2008-12-17"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-007346-63/GB",
        "title": "Reumap: An Open Label phase II study of Bovine Intestinal Alkaline Phosphatase (bIAP), An Inflammation modulating moiety, in RA patients - GB",
        "timestamp": "2011-04-05"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-002564-40/DE",
        "title": "A Phase 1b/2a Study to Evaluate the Safety and Efficacy of AMG 592 in Subjects With Active Systemic Lupus Erythematosus With Inadequate Response to Standard of Care Therapy. - DE",
        "timestamp": "2018-04-10"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-019964-36/BE",
        "title": "A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Safety and Efficacy of CCX354-C in Subjects with Rheumatoid Arthritis Partially Responsive to Methotrexate Therapy - BE",
        "timestamp": "2010-08-26"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-019964-36/HU",
        "title": "A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Safety and Efficacy of CCX354-C in Subjects with Rheumatoid Arthritis Partially Responsive to Methotrexate Therapy - HU",
        "timestamp": "2010-08-26"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-019964-36/CZ",
        "title": "A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Safety and Efficacy of CCX354-C in Subjects with Rheumatoid Arthritis Partially Responsive to Methotrexate Therapy - CZ",
        "timestamp": "2010-08-26"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-019964-36/DE",
        "title": "A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Safety and Efficacy of CCX354-C in Subjects with Rheumatoid Arthritis Partially Responsive to Methotrexate Therapy - DE",
        "timestamp": "2010-08-26"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-004529-28/HU",
        "title": "A Phase 2a, Randomized, Multicenter, Double-blind, Placebo-controlled, Parallel-group Study of JNJ-40346527 in Subjects with Active Rheumatoid Arthritis Despite Disease-modifying Antirheumatic Drug... - HU",
        "timestamp": "2012-04-18"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-004529-28/PL",
        "title": "A Phase 2a, Randomized, Multicenter, Double-blind, Placebo-controlled, Parallel-group Study of JNJ-40346527 in Subjects with Active Rheumatoid Arthritis Despite Disease-modifying Antirheumatic Drug... - PL",
        "timestamp": "2012-04-18"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-004529-28/CZ",
        "title": "A Phase 2a, Randomized, Multicenter, Double-blind, Placebo-controlled, Parallel-group Study of JNJ-40346527 in Subjects with Active Rheumatoid Arthritis Despite Disease-modifying Antirheumatic Drug... - CZ",
        "timestamp": "2012-04-18"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-004529-28/BG",
        "title": "A Phase 2a, Randomized, Multicenter, Double-blind, Placebo-controlled, Parallel-group Study of JNJ-40346527 in Subjects with Active Rheumatoid Arthritis Despite Disease-modifying Antirheumatic Drug... - BG",
        "timestamp": "2012-04-18"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-004529-28/results",
        "title": "A Phase 2a, Randomized, Multicenter, Double-blind, Placebo-controlled, Parallel-group Study of JNJ-40346527 in Subjects with Active Rheumatoid Arthritis Despite Disease-modifying Antirheumatic Drug... - View results",
        "timestamp": "2012-04-18"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-001999-38/BE",
        "title": "A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Clinical Efficacy of Neovacs’ TNF-Kinoid in Adult Subjects with Active Rheumatoid Arthritis despite Methotrexate Therapy - BE",
        "timestamp": "2013-10-07"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-001999-38/HU",
        "title": "A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Clinical Efficacy of Neovacs’ TNF-Kinoid in Adult Subjects with Active Rheumatoid Arthritis despite Methotrexate Therapy - HU",
        "timestamp": "2013-10-07"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-001999-38/CZ",
        "title": "A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Clinical Efficacy of Neovacs’ TNF-Kinoid in Adult Subjects with Active Rheumatoid Arthritis despite Methotrexate Therapy - CZ",
        "timestamp": "2013-10-07"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-001999-38/PL",
        "title": "A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Clinical Efficacy of Neovacs’ TNF-Kinoid in Adult Subjects with Active Rheumatoid Arthritis despite Methotrexate Therapy - PL",
        "timestamp": "2013-10-07"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-012520-84/HU",
        "title": "A 2-Part Open-label Study to Assess the Clinical Benefit and Long-term Safety of Etanercept in Children and Adolescents With Extended Oligoarticular Juvenile Idiopathic Arthritis, Enthesitis-Relate... - HU",
        "timestamp": "2009-08-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-012520-84/DE",
        "title": "A 2-Part Open-label Study to Assess the Clinical Benefit and Long-term Safety of Etanercept in Children and Adolescents With Extended Oligoarticular Juvenile Idiopathic Arthritis, Enthesitis-Relate... - DE",
        "timestamp": "2009-08-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-012520-84/BE",
        "title": "A 2-Part Open-label Study to Assess the Clinical Benefit and Long-term Safety of Etanercept in Children and Adolescents With Extended Oligoarticular Juvenile Idiopathic Arthritis, Enthesitis-Relate... - BE",
        "timestamp": "2009-08-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-012520-84/CZ",
        "title": "A 2-Part Open-label Study to Assess the Clinical Benefit and Long-term Safety of Etanercept in Children and Adolescents With Extended Oligoarticular Juvenile Idiopathic Arthritis, Enthesitis-Relate... - CZ",
        "timestamp": "2009-08-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-012520-84/FR",
        "title": "A 2-Part Open-label Study to Assess the Clinical Benefit and Long-term Safety of Etanercept in Children and Adolescents With Extended Oligoarticular Juvenile Idiopathic Arthritis, Enthesitis-Relate... - FR",
        "timestamp": "2009-08-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-012520-84/SI",
        "title": "A 2-Part Open-label Study to Assess the Clinical Benefit and Long-term Safety of Etanercept in Children and Adolescents With Extended Oligoarticular Juvenile Idiopathic Arthritis, Enthesitis-Relate... - SI",
        "timestamp": "2009-08-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-012520-84/ES",
        "title": "A 2-Part Open-label Study to Assess the Clinical Benefit and Long-term Safety of Etanercept in Children and Adolescents With Extended Oligoarticular Juvenile Idiopathic Arthritis, Enthesitis-Relate... - ES",
        "timestamp": "2009-08-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-012520-84/SE",
        "title": "A 2-Part Open-label Study to Assess the Clinical Benefit and Long-term Safety of Etanercept in Children and Adolescents With Extended Oligoarticular Juvenile Idiopathic Arthritis, Enthesitis-Relate... - SE",
        "timestamp": "2009-08-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-012520-84/SK",
        "title": "A 2-Part Open-label Study to Assess the Clinical Benefit and Long-term Safety of Etanercept in Children and Adolescents With Extended Oligoarticular Juvenile Idiopathic Arthritis, Enthesitis-Relate... - SK",
        "timestamp": "2009-08-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-012520-84/LT",
        "title": "A 2-Part Open-label Study to Assess the Clinical Benefit and Long-term Safety of Etanercept in Children and Adolescents With Extended Oligoarticular Juvenile Idiopathic Arthritis, Enthesitis-Relate... - LT",
        "timestamp": "2009-08-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-012520-84/NL",
        "title": "A 2-Part Open-label Study to Assess the Clinical Benefit and Long-term Safety of Etanercept in Children and Adolescents With Extended Oligoarticular Juvenile Idiopathic Arthritis, Enthesitis-Relate... - NL",
        "timestamp": "2009-08-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-012520-84/LV",
        "title": "A 2-Part Open-label Study to Assess the Clinical Benefit and Long-term Safety of Etanercept in Children and Adolescents With Extended Oligoarticular Juvenile Idiopathic Arthritis, Enthesitis-Relate... - LV",
        "timestamp": "2009-08-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-012520-84/GR",
        "title": "A 2-Part Open-label Study to Assess the Clinical Benefit and Long-term Safety of Etanercept in Children and Adolescents With Extended Oligoarticular Juvenile Idiopathic Arthritis, Enthesitis-Relate... - GR",
        "timestamp": "2009-08-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-012520-84/DK",
        "title": "A 2-Part Open-label Study to Assess the Clinical Benefit and Long-term Safety of Etanercept in Children and Adolescents With Extended Oligoarticular Juvenile Idiopathic Arthritis, Enthesitis-Relate... - DK",
        "timestamp": "2009-08-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-012520-84/IT",
        "title": "A 2-Part Open-label Study to Assess the Clinical Benefit and Long-term Safety of Etanercept in Children and Adolescents With Extended Oligoarticular Juvenile Idiopathic Arthritis, Enthesitis-Relate... - IT",
        "timestamp": "2009-08-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-012520-84/3rd",
        "title": "A 2-Part Open-label Study to Assess the Clinical Benefit and Long-term Safety of Etanercept in Children and Adolescents With Extended Oligoarticular Juvenile Idiopathic Arthritis, Enthesitis-Relate... - Outside EU/EEA",
        "timestamp": "2009-08-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-012520-84/results",
        "title": "A 2-Part Open-label Study to Assess the Clinical Benefit and Long-term Safety of Etanercept in Children and Adolescents With Extended Oligoarticular Juvenile Idiopathic Arthritis, Enthesitis-Relate... - View results",
        "timestamp": "2009-08-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-006129-29/DE",
        "title": "A multicentre, randomized, double-blind, placebo-controlled study to evaluate the safety, preliminary clinical activity and immunogenicity of multiple doses of MOR103 administered intravenously to ... - DE",
        "timestamp": "2009-11-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-006129-29/NL",
        "title": "A multicentre, randomized, double-blind, placebo-controlled study to evaluate the safety, preliminary clinical activity and immunogenicity of multiple doses of MOR103 administered intravenously to ... - NL",
        "timestamp": "2009-11-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-006129-29/BG",
        "title": "A multicentre, randomized, double-blind, placebo-controlled study to evaluate the safety, preliminary clinical activity and immunogenicity of multiple doses of MOR103 administered intravenously to ... - BG",
        "timestamp": "2009-11-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-006129-29/PL",
        "title": "A multicentre, randomized, double-blind, placebo-controlled study to evaluate the safety, preliminary clinical activity and immunogenicity of multiple doses of MOR103 administered intravenously to ... - PL",
        "timestamp": "2009-11-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-003771-37/HU",
        "title": "A double-blind, randomized, placebo controlled, dose escalation, multi-center phase I/II trial of HuMax-CD20, a fully human monoclonal anti-CD20 antibody, in patients with active rheumatoid arthrit... - HU",
        "timestamp": "2006-03-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-003771-37/results",
        "title": "A double-blind, randomized, placebo controlled, dose escalation, multi-center phase I/II trial of HuMax-CD20, a fully human monoclonal anti-CD20 antibody, in patients with active rheumatoid arthrit... - View results",
        "timestamp": "2006-03-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-003069-42/EE",
        "title": "A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTI-CENTER STUDY TO EVALUATE THE SUPERIORITY OF CRX-102 OVER EACH OF ITS COMPONENTS WHEN GIVEN TO SUBJECTS WITH ACTIVE RHEUMATOID ARTHRITIS (RA) - EE",
        "timestamp": "2007-10-31"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-003069-42/GB",
        "title": "A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTI-CENTER STUDY TO EVALUATE THE SUPERIORITY OF CRX-102 OVER EACH OF ITS COMPONENTS WHEN GIVEN TO SUBJECTS WITH ACTIVE RHEUMATOID ARTHRITIS (RA) - GB",
        "timestamp": "2007-10-31"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-003069-42/HU",
        "title": "A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTI-CENTER STUDY TO EVALUATE THE SUPERIORITY OF CRX-102 OVER EACH OF ITS COMPONENTS WHEN GIVEN TO SUBJECTS WITH ACTIVE RHEUMATOID ARTHRITIS (RA) - HU",
        "timestamp": "2007-10-31"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-003069-42/LT",
        "title": "A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTI-CENTER STUDY TO EVALUATE THE SUPERIORITY OF CRX-102 OVER EACH OF ITS COMPONENTS WHEN GIVEN TO SUBJECTS WITH ACTIVE RHEUMATOID ARTHRITIS (RA) - LT",
        "timestamp": "2007-10-31"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-003166-18/FR",
        "title": "Tolérance et efficacité du Rituximab dans le syndrome du Sjögren - FR",
        "timestamp": "2007-08-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-003051-35/DE",
        "title": "Efficacy of BELImumab for therapy-resistant SKIN manifestations in patients with lupus erythematosus (LE): A phase III, multicenter, randomized, double-blind, placebo-controlled, 24-week trial (BEL... - DE",
        "timestamp": "2018-10-09"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-004244-33/DE",
        "title": "A Randomized, Double-Blind, Placebo-Controlled Multiple Ascending Dose Study of Intravenous ATYR1923 in Patients with Pulmonary Sarcoidosis - DE",
        "timestamp": "2019-10-21"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-003933-14/LV",
        "title": "A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Effect of Filgotinib on Semen Parameters in Adult Males with active Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosin... - LV",
        "timestamp": "2019-05-27"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-003933-14/EE",
        "title": "A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Effect of Filgotinib on Semen Parameters in Adult Males with active Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosin... - EE",
        "timestamp": "2019-05-27"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-003933-14/BG",
        "title": "A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Effect of Filgotinib on Semen Parameters in Adult Males with active Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosin... - BG",
        "timestamp": "2019-05-27"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-003933-14/ES",
        "title": "A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Effect of Filgotinib on Semen Parameters in Adult Males with active Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosin... - ES",
        "timestamp": "2019-05-27"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-004284-30/DE",
        "title": "Effectiveness of Canakinumab for first line steroid free treatment in systemic onset juvenile idiopathic arthritis / juvenile Still’s disease - DE",
        "timestamp": "2020-02-13"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-001808-11/GB",
        "title": "A Phase 2b, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy, safety, and tolerability of cenerimod in subjects with moderate to severe syste... - GB",
        "timestamp": "2018-12-17"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-001808-11/ES",
        "title": "A Phase 2b, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy, safety, and tolerability of cenerimod in subjects with moderate to severe syste... - ES",
        "timestamp": "2018-12-17"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-001808-11/HU",
        "title": "A Phase 2b, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy, safety, and tolerability of cenerimod in subjects with moderate to severe syste... - HU",
        "timestamp": "2018-12-17"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-001808-11/BG",
        "title": "A Phase 2b, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy, safety, and tolerability of cenerimod in subjects with moderate to severe syste... - BG",
        "timestamp": "2018-12-17"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-000867-26/GB",
        "title": "A 52-week, phase 3, multicentre, randomised, double blind, efficacy and safety study, comparing GSK3196165 with placebo and with tofacitinib in combination with conventional synthetic DMARDs, in pa... - GB",
        "timestamp": "2019-12-10"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-000867-26/DE",
        "title": "A 52-week, phase 3, multicentre, randomised, double blind, efficacy and safety study, comparing GSK3196165 with placebo and with tofacitinib in combination with conventional synthetic DMARDs, in pa... - DE",
        "timestamp": "2019-12-10"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-000867-26/ES",
        "title": "A 52-week, phase 3, multicentre, randomised, double blind, efficacy and safety study, comparing GSK3196165 with placebo and with tofacitinib in combination with conventional synthetic DMARDs, in pa... - ES",
        "timestamp": "2019-12-10"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-000867-26/PL",
        "title": "A 52-week, phase 3, multicentre, randomised, double blind, efficacy and safety study, comparing GSK3196165 with placebo and with tofacitinib in combination with conventional synthetic DMARDs, in pa... - PL",
        "timestamp": "2019-12-10"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-000867-26/BG",
        "title": "A 52-week, phase 3, multicentre, randomised, double blind, efficacy and safety study, comparing GSK3196165 with placebo and with tofacitinib in combination with conventional synthetic DMARDs, in pa... - BG",
        "timestamp": "2019-12-10"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-000867-26/EE",
        "title": "A 52-week, phase 3, multicentre, randomised, double blind, efficacy and safety study, comparing GSK3196165 with placebo and with tofacitinib in combination with conventional synthetic DMARDs, in pa... - EE",
        "timestamp": "2019-12-10"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-000867-26/HU",
        "title": "A 52-week, phase 3, multicentre, randomised, double blind, efficacy and safety study, comparing GSK3196165 with placebo and with tofacitinib in combination with conventional synthetic DMARDs, in pa... - HU",
        "timestamp": "2019-12-10"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-001114-26/DE",
        "title": "A Phase 4 Trial Assessing the ImPact of Residual Inflammation Detected via Imaging TEchniques, Drug Levels and Patient Characteristics on the Outcome of Dose TaperIng of Adalimumab in Clinical Remi... - DE",
        "timestamp": "2014-11-10"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-001114-26/IE",
        "title": "A Phase 4 Trial Assessing the ImPact of Residual Inflammation Detected via Imaging TEchniques, Drug Levels and Patient Characteristics on the Outcome of Dose TaperIng of Adalimumab in Clinical Remi... - IE",
        "timestamp": "2014-11-10"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-001114-26/GB",
        "title": "A Phase 4 Trial Assessing the ImPact of Residual Inflammation Detected via Imaging TEchniques, Drug Levels and Patient Characteristics on the Outcome of Dose TaperIng of Adalimumab in Clinical Remi... - GB",
        "timestamp": "2014-11-10"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-001114-26/SE",
        "title": "A Phase 4 Trial Assessing the ImPact of Residual Inflammation Detected via Imaging TEchniques, Drug Levels and Patient Characteristics on the Outcome of Dose TaperIng of Adalimumab in Clinical Remi... - SE",
        "timestamp": "2014-11-10"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-001114-26/ES",
        "title": "A Phase 4 Trial Assessing the ImPact of Residual Inflammation Detected via Imaging TEchniques, Drug Levels and Patient Characteristics on the Outcome of Dose TaperIng of Adalimumab in Clinical Remi... - ES",
        "timestamp": "2014-11-10"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-001114-26/HU",
        "title": "A Phase 4 Trial Assessing the ImPact of Residual Inflammation Detected via Imaging TEchniques, Drug Levels and Patient Characteristics on the Outcome of Dose TaperIng of Adalimumab in Clinical Remi... - HU",
        "timestamp": "2014-11-10"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-001114-26/IT",
        "title": "A Phase 4 Trial Assessing the ImPact of Residual Inflammation Detected via Imaging TEchniques, Drug Levels and Patient Characteristics on the Outcome of Dose TaperIng of Adalimumab in Clinical Remi... - IT",
        "timestamp": "2014-11-10"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-001114-26/NL",
        "title": "A Phase 4 Trial Assessing the ImPact of Residual Inflammation Detected via Imaging TEchniques, Drug Levels and Patient Characteristics on the Outcome of Dose TaperIng of Adalimumab in Clinical Remi... - NL",
        "timestamp": "2014-11-10"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-001114-26/AT",
        "title": "A Phase 4 Trial Assessing the ImPact of Residual Inflammation Detected via Imaging TEchniques, Drug Levels and Patient Characteristics on the Outcome of Dose TaperIng of Adalimumab in Clinical Remi... - AT",
        "timestamp": "2014-11-10"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-001114-26/GR",
        "title": "A Phase 4 Trial Assessing the ImPact of Residual Inflammation Detected via Imaging TEchniques, Drug Levels and Patient Characteristics on the Outcome of Dose TaperIng of Adalimumab in Clinical Remi... - GR",
        "timestamp": "2014-11-10"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-001114-26/results",
        "title": "A Phase 4 Trial Assessing the ImPact of Residual Inflammation Detected via Imaging TEchniques, Drug Levels and Patient Characteristics on the Outcome of Dose TaperIng of Adalimumab in Clinical Remi... - View results",
        "timestamp": "2014-11-10"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-003637-14/EE",
        "title": "A randomized, double-blind, placebo-controlled, multicenter, Phase II study to assess the efficacy and safety of filgotinib administered for 16 weeks to subjects with moderately to severely active ... - EE",
        "timestamp": "2017-01-26"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-003637-14/ES",
        "title": "A randomized, double-blind, placebo-controlled, multicenter, Phase II study to assess the efficacy and safety of filgotinib administered for 16 weeks to subjects with moderately to severely active ... - ES",
        "timestamp": "2017-01-26"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-003637-14/CZ",
        "title": "A randomized, double-blind, placebo-controlled, multicenter, Phase II study to assess the efficacy and safety of filgotinib administered for 16 weeks to subjects with moderately to severely active ... - CZ",
        "timestamp": "2017-01-26"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-003637-14/BE",
        "title": "A randomized, double-blind, placebo-controlled, multicenter, Phase II study to assess the efficacy and safety of filgotinib administered for 16 weeks to subjects with moderately to severely active ... - BE",
        "timestamp": "2017-01-26"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-003637-14/BG",
        "title": "A randomized, double-blind, placebo-controlled, multicenter, Phase II study to assess the efficacy and safety of filgotinib administered for 16 weeks to subjects with moderately to severely active ... - BG",
        "timestamp": "2017-01-26"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-003637-14/results",
        "title": "A randomized, double-blind, placebo-controlled, multicenter, Phase II study to assess the efficacy and safety of filgotinib administered for 16 weeks to subjects with moderately to severely active ... - View results",
        "timestamp": "2017-01-26"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-000828-40/FR",
        "title": "A Phase IIIB, multi-centre, double-blind randomized, placebo-controlled, parallel group 52-week study to evaluate safety and efficacy of the PEGylated anti-TNFα Fab′fragment, certolizumab pegol, ad... - FR",
        "timestamp": "2008-02-26"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-000828-40/DE",
        "title": "A Phase IIIB, multi-centre, double-blind randomized, placebo-controlled, parallel group 52-week study to evaluate safety and efficacy of the PEGylated anti-TNFα Fab′fragment, certolizumab pegol, ad... - DE",
        "timestamp": "2008-02-26"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-000828-40/AT",
        "title": "A Phase IIIB, multi-centre, double-blind randomized, placebo-controlled, parallel group 52-week study to evaluate safety and efficacy of the PEGylated anti-TNFα Fab′fragment, certolizumab pegol, ad... - AT",
        "timestamp": "2008-02-26"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-000828-40/IT",
        "title": "A Phase IIIB, multi-centre, double-blind randomized, placebo-controlled, parallel group 52-week study to evaluate safety and efficacy of the PEGylated anti-TNFα Fab′fragment, certolizumab pegol, ad... - IT",
        "timestamp": "2008-02-26"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-000828-40/PL",
        "title": "A Phase IIIB, multi-centre, double-blind randomized, placebo-controlled, parallel group 52-week study to evaluate safety and efficacy of the PEGylated anti-TNFα Fab′fragment, certolizumab pegol, ad... - PL",
        "timestamp": "2008-02-26"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-000828-40/results",
        "title": "A Phase IIIB, multi-centre, double-blind randomized, placebo-controlled, parallel group 52-week study to evaluate safety and efficacy of the PEGylated anti-TNFα Fab′fragment, certolizumab pegol, ad... - View results",
        "timestamp": "2008-02-26"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-004834-11/DK",
        "title": "A randomized, double blind, placebo-controlled, dose response, phase II, multicentre trial to evaluate the efficacy, safety and pharmacokinetics of oral CR6086 administered at the doses of 30, 90 o... - DK",
        "timestamp": "2017-07-06"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-004834-11/BG",
        "title": "A randomized, double blind, placebo-controlled, dose response, phase II, multicentre trial to evaluate the efficacy, safety and pharmacokinetics of oral CR6086 administered at the doses of 30, 90 o... - BG",
        "timestamp": "2017-07-06"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-004834-11/PL",
        "title": "A randomized, double blind, placebo-controlled, dose response, phase II, multicentre trial to evaluate the efficacy, safety and pharmacokinetics of oral CR6086 administered at the doses of 30, 90 o... - PL",
        "timestamp": "2017-07-06"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-004834-11/CZ",
        "title": "A randomized, double blind, placebo-controlled, dose response, phase II, multicentre trial to evaluate the efficacy, safety and pharmacokinetics of oral CR6086 administered at the doses of 30, 90 o... - CZ",
        "timestamp": "2017-07-06"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-004834-11/GB",
        "title": "A randomized, double blind, placebo-controlled, dose response, phase II, multicentre trial to evaluate the efficacy, safety and pharmacokinetics of oral CR6086 administered at the doses of 30, 90 o... - GB",
        "timestamp": "2017-07-06"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-003984-72/LV",
        "title": "A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Investigate the Safety and Efficacy of ABT-494 with Background Methotrexate (MTX) in Subjects with Active Rheumatoid Arthritis (RA) ... - LV",
        "timestamp": "2014-05-30"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-003984-72/HU",
        "title": "A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Investigate the Safety and Efficacy of ABT-494 with Background Methotrexate (MTX) in Subjects with Active Rheumatoid Arthritis (RA) ... - HU",
        "timestamp": "2014-05-30"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-003984-72/CZ",
        "title": "A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Investigate the Safety and Efficacy of ABT-494 with Background Methotrexate (MTX) in Subjects with Active Rheumatoid Arthritis (RA) ... - CZ",
        "timestamp": "2014-05-30"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-003984-72/SK",
        "title": "A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Investigate the Safety and Efficacy of ABT-494 with Background Methotrexate (MTX) in Subjects with Active Rheumatoid Arthritis (RA) ... - SK",
        "timestamp": "2014-05-30"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-003984-72/ES",
        "title": "A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Investigate the Safety and Efficacy of ABT-494 with Background Methotrexate (MTX) in Subjects with Active Rheumatoid Arthritis (RA) ... - ES",
        "timestamp": "2014-05-30"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-003984-72/results",
        "title": "A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Investigate the Safety and Efficacy of ABT-494 with Background Methotrexate (MTX) in Subjects with Active Rheumatoid Arthritis (RA) ... - View results",
        "timestamp": "2014-05-30"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-022243-38/LT",
        "title": "A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study of CNTO 136 (sirukumab), a Human Anti-IL-6 Monoclonal Antibody, Administered Subcutaneously, in Subjects with Activ... - LT",
        "timestamp": "2012-07-11"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-022243-38/DE",
        "title": "A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study of CNTO 136 (sirukumab), a Human Anti-IL-6 Monoclonal Antibody, Administered Subcutaneously, in Subjects with Activ... - DE",
        "timestamp": "2012-07-11"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-022243-38/GB",
        "title": "A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study of CNTO 136 (sirukumab), a Human Anti-IL-6 Monoclonal Antibody, Administered Subcutaneously, in Subjects with Activ... - GB",
        "timestamp": "2012-07-11"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-022243-38/AT",
        "title": "A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study of CNTO 136 (sirukumab), a Human Anti-IL-6 Monoclonal Antibody, Administered Subcutaneously, in Subjects with Activ... - AT",
        "timestamp": "2012-07-11"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-022243-38/ES",
        "title": "A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study of CNTO 136 (sirukumab), a Human Anti-IL-6 Monoclonal Antibody, Administered Subcutaneously, in Subjects with Activ... - ES",
        "timestamp": "2012-07-11"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-022243-38/PT",
        "title": "A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study of CNTO 136 (sirukumab), a Human Anti-IL-6 Monoclonal Antibody, Administered Subcutaneously, in Subjects with Activ... - PT",
        "timestamp": "2012-07-11"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-022243-38/BE",
        "title": "A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study of CNTO 136 (sirukumab), a Human Anti-IL-6 Monoclonal Antibody, Administered Subcutaneously, in Subjects with Activ... - BE",
        "timestamp": "2012-07-11"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-022243-38/IT",
        "title": "A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study of CNTO 136 (sirukumab), a Human Anti-IL-6 Monoclonal Antibody, Administered Subcutaneously, in Subjects with Activ... - IT",
        "timestamp": "2012-07-11"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-022243-38/NL",
        "title": "A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study of CNTO 136 (sirukumab), a Human Anti-IL-6 Monoclonal Antibody, Administered Subcutaneously, in Subjects with Activ... - NL",
        "timestamp": "2012-07-11"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-022243-38/results",
        "title": "A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study of CNTO 136 (sirukumab), a Human Anti-IL-6 Monoclonal Antibody, Administered Subcutaneously, in Subjects with Activ... - View results",
        "timestamp": "2012-07-11"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-002798-80/ES",
        "title": "A Phase 3 Randomized Placebo Controlled Study to Evaluate the Efficacy and Safety of Abatacept Subcutaneous Injection in Adults with Active Psoriatic Arthritis - ES",
        "timestamp": "2013-08-02"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-002798-80/DE",
        "title": "A Phase 3 Randomized Placebo Controlled Study to Evaluate the Efficacy and Safety of Abatacept Subcutaneous Injection in Adults with Active Psoriatic Arthritis - DE",
        "timestamp": "2013-08-02"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-002798-80/GR",
        "title": "A Phase 3 Randomized Placebo Controlled Study to Evaluate the Efficacy and Safety of Abatacept Subcutaneous Injection in Adults with Active Psoriatic Arthritis - GR",
        "timestamp": "2013-08-02"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-002798-80/IT",
        "title": "A Phase 3 Randomized Placebo Controlled Study to Evaluate the Efficacy and Safety of Abatacept Subcutaneous Injection in Adults with Active Psoriatic Arthritis - IT",
        "timestamp": "2013-08-02"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-002798-80/CZ",
        "title": "A Phase 3 Randomized Placebo Controlled Study to Evaluate the Efficacy and Safety of Abatacept Subcutaneous Injection in Adults with Active Psoriatic Arthritis - CZ",
        "timestamp": "2013-08-02"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-002798-80/PL",
        "title": "A Phase 3 Randomized Placebo Controlled Study to Evaluate the Efficacy and Safety of Abatacept Subcutaneous Injection in Adults with Active Psoriatic Arthritis - PL",
        "timestamp": "2013-08-02"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-004019-37/DE",
        "title": "A Phase 2 Study to Investigate the Safety and Efficacy of ABT-122 Given with Methotrexate in Subjects with Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate - DE",
        "timestamp": "2015-01-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-004019-37/HU",
        "title": "A Phase 2 Study to Investigate the Safety and Efficacy of ABT-122 Given with Methotrexate in Subjects with Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate - HU",
        "timestamp": "2015-01-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-004019-37/BG",
        "title": "A Phase 2 Study to Investigate the Safety and Efficacy of ABT-122 Given with Methotrexate in Subjects with Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate - BG",
        "timestamp": "2015-01-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-004019-37/CZ",
        "title": "A Phase 2 Study to Investigate the Safety and Efficacy of ABT-122 Given with Methotrexate in Subjects with Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate - CZ",
        "timestamp": "2015-01-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-004019-37/DK",
        "title": "A Phase 2 Study to Investigate the Safety and Efficacy of ABT-122 Given with Methotrexate in Subjects with Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate - DK",
        "timestamp": "2015-01-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-004019-37/RO",
        "title": "A Phase 2 Study to Investigate the Safety and Efficacy of ABT-122 Given with Methotrexate in Subjects with Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate - RO",
        "timestamp": "2015-01-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-004019-37/results",
        "title": "A Phase 2 Study to Investigate the Safety and Efficacy of ABT-122 Given with Methotrexate in Subjects with Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate - View results",
        "timestamp": "2015-01-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-005525-11/DE",
        "title": "A randomized, placebo controlled, double-blind, parallel group study to compare the safety and reduction in disease activity with the combination of rituximab (MabThera) and tocilizumab (Actemra) v... - DE",
        "timestamp": "2009-04-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-005525-11/ES",
        "title": "A randomized, placebo controlled, double-blind, parallel group study to compare the safety and reduction in disease activity with the combination of rituximab (MabThera) and tocilizumab (Actemra) v... - ES",
        "timestamp": "2009-04-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-005525-11/NL",
        "title": "A randomized, placebo controlled, double-blind, parallel group study to compare the safety and reduction in disease activity with the combination of rituximab (MabThera) and tocilizumab (Actemra) v... - NL",
        "timestamp": "2009-04-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-005525-11/GB",
        "title": "A randomized, placebo controlled, double-blind, parallel group study to compare the safety and reduction in disease activity with the combination of rituximab (MabThera) and tocilizumab (Actemra) v... - GB",
        "timestamp": "2009-04-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-005525-11/FR",
        "title": "A randomized, placebo controlled, double-blind, parallel group study to compare the safety and reduction in disease activity with the combination of rituximab (MabThera) and tocilizumab (Actemra) v... - FR",
        "timestamp": "2009-04-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-005525-11/GR",
        "title": "A randomized, placebo controlled, double-blind, parallel group study to compare the safety and reduction in disease activity with the combination of rituximab (MabThera) and tocilizumab (Actemra) v... - GR",
        "timestamp": "2009-04-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-001102-42/HU",
        "title": "A MULTICENTER, PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BIMEKIZUMAB IN SUBJECTS WITH ACTIVE ANKYLOSING SPOND... - HU",
        "timestamp": "2016-11-21"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-001102-42/ES",
        "title": "A MULTICENTER, PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BIMEKIZUMAB IN SUBJECTS WITH ACTIVE ANKYLOSING SPOND... - ES",
        "timestamp": "2016-11-21"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-001102-42/CZ",
        "title": "A MULTICENTER, PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BIMEKIZUMAB IN SUBJECTS WITH ACTIVE ANKYLOSING SPOND... - CZ",
        "timestamp": "2016-11-21"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-001102-42/DE",
        "title": "A MULTICENTER, PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BIMEKIZUMAB IN SUBJECTS WITH ACTIVE ANKYLOSING SPOND... - DE",
        "timestamp": "2016-11-21"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-001102-42/BG",
        "title": "A MULTICENTER, PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BIMEKIZUMAB IN SUBJECTS WITH ACTIVE ANKYLOSING SPOND... - BG",
        "timestamp": "2016-11-21"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-001102-42/GB",
        "title": "A MULTICENTER, PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BIMEKIZUMAB IN SUBJECTS WITH ACTIVE ANKYLOSING SPOND... - GB",
        "timestamp": "2016-11-21"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-001102-42/results",
        "title": "A MULTICENTER, PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BIMEKIZUMAB IN SUBJECTS WITH ACTIVE ANKYLOSING SPOND... - View results",
        "timestamp": "2016-11-21"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-000372-95/CZ",
        "title": "A Phase II Multicenter, Randomized, Double-blind, Placebo controlled, Dose-range Finding Study to Evaluate the Safety and Efficacy of ALX 0061 Administered Subcutaneously in Subjects with Moderate ... - CZ",
        "timestamp": "2015-08-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-000372-95/DE",
        "title": "A Phase II Multicenter, Randomized, Double-blind, Placebo controlled, Dose-range Finding Study to Evaluate the Safety and Efficacy of ALX 0061 Administered Subcutaneously in Subjects with Moderate ... - DE",
        "timestamp": "2015-08-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-000372-95/PT",
        "title": "A Phase II Multicenter, Randomized, Double-blind, Placebo controlled, Dose-range Finding Study to Evaluate the Safety and Efficacy of ALX 0061 Administered Subcutaneously in Subjects with Moderate ... - PT",
        "timestamp": "2015-08-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-000372-95/HU",
        "title": "A Phase II Multicenter, Randomized, Double-blind, Placebo controlled, Dose-range Finding Study to Evaluate the Safety and Efficacy of ALX 0061 Administered Subcutaneously in Subjects with Moderate ... - HU",
        "timestamp": "2015-08-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-000372-95/ES",
        "title": "A Phase II Multicenter, Randomized, Double-blind, Placebo controlled, Dose-range Finding Study to Evaluate the Safety and Efficacy of ALX 0061 Administered Subcutaneously in Subjects with Moderate ... - ES",
        "timestamp": "2015-08-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-000372-95/results",
        "title": "A Phase II Multicenter, Randomized, Double-blind, Placebo controlled, Dose-range Finding Study to Evaluate the Safety and Efficacy of ALX 0061 Administered Subcutaneously in Subjects with Moderate ... - View results",
        "timestamp": "2015-08-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-003558-83/GB",
        "title": "A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneous AMG 108 in Subjects with Rheumatoid Arthritis - GB",
        "timestamp": "2006-03-21"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-003558-83/SK",
        "title": "A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneous AMG 108 in Subjects with Rheumatoid Arthritis - SK",
        "timestamp": "2006-03-21"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-003558-83/CZ",
        "title": "A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneous AMG 108 in Subjects with Rheumatoid Arthritis - CZ",
        "timestamp": "2006-03-21"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-003558-83/SE",
        "title": "A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneous AMG 108 in Subjects with Rheumatoid Arthritis - SE",
        "timestamp": "2006-03-21"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-003558-83/ES",
        "title": "A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneous AMG 108 in Subjects with Rheumatoid Arthritis - ES",
        "timestamp": "2006-03-21"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-003558-83/IE",
        "title": "A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneous AMG 108 in Subjects with Rheumatoid Arthritis - IE",
        "timestamp": "2006-03-21"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-003558-83/AT",
        "title": "A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneous AMG 108 in Subjects with Rheumatoid Arthritis - AT",
        "timestamp": "2006-03-21"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-003558-83/NL",
        "title": "A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneous AMG 108 in Subjects with Rheumatoid Arthritis - NL",
        "timestamp": "2006-03-21"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-003558-83/BE",
        "title": "A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneous AMG 108 in Subjects with Rheumatoid Arthritis - BE",
        "timestamp": "2006-03-21"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-003558-83/IT",
        "title": "A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneous AMG 108 in Subjects with Rheumatoid Arthritis - IT",
        "timestamp": "2006-03-21"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-003558-83/EE",
        "title": "A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneous AMG 108 in Subjects with Rheumatoid Arthritis - EE",
        "timestamp": "2006-03-21"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-003558-83/LV",
        "title": "A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneous AMG 108 in Subjects with Rheumatoid Arthritis - LV",
        "timestamp": "2006-03-21"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-003558-83/results",
        "title": "A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneous AMG 108 in Subjects with Rheumatoid Arthritis - View results",
        "timestamp": "2006-03-21"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-023782-22/ES",
        "title": "A PHASE 2, RANDOMIZED, DOUBLE-BLIND ASSESSMENT OF EFFICACY AND SAFETY OF PF-04171327(1, 5, 10, 15 MG DOSE, DAILY) COMPARED TO 5 MG AND 10 MG PREDNISONE DAILY AND PLACEBO DAILY IN SUBJECTS WITH RHEU... - ES",
        "timestamp": "2011-12-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-023782-22/CZ",
        "title": "A PHASE 2, RANDOMIZED, DOUBLE-BLIND ASSESSMENT OF EFFICACY AND SAFETY OF PF-04171327(1, 5, 10, 15 MG DOSE, DAILY) COMPARED TO 5 MG AND 10 MG PREDNISONE DAILY AND PLACEBO DAILY IN SUBJECTS WITH RHEU... - CZ",
        "timestamp": "2011-12-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-023782-22/DE",
        "title": "A PHASE 2, RANDOMIZED, DOUBLE-BLIND ASSESSMENT OF EFFICACY AND SAFETY OF PF-04171327(1, 5, 10, 15 MG DOSE, DAILY) COMPARED TO 5 MG AND 10 MG PREDNISONE DAILY AND PLACEBO DAILY IN SUBJECTS WITH RHEU... - DE",
        "timestamp": "2011-12-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-023782-22/HU",
        "title": "A PHASE 2, RANDOMIZED, DOUBLE-BLIND ASSESSMENT OF EFFICACY AND SAFETY OF PF-04171327(1, 5, 10, 15 MG DOSE, DAILY) COMPARED TO 5 MG AND 10 MG PREDNISONE DAILY AND PLACEBO DAILY IN SUBJECTS WITH RHEU... - HU",
        "timestamp": "2011-12-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-023782-22/SK",
        "title": "A PHASE 2, RANDOMIZED, DOUBLE-BLIND ASSESSMENT OF EFFICACY AND SAFETY OF PF-04171327(1, 5, 10, 15 MG DOSE, DAILY) COMPARED TO 5 MG AND 10 MG PREDNISONE DAILY AND PLACEBO DAILY IN SUBJECTS WITH RHEU... - SK",
        "timestamp": "2011-12-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-023782-22/BG",
        "title": "A PHASE 2, RANDOMIZED, DOUBLE-BLIND ASSESSMENT OF EFFICACY AND SAFETY OF PF-04171327(1, 5, 10, 15 MG DOSE, DAILY) COMPARED TO 5 MG AND 10 MG PREDNISONE DAILY AND PLACEBO DAILY IN SUBJECTS WITH RHEU... - BG",
        "timestamp": "2011-12-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-023782-22/results",
        "title": "A PHASE 2, RANDOMIZED, DOUBLE-BLIND ASSESSMENT OF EFFICACY AND SAFETY OF PF-04171327(1, 5, 10, 15 MG DOSE, DAILY) COMPARED TO 5 MG AND 10 MG PREDNISONE DAILY AND PLACEBO DAILY IN SUBJECTS WITH RHEU... - View results",
        "timestamp": "2011-12-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-000868-18/GB",
        "title": "A 24-week, phase 3, multicentre, randomised, double-blind, efficacy and safety study, comparing GSK3196165 with placebo and with sarilumab, in combination with conventional synthetic DMARDs, in par... - GB",
        "timestamp": "2019-12-02"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-000868-18/PL",
        "title": "A 24-week, phase 3, multicentre, randomised, double-blind, efficacy and safety study, comparing GSK3196165 with placebo and with sarilumab, in combination with conventional synthetic DMARDs, in par... - PL",
        "timestamp": "2019-12-02"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-000868-18/LT",
        "title": "A 24-week, phase 3, multicentre, randomised, double-blind, efficacy and safety study, comparing GSK3196165 with placebo and with sarilumab, in combination with conventional synthetic DMARDs, in par... - LT",
        "timestamp": "2019-12-02"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-000868-18/ES",
        "title": "A 24-week, phase 3, multicentre, randomised, double-blind, efficacy and safety study, comparing GSK3196165 with placebo and with sarilumab, in combination with conventional synthetic DMARDs, in par... - ES",
        "timestamp": "2019-12-02"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-000868-18/CZ",
        "title": "A 24-week, phase 3, multicentre, randomised, double-blind, efficacy and safety study, comparing GSK3196165 with placebo and with sarilumab, in combination with conventional synthetic DMARDs, in par... - CZ",
        "timestamp": "2019-12-02"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-000868-18/HU",
        "title": "A 24-week, phase 3, multicentre, randomised, double-blind, efficacy and safety study, comparing GSK3196165 with placebo and with sarilumab, in combination with conventional synthetic DMARDs, in par... - HU",
        "timestamp": "2019-12-02"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-004175-12/HU",
        "title": "A PHASE 2B, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTICENTER, DOSE RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY PROFILE OF PF-06700841 IN PARTICIPANTS WITH ACTIVE SYSTEMIC LUPUS ERYTH... - HU",
        "timestamp": "2019-09-23"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-004175-12/BG",
        "title": "A PHASE 2B, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTICENTER, DOSE RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY PROFILE OF PF-06700841 IN PARTICIPANTS WITH ACTIVE SYSTEMIC LUPUS ERYTH... - BG",
        "timestamp": "2019-09-23"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-004175-12/PT",
        "title": "A PHASE 2B, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTICENTER, DOSE RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY PROFILE OF PF-06700841 IN PARTICIPANTS WITH ACTIVE SYSTEMIC LUPUS ERYTH... - PT",
        "timestamp": "2019-09-23"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-004175-12/DE",
        "title": "A PHASE 2B, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTICENTER, DOSE RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY PROFILE OF PF-06700841 IN PARTICIPANTS WITH ACTIVE SYSTEMIC LUPUS ERYTH... - DE",
        "timestamp": "2019-09-23"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-004175-12/PL",
        "title": "A PHASE 2B, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTICENTER, DOSE RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY PROFILE OF PF-06700841 IN PARTICIPANTS WITH ACTIVE SYSTEMIC LUPUS ERYTH... - PL",
        "timestamp": "2019-09-23"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-004175-12/ES",
        "title": "A PHASE 2B, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTICENTER, DOSE RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY PROFILE OF PF-06700841 IN PARTICIPANTS WITH ACTIVE SYSTEMIC LUPUS ERYTH... - ES",
        "timestamp": "2019-09-23"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-003814-18/DE",
        "title": "A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 52-Week Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006) Administered Subcutaneously (SC) to Subjects with Sys... - DE",
        "timestamp": "2012-05-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-003814-18/HU",
        "title": "A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 52-Week Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006) Administered Subcutaneously (SC) to Subjects with Sys... - HU",
        "timestamp": "2012-05-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-003814-18/AT",
        "title": "A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 52-Week Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006) Administered Subcutaneously (SC) to Subjects with Sys... - AT",
        "timestamp": "2012-05-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-003814-18/CZ",
        "title": "A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 52-Week Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006) Administered Subcutaneously (SC) to Subjects with Sys... - CZ",
        "timestamp": "2012-05-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-003814-18/SE",
        "title": "A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 52-Week Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006) Administered Subcutaneously (SC) to Subjects with Sys... - SE",
        "timestamp": "2012-05-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-003814-18/BE",
        "title": "A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 52-Week Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006) Administered Subcutaneously (SC) to Subjects with Sys... - BE",
        "timestamp": "2012-05-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-003814-18/PT",
        "title": "A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 52-Week Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006) Administered Subcutaneously (SC) to Subjects with Sys... - PT",
        "timestamp": "2012-05-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-003814-18/ES",
        "title": "A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 52-Week Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006) Administered Subcutaneously (SC) to Subjects with Sys... - ES",
        "timestamp": "2012-05-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-003814-18/DK",
        "title": "A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 52-Week Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006) Administered Subcutaneously (SC) to Subjects with Sys... - DK",
        "timestamp": "2012-05-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-003814-18/GB",
        "title": "A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 52-Week Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006) Administered Subcutaneously (SC) to Subjects with Sys... - GB",
        "timestamp": "2012-05-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-003814-18/BG",
        "title": "A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 52-Week Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006) Administered Subcutaneously (SC) to Subjects with Sys... - BG",
        "timestamp": "2012-05-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-003814-18/IT",
        "title": "A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 52-Week Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006) Administered Subcutaneously (SC) to Subjects with Sys... - IT",
        "timestamp": "2012-05-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-003814-18/PL",
        "title": "A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 52-Week Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006) Administered Subcutaneously (SC) to Subjects with Sys... - PL",
        "timestamp": "2012-05-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-003814-18/results",
        "title": "A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 52-Week Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006) Administered Subcutaneously (SC) to Subjects with Sys... - View results",
        "timestamp": "2012-05-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-007510-30/HU",
        "title": "A PHASE 2, RANDOMIZED, DOUBLE-BLIND, MULTICENTER, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO INVESTIGATE THE SAFETY, EFFICACY, PHARMACOKINETICS AND PHARMACODYNAMICS  OF 12 WEEKS OF TREATMENT WITH ... - HU",
        "timestamp": "2009-02-09"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-007510-30/PL",
        "title": "A PHASE 2, RANDOMIZED, DOUBLE-BLIND, MULTICENTER, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO INVESTIGATE THE SAFETY, EFFICACY, PHARMACOKINETICS AND PHARMACODYNAMICS  OF 12 WEEKS OF TREATMENT WITH ... - PL",
        "timestamp": "2009-02-09"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020744-35/GB",
        "title": "A Phase III, Multi-Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study of Two Dosing Regimens of Fostamatinib Disodium in Rheumatoid Arthritis Patients with an  Inadequate Re... - GB",
        "timestamp": "2010-10-26"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020744-35/DE",
        "title": "A Phase III, Multi-Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study of Two Dosing Regimens of Fostamatinib Disodium in Rheumatoid Arthritis Patients with an  Inadequate Re... - DE",
        "timestamp": "2010-10-26"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020744-35/LV",
        "title": "A Phase III, Multi-Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study of Two Dosing Regimens of Fostamatinib Disodium in Rheumatoid Arthritis Patients with an  Inadequate Re... - LV",
        "timestamp": "2010-10-26"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020744-35/LT",
        "title": "A Phase III, Multi-Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study of Two Dosing Regimens of Fostamatinib Disodium in Rheumatoid Arthritis Patients with an  Inadequate Re... - LT",
        "timestamp": "2010-10-26"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020744-35/CZ",
        "title": "A Phase III, Multi-Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study of Two Dosing Regimens of Fostamatinib Disodium in Rheumatoid Arthritis Patients with an  Inadequate Re... - CZ",
        "timestamp": "2010-10-26"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020744-35/PT",
        "title": "A Phase III, Multi-Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study of Two Dosing Regimens of Fostamatinib Disodium in Rheumatoid Arthritis Patients with an  Inadequate Re... - PT",
        "timestamp": "2010-10-26"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020744-35/ES",
        "title": "A Phase III, Multi-Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study of Two Dosing Regimens of Fostamatinib Disodium in Rheumatoid Arthritis Patients with an  Inadequate Re... - ES",
        "timestamp": "2010-10-26"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020744-35/IT",
        "title": "A Phase III, Multi-Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study of Two Dosing Regimens of Fostamatinib Disodium in Rheumatoid Arthritis Patients with an  Inadequate Re... - IT",
        "timestamp": "2010-10-26"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020744-35/results",
        "title": "A Phase III, Multi-Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study of Two Dosing Regimens of Fostamatinib Disodium in Rheumatoid Arthritis Patients with an  Inadequate Re... - View results",
        "timestamp": "2010-10-26"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-022242-24/LT",
        "title": "A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study of CNTO 136 (sirukumab), a Human Anti-IL-6 Monoclonal Antibody, Administered Subcutaneously, in Subjects with Activ... - LT",
        "timestamp": "2012-07-11"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-022242-24/BG",
        "title": "A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study of CNTO 136 (sirukumab), a Human Anti-IL-6 Monoclonal Antibody, Administered Subcutaneously, in Subjects with Activ... - BG",
        "timestamp": "2012-07-11"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-022242-24/results",
        "title": "A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study of CNTO 136 (sirukumab), a Human Anti-IL-6 Monoclonal Antibody, Administered Subcutaneously, in Subjects with Activ... - View results",
        "timestamp": "2012-07-11"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-007859-14/HU",
        "title": "A 12-WEEK, PHASE 2, RANDOMIZED, DOUBLE-BLIND, MULTICENTER, PLACEBO CONTROLLED STUDY TO INVESTIGATE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF ARRY-438162, ADMINISTERED ORALLY DAILY IN PATIENTS WI... - HU",
        "timestamp": "2008-05-22"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-007859-14/PL",
        "title": "A 12-WEEK, PHASE 2, RANDOMIZED, DOUBLE-BLIND, MULTICENTER, PLACEBO CONTROLLED STUDY TO INVESTIGATE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF ARRY-438162, ADMINISTERED ORALLY DAILY IN PATIENTS WI... - PL",
        "timestamp": "2008-05-22"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-007859-14/results",
        "title": "A 12-WEEK, PHASE 2, RANDOMIZED, DOUBLE-BLIND, MULTICENTER, PLACEBO CONTROLLED STUDY TO INVESTIGATE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF ARRY-438162, ADMINISTERED ORALLY DAILY IN PATIENTS WI... - View results",
        "timestamp": "2008-05-22"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-003140-39/BG",
        "title": "A Multicenter, Randomized, Double-blind, PlacebO-controlled, Parallel-group Study to EValuate the Efficacy and Safety of JTE-051 Administered for 12 Weeks to Subjects with Active Rheumatoid Arthrit... - BG",
        "timestamp": "2016-12-05"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-003140-39/PL",
        "title": "A Multicenter, Randomized, Double-blind, PlacebO-controlled, Parallel-group Study to EValuate the Efficacy and Safety of JTE-051 Administered for 12 Weeks to Subjects with Active Rheumatoid Arthrit... - PL",
        "timestamp": "2016-12-05"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-003140-39/results",
        "title": "A Multicenter, Randomized, Double-blind, PlacebO-controlled, Parallel-group Study to EValuate the Efficacy and Safety of JTE-051 Administered for 12 Weeks to Subjects with Active Rheumatoid Arthrit... - View results",
        "timestamp": "2016-12-05"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-001532-35/HU",
        "title": "A Phase II, Dose Ranging, Exploratory Clinical Study to Assess the Efficacy, Pharmacodynamics, Pharmacokinetics, and Safety of LNP1955 in Patients with Moderate to Severe Rheumatoid Arthritis. - HU",
        "timestamp": "2016-08-08"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-001532-35/BG",
        "title": "A Phase II, Dose Ranging, Exploratory Clinical Study to Assess the Efficacy, Pharmacodynamics, Pharmacokinetics, and Safety of LNP1955 in Patients with Moderate to Severe Rheumatoid Arthritis. - BG",
        "timestamp": "2016-08-08"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-001532-35/results",
        "title": "A Phase II, Dose Ranging, Exploratory Clinical Study to Assess the Efficacy, Pharmacodynamics, Pharmacokinetics, and Safety of LNP1955 in Patients with Moderate to Severe Rheumatoid Arthritis. - View results",
        "timestamp": "2016-08-08"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-000385-35/IT",
        "title": "MULTICENTER, OPEN LABEL STUDY TO EVALUATE THE PREDICTABILITY OF EARLY RESPONSE TO CERTOLIZUMAB PEGOL (IN COMBINATION WITH METHOTREXATE) AS CONFIRMED AT WEEK 52 IN SUBJECTS WITH MODERATE-SEVERE RHEU... - IT",
        "timestamp": "2011-08-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-000385-35/results",
        "title": "MULTICENTER, OPEN LABEL STUDY TO EVALUATE THE PREDICTABILITY OF EARLY RESPONSE TO CERTOLIZUMAB PEGOL (IN COMBINATION WITH METHOTREXATE) AS CONFIRMED AT WEEK 52 IN SUBJECTS WITH MODERATE-SEVERE RHEU... - View results",
        "timestamp": "2011-08-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-002846-36/DE",
        "title": "A PHASE 2A, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO COMPARE 3 DOSE LEVELS OF CP 690,550 VERSUS PLACEBO,  ADMINISTERED ORALLY TWICE DAILY (BID) FOR 6 WEEKS, IN THE TREATME... - DE",
        "timestamp": "2005-06-14"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-002846-36/IT",
        "title": "A PHASE 2A, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO COMPARE 3 DOSE LEVELS OF CP 690,550 VERSUS PLACEBO,  ADMINISTERED ORALLY TWICE DAILY (BID) FOR 6 WEEKS, IN THE TREATME... - IT",
        "timestamp": "2005-06-14"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-002846-36/SK",
        "title": "A PHASE 2A, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO COMPARE 3 DOSE LEVELS OF CP 690,550 VERSUS PLACEBO,  ADMINISTERED ORALLY TWICE DAILY (BID) FOR 6 WEEKS, IN THE TREATME... - SK",
        "timestamp": "2005-06-14"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-002846-36/AT",
        "title": "A PHASE 2A, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO COMPARE 3 DOSE LEVELS OF CP 690,550 VERSUS PLACEBO,  ADMINISTERED ORALLY TWICE DAILY (BID) FOR 6 WEEKS, IN THE TREATME... - AT",
        "timestamp": "2005-06-14"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-002846-36/ES",
        "title": "A PHASE 2A, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO COMPARE 3 DOSE LEVELS OF CP 690,550 VERSUS PLACEBO,  ADMINISTERED ORALLY TWICE DAILY (BID) FOR 6 WEEKS, IN THE TREATME... - ES",
        "timestamp": "2005-06-14"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-002846-36/results",
        "title": "A PHASE 2A, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO COMPARE 3 DOSE LEVELS OF CP 690,550 VERSUS PLACEBO,  ADMINISTERED ORALLY TWICE DAILY (BID) FOR 6 WEEKS, IN THE TREATME... - View results",
        "timestamp": "2005-06-14"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-015978-35/FR",
        "title": "Etude ouverte de phase 2 de 52 semaines visant à établir l'efficacité et la tolérance du Belimumab (HGS1006, LymphoStat-B), un anticorps monoclonal humanisé anti-BLys (BAFF), chez des patients att... - FR",
        "timestamp": "2009-11-30"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020423-51/DE",
        "title": "Remission Induction by Etanercept in Enthesitis related Arthritis JIA-Patients (juvenile undifferentiated Spondylarthropathy) - DE",
        "timestamp": "2011-02-17"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-005218-38/FR",
        "title": "Essai prospectif Randomisé contre placebo  en double aveugle de l’hydroxychloroQUine dans le traitement du syndrome de sJOgren primitif (JOQUER) - FR",
        "timestamp": "2008-01-31"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003724-20/HU",
        "title": "A Phase 2, Double-Blind, Parallel, Placebo-Controlled, Randomized Study to Evaluate Multiple Dose Levels of IPI- 145 with Background Methotrexate in Subjects with Active Rheumatoid Arthritis and an... - HU",
        "timestamp": "2013-02-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003724-20/DE",
        "title": "A Phase 2, Double-Blind, Parallel, Placebo-Controlled, Randomized Study to Evaluate Multiple Dose Levels of IPI- 145 with Background Methotrexate in Subjects with Active Rheumatoid Arthritis and an... - DE",
        "timestamp": "2013-02-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003724-20/BG",
        "title": "A Phase 2, Double-Blind, Parallel, Placebo-Controlled, Randomized Study to Evaluate Multiple Dose Levels of IPI- 145 with Background Methotrexate in Subjects with Active Rheumatoid Arthritis and an... - BG",
        "timestamp": "2013-02-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003724-20/RO",
        "title": "A Phase 2, Double-Blind, Parallel, Placebo-Controlled, Randomized Study to Evaluate Multiple Dose Levels of IPI- 145 with Background Methotrexate in Subjects with Active Rheumatoid Arthritis and an... - RO",
        "timestamp": "2013-02-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003724-20/results",
        "title": "A Phase 2, Double-Blind, Parallel, Placebo-Controlled, Randomized Study to Evaluate Multiple Dose Levels of IPI- 145 with Background Methotrexate in Subjects with Active Rheumatoid Arthritis and an... - View results",
        "timestamp": "2013-02-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-006527-13/BG",
        "title": "A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Finding Study of the Safety and Efficacy of Daily CF101 Administered Orally, When Added to Weekly Methotre... - BG",
        "timestamp": "2008-06-18"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-006527-13/results",
        "title": "A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Finding Study of the Safety and Efficacy of Daily CF101 Administered Orally, When Added to Weekly Methotre... - View results",
        "timestamp": "2008-06-18"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-006020-20/HU",
        "title": "A Phase 2b, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Dose-Finding, Multi-Center Study to Evaluate the Safety and Efficacy of ASP015K in Moderate to Severe Rheumatoid Arthritis ... - HU",
        "timestamp": "2012-09-07"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-006020-20/CZ",
        "title": "A Phase 2b, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Dose-Finding, Multi-Center Study to Evaluate the Safety and Efficacy of ASP015K in Moderate to Severe Rheumatoid Arthritis ... - CZ",
        "timestamp": "2012-09-07"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-006020-20/PL",
        "title": "A Phase 2b, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Dose-Finding, Multi-Center Study to Evaluate the Safety and Efficacy of ASP015K in Moderate to Severe Rheumatoid Arthritis ... - PL",
        "timestamp": "2012-09-07"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-006020-20/BG",
        "title": "A Phase 2b, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Dose-Finding, Multi-Center Study to Evaluate the Safety and Efficacy of ASP015K in Moderate to Severe Rheumatoid Arthritis ... - BG",
        "timestamp": "2012-09-07"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-006020-20/results",
        "title": "A Phase 2b, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Dose-Finding, Multi-Center Study to Evaluate the Safety and Efficacy of ASP015K in Moderate to Severe Rheumatoid Arthritis ... - View results",
        "timestamp": "2012-09-07"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-000743-34/BE",
        "title": "A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Dose Study of R935788 in Patients with Rheumatoid Arthritis Who Have Failed at Least One Biologic - BE",
        "timestamp": "2008-06-18"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-000743-34/FR",
        "title": "A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Dose Study of R935788 in Patients with Rheumatoid Arthritis Who Have Failed at Least One Biologic - FR",
        "timestamp": "2008-06-18"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-000743-34/DE",
        "title": "A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Dose Study of R935788 in Patients with Rheumatoid Arthritis Who Have Failed at Least One Biologic - DE",
        "timestamp": "2008-06-18"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-000743-34/IT",
        "title": "A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Dose Study of R935788 in Patients with Rheumatoid Arthritis Who Have Failed at Least One Biologic - IT",
        "timestamp": "2008-06-18"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-021430-64/GB",
        "title": "A randomised double blind placebo controlled clinical trial of anti B-cell therapy in patients with primary Sjögren’s syndrome. - GB",
        "timestamp": "2010-12-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-021430-64/results",
        "title": "A randomised double blind placebo controlled clinical trial of anti B-cell therapy in patients with primary Sjögren’s syndrome. - View results",
        "timestamp": "2010-12-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-002024-40/ES",
        "title": "A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BMS-817399 in Adults with Active, Moderate to Severe Rheumato... - ES",
        "timestamp": "2012-02-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-002024-40/results",
        "title": "A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BMS-817399 in Adults with Active, Moderate to Severe Rheumato... - View results",
        "timestamp": "2012-02-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-005027-25/ES",
        "title": "A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3\nStudy of Baricitinib in Patients with Systemic Lupus Erythematosus - ES",
        "timestamp": "2018-09-21"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-002132-26/GB",
        "title": "A randomized placebo-controlled, multicenter, blinded Phase I/II study of the safety of escalating single intravenous doses of ocrelizumab (Ro 496-4913, PRO70769, rhuMAb 2H7) in patients with moder... - GB",
        "timestamp": "2008-02-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-002132-26/ES",
        "title": "A randomized placebo-controlled, multicenter, blinded Phase I/II study of the safety of escalating single intravenous doses of ocrelizumab (Ro 496-4913, PRO70769, rhuMAb 2H7) in patients with moder... - ES",
        "timestamp": "2008-02-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-002132-26/results",
        "title": "A randomized placebo-controlled, multicenter, blinded Phase I/II study of the safety of escalating single intravenous doses of ocrelizumab (Ro 496-4913, PRO70769, rhuMAb 2H7) in patients with moder... - View results",
        "timestamp": "2008-02-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-001645-41/DE",
        "title": "An adaptive Phase II study to evaluate the efficacy, pharmacodynamics, safety and tolerability of GSK2586184 in patients with active systemic lupus erythematosus. - DE",
        "timestamp": "2013-02-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-001645-41/HU",
        "title": "An adaptive Phase II study to evaluate the efficacy, pharmacodynamics, safety and tolerability of GSK2586184 in patients with active systemic lupus erythematosus. - HU",
        "timestamp": "2013-02-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-001645-41/SE",
        "title": "An adaptive Phase II study to evaluate the efficacy, pharmacodynamics, safety and tolerability of GSK2586184 in patients with active systemic lupus erythematosus. - SE",
        "timestamp": "2013-02-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-001645-41/ES",
        "title": "An adaptive Phase II study to evaluate the efficacy, pharmacodynamics, safety and tolerability of GSK2586184 in patients with active systemic lupus erythematosus. - ES",
        "timestamp": "2013-02-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-001645-41/GR",
        "title": "An adaptive Phase II study to evaluate the efficacy, pharmacodynamics, safety and tolerability of GSK2586184 in patients with active systemic lupus erythematosus. - GR",
        "timestamp": "2013-02-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-001645-41/EE",
        "title": "An adaptive Phase II study to evaluate the efficacy, pharmacodynamics, safety and tolerability of GSK2586184 in patients with active systemic lupus erythematosus. - EE",
        "timestamp": "2013-02-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-001645-41/CZ",
        "title": "An adaptive Phase II study to evaluate the efficacy, pharmacodynamics, safety and tolerability of GSK2586184 in patients with active systemic lupus erythematosus. - CZ",
        "timestamp": "2013-02-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-001645-41/PL",
        "title": "An adaptive Phase II study to evaluate the efficacy, pharmacodynamics, safety and tolerability of GSK2586184 in patients with active systemic lupus erythematosus. - PL",
        "timestamp": "2013-02-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-001645-41/results",
        "title": "An adaptive Phase II study to evaluate the efficacy, pharmacodynamics, safety and tolerability of GSK2586184 in patients with active systemic lupus erythematosus. - View results",
        "timestamp": "2013-02-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-006070-73/DE",
        "title": "A Multi-Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study of the Effect of Fostamatinib 100 mg Twice Daily on 24-hour Ambulatory Blood Pressure in Patients with Rheumatoid ... - DE",
        "timestamp": "2012-08-28"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-006070-73/CZ",
        "title": "A Multi-Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study of the Effect of Fostamatinib 100 mg Twice Daily on 24-hour Ambulatory Blood Pressure in Patients with Rheumatoid ... - CZ",
        "timestamp": "2012-08-28"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-006070-73/BG",
        "title": "A Multi-Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study of the Effect of Fostamatinib 100 mg Twice Daily on 24-hour Ambulatory Blood Pressure in Patients with Rheumatoid ... - BG",
        "timestamp": "2012-08-28"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-006070-73/results",
        "title": "A Multi-Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study of the Effect of Fostamatinib 100 mg Twice Daily on 24-hour Ambulatory Blood Pressure in Patients with Rheumatoid ... - View results",
        "timestamp": "2012-08-28"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-004808-19/GB",
        "title": "A multi-center, randomized, double-blind, placebo-controlled, parallel group study to assess the safety, tolerability, pharmacokinetics and preliminary efficacy of CFZ533 in patients with primary S... - GB",
        "timestamp": "2014-07-23"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-004808-19/HU",
        "title": "A multi-center, randomized, double-blind, placebo-controlled, parallel group study to assess the safety, tolerability, pharmacokinetics and preliminary efficacy of CFZ533 in patients with primary S... - HU",
        "timestamp": "2014-07-23"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-004808-19/DE",
        "title": "A multi-center, randomized, double-blind, placebo-controlled, parallel group study to assess the safety, tolerability, pharmacokinetics and preliminary efficacy of CFZ533 in patients with primary S... - DE",
        "timestamp": "2014-07-23"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-004808-19/results",
        "title": "A multi-center, randomized, double-blind, placebo-controlled, parallel group study to assess the safety, tolerability, pharmacokinetics and preliminary efficacy of CFZ533 in patients with primary S... - View results",
        "timestamp": "2014-07-23"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-003050-32/DE",
        "title": "A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-\r\nControlled, 104-Week Study to Evaluate the Efficacy and Safety of Belimumab\r\nAdministered in Combination with Rituximab to Adult Subject... - DE",
        "timestamp": "2018-01-09"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-003050-32/NL",
        "title": "A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-\r\nControlled, 104-Week Study to Evaluate the Efficacy and Safety of Belimumab\r\nAdministered in Combination with Rituximab to Adult Subject... - NL",
        "timestamp": "2018-01-09"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-003050-32/ES",
        "title": "A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-\r\nControlled, 104-Week Study to Evaluate the Efficacy and Safety of Belimumab\r\nAdministered in Combination with Rituximab to Adult Subject... - ES",
        "timestamp": "2018-01-09"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-007788-17/CZ",
        "title": "PHASE 3, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF THE EFFICACY AND SAFETY OF 2 DOSES OF CP 690,550 MONOTHERAPY IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS - CZ",
        "timestamp": "2009-05-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-007788-17/DE",
        "title": "PHASE 3, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF THE EFFICACY AND SAFETY OF 2 DOSES OF CP 690,550 MONOTHERAPY IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS - DE",
        "timestamp": "2009-05-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-007788-17/BG",
        "title": "PHASE 3, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF THE EFFICACY AND SAFETY OF 2 DOSES OF CP 690,550 MONOTHERAPY IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS - BG",
        "timestamp": "2009-05-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-007788-17/results",
        "title": "PHASE 3, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF THE EFFICACY AND SAFETY OF 2 DOSES OF CP 690,550 MONOTHERAPY IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS - View results",
        "timestamp": "2009-05-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-012705-19/HU",
        "title": "A Phase 2, Multi-center, Randomized, Double-blind, Placebo-controlled, Multiple-dose Study to Determine the Safety and Efficacy of Daily Orally Administered LX3305 in Subjects with Active Rheumatoi... - HU",
        "timestamp": "2009-08-17"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-012705-19/CZ",
        "title": "A Phase 2, Multi-center, Randomized, Double-blind, Placebo-controlled, Multiple-dose Study to Determine the Safety and Efficacy of Daily Orally Administered LX3305 in Subjects with Active Rheumatoi... - CZ",
        "timestamp": "2009-08-17"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-012705-19/BG",
        "title": "A Phase 2, Multi-center, Randomized, Double-blind, Placebo-controlled, Multiple-dose Study to Determine the Safety and Efficacy of Daily Orally Administered LX3305 in Subjects with Active Rheumatoi... - BG",
        "timestamp": "2009-08-17"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-012705-19/results",
        "title": "A Phase 2, Multi-center, Randomized, Double-blind, Placebo-controlled, Multiple-dose Study to Determine the Safety and Efficacy of Daily Orally Administered LX3305 in Subjects with Active Rheumatoi... - View results",
        "timestamp": "2009-08-17"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-001203-79/HU",
        "title": "A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of BMS-986165 in Subjects with Systemic Lupus Erythematosus - HU",
        "timestamp": "2017-12-04"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-001203-79/PL",
        "title": "A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of BMS-986165 in Subjects with Systemic Lupus Erythematosus - PL",
        "timestamp": "2017-12-04"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-001203-79/ES",
        "title": "A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of BMS-986165 in Subjects with Systemic Lupus Erythematosus - ES",
        "timestamp": "2017-12-04"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-001417-32/DE",
        "title": "A Multicenter, Randomized, Double-blind, Parallel Group Study of CNTO 136 (sirukumab) Administered Subcutaneously as Monotherapy Compared With Adalimumab Monotherapy, in Subjects with Active Rheuma... - DE",
        "timestamp": "2014-06-02"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-001417-32/HU",
        "title": "A Multicenter, Randomized, Double-blind, Parallel Group Study of CNTO 136 (sirukumab) Administered Subcutaneously as Monotherapy Compared With Adalimumab Monotherapy, in Subjects with Active Rheuma... - HU",
        "timestamp": "2014-06-02"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-001417-32/LT",
        "title": "A Multicenter, Randomized, Double-blind, Parallel Group Study of CNTO 136 (sirukumab) Administered Subcutaneously as Monotherapy Compared With Adalimumab Monotherapy, in Subjects with Active Rheuma... - LT",
        "timestamp": "2014-06-02"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-001417-32/ES",
        "title": "A Multicenter, Randomized, Double-blind, Parallel Group Study of CNTO 136 (sirukumab) Administered Subcutaneously as Monotherapy Compared With Adalimumab Monotherapy, in Subjects with Active Rheuma... - ES",
        "timestamp": "2014-06-02"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-001417-32/BG",
        "title": "A Multicenter, Randomized, Double-blind, Parallel Group Study of CNTO 136 (sirukumab) Administered Subcutaneously as Monotherapy Compared With Adalimumab Monotherapy, in Subjects with Active Rheuma... - BG",
        "timestamp": "2014-06-02"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-001417-32/results",
        "title": "A Multicenter, Randomized, Double-blind, Parallel Group Study of CNTO 136 (sirukumab) Administered Subcutaneously as Monotherapy Compared With Adalimumab Monotherapy, in Subjects with Active Rheuma... - View results",
        "timestamp": "2014-06-02"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-004574-17/ES",
        "title": "A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLEBLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-220 IN SUBJECTS WITH ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS - ES",
        "timestamp": "2017-06-08"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-004574-17/HU",
        "title": "A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLEBLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-220 IN SUBJECTS WITH ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS - HU",
        "timestamp": "2017-06-08"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-004574-17/DE",
        "title": "A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLEBLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-220 IN SUBJECTS WITH ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS - DE",
        "timestamp": "2017-06-08"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-004574-17/BE",
        "title": "A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLEBLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-220 IN SUBJECTS WITH ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS - BE",
        "timestamp": "2017-06-08"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-004574-17/FR",
        "title": "A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLEBLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-220 IN SUBJECTS WITH ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS - FR",
        "timestamp": "2017-06-08"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-006018-15/BE",
        "title": "A Phase 2b, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Dose-Finding, Multi-Center Study to Evaluate the Safety and Efficacy of ASP015K in Moderate to Severe Rheumatoid Arthritis ... - BE",
        "timestamp": "2012-07-28"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-006018-15/CZ",
        "title": "A Phase 2b, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Dose-Finding, Multi-Center Study to Evaluate the Safety and Efficacy of ASP015K in Moderate to Severe Rheumatoid Arthritis ... - CZ",
        "timestamp": "2012-07-28"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-006018-15/PL",
        "title": "A Phase 2b, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Dose-Finding, Multi-Center Study to Evaluate the Safety and Efficacy of ASP015K in Moderate to Severe Rheumatoid Arthritis ... - PL",
        "timestamp": "2012-07-28"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-006018-15/HU",
        "title": "A Phase 2b, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Dose-Finding, Multi-Center Study to Evaluate the Safety and Efficacy of ASP015K in Moderate to Severe Rheumatoid Arthritis ... - HU",
        "timestamp": "2012-07-28"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-006018-15/BG",
        "title": "A Phase 2b, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Dose-Finding, Multi-Center Study to Evaluate the Safety and Efficacy of ASP015K in Moderate to Severe Rheumatoid Arthritis ... - BG",
        "timestamp": "2012-07-28"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-006018-15/results",
        "title": "A Phase 2b, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Dose-Finding, Multi-Center Study to Evaluate the Safety and Efficacy of ASP015K in Moderate to Severe Rheumatoid Arthritis ... - View results",
        "timestamp": "2012-07-28"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-005036-24/SE",
        "title": "A PHASE 2B, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, MULTICENTER STUDY TO COMPARE 6 DOSE REGIMENS OF CP 690,550 VS. PLACEBO, EACH COMBINED WITH METHOTREXATE, ADMINISTERED FOR 6 MONTHS IN THE T... - SE",
        "timestamp": "2007-05-04"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-005036-24/SK",
        "title": "A PHASE 2B, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, MULTICENTER STUDY TO COMPARE 6 DOSE REGIMENS OF CP 690,550 VS. PLACEBO, EACH COMBINED WITH METHOTREXATE, ADMINISTERED FOR 6 MONTHS IN THE T... - SK",
        "timestamp": "2007-05-04"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-005036-24/CZ",
        "title": "A PHASE 2B, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, MULTICENTER STUDY TO COMPARE 6 DOSE REGIMENS OF CP 690,550 VS. PLACEBO, EACH COMBINED WITH METHOTREXATE, ADMINISTERED FOR 6 MONTHS IN THE T... - CZ",
        "timestamp": "2007-05-04"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-005036-24/HU",
        "title": "A PHASE 2B, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, MULTICENTER STUDY TO COMPARE 6 DOSE REGIMENS OF CP 690,550 VS. PLACEBO, EACH COMBINED WITH METHOTREXATE, ADMINISTERED FOR 6 MONTHS IN THE T... - HU",
        "timestamp": "2007-05-04"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-005036-24/BG",
        "title": "A PHASE 2B, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, MULTICENTER STUDY TO COMPARE 6 DOSE REGIMENS OF CP 690,550 VS. PLACEBO, EACH COMBINED WITH METHOTREXATE, ADMINISTERED FOR 6 MONTHS IN THE T... - BG",
        "timestamp": "2007-05-04"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-005036-24/results",
        "title": "A PHASE 2B, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, MULTICENTER STUDY TO COMPARE 6 DOSE REGIMENS OF CP 690,550 VS. PLACEBO, EACH COMBINED WITH METHOTREXATE, ADMINISTERED FOR 6 MONTHS IN THE T... - View results",
        "timestamp": "2007-05-04"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-005028-11/GB",
        "title": "A Phase 3, Double-Blind, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients with Systemic Lupus Erythematosus (SLE) - GB",
        "timestamp": "2019-10-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-005028-11/CZ",
        "title": "A Phase 3, Double-Blind, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients with Systemic Lupus Erythematosus (SLE) - CZ",
        "timestamp": "2019-10-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-005028-11/AT",
        "title": "A Phase 3, Double-Blind, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients with Systemic Lupus Erythematosus (SLE) - AT",
        "timestamp": "2019-10-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-005028-11/HU",
        "title": "A Phase 3, Double-Blind, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients with Systemic Lupus Erythematosus (SLE) - HU",
        "timestamp": "2019-10-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-005028-11/PL",
        "title": "A Phase 3, Double-Blind, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients with Systemic Lupus Erythematosus (SLE) - PL",
        "timestamp": "2019-10-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-005028-11/ES",
        "title": "A Phase 3, Double-Blind, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients with Systemic Lupus Erythematosus (SLE) - ES",
        "timestamp": "2019-10-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-003538-16/LT",
        "title": "A Randomized, Double-blind, Parallel, Placebo-controlled Study Assessing The Efficacy and Safety of Sarilumab Added To non-biologic DMARD Therapy In Patients With Rheumatoid Arthritis Who Are Inade... - LT",
        "timestamp": "2013-02-04"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-003538-16/CZ",
        "title": "A Randomized, Double-blind, Parallel, Placebo-controlled Study Assessing The Efficacy and Safety of Sarilumab Added To non-biologic DMARD Therapy In Patients With Rheumatoid Arthritis Who Are Inade... - CZ",
        "timestamp": "2013-02-04"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-003538-16/HU",
        "title": "A Randomized, Double-blind, Parallel, Placebo-controlled Study Assessing The Efficacy and Safety of Sarilumab Added To non-biologic DMARD Therapy In Patients With Rheumatoid Arthritis Who Are Inade... - HU",
        "timestamp": "2013-02-04"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-003538-16/ES",
        "title": "A Randomized, Double-blind, Parallel, Placebo-controlled Study Assessing The Efficacy and Safety of Sarilumab Added To non-biologic DMARD Therapy In Patients With Rheumatoid Arthritis Who Are Inade... - ES",
        "timestamp": "2013-02-04"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-003538-16/DE",
        "title": "A Randomized, Double-blind, Parallel, Placebo-controlled Study Assessing The Efficacy and Safety of Sarilumab Added To non-biologic DMARD Therapy In Patients With Rheumatoid Arthritis Who Are Inade... - DE",
        "timestamp": "2013-02-04"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-003538-16/PT",
        "title": "A Randomized, Double-blind, Parallel, Placebo-controlled Study Assessing The Efficacy and Safety of Sarilumab Added To non-biologic DMARD Therapy In Patients With Rheumatoid Arthritis Who Are Inade... - PT",
        "timestamp": "2013-02-04"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-003538-16/GR",
        "title": "A Randomized, Double-blind, Parallel, Placebo-controlled Study Assessing The Efficacy and Safety of Sarilumab Added To non-biologic DMARD Therapy In Patients With Rheumatoid Arthritis Who Are Inade... - GR",
        "timestamp": "2013-02-04"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-003538-16/AT",
        "title": "A Randomized, Double-blind, Parallel, Placebo-controlled Study Assessing The Efficacy and Safety of Sarilumab Added To non-biologic DMARD Therapy In Patients With Rheumatoid Arthritis Who Are Inade... - AT",
        "timestamp": "2013-02-04"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-003538-16/IT",
        "title": "A Randomized, Double-blind, Parallel, Placebo-controlled Study Assessing The Efficacy and Safety of Sarilumab Added To non-biologic DMARD Therapy In Patients With Rheumatoid Arthritis Who Are Inade... - IT",
        "timestamp": "2013-02-04"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-003538-16/SK",
        "title": "A Randomized, Double-blind, Parallel, Placebo-controlled Study Assessing The Efficacy and Safety of Sarilumab Added To non-biologic DMARD Therapy In Patients With Rheumatoid Arthritis Who Are Inade... - SK",
        "timestamp": "2013-02-04"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-003538-16/PL",
        "title": "A Randomized, Double-blind, Parallel, Placebo-controlled Study Assessing The Efficacy and Safety of Sarilumab Added To non-biologic DMARD Therapy In Patients With Rheumatoid Arthritis Who Are Inade... - PL",
        "timestamp": "2013-02-04"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-003538-16/results",
        "title": "A Randomized, Double-blind, Parallel, Placebo-controlled Study Assessing The Efficacy and Safety of Sarilumab Added To non-biologic DMARD Therapy In Patients With Rheumatoid Arthritis Who Are Inade... - View results",
        "timestamp": "2013-02-04"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-005177-21/GB",
        "title": "A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled 76 week Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-BLyS Ant... - GB",
        "timestamp": "2007-05-29"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-005177-21/BE",
        "title": "A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled 76 week Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-BLyS Ant... - BE",
        "timestamp": "2007-05-29"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-005177-21/DE",
        "title": "A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled 76 week Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-BLyS Ant... - DE",
        "timestamp": "2007-05-29"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-005177-21/AT",
        "title": "A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled 76 week Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-BLyS Ant... - AT",
        "timestamp": "2007-05-29"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-005177-21/CZ",
        "title": "A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled 76 week Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-BLyS Ant... - CZ",
        "timestamp": "2007-05-29"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-005177-21/ES",
        "title": "A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled 76 week Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-BLyS Ant... - ES",
        "timestamp": "2007-05-29"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-005177-21/SK",
        "title": "A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled 76 week Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-BLyS Ant... - SK",
        "timestamp": "2007-05-29"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-005177-21/SE",
        "title": "A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled 76 week Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-BLyS Ant... - SE",
        "timestamp": "2007-05-29"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-005177-21/NL",
        "title": "A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled 76 week Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-BLyS Ant... - NL",
        "timestamp": "2007-05-29"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-005177-21/IT",
        "title": "A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled 76 week Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-BLyS Ant... - IT",
        "timestamp": "2007-05-29"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-005177-21/FR",
        "title": "A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled 76 week Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-BLyS Ant... - FR",
        "timestamp": "2007-05-29"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-005177-21/results",
        "title": "A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled 76 week Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-BLyS Ant... - View results",
        "timestamp": "2007-05-29"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-019872-65/DE",
        "title": "A Phase III, Two-Part, Randomized, Double-Blind, Active Comparator-Controlled, Multicenter Clinical Trial to Study the Relative Efficacy and Tolerability of Two Doses of MK-0663/Etoricoxib in Patie... - DE",
        "timestamp": None
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-019872-65/HU",
        "title": "A Phase III, Two-Part, Randomized, Double-Blind, Active Comparator-Controlled, Multicenter Clinical Trial to Study the Relative Efficacy and Tolerability of Two Doses of MK-0663/Etoricoxib in Patie... - HU",
        "timestamp": None
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-019872-65/FI",
        "title": "A Phase III, Two-Part, Randomized, Double-Blind, Active Comparator-Controlled, Multicenter Clinical Trial to Study the Relative Efficacy and Tolerability of Two Doses of MK-0663/Etoricoxib in Patie... - FI",
        "timestamp": None
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-019872-65/BE",
        "title": "A Phase III, Two-Part, Randomized, Double-Blind, Active Comparator-Controlled, Multicenter Clinical Trial to Study the Relative Efficacy and Tolerability of Two Doses of MK-0663/Etoricoxib in Patie... - BE",
        "timestamp": None
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-019872-65/AT",
        "title": "A Phase III, Two-Part, Randomized, Double-Blind, Active Comparator-Controlled, Multicenter Clinical Trial to Study the Relative Efficacy and Tolerability of Two Doses of MK-0663/Etoricoxib in Patie... - AT",
        "timestamp": None
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-019872-65/GB",
        "title": "A Phase III, Two-Part, Randomized, Double-Blind, Active Comparator-Controlled, Multicenter Clinical Trial to Study the Relative Efficacy and Tolerability of Two Doses of MK-0663/Etoricoxib in Patie... - GB",
        "timestamp": None
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-019872-65/EE",
        "title": "A Phase III, Two-Part, Randomized, Double-Blind, Active Comparator-Controlled, Multicenter Clinical Trial to Study the Relative Efficacy and Tolerability of Two Doses of MK-0663/Etoricoxib in Patie... - EE",
        "timestamp": None
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-019872-65/SK",
        "title": "A Phase III, Two-Part, Randomized, Double-Blind, Active Comparator-Controlled, Multicenter Clinical Trial to Study the Relative Efficacy and Tolerability of Two Doses of MK-0663/Etoricoxib in Patie... - SK",
        "timestamp": None
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-019872-65/CZ",
        "title": "A Phase III, Two-Part, Randomized, Double-Blind, Active Comparator-Controlled, Multicenter Clinical Trial to Study the Relative Efficacy and Tolerability of Two Doses of MK-0663/Etoricoxib in Patie... - CZ",
        "timestamp": None
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-019872-65/LT",
        "title": "A Phase III, Two-Part, Randomized, Double-Blind, Active Comparator-Controlled, Multicenter Clinical Trial to Study the Relative Efficacy and Tolerability of Two Doses of MK-0663/Etoricoxib in Patie... - LT",
        "timestamp": None
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-019872-65/results",
        "title": "A Phase III, Two-Part, Randomized, Double-Blind, Active Comparator-Controlled, Multicenter Clinical Trial to Study the Relative Efficacy and Tolerability of Two Doses of MK-0663/Etoricoxib in Patie... - View results",
        "timestamp": None
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-010582-23/DE",
        "title": "A Golimumab Phase 3b, Multicenter, Switch Assessment of Subcutaneous and Intravenous Efficacy in Rheumatoid Arthritis Patients Who Have Inadequate Disease Control Despite Treatment with Etanercept ... - DE",
        "timestamp": "2010-01-04"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-010582-23/BE",
        "title": "A Golimumab Phase 3b, Multicenter, Switch Assessment of Subcutaneous and Intravenous Efficacy in Rheumatoid Arthritis Patients Who Have Inadequate Disease Control Despite Treatment with Etanercept ... - BE",
        "timestamp": "2010-01-04"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-010582-23/AT",
        "title": "A Golimumab Phase 3b, Multicenter, Switch Assessment of Subcutaneous and Intravenous Efficacy in Rheumatoid Arthritis Patients Who Have Inadequate Disease Control Despite Treatment with Etanercept ... - AT",
        "timestamp": "2010-01-04"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-010582-23/SE",
        "title": "A Golimumab Phase 3b, Multicenter, Switch Assessment of Subcutaneous and Intravenous Efficacy in Rheumatoid Arthritis Patients Who Have Inadequate Disease Control Despite Treatment with Etanercept ... - SE",
        "timestamp": "2010-01-04"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-010582-23/GR",
        "title": "A Golimumab Phase 3b, Multicenter, Switch Assessment of Subcutaneous and Intravenous Efficacy in Rheumatoid Arthritis Patients Who Have Inadequate Disease Control Despite Treatment with Etanercept ... - GR",
        "timestamp": "2010-01-04"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-010582-23/IT",
        "title": "A Golimumab Phase 3b, Multicenter, Switch Assessment of Subcutaneous and Intravenous Efficacy in Rheumatoid Arthritis Patients Who Have Inadequate Disease Control Despite Treatment with Etanercept ... - IT",
        "timestamp": "2010-01-04"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-010582-23/GB",
        "title": "A Golimumab Phase 3b, Multicenter, Switch Assessment of Subcutaneous and Intravenous Efficacy in Rheumatoid Arthritis Patients Who Have Inadequate Disease Control Despite Treatment with Etanercept ... - GB",
        "timestamp": "2010-01-04"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-010582-23/results",
        "title": "A Golimumab Phase 3b, Multicenter, Switch Assessment of Subcutaneous and Intravenous Efficacy in Rheumatoid Arthritis Patients Who Have Inadequate Disease Control Despite Treatment with Etanercept ... - View results",
        "timestamp": "2010-01-04"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-010714-30/DE",
        "title": "A Phase 2, Multicenter, Randomized, Double blind, Parallel group, Placebo controlled Study Evaluating the Safety and Efficacy of Treatment with Ustekinumab or Golimumab in Subjects with Chronic Sar... - DE",
        "timestamp": "2009-10-23"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-010714-30/BE",
        "title": "A Phase 2, Multicenter, Randomized, Double blind, Parallel group, Placebo controlled Study Evaluating the Safety and Efficacy of Treatment with Ustekinumab or Golimumab in Subjects with Chronic Sar... - BE",
        "timestamp": "2009-10-23"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-010714-30/GB",
        "title": "A Phase 2, Multicenter, Randomized, Double blind, Parallel group, Placebo controlled Study Evaluating the Safety and Efficacy of Treatment with Ustekinumab or Golimumab in Subjects with Chronic Sar... - GB",
        "timestamp": "2009-10-23"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-010714-30/DK",
        "title": "A Phase 2, Multicenter, Randomized, Double blind, Parallel group, Placebo controlled Study Evaluating the Safety and Efficacy of Treatment with Ustekinumab or Golimumab in Subjects with Chronic Sar... - DK",
        "timestamp": "2009-10-23"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-010714-30/FR",
        "title": "A Phase 2, Multicenter, Randomized, Double blind, Parallel group, Placebo controlled Study Evaluating the Safety and Efficacy of Treatment with Ustekinumab or Golimumab in Subjects with Chronic Sar... - FR",
        "timestamp": "2009-10-23"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-010714-30/IT",
        "title": "A Phase 2, Multicenter, Randomized, Double blind, Parallel group, Placebo controlled Study Evaluating the Safety and Efficacy of Treatment with Ustekinumab or Golimumab in Subjects with Chronic Sar... - IT",
        "timestamp": "2009-10-23"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-010714-30/NL",
        "title": "A Phase 2, Multicenter, Randomized, Double blind, Parallel group, Placebo controlled Study Evaluating the Safety and Efficacy of Treatment with Ustekinumab or Golimumab in Subjects with Chronic Sar... - NL",
        "timestamp": "2009-10-23"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-010714-30/results",
        "title": "A Phase 2, Multicenter, Randomized, Double blind, Parallel group, Placebo controlled Study Evaluating the Safety and Efficacy of Treatment with Ustekinumab or Golimumab in Subjects with Chronic Sar... - View results",
        "timestamp": "2009-10-23"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-014296-40/DE",
        "title": "PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE SAFETY AND EFFICACY OF 2 DOSES OF CP-690,550 IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS ON BACKGROUND METHOTREXATE WITH INADEQUA... - DE",
        "timestamp": "2009-11-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-014296-40/ES",
        "title": "PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE SAFETY AND EFFICACY OF 2 DOSES OF CP-690,550 IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS ON BACKGROUND METHOTREXATE WITH INADEQUA... - ES",
        "timestamp": "2009-11-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-014296-40/IE",
        "title": "PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE SAFETY AND EFFICACY OF 2 DOSES OF CP-690,550 IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS ON BACKGROUND METHOTREXATE WITH INADEQUA... - IE",
        "timestamp": "2009-11-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-014296-40/BE",
        "title": "PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE SAFETY AND EFFICACY OF 2 DOSES OF CP-690,550 IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS ON BACKGROUND METHOTREXATE WITH INADEQUA... - BE",
        "timestamp": "2009-11-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-014296-40/FR",
        "title": "PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE SAFETY AND EFFICACY OF 2 DOSES OF CP-690,550 IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS ON BACKGROUND METHOTREXATE WITH INADEQUA... - FR",
        "timestamp": "2009-11-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-014296-40/AT",
        "title": "PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE SAFETY AND EFFICACY OF 2 DOSES OF CP-690,550 IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS ON BACKGROUND METHOTREXATE WITH INADEQUA... - AT",
        "timestamp": "2009-11-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-014296-40/IT",
        "title": "PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE SAFETY AND EFFICACY OF 2 DOSES OF CP-690,550 IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS ON BACKGROUND METHOTREXATE WITH INADEQUA... - IT",
        "timestamp": "2009-11-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-014296-40/GB",
        "title": "PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE SAFETY AND EFFICACY OF 2 DOSES OF CP-690,550 IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS ON BACKGROUND METHOTREXATE WITH INADEQUA... - GB",
        "timestamp": "2009-11-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-014296-40/results",
        "title": "PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE SAFETY AND EFFICACY OF 2 DOSES OF CP-690,550 IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS ON BACKGROUND METHOTREXATE WITH INADEQUA... - View results",
        "timestamp": "2009-11-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-000443-33/HU",
        "title": "A Double-Blind, Randomized, Parallel-Group, Active-Control Study to Compare the Efficacy and Safety of CHS-0214 Versus Enbrel® in Subjects With Rheumatoid Arthritis and Inadequate Response to Treat... - HU",
        "timestamp": "2014-09-09"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-000443-33/IT",
        "title": "A Double-Blind, Randomized, Parallel-Group, Active-Control Study to Compare the Efficacy and Safety of CHS-0214 Versus Enbrel® in Subjects With Rheumatoid Arthritis and Inadequate Response to Treat... - IT",
        "timestamp": "2014-09-09"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-000443-33/GB",
        "title": "A Double-Blind, Randomized, Parallel-Group, Active-Control Study to Compare the Efficacy and Safety of CHS-0214 Versus Enbrel® in Subjects With Rheumatoid Arthritis and Inadequate Response to Treat... - GB",
        "timestamp": "2014-09-09"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-000443-33/ES",
        "title": "A Double-Blind, Randomized, Parallel-Group, Active-Control Study to Compare the Efficacy and Safety of CHS-0214 Versus Enbrel® in Subjects With Rheumatoid Arthritis and Inadequate Response to Treat... - ES",
        "timestamp": "2014-09-09"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-000443-33/DE",
        "title": "A Double-Blind, Randomized, Parallel-Group, Active-Control Study to Compare the Efficacy and Safety of CHS-0214 Versus Enbrel® in Subjects With Rheumatoid Arthritis and Inadequate Response to Treat... - DE",
        "timestamp": "2014-09-09"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-000443-33/PL",
        "title": "A Double-Blind, Randomized, Parallel-Group, Active-Control Study to Compare the Efficacy and Safety of CHS-0214 Versus Enbrel® in Subjects With Rheumatoid Arthritis and Inadequate Response to Treat... - PL",
        "timestamp": "2014-09-09"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-000443-33/results",
        "title": "A Double-Blind, Randomized, Parallel-Group, Active-Control Study to Compare the Efficacy and Safety of CHS-0214 Versus Enbrel® in Subjects With Rheumatoid Arthritis and Inadequate Response to Treat... - View results",
        "timestamp": "2014-09-09"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-000368-88/GB",
        "title": "A Multi-center, Randomized Parallel Group, Placebo-Controlled Double-Blind Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of Belimumab, a Human Monoclonal Anti-BLyS Antibody, Plus Sta... - GB",
        "timestamp": "2012-06-13"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-000368-88/ES",
        "title": "A Multi-center, Randomized Parallel Group, Placebo-Controlled Double-Blind Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of Belimumab, a Human Monoclonal Anti-BLyS Antibody, Plus Sta... - ES",
        "timestamp": "2012-06-13"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-000368-88/PL",
        "title": "A Multi-center, Randomized Parallel Group, Placebo-Controlled Double-Blind Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of Belimumab, a Human Monoclonal Anti-BLyS Antibody, Plus Sta... - PL",
        "timestamp": "2012-06-13"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-000368-88/NL",
        "title": "A Multi-center, Randomized Parallel Group, Placebo-Controlled Double-Blind Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of Belimumab, a Human Monoclonal Anti-BLyS Antibody, Plus Sta... - NL",
        "timestamp": "2012-06-13"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-000368-88/IT",
        "title": "A Multi-center, Randomized Parallel Group, Placebo-Controlled Double-Blind Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of Belimumab, a Human Monoclonal Anti-BLyS Antibody, Plus Sta... - IT",
        "timestamp": "2012-06-13"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-000368-88/3rd",
        "title": "A Multi-center, Randomized Parallel Group, Placebo-Controlled Double-Blind Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of Belimumab, a Human Monoclonal Anti-BLyS Antibody, Plus Sta... - Outside EU/EEA",
        "timestamp": "2012-06-13"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-000368-88/results",
        "title": "A Multi-center, Randomized Parallel Group, Placebo-Controlled Double-Blind Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of Belimumab, a Human Monoclonal Anti-BLyS Antibody, Plus Sta... - View results",
        "timestamp": "2012-06-13"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-004633-96/GB",
        "title": "A Multicentre, Randomised, Double-blind, Placebo-controlled, Phase 3 Study Evaluating the Efficacy and Safety of Two Doses of Anifrolumab in Adult Subjects with Active Systemic Lupus Erythematosus - GB",
        "timestamp": "2015-07-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-004633-96/DE",
        "title": "A Multicentre, Randomised, Double-blind, Placebo-controlled, Phase 3 Study Evaluating the Efficacy and Safety of Two Doses of Anifrolumab in Adult Subjects with Active Systemic Lupus Erythematosus - DE",
        "timestamp": "2015-07-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-004633-96/HU",
        "title": "A Multicentre, Randomised, Double-blind, Placebo-controlled, Phase 3 Study Evaluating the Efficacy and Safety of Two Doses of Anifrolumab in Adult Subjects with Active Systemic Lupus Erythematosus - HU",
        "timestamp": "2015-07-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-004633-96/PL",
        "title": "A Multicentre, Randomised, Double-blind, Placebo-controlled, Phase 3 Study Evaluating the Efficacy and Safety of Two Doses of Anifrolumab in Adult Subjects with Active Systemic Lupus Erythematosus - PL",
        "timestamp": "2015-07-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-004633-96/RO",
        "title": "A Multicentre, Randomised, Double-blind, Placebo-controlled, Phase 3 Study Evaluating the Efficacy and Safety of Two Doses of Anifrolumab in Adult Subjects with Active Systemic Lupus Erythematosus - RO",
        "timestamp": "2015-07-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-004633-96/IT",
        "title": "A Multicentre, Randomised, Double-blind, Placebo-controlled, Phase 3 Study Evaluating the Efficacy and Safety of Two Doses of Anifrolumab in Adult Subjects with Active Systemic Lupus Erythematosus - IT",
        "timestamp": "2015-07-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-004633-96/results",
        "title": "A Multicentre, Randomised, Double-blind, Placebo-controlled, Phase 3 Study Evaluating the Efficacy and Safety of Two Doses of Anifrolumab in Adult Subjects with Active Systemic Lupus Erythematosus - View results",
        "timestamp": "2015-07-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-004915-22/HU",
        "title": "A LONG-TERM, OPEN-LABEL FOLLOW-UP STUDY OF CP-690,550 FOR TREATMENT OF JUVENILE IDIOPATHIC ARTHRITIS (JIA) - HU",
        "timestamp": "2012-08-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-004915-22/PL",
        "title": "A LONG-TERM, OPEN-LABEL FOLLOW-UP STUDY OF CP-690,550 FOR TREATMENT OF JUVENILE IDIOPATHIC ARTHRITIS (JIA) - PL",
        "timestamp": "2012-08-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-004915-22/DE",
        "title": "A LONG-TERM, OPEN-LABEL FOLLOW-UP STUDY OF CP-690,550 FOR TREATMENT OF JUVENILE IDIOPATHIC ARTHRITIS (JIA) - DE",
        "timestamp": "2012-08-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-004915-22/SK",
        "title": "A LONG-TERM, OPEN-LABEL FOLLOW-UP STUDY OF CP-690,550 FOR TREATMENT OF JUVENILE IDIOPATHIC ARTHRITIS (JIA) - SK",
        "timestamp": "2012-08-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-004915-22/IT",
        "title": "A LONG-TERM, OPEN-LABEL FOLLOW-UP STUDY OF CP-690,550 FOR TREATMENT OF JUVENILE IDIOPATHIC ARTHRITIS (JIA) - IT",
        "timestamp": "2012-08-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-004915-22/ES",
        "title": "A LONG-TERM, OPEN-LABEL FOLLOW-UP STUDY OF CP-690,550 FOR TREATMENT OF JUVENILE IDIOPATHIC ARTHRITIS (JIA) - ES",
        "timestamp": "2012-08-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-004915-22/GB",
        "title": "A LONG-TERM, OPEN-LABEL FOLLOW-UP STUDY OF CP-690,550 FOR TREATMENT OF JUVENILE IDIOPATHIC ARTHRITIS (JIA) - GB",
        "timestamp": "2012-08-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-004915-22/BE",
        "title": "A LONG-TERM, OPEN-LABEL FOLLOW-UP STUDY OF CP-690,550 FOR TREATMENT OF JUVENILE IDIOPATHIC ARTHRITIS (JIA) - BE",
        "timestamp": "2012-08-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-004632-19/LT",
        "title": "A Multicentre, Randomised, Double-blind, Placebo-controlled, Phase 3 Study Evaluating the Efficacy and Safety of Anifrolumab in Adult Subjects with Active Systemic Lupus Erythematosus - LT",
        "timestamp": "2015-08-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-004632-19/BE",
        "title": "A Multicentre, Randomised, Double-blind, Placebo-controlled, Phase 3 Study Evaluating the Efficacy and Safety of Anifrolumab in Adult Subjects with Active Systemic Lupus Erythematosus - BE",
        "timestamp": "2015-08-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-004632-19/ES",
        "title": "A Multicentre, Randomised, Double-blind, Placebo-controlled, Phase 3 Study Evaluating the Efficacy and Safety of Anifrolumab in Adult Subjects with Active Systemic Lupus Erythematosus - ES",
        "timestamp": "2015-08-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-004632-19/CZ",
        "title": "A Multicentre, Randomised, Double-blind, Placebo-controlled, Phase 3 Study Evaluating the Efficacy and Safety of Anifrolumab in Adult Subjects with Active Systemic Lupus Erythematosus - CZ",
        "timestamp": "2015-08-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-004632-19/DE",
        "title": "A Multicentre, Randomised, Double-blind, Placebo-controlled, Phase 3 Study Evaluating the Efficacy and Safety of Anifrolumab in Adult Subjects with Active Systemic Lupus Erythematosus - DE",
        "timestamp": "2015-08-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-004632-19/BG",
        "title": "A Multicentre, Randomised, Double-blind, Placebo-controlled, Phase 3 Study Evaluating the Efficacy and Safety of Anifrolumab in Adult Subjects with Active Systemic Lupus Erythematosus - BG",
        "timestamp": "2015-08-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-004632-19/results",
        "title": "A Multicentre, Randomised, Double-blind, Placebo-controlled, Phase 3 Study Evaluating the Efficacy and Safety of Anifrolumab in Adult Subjects with Active Systemic Lupus Erythematosus - View results",
        "timestamp": "2015-08-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-000107-40/GB",
        "title": "A Phase IIb, 12 week Randomized, Double-Blind, Parallel Group, Placebo-Controlled study to evaluate Efficacy, Safety and Tolerability of 2, 4 and 6 mg of Revamilast in patients with Active Rheumato... - GB",
        "timestamp": "2011-06-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-000107-40/results",
        "title": "A Phase IIb, 12 week Randomized, Double-Blind, Parallel Group, Placebo-Controlled study to evaluate Efficacy, Safety and Tolerability of 2, 4 and 6 mg of Revamilast in patients with Active Rheumato... - View results",
        "timestamp": "2011-06-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-000420-15/DE",
        "title": "A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTICENTER, DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF-04236921 IN SUBJECTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) - DE",
        "timestamp": "2012-06-21"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-000420-15/HU",
        "title": "A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTICENTER, DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF-04236921 IN SUBJECTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) - HU",
        "timestamp": "2012-06-21"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-000420-15/results",
        "title": "A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTICENTER, DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF-04236921 IN SUBJECTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) - View results",
        "timestamp": "2012-06-21"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-013223-37/CZ",
        "title": "A PHASE 2A, RANDOMIZED, DOUBLE-BLIND, ACTIVE AND PLACEBO CONTROLLED STUDY OF PF-04171327 IN THE TREATMENT OF THE SIGNS AND SYMPTOMS OF RHEUMATOID ARTHRITIS - CZ",
        "timestamp": "2009-11-10"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-013223-37/HU",
        "title": "A PHASE 2A, RANDOMIZED, DOUBLE-BLIND, ACTIVE AND PLACEBO CONTROLLED STUDY OF PF-04171327 IN THE TREATMENT OF THE SIGNS AND SYMPTOMS OF RHEUMATOID ARTHRITIS - HU",
        "timestamp": "2009-11-10"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-013223-37/ES",
        "title": "A PHASE 2A, RANDOMIZED, DOUBLE-BLIND, ACTIVE AND PLACEBO CONTROLLED STUDY OF PF-04171327 IN THE TREATMENT OF THE SIGNS AND SYMPTOMS OF RHEUMATOID ARTHRITIS - ES",
        "timestamp": "2009-11-10"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-013223-37/results",
        "title": "A PHASE 2A, RANDOMIZED, DOUBLE-BLIND, ACTIVE AND PLACEBO CONTROLLED STUDY OF PF-04171327 IN THE TREATMENT OF THE SIGNS AND SYMPTOMS OF RHEUMATOID ARTHRITIS - View results",
        "timestamp": "2009-11-10"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-018674-20/FR",
        "title": "A Phase 3b, Randomized, Active Controlled Trial to Evaluate the Efficacy and Safety of\nAbatacept SC in Combination with Methotrexate in Inducing Clinical Remission\nCompared to Methotrexate Monother... - FR",
        "timestamp": "2010-09-10"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-018674-20/DE",
        "title": "A Phase 3b, Randomized, Active Controlled Trial to Evaluate the Efficacy and Safety of\nAbatacept SC in Combination with Methotrexate in Inducing Clinical Remission\nCompared to Methotrexate Monother... - DE",
        "timestamp": "2010-09-10"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-018674-20/BE",
        "title": "A Phase 3b, Randomized, Active Controlled Trial to Evaluate the Efficacy and Safety of\nAbatacept SC in Combination with Methotrexate in Inducing Clinical Remission\nCompared to Methotrexate Monother... - BE",
        "timestamp": "2010-09-10"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-018674-20/SE",
        "title": "A Phase 3b, Randomized, Active Controlled Trial to Evaluate the Efficacy and Safety of\nAbatacept SC in Combination with Methotrexate in Inducing Clinical Remission\nCompared to Methotrexate Monother... - SE",
        "timestamp": "2010-09-10"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-018674-20/FI",
        "title": "A Phase 3b, Randomized, Active Controlled Trial to Evaluate the Efficacy and Safety of\nAbatacept SC in Combination with Methotrexate in Inducing Clinical Remission\nCompared to Methotrexate Monother... - FI",
        "timestamp": "2010-09-10"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-018674-20/DK",
        "title": "A Phase 3b, Randomized, Active Controlled Trial to Evaluate the Efficacy and Safety of\nAbatacept SC in Combination with Methotrexate in Inducing Clinical Remission\nCompared to Methotrexate Monother... - DK",
        "timestamp": "2010-09-10"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-018674-20/IT",
        "title": "A Phase 3b, Randomized, Active Controlled Trial to Evaluate the Efficacy and Safety of\nAbatacept SC in Combination with Methotrexate in Inducing Clinical Remission\nCompared to Methotrexate Monother... - IT",
        "timestamp": "2010-09-10"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-018674-20/results",
        "title": "A Phase 3b, Randomized, Active Controlled Trial to Evaluate the Efficacy and Safety of\nAbatacept SC in Combination with Methotrexate in Inducing Clinical Remission\nCompared to Methotrexate Monother... - View results",
        "timestamp": "2010-09-10"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-001341-86/DE",
        "title": "A Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Neutralization of the Interferon Gene Signature and the Clinical Efficacy of IFNα-Kinoid in Adult Subjects with Syste... - DE",
        "timestamp": "2015-11-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-001341-86/BE",
        "title": "A Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Neutralization of the Interferon Gene Signature and the Clinical Efficacy of IFNα-Kinoid in Adult Subjects with Syste... - BE",
        "timestamp": "2015-11-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-001341-86/HR",
        "title": "A Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Neutralization of the Interferon Gene Signature and the Clinical Efficacy of IFNα-Kinoid in Adult Subjects with Syste... - HR",
        "timestamp": "2015-11-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-001341-86/ES",
        "title": "A Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Neutralization of the Interferon Gene Signature and the Clinical Efficacy of IFNα-Kinoid in Adult Subjects with Syste... - ES",
        "timestamp": "2015-11-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-001341-86/BG",
        "title": "A Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Neutralization of the Interferon Gene Signature and the Clinical Efficacy of IFNα-Kinoid in Adult Subjects with Syste... - BG",
        "timestamp": "2015-11-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-001341-86/results",
        "title": "A Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Neutralization of the Interferon Gene Signature and the Clinical Efficacy of IFNα-Kinoid in Adult Subjects with Syste... - View results",
        "timestamp": "2015-11-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-004720-35/SE",
        "title": "A multicenter, randomized, open-label, blinded-assessor, phase 4 study in patients with early rheumatoid arthritis to compare active conventional therapy versus three biologic treatments, and two d... - SE",
        "timestamp": "2012-05-28"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-004720-35/IS",
        "title": "A multicenter, randomized, open-label, blinded-assessor, phase 4 study in patients with early rheumatoid arthritis to compare active conventional therapy versus three biologic treatments, and two d... - IS",
        "timestamp": "2012-05-28"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-004720-35/DK",
        "title": "A multicenter, randomized, open-label, blinded-assessor, phase 4 study in patients with early rheumatoid arthritis to compare active conventional therapy versus three biologic treatments, and two d... - DK",
        "timestamp": "2012-05-28"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-004720-35/FI",
        "title": "A multicenter, randomized, open-label, blinded-assessor, phase 4 study in patients with early rheumatoid arthritis to compare active conventional therapy versus three biologic treatments, and two d... - FI",
        "timestamp": "2012-05-28"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-004720-35/NO",
        "title": "A multicenter, randomized, open-label, blinded-assessor, phase 4 study in patients with early rheumatoid arthritis to compare active conventional therapy versus three biologic treatments, and two d... - NO",
        "timestamp": "2012-05-28"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-004720-35/NL",
        "title": "A multicenter, randomized, open-label, blinded-assessor, phase 4 study in patients with early rheumatoid arthritis to compare active conventional therapy versus three biologic treatments, and two d... - NL",
        "timestamp": "2012-05-28"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-017438-32/DE",
        "title": "A 12-week, double-blind, randomized, parallel-group, placebo-controlled study of 4 doses of VX-509 in subjects with active rheumatoid arthritis - DE",
        "timestamp": None
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-017438-32/BE",
        "title": "A 12-week, double-blind, randomized, parallel-group, placebo-controlled study of 4 doses of VX-509 in subjects with active rheumatoid arthritis - BE",
        "timestamp": None
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-017438-32/HU",
        "title": "A 12-week, double-blind, randomized, parallel-group, placebo-controlled study of 4 doses of VX-509 in subjects with active rheumatoid arthritis - HU",
        "timestamp": None
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-017438-32/PL",
        "title": "A 12-week, double-blind, randomized, parallel-group, placebo-controlled study of 4 doses of VX-509 in subjects with active rheumatoid arthritis - PL",
        "timestamp": None
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-017438-32/results",
        "title": "A 12-week, double-blind, randomized, parallel-group, placebo-controlled study of 4 doses of VX-509 in subjects with active rheumatoid arthritis - View results",
        "timestamp": None
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-004051-19/DE",
        "title": "A Phase IIB, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Abatacept in Combination Therapy with Glucocorticosteroids vs. Placebo plus Gluc... - DE",
        "timestamp": "2005-05-13"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-004051-19/GB",
        "title": "A Phase IIB, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Abatacept in Combination Therapy with Glucocorticosteroids vs. Placebo plus Gluc... - GB",
        "timestamp": "2005-05-13"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-004051-19/SE",
        "title": "A Phase IIB, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Abatacept in Combination Therapy with Glucocorticosteroids vs. Placebo plus Gluc... - SE",
        "timestamp": "2005-05-13"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-004051-19/BE",
        "title": "A Phase IIB, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Abatacept in Combination Therapy with Glucocorticosteroids vs. Placebo plus Gluc... - BE",
        "timestamp": "2005-05-13"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-004051-19/AT",
        "title": "A Phase IIB, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Abatacept in Combination Therapy with Glucocorticosteroids vs. Placebo plus Gluc... - AT",
        "timestamp": "2005-05-13"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-004051-19/IT",
        "title": "A Phase IIB, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Abatacept in Combination Therapy with Glucocorticosteroids vs. Placebo plus Gluc... - IT",
        "timestamp": "2005-05-13"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-001039-11/GB",
        "title": "A PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE SAFETY AND EFFICACY OF GDC-0853 IN PATIENTS WITH\r\nMODERATE TO SEVERE ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS - GB",
        "timestamp": "2016-11-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-001039-11/PT",
        "title": "A PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE SAFETY AND EFFICACY OF GDC-0853 IN PATIENTS WITH\r\nMODERATE TO SEVERE ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS - PT",
        "timestamp": "2016-11-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-001039-11/ES",
        "title": "A PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE SAFETY AND EFFICACY OF GDC-0853 IN PATIENTS WITH\r\nMODERATE TO SEVERE ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS - ES",
        "timestamp": "2016-11-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-001039-11/BG",
        "title": "A PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE SAFETY AND EFFICACY OF GDC-0853 IN PATIENTS WITH\r\nMODERATE TO SEVERE ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS - BG",
        "timestamp": "2016-11-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-001039-11/DE",
        "title": "A PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE SAFETY AND EFFICACY OF GDC-0853 IN PATIENTS WITH\r\nMODERATE TO SEVERE ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS - DE",
        "timestamp": "2016-11-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-021184-32/DE",
        "title": "A randomized, double-blind, controlled study to evaluate pharmacokinetics, pharmacodynamics, safety and efficacy of GP2013 and rituximab in patients with rheumatoid arthritis refractory or intolera... - DE",
        "timestamp": "2010-11-30"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-021184-32/FR",
        "title": "A randomized, double-blind, controlled study to evaluate pharmacokinetics, pharmacodynamics, safety and efficacy of GP2013 and rituximab in patients with rheumatoid arthritis refractory or intolera... - FR",
        "timestamp": "2010-11-30"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-021184-32/ES",
        "title": "A randomized, double-blind, controlled study to evaluate pharmacokinetics, pharmacodynamics, safety and efficacy of GP2013 and rituximab in patients with rheumatoid arthritis refractory or intolera... - ES",
        "timestamp": "2010-11-30"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-021184-32/AT",
        "title": "A randomized, double-blind, controlled study to evaluate pharmacokinetics, pharmacodynamics, safety and efficacy of GP2013 and rituximab in patients with rheumatoid arthritis refractory or intolera... - AT",
        "timestamp": "2010-11-30"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-021184-32/IT",
        "title": "A randomized, double-blind, controlled study to evaluate pharmacokinetics, pharmacodynamics, safety and efficacy of GP2013 and rituximab in patients with rheumatoid arthritis refractory or intolera... - IT",
        "timestamp": "2010-11-30"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-021184-32/BE",
        "title": "A randomized, double-blind, controlled study to evaluate pharmacokinetics, pharmacodynamics, safety and efficacy of GP2013 and rituximab in patients with rheumatoid arthritis refractory or intolera... - BE",
        "timestamp": "2010-11-30"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-021184-32/EE",
        "title": "A randomized, double-blind, controlled study to evaluate pharmacokinetics, pharmacodynamics, safety and efficacy of GP2013 and rituximab in patients with rheumatoid arthritis refractory or intolera... - EE",
        "timestamp": "2010-11-30"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-021184-32/HU",
        "title": "A randomized, double-blind, controlled study to evaluate pharmacokinetics, pharmacodynamics, safety and efficacy of GP2013 and rituximab in patients with rheumatoid arthritis refractory or intolera... - HU",
        "timestamp": "2010-11-30"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-021184-32/PL",
        "title": "A randomized, double-blind, controlled study to evaluate pharmacokinetics, pharmacodynamics, safety and efficacy of GP2013 and rituximab in patients with rheumatoid arthritis refractory or intolera... - PL",
        "timestamp": "2010-11-30"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-021184-32/BG",
        "title": "A randomized, double-blind, controlled study to evaluate pharmacokinetics, pharmacodynamics, safety and efficacy of GP2013 and rituximab in patients with rheumatoid arthritis refractory or intolera... - BG",
        "timestamp": "2010-11-30"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-021184-32/GB",
        "title": "A randomized, double-blind, controlled study to evaluate pharmacokinetics, pharmacodynamics, safety and efficacy of GP2013 and rituximab in patients with rheumatoid arthritis refractory or intolera... - GB",
        "timestamp": "2010-11-30"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-021184-32/results",
        "title": "A randomized, double-blind, controlled study to evaluate pharmacokinetics, pharmacodynamics, safety and efficacy of GP2013 and rituximab in patients with rheumatoid arthritis refractory or intolera... - View results",
        "timestamp": "2010-11-30"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-004854-12/NL",
        "title": "An Open-label Single-arm Pharmacokinetic Trial, Investigating the Effect of CYP3A4 inhibitor Ritonavir on the Pharmacokinetics of Erlotinib - NL",
        "timestamp": "2019-04-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-000604-88/GB",
        "title": "A phase IV, two-arm, open-label, single-centre randomised pilot study to assess the feasibility of immeidate or deferred switching of HIV-infected individuals intolerant of efavirenz, ritonavir-boo... - GB",
        "timestamp": "2008-04-04"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-005056-13/NL",
        "title": "M17DOC: Multicenter safety, feasibility and pharmacokinetic phase I trial of ModraDoc006/r in patients with metastatic castration-resistant prostate cancer - NL",
        "timestamp": "2017-03-30"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-000649-11/GB",
        "title": "A phase IV, open-label, single centre, single-arm, pilot study to assess Cerebrospinal fluid INflammatory markers after Addition of Maraviroc to MONotherapy darunavir/ritonavir – The CINAMMON Study... - GB",
        "timestamp": "2012-08-22"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-000649-11/ES",
        "title": "A phase IV, open-label, single centre, single-arm, pilot study to assess Cerebrospinal fluid INflammatory markers after Addition of Maraviroc to MONotherapy darunavir/ritonavir – The CINAMMON Study... - ES",
        "timestamp": "2012-08-22"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-000649-11/results",
        "title": "A phase IV, open-label, single centre, single-arm, pilot study to assess Cerebrospinal fluid INflammatory markers after Addition of Maraviroc to MONotherapy darunavir/ritonavir – The CINAMMON Study... - View results",
        "timestamp": "2012-08-22"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-013287-39/ES",
        "title": "RANDOMISED AND PROSPECTIVE CLINICAL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LOPINAVIR/RITONAVIR MONOTHERAPY VS DARUNAVIR/RITONAVIR MONOTHERAPIES AS SIMPLIFICATION SWITCHING STRATEGIES OF PI/NN... - ES",
        "timestamp": "2009-09-25"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-013287-39/results",
        "title": "RANDOMISED AND PROSPECTIVE CLINICAL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LOPINAVIR/RITONAVIR MONOTHERAPY VS DARUNAVIR/RITONAVIR MONOTHERAPIES AS SIMPLIFICATION SWITCHING STRATEGIES OF PI/NN... - View results",
        "timestamp": "2009-09-25"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-002700-78/BE",
        "title": "Supersaturation and precipitation of ritonavir in the gastrointestinal tract of healthy volunteers - BE",
        "timestamp": "2016-10-28"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-004844-59/FR",
        "title": "A two part, randomized, placebo controlled study to evaluate the pharmacokinetics and cardiovascular pharmacodynamics of AEB071 in combination with ritonavir in healthy volunteers - FR",
        "timestamp": "2008-01-31"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-004844-59/results",
        "title": "A two part, randomized, placebo controlled study to evaluate the pharmacokinetics and cardiovascular pharmacodynamics of AEB071 in combination with ritonavir in healthy volunteers - View results",
        "timestamp": "2008-01-31"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-000932-19/GB",
        "title": "A phase IV study to assess the feasibility of substituting double ritonavir-boosted protease inhibitors (PI) with ritonavir-boosted darunavir (DRV/r) in HIV-infected individuals with viral suppress... - GB",
        "timestamp": "2008-02-25"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-005609-76/GB",
        "title": "EFFECT OF DIFFERENT MEALS ON THE PHARMACOKINETIC PROFILE OF SAQUINAVIR AT STEADY STATE IN HIV-INFECTED PATIENTS TREATED WITH SAQUINAVIR/RITONAVIR 1000/100 mg BID. - GB",
        "timestamp": "2006-11-28"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-004430-41/GB",
        "title": "Effect of food on the pharmacokinetic profile of saquinavir at steady state in HIV-infected patients treated with saquinavir/ritonavir 1000/100 mg b.i.d. - GB",
        "timestamp": "2005-11-04"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-002864-24/NL",
        "title": "Drug interactions between ATOvaquone used in MAlaria prophylaxis and antiretroviral agents in HIV-1 infected patients (ATOMA) - NL",
        "timestamp": "2006-09-25"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-002864-24/results",
        "title": "Drug interactions between ATOvaquone used in MAlaria prophylaxis and antiretroviral agents in HIV-1 infected patients (ATOMA) - View results",
        "timestamp": "2006-09-25"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-001913-14/GB",
        "title": "A randomized crossover study of the effects of zinc sulphate supplementation on atazanavir/ritonavir-associated hyperbilirubinemia - GB",
        "timestamp": "2011-11-08"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-013648-35/IE",
        "title": "KONCERT \nA Kaletra ONCE daily Randomised Trial of the pharmacokinetics, safety and efficacy of twice-daily versus once-daily lopinavir/ritonavir tablets dosed by weight as part of combination antir... - IE",
        "timestamp": "2010-06-23"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-013648-35/NL",
        "title": "KONCERT \nA Kaletra ONCE daily Randomised Trial of the pharmacokinetics, safety and efficacy of twice-daily versus once-daily lopinavir/ritonavir tablets dosed by weight as part of combination antir... - NL",
        "timestamp": "2010-06-23"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-013648-35/FR",
        "title": "KONCERT \nA Kaletra ONCE daily Randomised Trial of the pharmacokinetics, safety and efficacy of twice-daily versus once-daily lopinavir/ritonavir tablets dosed by weight as part of combination antir... - FR",
        "timestamp": "2010-06-23"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-013648-35/GB",
        "title": "KONCERT \nA Kaletra ONCE daily Randomised Trial of the pharmacokinetics, safety and efficacy of twice-daily versus once-daily lopinavir/ritonavir tablets dosed by weight as part of combination antir... - GB",
        "timestamp": "2010-06-23"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-013648-35/ES",
        "title": "KONCERT \nA Kaletra ONCE daily Randomised Trial of the pharmacokinetics, safety and efficacy of twice-daily versus once-daily lopinavir/ritonavir tablets dosed by weight as part of combination antir... - ES",
        "timestamp": "2010-06-23"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-013648-35/PT",
        "title": "KONCERT \nA Kaletra ONCE daily Randomised Trial of the pharmacokinetics, safety and efficacy of twice-daily versus once-daily lopinavir/ritonavir tablets dosed by weight as part of combination antir... - PT",
        "timestamp": "2010-06-23"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-013648-35/BE",
        "title": "KONCERT \nA Kaletra ONCE daily Randomised Trial of the pharmacokinetics, safety and efficacy of twice-daily versus once-daily lopinavir/ritonavir tablets dosed by weight as part of combination antir... - BE",
        "timestamp": "2010-06-23"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-013648-35/DE",
        "title": "KONCERT \nA Kaletra ONCE daily Randomised Trial of the pharmacokinetics, safety and efficacy of twice-daily versus once-daily lopinavir/ritonavir tablets dosed by weight as part of combination antir... - DE",
        "timestamp": "2010-06-23"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005981-39/ES",
        "title": "Pilot simplification study to Lopinavir/ritonavir 800/200 mg monotherapy regimen once daily - ES",
        "timestamp": "2012-03-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-021159-25/ES",
        "title": "INTERACCIONES FARMACOLÓGICAS ENTRE LA SILIMARINA Y DARUNAVIR/RITONAVIR - ES",
        "timestamp": "2010-11-08"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-021159-25/results",
        "title": "INTERACCIONES FARMACOLÓGICAS ENTRE LA SILIMARINA Y DARUNAVIR/RITONAVIR - View results",
        "timestamp": "2010-11-08"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-003077-15/DE",
        "title": "A Phase 2, Open-Label Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Activity of Titrating-Dose Lonafarnib in Combination with Ritonavir in Patients Chronically Infected w... - DE",
        "timestamp": "2015-11-23"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-013265-26/ES",
        "title": "INTERACCIONES FARMACOLÓGICAS ENTRE ECHINACEA PURPUREA Y DARUNAVIR/RITONAVIR - ES",
        "timestamp": "2009-11-11"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-013265-26/results",
        "title": "INTERACCIONES FARMACOLÓGICAS ENTRE ECHINACEA PURPUREA Y DARUNAVIR/RITONAVIR - View results",
        "timestamp": "2009-11-11"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-002663-10/GB",
        "title": "A phase IV, open-label single-arm study investigating the pharmacokinetics and pharmacodynamics of the antiretroviral combination of rilpivirine and ritonavir-boosted darunavir in therapy-naive HIV... - GB",
        "timestamp": "2012-11-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-002663-10/results",
        "title": "A phase IV, open-label single-arm study investigating the pharmacokinetics and pharmacodynamics of the antiretroviral combination of rilpivirine and ritonavir-boosted darunavir in therapy-naive HIV... - View results",
        "timestamp": "2012-11-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-002585-19/GB",
        "title": "A 24-week, randomised, open-label, 2-arm study to compare the tolerability and efficacy of saquinavir tablets with ritonavir versus lopinavir/ritonavir tablets in HIV 1 infected adults switching fr... - GB",
        "timestamp": "2006-08-02"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-001107-12/ES",
        "title": "Ensayo Clínico aleatorizado, abierto, de no inferioridad y con seguimiento a 96 semanas sobre la eficacia de azatanavir / ritonavir  + lamivudina como tratamiento de mantenimiento en pacientes con ... - ES",
        "timestamp": "2011-07-15"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-004854-12/NL",
        "title": "An Open-label Single-arm Pharmacokinetic Trial, Investigating the Effect of CYP3A4 inhibitor Ritonavir on the Pharmacokinetics of Erlotinib - NL",
        "timestamp": "2019-04-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-000604-88/GB",
        "title": "A phase IV, two-arm, open-label, single-centre randomised pilot study to assess the feasibility of immeidate or deferred switching of HIV-infected individuals intolerant of efavirenz, ritonavir-boo... - GB",
        "timestamp": "2008-04-04"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-005056-13/NL",
        "title": "M17DOC: Multicenter safety, feasibility and pharmacokinetic phase I trial of ModraDoc006/r in patients with metastatic castration-resistant prostate cancer - NL",
        "timestamp": "2017-03-30"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-000649-11/GB",
        "title": "A phase IV, open-label, single centre, single-arm, pilot study to assess Cerebrospinal fluid INflammatory markers after Addition of Maraviroc to MONotherapy darunavir/ritonavir – The CINAMMON Study... - GB",
        "timestamp": "2012-08-22"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-000649-11/ES",
        "title": "A phase IV, open-label, single centre, single-arm, pilot study to assess Cerebrospinal fluid INflammatory markers after Addition of Maraviroc to MONotherapy darunavir/ritonavir – The CINAMMON Study... - ES",
        "timestamp": "2012-08-22"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-000649-11/results",
        "title": "A phase IV, open-label, single centre, single-arm, pilot study to assess Cerebrospinal fluid INflammatory markers after Addition of Maraviroc to MONotherapy darunavir/ritonavir – The CINAMMON Study... - View results",
        "timestamp": "2012-08-22"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-013287-39/ES",
        "title": "RANDOMISED AND PROSPECTIVE CLINICAL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LOPINAVIR/RITONAVIR MONOTHERAPY VS DARUNAVIR/RITONAVIR MONOTHERAPIES AS SIMPLIFICATION SWITCHING STRATEGIES OF PI/NN... - ES",
        "timestamp": "2009-09-25"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-013287-39/results",
        "title": "RANDOMISED AND PROSPECTIVE CLINICAL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LOPINAVIR/RITONAVIR MONOTHERAPY VS DARUNAVIR/RITONAVIR MONOTHERAPIES AS SIMPLIFICATION SWITCHING STRATEGIES OF PI/NN... - View results",
        "timestamp": "2009-09-25"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-002700-78/BE",
        "title": "Supersaturation and precipitation of ritonavir in the gastrointestinal tract of healthy volunteers - BE",
        "timestamp": "2016-10-28"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-004844-59/FR",
        "title": "A two part, randomized, placebo controlled study to evaluate the pharmacokinetics and cardiovascular pharmacodynamics of AEB071 in combination with ritonavir in healthy volunteers - FR",
        "timestamp": "2008-01-31"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-004844-59/results",
        "title": "A two part, randomized, placebo controlled study to evaluate the pharmacokinetics and cardiovascular pharmacodynamics of AEB071 in combination with ritonavir in healthy volunteers - View results",
        "timestamp": "2008-01-31"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-000932-19/GB",
        "title": "A phase IV study to assess the feasibility of substituting double ritonavir-boosted protease inhibitors (PI) with ritonavir-boosted darunavir (DRV/r) in HIV-infected individuals with viral suppress... - GB",
        "timestamp": "2008-02-25"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-005609-76/GB",
        "title": "EFFECT OF DIFFERENT MEALS ON THE PHARMACOKINETIC PROFILE OF SAQUINAVIR AT STEADY STATE IN HIV-INFECTED PATIENTS TREATED WITH SAQUINAVIR/RITONAVIR 1000/100 mg BID. - GB",
        "timestamp": "2006-11-28"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-004430-41/GB",
        "title": "Effect of food on the pharmacokinetic profile of saquinavir at steady state in HIV-infected patients treated with saquinavir/ritonavir 1000/100 mg b.i.d. - GB",
        "timestamp": "2005-11-04"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-002864-24/NL",
        "title": "Drug interactions between ATOvaquone used in MAlaria prophylaxis and antiretroviral agents in HIV-1 infected patients (ATOMA) - NL",
        "timestamp": "2006-09-25"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-002864-24/results",
        "title": "Drug interactions between ATOvaquone used in MAlaria prophylaxis and antiretroviral agents in HIV-1 infected patients (ATOMA) - View results",
        "timestamp": "2006-09-25"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-001913-14/GB",
        "title": "A randomized crossover study of the effects of zinc sulphate supplementation on atazanavir/ritonavir-associated hyperbilirubinemia - GB",
        "timestamp": "2011-11-08"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-013648-35/IE",
        "title": "KONCERT \nA Kaletra ONCE daily Randomised Trial of the pharmacokinetics, safety and efficacy of twice-daily versus once-daily lopinavir/ritonavir tablets dosed by weight as part of combination antir... - IE",
        "timestamp": "2010-06-23"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-013648-35/NL",
        "title": "KONCERT \nA Kaletra ONCE daily Randomised Trial of the pharmacokinetics, safety and efficacy of twice-daily versus once-daily lopinavir/ritonavir tablets dosed by weight as part of combination antir... - NL",
        "timestamp": "2010-06-23"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-013648-35/FR",
        "title": "KONCERT \nA Kaletra ONCE daily Randomised Trial of the pharmacokinetics, safety and efficacy of twice-daily versus once-daily lopinavir/ritonavir tablets dosed by weight as part of combination antir... - FR",
        "timestamp": "2010-06-23"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-013648-35/GB",
        "title": "KONCERT \nA Kaletra ONCE daily Randomised Trial of the pharmacokinetics, safety and efficacy of twice-daily versus once-daily lopinavir/ritonavir tablets dosed by weight as part of combination antir... - GB",
        "timestamp": "2010-06-23"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-013648-35/ES",
        "title": "KONCERT \nA Kaletra ONCE daily Randomised Trial of the pharmacokinetics, safety and efficacy of twice-daily versus once-daily lopinavir/ritonavir tablets dosed by weight as part of combination antir... - ES",
        "timestamp": "2010-06-23"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-013648-35/PT",
        "title": "KONCERT \nA Kaletra ONCE daily Randomised Trial of the pharmacokinetics, safety and efficacy of twice-daily versus once-daily lopinavir/ritonavir tablets dosed by weight as part of combination antir... - PT",
        "timestamp": "2010-06-23"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-013648-35/BE",
        "title": "KONCERT \nA Kaletra ONCE daily Randomised Trial of the pharmacokinetics, safety and efficacy of twice-daily versus once-daily lopinavir/ritonavir tablets dosed by weight as part of combination antir... - BE",
        "timestamp": "2010-06-23"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-013648-35/DE",
        "title": "KONCERT \nA Kaletra ONCE daily Randomised Trial of the pharmacokinetics, safety and efficacy of twice-daily versus once-daily lopinavir/ritonavir tablets dosed by weight as part of combination antir... - DE",
        "timestamp": "2010-06-23"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005981-39/ES",
        "title": "Pilot simplification study to Lopinavir/ritonavir 800/200 mg monotherapy regimen once daily - ES",
        "timestamp": "2012-03-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-021159-25/ES",
        "title": "INTERACCIONES FARMACOLÓGICAS ENTRE LA SILIMARINA Y DARUNAVIR/RITONAVIR - ES",
        "timestamp": "2010-11-08"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-021159-25/results",
        "title": "INTERACCIONES FARMACOLÓGICAS ENTRE LA SILIMARINA Y DARUNAVIR/RITONAVIR - View results",
        "timestamp": "2010-11-08"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-003077-15/DE",
        "title": "A Phase 2, Open-Label Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Activity of Titrating-Dose Lonafarnib in Combination with Ritonavir in Patients Chronically Infected w... - DE",
        "timestamp": "2015-11-23"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-013265-26/ES",
        "title": "INTERACCIONES FARMACOLÓGICAS ENTRE ECHINACEA PURPUREA Y DARUNAVIR/RITONAVIR - ES",
        "timestamp": "2009-11-11"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-013265-26/results",
        "title": "INTERACCIONES FARMACOLÓGICAS ENTRE ECHINACEA PURPUREA Y DARUNAVIR/RITONAVIR - View results",
        "timestamp": "2009-11-11"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-002663-10/GB",
        "title": "A phase IV, open-label single-arm study investigating the pharmacokinetics and pharmacodynamics of the antiretroviral combination of rilpivirine and ritonavir-boosted darunavir in therapy-naive HIV... - GB",
        "timestamp": "2012-11-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-002663-10/results",
        "title": "A phase IV, open-label single-arm study investigating the pharmacokinetics and pharmacodynamics of the antiretroviral combination of rilpivirine and ritonavir-boosted darunavir in therapy-naive HIV... - View results",
        "timestamp": "2012-11-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-002585-19/GB",
        "title": "A 24-week, randomised, open-label, 2-arm study to compare the tolerability and efficacy of saquinavir tablets with ritonavir versus lopinavir/ritonavir tablets in HIV 1 infected adults switching fr... - GB",
        "timestamp": "2006-08-02"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-001107-12/ES",
        "title": "Ensayo Clínico aleatorizado, abierto, de no inferioridad y con seguimiento a 96 semanas sobre la eficacia de azatanavir / ritonavir  + lamivudina como tratamiento de mantenimiento en pacientes con ... - ES",
        "timestamp": "2011-07-15"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-000496-64/ES",
        "title": "Viral suppression in Cerebrospinal Fluid in HIV-1 infected patients receiving Ritonavir-boosted Atazanavir plus lamivudine dual theraphy. SCALA study - ES",
        "timestamp": "2014-04-23"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-005979-34/ES",
        "title": "ESTUDIO PILOTO, ABIERTO, COMPARATIVO Y ALEATORIZADO PARA EVALUAR LA EFICACIA Y SEGURIDAD DE DARUNAVIR/RITONAVIR 900/100 MG UNA VEZ AL DIA COMO ESTRATEGIA DE SIMPLIFICACION DEL TRATAMIENTO ANTIRRETR... - ES",
        "timestamp": "2008-01-22"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-005979-34/results",
        "title": "ESTUDIO PILOTO, ABIERTO, COMPARATIVO Y ALEATORIZADO PARA EVALUAR LA EFICACIA Y SEGURIDAD DE DARUNAVIR/RITONAVIR 900/100 MG UNA VEZ AL DIA COMO ESTRATEGIA DE SIMPLIFICACION DEL TRATAMIENTO ANTIRRETR... - View results",
        "timestamp": "2008-01-22"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-000666-37/GB",
        "title": "A Randomised, Controlled, Open-Label, 48-Week, Study To Asses Differences in Changes In Plasma Lipid Profile Between Patients On Saquinavir/Ritonavir Or Atazanavir/Ritonavir In Combination With Ten... - GB",
        "timestamp": "2006-06-05"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-000666-37/DE",
        "title": "A Randomised, Controlled, Open-Label, 48-Week, Study To Asses Differences in Changes In Plasma Lipid Profile Between Patients On Saquinavir/Ritonavir Or Atazanavir/Ritonavir In Combination With Ten... - DE",
        "timestamp": "2006-06-05"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-005579-16/DE",
        "title": "Study of Once-Daily Versus Twice-Daily Fosamprenavir plus Ritonavir, Administered with Abacavir/Lamivudine Once-Daily in Antiretroviral-Naïve HIV-1 Infected Adult Subjects. - DE",
        "timestamp": "2007-04-13"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-005579-16/BE",
        "title": "Study of Once-Daily Versus Twice-Daily Fosamprenavir plus Ritonavir, Administered with Abacavir/Lamivudine Once-Daily in Antiretroviral-Naïve HIV-1 Infected Adult Subjects. - BE",
        "timestamp": "2007-04-13"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-005579-16/GB",
        "title": "Study of Once-Daily Versus Twice-Daily Fosamprenavir plus Ritonavir, Administered with Abacavir/Lamivudine Once-Daily in Antiretroviral-Naïve HIV-1 Infected Adult Subjects. - GB",
        "timestamp": "2007-04-13"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-005579-16/FR",
        "title": "Study of Once-Daily Versus Twice-Daily Fosamprenavir plus Ritonavir, Administered with Abacavir/Lamivudine Once-Daily in Antiretroviral-Naïve HIV-1 Infected Adult Subjects. - FR",
        "timestamp": "2007-04-13"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-005579-16/ES",
        "title": "Study of Once-Daily Versus Twice-Daily Fosamprenavir plus Ritonavir, Administered with Abacavir/Lamivudine Once-Daily in Antiretroviral-Naïve HIV-1 Infected Adult Subjects. - ES",
        "timestamp": "2007-04-13"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-005579-16/IT",
        "title": "Study of Once-Daily Versus Twice-Daily Fosamprenavir plus Ritonavir, Administered with Abacavir/Lamivudine Once-Daily in Antiretroviral-Naïve HIV-1 Infected Adult Subjects. - IT",
        "timestamp": "2007-04-13"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-005579-16/results",
        "title": "Study of Once-Daily Versus Twice-Daily Fosamprenavir plus Ritonavir, Administered with Abacavir/Lamivudine Once-Daily in Antiretroviral-Naïve HIV-1 Infected Adult Subjects. - View results",
        "timestamp": "2007-04-13"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-000748-14/CZ",
        "title": "A Phase 3, Randomized, Open-label Study of Lopinavir/ritonavir Tablets 800/200 mg Once-daily Versus 400/100 mg Twice-daily when Coadministered with Nucleoside/Nucleotide Reverse Transcriptase Inhib... - CZ",
        "timestamp": "2006-08-14"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-000748-14/BE",
        "title": "A Phase 3, Randomized, Open-label Study of Lopinavir/ritonavir Tablets 800/200 mg Once-daily Versus 400/100 mg Twice-daily when Coadministered with Nucleoside/Nucleotide Reverse Transcriptase Inhib... - BE",
        "timestamp": "2006-08-14"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-000748-14/ES",
        "title": "A Phase 3, Randomized, Open-label Study of Lopinavir/ritonavir Tablets 800/200 mg Once-daily Versus 400/100 mg Twice-daily when Coadministered with Nucleoside/Nucleotide Reverse Transcriptase Inhib... - ES",
        "timestamp": "2006-08-14"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-000748-14/DE",
        "title": "A Phase 3, Randomized, Open-label Study of Lopinavir/ritonavir Tablets 800/200 mg Once-daily Versus 400/100 mg Twice-daily when Coadministered with Nucleoside/Nucleotide Reverse Transcriptase Inhib... - DE",
        "timestamp": "2006-08-14"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-000748-14/IE",
        "title": "A Phase 3, Randomized, Open-label Study of Lopinavir/ritonavir Tablets 800/200 mg Once-daily Versus 400/100 mg Twice-daily when Coadministered with Nucleoside/Nucleotide Reverse Transcriptase Inhib... - IE",
        "timestamp": "2006-08-14"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-000748-14/PT",
        "title": "A Phase 3, Randomized, Open-label Study of Lopinavir/ritonavir Tablets 800/200 mg Once-daily Versus 400/100 mg Twice-daily when Coadministered with Nucleoside/Nucleotide Reverse Transcriptase Inhib... - PT",
        "timestamp": "2006-08-14"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-000748-14/GR",
        "title": "A Phase 3, Randomized, Open-label Study of Lopinavir/ritonavir Tablets 800/200 mg Once-daily Versus 400/100 mg Twice-daily when Coadministered with Nucleoside/Nucleotide Reverse Transcriptase Inhib... - GR",
        "timestamp": "2006-08-14"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-000748-14/IT",
        "title": "A Phase 3, Randomized, Open-label Study of Lopinavir/ritonavir Tablets 800/200 mg Once-daily Versus 400/100 mg Twice-daily when Coadministered with Nucleoside/Nucleotide Reverse Transcriptase Inhib... - IT",
        "timestamp": "2006-08-14"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-000748-14/GB",
        "title": "A Phase 3, Randomized, Open-label Study of Lopinavir/ritonavir Tablets 800/200 mg Once-daily Versus 400/100 mg Twice-daily when Coadministered with Nucleoside/Nucleotide Reverse Transcriptase Inhib... - GB",
        "timestamp": "2006-08-14"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-000748-14/results",
        "title": "A Phase 3, Randomized, Open-label Study of Lopinavir/ritonavir Tablets 800/200 mg Once-daily Versus 400/100 mg Twice-daily when Coadministered with Nucleoside/Nucleotide Reverse Transcriptase Inhib... - View results",
        "timestamp": "2006-08-14"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-000881-22/FR",
        "title": "A Randomized, Open-label, Study of Lopinavir/ritonavir 400/100 mg Tablet Twice-Daily + Co-formulated Emtricitabine/Tenofovir Disoproxil Fumarate 200/300 mg Once-Daily Versus Lopinavir/ritonavir 400... - FR",
        "timestamp": "2008-07-17"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-000881-22/ES",
        "title": "A Randomized, Open-label, Study of Lopinavir/ritonavir 400/100 mg Tablet Twice-Daily + Co-formulated Emtricitabine/Tenofovir Disoproxil Fumarate 200/300 mg Once-Daily Versus Lopinavir/ritonavir 400... - ES",
        "timestamp": "2008-07-17"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-000881-22/IT",
        "title": "A Randomized, Open-label, Study of Lopinavir/ritonavir 400/100 mg Tablet Twice-Daily + Co-formulated Emtricitabine/Tenofovir Disoproxil Fumarate 200/300 mg Once-Daily Versus Lopinavir/ritonavir 400... - IT",
        "timestamp": "2008-07-17"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-000881-22/results",
        "title": "A Randomized, Open-label, Study of Lopinavir/ritonavir 400/100 mg Tablet Twice-Daily + Co-formulated Emtricitabine/Tenofovir Disoproxil Fumarate 200/300 mg Once-Daily Versus Lopinavir/ritonavir 400... - View results",
        "timestamp": "2008-07-17"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-004544-37/FR",
        "title": "Etude ouverte, non comparative, évaluant chez des patients infectés par le VIH-1, ayant une charge virale indétectable avec un traitement comportant un inhibiteur de la protéase potentialisé par du... - FR",
        "timestamp": "2009-03-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-005473-35/ES",
        "title": "PILOT STUDY TO ASSESS THE ROLE OF IMMUNE ACTIVATION AND APOPTOSIS AS A MARKER FOR TREATMENT INTENSIFICATION WITH RALTEGRAVIR IN HIV-INFECTED PATIENTS ON ANTIRETROVIRAL THERAPY WITH LONG-TERM VIRAL ... - ES",
        "timestamp": "2008-11-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-005473-35/results",
        "title": "PILOT STUDY TO ASSESS THE ROLE OF IMMUNE ACTIVATION AND APOPTOSIS AS A MARKER FOR TREATMENT INTENSIFICATION WITH RALTEGRAVIR IN HIV-INFECTED PATIENTS ON ANTIRETROVIRAL THERAPY WITH LONG-TERM VIRAL ... - View results",
        "timestamp": "2008-11-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-023008-29/ES",
        "title": "Estudio Fase 3, Aleatorizado, Abierto, Controlado de Lopinavir/Ritonavir y Lamivudina versus terapia estándar en Pacientes Infectados con HIV-1 Naïve. - ES",
        "timestamp": "2011-01-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-019446-38/ES",
        "title": "Estudio Exploratorio Transversal para Comparar la Eficacia Virológica en el LCR y el Estado Neurocognitivo en Pacientes Infectados por el VIH-1 en Tratamiento Prolongado (> 3 años) con Lopinavir/ri... - ES",
        "timestamp": "2010-06-04"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-019446-38/results",
        "title": "Estudio Exploratorio Transversal para Comparar la Eficacia Virológica en el LCR y el Estado Neurocognitivo en Pacientes Infectados por el VIH-1 en Tratamiento Prolongado (> 3 años) con Lopinavir/ri... - View results",
        "timestamp": "2010-06-04"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-011868-11/ES",
        "title": "ENSAYO CLÍNICO PILOTO PARA EVALUAR LA SEGURIDAD Y EFICACIA DE CAMBIAR EL ITINAN O EL IP A MARAVIROC EN PACIENTES INFECTADOS POR EL VIH-1 CON CARGA VIRAL INDETECTABLE Y DISLIPEMIA ASOCIADA A LOS ANT... - ES",
        "timestamp": "2009-07-30"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-011868-11/results",
        "title": "ENSAYO CLÍNICO PILOTO PARA EVALUAR LA SEGURIDAD Y EFICACIA DE CAMBIAR EL ITINAN O EL IP A MARAVIROC EN PACIENTES INFECTADOS POR EL VIH-1 CON CARGA VIRAL INDETECTABLE Y DISLIPEMIA ASOCIADA A LOS ANT... - View results",
        "timestamp": "2009-07-30"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-004990-27/IT",
        "title": "The pharmacokinetic interaction between TMC114, lopinavir and ritonavir, in HIV-1 infected subjects. - IT",
        "timestamp": "2005-05-09"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-004990-27/results",
        "title": "The pharmacokinetic interaction between TMC114, lopinavir and ritonavir, in HIV-1 infected subjects. - View results",
        "timestamp": "2005-05-09"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-004617-34/GB",
        "title": "A phase I/II study of Invirase® boosted with Ritonavir in HIV infected infants and children 4 months to less than 6 years old - GB",
        "timestamp": "2008-01-15"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-004617-34/results",
        "title": "A phase I/II study of Invirase® boosted with Ritonavir in HIV infected infants and children 4 months to less than 6 years old - View results",
        "timestamp": "2008-01-15"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-001323-37/ES",
        "title": "Phase IV-III, open-label, randomized, comparative study, to evaluate the safety and efficacy of the nucleoside supression of a triple therapy based on lopinavir-ritonavir vs. continuous triple ther... - ES",
        "timestamp": "2004-11-29"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-002012-33/ES",
        "title": "An Open-Label Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir With or Without Dasabuvir in Adults With Genotype 1a or Genotype 4 Chronic Hepatitis C Virus (HCV) Infec... - ES",
        "timestamp": "2015-09-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-002012-33/results",
        "title": "An Open-Label Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir With or Without Dasabuvir in Adults With Genotype 1a or Genotype 4 Chronic Hepatitis C Virus (HCV) Infec... - View results",
        "timestamp": "2015-09-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-005550-18/DE",
        "title": "A Phase III Multicenter, Open-Label, Randomized Study to Evaluate a Switch to MK-1439A in HIV-1-Infected Subjects Virologically Suppressed on a Regimen of a Ritonavir-boosted Protease Inhibitor and... - DE",
        "timestamp": "2015-08-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-005550-18/AT",
        "title": "A Phase III Multicenter, Open-Label, Randomized Study to Evaluate a Switch to MK-1439A in HIV-1-Infected Subjects Virologically Suppressed on a Regimen of a Ritonavir-boosted Protease Inhibitor and... - AT",
        "timestamp": "2015-08-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-005550-18/DK",
        "title": "A Phase III Multicenter, Open-Label, Randomized Study to Evaluate a Switch to MK-1439A in HIV-1-Infected Subjects Virologically Suppressed on a Regimen of a Ritonavir-boosted Protease Inhibitor and... - DK",
        "timestamp": "2015-08-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-005550-18/BE",
        "title": "A Phase III Multicenter, Open-Label, Randomized Study to Evaluate a Switch to MK-1439A in HIV-1-Infected Subjects Virologically Suppressed on a Regimen of a Ritonavir-boosted Protease Inhibitor and... - BE",
        "timestamp": "2015-08-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-005550-18/IT",
        "title": "A Phase III Multicenter, Open-Label, Randomized Study to Evaluate a Switch to MK-1439A in HIV-1-Infected Subjects Virologically Suppressed on a Regimen of a Ritonavir-boosted Protease Inhibitor and... - IT",
        "timestamp": "2015-08-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-005550-18/ES",
        "title": "A Phase III Multicenter, Open-Label, Randomized Study to Evaluate a Switch to MK-1439A in HIV-1-Infected Subjects Virologically Suppressed on a Regimen of a Ritonavir-boosted Protease Inhibitor and... - ES",
        "timestamp": "2015-08-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-005550-18/PL",
        "title": "A Phase III Multicenter, Open-Label, Randomized Study to Evaluate a Switch to MK-1439A in HIV-1-Infected Subjects Virologically Suppressed on a Regimen of a Ritonavir-boosted Protease Inhibitor and... - PL",
        "timestamp": "2015-08-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-000285-30/3rd",
        "title": "Continued access to darunavir/ritonavir (DRV/rtv) in HIV-1 infected adults, adolescents and children aged 3 years and above. - Outside EU/EEA",
        "timestamp": "2018-01-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-004809-29/IT",
        "title": "The steady state pharmacokinetics (PK) of atazanavir boosted with ritonavir during pregnancy and postpartum in HIV-1 infected pregnant women - IT",
        "timestamp": "2006-01-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-008190-58/DE",
        "title": "A Phase IIa, open-label, randomized trial in treatment-naïve HIV-1-infected subjects to determine the antiviral activity of 14 days of monotherapy with 4 different dose regimens of TMC310911 co-adm... - DE",
        "timestamp": "2009-04-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-008190-58/results",
        "title": "A Phase IIa, open-label, randomized trial in treatment-naïve HIV-1-infected subjects to determine the antiviral activity of 14 days of monotherapy with 4 different dose regimens of TMC310911 co-adm... - View results",
        "timestamp": "2009-04-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-004825-35/ES",
        "title": "ENSAYO CLÍNICO PILOTO PARA EVALUAR LA SEGURIDAD DE LA REDUCCION DE DOSIS DE RITONAVIR EN PACIENTES INFECTADOS POR EL VIH EN TRATAMIENTO CON TIPRANAVIR/RITONAVIR 500/200 MG CADA 12 HORAS. - ES",
        "timestamp": "2007-12-05"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-004825-35/results",
        "title": "ENSAYO CLÍNICO PILOTO PARA EVALUAR LA SEGURIDAD DE LA REDUCCION DE DOSIS DE RITONAVIR EN PACIENTES INFECTADOS POR EL VIH EN TRATAMIENTO CON TIPRANAVIR/RITONAVIR 500/200 MG CADA 12 HORAS. - View results",
        "timestamp": "2007-12-05"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-000060-27/IT",
        "title": "A Phase IIIB, Randomized, Open-Label, Multicenter Study of the Safety and Efficacy of GW433908  700mg BID  plus ritonavir  100mg BID  Versus Lopinavir/ritonavir  400mg/100mg  BID  when Administered... - IT",
        "timestamp": "2004-06-30"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-000060-27/results",
        "title": "A Phase IIIB, Randomized, Open-Label, Multicenter Study of the Safety and Efficacy of GW433908  700mg BID  plus ritonavir  100mg BID  Versus Lopinavir/ritonavir  400mg/100mg  BID  when Administered... - View results",
        "timestamp": "2004-06-30"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-001430-32/IE",
        "title": "A Phase 3, Randomized, Open-label, Study of Lopinavir/ritonavir Tablets Versus Soft Gel Capsules and Once Daily Versus Twice Daily Administration, when Coadministered with NRTIs in Antiretroviral N... - IE",
        "timestamp": "2005-11-18"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-001430-32/GB",
        "title": "A Phase 3, Randomized, Open-label, Study of Lopinavir/ritonavir Tablets Versus Soft Gel Capsules and Once Daily Versus Twice Daily Administration, when Coadministered with NRTIs in Antiretroviral N... - GB",
        "timestamp": "2005-11-18"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-001430-32/DE",
        "title": "A Phase 3, Randomized, Open-label, Study of Lopinavir/ritonavir Tablets Versus Soft Gel Capsules and Once Daily Versus Twice Daily Administration, when Coadministered with NRTIs in Antiretroviral N... - DE",
        "timestamp": "2005-11-18"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-001430-32/CZ",
        "title": "A Phase 3, Randomized, Open-label, Study of Lopinavir/ritonavir Tablets Versus Soft Gel Capsules and Once Daily Versus Twice Daily Administration, when Coadministered with NRTIs in Antiretroviral N... - CZ",
        "timestamp": "2005-11-18"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-001430-32/BE",
        "title": "A Phase 3, Randomized, Open-label, Study of Lopinavir/ritonavir Tablets Versus Soft Gel Capsules and Once Daily Versus Twice Daily Administration, when Coadministered with NRTIs in Antiretroviral N... - BE",
        "timestamp": "2005-11-18"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-001430-32/ES",
        "title": "A Phase 3, Randomized, Open-label, Study of Lopinavir/ritonavir Tablets Versus Soft Gel Capsules and Once Daily Versus Twice Daily Administration, when Coadministered with NRTIs in Antiretroviral N... - ES",
        "timestamp": "2005-11-18"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-001430-32/GR",
        "title": "A Phase 3, Randomized, Open-label, Study of Lopinavir/ritonavir Tablets Versus Soft Gel Capsules and Once Daily Versus Twice Daily Administration, when Coadministered with NRTIs in Antiretroviral N... - GR",
        "timestamp": "2005-11-18"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-001430-32/IT",
        "title": "A Phase 3, Randomized, Open-label, Study of Lopinavir/ritonavir Tablets Versus Soft Gel Capsules and Once Daily Versus Twice Daily Administration, when Coadministered with NRTIs in Antiretroviral N... - IT",
        "timestamp": "2005-11-18"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-001430-32/results",
        "title": "A Phase 3, Randomized, Open-label, Study of Lopinavir/ritonavir Tablets Versus Soft Gel Capsules and Once Daily Versus Twice Daily Administration, when Coadministered with NRTIs in Antiretroviral N... - View results",
        "timestamp": "2005-11-18"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-002720-27/ES",
        "title": "Simplification from Tenofovir plus Lamivudine or Emtricitabine plus Ritonavir-Boosted-Protease Inhibitor to Ritonavir-Boosted-Atazanavir plus Lamivudine in Virologically-Suppressed-HIV-Infected Adu... - ES",
        "timestamp": "2014-12-04"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-012283-14/IE",
        "title": "A randomised open‐label study comparing the safety and efficacy of ritonavir boosted lopinavir and 2‐3N(t)RTI backbone versus ritonavir boosted lopinavir and raltegravir in participants virological... - IE",
        "timestamp": "2010-08-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-012283-14/FR",
        "title": "A randomised open‐label study comparing the safety and efficacy of ritonavir boosted lopinavir and 2‐3N(t)RTI backbone versus ritonavir boosted lopinavir and raltegravir in participants virological... - FR",
        "timestamp": "2010-08-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-012283-14/GB",
        "title": "A randomised open‐label study comparing the safety and efficacy of ritonavir boosted lopinavir and 2‐3N(t)RTI backbone versus ritonavir boosted lopinavir and raltegravir in participants virological... - GB",
        "timestamp": "2010-08-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-012283-14/DE",
        "title": "A randomised open‐label study comparing the safety and efficacy of ritonavir boosted lopinavir and 2‐3N(t)RTI backbone versus ritonavir boosted lopinavir and raltegravir in participants virological... - DE",
        "timestamp": "2010-08-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-001611-38/ES",
        "title": "Estudio piloto prospectivo de la farmacocinética y farmacodinamia de la interaciión entre tipranavir/ritonavir y raltegravir en pacientes infectados por el VIH-1 - ES",
        "timestamp": "2008-06-27"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-004736-23/3rd",
        "title": "A Phase 2, Open-Label, Multicenter Study of the Safety of Ritonavir-Boosted GS-9137 (GS-9137/r) Administered in Combination with Other Antiretroviral Agents for the Treatment of HIV-1 Infected Subj... - Outside EU/EEA",
        "timestamp": "2015-02-18"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-004736-23/results",
        "title": "A Phase 2, Open-Label, Multicenter Study of the Safety of Ritonavir-Boosted GS-9137 (GS-9137/r) Administered in Combination with Other Antiretroviral Agents for the Treatment of HIV-1 Infected Subj... - View results",
        "timestamp": "2015-02-18"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-003300-21/3rd",
        "title": "A Prospective Single Arm, Open-label, International, Multicenter Study to Evaluate the Safety of Atazanavir (ATV) Capsule Boosted with Ritonavir (RTV) with an Optimized NRTI Background Therapy, in ... - Outside EU/EEA",
        "timestamp": "2014-10-02"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-003300-21/results",
        "title": "A Prospective Single Arm, Open-label, International, Multicenter Study to Evaluate the Safety of Atazanavir (ATV) Capsule Boosted with Ritonavir (RTV) with an Optimized NRTI Background Therapy, in ... - View results",
        "timestamp": "2014-10-02"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-001127-69/AT",
        "title": "A Phase 3 Multicenter, Double-Blind, Randomized, Active Comparator-Controlled Clinical Trial to Evaluate the Safety and Efficacy of Doravirine (MK-1439) 100 mg Once Daily Versus Darunavir 800 mg On... - AT",
        "timestamp": "2015-01-07"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-001127-69/GB",
        "title": "A Phase 3 Multicenter, Double-Blind, Randomized, Active Comparator-Controlled Clinical Trial to Evaluate the Safety and Efficacy of Doravirine (MK-1439) 100 mg Once Daily Versus Darunavir 800 mg On... - GB",
        "timestamp": "2015-01-07"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-001127-69/DE",
        "title": "A Phase 3 Multicenter, Double-Blind, Randomized, Active Comparator-Controlled Clinical Trial to Evaluate the Safety and Efficacy of Doravirine (MK-1439) 100 mg Once Daily Versus Darunavir 800 mg On... - DE",
        "timestamp": "2015-01-07"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-001127-69/DK",
        "title": "A Phase 3 Multicenter, Double-Blind, Randomized, Active Comparator-Controlled Clinical Trial to Evaluate the Safety and Efficacy of Doravirine (MK-1439) 100 mg Once Daily Versus Darunavir 800 mg On... - DK",
        "timestamp": "2015-01-07"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-001127-69/ES",
        "title": "A Phase 3 Multicenter, Double-Blind, Randomized, Active Comparator-Controlled Clinical Trial to Evaluate the Safety and Efficacy of Doravirine (MK-1439) 100 mg Once Daily Versus Darunavir 800 mg On... - ES",
        "timestamp": "2015-01-07"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-001127-69/RO",
        "title": "A Phase 3 Multicenter, Double-Blind, Randomized, Active Comparator-Controlled Clinical Trial to Evaluate the Safety and Efficacy of Doravirine (MK-1439) 100 mg Once Daily Versus Darunavir 800 mg On... - RO",
        "timestamp": "2015-01-07"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-001127-69/PT",
        "title": "A Phase 3 Multicenter, Double-Blind, Randomized, Active Comparator-Controlled Clinical Trial to Evaluate the Safety and Efficacy of Doravirine (MK-1439) 100 mg Once Daily Versus Darunavir 800 mg On... - PT",
        "timestamp": "2015-01-07"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-024652-28/ES",
        "title": "Estudio para evaluar la actividad y la tolerabilidad de la biterapia con lopinavir/ritonavir y 3TC en sustitución de una triple terapia que incluya lopinavir/ritonavir y 3TC ó FTC en pacientes con ... - ES",
        "timestamp": "2011-08-08"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-001060-21/IT",
        "title": "Safety and efficacy of switching a stable combined antiretroviral therapeutic regimen to atazanavir with ritonavir plus lamivudine in treatment experienced HIV positive patients with full and stabl... - IT",
        "timestamp": "2011-10-17"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-001477-13/DE",
        "title": "An Open-Label Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with Ribavirin in Adults with Genotype 1 and Ombitasvir/Paritabprevir/Ritonavir with Ribav... - DE",
        "timestamp": "2014-11-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-001477-13/results",
        "title": "An Open-Label Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with Ribavirin in Adults with Genotype 1 and Ombitasvir/Paritabprevir/Ritonavir with Ribav... - View results",
        "timestamp": "2014-11-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-003799-35/ES",
        "title": "Comparison of two antiretroviral regimens in HIV Post-exposure Prophylaxis: TDF-FTC (Truvada®) + Lopinavir/ritonavir (kaletra®) versus TDF-FTC (Truvada®) + raltegravir (Isentress®) - ES",
        "timestamp": "2012-01-05"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-004692-22/IT",
        "title": "MARAT Study “Pharmacokinetics of MARaviroc and boosted ATazanavir dual regimen in stable HIV-infected patients” - IT",
        "timestamp": "2015-11-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-003370-33/DE",
        "title": "An Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Treatment-Naïve Adults With Genotype 1b Hepatitis C Virus (HCV) Without Cir... - DE",
        "timestamp": "2016-01-05"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-003370-33/GB",
        "title": "An Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Treatment-Naïve Adults With Genotype 1b Hepatitis C Virus (HCV) Without Cir... - GB",
        "timestamp": "2016-01-05"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-003370-33/ES",
        "title": "An Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Treatment-Naïve Adults With Genotype 1b Hepatitis C Virus (HCV) Without Cir... - ES",
        "timestamp": "2016-01-05"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-003370-33/IT",
        "title": "An Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Treatment-Naïve Adults With Genotype 1b Hepatitis C Virus (HCV) Without Cir... - IT",
        "timestamp": "2016-01-05"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-003370-33/results",
        "title": "An Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Treatment-Naïve Adults With Genotype 1b Hepatitis C Virus (HCV) Without Cir... - View results",
        "timestamp": "2016-01-05"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-006179-11/GB",
        "title": "A Phase II, open-label trial, to investigate pharmacokinetics, safety, tolerability and antiviral activity of TMC114/rtv b.i.d. in treatment-experienced HIV-1 infected children and adolescents. - GB",
        "timestamp": "2006-08-14"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-006179-11/ES",
        "title": "A Phase II, open-label trial, to investigate pharmacokinetics, safety, tolerability and antiviral activity of TMC114/rtv b.i.d. in treatment-experienced HIV-1 infected children and adolescents. - ES",
        "timestamp": "2006-08-14"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-006179-11/IT",
        "title": "A Phase II, open-label trial, to investigate pharmacokinetics, safety, tolerability and antiviral activity of TMC114/rtv b.i.d. in treatment-experienced HIV-1 infected children and adolescents. - IT",
        "timestamp": "2006-08-14"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-006179-11/3rd",
        "title": "A Phase II, open-label trial, to investigate pharmacokinetics, safety, tolerability and antiviral activity of TMC114/rtv b.i.d. in treatment-experienced HIV-1 infected children and adolescents. - Outside EU/EEA",
        "timestamp": "2006-08-14"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-006179-11/results",
        "title": "A Phase II, open-label trial, to investigate pharmacokinetics, safety, tolerability and antiviral activity of TMC114/rtv b.i.d. in treatment-experienced HIV-1 infected children and adolescents. - View results",
        "timestamp": "2006-08-14"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-001136-47/ES",
        "title": "ESTUDIO PILOTO, ABIERTO, COMPARATIVO Y RANDOMIZADO PARA EVALUAR LA EFICACIA Y SEGURIDAD DE SAQUINAVIR/RITONAVIR EN MONOTERAPIA \n vs TERAPIA HAART ESTÁNDAR  COMO TERAPIA DE MANTENIMIENTO - ES",
        "timestamp": "2006-05-25"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-001136-47/results",
        "title": "ESTUDIO PILOTO, ABIERTO, COMPARATIVO Y RANDOMIZADO PARA EVALUAR LA EFICACIA Y SEGURIDAD DE SAQUINAVIR/RITONAVIR EN MONOTERAPIA \n vs TERAPIA HAART ESTÁNDAR  COMO TERAPIA DE MANTENIMIENTO - View results",
        "timestamp": "2006-05-25"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-014430-25/ES",
        "title": "Ensayo clínico abierto, aleatorizado, para comparar la calidad de vida de los pacientes VIH+ que inician monoterapia con comprimidos de LPV/r vs triple terapia que contengan un IP potenciado - ES",
        "timestamp": "2009-12-17"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-003401-27/ES",
        "title": "Ensayo clínico controlado, aleatorizado, abierto, de 48 semanas de duración, para evaluar la seguridad, tolerabilidad y actividad de raltegravir en sustitución de los inhibidores de la proteasa (IP... - ES",
        "timestamp": "2008-02-06"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-001895-11/GB",
        "title": "A 96 Week Study Comparing the Antiviral Efficacy and Safety of Atazanavir/ritonavir with Lopinavir/ritonavir, Each in Combination with Fixed Dose Tenofovir-Emtricitabine in HIV-1 Infected Treatment... - GB",
        "timestamp": "2006-02-07"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-001895-11/DE",
        "title": "A 96 Week Study Comparing the Antiviral Efficacy and Safety of Atazanavir/ritonavir with Lopinavir/ritonavir, Each in Combination with Fixed Dose Tenofovir-Emtricitabine in HIV-1 Infected Treatment... - DE",
        "timestamp": "2006-02-07"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-001895-11/AT",
        "title": "A 96 Week Study Comparing the Antiviral Efficacy and Safety of Atazanavir/ritonavir with Lopinavir/ritonavir, Each in Combination with Fixed Dose Tenofovir-Emtricitabine in HIV-1 Infected Treatment... - AT",
        "timestamp": "2006-02-07"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-001895-11/BE",
        "title": "A 96 Week Study Comparing the Antiviral Efficacy and Safety of Atazanavir/ritonavir with Lopinavir/ritonavir, Each in Combination with Fixed Dose Tenofovir-Emtricitabine in HIV-1 Infected Treatment... - BE",
        "timestamp": "2006-02-07"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-001895-11/PT",
        "title": "A 96 Week Study Comparing the Antiviral Efficacy and Safety of Atazanavir/ritonavir with Lopinavir/ritonavir, Each in Combination with Fixed Dose Tenofovir-Emtricitabine in HIV-1 Infected Treatment... - PT",
        "timestamp": "2006-02-07"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-001895-11/ES",
        "title": "A 96 Week Study Comparing the Antiviral Efficacy and Safety of Atazanavir/ritonavir with Lopinavir/ritonavir, Each in Combination with Fixed Dose Tenofovir-Emtricitabine in HIV-1 Infected Treatment... - ES",
        "timestamp": "2006-02-07"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-001895-11/DK",
        "title": "A 96 Week Study Comparing the Antiviral Efficacy and Safety of Atazanavir/ritonavir with Lopinavir/ritonavir, Each in Combination with Fixed Dose Tenofovir-Emtricitabine in HIV-1 Infected Treatment... - DK",
        "timestamp": "2006-02-07"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-001895-11/IT",
        "title": "A 96 Week Study Comparing the Antiviral Efficacy and Safety of Atazanavir/ritonavir with Lopinavir/ritonavir, Each in Combination with Fixed Dose Tenofovir-Emtricitabine in HIV-1 Infected Treatment... - IT",
        "timestamp": "2006-02-07"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-001895-11/results",
        "title": "A 96 Week Study Comparing the Antiviral Efficacy and Safety of Atazanavir/ritonavir with Lopinavir/ritonavir, Each in Combination with Fixed Dose Tenofovir-Emtricitabine in HIV-1 Infected Treatment... - View results",
        "timestamp": "2006-02-07"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-003298-26/NL",
        "title": "A phase IV, randomized, open label, cross-over, intervention trial to investigate the effect of the switch of lopinavir-ritonavir to raltegravir on endothelial function, chronic inflammation, immun... - NL",
        "timestamp": "2011-11-29"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-004556-11/IT",
        "title": "Randomized,multicenter,open-label, study of monoterapy with darunavir/ritonavir or lopinavir/ritonavir vs standard of care in virologically suppressed HIV-infected patients. - IT",
        "timestamp": "2013-06-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-004556-11/results",
        "title": "Randomized,multicenter,open-label, study of monoterapy with darunavir/ritonavir or lopinavir/ritonavir vs standard of care in virologically suppressed HIV-infected patients. - View results",
        "timestamp": "2013-06-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-006297-23/GB",
        "title": "A study of the pharmacokinetics of new formulation lopinavir/ritonavir in the genital tract and plasma of HIV infected women in pregnancy - GB",
        "timestamp": "2007-06-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-006297-23/results",
        "title": "A study of the pharmacokinetics of new formulation lopinavir/ritonavir in the genital tract and plasma of HIV infected women in pregnancy - View results",
        "timestamp": "2007-06-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-006272-39/ES",
        "title": "CLINICAL TRIAL TO EVALUATE THE EFFICACY, SAFETY AND ECONOMIC IMPACT OF REDUCING DOSES OF DARUNAVIR IN PATIENTS INFECTED WITH HIV TREATED WITH DARUNAVIR / RITONAVIR ONCE A DAY - ES",
        "timestamp": "2012-04-26"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-006272-39/results",
        "title": "CLINICAL TRIAL TO EVALUATE THE EFFICACY, SAFETY AND ECONOMIC IMPACT OF REDUCING DOSES OF DARUNAVIR IN PATIENTS INFECTED WITH HIV TREATED WITH DARUNAVIR / RITONAVIR ONCE A DAY - View results",
        "timestamp": "2012-04-26"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-024537-23/GB",
        "title": "A Prospective Single Arm, Open-Label, International, Multicenter Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Atazanavir (ATV) Powder boosted with Ritonavir (RTV) with an Optimize... - GB",
        "timestamp": "2011-06-22"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-024537-23/PL",
        "title": "A Prospective Single Arm, Open-Label, International, Multicenter Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Atazanavir (ATV) Powder boosted with Ritonavir (RTV) with an Optimize... - PL",
        "timestamp": "2011-06-22"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-024537-23/ES",
        "title": "A Prospective Single Arm, Open-Label, International, Multicenter Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Atazanavir (ATV) Powder boosted with Ritonavir (RTV) with an Optimize... - ES",
        "timestamp": "2011-06-22"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-024537-23/3rd",
        "title": "A Prospective Single Arm, Open-Label, International, Multicenter Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Atazanavir (ATV) Powder boosted with Ritonavir (RTV) with an Optimize... - Outside EU/EEA",
        "timestamp": "2011-06-22"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-024537-23/results",
        "title": "A Prospective Single Arm, Open-Label, International, Multicenter Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Atazanavir (ATV) Powder boosted with Ritonavir (RTV) with an Optimize... - View results",
        "timestamp": "2011-06-22"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-004483-30/BE",
        "title": "A Phase 3b Randomized, Open Label Study to Evaluate Switching from Regimens Consisting of a Ritonavir-boosted Protease Inhibitor (PI/r) plus Emtricitabine/Tenofovir Fixed-Dose Combination (FTC/TDF)... - BE",
        "timestamp": "2012-01-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-004483-30/DE",
        "title": "A Phase 3b Randomized, Open Label Study to Evaluate Switching from Regimens Consisting of a Ritonavir-boosted Protease Inhibitor (PI/r) plus Emtricitabine/Tenofovir Fixed-Dose Combination (FTC/TDF)... - DE",
        "timestamp": "2012-01-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-004483-30/ES",
        "title": "A Phase 3b Randomized, Open Label Study to Evaluate Switching from Regimens Consisting of a Ritonavir-boosted Protease Inhibitor (PI/r) plus Emtricitabine/Tenofovir Fixed-Dose Combination (FTC/TDF)... - ES",
        "timestamp": "2012-01-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-004483-30/AT",
        "title": "A Phase 3b Randomized, Open Label Study to Evaluate Switching from Regimens Consisting of a Ritonavir-boosted Protease Inhibitor (PI/r) plus Emtricitabine/Tenofovir Fixed-Dose Combination (FTC/TDF)... - AT",
        "timestamp": "2012-01-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-004483-30/PT",
        "title": "A Phase 3b Randomized, Open Label Study to Evaluate Switching from Regimens Consisting of a Ritonavir-boosted Protease Inhibitor (PI/r) plus Emtricitabine/Tenofovir Fixed-Dose Combination (FTC/TDF)... - PT",
        "timestamp": "2012-01-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-004483-30/GB",
        "title": "A Phase 3b Randomized, Open Label Study to Evaluate Switching from Regimens Consisting of a Ritonavir-boosted Protease Inhibitor (PI/r) plus Emtricitabine/Tenofovir Fixed-Dose Combination (FTC/TDF)... - GB",
        "timestamp": "2012-01-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-004483-30/IT",
        "title": "A Phase 3b Randomized, Open Label Study to Evaluate Switching from Regimens Consisting of a Ritonavir-boosted Protease Inhibitor (PI/r) plus Emtricitabine/Tenofovir Fixed-Dose Combination (FTC/TDF)... - IT",
        "timestamp": "2012-01-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-004483-30/results",
        "title": "A Phase 3b Randomized, Open Label Study to Evaluate Switching from Regimens Consisting of a Ritonavir-boosted Protease Inhibitor (PI/r) plus Emtricitabine/Tenofovir Fixed-Dose Combination (FTC/TDF)... - View results",
        "timestamp": "2012-01-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-001476-37/ES",
        "title": "SMILE: Strategy for Maintenance of HIV suppression with elvitegravir+darunavir/ritonavir in children (PENTA 17) - \r\nA two-arm, Phase 2/3 multicentre, open-label, randomised study evaluating safety ... - ES",
        "timestamp": "2015-12-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-001476-37/PT",
        "title": "SMILE: Strategy for Maintenance of HIV suppression with elvitegravir+darunavir/ritonavir in children (PENTA 17) - \r\nA two-arm, Phase 2/3 multicentre, open-label, randomised study evaluating safety ... - PT",
        "timestamp": "2015-12-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-001476-37/GB",
        "title": "SMILE: Strategy for Maintenance of HIV suppression with elvitegravir+darunavir/ritonavir in children (PENTA 17) - \r\nA two-arm, Phase 2/3 multicentre, open-label, randomised study evaluating safety ... - GB",
        "timestamp": "2015-12-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-001476-37/BE",
        "title": "SMILE: Strategy for Maintenance of HIV suppression with elvitegravir+darunavir/ritonavir in children (PENTA 17) - \r\nA two-arm, Phase 2/3 multicentre, open-label, randomised study evaluating safety ... - BE",
        "timestamp": "2015-12-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-001476-37/DE",
        "title": "SMILE: Strategy for Maintenance of HIV suppression with elvitegravir+darunavir/ritonavir in children (PENTA 17) - \r\nA two-arm, Phase 2/3 multicentre, open-label, randomised study evaluating safety ... - DE",
        "timestamp": "2015-12-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-001476-37/FR",
        "title": "SMILE: Strategy for Maintenance of HIV suppression with elvitegravir+darunavir/ritonavir in children (PENTA 17) - \r\nA two-arm, Phase 2/3 multicentre, open-label, randomised study evaluating safety ... - FR",
        "timestamp": "2015-12-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-007882-19/IT",
        "title": "A pilot, randomized trial to evaluate the lipid profile after antiretroviral \nregimens including nevirapine or atazanavir boosted with ritonavir in HIV-positive patients naive for antiretrovirals - IT",
        "timestamp": "2006-10-09"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-001049-10/ES",
        "title": "Open-label Study to Evaluate the Safety and Efficacy of the Combination of Ombitasvir, Paritaprevir/r ± Dasabuvir with Ribavirin (RBV) in Adult Patients with GT1 or GT4 Chronic HCV Infection and Re... - ES",
        "timestamp": "2015-09-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-001049-10/results",
        "title": "Open-label Study to Evaluate the Safety and Efficacy of the Combination of Ombitasvir, Paritaprevir/r ± Dasabuvir with Ribavirin (RBV) in Adult Patients with GT1 or GT4 Chronic HCV Infection and Re... - View results",
        "timestamp": "2015-09-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-021624-99/DE",
        "title": "A multi-centre, non-controlled, non-randomised  IST to evaluate the plasma level of antiretroviral substances, the viral resistance profile and their impact on the clinical response in HIV infected... - DE",
        "timestamp": "2012-06-14"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-003167-54/GB",
        "title": "A Phase 3, Matrix Design, Partially Double-Blind, Randomized Study of the Efficacy and Safety of 50 mg Lonafarnib/100 mg Ritonavir BID with and without 180 mcg PEG IFN-alfa-2a for 48 Weeks Compared... - GB",
        "timestamp": "2019-05-09"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-003167-54/FR",
        "title": "A Phase 3, Matrix Design, Partially Double-Blind, Randomized Study of the Efficacy and Safety of 50 mg Lonafarnib/100 mg Ritonavir BID with and without 180 mcg PEG IFN-alfa-2a for 48 Weeks Compared... - FR",
        "timestamp": "2019-05-09"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-003167-54/BG",
        "title": "A Phase 3, Matrix Design, Partially Double-Blind, Randomized Study of the Efficacy and Safety of 50 mg Lonafarnib/100 mg Ritonavir BID with and without 180 mcg PEG IFN-alfa-2a for 48 Weeks Compared... - BG",
        "timestamp": "2019-05-09"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-003167-54/GR",
        "title": "A Phase 3, Matrix Design, Partially Double-Blind, Randomized Study of the Efficacy and Safety of 50 mg Lonafarnib/100 mg Ritonavir BID with and without 180 mcg PEG IFN-alfa-2a for 48 Weeks Compared... - GR",
        "timestamp": "2019-05-09"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-003167-54/ES",
        "title": "A Phase 3, Matrix Design, Partially Double-Blind, Randomized Study of the Efficacy and Safety of 50 mg Lonafarnib/100 mg Ritonavir BID with and without 180 mcg PEG IFN-alfa-2a for 48 Weeks Compared... - ES",
        "timestamp": "2019-05-09"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-003167-54/SE",
        "title": "A Phase 3, Matrix Design, Partially Double-Blind, Randomized Study of the Efficacy and Safety of 50 mg Lonafarnib/100 mg Ritonavir BID with and without 180 mcg PEG IFN-alfa-2a for 48 Weeks Compared... - SE",
        "timestamp": "2019-05-09"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-004464-30/ES",
        "title": "Impact of Raltegravir Intensification on HIV-1-infected Subjects with Complete Viral Suppression under Monotherapy with Protease Inhibitors. A 24-week controlled, open-label, proof-of-concept pilot... - ES",
        "timestamp": "2011-11-22"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-006041-13/ES",
        "title": "“ESTUDIO EN FASE IV de la Pauta de Rescate a través de OptimizacióN y simplificacióN de las dosis de Ritonavir en un régimen que contiene Tipranavir como parte del tratamiento” - ES",
        "timestamp": "2007-04-23"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-005996-17/IT",
        "title": "A pilot, open label, multicenter, randomized clinical trial on Lopinavir/ritonavir-monotherapy vs Lopinavir/ritonavir plus selected Nucs, in HIV/HCV ARV-naive coinfected patients with chronic hepat... - IT",
        "timestamp": "2007-02-02"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-005143-24/GB",
        "title": "A Multipart, Open-label Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir With and Without Dasabuvir Coadministered With and Without Ribavirin in Adults With Genotype 1... - GB",
        "timestamp": "2015-07-28"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-005143-24/ES",
        "title": "A Multipart, Open-label Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir With and Without Dasabuvir Coadministered With and Without Ribavirin in Adults With Genotype 1... - ES",
        "timestamp": "2015-07-28"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-005143-24/results",
        "title": "A Multipart, Open-label Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir With and Without Dasabuvir Coadministered With and Without Ribavirin in Adults With Genotype 1... - View results",
        "timestamp": "2015-07-28"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-005119-76/ES",
        "title": "Phase IIIb Multicenter, Single Arm, Open-label Pilot Study to Evaluate the Effectiveness and Safety of Maintenance with Atazanavir/ritonavir as Single Enhanced Protease Inhibitor Therapy in HIV-Inf... - ES",
        "timestamp": "2006-05-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-005119-76/results",
        "title": "Phase IIIb Multicenter, Single Arm, Open-label Pilot Study to Evaluate the Effectiveness and Safety of Maintenance with Atazanavir/ritonavir as Single Enhanced Protease Inhibitor Therapy in HIV-Inf... - View results",
        "timestamp": "2006-05-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-006042-33/IT",
        "title": "A pilot, open label, multicenter, randomized clinical trial on Lopinavir/Ritonavir-monotherapy vs Lopinavir/Ritonavir plus selected Nucs, in HIV/HCV  coinfected patients with chronic hepatitis C or... - IT",
        "timestamp": "2007-02-01"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-004698-39/DE",
        "title": "Randomized, double-blind, placebo-controlled 7 day monotherapy Phase IIa study to evaluate the antiviral activity and safety of  oral administered RTV-boosted BILR 355 (75 mg and 150 mg twice daily... - DE",
        "timestamp": "2006-02-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-004698-39/results",
        "title": "Randomized, double-blind, placebo-controlled 7 day monotherapy Phase IIa study to evaluate the antiviral activity and safety of  oral administered RTV-boosted BILR 355 (75 mg and 150 mg twice daily... - View results",
        "timestamp": "2006-02-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-021785-30/DE",
        "title": "A MULTICENTER, RANDOMIZED, DOUBLE BLIND, COMPARATIVE TRIAL OF MARAVIROC + DARUNAVIR/RITONAVIR VERSUS EMTRICITABINE/TENOFOVIR + DARUNAVIR/RITONAVIR FOR THE TREATMENT OF ANTIRETROVIRAL NAÏVE HIV INFE... - DE",
        "timestamp": "2011-12-07"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-021785-30/HU",
        "title": "A MULTICENTER, RANDOMIZED, DOUBLE BLIND, COMPARATIVE TRIAL OF MARAVIROC + DARUNAVIR/RITONAVIR VERSUS EMTRICITABINE/TENOFOVIR + DARUNAVIR/RITONAVIR FOR THE TREATMENT OF ANTIRETROVIRAL NAÏVE HIV INFE... - HU",
        "timestamp": "2011-12-07"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-021785-30/SE",
        "title": "A MULTICENTER, RANDOMIZED, DOUBLE BLIND, COMPARATIVE TRIAL OF MARAVIROC + DARUNAVIR/RITONAVIR VERSUS EMTRICITABINE/TENOFOVIR + DARUNAVIR/RITONAVIR FOR THE TREATMENT OF ANTIRETROVIRAL NAÏVE HIV INFE... - SE",
        "timestamp": "2011-12-07"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-021785-30/FI",
        "title": "A MULTICENTER, RANDOMIZED, DOUBLE BLIND, COMPARATIVE TRIAL OF MARAVIROC + DARUNAVIR/RITONAVIR VERSUS EMTRICITABINE/TENOFOVIR + DARUNAVIR/RITONAVIR FOR THE TREATMENT OF ANTIRETROVIRAL NAÏVE HIV INFE... - FI",
        "timestamp": "2011-12-07"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-021785-30/BE",
        "title": "A MULTICENTER, RANDOMIZED, DOUBLE BLIND, COMPARATIVE TRIAL OF MARAVIROC + DARUNAVIR/RITONAVIR VERSUS EMTRICITABINE/TENOFOVIR + DARUNAVIR/RITONAVIR FOR THE TREATMENT OF ANTIRETROVIRAL NAÏVE HIV INFE... - BE",
        "timestamp": "2011-12-07"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-021785-30/ES",
        "title": "A MULTICENTER, RANDOMIZED, DOUBLE BLIND, COMPARATIVE TRIAL OF MARAVIROC + DARUNAVIR/RITONAVIR VERSUS EMTRICITABINE/TENOFOVIR + DARUNAVIR/RITONAVIR FOR THE TREATMENT OF ANTIRETROVIRAL NAÏVE HIV INFE... - ES",
        "timestamp": "2011-12-07"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-021785-30/GB",
        "title": "A MULTICENTER, RANDOMIZED, DOUBLE BLIND, COMPARATIVE TRIAL OF MARAVIROC + DARUNAVIR/RITONAVIR VERSUS EMTRICITABINE/TENOFOVIR + DARUNAVIR/RITONAVIR FOR THE TREATMENT OF ANTIRETROVIRAL NAÏVE HIV INFE... - GB",
        "timestamp": "2011-12-07"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-021785-30/AT",
        "title": "A MULTICENTER, RANDOMIZED, DOUBLE BLIND, COMPARATIVE TRIAL OF MARAVIROC + DARUNAVIR/RITONAVIR VERSUS EMTRICITABINE/TENOFOVIR + DARUNAVIR/RITONAVIR FOR THE TREATMENT OF ANTIRETROVIRAL NAÏVE HIV INFE... - AT",
        "timestamp": "2011-12-07"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-021785-30/DK",
        "title": "A MULTICENTER, RANDOMIZED, DOUBLE BLIND, COMPARATIVE TRIAL OF MARAVIROC + DARUNAVIR/RITONAVIR VERSUS EMTRICITABINE/TENOFOVIR + DARUNAVIR/RITONAVIR FOR THE TREATMENT OF ANTIRETROVIRAL NAÏVE HIV INFE... - DK",
        "timestamp": "2011-12-07"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-021785-30/NL",
        "title": "A MULTICENTER, RANDOMIZED, DOUBLE BLIND, COMPARATIVE TRIAL OF MARAVIROC + DARUNAVIR/RITONAVIR VERSUS EMTRICITABINE/TENOFOVIR + DARUNAVIR/RITONAVIR FOR THE TREATMENT OF ANTIRETROVIRAL NAÏVE HIV INFE... - NL",
        "timestamp": "2011-12-07"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-021785-30/PT",
        "title": "A MULTICENTER, RANDOMIZED, DOUBLE BLIND, COMPARATIVE TRIAL OF MARAVIROC + DARUNAVIR/RITONAVIR VERSUS EMTRICITABINE/TENOFOVIR + DARUNAVIR/RITONAVIR FOR THE TREATMENT OF ANTIRETROVIRAL NAÏVE HIV INFE... - PT",
        "timestamp": "2011-12-07"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-021785-30/PL",
        "title": "A MULTICENTER, RANDOMIZED, DOUBLE BLIND, COMPARATIVE TRIAL OF MARAVIROC + DARUNAVIR/RITONAVIR VERSUS EMTRICITABINE/TENOFOVIR + DARUNAVIR/RITONAVIR FOR THE TREATMENT OF ANTIRETROVIRAL NAÏVE HIV INFE... - PL",
        "timestamp": "2011-12-07"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-021785-30/IT",
        "title": "A MULTICENTER, RANDOMIZED, DOUBLE BLIND, COMPARATIVE TRIAL OF MARAVIROC + DARUNAVIR/RITONAVIR VERSUS EMTRICITABINE/TENOFOVIR + DARUNAVIR/RITONAVIR FOR THE TREATMENT OF ANTIRETROVIRAL NAÏVE HIV INFE... - IT",
        "timestamp": "2011-12-07"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-021785-30/results",
        "title": "A MULTICENTER, RANDOMIZED, DOUBLE BLIND, COMPARATIVE TRIAL OF MARAVIROC + DARUNAVIR/RITONAVIR VERSUS EMTRICITABINE/TENOFOVIR + DARUNAVIR/RITONAVIR FOR THE TREATMENT OF ANTIRETROVIRAL NAÏVE HIV INFE... - View results",
        "timestamp": "2011-12-07"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-004630-25/3rd",
        "title": "A Phase II, open label trial, to evaluate pharmacokinetics, safety, tolerability and antiviral activity of DRV in combination with low-dose ritonavir (DRV/rtv) in treatment-experienced HIV-1 infect... - Outside EU/EEA",
        "timestamp": "2014-02-25"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-004630-25/results",
        "title": "A Phase II, open label trial, to evaluate pharmacokinetics, safety, tolerability and antiviral activity of DRV in combination with low-dose ritonavir (DRV/rtv) in treatment-experienced HIV-1 infect... - View results",
        "timestamp": "2014-02-25"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-001431-30/GB",
        "title": "A Randomized, Open Label Study Assessing Safety, Tolerability, and Efficacy of an Induction/Maintenance Treatment Strategy Including Lopinavir/ritonavir (LPV/r) plus Tenofovir Disoproxil Fumarate (... - GB",
        "timestamp": "2005-07-30"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-001431-30/IE",
        "title": "A Randomized, Open Label Study Assessing Safety, Tolerability, and Efficacy of an Induction/Maintenance Treatment Strategy Including Lopinavir/ritonavir (LPV/r) plus Tenofovir Disoproxil Fumarate (... - IE",
        "timestamp": "2005-07-30"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-021622-35/DE",
        "title": "A monocenter, non-controlled, non-randomized IST to compare bioavailability of Kaletra softgelcapsules or -suspension to Kaletra tablets in pediatric patients – C2T - DE",
        "timestamp": "2011-08-11"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-005022-31/GB",
        "title": "Effect of a High-Fat or a Light Meal Relative to Fasting Conditions on the Pharmacokinetics of Atazanavir when Administered with Ritonavir in Healthy Subjects - GB",
        "timestamp": "2006-01-31"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-005022-31/results",
        "title": "Effect of a High-Fat or a Light Meal Relative to Fasting Conditions on the Pharmacokinetics of Atazanavir when Administered with Ritonavir in Healthy Subjects - View results",
        "timestamp": "2006-01-31"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-000816-24/ES",
        "title": "A Pilot, Open-Label, Randomized, Comparative Study of the Antiviral Efficacy of Lopinavir/Ritonavir Single-Drug Regimen versus Lopinavir/Ritonavir in Combination with Lamivudine/Zidovudine in Antir... - ES",
        "timestamp": "2004-10-28"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-000816-24/IT",
        "title": "A Pilot, Open-Label, Randomized, Comparative Study of the Antiviral Efficacy of Lopinavir/Ritonavir Single-Drug Regimen versus Lopinavir/Ritonavir in Combination with Lamivudine/Zidovudine in Antir... - IT",
        "timestamp": "2004-10-28"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-000816-24/results",
        "title": "A Pilot, Open-Label, Randomized, Comparative Study of the Antiviral Efficacy of Lopinavir/Ritonavir Single-Drug Regimen versus Lopinavir/Ritonavir in Combination with Lamivudine/Zidovudine in Antir... - View results",
        "timestamp": "2004-10-28"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-000948-25/ES",
        "title": "Determinación de niveles plasmáticos e intracelulares de los inhibidores de la transcriptasa inversa análogos a nucleósidos (NRTI) y del análogo a nucleótido tenofovir disoproxil fumarato (TDF) en ... - ES",
        "timestamp": "2004-10-01"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-000948-25/results",
        "title": "Determinación de niveles plasmáticos e intracelulares de los inhibidores de la transcriptasa inversa análogos a nucleósidos (NRTI) y del análogo a nucleótido tenofovir disoproxil fumarato (TDF) en ... - View results",
        "timestamp": "2004-10-01"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-002296-16/ES",
        "title": "Ensayo para evaluar la eficacia, seguridad y tolerabilidad, de una estrategia de simplificacion temprana a Trizivir, en pacientes con supresion virologica tras tratamiento antiretroviral con Combiv... - ES",
        "timestamp": "2004-11-26"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-002486-36/HU",
        "title": "A randomized, controlled, open-label trial to compare the efficacy, safety and tolerability of TMC114/ritonavir versus lopinavir/ritonavir in treatment-naïve HIV-1 infected subjects.\n\nA substudy of... - HU",
        "timestamp": "2006-01-25"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-002486-36/AT",
        "title": "A randomized, controlled, open-label trial to compare the efficacy, safety and tolerability of TMC114/ritonavir versus lopinavir/ritonavir in treatment-naïve HIV-1 infected subjects.\n\nA substudy of... - AT",
        "timestamp": "2006-01-25"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-002486-36/DE",
        "title": "A randomized, controlled, open-label trial to compare the efficacy, safety and tolerability of TMC114/ritonavir versus lopinavir/ritonavir in treatment-naïve HIV-1 infected subjects.\n\nA substudy of... - DE",
        "timestamp": "2006-01-25"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-002486-36/GB",
        "title": "A randomized, controlled, open-label trial to compare the efficacy, safety and tolerability of TMC114/ritonavir versus lopinavir/ritonavir in treatment-naïve HIV-1 infected subjects.\n\nA substudy of... - GB",
        "timestamp": "2006-01-25"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-002486-36/DK",
        "title": "A randomized, controlled, open-label trial to compare the efficacy, safety and tolerability of TMC114/ritonavir versus lopinavir/ritonavir in treatment-naïve HIV-1 infected subjects.\n\nA substudy of... - DK",
        "timestamp": "2006-01-25"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-002486-36/ES",
        "title": "A randomized, controlled, open-label trial to compare the efficacy, safety and tolerability of TMC114/ritonavir versus lopinavir/ritonavir in treatment-naïve HIV-1 infected subjects.\n\nA substudy of... - ES",
        "timestamp": "2006-01-25"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-002486-36/BE",
        "title": "A randomized, controlled, open-label trial to compare the efficacy, safety and tolerability of TMC114/ritonavir versus lopinavir/ritonavir in treatment-naïve HIV-1 infected subjects.\n\nA substudy of... - BE",
        "timestamp": "2006-01-25"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-002486-36/IT",
        "title": "A randomized, controlled, open-label trial to compare the efficacy, safety and tolerability of TMC114/ritonavir versus lopinavir/ritonavir in treatment-naïve HIV-1 infected subjects.\n\nA substudy of... - IT",
        "timestamp": "2006-01-25"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-002486-36/PT",
        "title": "A randomized, controlled, open-label trial to compare the efficacy, safety and tolerability of TMC114/ritonavir versus lopinavir/ritonavir in treatment-naïve HIV-1 infected subjects.\n\nA substudy of... - PT",
        "timestamp": "2006-01-25"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-002486-36/GR",
        "title": "A randomized, controlled, open-label trial to compare the efficacy, safety and tolerability of TMC114/ritonavir versus lopinavir/ritonavir in treatment-naïve HIV-1 infected subjects.\n\nA substudy of... - GR",
        "timestamp": "2006-01-25"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-002486-36/results",
        "title": "A randomized, controlled, open-label trial to compare the efficacy, safety and tolerability of TMC114/ritonavir versus lopinavir/ritonavir in treatment-naïve HIV-1 infected subjects.\n\nA substudy of... - View results",
        "timestamp": "2006-01-25"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-001953-18/BE",
        "title": "An Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of Ombitasvir/ ABT-450/ Ritonavir and Dasabuvir in Adults with Genotype 1b Chronic Hepatitis C Virus (HCV) Infection and Cirrhosi... - BE",
        "timestamp": "2014-10-13"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-001953-18/results",
        "title": "An Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of Ombitasvir/ ABT-450/ Ritonavir and Dasabuvir in Adults with Genotype 1b Chronic Hepatitis C Virus (HCV) Infection and Cirrhosi... - View results",
        "timestamp": "2014-10-13"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-007934-21/IT",
        "title": "Intracellular concentration of Antiretrovirals)INCA STADY - IT",
        "timestamp": "2007-06-27"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-023316-13/IT",
        "title": "Randomized multicenter study on security and efficacy of therapeutic switch to maraviroc + darunavir/ritonavir once daily  in patients who are in triple antiretroviral regimen with three drugs belo... - IT",
        "timestamp": "2011-05-23"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-011273-32/IT",
        "title": "Pilot study for the evaluation of the safety and the feasibility of treatment simplification to atazanavir/ritonavir + lamivudine in patients on stable treatment with two NRTIs + atazanavir/ritonav... - IT",
        "timestamp": "2009-05-07"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-003748-12/ES",
        "title": "“Estudio Fase IV-III, comparativo, aleatorizado y abierto para evaluar\nla eficacia para la recuperación de grasa periférica (o de extremidades) de\nlopinavir/ritonavir en monoterapia versus abacavir... - ES",
        "timestamp": "2008-09-04"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020442-10/IT",
        "title": "Efficacy of atazanavir/ritonavir monotherapy as maintenance in patients with viral suppression. Randomized, open label non inferiority trial.  (MODAt STUDY) - IT",
        "timestamp": "2010-07-26"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020442-10/results",
        "title": "Efficacy of atazanavir/ritonavir monotherapy as maintenance in patients with viral suppression. Randomized, open label non inferiority trial.  (MODAt STUDY) - View results",
        "timestamp": "2010-07-26"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-001749-25/IE",
        "title": "An open label safety study of fosamprenavir/ritonavir (FPV/rtv (Telzir)) administered to HIV/HCV co-infected patients over 96 weeks - IE",
        "timestamp": "2008-06-18"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-001749-25/ES",
        "title": "An open label safety study of fosamprenavir/ritonavir (FPV/rtv (Telzir)) administered to HIV/HCV co-infected patients over 96 weeks - ES",
        "timestamp": "2008-06-18"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-000935-18/GB",
        "title": "TAILoR – (TelmisArtan and InsuLin Resistance in HIV): A Dose-Ranging Phase II Randomised Open-Labelled Trial of Telmisartan as a strategy for the Reduction of Insulin Resistance in HIV-Positive Ind... - GB",
        "timestamp": "2012-06-28"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-000935-18/results",
        "title": "TAILoR – (TelmisArtan and InsuLin Resistance in HIV): A Dose-Ranging Phase II Randomised Open-Labelled Trial of Telmisartan as a strategy for the Reduction of Insulin Resistance in HIV-Positive Ind... - View results",
        "timestamp": "2012-06-28"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-003203-12/FR",
        "title": "Pharmacocinétique de l’atazanavir chez des patients infectés par le VIH, traités en première ligne par l’association atazanavir+ritonavir et emtricitabine+ténofovir en prise unique. - FR",
        "timestamp": "2007-08-17"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-002095-93/GB",
        "title": "A Randomized, Open Label, Phase 4 Study Evaluating the Renal Effect of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF or  other Tenofovir DF-containing Regimens (Ritonavir-boosted Atazanavir  p... - GB",
        "timestamp": "2014-09-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-002095-93/BE",
        "title": "A Randomized, Open Label, Phase 4 Study Evaluating the Renal Effect of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF or  other Tenofovir DF-containing Regimens (Ritonavir-boosted Atazanavir  p... - BE",
        "timestamp": "2014-09-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-002095-93/ES",
        "title": "A Randomized, Open Label, Phase 4 Study Evaluating the Renal Effect of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF or  other Tenofovir DF-containing Regimens (Ritonavir-boosted Atazanavir  p... - ES",
        "timestamp": "2014-09-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-002095-93/IE",
        "title": "A Randomized, Open Label, Phase 4 Study Evaluating the Renal Effect of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF or  other Tenofovir DF-containing Regimens (Ritonavir-boosted Atazanavir  p... - IE",
        "timestamp": "2014-09-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-002095-93/results",
        "title": "A Randomized, Open Label, Phase 4 Study Evaluating the Renal Effect of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF or  other Tenofovir DF-containing Regimens (Ritonavir-boosted Atazanavir  p... - View results",
        "timestamp": "2014-09-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-000594-22/HU",
        "title": "A randomized, controlled, open-label trial to compare the efficacy, safety and tolerability of TMC114/RTV versus LPV/RTV in treatment-experienced HIV-1 infected subjects. - HU",
        "timestamp": "2005-06-13"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-000594-22/AT",
        "title": "A randomized, controlled, open-label trial to compare the efficacy, safety and tolerability of TMC114/RTV versus LPV/RTV in treatment-experienced HIV-1 infected subjects. - AT",
        "timestamp": "2005-06-13"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-000594-22/GB",
        "title": "A randomized, controlled, open-label trial to compare the efficacy, safety and tolerability of TMC114/RTV versus LPV/RTV in treatment-experienced HIV-1 infected subjects. - GB",
        "timestamp": "2005-06-13"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-000594-22/DE",
        "title": "A randomized, controlled, open-label trial to compare the efficacy, safety and tolerability of TMC114/RTV versus LPV/RTV in treatment-experienced HIV-1 infected subjects. - DE",
        "timestamp": "2005-06-13"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-000594-22/DK",
        "title": "A randomized, controlled, open-label trial to compare the efficacy, safety and tolerability of TMC114/RTV versus LPV/RTV in treatment-experienced HIV-1 infected subjects. - DK",
        "timestamp": "2005-06-13"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-000594-22/BE",
        "title": "A randomized, controlled, open-label trial to compare the efficacy, safety and tolerability of TMC114/RTV versus LPV/RTV in treatment-experienced HIV-1 infected subjects. - BE",
        "timestamp": "2005-06-13"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-000594-22/ES",
        "title": "A randomized, controlled, open-label trial to compare the efficacy, safety and tolerability of TMC114/RTV versus LPV/RTV in treatment-experienced HIV-1 infected subjects. - ES",
        "timestamp": "2005-06-13"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-000594-22/IT",
        "title": "A randomized, controlled, open-label trial to compare the efficacy, safety and tolerability of TMC114/RTV versus LPV/RTV in treatment-experienced HIV-1 infected subjects. - IT",
        "timestamp": "2005-06-13"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-000594-22/results",
        "title": "A randomized, controlled, open-label trial to compare the efficacy, safety and tolerability of TMC114/RTV versus LPV/RTV in treatment-experienced HIV-1 infected subjects. - View results",
        "timestamp": "2005-06-13"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-000111-41/ES",
        "title": "An Open-Label, Multicenter Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Ombitasvir (OBV), Paritaprevir (PTV), Ritonavir (RTV) With or Without Dasabuvir (DSV) and With or Without ... - ES",
        "timestamp": "2016-04-01"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-000111-41/DE",
        "title": "An Open-Label, Multicenter Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Ombitasvir (OBV), Paritaprevir (PTV), Ritonavir (RTV) With or Without Dasabuvir (DSV) and With or Without ... - DE",
        "timestamp": "2016-04-01"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-000111-41/BE",
        "title": "An Open-Label, Multicenter Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Ombitasvir (OBV), Paritaprevir (PTV), Ritonavir (RTV) With or Without Dasabuvir (DSV) and With or Without ... - BE",
        "timestamp": "2016-04-01"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-006439-12/BE",
        "title": "Strategic Timing of AntiRetroviral Treatment(START) - BE",
        "timestamp": "2009-05-25"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-006439-12/FI",
        "title": "Strategic Timing of AntiRetroviral Treatment(START) - FI",
        "timestamp": "2009-05-25"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-006439-12/ES",
        "title": "Strategic Timing of AntiRetroviral Treatment(START) - ES",
        "timestamp": "2009-05-25"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-006439-12/DE",
        "title": "Strategic Timing of AntiRetroviral Treatment(START) - DE",
        "timestamp": "2009-05-25"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-006439-12/GB",
        "title": "Strategic Timing of AntiRetroviral Treatment(START) - GB",
        "timestamp": "2009-05-25"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-006439-12/GR",
        "title": "Strategic Timing of AntiRetroviral Treatment(START) - GR",
        "timestamp": "2009-05-25"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-006439-12/IT",
        "title": "Strategic Timing of AntiRetroviral Treatment(START) - IT",
        "timestamp": "2009-05-25"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-006439-12/SE",
        "title": "Strategic Timing of AntiRetroviral Treatment(START) - SE",
        "timestamp": "2009-05-25"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-006439-12/PT",
        "title": "Strategic Timing of AntiRetroviral Treatment(START) - PT",
        "timestamp": "2009-05-25"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-006439-12/IE",
        "title": "Strategic Timing of AntiRetroviral Treatment(START) - IE",
        "timestamp": "2009-05-25"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-006439-12/EE",
        "title": "Strategic Timing of AntiRetroviral Treatment(START) - EE",
        "timestamp": "2009-05-25"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-006439-12/NO",
        "title": "Strategic Timing of AntiRetroviral Treatment(START) - NO",
        "timestamp": "2009-05-25"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-006439-12/AT",
        "title": "Strategic Timing of AntiRetroviral Treatment(START) - AT",
        "timestamp": "2009-05-25"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-006439-12/CZ",
        "title": "Strategic Timing of AntiRetroviral Treatment(START) - CZ",
        "timestamp": "2009-05-25"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-003133-16/IT",
        "title": "Efficacy and Safety of VICRIVIROC in HIV-Infected Treatment-Naïve Subjects - IT",
        "timestamp": "2008-02-15"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-003133-16/ES",
        "title": "Efficacy and Safety of VICRIVIROC in HIV-Infected Treatment-Naïve Subjects - ES",
        "timestamp": "2008-02-15"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-003133-16/PT",
        "title": "Efficacy and Safety of VICRIVIROC in HIV-Infected Treatment-Naïve Subjects - PT",
        "timestamp": "2008-02-15"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-003133-16/DE",
        "title": "Efficacy and Safety of VICRIVIROC in HIV-Infected Treatment-Naïve Subjects - DE",
        "timestamp": "2008-02-15"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-003133-16/results",
        "title": "Efficacy and Safety of VICRIVIROC in HIV-Infected Treatment-Naïve Subjects - View results",
        "timestamp": "2008-02-15"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-016361-28/PL",
        "title": "A Prospective Single Arm, Open-label, International, Multicenter Study to Evaluate the\nSafety, Efficacy and Pharmacokinetics of Atazanavir (ATV) Powder Boosted with\nRitonavir (RTV) Liquid with an O... - PL",
        "timestamp": "2011-01-26"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-016361-28/IT",
        "title": "A Prospective Single Arm, Open-label, International, Multicenter Study to Evaluate the\nSafety, Efficacy and Pharmacokinetics of Atazanavir (ATV) Powder Boosted with\nRitonavir (RTV) Liquid with an O... - IT",
        "timestamp": "2011-01-26"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-016361-28/3rd",
        "title": "A Prospective Single Arm, Open-label, International, Multicenter Study to Evaluate the\nSafety, Efficacy and Pharmacokinetics of Atazanavir (ATV) Powder Boosted with\nRitonavir (RTV) Liquid with an O... - Outside EU/EEA",
        "timestamp": "2011-01-26"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-016361-28/results",
        "title": "A Prospective Single Arm, Open-label, International, Multicenter Study to Evaluate the\nSafety, Efficacy and Pharmacokinetics of Atazanavir (ATV) Powder Boosted with\nRitonavir (RTV) Liquid with an O... - View results",
        "timestamp": "2011-01-26"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-003704-39/GB",
        "title": "An open label study examining the efficacy and cardiovascular risk of immediate versus deferred switch from a boosted PI to dolutegravir (DTG) in HIV infected patients with stable virological suppr... - GB",
        "timestamp": "2014-04-01"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-003704-39/BE",
        "title": "An open label study examining the efficacy and cardiovascular risk of immediate versus deferred switch from a boosted PI to dolutegravir (DTG) in HIV infected patients with stable virological suppr... - BE",
        "timestamp": "2014-04-01"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-003704-39/ES",
        "title": "An open label study examining the efficacy and cardiovascular risk of immediate versus deferred switch from a boosted PI to dolutegravir (DTG) in HIV infected patients with stable virological suppr... - ES",
        "timestamp": "2014-04-01"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-003704-39/IT",
        "title": "An open label study examining the efficacy and cardiovascular risk of immediate versus deferred switch from a boosted PI to dolutegravir (DTG) in HIV infected patients with stable virological suppr... - IT",
        "timestamp": "2014-04-01"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-017013-29/GB",
        "title": "Continued access to darunavir/ritonavir (DRV/rtv) in HIV-1 infected children and adolescents aged 3 years and above - GB",
        "timestamp": "2010-07-08"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-017013-29/ES",
        "title": "Continued access to darunavir/ritonavir (DRV/rtv) in HIV-1 infected children and adolescents aged 3 years and above - ES",
        "timestamp": "2010-07-08"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-017013-29/FR",
        "title": "Continued access to darunavir/ritonavir (DRV/rtv) in HIV-1 infected children and adolescents aged 3 years and above - FR",
        "timestamp": "2010-07-08"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-017013-29/IT",
        "title": "Continued access to darunavir/ritonavir (DRV/rtv) in HIV-1 infected children and adolescents aged 3 years and above - IT",
        "timestamp": "2010-07-08"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-017013-29/results",
        "title": "Continued access to darunavir/ritonavir (DRV/rtv) in HIV-1 infected children and adolescents aged 3 years and above - View results",
        "timestamp": "2010-07-08"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-019584-10/ES",
        "title": "Estudio aleatorizado, abierto, multicéntrico, de búsqueda de dosis y duración del tratamiento para evaluar la respuesta virológica mantenida del inhibidor de proteasa VHC Danoprevir (RO5190591) ref... - ES",
        "timestamp": "2010-12-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-019584-10/DE",
        "title": "Estudio aleatorizado, abierto, multicéntrico, de búsqueda de dosis y duración del tratamiento para evaluar la respuesta virológica mantenida del inhibidor de proteasa VHC Danoprevir (RO5190591) ref... - DE",
        "timestamp": "2010-12-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-019584-10/GB",
        "title": "Estudio aleatorizado, abierto, multicéntrico, de búsqueda de dosis y duración del tratamiento para evaluar la respuesta virológica mantenida del inhibidor de proteasa VHC Danoprevir (RO5190591) ref... - GB",
        "timestamp": "2010-12-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-019584-10/AT",
        "title": "Estudio aleatorizado, abierto, multicéntrico, de búsqueda de dosis y duración del tratamiento para evaluar la respuesta virológica mantenida del inhibidor de proteasa VHC Danoprevir (RO5190591) ref... - AT",
        "timestamp": "2010-12-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-019584-10/FR",
        "title": "Estudio aleatorizado, abierto, multicéntrico, de búsqueda de dosis y duración del tratamiento para evaluar la respuesta virológica mantenida del inhibidor de proteasa VHC Danoprevir (RO5190591) ref... - FR",
        "timestamp": "2010-12-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-019584-10/IT",
        "title": "Estudio aleatorizado, abierto, multicéntrico, de búsqueda de dosis y duración del tratamiento para evaluar la respuesta virológica mantenida del inhibidor de proteasa VHC Danoprevir (RO5190591) ref... - IT",
        "timestamp": "2010-12-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-001635-23/BE",
        "title": "PROTEAse inhibitor (DRV/rtv) in mono- or triple therapy in suppressed HIV-1 infected subjects - BE",
        "timestamp": "2012-01-17"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-001635-23/GB",
        "title": "PROTEAse inhibitor (DRV/rtv) in mono- or triple therapy in suppressed HIV-1 infected subjects - GB",
        "timestamp": "2012-01-17"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-001635-23/IE",
        "title": "PROTEAse inhibitor (DRV/rtv) in mono- or triple therapy in suppressed HIV-1 infected subjects - IE",
        "timestamp": "2012-01-17"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-001635-23/DE",
        "title": "PROTEAse inhibitor (DRV/rtv) in mono- or triple therapy in suppressed HIV-1 infected subjects - DE",
        "timestamp": "2012-01-17"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-001635-23/ES",
        "title": "PROTEAse inhibitor (DRV/rtv) in mono- or triple therapy in suppressed HIV-1 infected subjects - ES",
        "timestamp": "2012-01-17"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-001635-23/AT",
        "title": "PROTEAse inhibitor (DRV/rtv) in mono- or triple therapy in suppressed HIV-1 infected subjects - AT",
        "timestamp": "2012-01-17"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-001635-23/HU",
        "title": "PROTEAse inhibitor (DRV/rtv) in mono- or triple therapy in suppressed HIV-1 infected subjects - HU",
        "timestamp": "2012-01-17"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-001635-23/DK",
        "title": "PROTEAse inhibitor (DRV/rtv) in mono- or triple therapy in suppressed HIV-1 infected subjects - DK",
        "timestamp": "2012-01-17"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-001635-23/IT",
        "title": "PROTEAse inhibitor (DRV/rtv) in mono- or triple therapy in suppressed HIV-1 infected subjects - IT",
        "timestamp": "2012-01-17"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-001635-23/SE",
        "title": "PROTEAse inhibitor (DRV/rtv) in mono- or triple therapy in suppressed HIV-1 infected subjects - SE",
        "timestamp": "2012-01-17"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-001635-23/PL",
        "title": "PROTEAse inhibitor (DRV/rtv) in mono- or triple therapy in suppressed HIV-1 infected subjects - PL",
        "timestamp": "2012-01-17"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-001635-23/results",
        "title": "PROTEAse inhibitor (DRV/rtv) in mono- or triple therapy in suppressed HIV-1 infected subjects - View results",
        "timestamp": "2012-01-17"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003708-11/BE",
        "title": "A Randomized, Double-blind Phase 3B Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Versus Ritonavir-Boosted Atazanavir Plus Emtrici... - BE",
        "timestamp": "2012-11-05"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003708-11/GB",
        "title": "A Randomized, Double-blind Phase 3B Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Versus Ritonavir-Boosted Atazanavir Plus Emtrici... - GB",
        "timestamp": "2012-11-05"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003708-11/PT",
        "title": "A Randomized, Double-blind Phase 3B Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Versus Ritonavir-Boosted Atazanavir Plus Emtrici... - PT",
        "timestamp": "2012-11-05"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003708-11/IT",
        "title": "A Randomized, Double-blind Phase 3B Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Versus Ritonavir-Boosted Atazanavir Plus Emtrici... - IT",
        "timestamp": "2012-11-05"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003708-11/FR",
        "title": "A Randomized, Double-blind Phase 3B Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Versus Ritonavir-Boosted Atazanavir Plus Emtrici... - FR",
        "timestamp": "2012-11-05"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003708-11/results",
        "title": "A Randomized, Double-blind Phase 3B Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Versus Ritonavir-Boosted Atazanavir Plus Emtrici... - View results",
        "timestamp": "2012-11-05"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-006260-52/BE",
        "title": "A multi-center, randomized, double blind, placebo-controlled Phase I/II trial to compare the safety, tolerability and immunogenicity of the therapeutic THV01 vaccination at 5x10E6 TU, 5x10E7 TU or ... - BE",
        "timestamp": "2012-10-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-006260-52/FR",
        "title": "A multi-center, randomized, double blind, placebo-controlled Phase I/II trial to compare the safety, tolerability and immunogenicity of the therapeutic THV01 vaccination at 5x10E6 TU, 5x10E7 TU or ... - FR",
        "timestamp": "2012-10-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-017032-41/GB",
        "title": "An Open-Label, Randomized Study Evaluating a Switch from a Regimen of Two Nucleoside Reverse Transcriptase Inhibitors plus any Third Agent to either a Regimen of Atazanavir/Ritonavir Once Daily and... - GB",
        "timestamp": "2011-08-01"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-017032-41/DE",
        "title": "An Open-Label, Randomized Study Evaluating a Switch from a Regimen of Two Nucleoside Reverse Transcriptase Inhibitors plus any Third Agent to either a Regimen of Atazanavir/Ritonavir Once Daily and... - DE",
        "timestamp": "2011-08-01"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-017032-41/ES",
        "title": "An Open-Label, Randomized Study Evaluating a Switch from a Regimen of Two Nucleoside Reverse Transcriptase Inhibitors plus any Third Agent to either a Regimen of Atazanavir/Ritonavir Once Daily and... - ES",
        "timestamp": "2011-08-01"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-017032-41/PL",
        "title": "An Open-Label, Randomized Study Evaluating a Switch from a Regimen of Two Nucleoside Reverse Transcriptase Inhibitors plus any Third Agent to either a Regimen of Atazanavir/Ritonavir Once Daily and... - PL",
        "timestamp": "2011-08-01"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-017032-41/IT",
        "title": "An Open-Label, Randomized Study Evaluating a Switch from a Regimen of Two Nucleoside Reverse Transcriptase Inhibitors plus any Third Agent to either a Regimen of Atazanavir/Ritonavir Once Daily and... - IT",
        "timestamp": "2011-08-01"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-017032-41/results",
        "title": "An Open-Label, Randomized Study Evaluating a Switch from a Regimen of Two Nucleoside Reverse Transcriptase Inhibitors plus any Third Agent to either a Regimen of Atazanavir/Ritonavir Once Daily and... - View results",
        "timestamp": "2011-08-01"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-007038-24/DE",
        "title": "PILOT STUDY OF NOVEL COMBINATION OF MARAVIROC + ATAZANAVIR/RITONAVIR VS ATAZANAVIR/RITONAVIR + EMTRICITABINE/TENOFOVIR FOR THE TREATMENT OF TREATMENT NAÏVE HIV-INFECTED PATIENTS WITH R5 HIV-1 - DE",
        "timestamp": "2009-06-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-007038-24/ES",
        "title": "PILOT STUDY OF NOVEL COMBINATION OF MARAVIROC + ATAZANAVIR/RITONAVIR VS ATAZANAVIR/RITONAVIR + EMTRICITABINE/TENOFOVIR FOR THE TREATMENT OF TREATMENT NAÏVE HIV-INFECTED PATIENTS WITH R5 HIV-1 - ES",
        "timestamp": "2009-06-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-007038-24/GB",
        "title": "PILOT STUDY OF NOVEL COMBINATION OF MARAVIROC + ATAZANAVIR/RITONAVIR VS ATAZANAVIR/RITONAVIR + EMTRICITABINE/TENOFOVIR FOR THE TREATMENT OF TREATMENT NAÏVE HIV-INFECTED PATIENTS WITH R5 HIV-1 - GB",
        "timestamp": "2009-06-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-007038-24/results",
        "title": "PILOT STUDY OF NOVEL COMBINATION OF MARAVIROC + ATAZANAVIR/RITONAVIR VS ATAZANAVIR/RITONAVIR + EMTRICITABINE/TENOFOVIR FOR THE TREATMENT OF TREATMENT NAÏVE HIV-INFECTED PATIENTS WITH R5 HIV-1 - View results",
        "timestamp": "2009-06-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-002349-12/IT",
        "title": "“Switching HIV-positive Women With Undetectable Viremia on Tenofovir/Emtricitabine plus Boosted Atazanavir to RALtegravir (400 mg twice-daily) plus Boosted ATazanavir (300/100 mg once-daily): A Pil... - IT",
        "timestamp": "2013-08-17"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-003629-86/ES",
        "title": "A Phase IIIb, randomized, open-label study of the safety and efficacy of GSK1349572 (dolutegravir, DTG) 50 mg once daily compared to darunavir/ritonavir (DRV/r) 800 mg/100 mg once daily each admini... - ES",
        "timestamp": "2012-01-27"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-003629-86/IT",
        "title": "A Phase IIIb, randomized, open-label study of the safety and efficacy of GSK1349572 (dolutegravir, DTG) 50 mg once daily compared to darunavir/ritonavir (DRV/r) 800 mg/100 mg once daily each admini... - IT",
        "timestamp": "2012-01-27"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-003629-86/results",
        "title": "A Phase IIIb, randomized, open-label study of the safety and efficacy of GSK1349572 (dolutegravir, DTG) 50 mg once daily compared to darunavir/ritonavir (DRV/r) 800 mg/100 mg once daily each admini... - View results",
        "timestamp": "2012-01-27"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-016455-21/ES",
        "title": "PILOT STUDY TO ASSESS THE EFFICACY AND SAFETY OF SWITCHING PROTEASE INHIBITOR TO ETRAVIRINE IN HIV-1-INFECTED SUBJECTS WITH VIREMIA SUPPRESSION (ESTUDIO PILOTO PARA EVALUAR LA EFICACIA Y SEGURIDAD ... - ES",
        "timestamp": "2009-12-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-016455-21/results",
        "title": "PILOT STUDY TO ASSESS THE EFFICACY AND SAFETY OF SWITCHING PROTEASE INHIBITOR TO ETRAVIRINE IN HIV-1-INFECTED SUBJECTS WITH VIREMIA SUPPRESSION (ESTUDIO PILOTO PARA EVALUAR LA EFICACIA Y SEGURIDAD ... - View results",
        "timestamp": "2009-12-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-015904-24/DE",
        "title": "An open, prospective study to compare the safety and efficacy of raltegravir vs. atazanavir / ritonavir, both in combination with tenofovir DF and emtricitabine, in the treatment of HIV-infection i... - DE",
        "timestamp": "2010-10-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-006268-42/ES",
        "title": "Tratamiento antirretroviral una vez al día en pacientes con infección por el VIH-1 no tratados previamente y con cifras de linfocitos CD4+ inferiores a 100 céls/mm3. Estudio prospectivo aleatorizad... - ES",
        "timestamp": "2007-07-05"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-003865-33/GB",
        "title": "A Phase IIb, 96 week, randomized, open-label, multicenter, parallel group, repeat dose study to evaluate the safety, tolerability, pharmacokinetics and antiviral effect of different doses and regim... - GB",
        "timestamp": "2005-02-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-003865-33/IT",
        "title": "A Phase IIb, 96 week, randomized, open-label, multicenter, parallel group, repeat dose study to evaluate the safety, tolerability, pharmacokinetics and antiviral effect of different doses and regim... - IT",
        "timestamp": "2005-02-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-003865-33/DE",
        "title": "A Phase IIb, 96 week, randomized, open-label, multicenter, parallel group, repeat dose study to evaluate the safety, tolerability, pharmacokinetics and antiviral effect of different doses and regim... - DE",
        "timestamp": "2005-02-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-003865-33/ES",
        "title": "A Phase IIb, 96 week, randomized, open-label, multicenter, parallel group, repeat dose study to evaluate the safety, tolerability, pharmacokinetics and antiviral effect of different doses and regim... - ES",
        "timestamp": "2005-02-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-003865-33/results",
        "title": "A Phase IIb, 96 week, randomized, open-label, multicenter, parallel group, repeat dose study to evaluate the safety, tolerability, pharmacokinetics and antiviral effect of different doses and regim... - View results",
        "timestamp": "2005-02-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-004124-38/DE",
        "title": "Randomized, Placebo-Controlled, Multiple-Dose Study to Evaluate the Pharmacodynamics, Safety and Pharmacokinetics of BMS-955176 (Double-Blinded) and BMS-955176 with Atazanavir +/- Ritonavir (Open-L... - DE",
        "timestamp": "2013-03-21"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-004124-38/GB",
        "title": "Randomized, Placebo-Controlled, Multiple-Dose Study to Evaluate the Pharmacodynamics, Safety and Pharmacokinetics of BMS-955176 (Double-Blinded) and BMS-955176 with Atazanavir +/- Ritonavir (Open-L... - GB",
        "timestamp": "2013-03-21"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-004124-38/results",
        "title": "Randomized, Placebo-Controlled, Multiple-Dose Study to Evaluate the Pharmacodynamics, Safety and Pharmacokinetics of BMS-955176 (Double-Blinded) and BMS-955176 with Atazanavir +/- Ritonavir (Open-L... - View results",
        "timestamp": "2013-03-21"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-004792-39/ES",
        "title": "Open-label, Single Arm, Phase 2 Study to Evaluate the Safety and Efficacy of the Combination of ABT-450/ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 Coadministered with Ribavirin (RBV) in Adul... - ES",
        "timestamp": "2013-02-27"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-004792-39/GB",
        "title": "Open-label, Single Arm, Phase 2 Study to Evaluate the Safety and Efficacy of the Combination of ABT-450/ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 Coadministered with Ribavirin (RBV) in Adul... - GB",
        "timestamp": "2013-02-27"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-004792-39/DE",
        "title": "Open-label, Single Arm, Phase 2 Study to Evaluate the Safety and Efficacy of the Combination of ABT-450/ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 Coadministered with Ribavirin (RBV) in Adul... - DE",
        "timestamp": "2013-02-27"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-004792-39/results",
        "title": "Open-label, Single Arm, Phase 2 Study to Evaluate the Safety and Efficacy of the Combination of ABT-450/ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 Coadministered with Ribavirin (RBV) in Adul... - View results",
        "timestamp": "2013-02-27"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-003896-38/IT",
        "title": "PHARMACOKINETICS AND PHARMACODYNAMICS IN THE OPTIMIZATION OF ANTIRETROVIRAL TREATMENT. - IT",
        "timestamp": "2007-07-05"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-002853-77/ES",
        "title": "PROSPECTIVE, RANDOMISED, CROSSOVER, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL TO ASSESS THE LIPID-LOWERING EFFECT OF ADDING TENOFOVIR/EMTRICITABINE CO-FORMULATION VS PLACEBO TO HIV-1-INFECTED SUBJECTS... - ES",
        "timestamp": "2011-10-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-002853-77/results",
        "title": "PROSPECTIVE, RANDOMISED, CROSSOVER, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL TO ASSESS THE LIPID-LOWERING EFFECT OF ADDING TENOFOVIR/EMTRICITABINE CO-FORMULATION VS PLACEBO TO HIV-1-INFECTED SUBJECTS... - View results",
        "timestamp": "2011-10-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-003438-12/ES",
        "title": "Ensayo Clínico aleatorizado para comparar la combinación ZDV + 3TC + ABC (Trizivir) frente a Lopinavir/R (Kaletra) en monoterapia en pacientes con supresión viral en tratamiento previo con ZDV + 3T... - ES",
        "timestamp": "2008-08-29"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-023264-40/IT",
        "title": "Efficacy in the central nervous system (CNS) of two combination regimens with different penetration rank in HIV-positive na�ve patients - IT",
        "timestamp": "2010-10-21"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000936-23/FR",
        "title": "Multi-centre, adaptive, randomized trial of the safety and efficacy of treatments of COVID-19 in hospitalized adults - FR",
        "timestamp": "2020-03-09"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001113-21/GB",
        "title": "Randomised Evaluation of COVID-19 Therapy (RECOVERY) - GB",
        "timestamp": "2020-03-17"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-022067-35/DE",
        "title": "INFORM-SVR: A Randomized, Multi-Center Study of Interferon-Free Treatment with a Combination of a Polymerase Inhibitor (RO5024048) and a Ritonavir boosted HCV Protease\r\nInhibitor (RO5190591/r, DNV/... - DE",
        "timestamp": "2011-02-17"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-022067-35/results",
        "title": "INFORM-SVR: A Randomized, Multi-Center Study of Interferon-Free Treatment with a Combination of a Polymerase Inhibitor (RO5024048) and a Ritonavir boosted HCV Protease\r\nInhibitor (RO5190591/r, DNV/... - View results",
        "timestamp": "2011-02-17"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-000725-37/3rd",
        "title": "A Phase 1 Study to Evaluate the Bioavailability of Boosted Age-Appropriate Pediatric Elvitegravir (EVG) Tablet or Suspension Formulation Compared with Adult EVG 150 mg Tablets in Healthy Adult Volu... - Outside EU/EEA",
        "timestamp": "2015-02-18"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-000725-37/results",
        "title": "A Phase 1 Study to Evaluate the Bioavailability of Boosted Age-Appropriate Pediatric Elvitegravir (EVG) Tablet or Suspension Formulation Compared with Adult EVG 150 mg Tablets in Healthy Adult Volu... - View results",
        "timestamp": "2015-02-18"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-021002-38/ES",
        "title": "Estudio sobre los efectos metabólicos de atazanavir/ritonavir versus darunavir/ritonavir en combinación con tenofovir/emtricitabina en pacientes infectados por el VIH-1 sin tratamiento previo: ensa... - ES",
        "timestamp": "2010-11-10"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003501-10/ES",
        "title": "Efficacy of dual antiretroviral treatment with maraviroc plus ritonavir-boosted darunavir in early rescue therapy in patients with HIV-1 infection: pilot, multicenter, randomized, controlled and op... - ES",
        "timestamp": "2013-04-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-007765-23/IT",
        "title": "MoLO study - Evaluation of cost/efficacy ratio of monotherapy with lopinavir/ritonavir versus standard in patients treated with protesi inhibotors in virologic suppressison. - IT",
        "timestamp": "2010-03-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-002069-39/ES",
        "title": "Comparación de dos combinaciones de antirretrovirales en la Profilaxis Post-Exposición al VIH-1: TDF-FTC (Truvada ®) + Lopinavir/Ritonavir (Kaletra ®) vs TDF-FTC (Truvada ®) + Maraviroc (Celsentri ... - ES",
        "timestamp": "2011-09-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-000547-85/ES",
        "title": "MULTICENTRE STUDY TO ASSESS CHANGES IN BONE MINERAL DENSITY OF THE SWITCH FROM PROTEASE INHIBITORS TO DOLUTEGRAVIR IN HIV-1-INFECTED SUBJECTS WITH LOW BONE MINERAL DENSITY - ES",
        "timestamp": "2013-09-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-000547-85/results",
        "title": "MULTICENTRE STUDY TO ASSESS CHANGES IN BONE MINERAL DENSITY OF THE SWITCH FROM PROTEASE INHIBITORS TO DOLUTEGRAVIR IN HIV-1-INFECTED SUBJECTS WITH LOW BONE MINERAL DENSITY - View results",
        "timestamp": "2013-09-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-002682-30/ES",
        "title": "Raltegravir-based regimen versus raltegravir-based regimen plus atorvastatin for reducing ?inflamaging? (aging-related complication) in HIV-infected patients older than 60 years. - ES",
        "timestamp": "2015-09-30"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-002682-30/results",
        "title": "Raltegravir-based regimen versus raltegravir-based regimen plus atorvastatin for reducing ?inflamaging? (aging-related complication) in HIV-infected patients older than 60 years. - View results",
        "timestamp": "2015-09-30"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-016090-14/ES",
        "title": "Análisis de los cambios en el tejido adiposo de pacientes con infección VIH y lipoatrofia en tratamiento con análogos de nucleósidos timidínicos, tras el cambio a monoterapia con Lopinavir/ritonavir - ES",
        "timestamp": "2009-12-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-003147-35/GB",
        "title": "A Randomized, Open-Label Study to Evaluate the Safety and Efficacy of the Co-Administration of Ombitasvir/ABT-450/Ritonavir (Ombitasvir/ABT-450/r) With Sofosbuvir (SOF) With or Without Ribavirin (R... - GB",
        "timestamp": "2014-12-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-003147-35/results",
        "title": "A Randomized, Open-Label Study to Evaluate the Safety and Efficacy of the Co-Administration of Ombitasvir/ABT-450/Ritonavir (Ombitasvir/ABT-450/r) With Sofosbuvir (SOF) With or Without Ribavirin (R... - View results",
        "timestamp": "2014-12-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-003562-90/FR",
        "title": "A phase IV open-label, multicentre, international trial of paritaprevir/ritonavir, ombitasvir, dasabuvir with or without ribavirin for people with chronic hepatitis C virus genotype 1 infection and... - FR",
        "timestamp": "2016-06-17"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-003562-90/results",
        "title": "A phase IV open-label, multicentre, international trial of paritaprevir/ritonavir, ombitasvir, dasabuvir with or without ribavirin for people with chronic hepatitis C virus genotype 1 infection and... - View results",
        "timestamp": "2016-06-17"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-000347-41/NL",
        "title": "Safety of extended use of the weekly oral docetaxel formulation ModraDoc006/r in patients with advanced solid tumours - NL",
        "timestamp": "2017-04-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-001111-39/NL",
        "title": "Once daily DArunavir/ritonavir in HIV-infected children 6-12 years old: a PHarmacokiNEtic validation of model-based dosing recommendations (DAPHNE) - NL",
        "timestamp": "2014-12-08"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-001111-39/results",
        "title": "Once daily DArunavir/ritonavir in HIV-infected children 6-12 years old: a PHarmacokiNEtic validation of model-based dosing recommendations (DAPHNE) - View results",
        "timestamp": "2014-12-08"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-002281-70/ES",
        "title": "Immune reconstitution in severely immunosuppressed antiretroviral-naive HIV-1?infected patients (<100 CD4+ T cells/?L) taking antiretroviral regimens based on dolutegravir or ritonavir-boosted daru... - ES",
        "timestamp": "2015-02-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005581-37/GB",
        "title": "Efficacy of Switch to Lopinavir/Ritonavir in Improving Cognitive function in Efavirenz treated patients - GB",
        "timestamp": "2012-08-06"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005581-37/results",
        "title": "Efficacy of Switch to Lopinavir/Ritonavir in Improving Cognitive function in Efavirenz treated patients - View results",
        "timestamp": "2012-08-06"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-002843-81/FR",
        "title": "Switch to Tenofovir Alafenamide (TAF), Emtricitabine (FTC), Bictegravir (BIC)(Biktarvy®) in HIV-1-infected patients over 65 years old at risk of polymedication - FR",
        "timestamp": "2020-01-07"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-005134-64/3rd",
        "title": "Phase I/II Open-Label, Pharmacokinetic and Safety Study of a Novel Protease Inhibitor (BMS-232632, ATAZANAVIR, ATV, REYATAZ™) in Combination Regimens in Antiretroviral Therapy (ART)-Naïve and Exper... - Outside EU/EEA",
        "timestamp": "2015-03-13"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-005134-64/results",
        "title": "Phase I/II Open-Label, Pharmacokinetic and Safety Study of a Novel Protease Inhibitor (BMS-232632, ATAZANAVIR, ATV, REYATAZ™) in Combination Regimens in Antiretroviral Therapy (ART)-Naïve and Exper... - View results",
        "timestamp": "2015-03-13"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-004476-12/FR",
        "title": "A randomised open-label study comparing the safety and efficacy of three different combination antiretroviral regimens as initial therapy for HIV infection. - FR",
        "timestamp": "2007-07-10"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-004476-12/IE",
        "title": "A randomised open-label study comparing the safety and efficacy of three different combination antiretroviral regimens as initial therapy for HIV infection. - IE",
        "timestamp": "2007-07-10"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-004476-12/DE",
        "title": "A randomised open-label study comparing the safety and efficacy of three different combination antiretroviral regimens as initial therapy for HIV infection. - DE",
        "timestamp": "2007-07-10"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-004476-12/GB",
        "title": "A randomised open-label study comparing the safety and efficacy of three different combination antiretroviral regimens as initial therapy for HIV infection. - GB",
        "timestamp": "2007-07-10"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-019585-90/AT",
        "title": "A Randomized, Open-label, Multicenter Study to Evaluate the Sustained Virologic Response of the HCV Protease Inhibitor Danoprevir Boosted with Low Dose Ritonavir (Danoprevir/r) and Copegus®, in Com... - AT",
        "timestamp": "2011-05-05"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-019585-90/DE",
        "title": "A Randomized, Open-label, Multicenter Study to Evaluate the Sustained Virologic Response of the HCV Protease Inhibitor Danoprevir Boosted with Low Dose Ritonavir (Danoprevir/r) and Copegus®, in Com... - DE",
        "timestamp": "2011-05-05"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-019585-90/GB",
        "title": "A Randomized, Open-label, Multicenter Study to Evaluate the Sustained Virologic Response of the HCV Protease Inhibitor Danoprevir Boosted with Low Dose Ritonavir (Danoprevir/r) and Copegus®, in Com... - GB",
        "timestamp": "2011-05-05"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-019585-90/IT",
        "title": "A Randomized, Open-label, Multicenter Study to Evaluate the Sustained Virologic Response of the HCV Protease Inhibitor Danoprevir Boosted with Low Dose Ritonavir (Danoprevir/r) and Copegus®, in Com... - IT",
        "timestamp": "2011-05-05"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-019585-90/ES",
        "title": "A Randomized, Open-label, Multicenter Study to Evaluate the Sustained Virologic Response of the HCV Protease Inhibitor Danoprevir Boosted with Low Dose Ritonavir (Danoprevir/r) and Copegus®, in Com... - ES",
        "timestamp": "2011-05-05"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003687-52/PT",
        "title": "A Randomized, Double-Blind, Controlled Study to Evaluate the Efficacy and Safety of the Combination of ABT-450/Ritonavir/ABT-267 (ABT 450/r/ABT-267) and ABT-333 With and Without Ribavirin (RBV) in ... - PT",
        "timestamp": "2013-03-01"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003687-52/BE",
        "title": "A Randomized, Double-Blind, Controlled Study to Evaluate the Efficacy and Safety of the Combination of ABT-450/Ritonavir/ABT-267 (ABT 450/r/ABT-267) and ABT-333 With and Without Ribavirin (RBV) in ... - BE",
        "timestamp": "2013-03-01"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003687-52/HU",
        "title": "A Randomized, Double-Blind, Controlled Study to Evaluate the Efficacy and Safety of the Combination of ABT-450/Ritonavir/ABT-267 (ABT 450/r/ABT-267) and ABT-333 With and Without Ribavirin (RBV) in ... - HU",
        "timestamp": "2013-03-01"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003687-52/AT",
        "title": "A Randomized, Double-Blind, Controlled Study to Evaluate the Efficacy and Safety of the Combination of ABT-450/Ritonavir/ABT-267 (ABT 450/r/ABT-267) and ABT-333 With and Without Ribavirin (RBV) in ... - AT",
        "timestamp": "2013-03-01"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003687-52/IT",
        "title": "A Randomized, Double-Blind, Controlled Study to Evaluate the Efficacy and Safety of the Combination of ABT-450/Ritonavir/ABT-267 (ABT 450/r/ABT-267) and ABT-333 With and Without Ribavirin (RBV) in ... - IT",
        "timestamp": "2013-03-01"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003687-52/ES",
        "title": "A Randomized, Double-Blind, Controlled Study to Evaluate the Efficacy and Safety of the Combination of ABT-450/Ritonavir/ABT-267 (ABT 450/r/ABT-267) and ABT-333 With and Without Ribavirin (RBV) in ... - ES",
        "timestamp": "2013-03-01"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003687-52/PL",
        "title": "A Randomized, Double-Blind, Controlled Study to Evaluate the Efficacy and Safety of the Combination of ABT-450/Ritonavir/ABT-267 (ABT 450/r/ABT-267) and ABT-333 With and Without Ribavirin (RBV) in ... - PL",
        "timestamp": "2013-03-01"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003687-52/results",
        "title": "A Randomized, Double-Blind, Controlled Study to Evaluate the Efficacy and Safety of the Combination of ABT-450/Ritonavir/ABT-267 (ABT 450/r/ABT-267) and ABT-333 With and Without Ribavirin (RBV) in ... - View results",
        "timestamp": "2013-03-01"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-001496-31/DE",
        "title": "A Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Ombitasvir/ABT-450/Ritonavir Coadministered with Ribavirin in Adults with Genotype 4 Chronic Hepatitis C Virus  Infection and C... - DE",
        "timestamp": "2014-12-18"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-001496-31/BE",
        "title": "A Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Ombitasvir/ABT-450/Ritonavir Coadministered with Ribavirin in Adults with Genotype 4 Chronic Hepatitis C Virus  Infection and C... - BE",
        "timestamp": "2014-12-18"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-001496-31/AT",
        "title": "A Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Ombitasvir/ABT-450/Ritonavir Coadministered with Ribavirin in Adults with Genotype 4 Chronic Hepatitis C Virus  Infection and C... - AT",
        "timestamp": "2014-12-18"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-001496-31/ES",
        "title": "A Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Ombitasvir/ABT-450/Ritonavir Coadministered with Ribavirin in Adults with Genotype 4 Chronic Hepatitis C Virus  Infection and C... - ES",
        "timestamp": "2014-12-18"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-001496-31/IT",
        "title": "A Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Ombitasvir/ABT-450/Ritonavir Coadministered with Ribavirin in Adults with Genotype 4 Chronic Hepatitis C Virus  Infection and C... - IT",
        "timestamp": "2014-12-18"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-001496-31/GR",
        "title": "A Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Ombitasvir/ABT-450/Ritonavir Coadministered with Ribavirin in Adults with Genotype 4 Chronic Hepatitis C Virus  Infection and C... - GR",
        "timestamp": "2014-12-18"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-001496-31/FR",
        "title": "A Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Ombitasvir/ABT-450/Ritonavir Coadministered with Ribavirin in Adults with Genotype 4 Chronic Hepatitis C Virus  Infection and C... - FR",
        "timestamp": "2014-12-18"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-001496-31/results",
        "title": "A Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Ombitasvir/ABT-450/Ritonavir Coadministered with Ribavirin in Adults with Genotype 4 Chronic Hepatitis C Virus  Infection and C... - View results",
        "timestamp": "2014-12-18"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-000865-21/IE",
        "title": "A Phase IV, Open-Label, Randomized, Multicenter Trial Assessing the Efficacy of a Treatment Maintenance Phase with Unboosted vs. Boosted Reyataz After an Induction Phase with Reyataz and Ritonavir ... - IE",
        "timestamp": "2005-09-28"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-000865-21/GB",
        "title": "A Phase IV, Open-Label, Randomized, Multicenter Trial Assessing the Efficacy of a Treatment Maintenance Phase with Unboosted vs. Boosted Reyataz After an Induction Phase with Reyataz and Ritonavir ... - GB",
        "timestamp": "2005-09-28"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-000865-21/ES",
        "title": "A Phase IV, Open-Label, Randomized, Multicenter Trial Assessing the Efficacy of a Treatment Maintenance Phase with Unboosted vs. Boosted Reyataz After an Induction Phase with Reyataz and Ritonavir ... - ES",
        "timestamp": "2005-09-28"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-000865-21/LV",
        "title": "A Phase IV, Open-Label, Randomized, Multicenter Trial Assessing the Efficacy of a Treatment Maintenance Phase with Unboosted vs. Boosted Reyataz After an Induction Phase with Reyataz and Ritonavir ... - LV",
        "timestamp": "2005-09-28"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-000865-21/DE",
        "title": "A Phase IV, Open-Label, Randomized, Multicenter Trial Assessing the Efficacy of a Treatment Maintenance Phase with Unboosted vs. Boosted Reyataz After an Induction Phase with Reyataz and Ritonavir ... - DE",
        "timestamp": "2005-09-28"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-000865-21/EE",
        "title": "A Phase IV, Open-Label, Randomized, Multicenter Trial Assessing the Efficacy of a Treatment Maintenance Phase with Unboosted vs. Boosted Reyataz After an Induction Phase with Reyataz and Ritonavir ... - EE",
        "timestamp": "2005-09-28"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-000865-21/IT",
        "title": "A Phase IV, Open-Label, Randomized, Multicenter Trial Assessing the Efficacy of a Treatment Maintenance Phase with Unboosted vs. Boosted Reyataz After an Induction Phase with Reyataz and Ritonavir ... - IT",
        "timestamp": "2005-09-28"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-000865-21/results",
        "title": "A Phase IV, Open-Label, Randomized, Multicenter Trial Assessing the Efficacy of a Treatment Maintenance Phase with Unboosted vs. Boosted Reyataz After an Induction Phase with Reyataz and Ritonavir ... - View results",
        "timestamp": "2005-09-28"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-016758-42/DE",
        "title": "A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Elvitegravir/Emtricitabine/Tenofovir Disoproxil Fumarate/GS-9350 Versus Ritonavir-Boosted Atazanavir Plus Emtricitab... - DE",
        "timestamp": "2010-06-28"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-016758-42/GB",
        "title": "A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Elvitegravir/Emtricitabine/Tenofovir Disoproxil Fumarate/GS-9350 Versus Ritonavir-Boosted Atazanavir Plus Emtricitab... - GB",
        "timestamp": "2010-06-28"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-016758-42/FR",
        "title": "A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Elvitegravir/Emtricitabine/Tenofovir Disoproxil Fumarate/GS-9350 Versus Ritonavir-Boosted Atazanavir Plus Emtricitab... - FR",
        "timestamp": "2010-06-28"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-016758-42/PT",
        "title": "A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Elvitegravir/Emtricitabine/Tenofovir Disoproxil Fumarate/GS-9350 Versus Ritonavir-Boosted Atazanavir Plus Emtricitab... - PT",
        "timestamp": "2010-06-28"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-016758-42/BE",
        "title": "A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Elvitegravir/Emtricitabine/Tenofovir Disoproxil Fumarate/GS-9350 Versus Ritonavir-Boosted Atazanavir Plus Emtricitab... - BE",
        "timestamp": "2010-06-28"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-016758-42/NL",
        "title": "A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Elvitegravir/Emtricitabine/Tenofovir Disoproxil Fumarate/GS-9350 Versus Ritonavir-Boosted Atazanavir Plus Emtricitab... - NL",
        "timestamp": "2010-06-28"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-016758-42/AT",
        "title": "A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Elvitegravir/Emtricitabine/Tenofovir Disoproxil Fumarate/GS-9350 Versus Ritonavir-Boosted Atazanavir Plus Emtricitab... - AT",
        "timestamp": "2010-06-28"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-016758-42/ES",
        "title": "A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Elvitegravir/Emtricitabine/Tenofovir Disoproxil Fumarate/GS-9350 Versus Ritonavir-Boosted Atazanavir Plus Emtricitab... - ES",
        "timestamp": "2010-06-28"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-016758-42/DK",
        "title": "A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Elvitegravir/Emtricitabine/Tenofovir Disoproxil Fumarate/GS-9350 Versus Ritonavir-Boosted Atazanavir Plus Emtricitab... - DK",
        "timestamp": "2010-06-28"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-016758-42/IT",
        "title": "A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Elvitegravir/Emtricitabine/Tenofovir Disoproxil Fumarate/GS-9350 Versus Ritonavir-Boosted Atazanavir Plus Emtricitab... - IT",
        "timestamp": "2010-06-28"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-016758-42/SE",
        "title": "A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Elvitegravir/Emtricitabine/Tenofovir Disoproxil Fumarate/GS-9350 Versus Ritonavir-Boosted Atazanavir Plus Emtricitab... - SE",
        "timestamp": "2010-06-28"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-016758-42/results",
        "title": "A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Elvitegravir/Emtricitabine/Tenofovir Disoproxil Fumarate/GS-9350 Versus Ritonavir-Boosted Atazanavir Plus Emtricitab... - View results",
        "timestamp": "2010-06-28"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-004631-37/IE",
        "title": "A Phase II, open-label trial, to evaluate pharmacokinetics, safety, tolerability and antiviral activity of DRV/rtv once daily in treatment-naïve HIV 1 infected adolescents aged between 12 and < 18 ... - IE",
        "timestamp": "2009-06-25"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-004631-37/GB",
        "title": "A Phase II, open-label trial, to evaluate pharmacokinetics, safety, tolerability and antiviral activity of DRV/rtv once daily in treatment-naïve HIV 1 infected adolescents aged between 12 and < 18 ... - GB",
        "timestamp": "2009-06-25"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-004631-37/FR",
        "title": "A Phase II, open-label trial, to evaluate pharmacokinetics, safety, tolerability and antiviral activity of DRV/rtv once daily in treatment-naïve HIV 1 infected adolescents aged between 12 and < 18 ... - FR",
        "timestamp": "2009-06-25"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-004631-37/ES",
        "title": "A Phase II, open-label trial, to evaluate pharmacokinetics, safety, tolerability and antiviral activity of DRV/rtv once daily in treatment-naïve HIV 1 infected adolescents aged between 12 and < 18 ... - ES",
        "timestamp": "2009-06-25"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-004631-37/IT",
        "title": "A Phase II, open-label trial, to evaluate pharmacokinetics, safety, tolerability and antiviral activity of DRV/rtv once daily in treatment-naïve HIV 1 infected adolescents aged between 12 and < 18 ... - IT",
        "timestamp": "2009-06-25"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-004631-37/3rd",
        "title": "A Phase II, open-label trial, to evaluate pharmacokinetics, safety, tolerability and antiviral activity of DRV/rtv once daily in treatment-naïve HIV 1 infected adolescents aged between 12 and < 18 ... - Outside EU/EEA",
        "timestamp": "2009-06-25"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-004631-37/results",
        "title": "A Phase II, open-label trial, to evaluate pharmacokinetics, safety, tolerability and antiviral activity of DRV/rtv once daily in treatment-naïve HIV 1 infected adolescents aged between 12 and < 18 ... - View results",
        "timestamp": "2009-06-25"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003088-23/BE",
        "title": "A Randomized, Open-Label Study to Evaluate the Safety and Efficacy of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 Coadministered\r\nwith Ribavirin (RBV) in Adults with Genotype 1 Chroni... - BE",
        "timestamp": "2012-12-17"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003088-23/DE",
        "title": "A Randomized, Open-Label Study to Evaluate the Safety and Efficacy of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 Coadministered\r\nwith Ribavirin (RBV) in Adults with Genotype 1 Chroni... - DE",
        "timestamp": "2012-12-17"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003088-23/GB",
        "title": "A Randomized, Open-Label Study to Evaluate the Safety and Efficacy of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 Coadministered\r\nwith Ribavirin (RBV) in Adults with Genotype 1 Chroni... - GB",
        "timestamp": "2012-12-17"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003088-23/ES",
        "title": "A Randomized, Open-Label Study to Evaluate the Safety and Efficacy of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 Coadministered\r\nwith Ribavirin (RBV) in Adults with Genotype 1 Chroni... - ES",
        "timestamp": "2012-12-17"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003088-23/IT",
        "title": "A Randomized, Open-Label Study to Evaluate the Safety and Efficacy of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 Coadministered\r\nwith Ribavirin (RBV) in Adults with Genotype 1 Chroni... - IT",
        "timestamp": "2012-12-17"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003088-23/FR",
        "title": "A Randomized, Open-Label Study to Evaluate the Safety and Efficacy of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 Coadministered\r\nwith Ribavirin (RBV) in Adults with Genotype 1 Chroni... - FR",
        "timestamp": "2012-12-17"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003088-23/results",
        "title": "A Randomized, Open-Label Study to Evaluate the Safety and Efficacy of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 Coadministered\r\nwith Ribavirin (RBV) in Adults with Genotype 1 Chroni... - View results",
        "timestamp": "2012-12-17"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-000783-25/ES",
        "title": "A Multicenter, Double-Blind, Randomized, Active-Controlled Study to Evaluate the Safety and Antiretroviral Activity of MK-0518 Versus KALETRA™ in HIV-Infected   Patients Switched from a Stable KALE... - ES",
        "timestamp": "2007-05-23"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-000783-25/DE",
        "title": "A Multicenter, Double-Blind, Randomized, Active-Controlled Study to Evaluate the Safety and Antiretroviral Activity of MK-0518 Versus KALETRA™ in HIV-Infected   Patients Switched from a Stable KALE... - DE",
        "timestamp": "2007-05-23"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-000783-25/GB",
        "title": "A Multicenter, Double-Blind, Randomized, Active-Controlled Study to Evaluate the Safety and Antiretroviral Activity of MK-0518 Versus KALETRA™ in HIV-Infected   Patients Switched from a Stable KALE... - GB",
        "timestamp": "2007-05-23"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-000783-25/DK",
        "title": "A Multicenter, Double-Blind, Randomized, Active-Controlled Study to Evaluate the Safety and Antiretroviral Activity of MK-0518 Versus KALETRA™ in HIV-Infected   Patients Switched from a Stable KALE... - DK",
        "timestamp": "2007-05-23"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-000783-25/IT",
        "title": "A Multicenter, Double-Blind, Randomized, Active-Controlled Study to Evaluate the Safety and Antiretroviral Activity of MK-0518 Versus KALETRA™ in HIV-Infected   Patients Switched from a Stable KALE... - IT",
        "timestamp": "2007-05-23"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-000783-25/PT",
        "title": "A Multicenter, Double-Blind, Randomized, Active-Controlled Study to Evaluate the Safety and Antiretroviral Activity of MK-0518 Versus KALETRA™ in HIV-Infected   Patients Switched from a Stable KALE... - PT",
        "timestamp": "2007-05-23"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-000783-25/results",
        "title": "A Multicenter, Double-Blind, Randomized, Active-Controlled Study to Evaluate the Safety and Antiretroviral Activity of MK-0518 Versus KALETRA™ in HIV-Infected   Patients Switched from a Stable KALE... - View results",
        "timestamp": "2007-05-23"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-004392-19/DE",
        "title": "A PHASE 2B MULTICENTER, RANDOMIZED, COMPARATIVE TRIAL OF UK-453,061 VERSUS ETRAVIRINE IN COMBINATION WITH DARUNAVIR/RITONAVIR AND A NUCLEOTIDE/NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR FOR THE TRE... - DE",
        "timestamp": "2009-05-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-004392-19/GB",
        "title": "A PHASE 2B MULTICENTER, RANDOMIZED, COMPARATIVE TRIAL OF UK-453,061 VERSUS ETRAVIRINE IN COMBINATION WITH DARUNAVIR/RITONAVIR AND A NUCLEOTIDE/NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR FOR THE TRE... - GB",
        "timestamp": "2009-05-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-004392-19/ES",
        "title": "A PHASE 2B MULTICENTER, RANDOMIZED, COMPARATIVE TRIAL OF UK-453,061 VERSUS ETRAVIRINE IN COMBINATION WITH DARUNAVIR/RITONAVIR AND A NUCLEOTIDE/NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR FOR THE TRE... - ES",
        "timestamp": "2009-05-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-004392-19/PT",
        "title": "A PHASE 2B MULTICENTER, RANDOMIZED, COMPARATIVE TRIAL OF UK-453,061 VERSUS ETRAVIRINE IN COMBINATION WITH DARUNAVIR/RITONAVIR AND A NUCLEOTIDE/NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR FOR THE TRE... - PT",
        "timestamp": "2009-05-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-004392-19/IT",
        "title": "A PHASE 2B MULTICENTER, RANDOMIZED, COMPARATIVE TRIAL OF UK-453,061 VERSUS ETRAVIRINE IN COMBINATION WITH DARUNAVIR/RITONAVIR AND A NUCLEOTIDE/NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR FOR THE TRE... - IT",
        "timestamp": "2009-05-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-004392-19/FR",
        "title": "A PHASE 2B MULTICENTER, RANDOMIZED, COMPARATIVE TRIAL OF UK-453,061 VERSUS ETRAVIRINE IN COMBINATION WITH DARUNAVIR/RITONAVIR AND A NUCLEOTIDE/NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR FOR THE TRE... - FR",
        "timestamp": "2009-05-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-004392-19/results",
        "title": "A PHASE 2B MULTICENTER, RANDOMIZED, COMPARATIVE TRIAL OF UK-453,061 VERSUS ETRAVIRINE IN COMBINATION WITH DARUNAVIR/RITONAVIR AND A NUCLEOTIDE/NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR FOR THE TRE... - View results",
        "timestamp": "2009-05-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-001939-61/BE",
        "title": "A randomized, open-label trial to compare the efficacy, safety and tolerability of DRV/rtv (800/100 mg) q.d. versus DRV/rtv (600/100 mg) b.i.d. in early treatment-experienced HIV-1 infected subjects. - BE",
        "timestamp": "2008-01-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-001939-61/GB",
        "title": "A randomized, open-label trial to compare the efficacy, safety and tolerability of DRV/rtv (800/100 mg) q.d. versus DRV/rtv (600/100 mg) b.i.d. in early treatment-experienced HIV-1 infected subjects. - GB",
        "timestamp": "2008-01-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-001939-61/HU",
        "title": "A randomized, open-label trial to compare the efficacy, safety and tolerability of DRV/rtv (800/100 mg) q.d. versus DRV/rtv (600/100 mg) b.i.d. in early treatment-experienced HIV-1 infected subjects. - HU",
        "timestamp": "2008-01-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-001939-61/FR",
        "title": "A randomized, open-label trial to compare the efficacy, safety and tolerability of DRV/rtv (800/100 mg) q.d. versus DRV/rtv (600/100 mg) b.i.d. in early treatment-experienced HIV-1 infected subjects. - FR",
        "timestamp": "2008-01-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-001939-61/AT",
        "title": "A randomized, open-label trial to compare the efficacy, safety and tolerability of DRV/rtv (800/100 mg) q.d. versus DRV/rtv (600/100 mg) b.i.d. in early treatment-experienced HIV-1 infected subjects. - AT",
        "timestamp": "2008-01-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-001939-61/ES",
        "title": "A randomized, open-label trial to compare the efficacy, safety and tolerability of DRV/rtv (800/100 mg) q.d. versus DRV/rtv (600/100 mg) b.i.d. in early treatment-experienced HIV-1 infected subjects. - ES",
        "timestamp": "2008-01-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-001939-61/IT",
        "title": "A randomized, open-label trial to compare the efficacy, safety and tolerability of DRV/rtv (800/100 mg) q.d. versus DRV/rtv (600/100 mg) b.i.d. in early treatment-experienced HIV-1 infected subjects. - IT",
        "timestamp": "2008-01-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-001939-61/DE",
        "title": "A randomized, open-label trial to compare the efficacy, safety and tolerability of DRV/rtv (800/100 mg) q.d. versus DRV/rtv (600/100 mg) b.i.d. in early treatment-experienced HIV-1 infected subjects. - DE",
        "timestamp": "2008-01-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-001939-61/results",
        "title": "A randomized, open-label trial to compare the efficacy, safety and tolerability of DRV/rtv (800/100 mg) q.d. versus DRV/rtv (600/100 mg) b.i.d. in early treatment-experienced HIV-1 infected subjects. - View results",
        "timestamp": "2008-01-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-003827-10/ES",
        "title": "A Phase III, Randomized, Controlled, Open-label, Multicentre, Three Arm Study to Compare the Efficacy and Safety of a Dual-boosted HIV-1 Protease Inhibitor (PI) regimen of Fosamprenavir (FPV)/ Lopi... - ES",
        "timestamp": "2004-12-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-003827-10/DE",
        "title": "A Phase III, Randomized, Controlled, Open-label, Multicentre, Three Arm Study to Compare the Efficacy and Safety of a Dual-boosted HIV-1 Protease Inhibitor (PI) regimen of Fosamprenavir (FPV)/ Lopi... - DE",
        "timestamp": "2004-12-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-003827-10/IT",
        "title": "A Phase III, Randomized, Controlled, Open-label, Multicentre, Three Arm Study to Compare the Efficacy and Safety of a Dual-boosted HIV-1 Protease Inhibitor (PI) regimen of Fosamprenavir (FPV)/ Lopi... - IT",
        "timestamp": "2004-12-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-003827-10/GB",
        "title": "A Phase III, Randomized, Controlled, Open-label, Multicentre, Three Arm Study to Compare the Efficacy and Safety of a Dual-boosted HIV-1 Protease Inhibitor (PI) regimen of Fosamprenavir (FPV)/ Lopi... - GB",
        "timestamp": "2004-12-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-003827-10/results",
        "title": "A Phase III, Randomized, Controlled, Open-label, Multicentre, Three Arm Study to Compare the Efficacy and Safety of a Dual-boosted HIV-1 Protease Inhibitor (PI) regimen of Fosamprenavir (FPV)/ Lopi... - View results",
        "timestamp": "2004-12-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-003249-41/BE",
        "title": "A multicentre phase IIa study to evaluate the efficacy and tolerability of ModraDoc006/r in patients with recurrent or metastatic HER-2 negative breast cancer, suitable for treatment with a taxane - BE",
        "timestamp": "2018-12-06"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-003249-41/DK",
        "title": "A multicentre phase IIa study to evaluate the efficacy and tolerability of ModraDoc006/r in patients with recurrent or metastatic HER-2 negative breast cancer, suitable for treatment with a taxane - DK",
        "timestamp": "2018-12-06"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-003249-41/ES",
        "title": "A multicentre phase IIa study to evaluate the efficacy and tolerability of ModraDoc006/r in patients with recurrent or metastatic HER-2 negative breast cancer, suitable for treatment with a taxane - ES",
        "timestamp": "2018-12-06"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-000638-21/DE",
        "title": "A Randomized, Open-Label, Multicenter Study of the Safety, Efficacy, and Tolerability of Combination Treatment of Setrobuvir, Danoprevir, Ritonavir, and Copegus® with or without Mericitabine in Tre... - DE",
        "timestamp": "2012-07-06"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-000638-21/PL",
        "title": "A Randomized, Open-Label, Multicenter Study of the Safety, Efficacy, and Tolerability of Combination Treatment of Setrobuvir, Danoprevir, Ritonavir, and Copegus® with or without Mericitabine in Tre... - PL",
        "timestamp": "2012-07-06"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-003163-31/GB",
        "title": "Open-Label, Multiple-Dose, Drug Interaction Study to Assess the Effect of Famotidine with or without Tenofovir on the Pharmacokinetics of Atazanavir when given with Ritonavir in HIV-Infected Subjec... - GB",
        "timestamp": "2006-11-28"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-003163-31/results",
        "title": "Open-Label, Multiple-Dose, Drug Interaction Study to Assess the Effect of Famotidine with or without Tenofovir on the Pharmacokinetics of Atazanavir when given with Ritonavir in HIV-Infected Subjec... - View results",
        "timestamp": "2006-11-28"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-009776-13/FR",
        "title": "Essai clinique comparant l’efficacité et la tolérance de deux stratégies thérapeutiques de maintenance: monothérapie par lopinavir/ritonavir ou trithérapie en comprimé unique quotidien par efaviren... - FR",
        "timestamp": "2009-07-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-006644-19/IT",
        "title": "Evaluation of inflammatory immune parameters predicting cardiovascular risk in HIV-1-infected antiretroviral therapy naive patients treated with atazanavir/ritonavir versus lopinavir/ritonavir base... - IT",
        "timestamp": "2009-01-29"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-002043-16/ES",
        "title": "Estudio fase IV, abierto, aleatorizado, controlado, para evaluar el efecto sobre el perfil lipídico del cambio de un régimen TARGA estable de dosis fija de abacavir/lamivudina (Kivexa) más lopinavi... - ES",
        "timestamp": "2008-09-02"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-002043-16/DE",
        "title": "Estudio fase IV, abierto, aleatorizado, controlado, para evaluar el efecto sobre el perfil lipídico del cambio de un régimen TARGA estable de dosis fija de abacavir/lamivudina (Kivexa) más lopinavi... - DE",
        "timestamp": "2008-09-02"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-002043-16/AT",
        "title": "Estudio fase IV, abierto, aleatorizado, controlado, para evaluar el efecto sobre el perfil lipídico del cambio de un régimen TARGA estable de dosis fija de abacavir/lamivudina (Kivexa) más lopinavi... - AT",
        "timestamp": "2008-09-02"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-002043-16/IT",
        "title": "Estudio fase IV, abierto, aleatorizado, controlado, para evaluar el efecto sobre el perfil lipídico del cambio de un régimen TARGA estable de dosis fija de abacavir/lamivudina (Kivexa) más lopinavi... - IT",
        "timestamp": "2008-09-02"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-002043-16/results",
        "title": "Estudio fase IV, abierto, aleatorizado, controlado, para evaluar el efecto sobre el perfil lipídico del cambio de un régimen TARGA estable de dosis fija de abacavir/lamivudina (Kivexa) más lopinavi... - View results",
        "timestamp": "2008-09-02"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-013657-14/DE",
        "title": "Randomized, Open label, Multiple-Dose Study to Evaluate the Pharmacodynamics,\nSafety and Pharmacokinetics of BMS-663068 in HIV-1 Infected Subjects - DE",
        "timestamp": "2009-11-10"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-013657-14/results",
        "title": "Randomized, Open label, Multiple-Dose Study to Evaluate the Pharmacodynamics,\nSafety and Pharmacokinetics of BMS-663068 in HIV-1 Infected Subjects - View results",
        "timestamp": "2009-11-10"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-003917-29/GB",
        "title": "A Phase 1B Study of the Safety and Pharmacokinetics of Ritonavir-Boosted Elvitegravir (GS-9137/r) Plus a Background Regimen (BR) in HIV-1 Infected, Antiretroviral Treatment-Experienced Adolescents - GB",
        "timestamp": "2008-11-11"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-003917-29/results",
        "title": "A Phase 1B Study of the Safety and Pharmacokinetics of Ritonavir-Boosted Elvitegravir (GS-9137/r) Plus a Background Regimen (BR) in HIV-1 Infected, Antiretroviral Treatment-Experienced Adolescents - View results",
        "timestamp": "2008-11-11"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005973-21/IT",
        "title": "A prospective, randomized, open-label trial of two abacavir/lamivudine based regimen (ABC/3TC + darunavir/ritonavir or ABC/3TC + raltegravir) in late presenter naïve patients (with CD4 count <200 c... - IT",
        "timestamp": "2013-11-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-001348-39/ES",
        "title": "A Phase II, randomized clinical trial to assess the impact of antiretroviral therapy over viral load in seminal fluid in antiretroviral-naive HIV-positive patients - ES",
        "timestamp": "2014-12-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-001193-34/ES",
        "title": "COMPARISON OF TWO ANTIRETROVIRAL ALTERNATIVE COMBINATIONS IN HIV-1 POST-EXPOSURE PROPHYLAXIS: TENOFOVIR+EMTRICITABINE (TRUVADA®) + LOPINAVIR/RITONAVIR (KALETRA®) VS TENOFOVIR+EMTRICITABINA+ COBICIS... - ES",
        "timestamp": "2014-07-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-000670-23/FR",
        "title": "Essai pilote évaluant un traitement antirétroviral associant le MK-0518, le darunavir/ritonavir (TMC114/r) et l’etravirine (TMC125) chez les patients infectés par le VIH-1, en échec virologique et ... - FR",
        "timestamp": "2007-03-21"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-004195-30/BE",
        "title": "A multi-center, randomized, double-blind, placebo-controlled Phase IIa trial to compare the safety of ABX464 given at a fixed dose to placebo in fully controlled HIV infected patients treated with ... - BE",
        "timestamp": "2016-05-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-004195-30/ES",
        "title": "A multi-center, randomized, double-blind, placebo-controlled Phase IIa trial to compare the safety of ABX464 given at a fixed dose to placebo in fully controlled HIV infected patients treated with ... - ES",
        "timestamp": "2016-05-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-004195-30/FR",
        "title": "A multi-center, randomized, double-blind, placebo-controlled Phase IIa trial to compare the safety of ABX464 given at a fixed dose to placebo in fully controlled HIV infected patients treated with ... - FR",
        "timestamp": "2016-05-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005762-38/ES",
        "title": "A Randomized, Open-Label Study to Evaluate the\nSafety and Efficacy of Coadministration of ABT-450\nwith Ritonavir (ABT-450/r) and ABT-267 in Adults\nwith Chronic Hepatitis C Virus Infection (PEARL-I) - ES",
        "timestamp": "2012-05-31"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005762-38/HU",
        "title": "A Randomized, Open-Label Study to Evaluate the\nSafety and Efficacy of Coadministration of ABT-450\nwith Ritonavir (ABT-450/r) and ABT-267 in Adults\nwith Chronic Hepatitis C Virus Infection (PEARL-I) - HU",
        "timestamp": "2012-05-31"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005762-38/IT",
        "title": "A Randomized, Open-Label Study to Evaluate the\nSafety and Efficacy of Coadministration of ABT-450\nwith Ritonavir (ABT-450/r) and ABT-267 in Adults\nwith Chronic Hepatitis C Virus Infection (PEARL-I) - IT",
        "timestamp": "2012-05-31"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005762-38/results",
        "title": "A Randomized, Open-Label Study to Evaluate the\nSafety and Efficacy of Coadministration of ABT-450\nwith Ritonavir (ABT-450/r) and ABT-267 in Adults\nwith Chronic Hepatitis C Virus Infection (PEARL-I) - View results",
        "timestamp": "2012-05-31"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-006076-38/GB",
        "title": "The Liverpool HIV TDM Registry: Studying influences upon plasma HIV drug exposure - GB",
        "timestamp": "2007-04-26"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-003584-45/ES",
        "title": "Estudio piloto de simplificación a Fosamprenavir/ritonavir (FPV/r) en monoterapia - ES",
        "timestamp": "2007-09-27"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-004519-67/ES",
        "title": "ENSAYO CLÍNICO PROSPECTIVO, ABIERTO Y ALEATORIZADO, SOBRE LA SEGURIDAD HEPÁTICA DEL TRATAMIENTO ANTIRRETROVIRAL QUE INCLUYE KALETRA VS NEVIRAPINA EN PACIENTES COINFECTADOS VIH/VHC. ESTUDIO KANELA. - ES",
        "timestamp": "2008-01-22"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-022455-31/GB",
        "title": "A Randomized, Open-Label, Multicenter Study to Evaluate the Antiviral Activity, Safety, and Pharmacokinetics, of ABT-450 with Ritonavir (ABT 450/r) in Combination with ABT-267 and/or ABT 333 With a... - GB",
        "timestamp": "2011-12-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-022455-31/ES",
        "title": "A Randomized, Open-Label, Multicenter Study to Evaluate the Antiviral Activity, Safety, and Pharmacokinetics, of ABT-450 with Ritonavir (ABT 450/r) in Combination with ABT-267 and/or ABT 333 With a... - ES",
        "timestamp": "2011-12-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-022455-31/results",
        "title": "A Randomized, Open-Label, Multicenter Study to Evaluate the Antiviral Activity, Safety, and Pharmacokinetics, of ABT-450 with Ritonavir (ABT 450/r) in Combination with ABT-267 and/or ABT 333 With a... - View results",
        "timestamp": "2011-12-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-001440-18/NL",
        "title": "Pharmacokinetic interactions between ivacaftor and cytochrome P450 3A4 inhibitors in cystic fibrosis patients and healthy controls - NL",
        "timestamp": "2018-05-30"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-003425-81/GB",
        "title": "Host genetic factors influencing drug disposition and response to HIV treatment - GB",
        "timestamp": "2007-03-29"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-000786-35/IT",
        "title": "A phase III, open-label, randomized, comparative study of the antiviral efficacy of ARV therapy with Lopinavir/Ritonavir (LPV/r - Kaletra) in combination with Tenofovir versus SOC (Kaletra in combi... - IT",
        "timestamp": "2004-11-02"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-000786-35/results",
        "title": "A phase III, open-label, randomized, comparative study of the antiviral efficacy of ARV therapy with Lopinavir/Ritonavir (LPV/r - Kaletra) in combination with Tenofovir versus SOC (Kaletra in combi... - View results",
        "timestamp": "2004-11-02"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-002698-29/ES",
        "title": "Efectos del tratamiento inicial con 2 pautas antirretrovirales estándares actuales sobre el metabolismo lipídico - ES",
        "timestamp": "2007-07-31"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-001658-10/GB",
        "title": "An open-label trial of TMC125 in HIV-1 infected subjects who were randomized in any sponsor selected TMC125 trial to an active control arm and either virologically failed or completed the entire tr... - GB",
        "timestamp": "2005-06-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-001658-10/BE",
        "title": "An open-label trial of TMC125 in HIV-1 infected subjects who were randomized in any sponsor selected TMC125 trial to an active control arm and either virologically failed or completed the entire tr... - BE",
        "timestamp": "2005-06-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-001658-10/IT",
        "title": "An open-label trial of TMC125 in HIV-1 infected subjects who were randomized in any sponsor selected TMC125 trial to an active control arm and either virologically failed or completed the entire tr... - IT",
        "timestamp": "2005-06-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-001658-10/PT",
        "title": "An open-label trial of TMC125 in HIV-1 infected subjects who were randomized in any sponsor selected TMC125 trial to an active control arm and either virologically failed or completed the entire tr... - PT",
        "timestamp": "2005-06-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-001658-10/ES",
        "title": "An open-label trial of TMC125 in HIV-1 infected subjects who were randomized in any sponsor selected TMC125 trial to an active control arm and either virologically failed or completed the entire tr... - ES",
        "timestamp": "2005-06-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-001658-10/results",
        "title": "An open-label trial of TMC125 in HIV-1 infected subjects who were randomized in any sponsor selected TMC125 trial to an active control arm and either virologically failed or completed the entire tr... - View results",
        "timestamp": "2005-06-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-016759-22/DE",
        "title": "A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of \r\nGS-9350-boosted Atazanavir Versus Ritonavir-boosted Atazanavir Each Administered with Emtricitabine/Tenofovir Diso... - DE",
        "timestamp": "2010-06-28"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-016759-22/BE",
        "title": "A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of \r\nGS-9350-boosted Atazanavir Versus Ritonavir-boosted Atazanavir Each Administered with Emtricitabine/Tenofovir Diso... - BE",
        "timestamp": "2010-06-28"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-016759-22/NL",
        "title": "A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of \r\nGS-9350-boosted Atazanavir Versus Ritonavir-boosted Atazanavir Each Administered with Emtricitabine/Tenofovir Diso... - NL",
        "timestamp": "2010-06-28"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-016759-22/FR",
        "title": "A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of \r\nGS-9350-boosted Atazanavir Versus Ritonavir-boosted Atazanavir Each Administered with Emtricitabine/Tenofovir Diso... - FR",
        "timestamp": "2010-06-28"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-016759-22/PT",
        "title": "A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of \r\nGS-9350-boosted Atazanavir Versus Ritonavir-boosted Atazanavir Each Administered with Emtricitabine/Tenofovir Diso... - PT",
        "timestamp": "2010-06-28"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-016759-22/GB",
        "title": "A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of \r\nGS-9350-boosted Atazanavir Versus Ritonavir-boosted Atazanavir Each Administered with Emtricitabine/Tenofovir Diso... - GB",
        "timestamp": "2010-06-28"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-016759-22/AT",
        "title": "A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of \r\nGS-9350-boosted Atazanavir Versus Ritonavir-boosted Atazanavir Each Administered with Emtricitabine/Tenofovir Diso... - AT",
        "timestamp": "2010-06-28"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-016759-22/ES",
        "title": "A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of \r\nGS-9350-boosted Atazanavir Versus Ritonavir-boosted Atazanavir Each Administered with Emtricitabine/Tenofovir Diso... - ES",
        "timestamp": "2010-06-28"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-016759-22/DK",
        "title": "A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of \r\nGS-9350-boosted Atazanavir Versus Ritonavir-boosted Atazanavir Each Administered with Emtricitabine/Tenofovir Diso... - DK",
        "timestamp": "2010-06-28"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-016759-22/IT",
        "title": "A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of \r\nGS-9350-boosted Atazanavir Versus Ritonavir-boosted Atazanavir Each Administered with Emtricitabine/Tenofovir Diso... - IT",
        "timestamp": "2010-06-28"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-016759-22/SE",
        "title": "A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of \r\nGS-9350-boosted Atazanavir Versus Ritonavir-boosted Atazanavir Each Administered with Emtricitabine/Tenofovir Diso... - SE",
        "timestamp": "2010-06-28"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-016759-22/results",
        "title": "A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of \r\nGS-9350-boosted Atazanavir Versus Ritonavir-boosted Atazanavir Each Administered with Emtricitabine/Tenofovir Diso... - View results",
        "timestamp": "2010-06-28"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-001866-15/FR",
        "title": "A prospective randomized, open-labelled, multi-centre trial comparing the safety and efficacy of Ritonavir-boosted Aptivus (Tipranavir, TPV/r) to that of Prezista® (Darunavir, DRV/r) in  three-clas... - FR",
        "timestamp": "2007-07-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-001866-15/ES",
        "title": "A prospective randomized, open-labelled, multi-centre trial comparing the safety and efficacy of Ritonavir-boosted Aptivus (Tipranavir, TPV/r) to that of Prezista® (Darunavir, DRV/r) in  three-clas... - ES",
        "timestamp": "2007-07-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-001866-15/DE",
        "title": "A prospective randomized, open-labelled, multi-centre trial comparing the safety and efficacy of Ritonavir-boosted Aptivus (Tipranavir, TPV/r) to that of Prezista® (Darunavir, DRV/r) in  three-clas... - DE",
        "timestamp": "2007-07-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-001866-15/GR",
        "title": "A prospective randomized, open-labelled, multi-centre trial comparing the safety and efficacy of Ritonavir-boosted Aptivus (Tipranavir, TPV/r) to that of Prezista® (Darunavir, DRV/r) in  three-clas... - GR",
        "timestamp": "2007-07-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-001866-15/PT",
        "title": "A prospective randomized, open-labelled, multi-centre trial comparing the safety and efficacy of Ritonavir-boosted Aptivus (Tipranavir, TPV/r) to that of Prezista® (Darunavir, DRV/r) in  three-clas... - PT",
        "timestamp": "2007-07-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-001866-15/IT",
        "title": "A prospective randomized, open-labelled, multi-centre trial comparing the safety and efficacy of Ritonavir-boosted Aptivus (Tipranavir, TPV/r) to that of Prezista® (Darunavir, DRV/r) in  three-clas... - IT",
        "timestamp": "2007-07-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-001866-15/BE",
        "title": "A prospective randomized, open-labelled, multi-centre trial comparing the safety and efficacy of Ritonavir-boosted Aptivus (Tipranavir, TPV/r) to that of Prezista® (Darunavir, DRV/r) in  three-clas... - BE",
        "timestamp": "2007-07-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-001866-15/results",
        "title": "A prospective randomized, open-labelled, multi-centre trial comparing the safety and efficacy of Ritonavir-boosted Aptivus (Tipranavir, TPV/r) to that of Prezista® (Darunavir, DRV/r) in  three-clas... - View results",
        "timestamp": "2007-07-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-005823-34/GB",
        "title": "A Phase IIIb, randomized, open-label study of the safety and\r\nefficacy of dolutegravir/abacavir/lamivudine once daily compared to atazanavir and ritonavir plus tenofovir/emtricitabine once daily in... - GB",
        "timestamp": "2013-10-11"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-005823-34/IT",
        "title": "A Phase IIIb, randomized, open-label study of the safety and\r\nefficacy of dolutegravir/abacavir/lamivudine once daily compared to atazanavir and ritonavir plus tenofovir/emtricitabine once daily in... - IT",
        "timestamp": "2013-10-11"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-005823-34/ES",
        "title": "A Phase IIIb, randomized, open-label study of the safety and\r\nefficacy of dolutegravir/abacavir/lamivudine once daily compared to atazanavir and ritonavir plus tenofovir/emtricitabine once daily in... - ES",
        "timestamp": "2013-10-11"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-005823-34/PT",
        "title": "A Phase IIIb, randomized, open-label study of the safety and\r\nefficacy of dolutegravir/abacavir/lamivudine once daily compared to atazanavir and ritonavir plus tenofovir/emtricitabine once daily in... - PT",
        "timestamp": "2013-10-11"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-005823-34/FR",
        "title": "A Phase IIIb, randomized, open-label study of the safety and\r\nefficacy of dolutegravir/abacavir/lamivudine once daily compared to atazanavir and ritonavir plus tenofovir/emtricitabine once daily in... - FR",
        "timestamp": "2013-10-11"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-005823-34/results",
        "title": "A Phase IIIb, randomized, open-label study of the safety and\r\nefficacy of dolutegravir/abacavir/lamivudine once daily compared to atazanavir and ritonavir plus tenofovir/emtricitabine once daily in... - View results",
        "timestamp": "2013-10-11"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-002694-13/ES",
        "title": "Estudio piloto, fase IV para analizar la seguridad de los combos Truvada vs Kivexa como parte de un TARGA basado en Kaletra. Estudio COMBOKA - ES",
        "timestamp": "2009-06-18"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-004129-28/SK",
        "title": "Study To Evaluate Safety, Tolerability, Pharmacokinetics and Antiviral Activity of Ritonavir-Boosted DANOPREVIR in Combination With Peginterferon Alfa-2a Plus Ribavirin in Treatment-naive Patients ... - SK",
        "timestamp": "2012-01-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-004129-28/results",
        "title": "Study To Evaluate Safety, Tolerability, Pharmacokinetics and Antiviral Activity of Ritonavir-Boosted DANOPREVIR in Combination With Peginterferon Alfa-2a Plus Ribavirin in Treatment-naive Patients ... - View results",
        "timestamp": "2012-01-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-005256-33/ES",
        "title": "Ensayo clínico multicéntrico, aleatorizado y abierto para evaluar tres dosis de Tipranavir potenciado con dosis bajas de ritonavir (500mg/200mg una vez al día, 250mg/100 mg dos veces al día y 500 m... - ES",
        "timestamp": "2007-09-14"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-005256-33/DE",
        "title": "Ensayo clínico multicéntrico, aleatorizado y abierto para evaluar tres dosis de Tipranavir potenciado con dosis bajas de ritonavir (500mg/200mg una vez al día, 250mg/100 mg dos veces al día y 500 m... - DE",
        "timestamp": "2007-09-14"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-005256-33/IT",
        "title": "Ensayo clínico multicéntrico, aleatorizado y abierto para evaluar tres dosis de Tipranavir potenciado con dosis bajas de ritonavir (500mg/200mg una vez al día, 250mg/100 mg dos veces al día y 500 m... - IT",
        "timestamp": "2007-09-14"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-005256-33/results",
        "title": "Ensayo clínico multicéntrico, aleatorizado y abierto para evaluar tres dosis de Tipranavir potenciado con dosis bajas de ritonavir (500mg/200mg una vez al día, 250mg/100 mg dos veces al día y 500 m... - View results",
        "timestamp": "2007-09-14"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-002818-38/IT",
        "title": "ESPrES 500 - Evaluation of the safety profile of the new 500 mg film-coated tablet (FCT) formulation of boosted saquinavir (Invirase 500 mg)  in  HIV-1 infected patients - IT",
        "timestamp": "2005-07-21"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-002818-38/results",
        "title": "ESPrES 500 - Evaluation of the safety profile of the new 500 mg film-coated tablet (FCT) formulation of boosted saquinavir (Invirase 500 mg)  in  HIV-1 infected patients - View results",
        "timestamp": "2005-07-21"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003754-84/HU",
        "title": "A Randomized, Open-Label Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT-267 and ABT-333 Co-administered with and without Ribavirin Compared to Telaprevir Co-administered with Pe... - HU",
        "timestamp": "2013-04-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003754-84/FI",
        "title": "A Randomized, Open-Label Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT-267 and ABT-333 Co-administered with and without Ribavirin Compared to Telaprevir Co-administered with Pe... - FI",
        "timestamp": "2013-04-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003754-84/SK",
        "title": "A Randomized, Open-Label Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT-267 and ABT-333 Co-administered with and without Ribavirin Compared to Telaprevir Co-administered with Pe... - SK",
        "timestamp": "2013-04-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003754-84/PL",
        "title": "A Randomized, Open-Label Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT-267 and ABT-333 Co-administered with and without Ribavirin Compared to Telaprevir Co-administered with Pe... - PL",
        "timestamp": "2013-04-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003754-84/results",
        "title": "A Randomized, Open-Label Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT-267 and ABT-333 Co-administered with and without Ribavirin Compared to Telaprevir Co-administered with Pe... - View results",
        "timestamp": "2013-04-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-010611-33/ES",
        "title": "Ensayo clínico para evaluar el efecto sobre la grasa subcutánea del cambio de EFV por LPV/r en pacientes infectados por VIH que desarrollaron lipoatrofia que sigue siendo clínicamente evidente a pe... - ES",
        "timestamp": "2009-09-28"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005270-35/IT",
        "title": "HIV-infected pregnant women treated with HAART: registry of pharmacokinetic  parameters of new and commonly used antiretrovirals - IT",
        "timestamp": "2011-12-07"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-001303-13/DE",
        "title": "HIV postexposure prophylaxis with Darunavir/r (PEPDar) - DE",
        "timestamp": "2011-07-26"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-001303-13/results",
        "title": "HIV postexposure prophylaxis with Darunavir/r (PEPDar) - View results",
        "timestamp": "2011-07-26"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-005522-29/GB",
        "title": "A Randomized, Double-Blind, Controlled Study to Evaluate the Efficacy and Safety of the Combination of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With and Without Ribavirin (RBV) in ... - GB",
        "timestamp": "2013-04-17"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-005522-29/results",
        "title": "A Randomized, Double-Blind, Controlled Study to Evaluate the Efficacy and Safety of the Combination of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With and Without Ribavirin (RBV) in ... - View results",
        "timestamp": "2013-04-17"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003738-18/HU",
        "title": "A Randomized, Open-Labeled Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT-267 and ABT-333 Co-administered with Ribavirin Compared to Telaprevir Co-administered with Pegylated In... - HU",
        "timestamp": "2013-04-26"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003738-18/FI",
        "title": "A Randomized, Open-Labeled Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT-267 and ABT-333 Co-administered with Ribavirin Compared to Telaprevir Co-administered with Pegylated In... - FI",
        "timestamp": "2013-04-26"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003738-18/SK",
        "title": "A Randomized, Open-Labeled Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT-267 and ABT-333 Co-administered with Ribavirin Compared to Telaprevir Co-administered with Pegylated In... - SK",
        "timestamp": "2013-04-26"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003738-18/PL",
        "title": "A Randomized, Open-Labeled Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT-267 and ABT-333 Co-administered with Ribavirin Compared to Telaprevir Co-administered with Pegylated In... - PL",
        "timestamp": "2013-04-26"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003738-18/results",
        "title": "A Randomized, Open-Labeled Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT-267 and ABT-333 Co-administered with Ribavirin Compared to Telaprevir Co-administered with Pegylated In... - View results",
        "timestamp": "2013-04-26"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-003447-21/GB",
        "title": "Randomised controlled trial of the tolerability and completion of maraviroc compared to Kaletra© in combination with Truvada© for HIV post-exposure prophylaxis - GB",
        "timestamp": "2011-12-15"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-003447-21/results",
        "title": "Randomised controlled trial of the tolerability and completion of maraviroc compared to Kaletra© in combination with Truvada© for HIV post-exposure prophylaxis - View results",
        "timestamp": "2011-12-15"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-014742-28/FR",
        "title": "Essai randomisé multicentrique de phase III évaluant chez des patients en primo-infection VIH-1 l’impact sur les réservoirs (par quantification de l’ADN-VIH-1 dans les PBMC) d’une combinaison compr... - FR",
        "timestamp": "2009-11-18"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-004820-24/ES",
        "title": "Cost-effectiveness of different  antiretroviral treatment in patients HIV naive. Randomized clinical, not masked, trial comparing DRVr3TC, ABC3TC (Kivexa) RPV, or EVG COBI FTC TDF (Stribild) for 48... - ES",
        "timestamp": "2015-06-02"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-001478-32/FR",
        "title": "An Exploratory Study to Evaluate the Kinetics of Viral Load Decline with Ombitasvir/ABT-450/Ritonavir (Ombitasvir/ABT-450/r) and Dasabuvir Therapy with Low Dose Ribavirin (RBV), Full Dose RBV or RB... - FR",
        "timestamp": "2015-01-07"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-001478-32/results",
        "title": "An Exploratory Study to Evaluate the Kinetics of Viral Load Decline with Ombitasvir/ABT-450/Ritonavir (Ombitasvir/ABT-450/r) and Dasabuvir Therapy with Low Dose Ribavirin (RBV), Full Dose RBV or RB... - View results",
        "timestamp": "2015-01-07"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-023503-10/ES",
        "title": "Ensayo clínico piloto, abierto, controlado y aleatorizado para evaluar la actividad de fosamprenavir frente al virus de la hepatitis C (VHC) genotipo 1 en pacientes coinfectados por el virus de la ... - ES",
        "timestamp": "2011-01-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-007935-14/IT",
        "title": "RIFART - IT",
        "timestamp": "2005-03-15"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-006200-11/FR",
        "title": "Prévention de la transmission du VIH-1 de la mère à l’enfant sans utilisation d’analogue nucléosidique - FR",
        "timestamp": "2007-03-09"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-002019-25/SE",
        "title": "A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 Co-administered with Ribavirin (RBV) in Treatme... - SE",
        "timestamp": "2013-03-13"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-002019-25/GB",
        "title": "A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 Co-administered with Ribavirin (RBV) in Treatme... - GB",
        "timestamp": "2013-03-13"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-002019-25/HU",
        "title": "A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 Co-administered with Ribavirin (RBV) in Treatme... - HU",
        "timestamp": "2013-03-13"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-002019-25/DE",
        "title": "A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 Co-administered with Ribavirin (RBV) in Treatme... - DE",
        "timestamp": "2013-03-13"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-002019-25/AT",
        "title": "A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 Co-administered with Ribavirin (RBV) in Treatme... - AT",
        "timestamp": "2013-03-13"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-002019-25/IT",
        "title": "A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 Co-administered with Ribavirin (RBV) in Treatme... - IT",
        "timestamp": "2013-03-13"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-002019-25/ES",
        "title": "A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 Co-administered with Ribavirin (RBV) in Treatme... - ES",
        "timestamp": "2013-03-13"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-002019-25/results",
        "title": "A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 Co-administered with Ribavirin (RBV) in Treatme... - View results",
        "timestamp": "2013-03-13"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-006437-40/BE",
        "title": "A randomised, controlled, opel-label trial to compare the efficacy, safety and tolerability of a treatment simplification by darunavir/ritonavir (DRV/r) 800/100 mg O.D. versus a triple combination ... - BE",
        "timestamp": "2007-02-05"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-006437-40/GB",
        "title": "A randomised, controlled, opel-label trial to compare the efficacy, safety and tolerability of a treatment simplification by darunavir/ritonavir (DRV/r) 800/100 mg O.D. versus a triple combination ... - GB",
        "timestamp": "2007-02-05"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-006437-40/HU",
        "title": "A randomised, controlled, opel-label trial to compare the efficacy, safety and tolerability of a treatment simplification by darunavir/ritonavir (DRV/r) 800/100 mg O.D. versus a triple combination ... - HU",
        "timestamp": "2007-02-05"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-006437-40/DK",
        "title": "A randomised, controlled, opel-label trial to compare the efficacy, safety and tolerability of a treatment simplification by darunavir/ritonavir (DRV/r) 800/100 mg O.D. versus a triple combination ... - DK",
        "timestamp": "2007-02-05"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-006437-40/DE",
        "title": "A randomised, controlled, opel-label trial to compare the efficacy, safety and tolerability of a treatment simplification by darunavir/ritonavir (DRV/r) 800/100 mg O.D. versus a triple combination ... - DE",
        "timestamp": "2007-02-05"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-006437-40/PT",
        "title": "A randomised, controlled, opel-label trial to compare the efficacy, safety and tolerability of a treatment simplification by darunavir/ritonavir (DRV/r) 800/100 mg O.D. versus a triple combination ... - PT",
        "timestamp": "2007-02-05"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-006437-40/ES",
        "title": "A randomised, controlled, opel-label trial to compare the efficacy, safety and tolerability of a treatment simplification by darunavir/ritonavir (DRV/r) 800/100 mg O.D. versus a triple combination ... - ES",
        "timestamp": "2007-02-05"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-006437-40/AT",
        "title": "A randomised, controlled, opel-label trial to compare the efficacy, safety and tolerability of a treatment simplification by darunavir/ritonavir (DRV/r) 800/100 mg O.D. versus a triple combination ... - AT",
        "timestamp": "2007-02-05"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-006437-40/IT",
        "title": "A randomised, controlled, opel-label trial to compare the efficacy, safety and tolerability of a treatment simplification by darunavir/ritonavir (DRV/r) 800/100 mg O.D. versus a triple combination ... - IT",
        "timestamp": "2007-02-05"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-006437-40/results",
        "title": "A randomised, controlled, opel-label trial to compare the efficacy, safety and tolerability of a treatment simplification by darunavir/ritonavir (DRV/r) 800/100 mg O.D. versus a triple combination ... - View results",
        "timestamp": "2007-02-05"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-022120-72/GB",
        "title": "The metabolic impact of Darunavir/ritonavir maintenance monotherapy after successful viral suppression with standard Atripla in HIV-1-infected patients (MIDAs). - GB",
        "timestamp": "2010-12-17"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-022120-72/results",
        "title": "The metabolic impact of Darunavir/ritonavir maintenance monotherapy after successful viral suppression with standard Atripla in HIV-1-infected patients (MIDAs). - View results",
        "timestamp": "2010-12-17"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-023178-37/GB",
        "title": "A Phase 3 Randomized, Open Label Study to Evaluate Switching from Regimens Consisting of a Ritonavir-boosted Protease Inhibitor and Two Nucleoside Reverse Transcriptase Inhibitors to Emtricitabine/... - GB",
        "timestamp": "2011-02-04"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-023178-37/DE",
        "title": "A Phase 3 Randomized, Open Label Study to Evaluate Switching from Regimens Consisting of a Ritonavir-boosted Protease Inhibitor and Two Nucleoside Reverse Transcriptase Inhibitors to Emtricitabine/... - DE",
        "timestamp": "2011-02-04"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-023178-37/ES",
        "title": "A Phase 3 Randomized, Open Label Study to Evaluate Switching from Regimens Consisting of a Ritonavir-boosted Protease Inhibitor and Two Nucleoside Reverse Transcriptase Inhibitors to Emtricitabine/... - ES",
        "timestamp": "2011-02-04"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-023178-37/BE",
        "title": "A Phase 3 Randomized, Open Label Study to Evaluate Switching from Regimens Consisting of a Ritonavir-boosted Protease Inhibitor and Two Nucleoside Reverse Transcriptase Inhibitors to Emtricitabine/... - BE",
        "timestamp": "2011-02-04"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-023178-37/IT",
        "title": "A Phase 3 Randomized, Open Label Study to Evaluate Switching from Regimens Consisting of a Ritonavir-boosted Protease Inhibitor and Two Nucleoside Reverse Transcriptase Inhibitors to Emtricitabine/... - IT",
        "timestamp": "2011-02-04"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-023178-37/AT",
        "title": "A Phase 3 Randomized, Open Label Study to Evaluate Switching from Regimens Consisting of a Ritonavir-boosted Protease Inhibitor and Two Nucleoside Reverse Transcriptase Inhibitors to Emtricitabine/... - AT",
        "timestamp": "2011-02-04"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-023178-37/results",
        "title": "A Phase 3 Randomized, Open Label Study to Evaluate Switching from Regimens Consisting of a Ritonavir-boosted Protease Inhibitor and Two Nucleoside Reverse Transcriptase Inhibitors to Emtricitabine/... - View results",
        "timestamp": "2011-02-04"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-001150-24/GB",
        "title": "A Phase IIB, Randomized, Multicenter, Parallel Group Study to Evaluate the Short-Term Safety, Pharmacokinetics and Antiviral Activity of Four Blinded Dosing Regimens of GW640385/Ritonavir Therapy C... - GB",
        "timestamp": "2005-07-28"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-001150-24/DE",
        "title": "A Phase IIB, Randomized, Multicenter, Parallel Group Study to Evaluate the Short-Term Safety, Pharmacokinetics and Antiviral Activity of Four Blinded Dosing Regimens of GW640385/Ritonavir Therapy C... - DE",
        "timestamp": "2005-07-28"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-001150-24/IT",
        "title": "A Phase IIB, Randomized, Multicenter, Parallel Group Study to Evaluate the Short-Term Safety, Pharmacokinetics and Antiviral Activity of Four Blinded Dosing Regimens of GW640385/Ritonavir Therapy C... - IT",
        "timestamp": "2005-07-28"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-001150-24/PT",
        "title": "A Phase IIB, Randomized, Multicenter, Parallel Group Study to Evaluate the Short-Term Safety, Pharmacokinetics and Antiviral Activity of Four Blinded Dosing Regimens of GW640385/Ritonavir Therapy C... - PT",
        "timestamp": "2005-07-28"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-001150-24/results",
        "title": "A Phase IIB, Randomized, Multicenter, Parallel Group Study to Evaluate the Short-Term Safety, Pharmacokinetics and Antiviral Activity of Four Blinded Dosing Regimens of GW640385/Ritonavir Therapy C... - View results",
        "timestamp": "2005-07-28"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-006417-32/FR",
        "title": "Vicriviroc in Combination Treatment with an Optimized ART Regimen in HIV-Infected Treatment-Experienced Subjects (VICTOR-E4) - FR",
        "timestamp": "2008-02-06"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-006417-32/ES",
        "title": "Vicriviroc in Combination Treatment with an Optimized ART Regimen in HIV-Infected Treatment-Experienced Subjects (VICTOR-E4) - ES",
        "timestamp": "2008-02-06"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-006417-32/DE",
        "title": "Vicriviroc in Combination Treatment with an Optimized ART Regimen in HIV-Infected Treatment-Experienced Subjects (VICTOR-E4) - DE",
        "timestamp": "2008-02-06"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-006417-32/PT",
        "title": "Vicriviroc in Combination Treatment with an Optimized ART Regimen in HIV-Infected Treatment-Experienced Subjects (VICTOR-E4) - PT",
        "timestamp": "2008-02-06"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-006417-32/IT",
        "title": "Vicriviroc in Combination Treatment with an Optimized ART Regimen in HIV-Infected Treatment-Experienced Subjects (VICTOR-E4) - IT",
        "timestamp": "2008-02-06"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-006417-32/GB",
        "title": "Vicriviroc in Combination Treatment with an Optimized ART Regimen in HIV-Infected Treatment-Experienced Subjects (VICTOR-E4) - GB",
        "timestamp": "2008-02-06"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-006417-32/results",
        "title": "Vicriviroc in Combination Treatment with an Optimized ART Regimen in HIV-Infected Treatment-Experienced Subjects (VICTOR-E4) - View results",
        "timestamp": "2008-02-06"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-001022-14/PT",
        "title": "An Open-Label, Multicenter Study to Evaluate Long-Term Outcomes with ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepa... - PT",
        "timestamp": "2014-09-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-001022-14/GB",
        "title": "An Open-Label, Multicenter Study to Evaluate Long-Term Outcomes with ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepa... - GB",
        "timestamp": "2014-09-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-001022-14/IE",
        "title": "An Open-Label, Multicenter Study to Evaluate Long-Term Outcomes with ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepa... - IE",
        "timestamp": "2014-09-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-001022-14/AT",
        "title": "An Open-Label, Multicenter Study to Evaluate Long-Term Outcomes with ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepa... - AT",
        "timestamp": "2014-09-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-001022-14/ES",
        "title": "An Open-Label, Multicenter Study to Evaluate Long-Term Outcomes with ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepa... - ES",
        "timestamp": "2014-09-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-001022-14/IT",
        "title": "An Open-Label, Multicenter Study to Evaluate Long-Term Outcomes with ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepa... - IT",
        "timestamp": "2014-09-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-001022-14/SE",
        "title": "An Open-Label, Multicenter Study to Evaluate Long-Term Outcomes with ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepa... - SE",
        "timestamp": "2014-09-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-001022-14/BE",
        "title": "An Open-Label, Multicenter Study to Evaluate Long-Term Outcomes with ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepa... - BE",
        "timestamp": "2014-09-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-001022-14/FI",
        "title": "An Open-Label, Multicenter Study to Evaluate Long-Term Outcomes with ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepa... - FI",
        "timestamp": "2014-09-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-001022-14/NL",
        "title": "An Open-Label, Multicenter Study to Evaluate Long-Term Outcomes with ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepa... - NL",
        "timestamp": "2014-09-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-001022-14/BG",
        "title": "An Open-Label, Multicenter Study to Evaluate Long-Term Outcomes with ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepa... - BG",
        "timestamp": "2014-09-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-001022-14/PL",
        "title": "An Open-Label, Multicenter Study to Evaluate Long-Term Outcomes with ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepa... - PL",
        "timestamp": "2014-09-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-001022-14/DK",
        "title": "An Open-Label, Multicenter Study to Evaluate Long-Term Outcomes with ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepa... - DK",
        "timestamp": "2014-09-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-001022-14/GR",
        "title": "An Open-Label, Multicenter Study to Evaluate Long-Term Outcomes with ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepa... - GR",
        "timestamp": "2014-09-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-002437-13/LT",
        "title": "Early access of TMC114 in combination with low-dose ritonavir (RTV) and other antiretrovirals (ARVs) in highly treatment experienced HIV-1 infected subjects with limited to no treatment options. - LT",
        "timestamp": "2006-05-09"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-002437-13/IT",
        "title": "Early access of TMC114 in combination with low-dose ritonavir (RTV) and other antiretrovirals (ARVs) in highly treatment experienced HIV-1 infected subjects with limited to no treatment options. - IT",
        "timestamp": "2006-05-09"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-002437-13/results",
        "title": "Early access of TMC114 in combination with low-dose ritonavir (RTV) and other antiretrovirals (ARVs) in highly treatment experienced HIV-1 infected subjects with limited to no treatment options. - View results",
        "timestamp": "2006-05-09"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005740-95/SE",
        "title": "A Randomized, Open-Label, Multicenter Study to Evaluate the Safety and Antiviral Activity of the Combination of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With and Without Ribavirin ... - SE",
        "timestamp": "2012-08-22"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005740-95/AT",
        "title": "A Randomized, Open-Label, Multicenter Study to Evaluate the Safety and Antiviral Activity of the Combination of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With and Without Ribavirin ... - AT",
        "timestamp": "2012-08-22"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005740-95/BE",
        "title": "A Randomized, Open-Label, Multicenter Study to Evaluate the Safety and Antiviral Activity of the Combination of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With and Without Ribavirin ... - BE",
        "timestamp": "2012-08-22"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005740-95/NL",
        "title": "A Randomized, Open-Label, Multicenter Study to Evaluate the Safety and Antiviral Activity of the Combination of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With and Without Ribavirin ... - NL",
        "timestamp": "2012-08-22"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005740-95/IT",
        "title": "A Randomized, Open-Label, Multicenter Study to Evaluate the Safety and Antiviral Activity of the Combination of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With and Without Ribavirin ... - IT",
        "timestamp": "2012-08-22"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005740-95/PT",
        "title": "A Randomized, Open-Label, Multicenter Study to Evaluate the Safety and Antiviral Activity of the Combination of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With and Without Ribavirin ... - PT",
        "timestamp": "2012-08-22"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005740-95/results",
        "title": "A Randomized, Open-Label, Multicenter Study to Evaluate the Safety and Antiviral Activity of the Combination of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With and Without Ribavirin ... - View results",
        "timestamp": "2012-08-22"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-002740-10/GB",
        "title": "A PHASE IV, OPEN-LABEL, RANDOMIZED, MULTICENTER TRIAL ASSESSING A REYATAZ-BASED SUBSTITUTION APPROACH IN THE MANAGEMENT OF LIPODYSTROPHY SYNDROME.  \nPharmacogenetics Blood Sample Amendment 01, vers... - GB",
        "timestamp": "2005-05-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-002740-10/DE",
        "title": "A PHASE IV, OPEN-LABEL, RANDOMIZED, MULTICENTER TRIAL ASSESSING A REYATAZ-BASED SUBSTITUTION APPROACH IN THE MANAGEMENT OF LIPODYSTROPHY SYNDROME.  \nPharmacogenetics Blood Sample Amendment 01, vers... - DE",
        "timestamp": "2005-05-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-002740-10/IT",
        "title": "A PHASE IV, OPEN-LABEL, RANDOMIZED, MULTICENTER TRIAL ASSESSING A REYATAZ-BASED SUBSTITUTION APPROACH IN THE MANAGEMENT OF LIPODYSTROPHY SYNDROME.  \nPharmacogenetics Blood Sample Amendment 01, vers... - IT",
        "timestamp": "2005-05-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-002740-10/ES",
        "title": "A PHASE IV, OPEN-LABEL, RANDOMIZED, MULTICENTER TRIAL ASSESSING A REYATAZ-BASED SUBSTITUTION APPROACH IN THE MANAGEMENT OF LIPODYSTROPHY SYNDROME.  \nPharmacogenetics Blood Sample Amendment 01, vers... - ES",
        "timestamp": "2005-05-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-002740-10/results",
        "title": "A PHASE IV, OPEN-LABEL, RANDOMIZED, MULTICENTER TRIAL ASSESSING A REYATAZ-BASED SUBSTITUTION APPROACH IN THE MANAGEMENT OF LIPODYSTROPHY SYNDROME.  \nPharmacogenetics Blood Sample Amendment 01, vers... - View results",
        "timestamp": "2005-05-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-003052-31/BE",
        "title": "A Phase 3, randomized, active-controlled, open-label study to evaluate the efficacy, safety and tolerability of switching to a darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) o... - BE",
        "timestamp": "2015-02-17"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-003052-31/SE",
        "title": "A Phase 3, randomized, active-controlled, open-label study to evaluate the efficacy, safety and tolerability of switching to a darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) o... - SE",
        "timestamp": "2015-02-17"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-003052-31/GB",
        "title": "A Phase 3, randomized, active-controlled, open-label study to evaluate the efficacy, safety and tolerability of switching to a darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) o... - GB",
        "timestamp": "2015-02-17"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-003052-31/ES",
        "title": "A Phase 3, randomized, active-controlled, open-label study to evaluate the efficacy, safety and tolerability of switching to a darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) o... - ES",
        "timestamp": "2015-02-17"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-003052-31/PL",
        "title": "A Phase 3, randomized, active-controlled, open-label study to evaluate the efficacy, safety and tolerability of switching to a darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) o... - PL",
        "timestamp": "2015-02-17"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-003052-31/FR",
        "title": "A Phase 3, randomized, active-controlled, open-label study to evaluate the efficacy, safety and tolerability of switching to a darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) o... - FR",
        "timestamp": "2015-02-17"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-015113-44/ES",
        "title": "Ensayo abierto, aleatorizado, de dos años de duración, en el que se comparan dos regímenes de primera línea en sujetos infectados por el VIH que no han recibido tratamiento antirretroviral previo: ... - ES",
        "timestamp": "2010-05-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-015113-44/FR",
        "title": "Ensayo abierto, aleatorizado, de dos años de duración, en el que se comparan dos regímenes de primera línea en sujetos infectados por el VIH que no han recibido tratamiento antirretroviral previo: ... - FR",
        "timestamp": "2010-05-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-015113-44/SE",
        "title": "Ensayo abierto, aleatorizado, de dos años de duración, en el que se comparan dos regímenes de primera línea en sujetos infectados por el VIH que no han recibido tratamiento antirretroviral previo: ... - SE",
        "timestamp": "2010-05-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-015113-44/IE",
        "title": "Ensayo abierto, aleatorizado, de dos años de duración, en el que se comparan dos regímenes de primera línea en sujetos infectados por el VIH que no han recibido tratamiento antirretroviral previo: ... - IE",
        "timestamp": "2010-05-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-015113-44/DK",
        "title": "Ensayo abierto, aleatorizado, de dos años de duración, en el que se comparan dos regímenes de primera línea en sujetos infectados por el VIH que no han recibido tratamiento antirretroviral previo: ... - DK",
        "timestamp": "2010-05-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-015113-44/PT",
        "title": "Ensayo abierto, aleatorizado, de dos años de duración, en el que se comparan dos regímenes de primera línea en sujetos infectados por el VIH que no han recibido tratamiento antirretroviral previo: ... - PT",
        "timestamp": "2010-05-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-015113-44/AT",
        "title": "Ensayo abierto, aleatorizado, de dos años de duración, en el que se comparan dos regímenes de primera línea en sujetos infectados por el VIH que no han recibido tratamiento antirretroviral previo: ... - AT",
        "timestamp": "2010-05-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-015113-44/DE",
        "title": "Ensayo abierto, aleatorizado, de dos años de duración, en el que se comparan dos regímenes de primera línea en sujetos infectados por el VIH que no han recibido tratamiento antirretroviral previo: ... - DE",
        "timestamp": "2010-05-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-015113-44/GB",
        "title": "Ensayo abierto, aleatorizado, de dos años de duración, en el que se comparan dos regímenes de primera línea en sujetos infectados por el VIH que no han recibido tratamiento antirretroviral previo: ... - GB",
        "timestamp": "2010-05-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-015113-44/PL",
        "title": "Ensayo abierto, aleatorizado, de dos años de duración, en el que se comparan dos regímenes de primera línea en sujetos infectados por el VIH que no han recibido tratamiento antirretroviral previo: ... - PL",
        "timestamp": "2010-05-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-015113-44/IT",
        "title": "Ensayo abierto, aleatorizado, de dos años de duración, en el que se comparan dos regímenes de primera línea en sujetos infectados por el VIH que no han recibido tratamiento antirretroviral previo: ... - IT",
        "timestamp": "2010-05-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-015113-44/BE",
        "title": "Ensayo abierto, aleatorizado, de dos años de duración, en el que se comparan dos regímenes de primera línea en sujetos infectados por el VIH que no han recibido tratamiento antirretroviral previo: ... - BE",
        "timestamp": "2010-05-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-015113-44/NL",
        "title": "Ensayo abierto, aleatorizado, de dos años de duración, en el que se comparan dos regímenes de primera línea en sujetos infectados por el VIH que no han recibido tratamiento antirretroviral previo: ... - NL",
        "timestamp": "2010-05-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-015113-44/HU",
        "title": "Ensayo abierto, aleatorizado, de dos años de duración, en el que se comparan dos regímenes de primera línea en sujetos infectados por el VIH que no han recibido tratamiento antirretroviral previo: ... - HU",
        "timestamp": "2010-05-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-015113-44/GR",
        "title": "Ensayo abierto, aleatorizado, de dos años de duración, en el que se comparan dos regímenes de primera línea en sujetos infectados por el VIH que no han recibido tratamiento antirretroviral previo: ... - GR",
        "timestamp": "2010-05-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-006117-32/IT",
        "title": "Tipranavir/ritonavir 500/100 mg bid as a simplification strategy in HIV-1 infected subjects with an ongoing Tipranavir 500mg/Ritonavir 200mg bid regimen and undetectable viral load. - IT",
        "timestamp": "2007-02-05"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-002405-47/GB",
        "title": "A randomised prospective study assessing changes in neuro-cognitive function, using a computerised test battery, in treatment naïve HIV-1 positive subjects commencing two different antiretroviral r... - GB",
        "timestamp": "2007-07-31"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-002405-47/results",
        "title": "A randomised prospective study assessing changes in neuro-cognitive function, using a computerised test battery, in treatment naïve HIV-1 positive subjects commencing two different antiretroviral r... - View results",
        "timestamp": "2007-07-31"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-004268-38/HU",
        "title": "Individual Patient Access to AbbVie ABT-450/ritopnavir/ABT-267 and ABT-333 Coadministeres with ribavirin (RBV) in Adult Liver Transplant Recipient with Genotype 1 Hepatitis C Virus Infection - HU",
        "timestamp": "2014-10-27"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-006287-11/IT",
        "title": "Virologic efficacy of Maraviroc in adult naive HIV patients with HIV-RNA>= 1000 copies/ml - IT",
        "timestamp": "2009-02-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-001564-37/AT",
        "title": "One arm, Open label, Interventional, non-comparative Study to assess Changes in Lipids and Lipoproteins in HIV infected Women with Hyperlipidemia after Switch from boosted Protease Inhibitors to Ra... - AT",
        "timestamp": "2013-12-02"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-001564-37/results",
        "title": "One arm, Open label, Interventional, non-comparative Study to assess Changes in Lipids and Lipoproteins in HIV infected Women with Hyperlipidemia after Switch from boosted Protease Inhibitors to Ra... - View results",
        "timestamp": "2013-12-02"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-000040-17/FR",
        "title": "Randomized, open-label and multicentric trial evaluating the non-inferiority of antiretroviral treatment taken 4 consecutive days per week versus continuous therapy 7/7 days per week in HIV-1 infec... - FR",
        "timestamp": "2017-07-02"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-016697-32/IT",
        "title": "PRotease-Inhibitors MOnotherapy Strategies as maintenance therapy in persons with fully suppressed HIV replication: results from an open-label randomized comparative trial (PRIMO Trial) - IT",
        "timestamp": "2010-07-29"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-016697-32/results",
        "title": "PRotease-Inhibitors MOnotherapy Strategies as maintenance therapy in persons with fully suppressed HIV replication: results from an open-label randomized comparative trial (PRIMO Trial) - View results",
        "timestamp": "2010-07-29"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-000486-37/ES",
        "title": "Rosuvastatin versus Protease Inhibitor Switching for Hypercholesterolaemia in HIV-infected Adults. - ES",
        "timestamp": "2013-07-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-002627-90/GB",
        "title": "Intracellular boosting of HIV protease inhibitors through inhibition of transport - a novel strategy for potentiating HIV therapy - GB",
        "timestamp": "2008-09-05"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-004627-28/IT",
        "title": "Switch from a current boosted rtv PI to ATV/rtv based HAART regimen. Effect on metabolic and hepatic toxicity in HIV/HCV coinfected patients (COAT Study). - IT",
        "timestamp": "2009-02-25"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-000515-14/ES",
        "title": "Comparative, randomized, open study to evaluate maintenance with Darunavir/ritonavir once daily plus Lamivudine once daily versus continuing Darunavir/ritonavir once-daily plus Tenofovir/Emtricitab... - ES",
        "timestamp": "2014-06-26"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-022413-26/DE",
        "title": "Immediate versus deferred antiretroviral therapy in HIV-infected patients presenting with acute AIDS-defining events (IDEAL-Study) - DE",
        "timestamp": "2011-07-29"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-010912-14/IT",
        "title": "MAraviroc In HIV/ HCV Coinfection and Liver fibrosis - IT",
        "timestamp": "2009-04-06"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-010887-41/FR",
        "title": "A randomized, exploratory, open-label 48-week trial with a 2-week Pre-Treatment Phase to investigate the pharmacokinetics, safety, tolerability and antiviral activity of etravirine (ETR) in combina... - FR",
        "timestamp": "2009-06-22"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-010887-41/results",
        "title": "A randomized, exploratory, open-label 48-week trial with a 2-week Pre-Treatment Phase to investigate the pharmacokinetics, safety, tolerability and antiviral activity of etravirine (ETR) in combina... - View results",
        "timestamp": "2009-06-22"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-002515-25/ES",
        "title": "Pharmacokinetic interactions  between Telaprevir and not powered Atazanavir with ritonavir in co-infected patients with HIV and HCV genotype 1 in treatment for chronic liver disease by HCV - ES",
        "timestamp": "2012-09-10"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-002383-34/IT",
        "title": "A randomised, controlled, open-label trial to compare brachial artery reactivity and cardiovascular risk of a treatment simplification by darunavir/ritonavir (DRV/r) 800/100 mg O.D. versus a triple... - IT",
        "timestamp": "2008-10-09"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-002383-34/results",
        "title": "A randomised, controlled, open-label trial to compare brachial artery reactivity and cardiovascular risk of a treatment simplification by darunavir/ritonavir (DRV/r) 800/100 mg O.D. versus a triple... - View results",
        "timestamp": "2008-10-09"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-000793-45/DE",
        "title": "Open-label safety study of TMC114 in combination with low dose RTV and other ARVs in highly experienced HIV-1 infected patients with limited or no treatment options. - DE",
        "timestamp": None
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-000793-45/IT",
        "title": "Open-label safety study of TMC114 in combination with low dose RTV and other ARVs in highly experienced HIV-1 infected patients with limited or no treatment options. - IT",
        "timestamp": None
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-000793-45/results",
        "title": "Open-label safety study of TMC114 in combination with low dose RTV and other ARVs in highly experienced HIV-1 infected patients with limited or no treatment options. - View results",
        "timestamp": None
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-018326-39/IE",
        "title": "An open-label, randomised pilot study comparing the efficacy, safety and tolerability of raltegravir with protease inhibitor-based therapy in treatment-naïve, HIV/Hepatitis C co-infected injecting ... - IE",
        "timestamp": "2010-04-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-005004-28/GB",
        "title": "Stratified Treatment OPtimisation for HCV-1 (STOPHCV-1) - GB",
        "timestamp": "2015-12-31"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-005004-28/results",
        "title": "Stratified Treatment OPtimisation for HCV-1 (STOPHCV-1) - View results",
        "timestamp": "2015-12-31"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-023749-30/IT",
        "title": "Studio PKCT - Pharmacokinetics of chemotherapy when given concurrently with antiretroviral (Protocol no. CSL01). - IT",
        "timestamp": "2011-10-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-023749-30/results",
        "title": "Studio PKCT - Pharmacokinetics of chemotherapy when given concurrently with antiretroviral (Protocol no. CSL01). - View results",
        "timestamp": "2011-10-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-010189-48/IT",
        "title": "Randomised trial comparing the introduction of an immediate or deferred new HAART regimen in failing HIV infected patients: the role of lamivudine monotherapy - IT",
        "timestamp": "2009-03-13"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-010189-48/results",
        "title": "Randomised trial comparing the introduction of an immediate or deferred new HAART regimen in failing HIV infected patients: the role of lamivudine monotherapy - View results",
        "timestamp": "2009-03-13"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-001247-39/HU",
        "title": "A Phase III, randomised, double-blind, placebo-controlled, multicentre, parallel group study to compare the efficacy and safety of GW873140 400mg BID in combination with a ritonavir-containing opti... - HU",
        "timestamp": "2005-08-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-001247-39/DE",
        "title": "A Phase III, randomised, double-blind, placebo-controlled, multicentre, parallel group study to compare the efficacy and safety of GW873140 400mg BID in combination with a ritonavir-containing opti... - DE",
        "timestamp": "2005-08-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-001247-39/IE",
        "title": "A Phase III, randomised, double-blind, placebo-controlled, multicentre, parallel group study to compare the efficacy and safety of GW873140 400mg BID in combination with a ritonavir-containing opti... - IE",
        "timestamp": "2005-08-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-001247-39/DK",
        "title": "A Phase III, randomised, double-blind, placebo-controlled, multicentre, parallel group study to compare the efficacy and safety of GW873140 400mg BID in combination with a ritonavir-containing opti... - DK",
        "timestamp": "2005-08-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-001247-39/GB",
        "title": "A Phase III, randomised, double-blind, placebo-controlled, multicentre, parallel group study to compare the efficacy and safety of GW873140 400mg BID in combination with a ritonavir-containing opti... - GB",
        "timestamp": "2005-08-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-001247-39/AT",
        "title": "A Phase III, randomised, double-blind, placebo-controlled, multicentre, parallel group study to compare the efficacy and safety of GW873140 400mg BID in combination with a ritonavir-containing opti... - AT",
        "timestamp": "2005-08-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-001247-39/results",
        "title": "A Phase III, randomised, double-blind, placebo-controlled, multicentre, parallel group study to compare the efficacy and safety of GW873140 400mg BID in combination with a ritonavir-containing opti... - View results",
        "timestamp": "2005-08-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-001246-16/HU",
        "title": "A Phase III, randomized, double-blind, placebo-controlled, multicenter, parallel group study to compare the efficacy and safety of GW873140 400mg BID in combination with a ritonavir-containing opti... - HU",
        "timestamp": "2005-08-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-001246-16/IE",
        "title": "A Phase III, randomized, double-blind, placebo-controlled, multicenter, parallel group study to compare the efficacy and safety of GW873140 400mg BID in combination with a ritonavir-containing opti... - IE",
        "timestamp": "2005-08-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-001246-16/DK",
        "title": "A Phase III, randomized, double-blind, placebo-controlled, multicenter, parallel group study to compare the efficacy and safety of GW873140 400mg BID in combination with a ritonavir-containing opti... - DK",
        "timestamp": "2005-08-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-001246-16/GB",
        "title": "A Phase III, randomized, double-blind, placebo-controlled, multicenter, parallel group study to compare the efficacy and safety of GW873140 400mg BID in combination with a ritonavir-containing opti... - GB",
        "timestamp": "2005-08-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-001246-16/AT",
        "title": "A Phase III, randomized, double-blind, placebo-controlled, multicenter, parallel group study to compare the efficacy and safety of GW873140 400mg BID in combination with a ritonavir-containing opti... - AT",
        "timestamp": "2005-08-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-001246-16/DE",
        "title": "A Phase III, randomized, double-blind, placebo-controlled, multicenter, parallel group study to compare the efficacy and safety of GW873140 400mg BID in combination with a ritonavir-containing opti... - DE",
        "timestamp": "2005-08-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-001246-16/results",
        "title": "A Phase III, randomized, double-blind, placebo-controlled, multicenter, parallel group study to compare the efficacy and safety of GW873140 400mg BID in combination with a ritonavir-containing opti... - View results",
        "timestamp": "2005-08-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-007995-81/DE",
        "title": "A Phase 2a, 2-Part, Randomized, Double Blind, Placebo Controlled, Parallel Group, Multicenter Study of Telaprevir in Combination with Peginterferon Alfa 2a (Pegasys®) and Ribavirin (Copegus®) in Su... - DE",
        "timestamp": "2010-04-28"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-007995-81/FR",
        "title": "A Phase 2a, 2-Part, Randomized, Double Blind, Placebo Controlled, Parallel Group, Multicenter Study of Telaprevir in Combination with Peginterferon Alfa 2a (Pegasys®) and Ribavirin (Copegus®) in Su... - FR",
        "timestamp": "2010-04-28"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-007995-81/ES",
        "title": "A Phase 2a, 2-Part, Randomized, Double Blind, Placebo Controlled, Parallel Group, Multicenter Study of Telaprevir in Combination with Peginterferon Alfa 2a (Pegasys®) and Ribavirin (Copegus®) in Su... - ES",
        "timestamp": "2010-04-28"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-007995-81/results",
        "title": "A Phase 2a, 2-Part, Randomized, Double Blind, Placebo Controlled, Parallel Group, Multicenter Study of Telaprevir in Combination with Peginterferon Alfa 2a (Pegasys®) and Ribavirin (Copegus®) in Su... - View results",
        "timestamp": "2010-04-28"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-000586-20/FR",
        "title": "A Phase 3 Randomized, Active-Controlled, Open-Label Clinical Study to Evaluate a Switch to Doravirine/Islatravir (DOR/ISL) Once-Daily in Participants With HIV-1 Virologically Suppressed on Antiretr... - FR",
        "timestamp": "2020-02-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-000586-20/GB",
        "title": "A Phase 3 Randomized, Active-Controlled, Open-Label Clinical Study to Evaluate a Switch to Doravirine/Islatravir (DOR/ISL) Once-Daily in Participants With HIV-1 Virologically Suppressed on Antiretr... - GB",
        "timestamp": "2020-02-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-004330-40/DE",
        "title": "Open-label, randomised clinical trial to compare the virological efficacy and safety of Atazanavir/Ritonavir on a background of Tenofovir and Emtricitabine vs. Nevirapine on same background, in HIV... - DE",
        "timestamp": "2006-09-13"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-004330-40/PT",
        "title": "Open-label, randomised clinical trial to compare the virological efficacy and safety of Atazanavir/Ritonavir on a background of Tenofovir and Emtricitabine vs. Nevirapine on same background, in HIV... - PT",
        "timestamp": "2006-09-13"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-004330-40/IT",
        "title": "Open-label, randomised clinical trial to compare the virological efficacy and safety of Atazanavir/Ritonavir on a background of Tenofovir and Emtricitabine vs. Nevirapine on same background, in HIV... - IT",
        "timestamp": "2006-09-13"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-004330-40/GB",
        "title": "Open-label, randomised clinical trial to compare the virological efficacy and safety of Atazanavir/Ritonavir on a background of Tenofovir and Emtricitabine vs. Nevirapine on same background, in HIV... - GB",
        "timestamp": "2006-09-13"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-004330-40/ES",
        "title": "Open-label, randomised clinical trial to compare the virological efficacy and safety of Atazanavir/Ritonavir on a background of Tenofovir and Emtricitabine vs. Nevirapine on same background, in HIV... - ES",
        "timestamp": "2006-09-13"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-004330-40/results",
        "title": "Open-label, randomised clinical trial to compare the virological efficacy and safety of Atazanavir/Ritonavir on a background of Tenofovir and Emtricitabine vs. Nevirapine on same background, in HIV... - View results",
        "timestamp": "2006-09-13"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-004225-26/DE",
        "title": "A Multicenter, Randomized, Double-Blind, Double-Dummy, Phase 3 Study of the Safety and Efficacy of Ritonavir-Boosted Elvitegravir (EVG/r) Versus Raltegravir (RAL)\r\nEach Administered With a Backgrou... - DE",
        "timestamp": "2008-08-13"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-004225-26/GB",
        "title": "A Multicenter, Randomized, Double-Blind, Double-Dummy, Phase 3 Study of the Safety and Efficacy of Ritonavir-Boosted Elvitegravir (EVG/r) Versus Raltegravir (RAL)\r\nEach Administered With a Backgrou... - GB",
        "timestamp": "2008-08-13"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-004225-26/NL",
        "title": "A Multicenter, Randomized, Double-Blind, Double-Dummy, Phase 3 Study of the Safety and Efficacy of Ritonavir-Boosted Elvitegravir (EVG/r) Versus Raltegravir (RAL)\r\nEach Administered With a Backgrou... - NL",
        "timestamp": "2008-08-13"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-004225-26/BE",
        "title": "A Multicenter, Randomized, Double-Blind, Double-Dummy, Phase 3 Study of the Safety and Efficacy of Ritonavir-Boosted Elvitegravir (EVG/r) Versus Raltegravir (RAL)\r\nEach Administered With a Backgrou... - BE",
        "timestamp": "2008-08-13"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-004225-26/ES",
        "title": "A Multicenter, Randomized, Double-Blind, Double-Dummy, Phase 3 Study of the Safety and Efficacy of Ritonavir-Boosted Elvitegravir (EVG/r) Versus Raltegravir (RAL)\r\nEach Administered With a Backgrou... - ES",
        "timestamp": "2008-08-13"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-004225-26/IT",
        "title": "A Multicenter, Randomized, Double-Blind, Double-Dummy, Phase 3 Study of the Safety and Efficacy of Ritonavir-Boosted Elvitegravir (EVG/r) Versus Raltegravir (RAL)\r\nEach Administered With a Backgrou... - IT",
        "timestamp": "2008-08-13"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-004225-26/PT",
        "title": "A Multicenter, Randomized, Double-Blind, Double-Dummy, Phase 3 Study of the Safety and Efficacy of Ritonavir-Boosted Elvitegravir (EVG/r) Versus Raltegravir (RAL)\r\nEach Administered With a Backgrou... - PT",
        "timestamp": "2008-08-13"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-004225-26/FR",
        "title": "A Multicenter, Randomized, Double-Blind, Double-Dummy, Phase 3 Study of the Safety and Efficacy of Ritonavir-Boosted Elvitegravir (EVG/r) Versus Raltegravir (RAL)\r\nEach Administered With a Backgrou... - FR",
        "timestamp": "2008-08-13"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-004225-26/results",
        "title": "A Multicenter, Randomized, Double-Blind, Double-Dummy, Phase 3 Study of the Safety and Efficacy of Ritonavir-Boosted Elvitegravir (EVG/r) Versus Raltegravir (RAL)\r\nEach Administered With a Backgrou... - View results",
        "timestamp": "2008-08-13"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-002555-42/BE",
        "title": "A Phase IIa, open-label trial to evaluate the safety, tolerability and efficacy of a 12 weeks combination therapy of TMC647055 and TMC435 with and without GSK2336805 with a pharmacokinetic enhancer... - BE",
        "timestamp": "2012-08-23"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-002555-42/DE",
        "title": "A Phase IIa, open-label trial to evaluate the safety, tolerability and efficacy of a 12 weeks combination therapy of TMC647055 and TMC435 with and without GSK2336805 with a pharmacokinetic enhancer... - DE",
        "timestamp": "2012-08-23"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-002555-42/results",
        "title": "A Phase IIa, open-label trial to evaluate the safety, tolerability and efficacy of a 12 weeks combination therapy of TMC647055 and TMC435 with and without GSK2336805 with a pharmacokinetic enhancer... - View results",
        "timestamp": "2012-08-23"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-018532-40/BE",
        "title": "A Phase 2b study to select a once daily oral dose of GSK2248761 in HIV-1 infected antiretroviral therapy experienced adults with non-nucleoside reverse transcriptase\ninhibitor (NNRTI) resistance - BE",
        "timestamp": "2010-10-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-018532-40/ES",
        "title": "A Phase 2b study to select a once daily oral dose of GSK2248761 in HIV-1 infected antiretroviral therapy experienced adults with non-nucleoside reverse transcriptase\ninhibitor (NNRTI) resistance - ES",
        "timestamp": "2010-10-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-018532-40/IT",
        "title": "A Phase 2b study to select a once daily oral dose of GSK2248761 in HIV-1 infected antiretroviral therapy experienced adults with non-nucleoside reverse transcriptase\ninhibitor (NNRTI) resistance - IT",
        "timestamp": "2010-10-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-018532-40/results",
        "title": "A Phase 2b study to select a once daily oral dose of GSK2248761 in HIV-1 infected antiretroviral therapy experienced adults with non-nucleoside reverse transcriptase\ninhibitor (NNRTI) resistance - View results",
        "timestamp": "2010-10-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-000582-21/DE",
        "title": "A multicentre Phase IIb trial to evaluate the efficacy and tolerability of ModraDoc006/r in subjects with metastatic Castration Resistant Prostate Cancer (mCRPC), suitable for treatment with a taxane. - DE",
        "timestamp": None
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-000582-21/CZ",
        "title": "A multicentre Phase IIb trial to evaluate the efficacy and tolerability of ModraDoc006/r in subjects with metastatic Castration Resistant Prostate Cancer (mCRPC), suitable for treatment with a taxane. - CZ",
        "timestamp": None
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-000582-21/HU",
        "title": "A multicentre Phase IIb trial to evaluate the efficacy and tolerability of ModraDoc006/r in subjects with metastatic Castration Resistant Prostate Cancer (mCRPC), suitable for treatment with a taxane. - HU",
        "timestamp": None
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-022293-14/ES",
        "title": "Optimized Phase III Trial of Immuno-stimulation with Maraviroc, a CCR5 antagonist, combined with Anti Retroviral Therapy (cART) in advanced, Late diagnosed HIV-1 infected patients with an AIDS-defi... - ES",
        "timestamp": "2012-08-22"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-022293-14/IT",
        "title": "Optimized Phase III Trial of Immuno-stimulation with Maraviroc, a CCR5 antagonist, combined with Anti Retroviral Therapy (cART) in advanced, Late diagnosed HIV-1 infected patients with an AIDS-defi... - IT",
        "timestamp": "2012-08-22"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-001287-23/BE",
        "title": "An open-label trial with TMC125 as part of an ART including TMC114/rtv and an investigator-selected OBR in HIV-1 infected subjects who participated in a DUET trial (TMC125-C206 or TMC125-C216). - BE",
        "timestamp": "2006-06-13"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-001287-23/DE",
        "title": "An open-label trial with TMC125 as part of an ART including TMC114/rtv and an investigator-selected OBR in HIV-1 infected subjects who participated in a DUET trial (TMC125-C206 or TMC125-C216). - DE",
        "timestamp": "2006-06-13"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-001287-23/ES",
        "title": "An open-label trial with TMC125 as part of an ART including TMC114/rtv and an investigator-selected OBR in HIV-1 infected subjects who participated in a DUET trial (TMC125-C206 or TMC125-C216). - ES",
        "timestamp": "2006-06-13"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-001287-23/FR",
        "title": "An open-label trial with TMC125 as part of an ART including TMC114/rtv and an investigator-selected OBR in HIV-1 infected subjects who participated in a DUET trial (TMC125-C206 or TMC125-C216). - FR",
        "timestamp": "2006-06-13"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-001287-23/IT",
        "title": "An open-label trial with TMC125 as part of an ART including TMC114/rtv and an investigator-selected OBR in HIV-1 infected subjects who participated in a DUET trial (TMC125-C206 or TMC125-C216). - IT",
        "timestamp": "2006-06-13"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-001287-23/PT",
        "title": "An open-label trial with TMC125 as part of an ART including TMC114/rtv and an investigator-selected OBR in HIV-1 infected subjects who participated in a DUET trial (TMC125-C206 or TMC125-C216). - PT",
        "timestamp": "2006-06-13"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-001287-23/results",
        "title": "An open-label trial with TMC125 as part of an ART including TMC114/rtv and an investigator-selected OBR in HIV-1 infected subjects who participated in a DUET trial (TMC125-C206 or TMC125-C216). - View results",
        "timestamp": "2006-06-13"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-001969-16/IT",
        "title": "A Phase 2/3 Multicenter, Open-Label, Multicohort, Two-Part Study Evaluating the Pharmacokinetics (PK), Safety, and Antiviral Activity of Elvitegravir (EVG) Administered with a Background Regimen (B... - IT",
        "timestamp": "2013-10-21"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-001969-16/DE",
        "title": "A Phase 2/3 Multicenter, Open-Label, Multicohort, Two-Part Study Evaluating the Pharmacokinetics (PK), Safety, and Antiviral Activity of Elvitegravir (EVG) Administered with a Background Regimen (B... - DE",
        "timestamp": "2013-10-21"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-001969-16/ES",
        "title": "A Phase 2/3 Multicenter, Open-Label, Multicohort, Two-Part Study Evaluating the Pharmacokinetics (PK), Safety, and Antiviral Activity of Elvitegravir (EVG) Administered with a Background Regimen (B... - ES",
        "timestamp": "2013-10-21"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-001969-16/3rd",
        "title": "A Phase 2/3 Multicenter, Open-Label, Multicohort, Two-Part Study Evaluating the Pharmacokinetics (PK), Safety, and Antiviral Activity of Elvitegravir (EVG) Administered with a Background Regimen (B... - Outside EU/EEA",
        "timestamp": "2013-10-21"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-001969-16/results",
        "title": "A Phase 2/3 Multicenter, Open-Label, Multicohort, Two-Part Study Evaluating the Pharmacokinetics (PK), Safety, and Antiviral Activity of Elvitegravir (EVG) Administered with a Background Regimen (B... - View results",
        "timestamp": "2013-10-21"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-000360-34/DE",
        "title": "DUALIS\r\nA prospective, multicenter, randomized, open-label trial to assess the safety, tolerability and efficacy of dual therapy with boosted Darunavir + Dolutegravir when switching from standard o... - DE",
        "timestamp": "2015-06-26"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-002880-26/GB",
        "title": "A Phase IV, Multi-center, Cross-sectional study to evaluate the I50L substitution among subjects experiencing virologic failure on a HAART regimen containing atazanavir (ATV)\n\nProtocol: version 2.0... - GB",
        "timestamp": "2005-04-06"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-002880-26/DE",
        "title": "A Phase IV, Multi-center, Cross-sectional study to evaluate the I50L substitution among subjects experiencing virologic failure on a HAART regimen containing atazanavir (ATV)\n\nProtocol: version 2.0... - DE",
        "timestamp": "2005-04-06"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-002880-26/IT",
        "title": "A Phase IV, Multi-center, Cross-sectional study to evaluate the I50L substitution among subjects experiencing virologic failure on a HAART regimen containing atazanavir (ATV)\n\nProtocol: version 2.0... - IT",
        "timestamp": "2005-04-06"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-002880-26/results",
        "title": "A Phase IV, Multi-center, Cross-sectional study to evaluate the I50L substitution among subjects experiencing virologic failure on a HAART regimen containing atazanavir (ATV)\n\nProtocol: version 2.0... - View results",
        "timestamp": "2005-04-06"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-000446-20/IE",
        "title": "A multi-centre randomised trial of therapeutic intervention at primary HIV-1 infection - IE",
        "timestamp": "2006-07-28"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-000446-20/ES",
        "title": "A multi-centre randomised trial of therapeutic intervention at primary HIV-1 infection - ES",
        "timestamp": "2006-07-28"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-000446-20/results",
        "title": "A multi-centre randomised trial of therapeutic intervention at primary HIV-1 infection - View results",
        "timestamp": "2006-07-28"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-003145-13/GB",
        "title": "A Phase III randomized, double-blinded, placebo-controlled trial to investigate the efficacy, tolerability and safety of TMC125 as part of an ART including TMC114/RTV and an investigator-selected O... - GB",
        "timestamp": "2006-07-06"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-003145-13/DE",
        "title": "A Phase III randomized, double-blinded, placebo-controlled trial to investigate the efficacy, tolerability and safety of TMC125 as part of an ART including TMC114/RTV and an investigator-selected O... - DE",
        "timestamp": "2006-07-06"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-003145-13/results",
        "title": "A Phase III randomized, double-blinded, placebo-controlled trial to investigate the efficacy, tolerability and safety of TMC125 as part of an ART including TMC114/RTV and an investigator-selected O... - View results",
        "timestamp": "2006-07-06"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-004750-42/ES",
        "title": "EFFICACY AND SAFETY OF A SIMPLIFICATION STRATEGY BASED ON DOLUTEGRAVIR AND DARUNAVIR / COBICISTAT VS OPTIMIZED TREATMENT IN SUPPRESSED HIV-1-INFECTED PATIENTS CARRYING ARCHIVED MULTIDRUG RESISTANCE... - ES",
        "timestamp": "2018-09-04"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-000274-35/ES",
        "title": "An open-label, randomized, controlled clinical trial to assess the safety, tolerability and efficacy of two dolutegravir-based simplification strategies in HIV-infected patients with prolonged viro... - ES",
        "timestamp": "2015-04-23"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-002087-17/HU",
        "title": "A Randomized, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults with Chronic Hepatitis C Virus Genotype 1 Infection (ENDURANCE-1) - HU",
        "timestamp": "2015-10-29"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-002087-17/PT",
        "title": "A Randomized, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults with Chronic Hepatitis C Virus Genotype 1 Infection (ENDURANCE-1) - PT",
        "timestamp": "2015-10-29"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-002087-17/BE",
        "title": "A Randomized, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults with Chronic Hepatitis C Virus Genotype 1 Infection (ENDURANCE-1) - BE",
        "timestamp": "2015-10-29"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-002087-17/AT",
        "title": "A Randomized, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults with Chronic Hepatitis C Virus Genotype 1 Infection (ENDURANCE-1) - AT",
        "timestamp": "2015-10-29"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-002087-17/SE",
        "title": "A Randomized, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults with Chronic Hepatitis C Virus Genotype 1 Infection (ENDURANCE-1) - SE",
        "timestamp": "2015-10-29"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-002087-17/DE",
        "title": "A Randomized, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults with Chronic Hepatitis C Virus Genotype 1 Infection (ENDURANCE-1) - DE",
        "timestamp": "2015-10-29"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-002087-17/LT",
        "title": "A Randomized, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults with Chronic Hepatitis C Virus Genotype 1 Infection (ENDURANCE-1) - LT",
        "timestamp": "2015-10-29"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-002087-17/ES",
        "title": "A Randomized, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults with Chronic Hepatitis C Virus Genotype 1 Infection (ENDURANCE-1) - ES",
        "timestamp": "2015-10-29"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-002087-17/PL",
        "title": "A Randomized, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults with Chronic Hepatitis C Virus Genotype 1 Infection (ENDURANCE-1) - PL",
        "timestamp": "2015-10-29"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-002087-17/GB",
        "title": "A Randomized, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults with Chronic Hepatitis C Virus Genotype 1 Infection (ENDURANCE-1) - GB",
        "timestamp": "2015-10-29"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-002087-17/IT",
        "title": "A Randomized, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults with Chronic Hepatitis C Virus Genotype 1 Infection (ENDURANCE-1) - IT",
        "timestamp": "2015-10-29"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-002087-17/results",
        "title": "A Randomized, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults with Chronic Hepatitis C Virus Genotype 1 Infection (ENDURANCE-1) - View results",
        "timestamp": "2015-10-29"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003073-26/GB",
        "title": "A Follow-up Study to Assess Resistance and Durability of Response to AbbVie Direct-Acting Antiviral Agent (DAA) Therapy in Subjects Who Participated in Phase 2 or 3 Clinical Studies for the Treatme... - GB",
        "timestamp": "2013-10-22"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003073-26/IE",
        "title": "A Follow-up Study to Assess Resistance and Durability of Response to AbbVie Direct-Acting Antiviral Agent (DAA) Therapy in Subjects Who Participated in Phase 2 or 3 Clinical Studies for the Treatme... - IE",
        "timestamp": "2013-10-22"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003073-26/DE",
        "title": "A Follow-up Study to Assess Resistance and Durability of Response to AbbVie Direct-Acting Antiviral Agent (DAA) Therapy in Subjects Who Participated in Phase 2 or 3 Clinical Studies for the Treatme... - DE",
        "timestamp": "2013-10-22"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003073-26/ES",
        "title": "A Follow-up Study to Assess Resistance and Durability of Response to AbbVie Direct-Acting Antiviral Agent (DAA) Therapy in Subjects Who Participated in Phase 2 or 3 Clinical Studies for the Treatme... - ES",
        "timestamp": "2013-10-22"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003073-26/HU",
        "title": "A Follow-up Study to Assess Resistance and Durability of Response to AbbVie Direct-Acting Antiviral Agent (DAA) Therapy in Subjects Who Participated in Phase 2 or 3 Clinical Studies for the Treatme... - HU",
        "timestamp": "2013-10-22"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003073-26/AT",
        "title": "A Follow-up Study to Assess Resistance and Durability of Response to AbbVie Direct-Acting Antiviral Agent (DAA) Therapy in Subjects Who Participated in Phase 2 or 3 Clinical Studies for the Treatme... - AT",
        "timestamp": "2013-10-22"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003073-26/BE",
        "title": "A Follow-up Study to Assess Resistance and Durability of Response to AbbVie Direct-Acting Antiviral Agent (DAA) Therapy in Subjects Who Participated in Phase 2 or 3 Clinical Studies for the Treatme... - BE",
        "timestamp": "2013-10-22"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003073-26/DK",
        "title": "A Follow-up Study to Assess Resistance and Durability of Response to AbbVie Direct-Acting Antiviral Agent (DAA) Therapy in Subjects Who Participated in Phase 2 or 3 Clinical Studies for the Treatme... - DK",
        "timestamp": "2013-10-22"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003073-26/PT",
        "title": "A Follow-up Study to Assess Resistance and Durability of Response to AbbVie Direct-Acting Antiviral Agent (DAA) Therapy in Subjects Who Participated in Phase 2 or 3 Clinical Studies for the Treatme... - PT",
        "timestamp": "2013-10-22"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003073-26/PL",
        "title": "A Follow-up Study to Assess Resistance and Durability of Response to AbbVie Direct-Acting Antiviral Agent (DAA) Therapy in Subjects Who Participated in Phase 2 or 3 Clinical Studies for the Treatme... - PL",
        "timestamp": "2013-10-22"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003073-26/CZ",
        "title": "A Follow-up Study to Assess Resistance and Durability of Response to AbbVie Direct-Acting Antiviral Agent (DAA) Therapy in Subjects Who Participated in Phase 2 or 3 Clinical Studies for the Treatme... - CZ",
        "timestamp": "2013-10-22"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003073-26/IT",
        "title": "A Follow-up Study to Assess Resistance and Durability of Response to AbbVie Direct-Acting Antiviral Agent (DAA) Therapy in Subjects Who Participated in Phase 2 or 3 Clinical Studies for the Treatme... - IT",
        "timestamp": "2013-10-22"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003073-26/results",
        "title": "A Follow-up Study to Assess Resistance and Durability of Response to AbbVie Direct-Acting Antiviral Agent (DAA) Therapy in Subjects Who Participated in Phase 2 or 3 Clinical Studies for the Treatme... - View results",
        "timestamp": "2013-10-22"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-005264-86/DE",
        "title": "Safety, efficacy and Pharmacokinetics of tipRanavir boosted with low-dose ritonavir (TPV/r) 500 mg/200 mg BID IN a racially and Gender diverse HIV positive treatment experienced population with a p... - DE",
        "timestamp": "2007-02-21"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-005264-86/ES",
        "title": "Safety, efficacy and Pharmacokinetics of tipRanavir boosted with low-dose ritonavir (TPV/r) 500 mg/200 mg BID IN a racially and Gender diverse HIV positive treatment experienced population with a p... - ES",
        "timestamp": "2007-02-21"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-005264-86/IT",
        "title": "Safety, efficacy and Pharmacokinetics of tipRanavir boosted with low-dose ritonavir (TPV/r) 500 mg/200 mg BID IN a racially and Gender diverse HIV positive treatment experienced population with a p... - IT",
        "timestamp": "2007-02-21"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-005264-86/results",
        "title": "Safety, efficacy and Pharmacokinetics of tipRanavir boosted with low-dose ritonavir (TPV/r) 500 mg/200 mg BID IN a racially and Gender diverse HIV positive treatment experienced population with a p... - View results",
        "timestamp": "2007-02-21"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-002656-14/GB",
        "title": "A randomised, prospective study, assessing changes in cerebral function in treatment naive HIV-1 infected subjects commencing either boosted atazanavir with Truvada or boosted darunavir with maravi... - GB",
        "timestamp": "2012-06-11"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-002656-14/results",
        "title": "A randomised, prospective study, assessing changes in cerebral function in treatment naive HIV-1 infected subjects commencing either boosted atazanavir with Truvada or boosted darunavir with maravi... - View results",
        "timestamp": "2012-06-11"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-003544-30/ES",
        "title": "Estudio piloto, multicéntrico, aleatorizado y abierto, para evaluar el tratamiento concomitante de la co-infección por el VHC/VIH con peg-interferón + ribavirina, y lopinavir/r como único agente an... - ES",
        "timestamp": "2007-12-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-014216-35/IT",
        "title": "REYAGEN study. Optimization of unboosted atazanavir dosing, when associated with tenofovir,\nguided by pharmacogenetics profile of HIV-patients - IT",
        "timestamp": "2009-10-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-006187-47/DK",
        "title": "A 48-Week, Randomized, Open-Label Phase 3b Study Comparing the Antiviral Efficacy and Safety of ATV/RTV Plus 3TC with ATV/RTV plus TDF/FTC in HIV-1-Infected, Treatment-Naive Subjects, Followed by a... - DK",
        "timestamp": "2012-11-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-006187-47/results",
        "title": "A 48-Week, Randomized, Open-Label Phase 3b Study Comparing the Antiviral Efficacy and Safety of ATV/RTV Plus 3TC with ATV/RTV plus TDF/FTC in HIV-1-Infected, Treatment-Naive Subjects, Followed by a... - View results",
        "timestamp": "2012-11-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-002582-39/IT",
        "title": "A multicenter, randomized, prospective, controlled study to evaluate the efficacy and the tolerability of a switch to a two different-dosed, nevirapine-based HAARTs in HIV-1 infected patients with ... - IT",
        "timestamp": "2006-07-10"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-023602-12/IT",
        "title": "A FEASIBILITY STUDY EVALUATING THE EFFICACY AND SAFETY OF SORAFENIB IN PATIENTS WITH ADVANCED HEPATOCELLULAR (HCC) CARCINOMA AND HIV INFECTION TREATED WITH HAART REGIMENS - IT",
        "timestamp": "2011-03-25"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003595-39/ES",
        "title": "A randomized, pilot clinical trial designed to compare, in human immunodeficiency virus infected patients who never have received antiretroviral therapy, the evolution of cerebral function and the ... - ES",
        "timestamp": "2013-02-06"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-005081-60/ES",
        "title": "MULTICENTER CLINICAL TRIAL TO DETERMINE THE INFLUENCE OF TREATMENT WITH DIRECT ANTIVIRAL AGENTS IN THE GLOMERULAR AND TUBULAR FUNCTION OF PATIENTS WITH CHRONIC HCV HEPATITIS - ES",
        "timestamp": "2017-04-21"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-007018-12/ES",
        "title": "“Estudio prospectivo, abierto, aleatorizado y cruzado sobre el efecto de la Hidroxicloroquina, 200mg al día, en factores inflamatorios y metabólicos relacionados con la enfermedad cardiovascular en... - ES",
        "timestamp": "2008-06-23"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-015647-16/IE",
        "title": "The pharmacokinetics of once daily Kaletra and methadone in a population of HIV positiive drug users. - IE",
        "timestamp": "2010-01-28"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-004197-42/DE",
        "title": "A proof of concept clinical trial assessing the safety of the coordinated undermining of survival paths by 9 repurposed drugs combined with metronomic temozolomide (CUSP9v3 Treatment Protocol) for ... - DE",
        "timestamp": "2016-08-02"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-000096-16/GB",
        "title": "A Randomized, Double-Blind, Phase II Study Comparing the Anti-Retroviral Safety and Efficacy of Dexelvucitabine (DFC) 200 mg Once Daily to Lamivudine (3TC) 300 mg Once Daily in Addition to Optimize... - GB",
        "timestamp": "2006-03-30"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-002050-66/IE",
        "title": "Treatment Interruption in Children with Chronic HIV-Infection: the TICCH Trial - IE",
        "timestamp": None
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-002050-66/ES",
        "title": "Treatment Interruption in Children with Chronic HIV-Infection: the TICCH Trial - ES",
        "timestamp": None
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-007004-29/IT",
        "title": "Maraviroc in HIV Acute INfection - IT",
        "timestamp": "2009-02-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-000355-94/DE",
        "title": "AN OPEN-LABEL, PARALLEL GROUP, SINGLE AND MULTIPLE DOSE STUDY TO EVALUATE THE PHARMACOKINETICS, SAFETY AND TOLERATION OF MARAVIROC ADMINISTERED TO SUBJECTS WITH VARIOUS DEGREES OF RENAL IMPAIRED AN... - DE",
        "timestamp": "2008-06-10"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-000355-94/results",
        "title": "AN OPEN-LABEL, PARALLEL GROUP, SINGLE AND MULTIPLE DOSE STUDY TO EVALUATE THE PHARMACOKINETICS, SAFETY AND TOLERATION OF MARAVIROC ADMINISTERED TO SUBJECTS WITH VARIOUS DEGREES OF RENAL IMPAIRED AN... - View results",
        "timestamp": "2008-06-10"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-004111-37/HU",
        "title": "Individual Patient Access to AbbVie ABT-450/rítonavir/ABT-267 and ABT\n333 Coadministered witb Ribavirín (RBV) in Patient with Genotype 1 Hepatitis C Vírus\nInfection witb Cirrhosis - HU",
        "timestamp": "2014-10-22"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-001164-32/IT",
        "title": "A RANDOMIZED STUDY, POSPECTIVE, ON THREE DIFFERENT STRATEGY OF HIV POSITIVE NAIVE FOR THE ANTIRETROVIRAL THERAPY - IT",
        "timestamp": "2005-04-05"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-001827-39/IT",
        "title": "NATIONAL, MULTICENTER, RANDOMISED, OPEN STUDY TO VALUATE THE EFFICACY OF DIFFERENT THERAPEUTIC STRATEGIES TO AVOID THE IMMUNOLOGIC FAILURE IN MULTIRESISTENT HIV-1 INFECTED PATIENTS. - IT",
        "timestamp": "2004-09-15"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-001246-33/AT",
        "title": "An open label trial of TMC114/RTV in HIV-1 infected subjects who were randomized in the trials TMC114-C201, TMC114-C207 or in sponsor selected Phase I trials. - AT",
        "timestamp": "2004-11-23"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-001246-33/GB",
        "title": "An open label trial of TMC114/RTV in HIV-1 infected subjects who were randomized in the trials TMC114-C201, TMC114-C207 or in sponsor selected Phase I trials. - GB",
        "timestamp": "2004-11-23"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-001246-33/IT",
        "title": "An open label trial of TMC114/RTV in HIV-1 infected subjects who were randomized in the trials TMC114-C201, TMC114-C207 or in sponsor selected Phase I trials. - IT",
        "timestamp": "2004-11-23"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-001246-33/DK",
        "title": "An open label trial of TMC114/RTV in HIV-1 infected subjects who were randomized in the trials TMC114-C201, TMC114-C207 or in sponsor selected Phase I trials. - DK",
        "timestamp": "2004-11-23"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-001246-33/results",
        "title": "An open label trial of TMC114/RTV in HIV-1 infected subjects who were randomized in the trials TMC114-C201, TMC114-C207 or in sponsor selected Phase I trials. - View results",
        "timestamp": "2004-11-23"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-011816-39/GB",
        "title": "A randomised, open label, prospective study to assess two different therapeutic strategies following first treatment failure in HIV-1 infected subjects.\n‘The First Failure Study’ : ‘FAST’ - GB",
        "timestamp": "2010-01-21"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-011816-39/results",
        "title": "A randomised, open label, prospective study to assess two different therapeutic strategies following first treatment failure in HIV-1 infected subjects.\n‘The First Failure Study’ : ‘FAST’ - View results",
        "timestamp": "2010-01-21"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-006716-30/IT",
        "title": "Randomized, controlled, multicentric trial to evaluate efficacy and safety of the switch from a LPV/r based therapy to an ATV/r or a NVP based treatment in association with ABC/3TC, in HIV patient ... - IT",
        "timestamp": "2006-12-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-005192-14/IT",
        "title": "Strategic study of dual-therapy with darunavir/ritonavir and rilpivirine QD versus triple-therapy in patients with suppressed viral load: virological efficacy and evaluation of non-HIV related morb... - IT",
        "timestamp": "2013-01-31"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-000251-24/ES",
        "title": "Impact of extremely early antiretroviral therapy to reduce VIral REservoir and induce functional CURE of HIV-1 infection. A pilot comparative study. - ES",
        "timestamp": "2015-06-10"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-004011-20/GB",
        "title": "A Phase 3, Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Switching from Regimens Consisting of Boosted Atazanavir or Darunavir plus either Emtricitabine/Tenofovir or Abacavir/... - GB",
        "timestamp": "2016-02-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-004011-20/DE",
        "title": "A Phase 3, Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Switching from Regimens Consisting of Boosted Atazanavir or Darunavir plus either Emtricitabine/Tenofovir or Abacavir/... - DE",
        "timestamp": "2016-02-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-004011-20/ES",
        "title": "A Phase 3, Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Switching from Regimens Consisting of Boosted Atazanavir or Darunavir plus either Emtricitabine/Tenofovir or Abacavir/... - ES",
        "timestamp": "2016-02-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-004011-20/BE",
        "title": "A Phase 3, Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Switching from Regimens Consisting of Boosted Atazanavir or Darunavir plus either Emtricitabine/Tenofovir or Abacavir/... - BE",
        "timestamp": "2016-02-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-002035-29/DE",
        "title": "A Randomized, Double-blind, Placebo-controlled Study to Evaluate the\r\nEfficacy and Safety of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267)\r\nand ABT-333 Co administered with Ribavirin (RBV) in Treat... - DE",
        "timestamp": "2013-01-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-002035-29/GB",
        "title": "A Randomized, Double-blind, Placebo-controlled Study to Evaluate the\r\nEfficacy and Safety of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267)\r\nand ABT-333 Co administered with Ribavirin (RBV) in Treat... - GB",
        "timestamp": "2013-01-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-002035-29/CZ",
        "title": "A Randomized, Double-blind, Placebo-controlled Study to Evaluate the\r\nEfficacy and Safety of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267)\r\nand ABT-333 Co administered with Ribavirin (RBV) in Treat... - CZ",
        "timestamp": "2013-01-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-002035-29/PT",
        "title": "A Randomized, Double-blind, Placebo-controlled Study to Evaluate the\r\nEfficacy and Safety of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267)\r\nand ABT-333 Co administered with Ribavirin (RBV) in Treat... - PT",
        "timestamp": "2013-01-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-002035-29/IE",
        "title": "A Randomized, Double-blind, Placebo-controlled Study to Evaluate the\r\nEfficacy and Safety of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267)\r\nand ABT-333 Co administered with Ribavirin (RBV) in Treat... - IE",
        "timestamp": "2013-01-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-002035-29/NL",
        "title": "A Randomized, Double-blind, Placebo-controlled Study to Evaluate the\r\nEfficacy and Safety of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267)\r\nand ABT-333 Co administered with Ribavirin (RBV) in Treat... - NL",
        "timestamp": "2013-01-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-002035-29/IT",
        "title": "A Randomized, Double-blind, Placebo-controlled Study to Evaluate the\r\nEfficacy and Safety of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267)\r\nand ABT-333 Co administered with Ribavirin (RBV) in Treat... - IT",
        "timestamp": "2013-01-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-002035-29/DK",
        "title": "A Randomized, Double-blind, Placebo-controlled Study to Evaluate the\r\nEfficacy and Safety of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267)\r\nand ABT-333 Co administered with Ribavirin (RBV) in Treat... - DK",
        "timestamp": "2013-01-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-002035-29/ES",
        "title": "A Randomized, Double-blind, Placebo-controlled Study to Evaluate the\r\nEfficacy and Safety of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267)\r\nand ABT-333 Co administered with Ribavirin (RBV) in Treat... - ES",
        "timestamp": "2013-01-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-002035-29/results",
        "title": "A Randomized, Double-blind, Placebo-controlled Study to Evaluate the\r\nEfficacy and Safety of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267)\r\nand ABT-333 Co administered with Ribavirin (RBV) in Treat... - View results",
        "timestamp": "2013-01-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005393-32/GB",
        "title": "An Open-Label Study to Evaluate the Safety, Antiviral Activity and Pharmacokinetics of Direct-Acting Antiviral Agent (DAA) Treatment in Combination with Peginterferon α-2a and Ribavirin (pegIFN/RBV... - GB",
        "timestamp": "2012-08-10"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005393-32/ES",
        "title": "An Open-Label Study to Evaluate the Safety, Antiviral Activity and Pharmacokinetics of Direct-Acting Antiviral Agent (DAA) Treatment in Combination with Peginterferon α-2a and Ribavirin (pegIFN/RBV... - ES",
        "timestamp": "2012-08-10"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005393-32/DE",
        "title": "An Open-Label Study to Evaluate the Safety, Antiviral Activity and Pharmacokinetics of Direct-Acting Antiviral Agent (DAA) Treatment in Combination with Peginterferon α-2a and Ribavirin (pegIFN/RBV... - DE",
        "timestamp": "2012-08-10"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005393-32/BE",
        "title": "An Open-Label Study to Evaluate the Safety, Antiviral Activity and Pharmacokinetics of Direct-Acting Antiviral Agent (DAA) Treatment in Combination with Peginterferon α-2a and Ribavirin (pegIFN/RBV... - BE",
        "timestamp": "2012-08-10"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005393-32/HU",
        "title": "An Open-Label Study to Evaluate the Safety, Antiviral Activity and Pharmacokinetics of Direct-Acting Antiviral Agent (DAA) Treatment in Combination with Peginterferon α-2a and Ribavirin (pegIFN/RBV... - HU",
        "timestamp": "2012-08-10"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005393-32/SE",
        "title": "An Open-Label Study to Evaluate the Safety, Antiviral Activity and Pharmacokinetics of Direct-Acting Antiviral Agent (DAA) Treatment in Combination with Peginterferon α-2a and Ribavirin (pegIFN/RBV... - SE",
        "timestamp": "2012-08-10"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005393-32/AT",
        "title": "An Open-Label Study to Evaluate the Safety, Antiviral Activity and Pharmacokinetics of Direct-Acting Antiviral Agent (DAA) Treatment in Combination with Peginterferon α-2a and Ribavirin (pegIFN/RBV... - AT",
        "timestamp": "2012-08-10"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005393-32/NL",
        "title": "An Open-Label Study to Evaluate the Safety, Antiviral Activity and Pharmacokinetics of Direct-Acting Antiviral Agent (DAA) Treatment in Combination with Peginterferon α-2a and Ribavirin (pegIFN/RBV... - NL",
        "timestamp": "2012-08-10"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005393-32/IT",
        "title": "An Open-Label Study to Evaluate the Safety, Antiviral Activity and Pharmacokinetics of Direct-Acting Antiviral Agent (DAA) Treatment in Combination with Peginterferon α-2a and Ribavirin (pegIFN/RBV... - IT",
        "timestamp": "2012-08-10"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005393-32/CZ",
        "title": "An Open-Label Study to Evaluate the Safety, Antiviral Activity and Pharmacokinetics of Direct-Acting Antiviral Agent (DAA) Treatment in Combination with Peginterferon α-2a and Ribavirin (pegIFN/RBV... - CZ",
        "timestamp": "2012-08-10"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005393-32/IE",
        "title": "An Open-Label Study to Evaluate the Safety, Antiviral Activity and Pharmacokinetics of Direct-Acting Antiviral Agent (DAA) Treatment in Combination with Peginterferon α-2a and Ribavirin (pegIFN/RBV... - IE",
        "timestamp": "2012-08-10"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005393-32/SK",
        "title": "An Open-Label Study to Evaluate the Safety, Antiviral Activity and Pharmacokinetics of Direct-Acting Antiviral Agent (DAA) Treatment in Combination with Peginterferon α-2a and Ribavirin (pegIFN/RBV... - SK",
        "timestamp": "2012-08-10"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005393-32/PT",
        "title": "An Open-Label Study to Evaluate the Safety, Antiviral Activity and Pharmacokinetics of Direct-Acting Antiviral Agent (DAA) Treatment in Combination with Peginterferon α-2a and Ribavirin (pegIFN/RBV... - PT",
        "timestamp": "2012-08-10"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005393-32/results",
        "title": "An Open-Label Study to Evaluate the Safety, Antiviral Activity and Pharmacokinetics of Direct-Acting Antiviral Agent (DAA) Treatment in Combination with Peginterferon α-2a and Ribavirin (pegIFN/RBV... - View results",
        "timestamp": "2012-08-10"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-003160-32/DE",
        "title": "A Phase III randomized, double-blinded, placebo-controlled trial to investigate the efficacy, tolerability and safety of TMC125 as part of an ART including TMC114/RTV and an investigator-selected O... - DE",
        "timestamp": "2005-12-13"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-003160-32/GB",
        "title": "A Phase III randomized, double-blinded, placebo-controlled trial to investigate the efficacy, tolerability and safety of TMC125 as part of an ART including TMC114/RTV and an investigator-selected O... - GB",
        "timestamp": "2005-12-13"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-003160-32/PT",
        "title": "A Phase III randomized, double-blinded, placebo-controlled trial to investigate the efficacy, tolerability and safety of TMC125 as part of an ART including TMC114/RTV and an investigator-selected O... - PT",
        "timestamp": "2005-12-13"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-003160-32/ES",
        "title": "A Phase III randomized, double-blinded, placebo-controlled trial to investigate the efficacy, tolerability and safety of TMC125 as part of an ART including TMC114/RTV and an investigator-selected O... - ES",
        "timestamp": "2005-12-13"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-003160-32/IT",
        "title": "A Phase III randomized, double-blinded, placebo-controlled trial to investigate the efficacy, tolerability and safety of TMC125 as part of an ART including TMC114/RTV and an investigator-selected O... - IT",
        "timestamp": "2005-12-13"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-003160-32/BE",
        "title": "A Phase III randomized, double-blinded, placebo-controlled trial to investigate the efficacy, tolerability and safety of TMC125 as part of an ART including TMC114/RTV and an investigator-selected O... - BE",
        "timestamp": "2005-12-13"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-003160-32/results",
        "title": "A Phase III randomized, double-blinded, placebo-controlled trial to investigate the efficacy, tolerability and safety of TMC125 as part of an ART including TMC114/RTV and an investigator-selected O... - View results",
        "timestamp": "2005-12-13"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-005023-33/FR",
        "title": "Safety and efficacy study of TPV boosted with low dose ritonavir (TPV/r) 500 mg/200 mg BID in antiretroviral treatment experienced HIV positive patients with HCV or HBV co-infection, with a pilot e... - FR",
        "timestamp": "2007-03-15"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-005023-33/PT",
        "title": "Safety and efficacy study of TPV boosted with low dose ritonavir (TPV/r) 500 mg/200 mg BID in antiretroviral treatment experienced HIV positive patients with HCV or HBV co-infection, with a pilot e... - PT",
        "timestamp": "2007-03-15"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-005023-33/ES",
        "title": "Safety and efficacy study of TPV boosted with low dose ritonavir (TPV/r) 500 mg/200 mg BID in antiretroviral treatment experienced HIV positive patients with HCV or HBV co-infection, with a pilot e... - ES",
        "timestamp": "2007-03-15"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-005023-33/DE",
        "title": "Safety and efficacy study of TPV boosted with low dose ritonavir (TPV/r) 500 mg/200 mg BID in antiretroviral treatment experienced HIV positive patients with HCV or HBV co-infection, with a pilot e... - DE",
        "timestamp": "2007-03-15"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-005023-33/IT",
        "title": "Safety and efficacy study of TPV boosted with low dose ritonavir (TPV/r) 500 mg/200 mg BID in antiretroviral treatment experienced HIV positive patients with HCV or HBV co-infection, with a pilot e... - IT",
        "timestamp": "2007-03-15"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-005023-33/results",
        "title": "Safety and efficacy study of TPV boosted with low dose ritonavir (TPV/r) 500 mg/200 mg BID in antiretroviral treatment experienced HIV positive patients with HCV or HBV co-infection, with a pilot e... - View results",
        "timestamp": "2007-03-15"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-004885-24/FR",
        "title": "Essai pilote multicentrique évaluant la capacité d’une stratégie de traitement antirétroviral intermittent à maintenir une stabilité immunologique chez des patients infectés par le VIH-1, jamais tr... - FR",
        "timestamp": "2009-01-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-001358-84/FR",
        "title": "Bone, Inflammation, Gut and Renal Biomarkers in Antiretroviral Naïve HIV-1 positive subjects commencing Antiretroviral Therapy - FR",
        "timestamp": "2018-10-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-021734-59/GB",
        "title": "Safety and Efficacy of 240 mg BI 201335 once daily in combination\r\nwith pegylated interferon alpha 2a and ribavirin for treatment of chronic\r\nHepatitis C (HCV) genotype 1 infection in HIV/HCV-co-in... - GB",
        "timestamp": "2011-08-11"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-021734-59/ES",
        "title": "Safety and Efficacy of 240 mg BI 201335 once daily in combination\r\nwith pegylated interferon alpha 2a and ribavirin for treatment of chronic\r\nHepatitis C (HCV) genotype 1 infection in HIV/HCV-co-in... - ES",
        "timestamp": "2011-08-11"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-021734-59/DE",
        "title": "Safety and Efficacy of 240 mg BI 201335 once daily in combination\r\nwith pegylated interferon alpha 2a and ribavirin for treatment of chronic\r\nHepatitis C (HCV) genotype 1 infection in HIV/HCV-co-in... - DE",
        "timestamp": "2011-08-11"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-021734-59/IT",
        "title": "Safety and Efficacy of 240 mg BI 201335 once daily in combination\r\nwith pegylated interferon alpha 2a and ribavirin for treatment of chronic\r\nHepatitis C (HCV) genotype 1 infection in HIV/HCV-co-in... - IT",
        "timestamp": "2011-08-11"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-021734-59/results",
        "title": "Safety and Efficacy of 240 mg BI 201335 once daily in combination\r\nwith pegylated interferon alpha 2a and ribavirin for treatment of chronic\r\nHepatitis C (HCV) genotype 1 infection in HIV/HCV-co-in... - View results",
        "timestamp": "2011-08-11"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-013648-35/IE",
        "title": "KONCERT \nA Kaletra ONCE daily Randomised Trial of the pharmacokinetics, safety and efficacy of twice-daily versus once-daily lopinavir/ritonavir tablets dosed by weight as part of combination antir... - IE",
        "timestamp": "2010-06-23"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-013648-35/NL",
        "title": "KONCERT \nA Kaletra ONCE daily Randomised Trial of the pharmacokinetics, safety and efficacy of twice-daily versus once-daily lopinavir/ritonavir tablets dosed by weight as part of combination antir... - NL",
        "timestamp": "2010-06-23"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-013648-35/FR",
        "title": "KONCERT \nA Kaletra ONCE daily Randomised Trial of the pharmacokinetics, safety and efficacy of twice-daily versus once-daily lopinavir/ritonavir tablets dosed by weight as part of combination antir... - FR",
        "timestamp": "2010-06-23"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-013648-35/GB",
        "title": "KONCERT \nA Kaletra ONCE daily Randomised Trial of the pharmacokinetics, safety and efficacy of twice-daily versus once-daily lopinavir/ritonavir tablets dosed by weight as part of combination antir... - GB",
        "timestamp": "2010-06-23"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-013648-35/ES",
        "title": "KONCERT \nA Kaletra ONCE daily Randomised Trial of the pharmacokinetics, safety and efficacy of twice-daily versus once-daily lopinavir/ritonavir tablets dosed by weight as part of combination antir... - ES",
        "timestamp": "2010-06-23"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-013648-35/PT",
        "title": "KONCERT \nA Kaletra ONCE daily Randomised Trial of the pharmacokinetics, safety and efficacy of twice-daily versus once-daily lopinavir/ritonavir tablets dosed by weight as part of combination antir... - PT",
        "timestamp": "2010-06-23"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-013648-35/BE",
        "title": "KONCERT \nA Kaletra ONCE daily Randomised Trial of the pharmacokinetics, safety and efficacy of twice-daily versus once-daily lopinavir/ritonavir tablets dosed by weight as part of combination antir... - BE",
        "timestamp": "2010-06-23"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-013648-35/DE",
        "title": "KONCERT \nA Kaletra ONCE daily Randomised Trial of the pharmacokinetics, safety and efficacy of twice-daily versus once-daily lopinavir/ritonavir tablets dosed by weight as part of combination antir... - DE",
        "timestamp": "2010-06-23"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005981-39/ES",
        "title": "Pilot simplification study to Lopinavir/ritonavir 800/200 mg monotherapy regimen once daily - ES",
        "timestamp": "2012-03-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-000438-38/GB",
        "title": "Efficacy of Lopinavir in Pregnancy: Pharmacokinetic and Virological Studies with Kaletra melt extruded tablet formulation - GB",
        "timestamp": "2007-04-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-000438-38/results",
        "title": "Efficacy of Lopinavir in Pregnancy: Pharmacokinetic and Virological Studies with Kaletra melt extruded tablet formulation - View results",
        "timestamp": "2007-04-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-006297-23/GB",
        "title": "A study of the pharmacokinetics of new formulation lopinavir/ritonavir in the genital tract and plasma of HIV infected women in pregnancy - GB",
        "timestamp": "2007-06-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-006297-23/results",
        "title": "A study of the pharmacokinetics of new formulation lopinavir/ritonavir in the genital tract and plasma of HIV infected women in pregnancy - View results",
        "timestamp": "2007-06-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-003066-18/ES",
        "title": "Estudio piloto, aleatorizado, nacional, multicéntrico, de eficacia inmunológica, comparando un régimen TARGA de tres fármacos (Tenofovir + Emtricitabina + Lopinavir/r) y cuatro fármacos (Tenofovir ... - ES",
        "timestamp": "2007-12-15"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-000748-14/CZ",
        "title": "A Phase 3, Randomized, Open-label Study of Lopinavir/ritonavir Tablets 800/200 mg Once-daily Versus 400/100 mg Twice-daily when Coadministered with Nucleoside/Nucleotide Reverse Transcriptase Inhib... - CZ",
        "timestamp": "2006-08-14"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-000748-14/BE",
        "title": "A Phase 3, Randomized, Open-label Study of Lopinavir/ritonavir Tablets 800/200 mg Once-daily Versus 400/100 mg Twice-daily when Coadministered with Nucleoside/Nucleotide Reverse Transcriptase Inhib... - BE",
        "timestamp": "2006-08-14"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-000748-14/ES",
        "title": "A Phase 3, Randomized, Open-label Study of Lopinavir/ritonavir Tablets 800/200 mg Once-daily Versus 400/100 mg Twice-daily when Coadministered with Nucleoside/Nucleotide Reverse Transcriptase Inhib... - ES",
        "timestamp": "2006-08-14"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-000748-14/DE",
        "title": "A Phase 3, Randomized, Open-label Study of Lopinavir/ritonavir Tablets 800/200 mg Once-daily Versus 400/100 mg Twice-daily when Coadministered with Nucleoside/Nucleotide Reverse Transcriptase Inhib... - DE",
        "timestamp": "2006-08-14"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-000748-14/IE",
        "title": "A Phase 3, Randomized, Open-label Study of Lopinavir/ritonavir Tablets 800/200 mg Once-daily Versus 400/100 mg Twice-daily when Coadministered with Nucleoside/Nucleotide Reverse Transcriptase Inhib... - IE",
        "timestamp": "2006-08-14"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-000748-14/PT",
        "title": "A Phase 3, Randomized, Open-label Study of Lopinavir/ritonavir Tablets 800/200 mg Once-daily Versus 400/100 mg Twice-daily when Coadministered with Nucleoside/Nucleotide Reverse Transcriptase Inhib... - PT",
        "timestamp": "2006-08-14"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-000748-14/GR",
        "title": "A Phase 3, Randomized, Open-label Study of Lopinavir/ritonavir Tablets 800/200 mg Once-daily Versus 400/100 mg Twice-daily when Coadministered with Nucleoside/Nucleotide Reverse Transcriptase Inhib... - GR",
        "timestamp": "2006-08-14"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-000748-14/IT",
        "title": "A Phase 3, Randomized, Open-label Study of Lopinavir/ritonavir Tablets 800/200 mg Once-daily Versus 400/100 mg Twice-daily when Coadministered with Nucleoside/Nucleotide Reverse Transcriptase Inhib... - IT",
        "timestamp": "2006-08-14"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-000748-14/GB",
        "title": "A Phase 3, Randomized, Open-label Study of Lopinavir/ritonavir Tablets 800/200 mg Once-daily Versus 400/100 mg Twice-daily when Coadministered with Nucleoside/Nucleotide Reverse Transcriptase Inhib... - GB",
        "timestamp": "2006-08-14"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-000748-14/results",
        "title": "A Phase 3, Randomized, Open-label Study of Lopinavir/ritonavir Tablets 800/200 mg Once-daily Versus 400/100 mg Twice-daily when Coadministered with Nucleoside/Nucleotide Reverse Transcriptase Inhib... - View results",
        "timestamp": "2006-08-14"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-000881-22/FR",
        "title": "A Randomized, Open-label, Study of Lopinavir/ritonavir 400/100 mg Tablet Twice-Daily + Co-formulated Emtricitabine/Tenofovir Disoproxil Fumarate 200/300 mg Once-Daily Versus Lopinavir/ritonavir 400... - FR",
        "timestamp": "2008-07-17"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-000881-22/ES",
        "title": "A Randomized, Open-label, Study of Lopinavir/ritonavir 400/100 mg Tablet Twice-Daily + Co-formulated Emtricitabine/Tenofovir Disoproxil Fumarate 200/300 mg Once-Daily Versus Lopinavir/ritonavir 400... - ES",
        "timestamp": "2008-07-17"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-000881-22/IT",
        "title": "A Randomized, Open-label, Study of Lopinavir/ritonavir 400/100 mg Tablet Twice-Daily + Co-formulated Emtricitabine/Tenofovir Disoproxil Fumarate 200/300 mg Once-Daily Versus Lopinavir/ritonavir 400... - IT",
        "timestamp": "2008-07-17"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-000881-22/results",
        "title": "A Randomized, Open-label, Study of Lopinavir/ritonavir 400/100 mg Tablet Twice-Daily + Co-formulated Emtricitabine/Tenofovir Disoproxil Fumarate 200/300 mg Once-Daily Versus Lopinavir/ritonavir 400... - View results",
        "timestamp": "2008-07-17"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-023008-29/ES",
        "title": "Estudio Fase 3, Aleatorizado, Abierto, Controlado de Lopinavir/Ritonavir y Lamivudina versus terapia estándar en Pacientes Infectados con HIV-1 Naïve. - ES",
        "timestamp": "2011-01-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-019446-38/ES",
        "title": "Estudio Exploratorio Transversal para Comparar la Eficacia Virológica en el LCR y el Estado Neurocognitivo en Pacientes Infectados por el VIH-1 en Tratamiento Prolongado (> 3 años) con Lopinavir/ri... - ES",
        "timestamp": "2010-06-04"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-019446-38/results",
        "title": "Estudio Exploratorio Transversal para Comparar la Eficacia Virológica en el LCR y el Estado Neurocognitivo en Pacientes Infectados por el VIH-1 en Tratamiento Prolongado (> 3 años) con Lopinavir/ri... - View results",
        "timestamp": "2010-06-04"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-001323-37/ES",
        "title": "Phase IV-III, open-label, randomized, comparative study, to evaluate the safety and efficacy of the nucleoside supression of a triple therapy based on lopinavir-ritonavir vs. continuous triple ther... - ES",
        "timestamp": "2004-11-29"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-001430-32/IE",
        "title": "A Phase 3, Randomized, Open-label, Study of Lopinavir/ritonavir Tablets Versus Soft Gel Capsules and Once Daily Versus Twice Daily Administration, when Coadministered with NRTIs in Antiretroviral N... - IE",
        "timestamp": "2005-11-18"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-001430-32/GB",
        "title": "A Phase 3, Randomized, Open-label, Study of Lopinavir/ritonavir Tablets Versus Soft Gel Capsules and Once Daily Versus Twice Daily Administration, when Coadministered with NRTIs in Antiretroviral N... - GB",
        "timestamp": "2005-11-18"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-001430-32/DE",
        "title": "A Phase 3, Randomized, Open-label, Study of Lopinavir/ritonavir Tablets Versus Soft Gel Capsules and Once Daily Versus Twice Daily Administration, when Coadministered with NRTIs in Antiretroviral N... - DE",
        "timestamp": "2005-11-18"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-001430-32/CZ",
        "title": "A Phase 3, Randomized, Open-label, Study of Lopinavir/ritonavir Tablets Versus Soft Gel Capsules and Once Daily Versus Twice Daily Administration, when Coadministered with NRTIs in Antiretroviral N... - CZ",
        "timestamp": "2005-11-18"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-001430-32/BE",
        "title": "A Phase 3, Randomized, Open-label, Study of Lopinavir/ritonavir Tablets Versus Soft Gel Capsules and Once Daily Versus Twice Daily Administration, when Coadministered with NRTIs in Antiretroviral N... - BE",
        "timestamp": "2005-11-18"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-001430-32/ES",
        "title": "A Phase 3, Randomized, Open-label, Study of Lopinavir/ritonavir Tablets Versus Soft Gel Capsules and Once Daily Versus Twice Daily Administration, when Coadministered with NRTIs in Antiretroviral N... - ES",
        "timestamp": "2005-11-18"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-001430-32/GR",
        "title": "A Phase 3, Randomized, Open-label, Study of Lopinavir/ritonavir Tablets Versus Soft Gel Capsules and Once Daily Versus Twice Daily Administration, when Coadministered with NRTIs in Antiretroviral N... - GR",
        "timestamp": "2005-11-18"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-001430-32/IT",
        "title": "A Phase 3, Randomized, Open-label, Study of Lopinavir/ritonavir Tablets Versus Soft Gel Capsules and Once Daily Versus Twice Daily Administration, when Coadministered with NRTIs in Antiretroviral N... - IT",
        "timestamp": "2005-11-18"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-001430-32/results",
        "title": "A Phase 3, Randomized, Open-label, Study of Lopinavir/ritonavir Tablets Versus Soft Gel Capsules and Once Daily Versus Twice Daily Administration, when Coadministered with NRTIs in Antiretroviral N... - View results",
        "timestamp": "2005-11-18"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-000060-27/IT",
        "title": "A Phase IIIB, Randomized, Open-Label, Multicenter Study of the Safety and Efficacy of GW433908  700mg BID  plus ritonavir  100mg BID  Versus Lopinavir/ritonavir  400mg/100mg  BID  when Administered... - IT",
        "timestamp": "2004-06-30"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-000060-27/results",
        "title": "A Phase IIIB, Randomized, Open-Label, Multicenter Study of the Safety and Efficacy of GW433908  700mg BID  plus ritonavir  100mg BID  Versus Lopinavir/ritonavir  400mg/100mg  BID  when Administered... - View results",
        "timestamp": "2004-06-30"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-012283-14/IE",
        "title": "A randomised open‐label study comparing the safety and efficacy of ritonavir boosted lopinavir and 2‐3N(t)RTI backbone versus ritonavir boosted lopinavir and raltegravir in participants virological... - IE",
        "timestamp": "2010-08-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-012283-14/FR",
        "title": "A randomised open‐label study comparing the safety and efficacy of ritonavir boosted lopinavir and 2‐3N(t)RTI backbone versus ritonavir boosted lopinavir and raltegravir in participants virological... - FR",
        "timestamp": "2010-08-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-012283-14/GB",
        "title": "A randomised open‐label study comparing the safety and efficacy of ritonavir boosted lopinavir and 2‐3N(t)RTI backbone versus ritonavir boosted lopinavir and raltegravir in participants virological... - GB",
        "timestamp": "2010-08-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-012283-14/DE",
        "title": "A randomised open‐label study comparing the safety and efficacy of ritonavir boosted lopinavir and 2‐3N(t)RTI backbone versus ritonavir boosted lopinavir and raltegravir in participants virological... - DE",
        "timestamp": "2010-08-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-002864-24/NL",
        "title": "Drug interactions between ATOvaquone used in MAlaria prophylaxis and antiretroviral agents in HIV-1 infected patients (ATOMA) - NL",
        "timestamp": "2006-09-25"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-002864-24/results",
        "title": "Drug interactions between ATOvaquone used in MAlaria prophylaxis and antiretroviral agents in HIV-1 infected patients (ATOMA) - View results",
        "timestamp": "2006-09-25"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-024652-28/ES",
        "title": "Estudio para evaluar la actividad y la tolerabilidad de la biterapia con lopinavir/ritonavir y 3TC en sustitución de una triple terapia que incluya lopinavir/ritonavir y 3TC ó FTC en pacientes con ... - ES",
        "timestamp": "2011-08-08"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-003799-35/ES",
        "title": "Comparison of two antiretroviral regimens in HIV Post-exposure Prophylaxis: TDF-FTC (Truvada®) + Lopinavir/ritonavir (kaletra®) versus TDF-FTC (Truvada®) + raltegravir (Isentress®) - ES",
        "timestamp": "2012-01-05"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-002296-16/ES",
        "title": "Ensayo para evaluar la eficacia, seguridad y tolerabilidad, de una estrategia de simplificacion temprana a Trizivir, en pacientes con supresion virologica tras tratamiento antiretroviral con Combiv... - ES",
        "timestamp": "2004-11-26"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-013287-39/ES",
        "title": "RANDOMISED AND PROSPECTIVE CLINICAL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LOPINAVIR/RITONAVIR MONOTHERAPY VS DARUNAVIR/RITONAVIR MONOTHERAPIES AS SIMPLIFICATION SWITCHING STRATEGIES OF PI/NN... - ES",
        "timestamp": "2009-09-25"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-013287-39/results",
        "title": "RANDOMISED AND PROSPECTIVE CLINICAL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LOPINAVIR/RITONAVIR MONOTHERAPY VS DARUNAVIR/RITONAVIR MONOTHERAPIES AS SIMPLIFICATION SWITCHING STRATEGIES OF PI/NN... - View results",
        "timestamp": "2009-09-25"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-006042-33/IT",
        "title": "A pilot, open label, multicenter, randomized clinical trial on Lopinavir/Ritonavir-monotherapy vs Lopinavir/Ritonavir plus selected Nucs, in HIV/HCV  coinfected patients with chronic hepatitis C or... - IT",
        "timestamp": "2007-02-01"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-014430-25/ES",
        "title": "Ensayo clínico abierto, aleatorizado, para comparar la calidad de vida de los pacientes VIH+ que inician monoterapia con comprimidos de LPV/r vs triple terapia que contengan un IP potenciado - ES",
        "timestamp": "2009-12-17"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-013648-35/IE",
        "title": "KONCERT \nA Kaletra ONCE daily Randomised Trial of the pharmacokinetics, safety and efficacy of twice-daily versus once-daily lopinavir/ritonavir tablets dosed by weight as part of combination antir... - IE",
        "timestamp": "2010-06-23"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-013648-35/NL",
        "title": "KONCERT \nA Kaletra ONCE daily Randomised Trial of the pharmacokinetics, safety and efficacy of twice-daily versus once-daily lopinavir/ritonavir tablets dosed by weight as part of combination antir... - NL",
        "timestamp": "2010-06-23"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-013648-35/FR",
        "title": "KONCERT \nA Kaletra ONCE daily Randomised Trial of the pharmacokinetics, safety and efficacy of twice-daily versus once-daily lopinavir/ritonavir tablets dosed by weight as part of combination antir... - FR",
        "timestamp": "2010-06-23"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-013648-35/GB",
        "title": "KONCERT \nA Kaletra ONCE daily Randomised Trial of the pharmacokinetics, safety and efficacy of twice-daily versus once-daily lopinavir/ritonavir tablets dosed by weight as part of combination antir... - GB",
        "timestamp": "2010-06-23"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-013648-35/ES",
        "title": "KONCERT \nA Kaletra ONCE daily Randomised Trial of the pharmacokinetics, safety and efficacy of twice-daily versus once-daily lopinavir/ritonavir tablets dosed by weight as part of combination antir... - ES",
        "timestamp": "2010-06-23"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-013648-35/PT",
        "title": "KONCERT \nA Kaletra ONCE daily Randomised Trial of the pharmacokinetics, safety and efficacy of twice-daily versus once-daily lopinavir/ritonavir tablets dosed by weight as part of combination antir... - PT",
        "timestamp": "2010-06-23"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-013648-35/BE",
        "title": "KONCERT \nA Kaletra ONCE daily Randomised Trial of the pharmacokinetics, safety and efficacy of twice-daily versus once-daily lopinavir/ritonavir tablets dosed by weight as part of combination antir... - BE",
        "timestamp": "2010-06-23"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-013648-35/DE",
        "title": "KONCERT \nA Kaletra ONCE daily Randomised Trial of the pharmacokinetics, safety and efficacy of twice-daily versus once-daily lopinavir/ritonavir tablets dosed by weight as part of combination antir... - DE",
        "timestamp": "2010-06-23"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005981-39/ES",
        "title": "Pilot simplification study to Lopinavir/ritonavir 800/200 mg monotherapy regimen once daily - ES",
        "timestamp": "2012-03-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-000438-38/GB",
        "title": "Efficacy of Lopinavir in Pregnancy: Pharmacokinetic and Virological Studies with Kaletra melt extruded tablet formulation - GB",
        "timestamp": "2007-04-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-000438-38/results",
        "title": "Efficacy of Lopinavir in Pregnancy: Pharmacokinetic and Virological Studies with Kaletra melt extruded tablet formulation - View results",
        "timestamp": "2007-04-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-006297-23/GB",
        "title": "A study of the pharmacokinetics of new formulation lopinavir/ritonavir in the genital tract and plasma of HIV infected women in pregnancy - GB",
        "timestamp": "2007-06-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-006297-23/results",
        "title": "A study of the pharmacokinetics of new formulation lopinavir/ritonavir in the genital tract and plasma of HIV infected women in pregnancy - View results",
        "timestamp": "2007-06-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-003066-18/ES",
        "title": "Estudio piloto, aleatorizado, nacional, multicéntrico, de eficacia inmunológica, comparando un régimen TARGA de tres fármacos (Tenofovir + Emtricitabina + Lopinavir/r) y cuatro fármacos (Tenofovir ... - ES",
        "timestamp": "2007-12-15"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-000748-14/CZ",
        "title": "A Phase 3, Randomized, Open-label Study of Lopinavir/ritonavir Tablets 800/200 mg Once-daily Versus 400/100 mg Twice-daily when Coadministered with Nucleoside/Nucleotide Reverse Transcriptase Inhib... - CZ",
        "timestamp": "2006-08-14"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-000748-14/BE",
        "title": "A Phase 3, Randomized, Open-label Study of Lopinavir/ritonavir Tablets 800/200 mg Once-daily Versus 400/100 mg Twice-daily when Coadministered with Nucleoside/Nucleotide Reverse Transcriptase Inhib... - BE",
        "timestamp": "2006-08-14"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-000748-14/ES",
        "title": "A Phase 3, Randomized, Open-label Study of Lopinavir/ritonavir Tablets 800/200 mg Once-daily Versus 400/100 mg Twice-daily when Coadministered with Nucleoside/Nucleotide Reverse Transcriptase Inhib... - ES",
        "timestamp": "2006-08-14"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-000748-14/DE",
        "title": "A Phase 3, Randomized, Open-label Study of Lopinavir/ritonavir Tablets 800/200 mg Once-daily Versus 400/100 mg Twice-daily when Coadministered with Nucleoside/Nucleotide Reverse Transcriptase Inhib... - DE",
        "timestamp": "2006-08-14"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-000748-14/IE",
        "title": "A Phase 3, Randomized, Open-label Study of Lopinavir/ritonavir Tablets 800/200 mg Once-daily Versus 400/100 mg Twice-daily when Coadministered with Nucleoside/Nucleotide Reverse Transcriptase Inhib... - IE",
        "timestamp": "2006-08-14"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-000748-14/PT",
        "title": "A Phase 3, Randomized, Open-label Study of Lopinavir/ritonavir Tablets 800/200 mg Once-daily Versus 400/100 mg Twice-daily when Coadministered with Nucleoside/Nucleotide Reverse Transcriptase Inhib... - PT",
        "timestamp": "2006-08-14"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-000748-14/GR",
        "title": "A Phase 3, Randomized, Open-label Study of Lopinavir/ritonavir Tablets 800/200 mg Once-daily Versus 400/100 mg Twice-daily when Coadministered with Nucleoside/Nucleotide Reverse Transcriptase Inhib... - GR",
        "timestamp": "2006-08-14"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-000748-14/IT",
        "title": "A Phase 3, Randomized, Open-label Study of Lopinavir/ritonavir Tablets 800/200 mg Once-daily Versus 400/100 mg Twice-daily when Coadministered with Nucleoside/Nucleotide Reverse Transcriptase Inhib... - IT",
        "timestamp": "2006-08-14"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-000748-14/GB",
        "title": "A Phase 3, Randomized, Open-label Study of Lopinavir/ritonavir Tablets 800/200 mg Once-daily Versus 400/100 mg Twice-daily when Coadministered with Nucleoside/Nucleotide Reverse Transcriptase Inhib... - GB",
        "timestamp": "2006-08-14"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-000748-14/results",
        "title": "A Phase 3, Randomized, Open-label Study of Lopinavir/ritonavir Tablets 800/200 mg Once-daily Versus 400/100 mg Twice-daily when Coadministered with Nucleoside/Nucleotide Reverse Transcriptase Inhib... - View results",
        "timestamp": "2006-08-14"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-000881-22/FR",
        "title": "A Randomized, Open-label, Study of Lopinavir/ritonavir 400/100 mg Tablet Twice-Daily + Co-formulated Emtricitabine/Tenofovir Disoproxil Fumarate 200/300 mg Once-Daily Versus Lopinavir/ritonavir 400... - FR",
        "timestamp": "2008-07-17"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-000881-22/ES",
        "title": "A Randomized, Open-label, Study of Lopinavir/ritonavir 400/100 mg Tablet Twice-Daily + Co-formulated Emtricitabine/Tenofovir Disoproxil Fumarate 200/300 mg Once-Daily Versus Lopinavir/ritonavir 400... - ES",
        "timestamp": "2008-07-17"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-000881-22/IT",
        "title": "A Randomized, Open-label, Study of Lopinavir/ritonavir 400/100 mg Tablet Twice-Daily + Co-formulated Emtricitabine/Tenofovir Disoproxil Fumarate 200/300 mg Once-Daily Versus Lopinavir/ritonavir 400... - IT",
        "timestamp": "2008-07-17"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-000881-22/results",
        "title": "A Randomized, Open-label, Study of Lopinavir/ritonavir 400/100 mg Tablet Twice-Daily + Co-formulated Emtricitabine/Tenofovir Disoproxil Fumarate 200/300 mg Once-Daily Versus Lopinavir/ritonavir 400... - View results",
        "timestamp": "2008-07-17"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-023008-29/ES",
        "title": "Estudio Fase 3, Aleatorizado, Abierto, Controlado de Lopinavir/Ritonavir y Lamivudina versus terapia estándar en Pacientes Infectados con HIV-1 Naïve. - ES",
        "timestamp": "2011-01-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-019446-38/ES",
        "title": "Estudio Exploratorio Transversal para Comparar la Eficacia Virológica en el LCR y el Estado Neurocognitivo en Pacientes Infectados por el VIH-1 en Tratamiento Prolongado (> 3 años) con Lopinavir/ri... - ES",
        "timestamp": "2010-06-04"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-019446-38/results",
        "title": "Estudio Exploratorio Transversal para Comparar la Eficacia Virológica en el LCR y el Estado Neurocognitivo en Pacientes Infectados por el VIH-1 en Tratamiento Prolongado (> 3 años) con Lopinavir/ri... - View results",
        "timestamp": "2010-06-04"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-001323-37/ES",
        "title": "Phase IV-III, open-label, randomized, comparative study, to evaluate the safety and efficacy of the nucleoside supression of a triple therapy based on lopinavir-ritonavir vs. continuous triple ther... - ES",
        "timestamp": "2004-11-29"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-001430-32/IE",
        "title": "A Phase 3, Randomized, Open-label, Study of Lopinavir/ritonavir Tablets Versus Soft Gel Capsules and Once Daily Versus Twice Daily Administration, when Coadministered with NRTIs in Antiretroviral N... - IE",
        "timestamp": "2005-11-18"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-001430-32/GB",
        "title": "A Phase 3, Randomized, Open-label, Study of Lopinavir/ritonavir Tablets Versus Soft Gel Capsules and Once Daily Versus Twice Daily Administration, when Coadministered with NRTIs in Antiretroviral N... - GB",
        "timestamp": "2005-11-18"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-001430-32/DE",
        "title": "A Phase 3, Randomized, Open-label, Study of Lopinavir/ritonavir Tablets Versus Soft Gel Capsules and Once Daily Versus Twice Daily Administration, when Coadministered with NRTIs in Antiretroviral N... - DE",
        "timestamp": "2005-11-18"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-001430-32/CZ",
        "title": "A Phase 3, Randomized, Open-label, Study of Lopinavir/ritonavir Tablets Versus Soft Gel Capsules and Once Daily Versus Twice Daily Administration, when Coadministered with NRTIs in Antiretroviral N... - CZ",
        "timestamp": "2005-11-18"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-001430-32/BE",
        "title": "A Phase 3, Randomized, Open-label, Study of Lopinavir/ritonavir Tablets Versus Soft Gel Capsules and Once Daily Versus Twice Daily Administration, when Coadministered with NRTIs in Antiretroviral N... - BE",
        "timestamp": "2005-11-18"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-001430-32/ES",
        "title": "A Phase 3, Randomized, Open-label, Study of Lopinavir/ritonavir Tablets Versus Soft Gel Capsules and Once Daily Versus Twice Daily Administration, when Coadministered with NRTIs in Antiretroviral N... - ES",
        "timestamp": "2005-11-18"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-001430-32/GR",
        "title": "A Phase 3, Randomized, Open-label, Study of Lopinavir/ritonavir Tablets Versus Soft Gel Capsules and Once Daily Versus Twice Daily Administration, when Coadministered with NRTIs in Antiretroviral N... - GR",
        "timestamp": "2005-11-18"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-001430-32/IT",
        "title": "A Phase 3, Randomized, Open-label, Study of Lopinavir/ritonavir Tablets Versus Soft Gel Capsules and Once Daily Versus Twice Daily Administration, when Coadministered with NRTIs in Antiretroviral N... - IT",
        "timestamp": "2005-11-18"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-001430-32/results",
        "title": "A Phase 3, Randomized, Open-label, Study of Lopinavir/ritonavir Tablets Versus Soft Gel Capsules and Once Daily Versus Twice Daily Administration, when Coadministered with NRTIs in Antiretroviral N... - View results",
        "timestamp": "2005-11-18"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-000060-27/IT",
        "title": "A Phase IIIB, Randomized, Open-Label, Multicenter Study of the Safety and Efficacy of GW433908  700mg BID  plus ritonavir  100mg BID  Versus Lopinavir/ritonavir  400mg/100mg  BID  when Administered... - IT",
        "timestamp": "2004-06-30"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-000060-27/results",
        "title": "A Phase IIIB, Randomized, Open-Label, Multicenter Study of the Safety and Efficacy of GW433908  700mg BID  plus ritonavir  100mg BID  Versus Lopinavir/ritonavir  400mg/100mg  BID  when Administered... - View results",
        "timestamp": "2004-06-30"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-012283-14/IE",
        "title": "A randomised open‐label study comparing the safety and efficacy of ritonavir boosted lopinavir and 2‐3N(t)RTI backbone versus ritonavir boosted lopinavir and raltegravir in participants virological... - IE",
        "timestamp": "2010-08-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-012283-14/FR",
        "title": "A randomised open‐label study comparing the safety and efficacy of ritonavir boosted lopinavir and 2‐3N(t)RTI backbone versus ritonavir boosted lopinavir and raltegravir in participants virological... - FR",
        "timestamp": "2010-08-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-012283-14/GB",
        "title": "A randomised open‐label study comparing the safety and efficacy of ritonavir boosted lopinavir and 2‐3N(t)RTI backbone versus ritonavir boosted lopinavir and raltegravir in participants virological... - GB",
        "timestamp": "2010-08-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-012283-14/DE",
        "title": "A randomised open‐label study comparing the safety and efficacy of ritonavir boosted lopinavir and 2‐3N(t)RTI backbone versus ritonavir boosted lopinavir and raltegravir in participants virological... - DE",
        "timestamp": "2010-08-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-002864-24/NL",
        "title": "Drug interactions between ATOvaquone used in MAlaria prophylaxis and antiretroviral agents in HIV-1 infected patients (ATOMA) - NL",
        "timestamp": "2006-09-25"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-002864-24/results",
        "title": "Drug interactions between ATOvaquone used in MAlaria prophylaxis and antiretroviral agents in HIV-1 infected patients (ATOMA) - View results",
        "timestamp": "2006-09-25"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-024652-28/ES",
        "title": "Estudio para evaluar la actividad y la tolerabilidad de la biterapia con lopinavir/ritonavir y 3TC en sustitución de una triple terapia que incluya lopinavir/ritonavir y 3TC ó FTC en pacientes con ... - ES",
        "timestamp": "2011-08-08"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-003799-35/ES",
        "title": "Comparison of two antiretroviral regimens in HIV Post-exposure Prophylaxis: TDF-FTC (Truvada®) + Lopinavir/ritonavir (kaletra®) versus TDF-FTC (Truvada®) + raltegravir (Isentress®) - ES",
        "timestamp": "2012-01-05"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-002296-16/ES",
        "title": "Ensayo para evaluar la eficacia, seguridad y tolerabilidad, de una estrategia de simplificacion temprana a Trizivir, en pacientes con supresion virologica tras tratamiento antiretroviral con Combiv... - ES",
        "timestamp": "2004-11-26"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-013287-39/ES",
        "title": "RANDOMISED AND PROSPECTIVE CLINICAL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LOPINAVIR/RITONAVIR MONOTHERAPY VS DARUNAVIR/RITONAVIR MONOTHERAPIES AS SIMPLIFICATION SWITCHING STRATEGIES OF PI/NN... - ES",
        "timestamp": "2009-09-25"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-013287-39/results",
        "title": "RANDOMISED AND PROSPECTIVE CLINICAL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LOPINAVIR/RITONAVIR MONOTHERAPY VS DARUNAVIR/RITONAVIR MONOTHERAPIES AS SIMPLIFICATION SWITCHING STRATEGIES OF PI/NN... - View results",
        "timestamp": "2009-09-25"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-006042-33/IT",
        "title": "A pilot, open label, multicenter, randomized clinical trial on Lopinavir/Ritonavir-monotherapy vs Lopinavir/Ritonavir plus selected Nucs, in HIV/HCV  coinfected patients with chronic hepatitis C or... - IT",
        "timestamp": "2007-02-01"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-014430-25/ES",
        "title": "Ensayo clínico abierto, aleatorizado, para comparar la calidad de vida de los pacientes VIH+ que inician monoterapia con comprimidos de LPV/r vs triple terapia que contengan un IP potenciado - ES",
        "timestamp": "2009-12-17"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-002585-19/GB",
        "title": "A 24-week, randomised, open-label, 2-arm study to compare the tolerability and efficacy of saquinavir tablets with ritonavir versus lopinavir/ritonavir tablets in HIV 1 infected adults switching fr... - GB",
        "timestamp": "2006-08-02"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-004990-27/IT",
        "title": "The pharmacokinetic interaction between TMC114, lopinavir and ritonavir, in HIV-1 infected subjects. - IT",
        "timestamp": "2005-05-09"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-004990-27/results",
        "title": "The pharmacokinetic interaction between TMC114, lopinavir and ritonavir, in HIV-1 infected subjects. - View results",
        "timestamp": "2005-05-09"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-003298-26/NL",
        "title": "A phase IV, randomized, open label, cross-over, intervention trial to investigate the effect of the switch of lopinavir-ritonavir to raltegravir on endothelial function, chronic inflammation, immun... - NL",
        "timestamp": "2011-11-29"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-005996-17/IT",
        "title": "A pilot, open label, multicenter, randomized clinical trial on Lopinavir/ritonavir-monotherapy vs Lopinavir/ritonavir plus selected Nucs, in HIV/HCV ARV-naive coinfected patients with chronic hepat... - IT",
        "timestamp": "2007-02-02"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-000604-88/GB",
        "title": "A phase IV, two-arm, open-label, single-centre randomised pilot study to assess the feasibility of immeidate or deferred switching of HIV-infected individuals intolerant of efavirenz, ritonavir-boo... - GB",
        "timestamp": "2008-04-04"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-003438-12/ES",
        "title": "Ensayo Clínico aleatorizado para comparar la combinación ZDV + 3TC + ABC (Trizivir) frente a Lopinavir/R (Kaletra) en monoterapia en pacientes con supresión viral en tratamiento previo con ZDV + 3T... - ES",
        "timestamp": "2008-08-29"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-004698-39/DE",
        "title": "Randomized, double-blind, placebo-controlled 7 day monotherapy Phase IIa study to evaluate the antiviral activity and safety of  oral administered RTV-boosted BILR 355 (75 mg and 150 mg twice daily... - DE",
        "timestamp": "2006-02-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-004698-39/results",
        "title": "Randomized, double-blind, placebo-controlled 7 day monotherapy Phase IIa study to evaluate the antiviral activity and safety of  oral administered RTV-boosted BILR 355 (75 mg and 150 mg twice daily... - View results",
        "timestamp": "2006-02-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-001431-30/GB",
        "title": "A Randomized, Open Label Study Assessing Safety, Tolerability, and Efficacy of an Induction/Maintenance Treatment Strategy Including Lopinavir/ritonavir (LPV/r) plus Tenofovir Disoproxil Fumarate (... - GB",
        "timestamp": "2005-07-30"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-001431-30/IE",
        "title": "A Randomized, Open Label Study Assessing Safety, Tolerability, and Efficacy of an Induction/Maintenance Treatment Strategy Including Lopinavir/ritonavir (LPV/r) plus Tenofovir Disoproxil Fumarate (... - IE",
        "timestamp": "2005-07-30"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-021622-35/DE",
        "title": "A monocenter, non-controlled, non-randomized IST to compare bioavailability of Kaletra softgelcapsules or -suspension to Kaletra tablets in pediatric patients – C2T - DE",
        "timestamp": "2011-08-11"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-004519-67/ES",
        "title": "ENSAYO CLÍNICO PROSPECTIVO, ABIERTO Y ALEATORIZADO, SOBRE LA SEGURIDAD HEPÁTICA DEL TRATAMIENTO ANTIRRETROVIRAL QUE INCLUYE KALETRA VS NEVIRAPINA EN PACIENTES COINFECTADOS VIH/VHC. ESTUDIO KANELA. - ES",
        "timestamp": "2008-01-22"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-000816-24/ES",
        "title": "A Pilot, Open-Label, Randomized, Comparative Study of the Antiviral Efficacy of Lopinavir/Ritonavir Single-Drug Regimen versus Lopinavir/Ritonavir in Combination with Lamivudine/Zidovudine in Antir... - ES",
        "timestamp": "2004-10-28"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-000816-24/IT",
        "title": "A Pilot, Open-Label, Randomized, Comparative Study of the Antiviral Efficacy of Lopinavir/Ritonavir Single-Drug Regimen versus Lopinavir/Ritonavir in Combination with Lamivudine/Zidovudine in Antir... - IT",
        "timestamp": "2004-10-28"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-000816-24/results",
        "title": "A Pilot, Open-Label, Randomized, Comparative Study of the Antiviral Efficacy of Lopinavir/Ritonavir Single-Drug Regimen versus Lopinavir/Ritonavir in Combination with Lamivudine/Zidovudine in Antir... - View results",
        "timestamp": "2004-10-28"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-000948-25/ES",
        "title": "Determinación de niveles plasmáticos e intracelulares de los inhibidores de la transcriptasa inversa análogos a nucleósidos (NRTI) y del análogo a nucleótido tenofovir disoproxil fumarato (TDF) en ... - ES",
        "timestamp": "2004-10-01"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-000948-25/results",
        "title": "Determinación de niveles plasmáticos e intracelulares de los inhibidores de la transcriptasa inversa análogos a nucleósidos (NRTI) y del análogo a nucleótido tenofovir disoproxil fumarato (TDF) en ... - View results",
        "timestamp": "2004-10-01"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-000786-35/IT",
        "title": "A phase III, open-label, randomized, comparative study of the antiviral efficacy of ARV therapy with Lopinavir/Ritonavir (LPV/r - Kaletra) in combination with Tenofovir versus SOC (Kaletra in combi... - IT",
        "timestamp": "2004-11-02"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-000786-35/results",
        "title": "A phase III, open-label, randomized, comparative study of the antiviral efficacy of ARV therapy with Lopinavir/Ritonavir (LPV/r - Kaletra) in combination with Tenofovir versus SOC (Kaletra in combi... - View results",
        "timestamp": "2004-11-02"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-003544-30/ES",
        "title": "Estudio piloto, multicéntrico, aleatorizado y abierto, para evaluar el tratamiento concomitante de la co-infección por el VHC/VIH con peg-interferón + ribavirina, y lopinavir/r como único agente an... - ES",
        "timestamp": "2007-12-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-021624-99/DE",
        "title": "A multi-centre, non-controlled, non-randomised  IST to evaluate the plasma level of antiretroviral substances, the viral resistance profile and their impact on the clinical response in HIV infected... - DE",
        "timestamp": "2012-06-14"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-003865-33/GB",
        "title": "A Phase IIb, 96 week, randomized, open-label, multicenter, parallel group, repeat dose study to evaluate the safety, tolerability, pharmacokinetics and antiviral effect of different doses and regim... - GB",
        "timestamp": "2005-02-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-003865-33/IT",
        "title": "A Phase IIb, 96 week, randomized, open-label, multicenter, parallel group, repeat dose study to evaluate the safety, tolerability, pharmacokinetics and antiviral effect of different doses and regim... - IT",
        "timestamp": "2005-02-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-003865-33/DE",
        "title": "A Phase IIb, 96 week, randomized, open-label, multicenter, parallel group, repeat dose study to evaluate the safety, tolerability, pharmacokinetics and antiviral effect of different doses and regim... - DE",
        "timestamp": "2005-02-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-003865-33/ES",
        "title": "A Phase IIb, 96 week, randomized, open-label, multicenter, parallel group, repeat dose study to evaluate the safety, tolerability, pharmacokinetics and antiviral effect of different doses and regim... - ES",
        "timestamp": "2005-02-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-003865-33/results",
        "title": "A Phase IIb, 96 week, randomized, open-label, multicenter, parallel group, repeat dose study to evaluate the safety, tolerability, pharmacokinetics and antiviral effect of different doses and regim... - View results",
        "timestamp": "2005-02-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-002486-36/HU",
        "title": "A randomized, controlled, open-label trial to compare the efficacy, safety and tolerability of TMC114/ritonavir versus lopinavir/ritonavir in treatment-naïve HIV-1 infected subjects.\n\nA substudy of... - HU",
        "timestamp": "2006-01-25"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-002486-36/AT",
        "title": "A randomized, controlled, open-label trial to compare the efficacy, safety and tolerability of TMC114/ritonavir versus lopinavir/ritonavir in treatment-naïve HIV-1 infected subjects.\n\nA substudy of... - AT",
        "timestamp": "2006-01-25"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-002486-36/DE",
        "title": "A randomized, controlled, open-label trial to compare the efficacy, safety and tolerability of TMC114/ritonavir versus lopinavir/ritonavir in treatment-naïve HIV-1 infected subjects.\n\nA substudy of... - DE",
        "timestamp": "2006-01-25"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-002486-36/GB",
        "title": "A randomized, controlled, open-label trial to compare the efficacy, safety and tolerability of TMC114/ritonavir versus lopinavir/ritonavir in treatment-naïve HIV-1 infected subjects.\n\nA substudy of... - GB",
        "timestamp": "2006-01-25"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-002486-36/DK",
        "title": "A randomized, controlled, open-label trial to compare the efficacy, safety and tolerability of TMC114/ritonavir versus lopinavir/ritonavir in treatment-naïve HIV-1 infected subjects.\n\nA substudy of... - DK",
        "timestamp": "2006-01-25"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-002486-36/ES",
        "title": "A randomized, controlled, open-label trial to compare the efficacy, safety and tolerability of TMC114/ritonavir versus lopinavir/ritonavir in treatment-naïve HIV-1 infected subjects.\n\nA substudy of... - ES",
        "timestamp": "2006-01-25"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-002486-36/BE",
        "title": "A randomized, controlled, open-label trial to compare the efficacy, safety and tolerability of TMC114/ritonavir versus lopinavir/ritonavir in treatment-naïve HIV-1 infected subjects.\n\nA substudy of... - BE",
        "timestamp": "2006-01-25"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-002486-36/IT",
        "title": "A randomized, controlled, open-label trial to compare the efficacy, safety and tolerability of TMC114/ritonavir versus lopinavir/ritonavir in treatment-naïve HIV-1 infected subjects.\n\nA substudy of... - IT",
        "timestamp": "2006-01-25"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-002486-36/PT",
        "title": "A randomized, controlled, open-label trial to compare the efficacy, safety and tolerability of TMC114/ritonavir versus lopinavir/ritonavir in treatment-naïve HIV-1 infected subjects.\n\nA substudy of... - PT",
        "timestamp": "2006-01-25"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-002486-36/GR",
        "title": "A randomized, controlled, open-label trial to compare the efficacy, safety and tolerability of TMC114/ritonavir versus lopinavir/ritonavir in treatment-naïve HIV-1 infected subjects.\n\nA substudy of... - GR",
        "timestamp": "2006-01-25"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-002486-36/results",
        "title": "A randomized, controlled, open-label trial to compare the efficacy, safety and tolerability of TMC114/ritonavir versus lopinavir/ritonavir in treatment-naïve HIV-1 infected subjects.\n\nA substudy of... - View results",
        "timestamp": "2006-01-25"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-001895-11/GB",
        "title": "A 96 Week Study Comparing the Antiviral Efficacy and Safety of Atazanavir/ritonavir with Lopinavir/ritonavir, Each in Combination with Fixed Dose Tenofovir-Emtricitabine in HIV-1 Infected Treatment... - GB",
        "timestamp": "2006-02-07"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-001895-11/DE",
        "title": "A 96 Week Study Comparing the Antiviral Efficacy and Safety of Atazanavir/ritonavir with Lopinavir/ritonavir, Each in Combination with Fixed Dose Tenofovir-Emtricitabine in HIV-1 Infected Treatment... - DE",
        "timestamp": "2006-02-07"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-001895-11/AT",
        "title": "A 96 Week Study Comparing the Antiviral Efficacy and Safety of Atazanavir/ritonavir with Lopinavir/ritonavir, Each in Combination with Fixed Dose Tenofovir-Emtricitabine in HIV-1 Infected Treatment... - AT",
        "timestamp": "2006-02-07"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-001895-11/BE",
        "title": "A 96 Week Study Comparing the Antiviral Efficacy and Safety of Atazanavir/ritonavir with Lopinavir/ritonavir, Each in Combination with Fixed Dose Tenofovir-Emtricitabine in HIV-1 Infected Treatment... - BE",
        "timestamp": "2006-02-07"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-001895-11/PT",
        "title": "A 96 Week Study Comparing the Antiviral Efficacy and Safety of Atazanavir/ritonavir with Lopinavir/ritonavir, Each in Combination with Fixed Dose Tenofovir-Emtricitabine in HIV-1 Infected Treatment... - PT",
        "timestamp": "2006-02-07"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-001895-11/ES",
        "title": "A 96 Week Study Comparing the Antiviral Efficacy and Safety of Atazanavir/ritonavir with Lopinavir/ritonavir, Each in Combination with Fixed Dose Tenofovir-Emtricitabine in HIV-1 Infected Treatment... - ES",
        "timestamp": "2006-02-07"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-001895-11/DK",
        "title": "A 96 Week Study Comparing the Antiviral Efficacy and Safety of Atazanavir/ritonavir with Lopinavir/ritonavir, Each in Combination with Fixed Dose Tenofovir-Emtricitabine in HIV-1 Infected Treatment... - DK",
        "timestamp": "2006-02-07"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-001895-11/IT",
        "title": "A 96 Week Study Comparing the Antiviral Efficacy and Safety of Atazanavir/ritonavir with Lopinavir/ritonavir, Each in Combination with Fixed Dose Tenofovir-Emtricitabine in HIV-1 Infected Treatment... - IT",
        "timestamp": "2006-02-07"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-001895-11/results",
        "title": "A 96 Week Study Comparing the Antiviral Efficacy and Safety of Atazanavir/ritonavir with Lopinavir/ritonavir, Each in Combination with Fixed Dose Tenofovir-Emtricitabine in HIV-1 Infected Treatment... - View results",
        "timestamp": "2006-02-07"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-004464-30/ES",
        "title": "Impact of Raltegravir Intensification on HIV-1-infected Subjects with Complete Viral Suppression under Monotherapy with Protease Inhibitors. A 24-week controlled, open-label, proof-of-concept pilot... - ES",
        "timestamp": "2011-11-22"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-003896-38/IT",
        "title": "PHARMACOKINETICS AND PHARMACODYNAMICS IN THE OPTIMIZATION OF ANTIRETROVIRAL TREATMENT. - IT",
        "timestamp": "2007-07-05"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000936-23/FR",
        "title": "Multi-centre, adaptive, randomized trial of the safety and efficacy of treatments of COVID-19 in hospitalized adults - FR",
        "timestamp": "2020-03-09"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001113-21/GB",
        "title": "Randomised Evaluation of COVID-19 Therapy (RECOVERY) - GB",
        "timestamp": "2020-03-17"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-001193-34/ES",
        "title": "COMPARISON OF TWO ANTIRETROVIRAL ALTERNATIVE COMBINATIONS IN HIV-1 POST-EXPOSURE PROPHYLAXIS: TENOFOVIR+EMTRICITABINE (TRUVADA®) + LOPINAVIR/RITONAVIR (KALETRA®) VS TENOFOVIR+EMTRICITABINA+ COBICIS... - ES",
        "timestamp": "2014-07-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-004556-11/IT",
        "title": "Randomized,multicenter,open-label, study of monoterapy with darunavir/ritonavir or lopinavir/ritonavir vs standard of care in virologically suppressed HIV-infected patients. - IT",
        "timestamp": "2013-06-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-004556-11/results",
        "title": "Randomized,multicenter,open-label, study of monoterapy with darunavir/ritonavir or lopinavir/ritonavir vs standard of care in virologically suppressed HIV-infected patients. - View results",
        "timestamp": "2013-06-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-007765-23/IT",
        "title": "MoLO study - Evaluation of cost/efficacy ratio of monotherapy with lopinavir/ritonavir versus standard in patients treated with protesi inhibotors in virologic suppressison. - IT",
        "timestamp": "2010-03-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-002069-39/ES",
        "title": "Comparación de dos combinaciones de antirretrovirales en la Profilaxis Post-Exposición al VIH-1: TDF-FTC (Truvada ®) + Lopinavir/Ritonavir (Kaletra ®) vs TDF-FTC (Truvada ®) + Maraviroc (Celsentri ... - ES",
        "timestamp": "2011-09-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-016090-14/ES",
        "title": "Análisis de los cambios en el tejido adiposo de pacientes con infección VIH y lipoatrofia en tratamiento con análogos de nucleósidos timidínicos, tras el cambio a monoterapia con Lopinavir/ritonavir - ES",
        "timestamp": "2009-12-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005581-37/GB",
        "title": "Efficacy of Switch to Lopinavir/Ritonavir in Improving Cognitive function in Efavirenz treated patients - GB",
        "timestamp": "2012-08-06"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005581-37/results",
        "title": "Efficacy of Switch to Lopinavir/Ritonavir in Improving Cognitive function in Efavirenz treated patients - View results",
        "timestamp": "2012-08-06"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-000594-22/HU",
        "title": "A randomized, controlled, open-label trial to compare the efficacy, safety and tolerability of TMC114/RTV versus LPV/RTV in treatment-experienced HIV-1 infected subjects. - HU",
        "timestamp": "2005-06-13"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-000594-22/AT",
        "title": "A randomized, controlled, open-label trial to compare the efficacy, safety and tolerability of TMC114/RTV versus LPV/RTV in treatment-experienced HIV-1 infected subjects. - AT",
        "timestamp": "2005-06-13"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-000594-22/GB",
        "title": "A randomized, controlled, open-label trial to compare the efficacy, safety and tolerability of TMC114/RTV versus LPV/RTV in treatment-experienced HIV-1 infected subjects. - GB",
        "timestamp": "2005-06-13"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-000594-22/DE",
        "title": "A randomized, controlled, open-label trial to compare the efficacy, safety and tolerability of TMC114/RTV versus LPV/RTV in treatment-experienced HIV-1 infected subjects. - DE",
        "timestamp": "2005-06-13"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-000594-22/DK",
        "title": "A randomized, controlled, open-label trial to compare the efficacy, safety and tolerability of TMC114/RTV versus LPV/RTV in treatment-experienced HIV-1 infected subjects. - DK",
        "timestamp": "2005-06-13"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-000594-22/BE",
        "title": "A randomized, controlled, open-label trial to compare the efficacy, safety and tolerability of TMC114/RTV versus LPV/RTV in treatment-experienced HIV-1 infected subjects. - BE",
        "timestamp": "2005-06-13"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-000594-22/ES",
        "title": "A randomized, controlled, open-label trial to compare the efficacy, safety and tolerability of TMC114/RTV versus LPV/RTV in treatment-experienced HIV-1 infected subjects. - ES",
        "timestamp": "2005-06-13"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-000594-22/IT",
        "title": "A randomized, controlled, open-label trial to compare the efficacy, safety and tolerability of TMC114/RTV versus LPV/RTV in treatment-experienced HIV-1 infected subjects. - IT",
        "timestamp": "2005-06-13"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-000594-22/results",
        "title": "A randomized, controlled, open-label trial to compare the efficacy, safety and tolerability of TMC114/RTV versus LPV/RTV in treatment-experienced HIV-1 infected subjects. - View results",
        "timestamp": "2005-06-13"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-003827-10/ES",
        "title": "A Phase III, Randomized, Controlled, Open-label, Multicentre, Three Arm Study to Compare the Efficacy and Safety of a Dual-boosted HIV-1 Protease Inhibitor (PI) regimen of Fosamprenavir (FPV)/ Lopi... - ES",
        "timestamp": "2004-12-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-003827-10/DE",
        "title": "A Phase III, Randomized, Controlled, Open-label, Multicentre, Three Arm Study to Compare the Efficacy and Safety of a Dual-boosted HIV-1 Protease Inhibitor (PI) regimen of Fosamprenavir (FPV)/ Lopi... - DE",
        "timestamp": "2004-12-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-003827-10/IT",
        "title": "A Phase III, Randomized, Controlled, Open-label, Multicentre, Three Arm Study to Compare the Efficacy and Safety of a Dual-boosted HIV-1 Protease Inhibitor (PI) regimen of Fosamprenavir (FPV)/ Lopi... - IT",
        "timestamp": "2004-12-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-003827-10/GB",
        "title": "A Phase III, Randomized, Controlled, Open-label, Multicentre, Three Arm Study to Compare the Efficacy and Safety of a Dual-boosted HIV-1 Protease Inhibitor (PI) regimen of Fosamprenavir (FPV)/ Lopi... - GB",
        "timestamp": "2004-12-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-003827-10/results",
        "title": "A Phase III, Randomized, Controlled, Open-label, Multicentre, Three Arm Study to Compare the Efficacy and Safety of a Dual-boosted HIV-1 Protease Inhibitor (PI) regimen of Fosamprenavir (FPV)/ Lopi... - View results",
        "timestamp": "2004-12-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-009776-13/FR",
        "title": "Essai clinique comparant l’efficacité et la tolérance de deux stratégies thérapeutiques de maintenance: monothérapie par lopinavir/ritonavir ou trithérapie en comprimé unique quotidien par efaviren... - FR",
        "timestamp": "2009-07-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-002043-16/ES",
        "title": "Estudio fase IV, abierto, aleatorizado, controlado, para evaluar el efecto sobre el perfil lipídico del cambio de un régimen TARGA estable de dosis fija de abacavir/lamivudina (Kivexa) más lopinavi... - ES",
        "timestamp": "2008-09-02"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-002043-16/DE",
        "title": "Estudio fase IV, abierto, aleatorizado, controlado, para evaluar el efecto sobre el perfil lipídico del cambio de un régimen TARGA estable de dosis fija de abacavir/lamivudina (Kivexa) más lopinavi... - DE",
        "timestamp": "2008-09-02"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-002043-16/AT",
        "title": "Estudio fase IV, abierto, aleatorizado, controlado, para evaluar el efecto sobre el perfil lipídico del cambio de un régimen TARGA estable de dosis fija de abacavir/lamivudina (Kivexa) más lopinavi... - AT",
        "timestamp": "2008-09-02"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-002043-16/IT",
        "title": "Estudio fase IV, abierto, aleatorizado, controlado, para evaluar el efecto sobre el perfil lipídico del cambio de un régimen TARGA estable de dosis fija de abacavir/lamivudina (Kivexa) más lopinavi... - IT",
        "timestamp": "2008-09-02"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-002043-16/results",
        "title": "Estudio fase IV, abierto, aleatorizado, controlado, para evaluar el efecto sobre el perfil lipídico del cambio de un régimen TARGA estable de dosis fija de abacavir/lamivudina (Kivexa) más lopinavi... - View results",
        "timestamp": "2008-09-02"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-006076-38/GB",
        "title": "The Liverpool HIV TDM Registry: Studying influences upon plasma HIV drug exposure - GB",
        "timestamp": "2007-04-26"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-003425-81/GB",
        "title": "Host genetic factors influencing drug disposition and response to HIV treatment - GB",
        "timestamp": "2007-03-29"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-002698-29/ES",
        "title": "Efectos del tratamiento inicial con 2 pautas antirretrovirales estándares actuales sobre el metabolismo lipídico - ES",
        "timestamp": "2007-07-31"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-002694-13/ES",
        "title": "Estudio piloto, fase IV para analizar la seguridad de los combos Truvada vs Kivexa como parte de un TARGA basado en Kaletra. Estudio COMBOKA - ES",
        "timestamp": "2009-06-18"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-010611-33/ES",
        "title": "Ensayo clínico para evaluar el efecto sobre la grasa subcutánea del cambio de EFV por LPV/r en pacientes infectados por VIH que desarrollaron lipoatrofia que sigue siendo clínicamente evidente a pe... - ES",
        "timestamp": "2009-09-28"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-003704-39/GB",
        "title": "An open label study examining the efficacy and cardiovascular risk of immediate versus deferred switch from a boosted PI to dolutegravir (DTG) in HIV infected patients with stable virological suppr... - GB",
        "timestamp": "2014-04-01"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-003704-39/BE",
        "title": "An open label study examining the efficacy and cardiovascular risk of immediate versus deferred switch from a boosted PI to dolutegravir (DTG) in HIV infected patients with stable virological suppr... - BE",
        "timestamp": "2014-04-01"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-003704-39/ES",
        "title": "An open label study examining the efficacy and cardiovascular risk of immediate versus deferred switch from a boosted PI to dolutegravir (DTG) in HIV infected patients with stable virological suppr... - ES",
        "timestamp": "2014-04-01"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-003704-39/IT",
        "title": "An open label study examining the efficacy and cardiovascular risk of immediate versus deferred switch from a boosted PI to dolutegravir (DTG) in HIV infected patients with stable virological suppr... - IT",
        "timestamp": "2014-04-01"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-003447-21/GB",
        "title": "Randomised controlled trial of the tolerability and completion of maraviroc compared to Kaletra© in combination with Truvada© for HIV post-exposure prophylaxis - GB",
        "timestamp": "2011-12-15"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-003447-21/results",
        "title": "Randomised controlled trial of the tolerability and completion of maraviroc compared to Kaletra© in combination with Truvada© for HIV post-exposure prophylaxis - View results",
        "timestamp": "2011-12-15"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-003748-12/ES",
        "title": "“Estudio Fase IV-III, comparativo, aleatorizado y abierto para evaluar\nla eficacia para la recuperación de grasa periférica (o de extremidades) de\nlopinavir/ritonavir en monoterapia versus abacavir... - ES",
        "timestamp": "2008-09-04"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-007935-14/IT",
        "title": "RIFART - IT",
        "timestamp": "2005-03-15"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-006200-11/FR",
        "title": "Prévention de la transmission du VIH-1 de la mère à l’enfant sans utilisation d’analogue nucléosidique - FR",
        "timestamp": "2007-03-09"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-005550-18/DE",
        "title": "A Phase III Multicenter, Open-Label, Randomized Study to Evaluate a Switch to MK-1439A in HIV-1-Infected Subjects Virologically Suppressed on a Regimen of a Ritonavir-boosted Protease Inhibitor and... - DE",
        "timestamp": "2015-08-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-005550-18/AT",
        "title": "A Phase III Multicenter, Open-Label, Randomized Study to Evaluate a Switch to MK-1439A in HIV-1-Infected Subjects Virologically Suppressed on a Regimen of a Ritonavir-boosted Protease Inhibitor and... - AT",
        "timestamp": "2015-08-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-005550-18/DK",
        "title": "A Phase III Multicenter, Open-Label, Randomized Study to Evaluate a Switch to MK-1439A in HIV-1-Infected Subjects Virologically Suppressed on a Regimen of a Ritonavir-boosted Protease Inhibitor and... - DK",
        "timestamp": "2015-08-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-005550-18/BE",
        "title": "A Phase III Multicenter, Open-Label, Randomized Study to Evaluate a Switch to MK-1439A in HIV-1-Infected Subjects Virologically Suppressed on a Regimen of a Ritonavir-boosted Protease Inhibitor and... - BE",
        "timestamp": "2015-08-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-005550-18/IT",
        "title": "A Phase III Multicenter, Open-Label, Randomized Study to Evaluate a Switch to MK-1439A in HIV-1-Infected Subjects Virologically Suppressed on a Regimen of a Ritonavir-boosted Protease Inhibitor and... - IT",
        "timestamp": "2015-08-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-005550-18/ES",
        "title": "A Phase III Multicenter, Open-Label, Randomized Study to Evaluate a Switch to MK-1439A in HIV-1-Infected Subjects Virologically Suppressed on a Regimen of a Ritonavir-boosted Protease Inhibitor and... - ES",
        "timestamp": "2015-08-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-005550-18/PL",
        "title": "A Phase III Multicenter, Open-Label, Randomized Study to Evaluate a Switch to MK-1439A in HIV-1-Infected Subjects Virologically Suppressed on a Regimen of a Ritonavir-boosted Protease Inhibitor and... - PL",
        "timestamp": "2015-08-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-006439-12/BE",
        "title": "Strategic Timing of AntiRetroviral Treatment(START) - BE",
        "timestamp": "2009-05-25"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-006439-12/FI",
        "title": "Strategic Timing of AntiRetroviral Treatment(START) - FI",
        "timestamp": "2009-05-25"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-006439-12/ES",
        "title": "Strategic Timing of AntiRetroviral Treatment(START) - ES",
        "timestamp": "2009-05-25"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-006439-12/DE",
        "title": "Strategic Timing of AntiRetroviral Treatment(START) - DE",
        "timestamp": "2009-05-25"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-006439-12/GB",
        "title": "Strategic Timing of AntiRetroviral Treatment(START) - GB",
        "timestamp": "2009-05-25"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-006439-12/GR",
        "title": "Strategic Timing of AntiRetroviral Treatment(START) - GR",
        "timestamp": "2009-05-25"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-006439-12/IT",
        "title": "Strategic Timing of AntiRetroviral Treatment(START) - IT",
        "timestamp": "2009-05-25"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-006439-12/SE",
        "title": "Strategic Timing of AntiRetroviral Treatment(START) - SE",
        "timestamp": "2009-05-25"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-006439-12/PT",
        "title": "Strategic Timing of AntiRetroviral Treatment(START) - PT",
        "timestamp": "2009-05-25"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-006439-12/IE",
        "title": "Strategic Timing of AntiRetroviral Treatment(START) - IE",
        "timestamp": "2009-05-25"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-006439-12/EE",
        "title": "Strategic Timing of AntiRetroviral Treatment(START) - EE",
        "timestamp": "2009-05-25"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-006439-12/NO",
        "title": "Strategic Timing of AntiRetroviral Treatment(START) - NO",
        "timestamp": "2009-05-25"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-006439-12/AT",
        "title": "Strategic Timing of AntiRetroviral Treatment(START) - AT",
        "timestamp": "2009-05-25"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-006439-12/CZ",
        "title": "Strategic Timing of AntiRetroviral Treatment(START) - CZ",
        "timestamp": "2009-05-25"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-005473-35/ES",
        "title": "PILOT STUDY TO ASSESS THE ROLE OF IMMUNE ACTIVATION AND APOPTOSIS AS A MARKER FOR TREATMENT INTENSIFICATION WITH RALTEGRAVIR IN HIV-INFECTED PATIENTS ON ANTIRETROVIRAL THERAPY WITH LONG-TERM VIRAL ... - ES",
        "timestamp": "2008-11-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-005473-35/results",
        "title": "PILOT STUDY TO ASSESS THE ROLE OF IMMUNE ACTIVATION AND APOPTOSIS AS A MARKER FOR TREATMENT INTENSIFICATION WITH RALTEGRAVIR IN HIV-INFECTED PATIENTS ON ANTIRETROVIRAL THERAPY WITH LONG-TERM VIRAL ... - View results",
        "timestamp": "2008-11-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-006268-42/ES",
        "title": "Tratamiento antirretroviral una vez al día en pacientes con infección por el VIH-1 no tratados previamente y con cifras de linfocitos CD4+ inferiores a 100 céls/mm3. Estudio prospectivo aleatorizad... - ES",
        "timestamp": "2007-07-05"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-006287-11/IT",
        "title": "Virologic efficacy of Maraviroc in adult naive HIV patients with HIV-RNA>= 1000 copies/ml - IT",
        "timestamp": "2009-02-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-001564-37/AT",
        "title": "One arm, Open label, Interventional, non-comparative Study to assess Changes in Lipids and Lipoproteins in HIV infected Women with Hyperlipidemia after Switch from boosted Protease Inhibitors to Ra... - AT",
        "timestamp": "2013-12-02"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-001564-37/results",
        "title": "One arm, Open label, Interventional, non-comparative Study to assess Changes in Lipids and Lipoproteins in HIV infected Women with Hyperlipidemia after Switch from boosted Protease Inhibitors to Ra... - View results",
        "timestamp": "2013-12-02"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-016697-32/IT",
        "title": "PRotease-Inhibitors MOnotherapy Strategies as maintenance therapy in persons with fully suppressed HIV replication: results from an open-label randomized comparative trial (PRIMO Trial) - IT",
        "timestamp": "2010-07-29"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-016697-32/results",
        "title": "PRotease-Inhibitors MOnotherapy Strategies as maintenance therapy in persons with fully suppressed HIV replication: results from an open-label randomized comparative trial (PRIMO Trial) - View results",
        "timestamp": "2010-07-29"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-023264-40/IT",
        "title": "Efficacy in the central nervous system (CNS) of two combination regimens with different penetration rank in HIV-positive na�ve patients - IT",
        "timestamp": "2010-10-21"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-002627-90/GB",
        "title": "Intracellular boosting of HIV protease inhibitors through inhibition of transport - a novel strategy for potentiating HIV therapy - GB",
        "timestamp": "2008-09-05"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-011868-11/ES",
        "title": "ENSAYO CLÍNICO PILOTO PARA EVALUAR LA SEGURIDAD Y EFICACIA DE CAMBIAR EL ITINAN O EL IP A MARAVIROC EN PACIENTES INFECTADOS POR EL VIH-1 CON CARGA VIRAL INDETECTABLE Y DISLIPEMIA ASOCIADA A LOS ANT... - ES",
        "timestamp": "2009-07-30"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-011868-11/results",
        "title": "ENSAYO CLÍNICO PILOTO PARA EVALUAR LA SEGURIDAD Y EFICACIA DE CAMBIAR EL ITINAN O EL IP A MARAVIROC EN PACIENTES INFECTADOS POR EL VIH-1 CON CARGA VIRAL INDETECTABLE Y DISLIPEMIA ASOCIADA A LOS ANT... - View results",
        "timestamp": "2009-07-30"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-000783-25/ES",
        "title": "A Multicenter, Double-Blind, Randomized, Active-Controlled Study to Evaluate the Safety and Antiretroviral Activity of MK-0518 Versus KALETRA™ in HIV-Infected   Patients Switched from a Stable KALE... - ES",
        "timestamp": "2007-05-23"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-000783-25/DE",
        "title": "A Multicenter, Double-Blind, Randomized, Active-Controlled Study to Evaluate the Safety and Antiretroviral Activity of MK-0518 Versus KALETRA™ in HIV-Infected   Patients Switched from a Stable KALE... - DE",
        "timestamp": "2007-05-23"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-000783-25/GB",
        "title": "A Multicenter, Double-Blind, Randomized, Active-Controlled Study to Evaluate the Safety and Antiretroviral Activity of MK-0518 Versus KALETRA™ in HIV-Infected   Patients Switched from a Stable KALE... - GB",
        "timestamp": "2007-05-23"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-000783-25/DK",
        "title": "A Multicenter, Double-Blind, Randomized, Active-Controlled Study to Evaluate the Safety and Antiretroviral Activity of MK-0518 Versus KALETRA™ in HIV-Infected   Patients Switched from a Stable KALE... - DK",
        "timestamp": "2007-05-23"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-000783-25/IT",
        "title": "A Multicenter, Double-Blind, Randomized, Active-Controlled Study to Evaluate the Safety and Antiretroviral Activity of MK-0518 Versus KALETRA™ in HIV-Infected   Patients Switched from a Stable KALE... - IT",
        "timestamp": "2007-05-23"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-000783-25/PT",
        "title": "A Multicenter, Double-Blind, Randomized, Active-Controlled Study to Evaluate the Safety and Antiretroviral Activity of MK-0518 Versus KALETRA™ in HIV-Infected   Patients Switched from a Stable KALE... - PT",
        "timestamp": "2007-05-23"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-000783-25/results",
        "title": "A Multicenter, Double-Blind, Randomized, Active-Controlled Study to Evaluate the Safety and Antiretroviral Activity of MK-0518 Versus KALETRA™ in HIV-Infected   Patients Switched from a Stable KALE... - View results",
        "timestamp": "2007-05-23"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-006644-19/IT",
        "title": "Evaluation of inflammatory immune parameters predicting cardiovascular risk in HIV-1-infected antiretroviral therapy naive patients treated with atazanavir/ritonavir versus lopinavir/ritonavir base... - IT",
        "timestamp": "2009-01-29"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-001969-16/IT",
        "title": "A Phase 2/3 Multicenter, Open-Label, Multicohort, Two-Part Study Evaluating the Pharmacokinetics (PK), Safety, and Antiviral Activity of Elvitegravir (EVG) Administered with a Background Regimen (B... - IT",
        "timestamp": "2013-10-21"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-001969-16/DE",
        "title": "A Phase 2/3 Multicenter, Open-Label, Multicohort, Two-Part Study Evaluating the Pharmacokinetics (PK), Safety, and Antiviral Activity of Elvitegravir (EVG) Administered with a Background Regimen (B... - DE",
        "timestamp": "2013-10-21"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-001969-16/ES",
        "title": "A Phase 2/3 Multicenter, Open-Label, Multicohort, Two-Part Study Evaluating the Pharmacokinetics (PK), Safety, and Antiviral Activity of Elvitegravir (EVG) Administered with a Background Regimen (B... - ES",
        "timestamp": "2013-10-21"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-001969-16/3rd",
        "title": "A Phase 2/3 Multicenter, Open-Label, Multicohort, Two-Part Study Evaluating the Pharmacokinetics (PK), Safety, and Antiviral Activity of Elvitegravir (EVG) Administered with a Background Regimen (B... - Outside EU/EEA",
        "timestamp": "2013-10-21"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-001969-16/results",
        "title": "A Phase 2/3 Multicenter, Open-Label, Multicohort, Two-Part Study Evaluating the Pharmacokinetics (PK), Safety, and Antiviral Activity of Elvitegravir (EVG) Administered with a Background Regimen (B... - View results",
        "timestamp": "2013-10-21"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-000446-20/IE",
        "title": "A multi-centre randomised trial of therapeutic intervention at primary HIV-1 infection - IE",
        "timestamp": "2006-07-28"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-000446-20/ES",
        "title": "A multi-centre randomised trial of therapeutic intervention at primary HIV-1 infection - ES",
        "timestamp": "2006-07-28"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-000446-20/results",
        "title": "A multi-centre randomised trial of therapeutic intervention at primary HIV-1 infection - View results",
        "timestamp": "2006-07-28"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-006260-52/BE",
        "title": "A multi-center, randomized, double blind, placebo-controlled Phase I/II trial to compare the safety, tolerability and immunogenicity of the therapeutic THV01 vaccination at 5x10E6 TU, 5x10E7 TU or ... - BE",
        "timestamp": "2012-10-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-006260-52/FR",
        "title": "A multi-center, randomized, double blind, placebo-controlled Phase I/II trial to compare the safety, tolerability and immunogenicity of the therapeutic THV01 vaccination at 5x10E6 TU, 5x10E7 TU or ... - FR",
        "timestamp": "2012-10-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-003052-31/BE",
        "title": "A Phase 3, randomized, active-controlled, open-label study to evaluate the efficacy, safety and tolerability of switching to a darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) o... - BE",
        "timestamp": "2015-02-17"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-003052-31/SE",
        "title": "A Phase 3, randomized, active-controlled, open-label study to evaluate the efficacy, safety and tolerability of switching to a darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) o... - SE",
        "timestamp": "2015-02-17"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-003052-31/GB",
        "title": "A Phase 3, randomized, active-controlled, open-label study to evaluate the efficacy, safety and tolerability of switching to a darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) o... - GB",
        "timestamp": "2015-02-17"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-003052-31/ES",
        "title": "A Phase 3, randomized, active-controlled, open-label study to evaluate the efficacy, safety and tolerability of switching to a darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) o... - ES",
        "timestamp": "2015-02-17"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-003052-31/PL",
        "title": "A Phase 3, randomized, active-controlled, open-label study to evaluate the efficacy, safety and tolerability of switching to a darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) o... - PL",
        "timestamp": "2015-02-17"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-003052-31/FR",
        "title": "A Phase 3, randomized, active-controlled, open-label study to evaluate the efficacy, safety and tolerability of switching to a darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) o... - FR",
        "timestamp": "2015-02-17"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-000547-85/ES",
        "title": "MULTICENTRE STUDY TO ASSESS CHANGES IN BONE MINERAL DENSITY OF THE SWITCH FROM PROTEASE INHIBITORS TO DOLUTEGRAVIR IN HIV-1-INFECTED SUBJECTS WITH LOW BONE MINERAL DENSITY - ES",
        "timestamp": "2013-09-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-000547-85/results",
        "title": "MULTICENTRE STUDY TO ASSESS CHANGES IN BONE MINERAL DENSITY OF THE SWITCH FROM PROTEASE INHIBITORS TO DOLUTEGRAVIR IN HIV-1-INFECTED SUBJECTS WITH LOW BONE MINERAL DENSITY - View results",
        "timestamp": "2013-09-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-002682-30/ES",
        "title": "Raltegravir-based regimen versus raltegravir-based regimen plus atorvastatin for reducing ?inflamaging? (aging-related complication) in HIV-infected patients older than 60 years. - ES",
        "timestamp": "2015-09-30"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-002682-30/results",
        "title": "Raltegravir-based regimen versus raltegravir-based regimen plus atorvastatin for reducing ?inflamaging? (aging-related complication) in HIV-infected patients older than 60 years. - View results",
        "timestamp": "2015-09-30"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-007018-12/ES",
        "title": "“Estudio prospectivo, abierto, aleatorizado y cruzado sobre el efecto de la Hidroxicloroquina, 200mg al día, en factores inflamatorios y metabólicos relacionados con la enfermedad cardiovascular en... - ES",
        "timestamp": "2008-06-23"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-015647-16/IE",
        "title": "The pharmacokinetics of once daily Kaletra and methadone in a population of HIV positiive drug users. - IE",
        "timestamp": "2010-01-28"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005270-35/IT",
        "title": "HIV-infected pregnant women treated with HAART: registry of pharmacokinetic  parameters of new and commonly used antiretrovirals - IT",
        "timestamp": "2011-12-07"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-001303-13/DE",
        "title": "HIV postexposure prophylaxis with Darunavir/r (PEPDar) - DE",
        "timestamp": "2011-07-26"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-001303-13/results",
        "title": "HIV postexposure prophylaxis with Darunavir/r (PEPDar) - View results",
        "timestamp": "2011-07-26"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-002050-66/IE",
        "title": "Treatment Interruption in Children with Chronic HIV-Infection: the TICCH Trial - IE",
        "timestamp": None
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-002050-66/ES",
        "title": "Treatment Interruption in Children with Chronic HIV-Infection: the TICCH Trial - ES",
        "timestamp": None
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-007004-29/IT",
        "title": "Maraviroc in HIV Acute INfection - IT",
        "timestamp": "2009-02-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-001827-39/IT",
        "title": "NATIONAL, MULTICENTER, RANDOMISED, OPEN STUDY TO VALUATE THE EFFICACY OF DIFFERENT THERAPEUTIC STRATEGIES TO AVOID THE IMMUNOLOGIC FAILURE IN MULTIRESISTENT HIV-1 INFECTED PATIENTS. - IT",
        "timestamp": "2004-09-15"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-000040-17/FR",
        "title": "Randomized, open-label and multicentric trial evaluating the non-inferiority of antiretroviral treatment taken 4 consecutive days per week versus continuous therapy 7/7 days per week in HIV-1 infec... - FR",
        "timestamp": "2017-07-02"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-004627-28/IT",
        "title": "Switch from a current boosted rtv PI to ATV/rtv based HAART regimen. Effect on metabolic and hepatic toxicity in HIV/HCV coinfected patients (COAT Study). - IT",
        "timestamp": "2009-02-25"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-004617-34/GB",
        "title": "A phase I/II study of Invirase® boosted with Ritonavir in HIV infected infants and children 4 months to less than 6 years old - GB",
        "timestamp": "2008-01-15"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-004617-34/results",
        "title": "A phase I/II study of Invirase® boosted with Ritonavir in HIV infected infants and children 4 months to less than 6 years old - View results",
        "timestamp": "2008-01-15"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-000935-18/GB",
        "title": "TAILoR – (TelmisArtan and InsuLin Resistance in HIV): A Dose-Ranging Phase II Randomised Open-Labelled Trial of Telmisartan as a strategy for the Reduction of Insulin Resistance in HIV-Positive Ind... - GB",
        "timestamp": "2012-06-28"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-000935-18/results",
        "title": "TAILoR – (TelmisArtan and InsuLin Resistance in HIV): A Dose-Ranging Phase II Randomised Open-Labelled Trial of Telmisartan as a strategy for the Reduction of Insulin Resistance in HIV-Positive Ind... - View results",
        "timestamp": "2012-06-28"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-021651-79/IT",
        "title": "Studio degli effetti immuno-virologici dell’interruzione di Maraviroc nei pazienti che stanno fallendo un regime contenente Maraviroc - IT",
        "timestamp": "2011-03-22"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-023749-30/IT",
        "title": "Studio PKCT - Pharmacokinetics of chemotherapy when given concurrently with antiretroviral (Protocol no. CSL01). - IT",
        "timestamp": "2011-10-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-023749-30/results",
        "title": "Studio PKCT - Pharmacokinetics of chemotherapy when given concurrently with antiretroviral (Protocol no. CSL01). - View results",
        "timestamp": "2011-10-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-010189-48/IT",
        "title": "Randomised trial comparing the introduction of an immediate or deferred new HAART regimen in failing HIV infected patients: the role of lamivudine monotherapy - IT",
        "timestamp": "2009-03-13"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-010189-48/results",
        "title": "Randomised trial comparing the introduction of an immediate or deferred new HAART regimen in failing HIV infected patients: the role of lamivudine monotherapy - View results",
        "timestamp": "2009-03-13"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-000586-20/FR",
        "title": "A Phase 3 Randomized, Active-Controlled, Open-Label Clinical Study to Evaluate a Switch to Doravirine/Islatravir (DOR/ISL) Once-Daily in Participants With HIV-1 Virologically Suppressed on Antiretr... - FR",
        "timestamp": "2020-02-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-000586-20/GB",
        "title": "A Phase 3 Randomized, Active-Controlled, Open-Label Clinical Study to Evaluate a Switch to Doravirine/Islatravir (DOR/ISL) Once-Daily in Participants With HIV-1 Virologically Suppressed on Antiretr... - GB",
        "timestamp": "2020-02-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-002805-30/IT",
        "title": "Strategic long term, immunologically driven treatment interruptions in previously naive patients starting HAART: a controlled, randomized, multicenter study - IT",
        "timestamp": "2006-06-29"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-004750-42/ES",
        "title": "EFFICACY AND SAFETY OF A SIMPLIFICATION STRATEGY BASED ON DOLUTEGRAVIR AND DARUNAVIR / COBICISTAT VS OPTIMIZED TREATMENT IN SUPPRESSED HIV-1-INFECTED PATIENTS CARRYING ARCHIVED MULTIDRUG RESISTANCE... - ES",
        "timestamp": "2018-09-04"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-000274-35/ES",
        "title": "An open-label, randomized, controlled clinical trial to assess the safety, tolerability and efficacy of two dolutegravir-based simplification strategies in HIV-infected patients with prolonged viro... - ES",
        "timestamp": "2015-04-23"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-004243-39/NL",
        "title": "A randomised study of interferon-free treatment for recently acquired hepatitis C in people who inject drugs and people with HIV coinfection. - NL",
        "timestamp": "2016-11-17"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-004243-39/GB",
        "title": "A randomised study of interferon-free treatment for recently acquired hepatitis C in people who inject drugs and people with HIV coinfection. - GB",
        "timestamp": "2016-11-17"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-000441-38/AT",
        "title": "Large, Simple Trial Comparing Two Strategies for Management of Anti-Retroviral Therapy (The SMART Study) - AT",
        "timestamp": "2005-04-26"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-000441-38/IT",
        "title": "Large, Simple Trial Comparing Two Strategies for Management of Anti-Retroviral Therapy (The SMART Study) - IT",
        "timestamp": "2005-04-26"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-000441-38/IE",
        "title": "Large, Simple Trial Comparing Two Strategies for Management of Anti-Retroviral Therapy (The SMART Study) - IE",
        "timestamp": "2005-04-26"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-013284-19/AT",
        "title": "Immune tolerance induction in MS patients with neutralizing antibodies against interferon-beta - AT",
        "timestamp": "2009-12-10"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-016678-34/GB",
        "title": "Exploring the Relationship Between Insulin Resistance and Interferon Resistance: Options to Overcome HCV Non-Response to Pegylated Interferon - GB",
        "timestamp": "2010-04-15"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-001008-37/SE",
        "title": "Analysis of the antibody level against interferon beta before and after increase of dose in MS therapy - SE",
        "timestamp": "2005-11-01"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-003570-89/NL",
        "title": "The effect of interferon beta-1a treatment on functional adaptation in Multiple Sclerosis (MS) - NL",
        "timestamp": "2011-12-02"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-000029-31/IE",
        "title": "A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of the Safety and Efficacy of Interferon gamma-Ib in patients with Idiopathic Pulmonary Fibrosis \nThe INSPIRE Trial - International Stu... - IE",
        "timestamp": "2005-01-28"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-005751-18/GB",
        "title": "A multi-centre randomised study to evaluate the efficacy of Betaferon-interferon-beta-1b (IFNB-1B) 500 mcg therapy in the induction of tolerance to IFNB in MS patients with neutralising antibodies ... - GB",
        "timestamp": "2006-09-07"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-005751-18/results",
        "title": "A multi-centre randomised study to evaluate the efficacy of Betaferon-interferon-beta-1b (IFNB-1B) 500 mcg therapy in the induction of tolerance to IFNB in MS patients with neutralising antibodies ... - View results",
        "timestamp": "2006-09-07"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-005450-30/AT",
        "title": "Anti-Biopharmaceutical Immunization: Prediction and analysis of clinical relevance to minimize the risk of immunization in multiple sclerosis patients on interferon-beta treatment - AT",
        "timestamp": "2014-01-08"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-005450-30/SE",
        "title": "Anti-Biopharmaceutical Immunization: Prediction and analysis of clinical relevance to minimize the risk of immunization in multiple sclerosis patients on interferon-beta treatment - SE",
        "timestamp": "2014-01-08"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-006208-52/DE",
        "title": "Mono-centre, open-label study to investigate the multi-dose pharmacokinetics, efficacy and safety of Interferon alpha-2b Cream in women with a history of cytological diagnosed  Pap IIID, with a con... - DE",
        "timestamp": "2009-03-09"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-016824-29/DK",
        "title": "REsPons på interferon-Alfa hos InterfeRon-β-neutraliserende antistof-positive patienter med multipel sklerose - DK",
        "timestamp": "2010-04-06"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-005545-20/BE",
        "title": "The CaStOR study\nCarcinoid Tumors after failure of Somatostatin analogs: a randomized phase III of Octreotide Lutate Peptid Receptor radionuclide Therapy (PRRT) versus inteRferon α-2b - BE",
        "timestamp": "2014-12-23"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-006333-27/LV",
        "title": "A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Study to Evaluate the Efficacy and Safety of PEGylated Interferon Beta-1a (BIIB017) in Subjects with Relapsing Multiple ... - LV",
        "timestamp": "2009-06-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-006333-27/EE",
        "title": "A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Study to Evaluate the Efficacy and Safety of PEGylated Interferon Beta-1a (BIIB017) in Subjects with Relapsing Multiple ... - EE",
        "timestamp": "2009-06-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-006333-27/DE",
        "title": "A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Study to Evaluate the Efficacy and Safety of PEGylated Interferon Beta-1a (BIIB017) in Subjects with Relapsing Multiple ... - DE",
        "timestamp": "2009-06-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-006333-27/BE",
        "title": "A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Study to Evaluate the Efficacy and Safety of PEGylated Interferon Beta-1a (BIIB017) in Subjects with Relapsing Multiple ... - BE",
        "timestamp": "2009-06-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-006333-27/NL",
        "title": "A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Study to Evaluate the Efficacy and Safety of PEGylated Interferon Beta-1a (BIIB017) in Subjects with Relapsing Multiple ... - NL",
        "timestamp": "2009-06-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-006333-27/ES",
        "title": "A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Study to Evaluate the Efficacy and Safety of PEGylated Interferon Beta-1a (BIIB017) in Subjects with Relapsing Multiple ... - ES",
        "timestamp": "2009-06-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-006333-27/CZ",
        "title": "A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Study to Evaluate the Efficacy and Safety of PEGylated Interferon Beta-1a (BIIB017) in Subjects with Relapsing Multiple ... - CZ",
        "timestamp": "2009-06-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-006333-27/BG",
        "title": "A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Study to Evaluate the Efficacy and Safety of PEGylated Interferon Beta-1a (BIIB017) in Subjects with Relapsing Multiple ... - BG",
        "timestamp": "2009-06-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-006333-27/GR",
        "title": "A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Study to Evaluate the Efficacy and Safety of PEGylated Interferon Beta-1a (BIIB017) in Subjects with Relapsing Multiple ... - GR",
        "timestamp": "2009-06-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-006333-27/GB",
        "title": "A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Study to Evaluate the Efficacy and Safety of PEGylated Interferon Beta-1a (BIIB017) in Subjects with Relapsing Multiple ... - GB",
        "timestamp": "2009-06-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-006333-27/results",
        "title": "A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Study to Evaluate the Efficacy and Safety of PEGylated Interferon Beta-1a (BIIB017) in Subjects with Relapsing Multiple ... - View results",
        "timestamp": "2009-06-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-000453-37/IT",
        "title": "Sequential treatment with nucleotide analogue and peg-interferon in patients with HBV-related chronic hepatitis. - IT",
        "timestamp": "2014-12-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-001012-19/NL",
        "title": "Effects of fingolimod on functional brain adaptation and clinical measures in multiple sclerosis - NL",
        "timestamp": "2014-12-17"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-004040-30/AT",
        "title": "Natalizumab de-escalation to interferon-beta-1b in patients with\r\nrelapsing-remitting multiple sclerosis: A multicenter study - AT",
        "timestamp": "2013-05-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-001367-13/AT",
        "title": "An open-label, prospective, single-centre, phase II study to assess dose and dose interval requirements with respect to efficacy and safety of AOP2014, PEG-Proline-Interferon alpha-2b, in patients ... - AT",
        "timestamp": "2014-08-08"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-001419-21/DE",
        "title": "An open label, randomised, non-inferiority trial of pegylated interferon, ribavirin and telaprevir versus pegylated interferon and ribavirin alone in the response guided treatment of acute hepatiti... - DE",
        "timestamp": "2013-08-15"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-003729-27/GB",
        "title": "Telaprevir in patients with genotype 3 HCV : pilot clinical study to evaluate efficacy and predictability of therapy in patients who have failed to respond to pegylated interferon and ribavirin - GB",
        "timestamp": "2013-11-15"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-003729-27/results",
        "title": "Telaprevir in patients with genotype 3 HCV : pilot clinical study to evaluate efficacy and predictability of therapy in patients who have failed to respond to pegylated interferon and ribavirin - View results",
        "timestamp": "2013-11-15"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-000282-35/CZ",
        "title": "A randomised, double-blind phase III study to evaluate the efficacy and safety of bevacizumab in combination with interferon alfa-2a (Roferon) versus interferon alfa-2a and placebo as first line tr... - CZ",
        "timestamp": "2004-09-29"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-000282-35/GB",
        "title": "A randomised, double-blind phase III study to evaluate the efficacy and safety of bevacizumab in combination with interferon alfa-2a (Roferon) versus interferon alfa-2a and placebo as first line tr... - GB",
        "timestamp": "2004-09-29"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-000282-35/IT",
        "title": "A randomised, double-blind phase III study to evaluate the efficacy and safety of bevacizumab in combination with interferon alfa-2a (Roferon) versus interferon alfa-2a and placebo as first line tr... - IT",
        "timestamp": "2004-09-29"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-000282-35/results",
        "title": "A randomised, double-blind phase III study to evaluate the efficacy and safety of bevacizumab in combination with interferon alfa-2a (Roferon) versus interferon alfa-2a and placebo as first line tr... - View results",
        "timestamp": "2004-09-29"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-000162-40/SE",
        "title": "Treatment of genital warts with Interferon alpha-2b Cream:  \na randomized, double blind, placebo-controlled study - SE",
        "timestamp": "2005-09-06"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-000162-40/DE",
        "title": "Treatment of genital warts with Interferon alpha-2b Cream:  \na randomized, double blind, placebo-controlled study - DE",
        "timestamp": "2005-09-06"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-004130-14/AT",
        "title": "A multicenter, randomized, rater-blind study to compare the efficacy and safety of natalizumab (300 mg IV every four weeks) with Interferon beta-1a (44 mcg SC three times a week) in subjects with r... - AT",
        "timestamp": "2005-02-17"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-004130-14/results",
        "title": "A multicenter, randomized, rater-blind study to compare the efficacy and safety of natalizumab (300 mg IV every four weeks) with Interferon beta-1a (44 mcg SC three times a week) in subjects with r... - View results",
        "timestamp": "2005-02-17"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-013284-19/AT",
        "title": "Immune tolerance induction in MS patients with neutralizing antibodies against interferon-beta - AT",
        "timestamp": "2009-12-10"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-016678-34/GB",
        "title": "Exploring the Relationship Between Insulin Resistance and Interferon Resistance: Options to Overcome HCV Non-Response to Pegylated Interferon - GB",
        "timestamp": "2010-04-15"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-001008-37/SE",
        "title": "Analysis of the antibody level against interferon beta before and after increase of dose in MS therapy - SE",
        "timestamp": "2005-11-01"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-003570-89/NL",
        "title": "The effect of interferon beta-1a treatment on functional adaptation in Multiple Sclerosis (MS) - NL",
        "timestamp": "2011-12-02"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-000029-31/IE",
        "title": "A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of the Safety and Efficacy of Interferon gamma-Ib in patients with Idiopathic Pulmonary Fibrosis \nThe INSPIRE Trial - International Stu... - IE",
        "timestamp": "2005-01-28"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-005751-18/GB",
        "title": "A multi-centre randomised study to evaluate the efficacy of Betaferon-interferon-beta-1b (IFNB-1B) 500 mcg therapy in the induction of tolerance to IFNB in MS patients with neutralising antibodies ... - GB",
        "timestamp": "2006-09-07"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-005751-18/results",
        "title": "A multi-centre randomised study to evaluate the efficacy of Betaferon-interferon-beta-1b (IFNB-1B) 500 mcg therapy in the induction of tolerance to IFNB in MS patients with neutralising antibodies ... - View results",
        "timestamp": "2006-09-07"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-005450-30/AT",
        "title": "Anti-Biopharmaceutical Immunization: Prediction and analysis of clinical relevance to minimize the risk of immunization in multiple sclerosis patients on interferon-beta treatment - AT",
        "timestamp": "2014-01-08"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-005450-30/SE",
        "title": "Anti-Biopharmaceutical Immunization: Prediction and analysis of clinical relevance to minimize the risk of immunization in multiple sclerosis patients on interferon-beta treatment - SE",
        "timestamp": "2014-01-08"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-006208-52/DE",
        "title": "Mono-centre, open-label study to investigate the multi-dose pharmacokinetics, efficacy and safety of Interferon alpha-2b Cream in women with a history of cytological diagnosed  Pap IIID, with a con... - DE",
        "timestamp": "2009-03-09"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-016824-29/DK",
        "title": "REsPons på interferon-Alfa hos InterfeRon-β-neutraliserende antistof-positive patienter med multipel sklerose - DK",
        "timestamp": "2010-04-06"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-005545-20/BE",
        "title": "The CaStOR study\nCarcinoid Tumors after failure of Somatostatin analogs: a randomized phase III of Octreotide Lutate Peptid Receptor radionuclide Therapy (PRRT) versus inteRferon α-2b - BE",
        "timestamp": "2014-12-23"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-006333-27/LV",
        "title": "A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Study to Evaluate the Efficacy and Safety of PEGylated Interferon Beta-1a (BIIB017) in Subjects with Relapsing Multiple ... - LV",
        "timestamp": "2009-06-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-006333-27/EE",
        "title": "A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Study to Evaluate the Efficacy and Safety of PEGylated Interferon Beta-1a (BIIB017) in Subjects with Relapsing Multiple ... - EE",
        "timestamp": "2009-06-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-006333-27/DE",
        "title": "A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Study to Evaluate the Efficacy and Safety of PEGylated Interferon Beta-1a (BIIB017) in Subjects with Relapsing Multiple ... - DE",
        "timestamp": "2009-06-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-006333-27/BE",
        "title": "A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Study to Evaluate the Efficacy and Safety of PEGylated Interferon Beta-1a (BIIB017) in Subjects with Relapsing Multiple ... - BE",
        "timestamp": "2009-06-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-006333-27/NL",
        "title": "A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Study to Evaluate the Efficacy and Safety of PEGylated Interferon Beta-1a (BIIB017) in Subjects with Relapsing Multiple ... - NL",
        "timestamp": "2009-06-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-006333-27/ES",
        "title": "A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Study to Evaluate the Efficacy and Safety of PEGylated Interferon Beta-1a (BIIB017) in Subjects with Relapsing Multiple ... - ES",
        "timestamp": "2009-06-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-006333-27/CZ",
        "title": "A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Study to Evaluate the Efficacy and Safety of PEGylated Interferon Beta-1a (BIIB017) in Subjects with Relapsing Multiple ... - CZ",
        "timestamp": "2009-06-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-006333-27/BG",
        "title": "A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Study to Evaluate the Efficacy and Safety of PEGylated Interferon Beta-1a (BIIB017) in Subjects with Relapsing Multiple ... - BG",
        "timestamp": "2009-06-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-006333-27/GR",
        "title": "A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Study to Evaluate the Efficacy and Safety of PEGylated Interferon Beta-1a (BIIB017) in Subjects with Relapsing Multiple ... - GR",
        "timestamp": "2009-06-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-006333-27/GB",
        "title": "A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Study to Evaluate the Efficacy and Safety of PEGylated Interferon Beta-1a (BIIB017) in Subjects with Relapsing Multiple ... - GB",
        "timestamp": "2009-06-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-006333-27/results",
        "title": "A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Study to Evaluate the Efficacy and Safety of PEGylated Interferon Beta-1a (BIIB017) in Subjects with Relapsing Multiple ... - View results",
        "timestamp": "2009-06-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-000453-37/IT",
        "title": "Sequential treatment with nucleotide analogue and peg-interferon in patients with HBV-related chronic hepatitis. - IT",
        "timestamp": "2014-12-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-001012-19/NL",
        "title": "Effects of fingolimod on functional brain adaptation and clinical measures in multiple sclerosis - NL",
        "timestamp": "2014-12-17"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-004040-30/AT",
        "title": "Natalizumab de-escalation to interferon-beta-1b in patients with\r\nrelapsing-remitting multiple sclerosis: A multicenter study - AT",
        "timestamp": "2013-05-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-001367-13/AT",
        "title": "An open-label, prospective, single-centre, phase II study to assess dose and dose interval requirements with respect to efficacy and safety of AOP2014, PEG-Proline-Interferon alpha-2b, in patients ... - AT",
        "timestamp": "2014-08-08"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-001419-21/DE",
        "title": "An open label, randomised, non-inferiority trial of pegylated interferon, ribavirin and telaprevir versus pegylated interferon and ribavirin alone in the response guided treatment of acute hepatiti... - DE",
        "timestamp": "2013-08-15"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-003729-27/GB",
        "title": "Telaprevir in patients with genotype 3 HCV : pilot clinical study to evaluate efficacy and predictability of therapy in patients who have failed to respond to pegylated interferon and ribavirin - GB",
        "timestamp": "2013-11-15"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-003729-27/results",
        "title": "Telaprevir in patients with genotype 3 HCV : pilot clinical study to evaluate efficacy and predictability of therapy in patients who have failed to respond to pegylated interferon and ribavirin - View results",
        "timestamp": "2013-11-15"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-000282-35/CZ",
        "title": "A randomised, double-blind phase III study to evaluate the efficacy and safety of bevacizumab in combination with interferon alfa-2a (Roferon) versus interferon alfa-2a and placebo as first line tr... - CZ",
        "timestamp": "2004-09-29"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-000282-35/GB",
        "title": "A randomised, double-blind phase III study to evaluate the efficacy and safety of bevacizumab in combination with interferon alfa-2a (Roferon) versus interferon alfa-2a and placebo as first line tr... - GB",
        "timestamp": "2004-09-29"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-000282-35/IT",
        "title": "A randomised, double-blind phase III study to evaluate the efficacy and safety of bevacizumab in combination with interferon alfa-2a (Roferon) versus interferon alfa-2a and placebo as first line tr... - IT",
        "timestamp": "2004-09-29"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-000282-35/results",
        "title": "A randomised, double-blind phase III study to evaluate the efficacy and safety of bevacizumab in combination with interferon alfa-2a (Roferon) versus interferon alfa-2a and placebo as first line tr... - View results",
        "timestamp": "2004-09-29"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-000162-40/SE",
        "title": "Treatment of genital warts with Interferon alpha-2b Cream:  \na randomized, double blind, placebo-controlled study - SE",
        "timestamp": "2005-09-06"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-000162-40/DE",
        "title": "Treatment of genital warts with Interferon alpha-2b Cream:  \na randomized, double blind, placebo-controlled study - DE",
        "timestamp": "2005-09-06"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-004130-14/AT",
        "title": "A multicenter, randomized, rater-blind study to compare the efficacy and safety of natalizumab (300 mg IV every four weeks) with Interferon beta-1a (44 mcg SC three times a week) in subjects with r... - AT",
        "timestamp": "2005-02-17"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-004130-14/results",
        "title": "A multicenter, randomized, rater-blind study to compare the efficacy and safety of natalizumab (300 mg IV every four weeks) with Interferon beta-1a (44 mcg SC three times a week) in subjects with r... - View results",
        "timestamp": "2005-02-17"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-003409-18/SE",
        "title": "An Open-label, Multicenter Study Evaluating the Efficacy and Safety of 24 or 48 weeks pegylated interferon alfa-2a 40 kD (PEGASYS®) Combination Therapy with Ribavirin (Copegus®) in Patients with Ch... - SE",
        "timestamp": "2006-11-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-003409-18/DK",
        "title": "An Open-label, Multicenter Study Evaluating the Efficacy and Safety of 24 or 48 weeks pegylated interferon alfa-2a 40 kD (PEGASYS®) Combination Therapy with Ribavirin (Copegus®) in Patients with Ch... - DK",
        "timestamp": "2006-11-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-003409-18/FI",
        "title": "An Open-label, Multicenter Study Evaluating the Efficacy and Safety of 24 or 48 weeks pegylated interferon alfa-2a 40 kD (PEGASYS®) Combination Therapy with Ribavirin (Copegus®) in Patients with Ch... - FI",
        "timestamp": "2006-11-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-022103-21/DE",
        "title": "Neoadjuvant treatment of locoregional metastases in malignant melanoma (AJCC stage IIIB/C) with Multiferon: a phase IIa DeCOG trial - DE",
        "timestamp": "2011-04-08"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-002812-10/DE",
        "title": "A prospective, randomised, open-label phase IIb clinical trial assessing the effect of pegylated Interferon alfa-2a (Pegasys®) 180 µg once weekly for 48 weeks in addition to an ongoing nucelos(t)id... - DE",
        "timestamp": "2012-01-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-000140-13/GB",
        "title": "A Phase I/II Open–Label study to Assess the Safety, Tolerability and Preliminary Efficacy of FP-1201 (Recombinant Human Interferon Beta) in the treatment of patients with Acute Lung Injury and Acut... - GB",
        "timestamp": "2008-05-09"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-003538-11/DE",
        "title": "Antiviral effect, safety and pharmacokinetics of BI 201335 NA in hepatitis C virus genotype 1 infected treatment-naïve and treatment-experienced patients for 24 weeks as combination therapy with pe... - DE",
        "timestamp": "2008-10-01"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-003538-11/ES",
        "title": "Antiviral effect, safety and pharmacokinetics of BI 201335 NA in hepatitis C virus genotype 1 infected treatment-naïve and treatment-experienced patients for 24 weeks as combination therapy with pe... - ES",
        "timestamp": "2008-10-01"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-003538-11/FR",
        "title": "Antiviral effect, safety and pharmacokinetics of BI 201335 NA in hepatitis C virus genotype 1 infected treatment-naïve and treatment-experienced patients for 24 weeks as combination therapy with pe... - FR",
        "timestamp": "2008-10-01"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-003538-11/NL",
        "title": "Antiviral effect, safety and pharmacokinetics of BI 201335 NA in hepatitis C virus genotype 1 infected treatment-naïve and treatment-experienced patients for 24 weeks as combination therapy with pe... - NL",
        "timestamp": "2008-10-01"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-003538-11/PT",
        "title": "Antiviral effect, safety and pharmacokinetics of BI 201335 NA in hepatitis C virus genotype 1 infected treatment-naïve and treatment-experienced patients for 24 weeks as combination therapy with pe... - PT",
        "timestamp": "2008-10-01"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-003538-11/GB",
        "title": "Antiviral effect, safety and pharmacokinetics of BI 201335 NA in hepatitis C virus genotype 1 infected treatment-naïve and treatment-experienced patients for 24 weeks as combination therapy with pe... - GB",
        "timestamp": "2008-10-01"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-003538-11/AT",
        "title": "Antiviral effect, safety and pharmacokinetics of BI 201335 NA in hepatitis C virus genotype 1 infected treatment-naïve and treatment-experienced patients for 24 weeks as combination therapy with pe... - AT",
        "timestamp": "2008-10-01"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-003538-11/CZ",
        "title": "Antiviral effect, safety and pharmacokinetics of BI 201335 NA in hepatitis C virus genotype 1 infected treatment-naïve and treatment-experienced patients for 24 weeks as combination therapy with pe... - CZ",
        "timestamp": "2008-10-01"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-003538-11/results",
        "title": "Antiviral effect, safety and pharmacokinetics of BI 201335 NA in hepatitis C virus genotype 1 infected treatment-naïve and treatment-experienced patients for 24 weeks as combination therapy with pe... - View results",
        "timestamp": "2008-10-01"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-000867-24/DE",
        "title": "A PHASE 2b, RANDOMIZED, MULTI-CENTER, ACTIVE-CONTROLLED, \nOPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ALBUFERON (RECOMBINANT HUMAN ALBUMIN-INTERFERON ALFA FUSION PROTEIN) IN COMBINATION... - DE",
        "timestamp": "2005-05-23"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-000867-24/CZ",
        "title": "A PHASE 2b, RANDOMIZED, MULTI-CENTER, ACTIVE-CONTROLLED, \nOPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ALBUFERON (RECOMBINANT HUMAN ALBUMIN-INTERFERON ALFA FUSION PROTEIN) IN COMBINATION... - CZ",
        "timestamp": "2005-05-23"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-000867-24/results",
        "title": "A PHASE 2b, RANDOMIZED, MULTI-CENTER, ACTIVE-CONTROLLED, \nOPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ALBUFERON (RECOMBINANT HUMAN ALBUMIN-INTERFERON ALFA FUSION PROTEIN) IN COMBINATION... - View results",
        "timestamp": "2005-05-23"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-006161-13/DE",
        "title": "A single arm Phase II study to assess efficacy and safety of bevacizumab in combination with the standard therapy (interferon alfa-2a and vinblastine) as first-line treatment for patients with meta... - DE",
        "timestamp": "2007-06-22"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-006161-13/results",
        "title": "A single arm Phase II study to assess efficacy and safety of bevacizumab in combination with the standard therapy (interferon alfa-2a and vinblastine) as first-line treatment for patients with meta... - View results",
        "timestamp": "2007-06-22"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-002180-33/PL",
        "title": "Multiple sclerosis therapy with transdermal myelin peptide stimulation. - PL",
        "timestamp": "2016-11-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-023677-19/IT",
        "title": "Bio-molecular effects of interferon-beta and d-vitamin association - IT",
        "timestamp": "2011-03-23"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-004403-37/DE",
        "title": "Eine monozentrische, randomisierte, kontrollierte Studie zur Untersuchung von Interferon-beta zur Behandlung der Multiplen-Sklerose (MS)-assoziierten und primären Uveitis intermedia im Vergleich zu... - DE",
        "timestamp": "2006-02-27"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-005388-34/IT",
        "title": "Single arm prospective clinical study to evaluate the efficacy  of combination therapy sofosbuvir+ribavirin+peg-interferon in experienced patients with HCV-GT1 - IT",
        "timestamp": "2015-05-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-006226-34/ES",
        "title": "Estudio multicéntrico, aleatorizado, de grupos paralelos, ciego para el evaluador, que compara la efectividad y seguridad de teriflunomida e interferón beta-1a en pacientes con esclerosis múltiple ... - ES",
        "timestamp": "2009-03-25"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-006226-34/DE",
        "title": "Estudio multicéntrico, aleatorizado, de grupos paralelos, ciego para el evaluador, que compara la efectividad y seguridad de teriflunomida e interferón beta-1a en pacientes con esclerosis múltiple ... - DE",
        "timestamp": "2009-03-25"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-006226-34/HU",
        "title": "Estudio multicéntrico, aleatorizado, de grupos paralelos, ciego para el evaluador, que compara la efectividad y seguridad de teriflunomida e interferón beta-1a en pacientes con esclerosis múltiple ... - HU",
        "timestamp": "2009-03-25"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-006226-34/CZ",
        "title": "Estudio multicéntrico, aleatorizado, de grupos paralelos, ciego para el evaluador, que compara la efectividad y seguridad de teriflunomida e interferón beta-1a en pacientes con esclerosis múltiple ... - CZ",
        "timestamp": "2009-03-25"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-006226-34/IT",
        "title": "Estudio multicéntrico, aleatorizado, de grupos paralelos, ciego para el evaluador, que compara la efectividad y seguridad de teriflunomida e interferón beta-1a en pacientes con esclerosis múltiple ... - IT",
        "timestamp": "2009-03-25"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-006226-34/GR",
        "title": "Estudio multicéntrico, aleatorizado, de grupos paralelos, ciego para el evaluador, que compara la efectividad y seguridad de teriflunomida e interferón beta-1a en pacientes con esclerosis múltiple ... - GR",
        "timestamp": "2009-03-25"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-006226-34/FR",
        "title": "Estudio multicéntrico, aleatorizado, de grupos paralelos, ciego para el evaluador, que compara la efectividad y seguridad de teriflunomida e interferón beta-1a en pacientes con esclerosis múltiple ... - FR",
        "timestamp": "2009-03-25"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-006226-34/BE",
        "title": "Estudio multicéntrico, aleatorizado, de grupos paralelos, ciego para el evaluador, que compara la efectividad y seguridad de teriflunomida e interferón beta-1a en pacientes con esclerosis múltiple ... - BE",
        "timestamp": "2009-03-25"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-006226-34/GB",
        "title": "Estudio multicéntrico, aleatorizado, de grupos paralelos, ciego para el evaluador, que compara la efectividad y seguridad de teriflunomida e interferón beta-1a en pacientes con esclerosis múltiple ... - GB",
        "timestamp": "2009-03-25"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-006226-34/results",
        "title": "Estudio multicéntrico, aleatorizado, de grupos paralelos, ciego para el evaluador, que compara la efectividad y seguridad de teriflunomida e interferón beta-1a en pacientes con esclerosis múltiple ... - View results",
        "timestamp": "2009-03-25"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-024477-39/LV",
        "title": "A Dose-Frequency Blinded, Multicenter, Extension Study to Determine the Long-Term Safety and Efficacy of PEGylated Interferon Beta-1a (BIIB017) in Subjects With Relapsing Multiple Sclerosis - LV",
        "timestamp": "2011-05-06"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-024477-39/BE",
        "title": "A Dose-Frequency Blinded, Multicenter, Extension Study to Determine the Long-Term Safety and Efficacy of PEGylated Interferon Beta-1a (BIIB017) in Subjects With Relapsing Multiple Sclerosis - BE",
        "timestamp": "2011-05-06"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-024477-39/DE",
        "title": "A Dose-Frequency Blinded, Multicenter, Extension Study to Determine the Long-Term Safety and Efficacy of PEGylated Interferon Beta-1a (BIIB017) in Subjects With Relapsing Multiple Sclerosis - DE",
        "timestamp": "2011-05-06"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-024477-39/ES",
        "title": "A Dose-Frequency Blinded, Multicenter, Extension Study to Determine the Long-Term Safety and Efficacy of PEGylated Interferon Beta-1a (BIIB017) in Subjects With Relapsing Multiple Sclerosis - ES",
        "timestamp": "2011-05-06"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-024477-39/BG",
        "title": "A Dose-Frequency Blinded, Multicenter, Extension Study to Determine the Long-Term Safety and Efficacy of PEGylated Interferon Beta-1a (BIIB017) in Subjects With Relapsing Multiple Sclerosis - BG",
        "timestamp": "2011-05-06"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-024477-39/EE",
        "title": "A Dose-Frequency Blinded, Multicenter, Extension Study to Determine the Long-Term Safety and Efficacy of PEGylated Interferon Beta-1a (BIIB017) in Subjects With Relapsing Multiple Sclerosis - EE",
        "timestamp": "2011-05-06"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-024477-39/GB",
        "title": "A Dose-Frequency Blinded, Multicenter, Extension Study to Determine the Long-Term Safety and Efficacy of PEGylated Interferon Beta-1a (BIIB017) in Subjects With Relapsing Multiple Sclerosis - GB",
        "timestamp": "2011-05-06"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-024477-39/GR",
        "title": "A Dose-Frequency Blinded, Multicenter, Extension Study to Determine the Long-Term Safety and Efficacy of PEGylated Interferon Beta-1a (BIIB017) in Subjects With Relapsing Multiple Sclerosis - GR",
        "timestamp": "2011-05-06"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-024477-39/CZ",
        "title": "A Dose-Frequency Blinded, Multicenter, Extension Study to Determine the Long-Term Safety and Efficacy of PEGylated Interferon Beta-1a (BIIB017) in Subjects With Relapsing Multiple Sclerosis - CZ",
        "timestamp": "2011-05-06"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-024477-39/results",
        "title": "A Dose-Frequency Blinded, Multicenter, Extension Study to Determine the Long-Term Safety and Efficacy of PEGylated Interferon Beta-1a (BIIB017) in Subjects With Relapsing Multiple Sclerosis - View results",
        "timestamp": "2011-05-06"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-000704-17/GB",
        "title": "A 12-month double-blind, randomized, multicenter, active controlled, parallel-group study comparing the efficacy and safety of 0.5 mg and 1.25 mg fingolimod (FTY720) administered orally once daily ... - GB",
        "timestamp": "2006-10-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-000704-17/DE",
        "title": "A 12-month double-blind, randomized, multicenter, active controlled, parallel-group study comparing the efficacy and safety of 0.5 mg and 1.25 mg fingolimod (FTY720) administered orally once daily ... - DE",
        "timestamp": "2006-10-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-000704-17/ES",
        "title": "A 12-month double-blind, randomized, multicenter, active controlled, parallel-group study comparing the efficacy and safety of 0.5 mg and 1.25 mg fingolimod (FTY720) administered orally once daily ... - ES",
        "timestamp": "2006-10-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-000704-17/BE",
        "title": "A 12-month double-blind, randomized, multicenter, active controlled, parallel-group study comparing the efficacy and safety of 0.5 mg and 1.25 mg fingolimod (FTY720) administered orally once daily ... - BE",
        "timestamp": "2006-10-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-000704-17/AT",
        "title": "A 12-month double-blind, randomized, multicenter, active controlled, parallel-group study comparing the efficacy and safety of 0.5 mg and 1.25 mg fingolimod (FTY720) administered orally once daily ... - AT",
        "timestamp": "2006-10-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-000704-17/HU",
        "title": "A 12-month double-blind, randomized, multicenter, active controlled, parallel-group study comparing the efficacy and safety of 0.5 mg and 1.25 mg fingolimod (FTY720) administered orally once daily ... - HU",
        "timestamp": "2006-10-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-000704-17/PT",
        "title": "A 12-month double-blind, randomized, multicenter, active controlled, parallel-group study comparing the efficacy and safety of 0.5 mg and 1.25 mg fingolimod (FTY720) administered orally once daily ... - PT",
        "timestamp": "2006-10-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-000704-17/GR",
        "title": "A 12-month double-blind, randomized, multicenter, active controlled, parallel-group study comparing the efficacy and safety of 0.5 mg and 1.25 mg fingolimod (FTY720) administered orally once daily ... - GR",
        "timestamp": "2006-10-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-000704-17/IT",
        "title": "A 12-month double-blind, randomized, multicenter, active controlled, parallel-group study comparing the efficacy and safety of 0.5 mg and 1.25 mg fingolimod (FTY720) administered orally once daily ... - IT",
        "timestamp": "2006-10-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-000704-17/results",
        "title": "A 12-month double-blind, randomized, multicenter, active controlled, parallel-group study comparing the efficacy and safety of 0.5 mg and 1.25 mg fingolimod (FTY720) administered orally once daily ... - View results",
        "timestamp": "2006-10-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-002634-24/SE",
        "title": "MultipleMS – Multiple-omics approach to accelerate personalised medicine in a prospective cohort of newly diagnosed MS and CIS patients. - SE",
        "timestamp": "2017-09-29"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-003098-42/CZ",
        "title": "A Multicenter, Open-Label, Immunogenicity and Safety Study of Avonex® (Interferon Beta-1a) 30 mcg Administered Subcutaneously to Subjects With Relapsing Multiple Sclerosis - CZ",
        "timestamp": "2009-01-06"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-003098-42/results",
        "title": "A Multicenter, Open-Label, Immunogenicity and Safety Study of Avonex® (Interferon Beta-1a) 30 mcg Administered Subcutaneously to Subjects With Relapsing Multiple Sclerosis - View results",
        "timestamp": "2009-01-06"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-003730-33/IT",
        "title": "Phase I-II study of the combination vemurafenib plus PEG-interferon in advanced melanoma patients harboring the V600BRAF mutation - IT",
        "timestamp": "2014-01-15"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-001261-17/IE",
        "title": "An Open-Label Study of the Safety of Subcutaneous Recombinant Interferon gamma-1b in Patients with Idiopathic Pulmonary Fibrosis - IE",
        "timestamp": "2005-01-28"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-024262-22/DE",
        "title": "Treatment optimization of newly diagnosed Ph/BCR-ABL positive patients with chronic myeloid leukemia (CML) in chronic phase with nilotinib vs. nilotinib plus interferon alpha induction and nilotini... - DE",
        "timestamp": "2012-08-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-024262-22/CZ",
        "title": "Treatment optimization of newly diagnosed Ph/BCR-ABL positive patients with chronic myeloid leukemia (CML) in chronic phase with nilotinib vs. nilotinib plus interferon alpha induction and nilotini... - CZ",
        "timestamp": "2012-08-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-006985-41/ES",
        "title": "Estudio piloto en fase III, mutlicéntrico, aleatorizado, controlado y abierto, sobre la eficacia de Interferón Pegilado alfa-2a a dosis de 90 mcg semanal en retrasar la aparición del primer evento ... - ES",
        "timestamp": "2007-05-13"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-001943-60/DK",
        "title": "Cellular immunity in adult Hepatitis B-vaccinated serologic non-responders - DK",
        "timestamp": "2011-06-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-008554-23/SE",
        "title": "Neutralizing Antibodies to Interferon beta in patients treated with Rebif New Formulation - SE",
        "timestamp": "2009-12-29"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-000753-22/GB",
        "title": "A phase I/II feasability trial to assess the safety, immunological activity and efficacy of TroVax plus interferon alpha in patients with advanced or metastatic renal cell cancer. - GB",
        "timestamp": "2006-05-04"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-000753-22/results",
        "title": "A phase I/II feasability trial to assess the safety, immunological activity and efficacy of TroVax plus interferon alpha in patients with advanced or metastatic renal cell cancer. - View results",
        "timestamp": "2006-05-04"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-000606-23/ES",
        "title": "Post-authorization safety study to check the potential association between the safety\nprofile of beta interferon 1a and the body mass index or pharmacodynamics during the\ntitration phase - ES",
        "timestamp": "2006-11-23"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-000606-23/results",
        "title": "Post-authorization safety study to check the potential association between the safety\nprofile of beta interferon 1a and the body mass index or pharmacodynamics during the\ntitration phase - View results",
        "timestamp": "2006-11-23"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-001919-31/DK",
        "title": "DALIAH\r\n\r\nA Danish Study of Low-dose Interferon Alpha Versus Hydroxyurea in the Treatment of Ph-negative Chronic Myeloid Neoplasias - A National Randomized Prospective Study With Focus on Efficacy,... - DK",
        "timestamp": "2011-09-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-006414-19/GB",
        "title": "Dynamic contrast enhanced MRI (DCE-MRI) assessment of the vascular changes induced with bevacizumab alone and in combination with interferon-α in patients with advanced renal cell carcinoma. - GB",
        "timestamp": "2009-04-27"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-006414-19/results",
        "title": "Dynamic contrast enhanced MRI (DCE-MRI) assessment of the vascular changes induced with bevacizumab alone and in combination with interferon-α in patients with advanced renal cell carcinoma. - View results",
        "timestamp": "2009-04-27"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005677-23/IT",
        "title": "A two-year, double-blind, randomized, multicenter, active controlled\r\nstudy to evaluate the safety and efficacy of fingolimod administered orally once daily versus interferon β-1a i.m. once weekly ... - IT",
        "timestamp": "2013-04-02"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005677-23/LT",
        "title": "A two-year, double-blind, randomized, multicenter, active controlled\r\nstudy to evaluate the safety and efficacy of fingolimod administered orally once daily versus interferon β-1a i.m. once weekly ... - LT",
        "timestamp": "2013-04-02"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005677-23/SK",
        "title": "A two-year, double-blind, randomized, multicenter, active controlled\r\nstudy to evaluate the safety and efficacy of fingolimod administered orally once daily versus interferon β-1a i.m. once weekly ... - SK",
        "timestamp": "2013-04-02"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005677-23/LV",
        "title": "A two-year, double-blind, randomized, multicenter, active controlled\r\nstudy to evaluate the safety and efficacy of fingolimod administered orally once daily versus interferon β-1a i.m. once weekly ... - LV",
        "timestamp": "2013-04-02"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005677-23/ES",
        "title": "A two-year, double-blind, randomized, multicenter, active controlled\r\nstudy to evaluate the safety and efficacy of fingolimod administered orally once daily versus interferon β-1a i.m. once weekly ... - ES",
        "timestamp": "2013-04-02"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005677-23/DE",
        "title": "A two-year, double-blind, randomized, multicenter, active controlled\r\nstudy to evaluate the safety and efficacy of fingolimod administered orally once daily versus interferon β-1a i.m. once weekly ... - DE",
        "timestamp": "2013-04-02"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005677-23/BG",
        "title": "A two-year, double-blind, randomized, multicenter, active controlled\r\nstudy to evaluate the safety and efficacy of fingolimod administered orally once daily versus interferon β-1a i.m. once weekly ... - BG",
        "timestamp": "2013-04-02"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005677-23/PL",
        "title": "A two-year, double-blind, randomized, multicenter, active controlled\r\nstudy to evaluate the safety and efficacy of fingolimod administered orally once daily versus interferon β-1a i.m. once weekly ... - PL",
        "timestamp": "2013-04-02"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005677-23/AT",
        "title": "A two-year, double-blind, randomized, multicenter, active controlled\r\nstudy to evaluate the safety and efficacy of fingolimod administered orally once daily versus interferon β-1a i.m. once weekly ... - AT",
        "timestamp": "2013-04-02"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005677-23/NL",
        "title": "A two-year, double-blind, randomized, multicenter, active controlled\r\nstudy to evaluate the safety and efficacy of fingolimod administered orally once daily versus interferon β-1a i.m. once weekly ... - NL",
        "timestamp": "2013-04-02"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005677-23/SE",
        "title": "A two-year, double-blind, randomized, multicenter, active controlled\r\nstudy to evaluate the safety and efficacy of fingolimod administered orally once daily versus interferon β-1a i.m. once weekly ... - SE",
        "timestamp": "2013-04-02"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005677-23/GB",
        "title": "A two-year, double-blind, randomized, multicenter, active controlled\r\nstudy to evaluate the safety and efficacy of fingolimod administered orally once daily versus interferon β-1a i.m. once weekly ... - GB",
        "timestamp": "2013-04-02"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005677-23/RO",
        "title": "A two-year, double-blind, randomized, multicenter, active controlled\r\nstudy to evaluate the safety and efficacy of fingolimod administered orally once daily versus interferon β-1a i.m. once weekly ... - RO",
        "timestamp": "2013-04-02"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005677-23/EE",
        "title": "A two-year, double-blind, randomized, multicenter, active controlled\r\nstudy to evaluate the safety and efficacy of fingolimod administered orally once daily versus interferon β-1a i.m. once weekly ... - EE",
        "timestamp": "2013-04-02"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005677-23/HR",
        "title": "A two-year, double-blind, randomized, multicenter, active controlled\r\nstudy to evaluate the safety and efficacy of fingolimod administered orally once daily versus interferon β-1a i.m. once weekly ... - HR",
        "timestamp": "2013-04-02"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-003587-39/SE",
        "title": "COMBAT-MS (COMparison Between All immunoTherapies for Multiple Sclerosis)\n\nA prospective long-term cohort study of safety, efficacy and patient’s satisfaction of MS disease modulatory treatments in... - SE",
        "timestamp": "2017-05-22"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-003008-38/CZ",
        "title": "An Open-Label, Randomized, Multicenter, Active-Controlled,\r\nParallel-Group Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 in\r\nPediatric Subjects Aged 10 to Less Than 18 Years f... - CZ",
        "timestamp": None
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-003008-38/FR",
        "title": "An Open-Label, Randomized, Multicenter, Active-Controlled,\r\nParallel-Group Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 in\r\nPediatric Subjects Aged 10 to Less Than 18 Years f... - FR",
        "timestamp": None
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-003008-38/PT",
        "title": "An Open-Label, Randomized, Multicenter, Active-Controlled,\r\nParallel-Group Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 in\r\nPediatric Subjects Aged 10 to Less Than 18 Years f... - PT",
        "timestamp": None
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-003008-38/BG",
        "title": "An Open-Label, Randomized, Multicenter, Active-Controlled,\r\nParallel-Group Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 in\r\nPediatric Subjects Aged 10 to Less Than 18 Years f... - BG",
        "timestamp": None
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-003008-38/HU",
        "title": "An Open-Label, Randomized, Multicenter, Active-Controlled,\r\nParallel-Group Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 in\r\nPediatric Subjects Aged 10 to Less Than 18 Years f... - HU",
        "timestamp": None
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-003008-38/BE",
        "title": "An Open-Label, Randomized, Multicenter, Active-Controlled,\r\nParallel-Group Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 in\r\nPediatric Subjects Aged 10 to Less Than 18 Years f... - BE",
        "timestamp": None
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-003008-38/SK",
        "title": "An Open-Label, Randomized, Multicenter, Active-Controlled,\r\nParallel-Group Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 in\r\nPediatric Subjects Aged 10 to Less Than 18 Years f... - SK",
        "timestamp": None
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-003008-38/GR",
        "title": "An Open-Label, Randomized, Multicenter, Active-Controlled,\r\nParallel-Group Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 in\r\nPediatric Subjects Aged 10 to Less Than 18 Years f... - GR",
        "timestamp": None
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-003008-38/DE",
        "title": "An Open-Label, Randomized, Multicenter, Active-Controlled,\r\nParallel-Group Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 in\r\nPediatric Subjects Aged 10 to Less Than 18 Years f... - DE",
        "timestamp": None
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-003008-38/ES",
        "title": "An Open-Label, Randomized, Multicenter, Active-Controlled,\r\nParallel-Group Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 in\r\nPediatric Subjects Aged 10 to Less Than 18 Years f... - ES",
        "timestamp": None
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-003008-38/HR",
        "title": "An Open-Label, Randomized, Multicenter, Active-Controlled,\r\nParallel-Group Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 in\r\nPediatric Subjects Aged 10 to Less Than 18 Years f... - HR",
        "timestamp": None
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-018146-38/FR",
        "title": "Multicenter randomized controlled study comparing the efficacy and safety of natural Multi-subtype interferon alpha (Multiferon) in association with ribavirin versus retreatment with pegylated inte... - FR",
        "timestamp": "2010-05-28"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-003751-38/FR",
        "title": "A multicenter, open-label, randomized, 2-arm, phase II trial of  pharmacodynamics, pharmacokinetics and safety of two dose regimens of  DEB025/alisporivir in combination with ribavirin therapy in c... - FR",
        "timestamp": "2014-03-27"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-003751-38/results",
        "title": "A multicenter, open-label, randomized, 2-arm, phase II trial of  pharmacodynamics, pharmacokinetics and safety of two dose regimens of  DEB025/alisporivir in combination with ribavirin therapy in c... - View results",
        "timestamp": "2014-03-27"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-003134-14/DE",
        "title": "A randomized, multinational, double-blind, placebo-controlled, parallel-group design pilot study to estimate the tolerability, safety, pharmacokinetics, and pharmacodynamic effects of teriflunomide... - DE",
        "timestamp": "2007-06-04"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-003134-14/IT",
        "title": "A randomized, multinational, double-blind, placebo-controlled, parallel-group design pilot study to estimate the tolerability, safety, pharmacokinetics, and pharmacodynamic effects of teriflunomide... - IT",
        "timestamp": "2007-06-04"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-003134-14/ES",
        "title": "A randomized, multinational, double-blind, placebo-controlled, parallel-group design pilot study to estimate the tolerability, safety, pharmacokinetics, and pharmacodynamic effects of teriflunomide... - ES",
        "timestamp": "2007-06-04"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-003134-14/results",
        "title": "A randomized, multinational, double-blind, placebo-controlled, parallel-group design pilot study to estimate the tolerability, safety, pharmacokinetics, and pharmacodynamic effects of teriflunomide... - View results",
        "timestamp": "2007-06-04"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-002635-28/IT",
        "title": "ASSESSMENT OF THE EFFICACY OF SUBTENON NATURAL LEUCOCYTIC INTERFERON-α (IFNα) FOR THE TREATMENT OF DIABETIC MACULAR EDEMA (DME): A PILOT STUDY. - IT",
        "timestamp": "2013-04-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-001192-34/ES",
        "title": "Open pilot study phase IV to treat co infected HCV-HIV patients after their relapse with interferon therapy.\nTratamiento de los pacientes con hepatitis crónica C infectados por el VIH que han recaí... - ES",
        "timestamp": "2006-01-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-004903-39/GB",
        "title": "A pilot multi-centre randomised controlled trial of sequential treatment with Mitoxantrone and Glatiramer Acetate vs. Interferon Beta-1a in early active relapsing remitting Multiple Sclerosis. - GB",
        "timestamp": "2005-07-26"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-005656-24/ES",
        "title": "ENSAYO CLÍNICO SOBRE LA EVOLUCIÓN Y EL IMPACTO DEL TRATAMIENTO FARMACOLÓGICO EN LA PERDIDA AXONAL PROGRESIVA EN PACIENTES QUE CON ESCLEROSIS MÚLTIPLE QUE HAN PRESENTADO UN PRIMER EPISODIO DESMIELIN... - ES",
        "timestamp": "2008-12-29"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-004787-30/DE",
        "title": "Modification of the visual outcome after optic neuritis in CIS or MS by Gilenya® - DE",
        "timestamp": "2012-10-26"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-019500-23/IT",
        "title": "Single Arm Salvage Therapy with Pegylated Interferon Alfa-2a for Patients with High Risk Polycythemia Vera or High Risk Essential Thrombocythemia who are Either Hydroxyurea Resistant or Intolerant ... - IT",
        "timestamp": "2012-02-15"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-004611-35/NL",
        "title": "Phase I/II study: on the toxicity and effects of combining the p53 synthetic long peptides vaccine with either Imiquimod or Interferon-alfa to induce polarized p53-specific immunity in patients tre... - NL",
        "timestamp": "2009-01-22"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-000524-14/SE",
        "title": "Comparison of virological response during high and low-dose regimen with natural IFN α in combination with ribavirin in patients with genotype 1 chronic hepatitis C who have experienced an incomple... - SE",
        "timestamp": "2006-06-22"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-001586-87/GB",
        "title": "A Phase 2, Double Blind, Placebo Controlled Study of RSLV-132 in Subjects with Primary Sjogren’s Syndrome - GB",
        "timestamp": "2016-09-29"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-012010-52/DK",
        "title": "Bevacizumab, Interleukin-2 and Interferon-alpha in metastathic renal cell carcinoma - DK",
        "timestamp": "2009-08-04"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-007446-54/NL",
        "title": "LOWERING VIRAL LOAD WITH NUCLEOS(T)IDE ANALOGUES PRIOR TO PEG-INTERFERON ALFA-2B TREATMENT TO INCREASE SUSTAINED RESPONSE IN HBEAG-POSITIVE CHRONIC HEPATITIS B (PADD-STUDY) - NL",
        "timestamp": "2009-03-26"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-000280-84/FI",
        "title": "COBRA: TOL+ INTERFERON-alpha COMBINED WITH VEMURAFENIB (BRAF-mutation positive patients) OR TOL + INTERFERON- alpha (BRAF-mutation negative patients) FOR PATIENTS WITH ADVANCED MELANOMA AS 1st CHEM... - FI",
        "timestamp": "2013-08-15"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-001918-16/DE",
        "title": "Combined Treatment of Sorafenib and pegylated interferon α2b in stage IV metastatic melanoma: a prospective non-randomized, multicenter Phase II Study\nSoraPeg Trial - DE",
        "timestamp": "2007-12-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-022467-36/DE",
        "title": "A phase II study about interferon gamma 1b to therapy the steroid-refractory bronchiolitis obliterans after allogenic stem cell therapy - DE",
        "timestamp": None
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-003295-12/DK",
        "title": "Combination Therapy Interferon Alpha + JAK1-2 Inhibitor in The Ph-Negative Chronic Myeloid Neoplasms - DK",
        "timestamp": "2013-10-31"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-007147-28/FR",
        "title": "A PHASE I/IIa DOSE ESCALATION STUDY OF REPEATED ADMINISTRATION OF “CYT107” (glyco-r-hIL-7) ADD ON TREATMENT IN GENOTYPE 1 or 4 HCV INFECTED PATIENTS RESISTANT TO PEGYLATED INTERFERON-ALPHA AND RIB... - FR",
        "timestamp": "2008-02-29"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-000815-15/IT",
        "title": "Effects of a late add-on therapy of pegylated interferon (peg-IFNA) to ongoing nucleos(t)ide\r\nanalogs (NUCs) in patients with chronic hepatitis B (CHB). - IT",
        "timestamp": "2015-07-22"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-005197-35/IE",
        "title": "A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma. - IE",
        "timestamp": "2017-06-06"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-005525-75/GB",
        "title": "An open label, randomised, pilot trial of pegylated interferon, ribavirin and telaprevir versus pegylated interferon and ribavirin alone in the response guided treatment of acute hepatitis C genoty... - GB",
        "timestamp": "2013-07-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-005525-75/results",
        "title": "An open label, randomised, pilot trial of pegylated interferon, ribavirin and telaprevir versus pegylated interferon and ribavirin alone in the response guided treatment of acute hepatitis C genoty... - View results",
        "timestamp": "2013-07-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-000706-36/DE",
        "title": "Optimization of treatment for patients with chronic hepatitis C infected with HCV-genotype 2 or 3: 12 vs. 24 weeks of treatment extension for patients without rapid virological response - DE",
        "timestamp": "2008-09-30"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-005084-32/GB",
        "title": "A randomized, double-blind, placebo-controlled, parallel group, multi-centre Phase IIa study in asthma patients comparing the efficacy and safety of once daily inhaled Interferon beta-1a to placebo... - GB",
        "timestamp": "2015-06-05"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-005084-32/ES",
        "title": "A randomized, double-blind, placebo-controlled, parallel group, multi-centre Phase IIa study in asthma patients comparing the efficacy and safety of once daily inhaled Interferon beta-1a to placebo... - ES",
        "timestamp": "2015-06-05"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-005084-32/FR",
        "title": "A randomized, double-blind, placebo-controlled, parallel group, multi-centre Phase IIa study in asthma patients comparing the efficacy and safety of once daily inhaled Interferon beta-1a to placebo... - FR",
        "timestamp": "2015-06-05"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-005084-32/results",
        "title": "A randomized, double-blind, placebo-controlled, parallel group, multi-centre Phase IIa study in asthma patients comparing the efficacy and safety of once daily inhaled Interferon beta-1a to placebo... - View results",
        "timestamp": "2015-06-05"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-004937-13/IT",
        "title": "multicentee randomized controlled study of azathioprine versus  iterferon beta in relapsing remitting multiple sclerosis - IT",
        "timestamp": "2006-08-17"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-003997-24/GB",
        "title": "Long-term extension of the multinational, double-blind, placebo controlled study PDY6045 and PDY6046 to document the safety of teriflunomide when added to treatment with interferon-beta or glatiram... - GB",
        "timestamp": "2008-07-08"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-003997-24/AT",
        "title": "Long-term extension of the multinational, double-blind, placebo controlled study PDY6045 and PDY6046 to document the safety of teriflunomide when added to treatment with interferon-beta or glatiram... - AT",
        "timestamp": "2008-07-08"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-003997-24/ES",
        "title": "Long-term extension of the multinational, double-blind, placebo controlled study PDY6045 and PDY6046 to document the safety of teriflunomide when added to treatment with interferon-beta or glatiram... - ES",
        "timestamp": "2008-07-08"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-003997-24/IT",
        "title": "Long-term extension of the multinational, double-blind, placebo controlled study PDY6045 and PDY6046 to document the safety of teriflunomide when added to treatment with interferon-beta or glatiram... - IT",
        "timestamp": "2008-07-08"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-003997-24/results",
        "title": "Long-term extension of the multinational, double-blind, placebo controlled study PDY6045 and PDY6046 to document the safety of teriflunomide when added to treatment with interferon-beta or glatiram... - View results",
        "timestamp": "2008-07-08"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-003793-26/HU",
        "title": "Phase 3b, Randomized, Open-Label Study of Bevacizumab + Temsirolimus\nvs. Bevacizumab + Interferon-Alfa as First-Line Treatment in Subjects With Advanced Renal Cell Carcinoma - HU",
        "timestamp": "2008-05-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-003793-26/ES",
        "title": "Phase 3b, Randomized, Open-Label Study of Bevacizumab + Temsirolimus\nvs. Bevacizumab + Interferon-Alfa as First-Line Treatment in Subjects With Advanced Renal Cell Carcinoma - ES",
        "timestamp": "2008-05-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-003793-26/FR",
        "title": "Phase 3b, Randomized, Open-Label Study of Bevacizumab + Temsirolimus\nvs. Bevacizumab + Interferon-Alfa as First-Line Treatment in Subjects With Advanced Renal Cell Carcinoma - FR",
        "timestamp": "2008-05-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-003793-26/BE",
        "title": "Phase 3b, Randomized, Open-Label Study of Bevacizumab + Temsirolimus\nvs. Bevacizumab + Interferon-Alfa as First-Line Treatment in Subjects With Advanced Renal Cell Carcinoma - BE",
        "timestamp": "2008-05-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-003793-26/PT",
        "title": "Phase 3b, Randomized, Open-Label Study of Bevacizumab + Temsirolimus\nvs. Bevacizumab + Interferon-Alfa as First-Line Treatment in Subjects With Advanced Renal Cell Carcinoma - PT",
        "timestamp": "2008-05-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-003793-26/CZ",
        "title": "Phase 3b, Randomized, Open-Label Study of Bevacizumab + Temsirolimus\nvs. Bevacizumab + Interferon-Alfa as First-Line Treatment in Subjects With Advanced Renal Cell Carcinoma - CZ",
        "timestamp": "2008-05-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-003793-26/DE",
        "title": "Phase 3b, Randomized, Open-Label Study of Bevacizumab + Temsirolimus\nvs. Bevacizumab + Interferon-Alfa as First-Line Treatment in Subjects With Advanced Renal Cell Carcinoma - DE",
        "timestamp": "2008-05-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-003793-26/SK",
        "title": "Phase 3b, Randomized, Open-Label Study of Bevacizumab + Temsirolimus\nvs. Bevacizumab + Interferon-Alfa as First-Line Treatment in Subjects With Advanced Renal Cell Carcinoma - SK",
        "timestamp": "2008-05-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-003793-26/NL",
        "title": "Phase 3b, Randomized, Open-Label Study of Bevacizumab + Temsirolimus\nvs. Bevacizumab + Interferon-Alfa as First-Line Treatment in Subjects With Advanced Renal Cell Carcinoma - NL",
        "timestamp": "2008-05-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-003793-26/IT",
        "title": "Phase 3b, Randomized, Open-Label Study of Bevacizumab + Temsirolimus\nvs. Bevacizumab + Interferon-Alfa as First-Line Treatment in Subjects With Advanced Renal Cell Carcinoma - IT",
        "timestamp": "2008-05-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-003793-26/GB",
        "title": "Phase 3b, Randomized, Open-Label Study of Bevacizumab + Temsirolimus\nvs. Bevacizumab + Interferon-Alfa as First-Line Treatment in Subjects With Advanced Renal Cell Carcinoma - GB",
        "timestamp": "2008-05-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-003793-26/results",
        "title": "Phase 3b, Randomized, Open-Label Study of Bevacizumab + Temsirolimus\nvs. Bevacizumab + Interferon-Alfa as First-Line Treatment in Subjects With Advanced Renal Cell Carcinoma - View results",
        "timestamp": "2008-05-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-000245-39/DE",
        "title": "Rescue effect of daily infusions with Legalon® SIL in Hepatitis C Virus-infected patients who are incomplete responders to standard pegylated interferon/ribavirin (dual therapy) or pegylated interf... - DE",
        "timestamp": "2013-09-11"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-000245-39/AT",
        "title": "Rescue effect of daily infusions with Legalon® SIL in Hepatitis C Virus-infected patients who are incomplete responders to standard pegylated interferon/ribavirin (dual therapy) or pegylated interf... - AT",
        "timestamp": "2013-09-11"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-018332-41/DK",
        "title": "A Randomized, Open-label, Parallel Group, Multicenter Pilot Study Evaluating the Efficacy and Safety of Alternative Dosing of Ribavirin vs. Standard of Care Dosing in Combination with Peginterferon... - DK",
        "timestamp": "2010-05-10"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-018332-41/FI",
        "title": "A Randomized, Open-label, Parallel Group, Multicenter Pilot Study Evaluating the Efficacy and Safety of Alternative Dosing of Ribavirin vs. Standard of Care Dosing in Combination with Peginterferon... - FI",
        "timestamp": "2010-05-10"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-000434-21/PT",
        "title": "PLENO – Open-label, Randomized, 2-arm, Active Comparator Study to Evaluate Safety and Tolerability in Portuguese Patients with Relapsing Remitting Multiple Sclerosis (MS) Transitioning from Current... - PT",
        "timestamp": "2016-11-14"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-001161-14/GB",
        "title": "A Phase 3 Randomized, Rater-Blinded Study Comparing Two Annual Cycles of Intravenous Alemtuzumab to Three-Times Weekly Subcutaneous Interferon Beta-1a (Rebif®) in treatment Naïve Patients with Rela... - GB",
        "timestamp": "2007-08-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-001161-14/DE",
        "title": "A Phase 3 Randomized, Rater-Blinded Study Comparing Two Annual Cycles of Intravenous Alemtuzumab to Three-Times Weekly Subcutaneous Interferon Beta-1a (Rebif®) in treatment Naïve Patients with Rela... - DE",
        "timestamp": "2007-08-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-001161-14/CZ",
        "title": "A Phase 3 Randomized, Rater-Blinded Study Comparing Two Annual Cycles of Intravenous Alemtuzumab to Three-Times Weekly Subcutaneous Interferon Beta-1a (Rebif®) in treatment Naïve Patients with Rela... - CZ",
        "timestamp": "2007-08-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-001161-14/SE",
        "title": "A Phase 3 Randomized, Rater-Blinded Study Comparing Two Annual Cycles of Intravenous Alemtuzumab to Three-Times Weekly Subcutaneous Interferon Beta-1a (Rebif®) in treatment Naïve Patients with Rela... - SE",
        "timestamp": "2007-08-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-001161-14/FR",
        "title": "A Phase 3 Randomized, Rater-Blinded Study Comparing Two Annual Cycles of Intravenous Alemtuzumab to Three-Times Weekly Subcutaneous Interferon Beta-1a (Rebif®) in treatment Naïve Patients with Rela... - FR",
        "timestamp": "2007-08-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-001161-14/PL",
        "title": "A Phase 3 Randomized, Rater-Blinded Study Comparing Two Annual Cycles of Intravenous Alemtuzumab to Three-Times Weekly Subcutaneous Interferon Beta-1a (Rebif®) in treatment Naïve Patients with Rela... - PL",
        "timestamp": "2007-08-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-001161-14/results",
        "title": "A Phase 3 Randomized, Rater-Blinded Study Comparing Two Annual Cycles of Intravenous Alemtuzumab to Three-Times Weekly Subcutaneous Interferon Beta-1a (Rebif®) in treatment Naïve Patients with Rela... - View results",
        "timestamp": "2007-08-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020315-36/SK",
        "title": "A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study To Evaluate The Efficacy And Safety Of Ocrelizumab In Comparison To Interferon Beta-1a (Rebif®) In Patients With Relapsing Multiple Sc... - SK",
        "timestamp": "2011-10-18"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020315-36/BE",
        "title": "A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study To Evaluate The Efficacy And Safety Of Ocrelizumab In Comparison To Interferon Beta-1a (Rebif®) In Patients With Relapsing Multiple Sc... - BE",
        "timestamp": "2011-10-18"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020315-36/SE",
        "title": "A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study To Evaluate The Efficacy And Safety Of Ocrelizumab In Comparison To Interferon Beta-1a (Rebif®) In Patients With Relapsing Multiple Sc... - SE",
        "timestamp": "2011-10-18"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020315-36/DE",
        "title": "A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study To Evaluate The Efficacy And Safety Of Ocrelizumab In Comparison To Interferon Beta-1a (Rebif®) In Patients With Relapsing Multiple Sc... - DE",
        "timestamp": "2011-10-18"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020315-36/ES",
        "title": "A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study To Evaluate The Efficacy And Safety Of Ocrelizumab In Comparison To Interferon Beta-1a (Rebif®) In Patients With Relapsing Multiple Sc... - ES",
        "timestamp": "2011-10-18"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020315-36/GB",
        "title": "A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study To Evaluate The Efficacy And Safety Of Ocrelizumab In Comparison To Interferon Beta-1a (Rebif®) In Patients With Relapsing Multiple Sc... - GB",
        "timestamp": "2011-10-18"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020315-36/BG",
        "title": "A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study To Evaluate The Efficacy And Safety Of Ocrelizumab In Comparison To Interferon Beta-1a (Rebif®) In Patients With Relapsing Multiple Sc... - BG",
        "timestamp": "2011-10-18"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020315-36/FR",
        "title": "A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study To Evaluate The Efficacy And Safety Of Ocrelizumab In Comparison To Interferon Beta-1a (Rebif®) In Patients With Relapsing Multiple Sc... - FR",
        "timestamp": "2011-10-18"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020315-36/IE",
        "title": "A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study To Evaluate The Efficacy And Safety Of Ocrelizumab In Comparison To Interferon Beta-1a (Rebif®) In Patients With Relapsing Multiple Sc... - IE",
        "timestamp": "2011-10-18"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020315-36/IT",
        "title": "A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study To Evaluate The Efficacy And Safety Of Ocrelizumab In Comparison To Interferon Beta-1a (Rebif®) In Patients With Relapsing Multiple Sc... - IT",
        "timestamp": "2011-10-18"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020315-36/CZ",
        "title": "A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study To Evaluate The Efficacy And Safety Of Ocrelizumab In Comparison To Interferon Beta-1a (Rebif®) In Patients With Relapsing Multiple Sc... - CZ",
        "timestamp": "2011-10-18"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020315-36/results",
        "title": "A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study To Evaluate The Efficacy And Safety Of Ocrelizumab In Comparison To Interferon Beta-1a (Rebif®) In Patients With Relapsing Multiple Sc... - View results",
        "timestamp": "2011-10-18"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-012579-90/DE",
        "title": "Antiviral effect and safety of once daily BI 201335 NA in hepatitis C virus genotype 1 infected treatment-naïve patients for 12 or 24 weeks as combination therapy with pegylated interferon-α 2a and... - DE",
        "timestamp": "2009-08-04"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-012579-90/FR",
        "title": "Antiviral effect and safety of once daily BI 201335 NA in hepatitis C virus genotype 1 infected treatment-naïve patients for 12 or 24 weeks as combination therapy with pegylated interferon-α 2a and... - FR",
        "timestamp": "2009-08-04"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-012579-90/AT",
        "title": "Antiviral effect and safety of once daily BI 201335 NA in hepatitis C virus genotype 1 infected treatment-naïve patients for 12 or 24 weeks as combination therapy with pegylated interferon-α 2a and... - AT",
        "timestamp": "2009-08-04"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-012579-90/results",
        "title": "Antiviral effect and safety of once daily BI 201335 NA in hepatitis C virus genotype 1 infected treatment-naïve patients for 12 or 24 weeks as combination therapy with pegylated interferon-α 2a and... - View results",
        "timestamp": "2009-08-04"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-002703-13/DE",
        "title": "A Phase 3, Randomized, Multi-Center Study to Evaluate the Efficacy and Safety of Albumin Interferon Alfa-2b (alb-IFN) in Combination with Ribavirin Compared with Peginterferon Alfa-2a (PEGASYS or P... - DE",
        "timestamp": "2007-03-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-002703-13/CZ",
        "title": "A Phase 3, Randomized, Multi-Center Study to Evaluate the Efficacy and Safety of Albumin Interferon Alfa-2b (alb-IFN) in Combination with Ribavirin Compared with Peginterferon Alfa-2a (PEGASYS or P... - CZ",
        "timestamp": "2007-03-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-002703-13/AT",
        "title": "A Phase 3, Randomized, Multi-Center Study to Evaluate the Efficacy and Safety of Albumin Interferon Alfa-2b (alb-IFN) in Combination with Ribavirin Compared with Peginterferon Alfa-2a (PEGASYS or P... - AT",
        "timestamp": "2007-03-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-002703-13/FR",
        "title": "A Phase 3, Randomized, Multi-Center Study to Evaluate the Efficacy and Safety of Albumin Interferon Alfa-2b (alb-IFN) in Combination with Ribavirin Compared with Peginterferon Alfa-2a (PEGASYS or P... - FR",
        "timestamp": "2007-03-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-002703-13/GB",
        "title": "A Phase 3, Randomized, Multi-Center Study to Evaluate the Efficacy and Safety of Albumin Interferon Alfa-2b (alb-IFN) in Combination with Ribavirin Compared with Peginterferon Alfa-2a (PEGASYS or P... - GB",
        "timestamp": "2007-03-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-002703-13/ES",
        "title": "A Phase 3, Randomized, Multi-Center Study to Evaluate the Efficacy and Safety of Albumin Interferon Alfa-2b (alb-IFN) in Combination with Ribavirin Compared with Peginterferon Alfa-2a (PEGASYS or P... - ES",
        "timestamp": "2007-03-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-002703-13/results",
        "title": "A Phase 3, Randomized, Multi-Center Study to Evaluate the Efficacy and Safety of Albumin Interferon Alfa-2b (alb-IFN) in Combination with Ribavirin Compared with Peginterferon Alfa-2a (PEGASYS or P... - View results",
        "timestamp": "2007-03-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-002704-34/BE",
        "title": "A Phase 3, Randomized, Multi-Center Study to Evaluate the Efficacy and Safety of Albumin Interferon Alfa-2b (alb-IFN) in Combination with Ribavirin Compared with Peginterferon Alfa-2a (PEGASYS or P... - BE",
        "timestamp": "2007-04-27"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-002704-34/FR",
        "title": "A Phase 3, Randomized, Multi-Center Study to Evaluate the Efficacy and Safety of Albumin Interferon Alfa-2b (alb-IFN) in Combination with Ribavirin Compared with Peginterferon Alfa-2a (PEGASYS or P... - FR",
        "timestamp": "2007-04-27"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-002704-34/SE",
        "title": "A Phase 3, Randomized, Multi-Center Study to Evaluate the Efficacy and Safety of Albumin Interferon Alfa-2b (alb-IFN) in Combination with Ribavirin Compared with Peginterferon Alfa-2a (PEGASYS or P... - SE",
        "timestamp": "2007-04-27"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-002704-34/GB",
        "title": "A Phase 3, Randomized, Multi-Center Study to Evaluate the Efficacy and Safety of Albumin Interferon Alfa-2b (alb-IFN) in Combination with Ribavirin Compared with Peginterferon Alfa-2a (PEGASYS or P... - GB",
        "timestamp": "2007-04-27"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-002704-34/DE",
        "title": "A Phase 3, Randomized, Multi-Center Study to Evaluate the Efficacy and Safety of Albumin Interferon Alfa-2b (alb-IFN) in Combination with Ribavirin Compared with Peginterferon Alfa-2a (PEGASYS or P... - DE",
        "timestamp": "2007-04-27"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-002704-34/ES",
        "title": "A Phase 3, Randomized, Multi-Center Study to Evaluate the Efficacy and Safety of Albumin Interferon Alfa-2b (alb-IFN) in Combination with Ribavirin Compared with Peginterferon Alfa-2a (PEGASYS or P... - ES",
        "timestamp": "2007-04-27"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-002704-34/results",
        "title": "A Phase 3, Randomized, Multi-Center Study to Evaluate the Efficacy and Safety of Albumin Interferon Alfa-2b (alb-IFN) in Combination with Ribavirin Compared with Peginterferon Alfa-2a (PEGASYS or P... - View results",
        "timestamp": "2007-04-27"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-000544-86/DE",
        "title": "A randomised, open-label, multi-center phase II study of first-line treatment with BAY 43-9006 (Sorafenib) versus standard treatment with Interferon alpha-2a in patients with unresectable and/or me... - DE",
        "timestamp": None
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-000544-86/GB",
        "title": "A randomised, open-label, multi-center phase II study of first-line treatment with BAY 43-9006 (Sorafenib) versus standard treatment with Interferon alpha-2a in patients with unresectable and/or me... - GB",
        "timestamp": None
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-000544-86/results",
        "title": "A randomised, open-label, multi-center phase II study of first-line treatment with BAY 43-9006 (Sorafenib) versus standard treatment with Interferon alpha-2a in patients with unresectable and/or me... - View results",
        "timestamp": None
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-015556-15/FI",
        "title": "A Multicenter, Randomized, Rater-Blind, Parallel-Group, Active Controlled Study to Evaluate the Benefits of Switching Therapy (Glatiramer Acetate or Interferon β 1a) to Natalizumab in Subjects wit... - FI",
        "timestamp": "2010-05-07"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-015556-15/SE",
        "title": "A Multicenter, Randomized, Rater-Blind, Parallel-Group, Active Controlled Study to Evaluate the Benefits of Switching Therapy (Glatiramer Acetate or Interferon β 1a) to Natalizumab in Subjects wit... - SE",
        "timestamp": "2010-05-07"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-015556-15/GB",
        "title": "A Multicenter, Randomized, Rater-Blind, Parallel-Group, Active Controlled Study to Evaluate the Benefits of Switching Therapy (Glatiramer Acetate or Interferon β 1a) to Natalizumab in Subjects wit... - GB",
        "timestamp": "2010-05-07"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-015556-15/DE",
        "title": "A Multicenter, Randomized, Rater-Blind, Parallel-Group, Active Controlled Study to Evaluate the Benefits of Switching Therapy (Glatiramer Acetate or Interferon β 1a) to Natalizumab in Subjects wit... - DE",
        "timestamp": "2010-05-07"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-015556-15/ES",
        "title": "A Multicenter, Randomized, Rater-Blind, Parallel-Group, Active Controlled Study to Evaluate the Benefits of Switching Therapy (Glatiramer Acetate or Interferon β 1a) to Natalizumab in Subjects wit... - ES",
        "timestamp": "2010-05-07"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-015556-15/CZ",
        "title": "A Multicenter, Randomized, Rater-Blind, Parallel-Group, Active Controlled Study to Evaluate the Benefits of Switching Therapy (Glatiramer Acetate or Interferon β 1a) to Natalizumab in Subjects wit... - CZ",
        "timestamp": "2010-05-07"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-015556-15/PT",
        "title": "A Multicenter, Randomized, Rater-Blind, Parallel-Group, Active Controlled Study to Evaluate the Benefits of Switching Therapy (Glatiramer Acetate or Interferon β 1a) to Natalizumab in Subjects wit... - PT",
        "timestamp": "2010-05-07"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-015556-15/HU",
        "title": "A Multicenter, Randomized, Rater-Blind, Parallel-Group, Active Controlled Study to Evaluate the Benefits of Switching Therapy (Glatiramer Acetate or Interferon β 1a) to Natalizumab in Subjects wit... - HU",
        "timestamp": "2010-05-07"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-015556-15/NL",
        "title": "A Multicenter, Randomized, Rater-Blind, Parallel-Group, Active Controlled Study to Evaluate the Benefits of Switching Therapy (Glatiramer Acetate or Interferon β 1a) to Natalizumab in Subjects wit... - NL",
        "timestamp": "2010-05-07"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-015556-15/SI",
        "title": "A Multicenter, Randomized, Rater-Blind, Parallel-Group, Active Controlled Study to Evaluate the Benefits of Switching Therapy (Glatiramer Acetate or Interferon β 1a) to Natalizumab in Subjects wit... - SI",
        "timestamp": "2010-05-07"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-015556-15/LV",
        "title": "A Multicenter, Randomized, Rater-Blind, Parallel-Group, Active Controlled Study to Evaluate the Benefits of Switching Therapy (Glatiramer Acetate or Interferon β 1a) to Natalizumab in Subjects wit... - LV",
        "timestamp": "2010-05-07"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-015556-15/AT",
        "title": "A Multicenter, Randomized, Rater-Blind, Parallel-Group, Active Controlled Study to Evaluate the Benefits of Switching Therapy (Glatiramer Acetate or Interferon β 1a) to Natalizumab in Subjects wit... - AT",
        "timestamp": "2010-05-07"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-015556-15/IT",
        "title": "A Multicenter, Randomized, Rater-Blind, Parallel-Group, Active Controlled Study to Evaluate the Benefits of Switching Therapy (Glatiramer Acetate or Interferon β 1a) to Natalizumab in Subjects wit... - IT",
        "timestamp": "2010-05-07"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-015556-15/DK",
        "title": "A Multicenter, Randomized, Rater-Blind, Parallel-Group, Active Controlled Study to Evaluate the Benefits of Switching Therapy (Glatiramer Acetate or Interferon β 1a) to Natalizumab in Subjects wit... - DK",
        "timestamp": "2010-05-07"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-015556-15/GR",
        "title": "A Multicenter, Randomized, Rater-Blind, Parallel-Group, Active Controlled Study to Evaluate the Benefits of Switching Therapy (Glatiramer Acetate or Interferon β 1a) to Natalizumab in Subjects wit... - GR",
        "timestamp": "2010-05-07"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-015556-15/results",
        "title": "A Multicenter, Randomized, Rater-Blind, Parallel-Group, Active Controlled Study to Evaluate the Benefits of Switching Therapy (Glatiramer Acetate or Interferon β 1a) to Natalizumab in Subjects wit... - View results",
        "timestamp": "2010-05-07"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-003799-13/SE",
        "title": "A multicentre, single arm, open-label, phase IIIb study to evaluate the safety and antigenicity of Rebif® (IFN-beta-1a) in subjects with relapsing forms of multiple sclerosis. - SE",
        "timestamp": "2005-02-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-003799-13/LT",
        "title": "A multicentre, single arm, open-label, phase IIIb study to evaluate the safety and antigenicity of Rebif® (IFN-beta-1a) in subjects with relapsing forms of multiple sclerosis. - LT",
        "timestamp": "2005-02-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-003799-13/IE",
        "title": "A multicentre, single arm, open-label, phase IIIb study to evaluate the safety and antigenicity of Rebif® (IFN-beta-1a) in subjects with relapsing forms of multiple sclerosis. - IE",
        "timestamp": "2005-02-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-003799-13/DK",
        "title": "A multicentre, single arm, open-label, phase IIIb study to evaluate the safety and antigenicity of Rebif® (IFN-beta-1a) in subjects with relapsing forms of multiple sclerosis. - DK",
        "timestamp": "2005-02-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-003799-13/GB",
        "title": "A multicentre, single arm, open-label, phase IIIb study to evaluate the safety and antigenicity of Rebif® (IFN-beta-1a) in subjects with relapsing forms of multiple sclerosis. - GB",
        "timestamp": "2005-02-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-003799-13/ES",
        "title": "A multicentre, single arm, open-label, phase IIIb study to evaluate the safety and antigenicity of Rebif® (IFN-beta-1a) in subjects with relapsing forms of multiple sclerosis. - ES",
        "timestamp": "2005-02-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-003799-13/results",
        "title": "A multicentre, single arm, open-label, phase IIIb study to evaluate the safety and antigenicity of Rebif® (IFN-beta-1a) in subjects with relapsing forms of multiple sclerosis. - View results",
        "timestamp": "2005-02-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-003246-93/HU",
        "title": "A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 Study Characterizing the Pharmacokinetics, Pharmacodynamics, and Safety of Anifrolumab following subcutaneous administration in ... - HU",
        "timestamp": "2016-12-06"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-003246-93/PL",
        "title": "A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 Study Characterizing the Pharmacokinetics, Pharmacodynamics, and Safety of Anifrolumab following subcutaneous administration in ... - PL",
        "timestamp": "2016-12-06"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-003246-93/results",
        "title": "A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 Study Characterizing the Pharmacokinetics, Pharmacodynamics, and Safety of Anifrolumab following subcutaneous administration in ... - View results",
        "timestamp": "2016-12-06"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-000337-12/HU",
        "title": "A multicentre, single arm, open-label, phase IV study to evaluate the immunogenicity and safety of subcutaneously administered r-hIFN beta-1a (Rebif) using clone 484-39 in the treatment of subjects... - HU",
        "timestamp": "2004-07-23"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-000337-12/results",
        "title": "A multicentre, single arm, open-label, phase IV study to evaluate the immunogenicity and safety of subcutaneously administered r-hIFN beta-1a (Rebif) using clone 484-39 in the treatment of subjects... - View results",
        "timestamp": "2004-07-23"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-005390-36/GB",
        "title": "Optimal utilisation of biologic drugs in Behçet’s Disease: a randomised controlled trial of infliximab (IFX) verses alpha interferon (aIFN), with genotyping and metabolomic profiling, towards a str... - GB",
        "timestamp": "2016-02-17"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-019501-41/IT",
        "title": "Randomized Trial of Pegylated Interferon Alfa-2a versus Hydroxyurea Therapy in the Treatment of High Risk Polycythemia Vera and High Risk Essential Thrombocythemia - IT",
        "timestamp": "2012-02-15"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-019501-41/SE",
        "title": "Randomized Trial of Pegylated Interferon Alfa-2a versus Hydroxyurea Therapy in the Treatment of High Risk Polycythemia Vera and High Risk Essential Thrombocythemia - SE",
        "timestamp": "2012-02-15"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-019501-41/GB",
        "title": "Randomized Trial of Pegylated Interferon Alfa-2a versus Hydroxyurea Therapy in the Treatment of High Risk Polycythemia Vera and High Risk Essential Thrombocythemia - GB",
        "timestamp": "2012-02-15"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-019501-41/DE",
        "title": "Randomized Trial of Pegylated Interferon Alfa-2a versus Hydroxyurea Therapy in the Treatment of High Risk Polycythemia Vera and High Risk Essential Thrombocythemia - DE",
        "timestamp": "2012-02-15"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-001162-32/GB",
        "title": "A Phase 3 Randomized, Rater- and Dose-Blinded Study Comparing Two Annual Cycles of Intravenous Low- and High-Dose Alemtuzumab to Three-Times Weekly Subcutaneous Interferon Beta-1a (Rebif®) in Patie... - GB",
        "timestamp": "2007-12-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-001162-32/NL",
        "title": "A Phase 3 Randomized, Rater- and Dose-Blinded Study Comparing Two Annual Cycles of Intravenous Low- and High-Dose Alemtuzumab to Three-Times Weekly Subcutaneous Interferon Beta-1a (Rebif®) in Patie... - NL",
        "timestamp": "2007-12-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-001162-32/SE",
        "title": "A Phase 3 Randomized, Rater- and Dose-Blinded Study Comparing Two Annual Cycles of Intravenous Low- and High-Dose Alemtuzumab to Three-Times Weekly Subcutaneous Interferon Beta-1a (Rebif®) in Patie... - SE",
        "timestamp": "2007-12-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-001162-32/DE",
        "title": "A Phase 3 Randomized, Rater- and Dose-Blinded Study Comparing Two Annual Cycles of Intravenous Low- and High-Dose Alemtuzumab to Three-Times Weekly Subcutaneous Interferon Beta-1a (Rebif®) in Patie... - DE",
        "timestamp": "2007-12-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-001162-32/FR",
        "title": "A Phase 3 Randomized, Rater- and Dose-Blinded Study Comparing Two Annual Cycles of Intravenous Low- and High-Dose Alemtuzumab to Three-Times Weekly Subcutaneous Interferon Beta-1a (Rebif®) in Patie... - FR",
        "timestamp": "2007-12-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-001162-32/BE",
        "title": "A Phase 3 Randomized, Rater- and Dose-Blinded Study Comparing Two Annual Cycles of Intravenous Low- and High-Dose Alemtuzumab to Three-Times Weekly Subcutaneous Interferon Beta-1a (Rebif®) in Patie... - BE",
        "timestamp": "2007-12-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-001162-32/ES",
        "title": "A Phase 3 Randomized, Rater- and Dose-Blinded Study Comparing Two Annual Cycles of Intravenous Low- and High-Dose Alemtuzumab to Three-Times Weekly Subcutaneous Interferon Beta-1a (Rebif®) in Patie... - ES",
        "timestamp": "2007-12-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-001162-32/CZ",
        "title": "A Phase 3 Randomized, Rater- and Dose-Blinded Study Comparing Two Annual Cycles of Intravenous Low- and High-Dose Alemtuzumab to Three-Times Weekly Subcutaneous Interferon Beta-1a (Rebif®) in Patie... - CZ",
        "timestamp": "2007-12-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-001162-32/AT",
        "title": "A Phase 3 Randomized, Rater- and Dose-Blinded Study Comparing Two Annual Cycles of Intravenous Low- and High-Dose Alemtuzumab to Three-Times Weekly Subcutaneous Interferon Beta-1a (Rebif®) in Patie... - AT",
        "timestamp": "2007-12-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-001162-32/IT",
        "title": "A Phase 3 Randomized, Rater- and Dose-Blinded Study Comparing Two Annual Cycles of Intravenous Low- and High-Dose Alemtuzumab to Three-Times Weekly Subcutaneous Interferon Beta-1a (Rebif®) in Patie... - IT",
        "timestamp": "2007-12-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-001162-32/DK",
        "title": "A Phase 3 Randomized, Rater- and Dose-Blinded Study Comparing Two Annual Cycles of Intravenous Low- and High-Dose Alemtuzumab to Three-Times Weekly Subcutaneous Interferon Beta-1a (Rebif®) in Patie... - DK",
        "timestamp": "2007-12-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-001162-32/PL",
        "title": "A Phase 3 Randomized, Rater- and Dose-Blinded Study Comparing Two Annual Cycles of Intravenous Low- and High-Dose Alemtuzumab to Three-Times Weekly Subcutaneous Interferon Beta-1a (Rebif®) in Patie... - PL",
        "timestamp": "2007-12-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-001162-32/results",
        "title": "A Phase 3 Randomized, Rater- and Dose-Blinded Study Comparing Two Annual Cycles of Intravenous Low- and High-Dose Alemtuzumab to Three-Times Weekly Subcutaneous Interferon Beta-1a (Rebif®) in Patie... - View results",
        "timestamp": "2007-12-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-004544-30/BE",
        "title": "A phase III, randomised, open label, active-controlled study of an\r\ninterferon-free regimen of BI 207127 in combination with Faldaprevir\r\nand Ribavirin compared to Telaprevir in combination with pe... - BE",
        "timestamp": "2013-04-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-004544-30/SE",
        "title": "A phase III, randomised, open label, active-controlled study of an\r\ninterferon-free regimen of BI 207127 in combination with Faldaprevir\r\nand Ribavirin compared to Telaprevir in combination with pe... - SE",
        "timestamp": "2013-04-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-004544-30/NO",
        "title": "A phase III, randomised, open label, active-controlled study of an\r\ninterferon-free regimen of BI 207127 in combination with Faldaprevir\r\nand Ribavirin compared to Telaprevir in combination with pe... - NO",
        "timestamp": "2013-04-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-004544-30/IT",
        "title": "A phase III, randomised, open label, active-controlled study of an\r\ninterferon-free regimen of BI 207127 in combination with Faldaprevir\r\nand Ribavirin compared to Telaprevir in combination with pe... - IT",
        "timestamp": "2013-04-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-004544-30/GB",
        "title": "A phase III, randomised, open label, active-controlled study of an\r\ninterferon-free regimen of BI 207127 in combination with Faldaprevir\r\nand Ribavirin compared to Telaprevir in combination with pe... - GB",
        "timestamp": "2013-04-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-004544-30/ES",
        "title": "A phase III, randomised, open label, active-controlled study of an\r\ninterferon-free regimen of BI 207127 in combination with Faldaprevir\r\nand Ribavirin compared to Telaprevir in combination with pe... - ES",
        "timestamp": "2013-04-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-004544-30/DE",
        "title": "A phase III, randomised, open label, active-controlled study of an\r\ninterferon-free regimen of BI 207127 in combination with Faldaprevir\r\nand Ribavirin compared to Telaprevir in combination with pe... - DE",
        "timestamp": "2013-04-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-004544-30/DK",
        "title": "A phase III, randomised, open label, active-controlled study of an\r\ninterferon-free regimen of BI 207127 in combination with Faldaprevir\r\nand Ribavirin compared to Telaprevir in combination with pe... - DK",
        "timestamp": "2013-04-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-004544-30/FR",
        "title": "A phase III, randomised, open label, active-controlled study of an\r\ninterferon-free regimen of BI 207127 in combination with Faldaprevir\r\nand Ribavirin compared to Telaprevir in combination with pe... - FR",
        "timestamp": "2013-04-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-004544-30/results",
        "title": "A phase III, randomised, open label, active-controlled study of an\r\ninterferon-free regimen of BI 207127 in combination with Faldaprevir\r\nand Ribavirin compared to Telaprevir in combination with pe... - View results",
        "timestamp": "2013-04-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-021734-59/GB",
        "title": "Safety and Efficacy of 240 mg BI 201335 once daily in combination\r\nwith pegylated interferon alpha 2a and ribavirin for treatment of chronic\r\nHepatitis C (HCV) genotype 1 infection in HIV/HCV-co-in... - GB",
        "timestamp": "2011-08-11"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-021734-59/ES",
        "title": "Safety and Efficacy of 240 mg BI 201335 once daily in combination\r\nwith pegylated interferon alpha 2a and ribavirin for treatment of chronic\r\nHepatitis C (HCV) genotype 1 infection in HIV/HCV-co-in... - ES",
        "timestamp": "2011-08-11"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-021734-59/DE",
        "title": "Safety and Efficacy of 240 mg BI 201335 once daily in combination\r\nwith pegylated interferon alpha 2a and ribavirin for treatment of chronic\r\nHepatitis C (HCV) genotype 1 infection in HIV/HCV-co-in... - DE",
        "timestamp": "2011-08-11"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-021734-59/IT",
        "title": "Safety and Efficacy of 240 mg BI 201335 once daily in combination\r\nwith pegylated interferon alpha 2a and ribavirin for treatment of chronic\r\nHepatitis C (HCV) genotype 1 infection in HIV/HCV-co-in... - IT",
        "timestamp": "2011-08-11"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-021734-59/results",
        "title": "Safety and Efficacy of 240 mg BI 201335 once daily in combination\r\nwith pegylated interferon alpha 2a and ribavirin for treatment of chronic\r\nHepatitis C (HCV) genotype 1 infection in HIV/HCV-co-in... - View results",
        "timestamp": "2011-08-11"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-002039-34/DE",
        "title": "An open-label, randomized, multicenter, active-controlled, dose-ranging study to evaluate the safety and efficacy of albinterferon alfa-2b administered every 4 weeks plus ribavirin in interferon al... - DE",
        "timestamp": "2008-12-15"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-002039-34/ES",
        "title": "An open-label, randomized, multicenter, active-controlled, dose-ranging study to evaluate the safety and efficacy of albinterferon alfa-2b administered every 4 weeks plus ribavirin in interferon al... - ES",
        "timestamp": "2008-12-15"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-002039-34/FR",
        "title": "An open-label, randomized, multicenter, active-controlled, dose-ranging study to evaluate the safety and efficacy of albinterferon alfa-2b administered every 4 weeks plus ribavirin in interferon al... - FR",
        "timestamp": "2008-12-15"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-002039-34/PL",
        "title": "An open-label, randomized, multicenter, active-controlled, dose-ranging study to evaluate the safety and efficacy of albinterferon alfa-2b administered every 4 weeks plus ribavirin in interferon al... - PL",
        "timestamp": "2008-12-15"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-002039-34/IT",
        "title": "An open-label, randomized, multicenter, active-controlled, dose-ranging study to evaluate the safety and efficacy of albinterferon alfa-2b administered every 4 weeks plus ribavirin in interferon al... - IT",
        "timestamp": "2008-12-15"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-002039-34/GR",
        "title": "An open-label, randomized, multicenter, active-controlled, dose-ranging study to evaluate the safety and efficacy of albinterferon alfa-2b administered every 4 weeks plus ribavirin in interferon al... - GR",
        "timestamp": "2008-12-15"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-002039-34/GB",
        "title": "An open-label, randomized, multicenter, active-controlled, dose-ranging study to evaluate the safety and efficacy of albinterferon alfa-2b administered every 4 weeks plus ribavirin in interferon al... - GB",
        "timestamp": "2008-12-15"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-002039-34/results",
        "title": "An open-label, randomized, multicenter, active-controlled, dose-ranging study to evaluate the safety and efficacy of albinterferon alfa-2b administered every 4 weeks plus ribavirin in interferon al... - View results",
        "timestamp": "2008-12-15"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003735-32/SK",
        "title": "A 96-weeks, prospective, multicentre, randomised, open label, active-controlled, parallel groups, phase 2b/3 study to compare efficacy and safety of masitinib to first line treatment, in patients w... - SK",
        "timestamp": "2015-04-01"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003735-32/GR",
        "title": "A 96-weeks, prospective, multicentre, randomised, open label, active-controlled, parallel groups, phase 2b/3 study to compare efficacy and safety of masitinib to first line treatment, in patients w... - GR",
        "timestamp": "2015-04-01"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-001286-17/PT",
        "title": "Exploratory trial to evaluate the risk-benefit ratio of the use of mitoxantrone in patients under treatment with high dose interferon-beta-1a for relapsing-remitting or relapsing secondary progresi... - PT",
        "timestamp": "2006-09-08"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-022110-29/GB",
        "title": "A randomised, double-blind, placebo-controlled Phase II study, comparing the efficacy and safety of inhaled SNG001 to placebo administered to COPD patients after the onset of a respiratory viral in... - GB",
        "timestamp": "2010-10-08"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-005770-72/IT",
        "title": "RAPSODY - RANDOMIZED, PROSPECTIVE TRIAL OF TWO SCHEDULES OF SORAFENIB 800 mg DAILY AND INTERFERON ALPHA IN METASTATIC RENAL CELL CARCINOMA  MRCC   A GOIRC PHASE II STUDY - IT",
        "timestamp": "2006-01-13"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-018870-19/IT",
        "title": "randomized study for hcv recurrence treatment in liver transplant patients with ribavirin pre-treatment for 8 weeks follwed by stadard therapy (48 weeks) with interferon pegylated and ribavirin vs ... - IT",
        "timestamp": "2009-09-17"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-004289-18/FI",
        "title": "A Multi-centre, Double Blind, Randomized, Placebo Controlled, Parallel Group Trial Investigating Minocycline versus placebo as add-on therapy in patients who are on treatment with Interferon-beta-1... - FI",
        "timestamp": "2006-01-26"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-004289-18/SE",
        "title": "A Multi-centre, Double Blind, Randomized, Placebo Controlled, Parallel Group Trial Investigating Minocycline versus placebo as add-on therapy in patients who are on treatment with Interferon-beta-1... - SE",
        "timestamp": "2006-01-26"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-004289-18/DK",
        "title": "A Multi-centre, Double Blind, Randomized, Placebo Controlled, Parallel Group Trial Investigating Minocycline versus placebo as add-on therapy in patients who are on treatment with Interferon-beta-1... - DK",
        "timestamp": "2006-01-26"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-004289-18/results",
        "title": "A Multi-centre, Double Blind, Randomized, Placebo Controlled, Parallel Group Trial Investigating Minocycline versus placebo as add-on therapy in patients who are on treatment with Interferon-beta-1... - View results",
        "timestamp": "2006-01-26"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-023023-19/IT",
        "title": "A 18-month, open-label, rater-blinded, randomized, multi-center, active-controlled, parallel-group pilot study to assess efficacy and safety of fingolimod (Gilenya) in comparison to interferon beta... - IT",
        "timestamp": "2010-12-28"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-023023-19/DE",
        "title": "A 18-month, open-label, rater-blinded, randomized, multi-center, active-controlled, parallel-group pilot study to assess efficacy and safety of fingolimod (Gilenya) in comparison to interferon beta... - DE",
        "timestamp": "2010-12-28"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-023023-19/results",
        "title": "A 18-month, open-label, rater-blinded, randomized, multi-center, active-controlled, parallel-group pilot study to assess efficacy and safety of fingolimod (Gilenya) in comparison to interferon beta... - View results",
        "timestamp": "2010-12-28"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-000127-42/AT",
        "title": "Non Responder- STUDY: \nMULTICENTER STUDY TO EVALUATE THE EFFICACY OF SILYMARIN \nIN  ADDITION TO  COMBINATION-THERAPY WITH PEGYLATED INTERFERON ALFA 2A (PEG-IFN ALFA 2A) AND RIBAVIRIN IN PATIENTS WI... - AT",
        "timestamp": "2005-03-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-001485-15/FR",
        "title": "A Multicenter, Open-label, Randomized Phase 2b Clinical Study to Assess Efficacy and Safety of Bulevirtide in Combination with Pegylated Interferon alfa-2a in Patients with Chronic Hepatitis Delta - FR",
        "timestamp": "2019-09-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-000121-19/DE",
        "title": "A Randomized Multicentre Phase II Trial Comparing Adjuvant Therapy in Patients with Resected Pancreatic Adenocarcinoma Treated with Interferon Alpha-2b and 5-FU Alone or in Combination with Either ... - DE",
        "timestamp": "2008-08-11"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-000121-19/results",
        "title": "A Randomized Multicentre Phase II Trial Comparing Adjuvant Therapy in Patients with Resected Pancreatic Adenocarcinoma Treated with Interferon Alpha-2b and 5-FU Alone or in Combination with Either ... - View results",
        "timestamp": "2008-08-11"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-023172-12/NL",
        "title": "A multi-center double-blind parallel-group placebo-controlled study of the efficacy and safety of teriflunomide in patients with relapsing multiple sclerosis who are treated with interferon-beta. - NL",
        "timestamp": "2011-02-15"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-023172-12/HU",
        "title": "A multi-center double-blind parallel-group placebo-controlled study of the efficacy and safety of teriflunomide in patients with relapsing multiple sclerosis who are treated with interferon-beta. - HU",
        "timestamp": "2011-02-15"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-023172-12/BE",
        "title": "A multi-center double-blind parallel-group placebo-controlled study of the efficacy and safety of teriflunomide in patients with relapsing multiple sclerosis who are treated with interferon-beta. - BE",
        "timestamp": "2011-02-15"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-023172-12/SE",
        "title": "A multi-center double-blind parallel-group placebo-controlled study of the efficacy and safety of teriflunomide in patients with relapsing multiple sclerosis who are treated with interferon-beta. - SE",
        "timestamp": "2011-02-15"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-023172-12/EE",
        "title": "A multi-center double-blind parallel-group placebo-controlled study of the efficacy and safety of teriflunomide in patients with relapsing multiple sclerosis who are treated with interferon-beta. - EE",
        "timestamp": "2011-02-15"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-023172-12/GB",
        "title": "A multi-center double-blind parallel-group placebo-controlled study of the efficacy and safety of teriflunomide in patients with relapsing multiple sclerosis who are treated with interferon-beta. - GB",
        "timestamp": "2011-02-15"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-023172-12/SK",
        "title": "A multi-center double-blind parallel-group placebo-controlled study of the efficacy and safety of teriflunomide in patients with relapsing multiple sclerosis who are treated with interferon-beta. - SK",
        "timestamp": "2011-02-15"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-023172-12/ES",
        "title": "A multi-center double-blind parallel-group placebo-controlled study of the efficacy and safety of teriflunomide in patients with relapsing multiple sclerosis who are treated with interferon-beta. - ES",
        "timestamp": "2011-02-15"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-023172-12/NO",
        "title": "A multi-center double-blind parallel-group placebo-controlled study of the efficacy and safety of teriflunomide in patients with relapsing multiple sclerosis who are treated with interferon-beta. - NO",
        "timestamp": "2011-02-15"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-023172-12/DE",
        "title": "A multi-center double-blind parallel-group placebo-controlled study of the efficacy and safety of teriflunomide in patients with relapsing multiple sclerosis who are treated with interferon-beta. - DE",
        "timestamp": "2011-02-15"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-023172-12/FI",
        "title": "A multi-center double-blind parallel-group placebo-controlled study of the efficacy and safety of teriflunomide in patients with relapsing multiple sclerosis who are treated with interferon-beta. - FI",
        "timestamp": "2011-02-15"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-023172-12/GR",
        "title": "A multi-center double-blind parallel-group placebo-controlled study of the efficacy and safety of teriflunomide in patients with relapsing multiple sclerosis who are treated with interferon-beta. - GR",
        "timestamp": "2011-02-15"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-023172-12/PT",
        "title": "A multi-center double-blind parallel-group placebo-controlled study of the efficacy and safety of teriflunomide in patients with relapsing multiple sclerosis who are treated with interferon-beta. - PT",
        "timestamp": "2011-02-15"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-023172-12/IT",
        "title": "A multi-center double-blind parallel-group placebo-controlled study of the efficacy and safety of teriflunomide in patients with relapsing multiple sclerosis who are treated with interferon-beta. - IT",
        "timestamp": "2011-02-15"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-023172-12/AT",
        "title": "A multi-center double-blind parallel-group placebo-controlled study of the efficacy and safety of teriflunomide in patients with relapsing multiple sclerosis who are treated with interferon-beta. - AT",
        "timestamp": "2011-02-15"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-023172-12/DK",
        "title": "A multi-center double-blind parallel-group placebo-controlled study of the efficacy and safety of teriflunomide in patients with relapsing multiple sclerosis who are treated with interferon-beta. - DK",
        "timestamp": "2011-02-15"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-023172-12/LT",
        "title": "A multi-center double-blind parallel-group placebo-controlled study of the efficacy and safety of teriflunomide in patients with relapsing multiple sclerosis who are treated with interferon-beta. - LT",
        "timestamp": "2011-02-15"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-023172-12/results",
        "title": "A multi-center double-blind parallel-group placebo-controlled study of the efficacy and safety of teriflunomide in patients with relapsing multiple sclerosis who are treated with interferon-beta. - View results",
        "timestamp": "2011-02-15"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-004885-14/GB",
        "title": "A Phase 3, Randomized, Double-Blind, Controlled Study Evaluating the Efficacy and Safety of Peginterferon Lambda-1a, with and without Daclatasvir, Compared to Peginterferon Alfa-2a, Each in Combina... - GB",
        "timestamp": "2012-11-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-004885-14/BE",
        "title": "A Phase 3, Randomized, Double-Blind, Controlled Study Evaluating the Efficacy and Safety of Peginterferon Lambda-1a, with and without Daclatasvir, Compared to Peginterferon Alfa-2a, Each in Combina... - BE",
        "timestamp": "2012-11-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-004885-14/FI",
        "title": "A Phase 3, Randomized, Double-Blind, Controlled Study Evaluating the Efficacy and Safety of Peginterferon Lambda-1a, with and without Daclatasvir, Compared to Peginterferon Alfa-2a, Each in Combina... - FI",
        "timestamp": "2012-11-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-004885-14/NL",
        "title": "A Phase 3, Randomized, Double-Blind, Controlled Study Evaluating the Efficacy and Safety of Peginterferon Lambda-1a, with and without Daclatasvir, Compared to Peginterferon Alfa-2a, Each in Combina... - NL",
        "timestamp": "2012-11-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-004885-14/IT",
        "title": "A Phase 3, Randomized, Double-Blind, Controlled Study Evaluating the Efficacy and Safety of Peginterferon Lambda-1a, with and without Daclatasvir, Compared to Peginterferon Alfa-2a, Each in Combina... - IT",
        "timestamp": "2012-11-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-004885-14/GR",
        "title": "A Phase 3, Randomized, Double-Blind, Controlled Study Evaluating the Efficacy and Safety of Peginterferon Lambda-1a, with and without Daclatasvir, Compared to Peginterferon Alfa-2a, Each in Combina... - GR",
        "timestamp": "2012-11-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-004885-14/results",
        "title": "A Phase 3, Randomized, Double-Blind, Controlled Study Evaluating the Efficacy and Safety of Peginterferon Lambda-1a, with and without Daclatasvir, Compared to Peginterferon Alfa-2a, Each in Combina... - View results",
        "timestamp": "2012-11-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-005161-11/IT",
        "title": "Treatment with leucocytic interferon-alpha more ribavirine towards peg-interferon to reduced doses more ribavirine in patients affections from positive chronic hepatitis HCV that in course of arran... - IT",
        "timestamp": "2005-08-01"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-001316-47/FI",
        "title": "Bevacizumab (Avastin™), dacarbazine and interferon α-2a (Roferon-A; IFN α-2a ) combination as a first-line therapy in patients with locally advancing or metastatic melanoma - FI",
        "timestamp": "2005-07-05"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-000492-32/FI",
        "title": "T cell and interferon expression in tonsils after sublingual\nimmunotherapy and/or nasal live attenuated influenza vaccine - FI",
        "timestamp": "2013-07-10"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-001072-22/FI",
        "title": "Clinical and virological efficacy of pegylated interferon alpha in the treatment of rhinovirus infection in patients with primary hypogammaglobulinemia: \r\nrandomized controlled trial - FI",
        "timestamp": "2016-01-26"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-001426-24/HU",
        "title": "Multicenter, open, randomized study for first-line treatment of multiple myeloma: thalidomide/dexamethasone vs. MP for induction therapy and thalidomide/Intron A vs. Intron A for maintenance therapy - HU",
        "timestamp": "2004-11-23"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-001426-24/results",
        "title": "Multicenter, open, randomized study for first-line treatment of multiple myeloma: thalidomide/dexamethasone vs. MP for induction therapy and thalidomide/Intron A vs. Intron A for maintenance therapy - View results",
        "timestamp": "2004-11-23"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-004406-42/ES",
        "title": "CLINICAL TRIAL TO ASSEES THE NON-INFERIORITY OF THE SUSPENSION OF PROPHYLACTIC TREATMENT WITH VALGANCICLOVIR IN  \r\nKIDNEY TRANSPLANT CMV-seropositive PATIENTS, WHO MANTEIN CD8+ CMV- CELLULAR IMMUNI... - ES",
        "timestamp": "2016-03-10"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-000077-38/SK",
        "title": "A randomized, open label, multi-center phase II study to compare bevacizumab plus RAD001 versus interferon alfa-2a and bevacizumab for the first-line treatment of patients with metastatic clear cel... - SK",
        "timestamp": "2008-10-09"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-000077-38/BE",
        "title": "A randomized, open label, multi-center phase II study to compare bevacizumab plus RAD001 versus interferon alfa-2a and bevacizumab for the first-line treatment of patients with metastatic clear cel... - BE",
        "timestamp": "2008-10-09"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-000077-38/GB",
        "title": "A randomized, open label, multi-center phase II study to compare bevacizumab plus RAD001 versus interferon alfa-2a and bevacizumab for the first-line treatment of patients with metastatic clear cel... - GB",
        "timestamp": "2008-10-09"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-000077-38/CZ",
        "title": "A randomized, open label, multi-center phase II study to compare bevacizumab plus RAD001 versus interferon alfa-2a and bevacizumab for the first-line treatment of patients with metastatic clear cel... - CZ",
        "timestamp": "2008-10-09"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-000077-38/HU",
        "title": "A randomized, open label, multi-center phase II study to compare bevacizumab plus RAD001 versus interferon alfa-2a and bevacizumab for the first-line treatment of patients with metastatic clear cel... - HU",
        "timestamp": "2008-10-09"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-000077-38/ES",
        "title": "A randomized, open label, multi-center phase II study to compare bevacizumab plus RAD001 versus interferon alfa-2a and bevacizumab for the first-line treatment of patients with metastatic clear cel... - ES",
        "timestamp": "2008-10-09"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-000077-38/DE",
        "title": "A randomized, open label, multi-center phase II study to compare bevacizumab plus RAD001 versus interferon alfa-2a and bevacizumab for the first-line treatment of patients with metastatic clear cel... - DE",
        "timestamp": "2008-10-09"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-000077-38/IT",
        "title": "A randomized, open label, multi-center phase II study to compare bevacizumab plus RAD001 versus interferon alfa-2a and bevacizumab for the first-line treatment of patients with metastatic clear cel... - IT",
        "timestamp": "2008-10-09"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-000077-38/FR",
        "title": "A randomized, open label, multi-center phase II study to compare bevacizumab plus RAD001 versus interferon alfa-2a and bevacizumab for the first-line treatment of patients with metastatic clear cel... - FR",
        "timestamp": "2008-10-09"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-000077-38/NL",
        "title": "A randomized, open label, multi-center phase II study to compare bevacizumab plus RAD001 versus interferon alfa-2a and bevacizumab for the first-line treatment of patients with metastatic clear cel... - NL",
        "timestamp": "2008-10-09"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-000077-38/results",
        "title": "A randomized, open label, multi-center phase II study to compare bevacizumab plus RAD001 versus interferon alfa-2a and bevacizumab for the first-line treatment of patients with metastatic clear cel... - View results",
        "timestamp": "2008-10-09"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020337-99/GB",
        "title": "A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study To Evaluate The Efficacy And Safety Of Ocrelizumab In Comparison To Interferon Beta-1a (Rebif®) In Patients With Relapsing Multiple Sc... - GB",
        "timestamp": "2011-10-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020337-99/CZ",
        "title": "A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study To Evaluate The Efficacy And Safety Of Ocrelizumab In Comparison To Interferon Beta-1a (Rebif®) In Patients With Relapsing Multiple Sc... - CZ",
        "timestamp": "2011-10-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020337-99/LV",
        "title": "A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study To Evaluate The Efficacy And Safety Of Ocrelizumab In Comparison To Interferon Beta-1a (Rebif®) In Patients With Relapsing Multiple Sc... - LV",
        "timestamp": "2011-10-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020337-99/HU",
        "title": "A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study To Evaluate The Efficacy And Safety Of Ocrelizumab In Comparison To Interferon Beta-1a (Rebif®) In Patients With Relapsing Multiple Sc... - HU",
        "timestamp": "2011-10-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020337-99/FI",
        "title": "A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study To Evaluate The Efficacy And Safety Of Ocrelizumab In Comparison To Interferon Beta-1a (Rebif®) In Patients With Relapsing Multiple Sc... - FI",
        "timestamp": "2011-10-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020337-99/DE",
        "title": "A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study To Evaluate The Efficacy And Safety Of Ocrelizumab In Comparison To Interferon Beta-1a (Rebif®) In Patients With Relapsing Multiple Sc... - DE",
        "timestamp": "2011-10-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020337-99/BE",
        "title": "A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study To Evaluate The Efficacy And Safety Of Ocrelizumab In Comparison To Interferon Beta-1a (Rebif®) In Patients With Relapsing Multiple Sc... - BE",
        "timestamp": "2011-10-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020337-99/SK",
        "title": "A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study To Evaluate The Efficacy And Safety Of Ocrelizumab In Comparison To Interferon Beta-1a (Rebif®) In Patients With Relapsing Multiple Sc... - SK",
        "timestamp": "2011-10-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020337-99/AT",
        "title": "A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study To Evaluate The Efficacy And Safety Of Ocrelizumab In Comparison To Interferon Beta-1a (Rebif®) In Patients With Relapsing Multiple Sc... - AT",
        "timestamp": "2011-10-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020337-99/NL",
        "title": "A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study To Evaluate The Efficacy And Safety Of Ocrelizumab In Comparison To Interferon Beta-1a (Rebif®) In Patients With Relapsing Multiple Sc... - NL",
        "timestamp": "2011-10-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020337-99/LT",
        "title": "A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study To Evaluate The Efficacy And Safety Of Ocrelizumab In Comparison To Interferon Beta-1a (Rebif®) In Patients With Relapsing Multiple Sc... - LT",
        "timestamp": "2011-10-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020337-99/EE",
        "title": "A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study To Evaluate The Efficacy And Safety Of Ocrelizumab In Comparison To Interferon Beta-1a (Rebif®) In Patients With Relapsing Multiple Sc... - EE",
        "timestamp": "2011-10-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020337-99/PT",
        "title": "A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study To Evaluate The Efficacy And Safety Of Ocrelizumab In Comparison To Interferon Beta-1a (Rebif®) In Patients With Relapsing Multiple Sc... - PT",
        "timestamp": "2011-10-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020337-99/BG",
        "title": "A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study To Evaluate The Efficacy And Safety Of Ocrelizumab In Comparison To Interferon Beta-1a (Rebif®) In Patients With Relapsing Multiple Sc... - BG",
        "timestamp": "2011-10-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020337-99/ES",
        "title": "A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study To Evaluate The Efficacy And Safety Of Ocrelizumab In Comparison To Interferon Beta-1a (Rebif®) In Patients With Relapsing Multiple Sc... - ES",
        "timestamp": "2011-10-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020337-99/PL",
        "title": "A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study To Evaluate The Efficacy And Safety Of Ocrelizumab In Comparison To Interferon Beta-1a (Rebif®) In Patients With Relapsing Multiple Sc... - PL",
        "timestamp": "2011-10-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020337-99/IT",
        "title": "A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study To Evaluate The Efficacy And Safety Of Ocrelizumab In Comparison To Interferon Beta-1a (Rebif®) In Patients With Relapsing Multiple Sc... - IT",
        "timestamp": "2011-10-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020337-99/results",
        "title": "A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study To Evaluate The Efficacy And Safety Of Ocrelizumab In Comparison To Interferon Beta-1a (Rebif®) In Patients With Relapsing Multiple Sc... - View results",
        "timestamp": "2011-10-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-003126-83/DE",
        "title": "A Phase III, Randomized, Double-Blind, Double Dummy, Multicenter Trial Comparing the Efficacy and Safety of 2 Doses of Daily Oral ONO 4641 (0.05 mg and 0.1 mg) versus Interferon-β-1a 30 µg IM Weekl... - DE",
        "timestamp": "2014-06-23"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-003126-83/BG",
        "title": "A Phase III, Randomized, Double-Blind, Double Dummy, Multicenter Trial Comparing the Efficacy and Safety of 2 Doses of Daily Oral ONO 4641 (0.05 mg and 0.1 mg) versus Interferon-β-1a 30 µg IM Weekl... - BG",
        "timestamp": "2014-06-23"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-003126-83/HU",
        "title": "A Phase III, Randomized, Double-Blind, Double Dummy, Multicenter Trial Comparing the Efficacy and Safety of 2 Doses of Daily Oral ONO 4641 (0.05 mg and 0.1 mg) versus Interferon-β-1a 30 µg IM Weekl... - HU",
        "timestamp": "2014-06-23"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-003126-83/GR",
        "title": "A Phase III, Randomized, Double-Blind, Double Dummy, Multicenter Trial Comparing the Efficacy and Safety of 2 Doses of Daily Oral ONO 4641 (0.05 mg and 0.1 mg) versus Interferon-β-1a 30 µg IM Weekl... - GR",
        "timestamp": "2014-06-23"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-003126-83/ES",
        "title": "A Phase III, Randomized, Double-Blind, Double Dummy, Multicenter Trial Comparing the Efficacy and Safety of 2 Doses of Daily Oral ONO 4641 (0.05 mg and 0.1 mg) versus Interferon-β-1a 30 µg IM Weekl... - ES",
        "timestamp": "2014-06-23"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-002772-13/IT",
        "title": "A multi-centre single-arm study to evaluate the efficacy and safety of BOCEPREVIR 44 weeks in addition to standard of care (SOC) in previously treatment failure (relapser, non-responders, both part... - IT",
        "timestamp": "2013-01-29"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-002772-13/results",
        "title": "A multi-centre single-arm study to evaluate the efficacy and safety of BOCEPREVIR 44 weeks in addition to standard of care (SOC) in previously treatment failure (relapser, non-responders, both part... - View results",
        "timestamp": "2013-01-29"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-001055-12/IT",
        "title": "Flu-like syndrome Inhibition Giving anti-histaminic Therapy. Randomized cross-over, single-center, randomized, placebo-controlled, double-blind study to evaluate the efficacy of cetirizine on Flu-l... - IT",
        "timestamp": "2015-05-28"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-001055-12/results",
        "title": "Flu-like syndrome Inhibition Giving anti-histaminic Therapy. Randomized cross-over, single-center, randomized, placebo-controlled, double-blind study to evaluate the efficacy of cetirizine on Flu-l... - View results",
        "timestamp": "2015-05-28"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-002376-42/IT",
        "title": "PHASE II TRIAL OF SEQUENTIAL CHEMO-IMMUNOTHERAPY WITH CAPECITABINE PLUS INTERFERON ALPHA2a FOLLOWED BY IL-2 IN PATIENTS WITH METASTATIC KIDNEY CANCER - IT",
        "timestamp": "2005-01-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-005385-12/BG",
        "title": "A Phase 2 Randomized, Open Label, Multi-center, Therapeutic Trial of the Efficacy, Immunogenicity, and Safety of GI-5005; an Inactivated Recombinant Saccharomyces cerevisiae Expressing a Hepatitis ... - BG",
        "timestamp": "2008-04-11"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-004717-25/IT",
        "title": "The benefit/risk profile of pegylated proline-Interferon alpha-2b (AOP2014) added to the best available strategy based on phlebotomies in low-risk patients with Polycythemia Vera (PV). The Low-PV r... - IT",
        "timestamp": "2016-07-08"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-007744-98/IT",
        "title": "INTERFERON alpha2 (IFN alpha2) as anti-angiogenic agent for the treatment of neovascular age-related macular degeneration: a pilot study. - IT",
        "timestamp": "2008-03-04"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-022067-35/DE",
        "title": "INFORM-SVR: A Randomized, Multi-Center Study of Interferon-Free Treatment with a Combination of a Polymerase Inhibitor (RO5024048) and a Ritonavir boosted HCV Protease\r\nInhibitor (RO5190591/r, DNV/... - DE",
        "timestamp": "2011-02-17"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-022067-35/results",
        "title": "INFORM-SVR: A Randomized, Multi-Center Study of Interferon-Free Treatment with a Combination of a Polymerase Inhibitor (RO5024048) and a Ritonavir boosted HCV Protease\r\nInhibitor (RO5190591/r, DNV/... - View results",
        "timestamp": "2011-02-17"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-003930-16/SE",
        "title": "A Multi-centre, Double Blind, Randomised, Placebo Controlled, Parallel Group Study Investigating Simvastatin as an Add-on Treatment to Interferon-beta-1a for the Treatment of Relapsing-Remitting Mu... - SE",
        "timestamp": "2006-01-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-003930-16/FI",
        "title": "A Multi-centre, Double Blind, Randomised, Placebo Controlled, Parallel Group Study Investigating Simvastatin as an Add-on Treatment to Interferon-beta-1a for the Treatment of Relapsing-Remitting Mu... - FI",
        "timestamp": "2006-01-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-003930-16/DK",
        "title": "A Multi-centre, Double Blind, Randomised, Placebo Controlled, Parallel Group Study Investigating Simvastatin as an Add-on Treatment to Interferon-beta-1a for the Treatment of Relapsing-Remitting Mu... - DK",
        "timestamp": "2006-01-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-003930-16/results",
        "title": "A Multi-centre, Double Blind, Randomised, Placebo Controlled, Parallel Group Study Investigating Simvastatin as an Add-on Treatment to Interferon-beta-1a for the Treatment of Relapsing-Remitting Mu... - View results",
        "timestamp": "2006-01-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-021716-42/PT",
        "title": "A phase III, randomised, double-blind and placebo-controlled study of once daily BI 201335 120 mg for 12 or 24 weeks or BI 201335 240 mg for 12 weeks in combination with pegylated interferon-α and ... - PT",
        "timestamp": "2011-03-11"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-021716-42/BE",
        "title": "A phase III, randomised, double-blind and placebo-controlled study of once daily BI 201335 120 mg for 12 or 24 weeks or BI 201335 240 mg for 12 weeks in combination with pegylated interferon-α and ... - BE",
        "timestamp": "2011-03-11"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-021716-42/GB",
        "title": "A phase III, randomised, double-blind and placebo-controlled study of once daily BI 201335 120 mg for 12 or 24 weeks or BI 201335 240 mg for 12 weeks in combination with pegylated interferon-α and ... - GB",
        "timestamp": "2011-03-11"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-021716-42/DE",
        "title": "A phase III, randomised, double-blind and placebo-controlled study of once daily BI 201335 120 mg for 12 or 24 weeks or BI 201335 240 mg for 12 weeks in combination with pegylated interferon-α and ... - DE",
        "timestamp": "2011-03-11"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-021716-42/ES",
        "title": "A phase III, randomised, double-blind and placebo-controlled study of once daily BI 201335 120 mg for 12 or 24 weeks or BI 201335 240 mg for 12 weeks in combination with pegylated interferon-α and ... - ES",
        "timestamp": "2011-03-11"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-021716-42/AT",
        "title": "A phase III, randomised, double-blind and placebo-controlled study of once daily BI 201335 120 mg for 12 or 24 weeks or BI 201335 240 mg for 12 weeks in combination with pegylated interferon-α and ... - AT",
        "timestamp": "2011-03-11"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-021716-42/results",
        "title": "A phase III, randomised, double-blind and placebo-controlled study of once daily BI 201335 120 mg for 12 or 24 weeks or BI 201335 240 mg for 12 weeks in combination with pegylated interferon-α and ... - View results",
        "timestamp": "2011-03-11"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-010788-18/GB",
        "title": "An Extension Protocol For Multiple Sclerosis Patients Who Participated in Genzyme-Sponsored Studies of Alemtuzumab - GB",
        "timestamp": "2009-07-01"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-010788-18/DE",
        "title": "An Extension Protocol For Multiple Sclerosis Patients Who Participated in Genzyme-Sponsored Studies of Alemtuzumab - DE",
        "timestamp": "2009-07-01"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-010788-18/BE",
        "title": "An Extension Protocol For Multiple Sclerosis Patients Who Participated in Genzyme-Sponsored Studies of Alemtuzumab - BE",
        "timestamp": "2009-07-01"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-010788-18/SE",
        "title": "An Extension Protocol For Multiple Sclerosis Patients Who Participated in Genzyme-Sponsored Studies of Alemtuzumab - SE",
        "timestamp": "2009-07-01"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-010788-18/AT",
        "title": "An Extension Protocol For Multiple Sclerosis Patients Who Participated in Genzyme-Sponsored Studies of Alemtuzumab - AT",
        "timestamp": "2009-07-01"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-010788-18/PL",
        "title": "An Extension Protocol For Multiple Sclerosis Patients Who Participated in Genzyme-Sponsored Studies of Alemtuzumab - PL",
        "timestamp": "2009-07-01"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-010788-18/CZ",
        "title": "An Extension Protocol For Multiple Sclerosis Patients Who Participated in Genzyme-Sponsored Studies of Alemtuzumab - CZ",
        "timestamp": "2009-07-01"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-010788-18/NL",
        "title": "An Extension Protocol For Multiple Sclerosis Patients Who Participated in Genzyme-Sponsored Studies of Alemtuzumab - NL",
        "timestamp": "2009-07-01"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-010788-18/DK",
        "title": "An Extension Protocol For Multiple Sclerosis Patients Who Participated in Genzyme-Sponsored Studies of Alemtuzumab - DK",
        "timestamp": "2009-07-01"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-010788-18/ES",
        "title": "An Extension Protocol For Multiple Sclerosis Patients Who Participated in Genzyme-Sponsored Studies of Alemtuzumab - ES",
        "timestamp": "2009-07-01"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-010788-18/IT",
        "title": "An Extension Protocol For Multiple Sclerosis Patients Who Participated in Genzyme-Sponsored Studies of Alemtuzumab - IT",
        "timestamp": "2009-07-01"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-010788-18/results",
        "title": "An Extension Protocol For Multiple Sclerosis Patients Who Participated in Genzyme-Sponsored Studies of Alemtuzumab - View results",
        "timestamp": "2009-07-01"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-006611-23/EE",
        "title": "Open-label, single-arm, phase II study of bevacizumab (AVASTIN®) in combination with low-dose interferon as first-line treatment of nephrectomised patients with metastatic clear cell renal cell car... - EE",
        "timestamp": "2008-10-27"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-006611-23/LT",
        "title": "Open-label, single-arm, phase II study of bevacizumab (AVASTIN®) in combination with low-dose interferon as first-line treatment of nephrectomised patients with metastatic clear cell renal cell car... - LT",
        "timestamp": "2008-10-27"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-006611-23/CZ",
        "title": "Open-label, single-arm, phase II study of bevacizumab (AVASTIN®) in combination with low-dose interferon as first-line treatment of nephrectomised patients with metastatic clear cell renal cell car... - CZ",
        "timestamp": "2008-10-27"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-006611-23/NL",
        "title": "Open-label, single-arm, phase II study of bevacizumab (AVASTIN®) in combination with low-dose interferon as first-line treatment of nephrectomised patients with metastatic clear cell renal cell car... - NL",
        "timestamp": "2008-10-27"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-006611-23/PT",
        "title": "Open-label, single-arm, phase II study of bevacizumab (AVASTIN®) in combination with low-dose interferon as first-line treatment of nephrectomised patients with metastatic clear cell renal cell car... - PT",
        "timestamp": "2008-10-27"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-006611-23/GB",
        "title": "Open-label, single-arm, phase II study of bevacizumab (AVASTIN®) in combination with low-dose interferon as first-line treatment of nephrectomised patients with metastatic clear cell renal cell car... - GB",
        "timestamp": "2008-10-27"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-006611-23/FI",
        "title": "Open-label, single-arm, phase II study of bevacizumab (AVASTIN®) in combination with low-dose interferon as first-line treatment of nephrectomised patients with metastatic clear cell renal cell car... - FI",
        "timestamp": "2008-10-27"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-006611-23/SE",
        "title": "Open-label, single-arm, phase II study of bevacizumab (AVASTIN®) in combination with low-dose interferon as first-line treatment of nephrectomised patients with metastatic clear cell renal cell car... - SE",
        "timestamp": "2008-10-27"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-006611-23/DE",
        "title": "Open-label, single-arm, phase II study of bevacizumab (AVASTIN®) in combination with low-dose interferon as first-line treatment of nephrectomised patients with metastatic clear cell renal cell car... - DE",
        "timestamp": "2008-10-27"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-006611-23/GR",
        "title": "Open-label, single-arm, phase II study of bevacizumab (AVASTIN®) in combination with low-dose interferon as first-line treatment of nephrectomised patients with metastatic clear cell renal cell car... - GR",
        "timestamp": "2008-10-27"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-006611-23/IT",
        "title": "Open-label, single-arm, phase II study of bevacizumab (AVASTIN®) in combination with low-dose interferon as first-line treatment of nephrectomised patients with metastatic clear cell renal cell car... - IT",
        "timestamp": "2008-10-27"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-006611-23/results",
        "title": "Open-label, single-arm, phase II study of bevacizumab (AVASTIN®) in combination with low-dose interferon as first-line treatment of nephrectomised patients with metastatic clear cell renal cell car... - View results",
        "timestamp": "2008-10-27"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-005450-23/ES",
        "title": "Estudio multinacional, multicéntrico, randomizado, de grupos paralelos realizado en pacientes con Esclerosis Múltiple Remitente Recurrente (RRMS) para evaluar la eficacia, seguridad y tolerabilidad... - ES",
        "timestamp": "2008-03-17"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-005450-23/EE",
        "title": "Estudio multinacional, multicéntrico, randomizado, de grupos paralelos realizado en pacientes con Esclerosis Múltiple Remitente Recurrente (RRMS) para evaluar la eficacia, seguridad y tolerabilidad... - EE",
        "timestamp": "2008-03-17"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-005450-23/CZ",
        "title": "Estudio multinacional, multicéntrico, randomizado, de grupos paralelos realizado en pacientes con Esclerosis Múltiple Remitente Recurrente (RRMS) para evaluar la eficacia, seguridad y tolerabilidad... - CZ",
        "timestamp": "2008-03-17"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-005450-23/IT",
        "title": "Estudio multinacional, multicéntrico, randomizado, de grupos paralelos realizado en pacientes con Esclerosis Múltiple Remitente Recurrente (RRMS) para evaluar la eficacia, seguridad y tolerabilidad... - IT",
        "timestamp": "2008-03-17"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-005450-23/SK",
        "title": "Estudio multinacional, multicéntrico, randomizado, de grupos paralelos realizado en pacientes con Esclerosis Múltiple Remitente Recurrente (RRMS) para evaluar la eficacia, seguridad y tolerabilidad... - SK",
        "timestamp": "2008-03-17"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-005450-23/LT",
        "title": "Estudio multinacional, multicéntrico, randomizado, de grupos paralelos realizado en pacientes con Esclerosis Múltiple Remitente Recurrente (RRMS) para evaluar la eficacia, seguridad y tolerabilidad... - LT",
        "timestamp": "2008-03-17"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-005450-23/BG",
        "title": "Estudio multinacional, multicéntrico, randomizado, de grupos paralelos realizado en pacientes con Esclerosis Múltiple Remitente Recurrente (RRMS) para evaluar la eficacia, seguridad y tolerabilidad... - BG",
        "timestamp": "2008-03-17"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-005450-23/DE",
        "title": "Estudio multinacional, multicéntrico, randomizado, de grupos paralelos realizado en pacientes con Esclerosis Múltiple Remitente Recurrente (RRMS) para evaluar la eficacia, seguridad y tolerabilidad... - DE",
        "timestamp": "2008-03-17"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-005450-23/results",
        "title": "Estudio multinacional, multicéntrico, randomizado, de grupos paralelos realizado en pacientes con Esclerosis Múltiple Remitente Recurrente (RRMS) para evaluar la eficacia, seguridad y tolerabilidad... - View results",
        "timestamp": "2008-03-17"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-002351-15/EE",
        "title": "A Phase III, Randomized, Double-Blind, Double Dummy, Multicenter Trial Comparing the Efficacy and Safety of 2 Doses of Daily Oral ONO 4641 (0.05 mg and 0.1 mg) versus Interferon-β-1a 30 µg IM Weekl... - EE",
        "timestamp": "2014-03-13"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-002351-15/LV",
        "title": "A Phase III, Randomized, Double-Blind, Double Dummy, Multicenter Trial Comparing the Efficacy and Safety of 2 Doses of Daily Oral ONO 4641 (0.05 mg and 0.1 mg) versus Interferon-β-1a 30 µg IM Weekl... - LV",
        "timestamp": "2014-03-13"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-002351-15/BG",
        "title": "A Phase III, Randomized, Double-Blind, Double Dummy, Multicenter Trial Comparing the Efficacy and Safety of 2 Doses of Daily Oral ONO 4641 (0.05 mg and 0.1 mg) versus Interferon-β-1a 30 µg IM Weekl... - BG",
        "timestamp": "2014-03-13"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-002351-15/HU",
        "title": "A Phase III, Randomized, Double-Blind, Double Dummy, Multicenter Trial Comparing the Efficacy and Safety of 2 Doses of Daily Oral ONO 4641 (0.05 mg and 0.1 mg) versus Interferon-β-1a 30 µg IM Weekl... - HU",
        "timestamp": "2014-03-13"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-002351-15/ES",
        "title": "A Phase III, Randomized, Double-Blind, Double Dummy, Multicenter Trial Comparing the Efficacy and Safety of 2 Doses of Daily Oral ONO 4641 (0.05 mg and 0.1 mg) versus Interferon-β-1a 30 µg IM Weekl... - ES",
        "timestamp": "2014-03-13"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-002351-15/PT",
        "title": "A Phase III, Randomized, Double-Blind, Double Dummy, Multicenter Trial Comparing the Efficacy and Safety of 2 Doses of Daily Oral ONO 4641 (0.05 mg and 0.1 mg) versus Interferon-β-1a 30 µg IM Weekl... - PT",
        "timestamp": "2014-03-13"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-002351-15/AT",
        "title": "A Phase III, Randomized, Double-Blind, Double Dummy, Multicenter Trial Comparing the Efficacy and Safety of 2 Doses of Daily Oral ONO 4641 (0.05 mg and 0.1 mg) versus Interferon-β-1a 30 µg IM Weekl... - AT",
        "timestamp": "2014-03-13"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-022568-11/DE",
        "title": "A Phase 2B, randomized study to evaluate the safety and efficacy of Pegylated Interferon Lambda (BMS-914143) administered with Ribavirin plus a single direct antiviral agent (BMS-790052 or BMS-6500... - DE",
        "timestamp": "2011-04-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-022568-11/IT",
        "title": "A Phase 2B, randomized study to evaluate the safety and efficacy of Pegylated Interferon Lambda (BMS-914143) administered with Ribavirin plus a single direct antiviral agent (BMS-790052 or BMS-6500... - IT",
        "timestamp": "2011-04-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-022568-11/ES",
        "title": "A Phase 2B, randomized study to evaluate the safety and efficacy of Pegylated Interferon Lambda (BMS-914143) administered with Ribavirin plus a single direct antiviral agent (BMS-790052 or BMS-6500... - ES",
        "timestamp": "2011-04-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-022568-11/results",
        "title": "A Phase 2B, randomized study to evaluate the safety and efficacy of Pegylated Interferon Lambda (BMS-914143) administered with Ribavirin plus a single direct antiviral agent (BMS-790052 or BMS-6500... - View results",
        "timestamp": "2011-04-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003463-22/ES",
        "title": "MAGNITUDE - A Phase 3 Evaluation of the Safety and Efficacy of Lambda/RBV/DCV in Treatment Naïve Subjects with Chronic HCV Infection, who have Underlying Mild or Moderate Hemophilia or Patients who... - ES",
        "timestamp": "2013-03-13"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003463-22/IT",
        "title": "MAGNITUDE - A Phase 3 Evaluation of the Safety and Efficacy of Lambda/RBV/DCV in Treatment Naïve Subjects with Chronic HCV Infection, who have Underlying Mild or Moderate Hemophilia or Patients who... - IT",
        "timestamp": "2013-03-13"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003463-22/NL",
        "title": "MAGNITUDE - A Phase 3 Evaluation of the Safety and Efficacy of Lambda/RBV/DCV in Treatment Naïve Subjects with Chronic HCV Infection, who have Underlying Mild or Moderate Hemophilia or Patients who... - NL",
        "timestamp": "2013-03-13"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003463-22/FR",
        "title": "MAGNITUDE - A Phase 3 Evaluation of the Safety and Efficacy of Lambda/RBV/DCV in Treatment Naïve Subjects with Chronic HCV Infection, who have Underlying Mild or Moderate Hemophilia or Patients who... - FR",
        "timestamp": "2013-03-13"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003463-22/RO",
        "title": "MAGNITUDE - A Phase 3 Evaluation of the Safety and Efficacy of Lambda/RBV/DCV in Treatment Naïve Subjects with Chronic HCV Infection, who have Underlying Mild or Moderate Hemophilia or Patients who... - RO",
        "timestamp": "2013-03-13"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003463-22/results",
        "title": "MAGNITUDE - A Phase 3 Evaluation of the Safety and Efficacy of Lambda/RBV/DCV in Treatment Naïve Subjects with Chronic HCV Infection, who have Underlying Mild or Moderate Hemophilia or Patients who... - View results",
        "timestamp": "2013-03-13"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-002082-19/BE",
        "title": "A Multinational, Multicenter, Randomized, Double-Blind,  Parallel-Group, Active-Control (Rater Blinded) Study, to Evaluate the Efficacy, Safety and Tolerability of 2 Doses of Oral administration of... - BE",
        "timestamp": "2013-11-25"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-002082-19/SE",
        "title": "A Multinational, Multicenter, Randomized, Double-Blind,  Parallel-Group, Active-Control (Rater Blinded) Study, to Evaluate the Efficacy, Safety and Tolerability of 2 Doses of Oral administration of... - SE",
        "timestamp": "2013-11-25"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-002082-19/FI",
        "title": "A Multinational, Multicenter, Randomized, Double-Blind,  Parallel-Group, Active-Control (Rater Blinded) Study, to Evaluate the Efficacy, Safety and Tolerability of 2 Doses of Oral administration of... - FI",
        "timestamp": "2013-11-25"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-002082-19/NL",
        "title": "A Multinational, Multicenter, Randomized, Double-Blind,  Parallel-Group, Active-Control (Rater Blinded) Study, to Evaluate the Efficacy, Safety and Tolerability of 2 Doses of Oral administration of... - NL",
        "timestamp": "2013-11-25"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-002082-19/ES",
        "title": "A Multinational, Multicenter, Randomized, Double-Blind,  Parallel-Group, Active-Control (Rater Blinded) Study, to Evaluate the Efficacy, Safety and Tolerability of 2 Doses of Oral administration of... - ES",
        "timestamp": "2013-11-25"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-002082-19/GB",
        "title": "A Multinational, Multicenter, Randomized, Double-Blind,  Parallel-Group, Active-Control (Rater Blinded) Study, to Evaluate the Efficacy, Safety and Tolerability of 2 Doses of Oral administration of... - GB",
        "timestamp": "2013-11-25"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-002082-19/DK",
        "title": "A Multinational, Multicenter, Randomized, Double-Blind,  Parallel-Group, Active-Control (Rater Blinded) Study, to Evaluate the Efficacy, Safety and Tolerability of 2 Doses of Oral administration of... - DK",
        "timestamp": "2013-11-25"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003508-11/CZ",
        "title": "A Double-Blinded, Randomized Control Study Evaluating the Efficacy and Safety of Peginterferon Lambda-1a Compared to Peginterferon alfa-2a, Each in Combination with Ribavirin, in the Treatment of N... - CZ",
        "timestamp": "2013-08-09"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003508-11/PL",
        "title": "A Double-Blinded, Randomized Control Study Evaluating the Efficacy and Safety of Peginterferon Lambda-1a Compared to Peginterferon alfa-2a, Each in Combination with Ribavirin, in the Treatment of N... - PL",
        "timestamp": "2013-08-09"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003508-11/results",
        "title": "A Double-Blinded, Randomized Control Study Evaluating the Efficacy and Safety of Peginterferon Lambda-1a Compared to Peginterferon alfa-2a, Each in Combination with Ribavirin, in the Treatment of N... - View results",
        "timestamp": "2013-08-09"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003280-22/GB",
        "title": "Phase 3 open label study evaluating the efficacy and safety of pegylated interferon lambda-1a, in combination with ribavirin and daclatasvir, for treatment of chronic HCV infection with treatment n... - GB",
        "timestamp": "2013-08-13"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003280-22/BE",
        "title": "Phase 3 open label study evaluating the efficacy and safety of pegylated interferon lambda-1a, in combination with ribavirin and daclatasvir, for treatment of chronic HCV infection with treatment n... - BE",
        "timestamp": "2013-08-13"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003280-22/IT",
        "title": "Phase 3 open label study evaluating the efficacy and safety of pegylated interferon lambda-1a, in combination with ribavirin and daclatasvir, for treatment of chronic HCV infection with treatment n... - IT",
        "timestamp": "2013-08-13"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003280-22/DE",
        "title": "Phase 3 open label study evaluating the efficacy and safety of pegylated interferon lambda-1a, in combination with ribavirin and daclatasvir, for treatment of chronic HCV infection with treatment n... - DE",
        "timestamp": "2013-08-13"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003280-22/ES",
        "title": "Phase 3 open label study evaluating the efficacy and safety of pegylated interferon lambda-1a, in combination with ribavirin and daclatasvir, for treatment of chronic HCV infection with treatment n... - ES",
        "timestamp": "2013-08-13"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003280-22/FR",
        "title": "Phase 3 open label study evaluating the efficacy and safety of pegylated interferon lambda-1a, in combination with ribavirin and daclatasvir, for treatment of chronic HCV infection with treatment n... - FR",
        "timestamp": "2013-08-13"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003280-22/results",
        "title": "Phase 3 open label study evaluating the efficacy and safety of pegylated interferon lambda-1a, in combination with ribavirin and daclatasvir, for treatment of chronic HCV infection with treatment n... - View results",
        "timestamp": "2013-08-13"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-021963-34/HU",
        "title": "A Phase 2, Randomized, Double-Blind, Comparator-Controlled, 12-week Trial of IMO-2125 plus Ribavirin in Patients Infected with Hepatitis C Virus who were Nonresponders to Pegylated-Interferon plus ... - HU",
        "timestamp": "2010-11-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-021963-34/BG",
        "title": "A Phase 2, Randomized, Double-Blind, Comparator-Controlled, 12-week Trial of IMO-2125 plus Ribavirin in Patients Infected with Hepatitis C Virus who were Nonresponders to Pegylated-Interferon plus ... - BG",
        "timestamp": "2010-11-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-000516-22/PT",
        "title": "A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, 3-\nArm, Parallel-Group Study in Pediatric Subjects Aged 10 Through 17 Years to Evaluate the Efficacy\nand Safety of BG00012 and BIIB017 ... - PT",
        "timestamp": None
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-000516-22/EE",
        "title": "A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, 3-\nArm, Parallel-Group Study in Pediatric Subjects Aged 10 Through 17 Years to Evaluate the Efficacy\nand Safety of BG00012 and BIIB017 ... - EE",
        "timestamp": None
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-000516-22/HU",
        "title": "A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, 3-\nArm, Parallel-Group Study in Pediatric Subjects Aged 10 Through 17 Years to Evaluate the Efficacy\nand Safety of BG00012 and BIIB017 ... - HU",
        "timestamp": None
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-002320-27/EE",
        "title": "A Phase 3, multi-center, randomized, Double-Blind, double-dummy, active controlled, parallel group study to evaluate the efficacy and safety of RPC1063 administered orally to relapsing multiple scl... - EE",
        "timestamp": "2014-11-21"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-002320-27/PT",
        "title": "A Phase 3, multi-center, randomized, Double-Blind, double-dummy, active controlled, parallel group study to evaluate the efficacy and safety of RPC1063 administered orally to relapsing multiple scl... - PT",
        "timestamp": "2014-11-21"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-002320-27/LV",
        "title": "A Phase 3, multi-center, randomized, Double-Blind, double-dummy, active controlled, parallel group study to evaluate the efficacy and safety of RPC1063 administered orally to relapsing multiple scl... - LV",
        "timestamp": "2014-11-21"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-002320-27/SE",
        "title": "A Phase 3, multi-center, randomized, Double-Blind, double-dummy, active controlled, parallel group study to evaluate the efficacy and safety of RPC1063 administered orally to relapsing multiple scl... - SE",
        "timestamp": "2014-11-21"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-002320-27/NL",
        "title": "A Phase 3, multi-center, randomized, Double-Blind, double-dummy, active controlled, parallel group study to evaluate the efficacy and safety of RPC1063 administered orally to relapsing multiple scl... - NL",
        "timestamp": "2014-11-21"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-002320-27/BG",
        "title": "A Phase 3, multi-center, randomized, Double-Blind, double-dummy, active controlled, parallel group study to evaluate the efficacy and safety of RPC1063 administered orally to relapsing multiple scl... - BG",
        "timestamp": "2014-11-21"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-002320-27/PL",
        "title": "A Phase 3, multi-center, randomized, Double-Blind, double-dummy, active controlled, parallel group study to evaluate the efficacy and safety of RPC1063 administered orally to relapsing multiple scl... - PL",
        "timestamp": "2014-11-21"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-002320-27/ES",
        "title": "A Phase 3, multi-center, randomized, Double-Blind, double-dummy, active controlled, parallel group study to evaluate the efficacy and safety of RPC1063 administered orally to relapsing multiple scl... - ES",
        "timestamp": "2014-11-21"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-002320-27/LT",
        "title": "A Phase 3, multi-center, randomized, Double-Blind, double-dummy, active controlled, parallel group study to evaluate the efficacy and safety of RPC1063 administered orally to relapsing multiple scl... - LT",
        "timestamp": "2014-11-21"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-002320-27/HU",
        "title": "A Phase 3, multi-center, randomized, Double-Blind, double-dummy, active controlled, parallel group study to evaluate the efficacy and safety of RPC1063 administered orally to relapsing multiple scl... - HU",
        "timestamp": "2014-11-21"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-002320-27/GB",
        "title": "A Phase 3, multi-center, randomized, Double-Blind, double-dummy, active controlled, parallel group study to evaluate the efficacy and safety of RPC1063 administered orally to relapsing multiple scl... - GB",
        "timestamp": "2014-11-21"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-002320-27/HR",
        "title": "A Phase 3, multi-center, randomized, Double-Blind, double-dummy, active controlled, parallel group study to evaluate the efficacy and safety of RPC1063 administered orally to relapsing multiple scl... - HR",
        "timestamp": "2014-11-21"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-002320-27/results",
        "title": "A Phase 3, multi-center, randomized, Double-Blind, double-dummy, active controlled, parallel group study to evaluate the efficacy and safety of RPC1063 administered orally to relapsing multiple scl... - View results",
        "timestamp": "2014-11-21"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-012459-96/ES",
        "title": "VALORACIÓN INTENSIVA DE LA CINÉTICA DEL RNA DEL VIRUS DE LA HEPATITIS C COMO PREDICTOR PRECOZ DE AUSENCIA DE RESPUESTA VIROLÓGICA SOSTENIDA EN PACIENTES CON HEPATITIS CRÓNICA POR VHC TRATADOS CON I... - ES",
        "timestamp": "2010-06-08"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-000495-24/DE",
        "title": "A Multicenter, Open-Label, Pilot Study to Explore the Safety and Efficacy of Intravenous Bortezomib in Patients with Hepatitis C - DE",
        "timestamp": None
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-023124-24/NL",
        "title": "Chemo-Immunotherapy, gemcitabine with pegylated interferon alpha-2b (Peg-Intron) with and without p53 synthetic long peptide (p53 SLP) vaccine, for patients with platinum resistant ovarian cancer.\n... - NL",
        "timestamp": "2011-03-02"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-015007-97/IT",
        "title": "Retinal Nerve Fiber Layer (RNFL) as measured by Optical Coherence Tomography (OCT) to      Depict axonal loss in Early RRMS treated with difFEreNt dosage of subCutaneous IFN bEta 1a - IT",
        "timestamp": "2010-02-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-001290-14/RO",
        "title": "Prospective Phase IV Clinical Trial on Effectiveness of Rebif Treatment of CIS and RMS Patients in Romania using Electronic Device RebiSmart™ - RO",
        "timestamp": "2014-10-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-001290-14/results",
        "title": "Prospective Phase IV Clinical Trial on Effectiveness of Rebif Treatment of CIS and RMS Patients in Romania using Electronic Device RebiSmart™ - View results",
        "timestamp": "2014-10-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-005670-71/IT",
        "title": "Dose-finding and Phase II study of the Combination of Bevacizumab  rhuMAb VEGF plus low- dose Immunotherapy and Chemotherapy in patients with   metastatic Renal Cell Cancer. - IT",
        "timestamp": "2006-02-09"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-001260-36/IT",
        "title": "Terapia PEG-Interferone alfa 2B+Ribavirina versus terapia PEG-Interferone alfa 2B + Ribavirina+ Terapia ormonale sostitutiva (TOS) nella prevenzione della progressione della fibrosi epatica nell’ep... - IT",
        "timestamp": "2008-03-04"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-005375-15/BE",
        "title": "Efficacy of maintenance therapy with rituximab after induction chemotherapy (R-CHOP vs R-FC) for elderly patients with mantle cell lymphoma not suitable for autologous stem cell transplantation - BE",
        "timestamp": "2006-04-21"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-002202-28/DK",
        "title": "Hepatitis C virusdynamik og immunaktivering hos HCV/HIV-koinficerede patienter under behandling med pegyleret interferon a-2a og ribavirin - DK",
        "timestamp": "2005-07-07"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-000503-15/IT",
        "title": "Experimental clinical open study, randomized, experimental group vs control group, for the evaluation of tolerability and the effects on magnetic resonance parameters and cognitive functions of mem... - IT",
        "timestamp": "2007-02-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-001420-29/DK",
        "title": "T cell therapy in combination with peginterferon for metastatic malignant melanoma - DK",
        "timestamp": "2015-12-18"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-001420-29/results",
        "title": "T cell therapy in combination with peginterferon for metastatic malignant melanoma - View results",
        "timestamp": "2015-12-18"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-001281-13/CZ",
        "title": "Observational Study of Early Interferon beta 1-a Treatment in High Risk Subjects after CIS (SET Study) - CZ",
        "timestamp": "2005-11-15"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-021628-84/BE",
        "title": "A randomized, open-label, Phase 3 study of telaprevir administered twice daily or every 8 hours in combination with pegylated interferon alfa-2a and ribavirin in treatment-naïve subjects with genot... - BE",
        "timestamp": "2011-03-29"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-021628-84/DE",
        "title": "A randomized, open-label, Phase 3 study of telaprevir administered twice daily or every 8 hours in combination with pegylated interferon alfa-2a and ribavirin in treatment-naïve subjects with genot... - DE",
        "timestamp": "2011-03-29"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-021628-84/GB",
        "title": "A randomized, open-label, Phase 3 study of telaprevir administered twice daily or every 8 hours in combination with pegylated interferon alfa-2a and ribavirin in treatment-naïve subjects with genot... - GB",
        "timestamp": "2011-03-29"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-021628-84/SE",
        "title": "A randomized, open-label, Phase 3 study of telaprevir administered twice daily or every 8 hours in combination with pegylated interferon alfa-2a and ribavirin in treatment-naïve subjects with genot... - SE",
        "timestamp": "2011-03-29"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-021628-84/AT",
        "title": "A randomized, open-label, Phase 3 study of telaprevir administered twice daily or every 8 hours in combination with pegylated interferon alfa-2a and ribavirin in treatment-naïve subjects with genot... - AT",
        "timestamp": "2011-03-29"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-021628-84/IE",
        "title": "A randomized, open-label, Phase 3 study of telaprevir administered twice daily or every 8 hours in combination with pegylated interferon alfa-2a and ribavirin in treatment-naïve subjects with genot... - IE",
        "timestamp": "2011-03-29"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-021628-84/PL",
        "title": "A randomized, open-label, Phase 3 study of telaprevir administered twice daily or every 8 hours in combination with pegylated interferon alfa-2a and ribavirin in treatment-naïve subjects with genot... - PL",
        "timestamp": "2011-03-29"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-021628-84/ES",
        "title": "A randomized, open-label, Phase 3 study of telaprevir administered twice daily or every 8 hours in combination with pegylated interferon alfa-2a and ribavirin in treatment-naïve subjects with genot... - ES",
        "timestamp": "2011-03-29"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-021628-84/IT",
        "title": "A randomized, open-label, Phase 3 study of telaprevir administered twice daily or every 8 hours in combination with pegylated interferon alfa-2a and ribavirin in treatment-naïve subjects with genot... - IT",
        "timestamp": "2011-03-29"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-021628-84/results",
        "title": "A randomized, open-label, Phase 3 study of telaprevir administered twice daily or every 8 hours in combination with pegylated interferon alfa-2a and ribavirin in treatment-naïve subjects with genot... - View results",
        "timestamp": "2011-03-29"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-000664-27/ES",
        "title": "A 34 week, open label, single cohort, exploratory study to evaluate the effect of FTY720 on chronic Hepatitis C in patients who are non-responsive to, or intolerant of Interferon-based antiviral th... - ES",
        "timestamp": "2004-12-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-000664-27/results",
        "title": "A 34 week, open label, single cohort, exploratory study to evaluate the effect of FTY720 on chronic Hepatitis C in patients who are non-responsive to, or intolerant of Interferon-based antiviral th... - View results",
        "timestamp": "2004-12-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-000814-35/ES",
        "title": "Eficacia de dosis bajas de interferón pegilado alfa-2a junto con ribavirina en el tratamiento de la hepatopatía crónica por virus C (genotipos 2 o 3) en pacientes coinfectados por el VIH (Efficacy ... - ES",
        "timestamp": "2007-12-04"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-001878-25/BG",
        "title": "A Randomized, Double-Blind Study to Evaluate the Safety and Antiviral Activity of IDX184 in Combination with Pegylated Interferon and Ribavirin for 12 Weeks in Treatment-Naïve Subjects with Genotyp... - BG",
        "timestamp": "2011-11-17"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-001878-25/results",
        "title": "A Randomized, Double-Blind Study to Evaluate the Safety and Antiviral Activity of IDX184 in Combination with Pegylated Interferon and Ribavirin for 12 Weeks in Treatment-Naïve Subjects with Genotyp... - View results",
        "timestamp": "2011-11-17"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-012344-17/IT",
        "title": "A  randomized, open label, single center, phase IIa controlled trial to assess tolerability, safety and effect of treatment with deferasirox plus standard antiviral therapy versus standard antivira... - IT",
        "timestamp": "2009-10-13"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-005707-18/DK",
        "title": "Clinical study of cerebral function in chronic hepatitis C virus patients treated with pegylated interferon alpha-2a and ribivirin - DK",
        "timestamp": "2008-08-07"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-001956-12/CZ",
        "title": "Monitoring of MxA mRNA Expression as a Marker of Rresponse to Interferon ß Therapy in Patients with Multiple Sclerosis. - CZ",
        "timestamp": "2011-05-25"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-001540-23/SE",
        "title": "A Scandinavian, randomized, rater-blinded study of single and double-dose (2x250 mcg e.o.d.) Betaferon in patients with early secondary progressive multiple sclerosis. - SE",
        "timestamp": "2006-03-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-001540-23/DK",
        "title": "A Scandinavian, randomized, rater-blinded study of single and double-dose (2x250 mcg e.o.d.) Betaferon in patients with early secondary progressive multiple sclerosis. - DK",
        "timestamp": "2006-03-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-001540-23/results",
        "title": "A Scandinavian, randomized, rater-blinded study of single and double-dose (2x250 mcg e.o.d.) Betaferon in patients with early secondary progressive multiple sclerosis. - View results",
        "timestamp": "2006-03-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-002781-21/GB",
        "title": "A clinical study to evaluate the biological effects of administering rimantadine in patients with hepatitis C virus (HCV) infection alongside standard combination therapy with pegylated interferon ... - GB",
        "timestamp": "2012-02-02"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-002781-21/results",
        "title": "A clinical study to evaluate the biological effects of administering rimantadine in patients with hepatitis C virus (HCV) infection alongside standard combination therapy with pegylated interferon ... - View results",
        "timestamp": "2012-02-02"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001023-14/GB",
        "title": "A randomised double-blind placebo-controlled trial to determine the safety and efficacy of inhaled SNG001 (IFNβ-1a for nebulisation) for the treatment of patients with confirmed SARS-CoV-2 infection - GB",
        "timestamp": "2020-03-17"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-004335-29/GB",
        "title": "A randomised controlled factorial pilot study investigating Omacor and/or Fluvastatin in patients with chronic hepatitis C who have not responded to standard combination anti-viral therapy. - GB",
        "timestamp": "2007-05-30"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-004335-29/results",
        "title": "A randomised controlled factorial pilot study investigating Omacor and/or Fluvastatin in patients with chronic hepatitis C who have not responded to standard combination anti-viral therapy. - View results",
        "timestamp": "2007-05-30"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001113-21/GB",
        "title": "Randomised Evaluation of COVID-19 Therapy (RECOVERY) - GB",
        "timestamp": "2020-03-17"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-001437-16/DE",
        "title": "A 3-year, multi-center study to evaluate optical coherence tomography as an outcome measure in patients with multiple sclerosis - DE",
        "timestamp": "2012-09-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-000995-41/DE",
        "title": "A double-blind, randomized, placebo-controlled multi-centre, phase II parallel dose-ranging study to assess the antifibrotic activity of GI262570 in chronic hepatitis C subjects with hepatic fibros... - DE",
        "timestamp": "2007-02-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-000995-41/CZ",
        "title": "A double-blind, randomized, placebo-controlled multi-centre, phase II parallel dose-ranging study to assess the antifibrotic activity of GI262570 in chronic hepatitis C subjects with hepatic fibros... - CZ",
        "timestamp": "2007-02-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-000995-41/results",
        "title": "A double-blind, randomized, placebo-controlled multi-centre, phase II parallel dose-ranging study to assess the antifibrotic activity of GI262570 in chronic hepatitis C subjects with hepatic fibros... - View results",
        "timestamp": "2007-02-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-001804-31/3rd",
        "title": "Ph3 trial of Glivec in CML-CP patients previously untreated with IFN-alfa - Outside EU/EEA",
        "timestamp": "2017-08-10"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-001804-31/results",
        "title": "Ph3 trial of Glivec in CML-CP patients previously untreated with IFN-alfa - View results",
        "timestamp": "2017-08-10"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-001647-12/ES",
        "title": "A Phase 2a, Open-Label, Study Evaluating the Safety and Anti-Viral Activity of ARB-001467 in Non-Cirrhotic, HBeAg-Negative Subjects with Chronic HBV Infection (Genotype A or B) in Combination with ... - ES",
        "timestamp": "2018-02-06"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-001647-12/PL",
        "title": "A Phase 2a, Open-Label, Study Evaluating the Safety and Anti-Viral Activity of ARB-001467 in Non-Cirrhotic, HBeAg-Negative Subjects with Chronic HBV Infection (Genotype A or B) in Combination with ... - PL",
        "timestamp": "2018-02-06"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-002093-30/ES",
        "title": "Extension protocol for patients with Chronic Myelogenous Leukemia (CML), Malignant Melanoma (MM) or Renal Cell Carcinoma (RCC) that have responded to treatment with Pegylated-interferon α-2a (PEG-I... - ES",
        "timestamp": "2005-12-22"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-002093-30/results",
        "title": "Extension protocol for patients with Chronic Myelogenous Leukemia (CML), Malignant Melanoma (MM) or Renal Cell Carcinoma (RCC) that have responded to treatment with Pegylated-interferon α-2a (PEG-I... - View results",
        "timestamp": "2005-12-22"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-005989-37/FI",
        "title": "CogniMS: observational study to assess cognition in patients with early Multiple Sclerosis - FI",
        "timestamp": "2006-03-29"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-004531-22/HU",
        "title": "Efficacy and Safety of Continuing for a Total of  48 or Prolonging for a Total of  72 weeks of Combined Treatment of Patients Receiving Pegasys and Copegus who are Biochemical Responders but Virolo... - HU",
        "timestamp": "2006-05-02"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-014600-66/NL",
        "title": "A multicentre, prospective, randomized open-label pilot study to assess the feasibility and preliminary efficacy of interferon gamma in combination with Anidulafungin for the treatment of candidemia - NL",
        "timestamp": "2010-08-10"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-003679-75/GB",
        "title": "A randomised, double-blind, placebo-controlled study, in COPD patients with and without a confirmed respiratory virus infection assessing anti-viral biomarker responses and clinical effects of inha... - GB",
        "timestamp": "2017-12-01"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-000773-60/LV",
        "title": "52 week multicenter, randomized, double-blind placebo-controlled trial evaluating\nthe efficacy and safety of SNMC in patients with chronic hepatitis C - LV",
        "timestamp": "2004-10-22"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-001622-24/IE",
        "title": "Phase III,multicentre,open-label,prospective randomised trial comparing Imatinib alone at 400mg versus 800mg daily versus Imatinib 400mg daily plus PEG Interferon-alpha with newly diagnosed chronic... - IE",
        "timestamp": None
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-001622-24/results",
        "title": "Phase III,multicentre,open-label,prospective randomised trial comparing Imatinib alone at 400mg versus 800mg daily versus Imatinib 400mg daily plus PEG Interferon-alpha with newly diagnosed chronic... - View results",
        "timestamp": None
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-000935-86/DE",
        "title": "Randomized, multicentric, partially double blind placebo-controlled phase II study for examining the influence of Ribavirin on the initial virological response in previous untreated patients with c... - DE",
        "timestamp": "2006-12-27"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-000935-86/results",
        "title": "Randomized, multicentric, partially double blind placebo-controlled phase II study for examining the influence of Ribavirin on the initial virological response in previous untreated patients with c... - View results",
        "timestamp": "2006-12-27"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-001881-14/IT",
        "title": "A phase II clinical trial to evaluate the safety and efficacy of interferon gamma in elevating frataxin levels in Friedreich ataxia patients - IT",
        "timestamp": "2013-03-01"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-005589-31/DK",
        "title": "4 Week treatment for Injecting Drug Users with chronic hepatitis C \n\nA phase 4, post marketing randomized clinical open label trial comparing 4 weeks of Ledipasvir/Sofosbuvir (co-formulated) and Ri... - DK",
        "timestamp": "2015-03-25"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-005129-18/IT",
        "title": "Multi-centre, randomised, open label pragmatic trial to compare the effectiveness and safety of interferon beta-1a (IFN-beta-1a) weekly i.m. and glatiramer-acetate (GA) in paediatric patients affec... - IT",
        "timestamp": None
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-001063-30/CZ",
        "title": "A Multi-center, Randomized, Double-Blind, Active-Control, 96 Week, Phase III Trial of the Efficacy and Safety of Clevudine Compared with Adefovir at Weeks 48 and 96 in Nucleoside Treatment-Naïve Pa... - CZ",
        "timestamp": "2007-06-28"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-001063-30/ES",
        "title": "A Multi-center, Randomized, Double-Blind, Active-Control, 96 Week, Phase III Trial of the Efficacy and Safety of Clevudine Compared with Adefovir at Weeks 48 and 96 in Nucleoside Treatment-Naïve Pa... - ES",
        "timestamp": "2007-06-28"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-001063-30/GB",
        "title": "A Multi-center, Randomized, Double-Blind, Active-Control, 96 Week, Phase III Trial of the Efficacy and Safety of Clevudine Compared with Adefovir at Weeks 48 and 96 in Nucleoside Treatment-Naïve Pa... - GB",
        "timestamp": "2007-06-28"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-001063-30/GR",
        "title": "A Multi-center, Randomized, Double-Blind, Active-Control, 96 Week, Phase III Trial of the Efficacy and Safety of Clevudine Compared with Adefovir at Weeks 48 and 96 in Nucleoside Treatment-Naïve Pa... - GR",
        "timestamp": "2007-06-28"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-001063-30/results",
        "title": "A Multi-center, Randomized, Double-Blind, Active-Control, 96 Week, Phase III Trial of the Efficacy and Safety of Clevudine Compared with Adefovir at Weeks 48 and 96 in Nucleoside Treatment-Naïve Pa... - View results",
        "timestamp": "2007-06-28"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-000773-71/DK",
        "title": "A multicenter phase II study evaluating the efficacy and tolerability of vemurafenib in combination with Pegylated Interferon and Interleukin-2 in patients with BRAF-mutated metastatic melanoma - DK",
        "timestamp": "2013-07-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-000523-40/BE",
        "title": "A Phase II Multicenter, Parallel-Group, Randomized, Dose-Ranging Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Following 12 Weeks of Oral Administration of G... - BE",
        "timestamp": "2012-09-11"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-000523-40/DE",
        "title": "A Phase II Multicenter, Parallel-Group, Randomized, Dose-Ranging Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Following 12 Weeks of Oral Administration of G... - DE",
        "timestamp": "2012-09-11"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-000523-40/BG",
        "title": "A Phase II Multicenter, Parallel-Group, Randomized, Dose-Ranging Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Following 12 Weeks of Oral Administration of G... - BG",
        "timestamp": "2012-09-11"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-000523-40/results",
        "title": "A Phase II Multicenter, Parallel-Group, Randomized, Dose-Ranging Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Following 12 Weeks of Oral Administration of G... - View results",
        "timestamp": "2012-09-11"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-004257-29/IE",
        "title": "A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon α-2b for Resected High-Risk Melanoma - IE",
        "timestamp": "2013-05-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-004257-29/3rd",
        "title": "A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon α-2b for Resected High-Risk Melanoma - Outside EU/EEA",
        "timestamp": "2013-05-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-003145-99/GB",
        "title": "A randomised placebo-controlled study of the safety and tolerability of a retinoid-X receptor agonist's ability to promote remyelination in people with relapsing-remitting multiple sclerosis alread... - GB",
        "timestamp": "2015-03-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-001061-14/CZ",
        "title": "A Multi-center, Randomized, Double-Blind, Active-Control, 96 Week, Phase III Trial of the Efficacy and Safety of Clevudine Compared with Adefovir at Weeks 48 and 96 in Nucleoside Treatment-Naïve Pa... - CZ",
        "timestamp": "2007-06-28"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-001061-14/ES",
        "title": "A Multi-center, Randomized, Double-Blind, Active-Control, 96 Week, Phase III Trial of the Efficacy and Safety of Clevudine Compared with Adefovir at Weeks 48 and 96 in Nucleoside Treatment-Naïve Pa... - ES",
        "timestamp": "2007-06-28"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-001061-14/GB",
        "title": "A Multi-center, Randomized, Double-Blind, Active-Control, 96 Week, Phase III Trial of the Efficacy and Safety of Clevudine Compared with Adefovir at Weeks 48 and 96 in Nucleoside Treatment-Naïve Pa... - GB",
        "timestamp": "2007-06-28"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-001061-14/GR",
        "title": "A Multi-center, Randomized, Double-Blind, Active-Control, 96 Week, Phase III Trial of the Efficacy and Safety of Clevudine Compared with Adefovir at Weeks 48 and 96 in Nucleoside Treatment-Naïve Pa... - GR",
        "timestamp": "2007-06-28"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-001061-14/results",
        "title": "A Multi-center, Randomized, Double-Blind, Active-Control, 96 Week, Phase III Trial of the Efficacy and Safety of Clevudine Compared with Adefovir at Weeks 48 and 96 in Nucleoside Treatment-Naïve Pa... - View results",
        "timestamp": "2007-06-28"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-001009-25/IT",
        "title": "Efficacy, safety and tolerability of Atorvastatin 40 mg in patients with Relapsing-remitting multIple sclerosis in treAtment with INterferoN-betA. - IT",
        "timestamp": "2005-07-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-001030-94/FR",
        "title": "Efficacy and safety of pegylated-proline-interferon alpha 2B (AOP2014) in maintaining deep molecular remissions in patients with chronic myeloid leukemia (CML) who discontinue ABL-kinase inhibitory... - FR",
        "timestamp": "2019-04-05"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-004974-16/GB",
        "title": "DOUBLE-BLIND PLACEBO-CONTROLLED RANDOMISED CLINICAL DOSE-RANGING STUDY TREATING MODERATE-SEVERE TRAUMATIC BRAIN INJURY PATIENTS WITH RECOMBINANT HUMAN INTERLEUKIN 1 RECEPTOR ANTAGONIST. - GB",
        "timestamp": "2018-11-08"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-002777-56/IT",
        "title": "Cross-sectional multicenter study evaluating the IL28B polymorphism in patients with HBeAg-negative chronic hepatitis B treated with pegylated interferon alfa-2a in the course of Peg.Be.Liver study - IT",
        "timestamp": "2012-08-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-002777-56/results",
        "title": "Cross-sectional multicenter study evaluating the IL28B polymorphism in patients with HBeAg-negative chronic hepatitis B treated with pegylated interferon alfa-2a in the course of Peg.Be.Liver study - View results",
        "timestamp": "2012-08-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-002793-23/GB",
        "title": "A Phase 3 Evaluation of Daclatasvir (BMS-790052) in Combination with Peg-Interferon Alfa-2a and Ribavirin in Treatment-Naive Subjects with Chronic Hepatitis C Genotype 4\r\n\r\nRevised Protocol Number ... - GB",
        "timestamp": "2012-03-07"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-002793-23/ES",
        "title": "A Phase 3 Evaluation of Daclatasvir (BMS-790052) in Combination with Peg-Interferon Alfa-2a and Ribavirin in Treatment-Naive Subjects with Chronic Hepatitis C Genotype 4\r\n\r\nRevised Protocol Number ... - ES",
        "timestamp": "2012-03-07"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-002793-23/IT",
        "title": "A Phase 3 Evaluation of Daclatasvir (BMS-790052) in Combination with Peg-Interferon Alfa-2a and Ribavirin in Treatment-Naive Subjects with Chronic Hepatitis C Genotype 4\r\n\r\nRevised Protocol Number ... - IT",
        "timestamp": "2012-03-07"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-002793-23/GR",
        "title": "A Phase 3 Evaluation of Daclatasvir (BMS-790052) in Combination with Peg-Interferon Alfa-2a and Ribavirin in Treatment-Naive Subjects with Chronic Hepatitis C Genotype 4\r\n\r\nRevised Protocol Number ... - GR",
        "timestamp": "2012-03-07"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-002793-23/results",
        "title": "A Phase 3 Evaluation of Daclatasvir (BMS-790052) in Combination with Peg-Interferon Alfa-2a and Ribavirin in Treatment-Naive Subjects with Chronic Hepatitis C Genotype 4\r\n\r\nRevised Protocol Number ... - View results",
        "timestamp": "2012-03-07"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-004321-25/NL",
        "title": "A phase II, single arm, multicenter study of nilotinib in combination with pegylated interferon α2b in patients with suboptimal molecular response or stable detectable molecular residual disease af... - NL",
        "timestamp": "2013-04-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-004321-25/SE",
        "title": "A phase II, single arm, multicenter study of nilotinib in combination with pegylated interferon α2b in patients with suboptimal molecular response or stable detectable molecular residual disease af... - SE",
        "timestamp": "2013-04-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-004321-25/NO",
        "title": "A phase II, single arm, multicenter study of nilotinib in combination with pegylated interferon α2b in patients with suboptimal molecular response or stable detectable molecular residual disease af... - NO",
        "timestamp": "2013-04-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-001010-17/GB",
        "title": "Nucleos(t)ide withdrawal in HBeAg negative hepatitis B virus infection to promote HBsAg clearance. (NUC-B) - GB",
        "timestamp": "2016-08-26"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-000820-34/PT",
        "title": "Comparison of Three Regimens of PEG-Intron plus Ribavirin in the Treatment of Chronic Hepatitis C, Genotype 2 or 3, in Previously Untreated Patients - PT",
        "timestamp": "2006-08-31"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-000820-34/results",
        "title": "Comparison of Three Regimens of PEG-Intron plus Ribavirin in the Treatment of Chronic Hepatitis C, Genotype 2 or 3, in Previously Untreated Patients - View results",
        "timestamp": "2006-08-31"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-004953-26/BE",
        "title": "CMV specific T cell therapy for the treatment of relapsing or therapy refractory CMV infection after allogeneic stem cell transplantation with a CMV-positive donor. - BE",
        "timestamp": "2016-03-11"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-002937-11/BE",
        "title": "Etude randomisée, en double insu et multicentrique de l'association Interferon pégylé alpha 2b-Ribavirine versus l'association Interferon pégylé alpha 2b-placebo dans le traitement au long cours (3... - BE",
        "timestamp": "2008-01-23"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-000899-25/FI",
        "title": "A Phase II Double-blind, Randomised, Parallel Group 2:1 Comparison of the Efficacy and Safety of FP-1201-lyo (Recombinant Human Interferon Beta-1a) and Placebo in the Prevention of Multi-Organ Fail... - FI",
        "timestamp": "2016-12-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-000899-25/EE",
        "title": "A Phase II Double-blind, Randomised, Parallel Group 2:1 Comparison of the Efficacy and Safety of FP-1201-lyo (Recombinant Human Interferon Beta-1a) and Placebo in the Prevention of Multi-Organ Fail... - EE",
        "timestamp": "2016-12-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-000899-25/LT",
        "title": "A Phase II Double-blind, Randomised, Parallel Group 2:1 Comparison of the Efficacy and Safety of FP-1201-lyo (Recombinant Human Interferon Beta-1a) and Placebo in the Prevention of Multi-Organ Fail... - LT",
        "timestamp": "2016-12-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-000899-25/GB",
        "title": "A Phase II Double-blind, Randomised, Parallel Group 2:1 Comparison of the Efficacy and Safety of FP-1201-lyo (Recombinant Human Interferon Beta-1a) and Placebo in the Prevention of Multi-Organ Fail... - GB",
        "timestamp": "2016-12-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-004701-11/BG",
        "title": "A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib Compared with an Interferon Beta 1a (Avonex®), in Participants with Relapsin... - BG",
        "timestamp": "2020-01-10"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-004700-19/BG",
        "title": "A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib Compared with an Interferon Beta 1a (Avonex®), in Participants with Relapsin... - BG",
        "timestamp": "2020-01-10"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-001207-19/DE",
        "title": "Randomized multicenter open label trial comparing the efficacy and safety of 48 versus 72 weeks of Peginterferon-alfa-2a plus daily Ribavirin and Amantadinsulfat in patients with chronic Hepatitis ... - DE",
        "timestamp": "2005-11-04"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-001207-19/results",
        "title": "Randomized multicenter open label trial comparing the efficacy and safety of 48 versus 72 weeks of Peginterferon-alfa-2a plus daily Ribavirin and Amantadinsulfat in patients with chronic Hepatitis ... - View results",
        "timestamp": "2005-11-04"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-004695-11/AT",
        "title": "A Phase 3 Blinded Randomized Study of Peginterferon Lambda-1a and Ribavirin Compared to Peginterferon Alfa-2a and Ribavirin, Each Administered with Telaprevir in Subjects with Genotype-1 Chronic He... - AT",
        "timestamp": "2013-06-11"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-004695-11/BE",
        "title": "A Phase 3 Blinded Randomized Study of Peginterferon Lambda-1a and Ribavirin Compared to Peginterferon Alfa-2a and Ribavirin, Each Administered with Telaprevir in Subjects with Genotype-1 Chronic He... - BE",
        "timestamp": "2013-06-11"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-004695-11/CZ",
        "title": "A Phase 3 Blinded Randomized Study of Peginterferon Lambda-1a and Ribavirin Compared to Peginterferon Alfa-2a and Ribavirin, Each Administered with Telaprevir in Subjects with Genotype-1 Chronic He... - CZ",
        "timestamp": "2013-06-11"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-004695-11/GB",
        "title": "A Phase 3 Blinded Randomized Study of Peginterferon Lambda-1a and Ribavirin Compared to Peginterferon Alfa-2a and Ribavirin, Each Administered with Telaprevir in Subjects with Genotype-1 Chronic He... - GB",
        "timestamp": "2013-06-11"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-004695-11/PL",
        "title": "A Phase 3 Blinded Randomized Study of Peginterferon Lambda-1a and Ribavirin Compared to Peginterferon Alfa-2a and Ribavirin, Each Administered with Telaprevir in Subjects with Genotype-1 Chronic He... - PL",
        "timestamp": "2013-06-11"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-004695-11/IT",
        "title": "A Phase 3 Blinded Randomized Study of Peginterferon Lambda-1a and Ribavirin Compared to Peginterferon Alfa-2a and Ribavirin, Each Administered with Telaprevir in Subjects with Genotype-1 Chronic He... - IT",
        "timestamp": "2013-06-11"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-004695-11/ES",
        "title": "A Phase 3 Blinded Randomized Study of Peginterferon Lambda-1a and Ribavirin Compared to Peginterferon Alfa-2a and Ribavirin, Each Administered with Telaprevir in Subjects with Genotype-1 Chronic He... - ES",
        "timestamp": "2013-06-11"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-004695-11/results",
        "title": "A Phase 3 Blinded Randomized Study of Peginterferon Lambda-1a and Ribavirin Compared to Peginterferon Alfa-2a and Ribavirin, Each Administered with Telaprevir in Subjects with Genotype-1 Chronic He... - View results",
        "timestamp": "2013-06-11"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-000620-26/BE",
        "title": "A Phase II/III, Open-label Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-3682B (MK-3682 + Grazoprevir + MK-8408 Fixed Dose Combination) in Subjects with Chronic H... - BE",
        "timestamp": "2016-11-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-005972-42/FR",
        "title": "A randomized, multicenter, two-arm, open-label, phase IIIb study to evaluate the satisfaction in relapsing Multiple Sclerosis subjects transitioning to Rebif® New Formulation (RNF) from Rebif® (Int... - FR",
        "timestamp": "2007-06-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-005972-42/DE",
        "title": "A randomized, multicenter, two-arm, open-label, phase IIIb study to evaluate the satisfaction in relapsing Multiple Sclerosis subjects transitioning to Rebif® New Formulation (RNF) from Rebif® (Int... - DE",
        "timestamp": "2007-06-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-005972-42/results",
        "title": "A randomized, multicenter, two-arm, open-label, phase IIIb study to evaluate the satisfaction in relapsing Multiple Sclerosis subjects transitioning to Rebif® New Formulation (RNF) from Rebif® (Int... - View results",
        "timestamp": "2007-06-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-001149-14/IT",
        "title": "A Phase 3, Randomized Study of SU011248 versus Interferon-a as First-Line Systemic Therapy for Patients with Metastatic Renal Cell Carcinoma. - IT",
        "timestamp": "2004-09-27"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-001149-14/ES",
        "title": "A Phase 3, Randomized Study of SU011248 versus Interferon-a as First-Line Systemic Therapy for Patients with Metastatic Renal Cell Carcinoma. - ES",
        "timestamp": "2004-09-27"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-001149-14/GB",
        "title": "A Phase 3, Randomized Study of SU011248 versus Interferon-a as First-Line Systemic Therapy for Patients with Metastatic Renal Cell Carcinoma. - GB",
        "timestamp": "2004-09-27"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-001149-14/results",
        "title": "A Phase 3, Randomized Study of SU011248 versus Interferon-a as First-Line Systemic Therapy for Patients with Metastatic Renal Cell Carcinoma. - View results",
        "timestamp": "2004-09-27"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-005560-13/DE",
        "title": "A multicenter randomised study comparing the efficacy of pegylated interferon-alfa-2a plus placebo vs. pegylated interfeorn-alfa-2a plus tenofovir for the treatment of chronic delta hepatitis- The ... - DE",
        "timestamp": "2009-06-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-005560-13/GR",
        "title": "A multicenter randomised study comparing the efficacy of pegylated interferon-alfa-2a plus placebo vs. pegylated interfeorn-alfa-2a plus tenofovir for the treatment of chronic delta hepatitis- The ... - GR",
        "timestamp": "2009-06-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-018197-66/PT",
        "title": "Safety, antiviral effect and pharmacokinetics of BI 207127 in combination with BI 201335 and with or without ribavirin for 4, 16, 24, 28 or 40 weeks in patients with chronic HCV genotype 1 infectio... - PT",
        "timestamp": "2010-04-29"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-018197-66/FR",
        "title": "Safety, antiviral effect and pharmacokinetics of BI 207127 in combination with BI 201335 and with or without ribavirin for 4, 16, 24, 28 or 40 weeks in patients with chronic HCV genotype 1 infectio... - FR",
        "timestamp": "2010-04-29"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-018197-66/DE",
        "title": "Safety, antiviral effect and pharmacokinetics of BI 207127 in combination with BI 201335 and with or without ribavirin for 4, 16, 24, 28 or 40 weeks in patients with chronic HCV genotype 1 infectio... - DE",
        "timestamp": "2010-04-29"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-018197-66/AT",
        "title": "Safety, antiviral effect and pharmacokinetics of BI 207127 in combination with BI 201335 and with or without ribavirin for 4, 16, 24, 28 or 40 weeks in patients with chronic HCV genotype 1 infectio... - AT",
        "timestamp": "2010-04-29"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-018197-66/ES",
        "title": "Safety, antiviral effect and pharmacokinetics of BI 207127 in combination with BI 201335 and with or without ribavirin for 4, 16, 24, 28 or 40 weeks in patients with chronic HCV genotype 1 infectio... - ES",
        "timestamp": "2010-04-29"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-018197-66/results",
        "title": "Safety, antiviral effect and pharmacokinetics of BI 207127 in combination with BI 201335 and with or without ribavirin for 4, 16, 24, 28 or 40 weeks in patients with chronic HCV genotype 1 infectio... - View results",
        "timestamp": "2010-04-29"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-005270-47/FI",
        "title": "International, multicenter, Phase IIIb study of subcutaneous every-other-day treatment of patients with relapsing multiple sclerosis with (Phase A) double-blind Betaseron/Betaferon 250 µg or 500 µg... - FI",
        "timestamp": "2007-04-23"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-005270-47/BE",
        "title": "International, multicenter, Phase IIIb study of subcutaneous every-other-day treatment of patients with relapsing multiple sclerosis with (Phase A) double-blind Betaseron/Betaferon 250 µg or 500 µg... - BE",
        "timestamp": "2007-04-23"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-005270-47/IE",
        "title": "International, multicenter, Phase IIIb study of subcutaneous every-other-day treatment of patients with relapsing multiple sclerosis with (Phase A) double-blind Betaseron/Betaferon 250 µg or 500 µg... - IE",
        "timestamp": "2007-04-23"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-005270-47/FR",
        "title": "International, multicenter, Phase IIIb study of subcutaneous every-other-day treatment of patients with relapsing multiple sclerosis with (Phase A) double-blind Betaseron/Betaferon 250 µg or 500 µg... - FR",
        "timestamp": "2007-04-23"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-005270-47/AT",
        "title": "International, multicenter, Phase IIIb study of subcutaneous every-other-day treatment of patients with relapsing multiple sclerosis with (Phase A) double-blind Betaseron/Betaferon 250 µg or 500 µg... - AT",
        "timestamp": "2007-04-23"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-005270-47/SE",
        "title": "International, multicenter, Phase IIIb study of subcutaneous every-other-day treatment of patients with relapsing multiple sclerosis with (Phase A) double-blind Betaseron/Betaferon 250 µg or 500 µg... - SE",
        "timestamp": "2007-04-23"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-005270-47/ES",
        "title": "International, multicenter, Phase IIIb study of subcutaneous every-other-day treatment of patients with relapsing multiple sclerosis with (Phase A) double-blind Betaseron/Betaferon 250 µg or 500 µg... - ES",
        "timestamp": "2007-04-23"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-005270-47/DE",
        "title": "International, multicenter, Phase IIIb study of subcutaneous every-other-day treatment of patients with relapsing multiple sclerosis with (Phase A) double-blind Betaseron/Betaferon 250 µg or 500 µg... - DE",
        "timestamp": "2007-04-23"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-005270-47/HU",
        "title": "International, multicenter, Phase IIIb study of subcutaneous every-other-day treatment of patients with relapsing multiple sclerosis with (Phase A) double-blind Betaseron/Betaferon 250 µg or 500 µg... - HU",
        "timestamp": "2007-04-23"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-005270-47/LV",
        "title": "International, multicenter, Phase IIIb study of subcutaneous every-other-day treatment of patients with relapsing multiple sclerosis with (Phase A) double-blind Betaseron/Betaferon 250 µg or 500 µg... - LV",
        "timestamp": "2007-04-23"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-005270-47/SI",
        "title": "International, multicenter, Phase IIIb study of subcutaneous every-other-day treatment of patients with relapsing multiple sclerosis with (Phase A) double-blind Betaseron/Betaferon 250 µg or 500 µg... - SI",
        "timestamp": "2007-04-23"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-005270-47/NL",
        "title": "International, multicenter, Phase IIIb study of subcutaneous every-other-day treatment of patients with relapsing multiple sclerosis with (Phase A) double-blind Betaseron/Betaferon 250 µg or 500 µg... - NL",
        "timestamp": "2007-04-23"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-005270-47/GR",
        "title": "International, multicenter, Phase IIIb study of subcutaneous every-other-day treatment of patients with relapsing multiple sclerosis with (Phase A) double-blind Betaseron/Betaferon 250 µg or 500 µg... - GR",
        "timestamp": "2007-04-23"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-005270-47/IT",
        "title": "International, multicenter, Phase IIIb study of subcutaneous every-other-day treatment of patients with relapsing multiple sclerosis with (Phase A) double-blind Betaseron/Betaferon 250 µg or 500 µg... - IT",
        "timestamp": "2007-04-23"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-005270-47/results",
        "title": "International, multicenter, Phase IIIb study of subcutaneous every-other-day treatment of patients with relapsing multiple sclerosis with (Phase A) double-blind Betaseron/Betaferon 250 µg or 500 µg... - View results",
        "timestamp": "2007-04-23"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-002022-10/ES",
        "title": "Protocolo multicéntrico abierto en el que se proporciona interferón pegilado alfa-2a (PEGASYS®) en monoterapia o en combinación con ribavirina (COPEGUS®) a pacientes con hepatitis C crónica que han... - ES",
        "timestamp": "2008-09-23"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-002022-10/AT",
        "title": "Protocolo multicéntrico abierto en el que se proporciona interferón pegilado alfa-2a (PEGASYS®) en monoterapia o en combinación con ribavirina (COPEGUS®) a pacientes con hepatitis C crónica que han... - AT",
        "timestamp": "2008-09-23"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-002022-10/FR",
        "title": "Protocolo multicéntrico abierto en el que se proporciona interferón pegilado alfa-2a (PEGASYS®) en monoterapia o en combinación con ribavirina (COPEGUS®) a pacientes con hepatitis C crónica que han... - FR",
        "timestamp": "2008-09-23"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-002022-10/IT",
        "title": "Protocolo multicéntrico abierto en el que se proporciona interferón pegilado alfa-2a (PEGASYS®) en monoterapia o en combinación con ribavirina (COPEGUS®) a pacientes con hepatitis C crónica que han... - IT",
        "timestamp": "2008-09-23"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-002022-10/DE",
        "title": "Protocolo multicéntrico abierto en el que se proporciona interferón pegilado alfa-2a (PEGASYS®) en monoterapia o en combinación con ribavirina (COPEGUS®) a pacientes con hepatitis C crónica que han... - DE",
        "timestamp": "2008-09-23"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-002022-10/results",
        "title": "Protocolo multicéntrico abierto en el que se proporciona interferón pegilado alfa-2a (PEGASYS®) en monoterapia o en combinación con ribavirina (COPEGUS®) a pacientes con hepatitis C crónica que han... - View results",
        "timestamp": "2008-09-23"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003534-17/ES",
        "title": "A phase II randomised, double-blind and placebo-controlled study of BI 207127 in combination with faldaprevir and ribavirin in patients with moderate hepatic impairment (Child-Pugh B) with genotype... - ES",
        "timestamp": "2013-04-05"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003534-17/DE",
        "title": "A phase II randomised, double-blind and placebo-controlled study of BI 207127 in combination with faldaprevir and ribavirin in patients with moderate hepatic impairment (Child-Pugh B) with genotype... - DE",
        "timestamp": "2013-04-05"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003534-17/GB",
        "title": "A phase II randomised, double-blind and placebo-controlled study of BI 207127 in combination with faldaprevir and ribavirin in patients with moderate hepatic impairment (Child-Pugh B) with genotype... - GB",
        "timestamp": "2013-04-05"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003534-17/IT",
        "title": "A phase II randomised, double-blind and placebo-controlled study of BI 207127 in combination with faldaprevir and ribavirin in patients with moderate hepatic impairment (Child-Pugh B) with genotype... - IT",
        "timestamp": "2013-04-05"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003534-17/IE",
        "title": "A phase II randomised, double-blind and placebo-controlled study of BI 207127 in combination with faldaprevir and ribavirin in patients with moderate hepatic impairment (Child-Pugh B) with genotype... - IE",
        "timestamp": "2013-04-05"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003534-17/FR",
        "title": "A phase II randomised, double-blind and placebo-controlled study of BI 207127 in combination with faldaprevir and ribavirin in patients with moderate hepatic impairment (Child-Pugh B) with genotype... - FR",
        "timestamp": "2013-04-05"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003534-17/results",
        "title": "A phase II randomised, double-blind and placebo-controlled study of BI 207127 in combination with faldaprevir and ribavirin in patients with moderate hepatic impairment (Child-Pugh B) with genotype... - View results",
        "timestamp": "2013-04-05"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-004182-60/SE",
        "title": "A Multicenter, Open-Label, Study to Evaluate the Efficacy and Safety of Glecaprevir/Pibrentasvir in Renally-Impaired Adults with Chronic Hepatitis C Virus Genotype 1 – 6 Infection - SE",
        "timestamp": "2017-05-08"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-004182-60/ES",
        "title": "A Multicenter, Open-Label, Study to Evaluate the Efficacy and Safety of Glecaprevir/Pibrentasvir in Renally-Impaired Adults with Chronic Hepatitis C Virus Genotype 1 – 6 Infection - ES",
        "timestamp": "2017-05-08"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-004182-60/DE",
        "title": "A Multicenter, Open-Label, Study to Evaluate the Efficacy and Safety of Glecaprevir/Pibrentasvir in Renally-Impaired Adults with Chronic Hepatitis C Virus Genotype 1 – 6 Infection - DE",
        "timestamp": "2017-05-08"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-004182-60/PL",
        "title": "A Multicenter, Open-Label, Study to Evaluate the Efficacy and Safety of Glecaprevir/Pibrentasvir in Renally-Impaired Adults with Chronic Hepatitis C Virus Genotype 1 – 6 Infection - PL",
        "timestamp": "2017-05-08"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-004182-60/GR",
        "title": "A Multicenter, Open-Label, Study to Evaluate the Efficacy and Safety of Glecaprevir/Pibrentasvir in Renally-Impaired Adults with Chronic Hepatitis C Virus Genotype 1 – 6 Infection - GR",
        "timestamp": "2017-05-08"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-004182-60/results",
        "title": "A Multicenter, Open-Label, Study to Evaluate the Efficacy and Safety of Glecaprevir/Pibrentasvir in Renally-Impaired Adults with Chronic Hepatitis C Virus Genotype 1 – 6 Infection - View results",
        "timestamp": "2017-05-08"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-003037-32/LT",
        "title": "A two-arm, randomized, double-blind, control group-compared, multicenter, phase IIIb study with monthly MRI and biomarker assessments to evaluate the efficacy, safety, and tolerability of Rebif® Ne... - LT",
        "timestamp": "2007-09-11"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-003037-32/DE",
        "title": "A two-arm, randomized, double-blind, control group-compared, multicenter, phase IIIb study with monthly MRI and biomarker assessments to evaluate the efficacy, safety, and tolerability of Rebif® Ne... - DE",
        "timestamp": "2007-09-11"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-003037-32/EE",
        "title": "A two-arm, randomized, double-blind, control group-compared, multicenter, phase IIIb study with monthly MRI and biomarker assessments to evaluate the efficacy, safety, and tolerability of Rebif® Ne... - EE",
        "timestamp": "2007-09-11"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-003037-32/IT",
        "title": "A two-arm, randomized, double-blind, control group-compared, multicenter, phase IIIb study with monthly MRI and biomarker assessments to evaluate the efficacy, safety, and tolerability of Rebif® Ne... - IT",
        "timestamp": "2007-09-11"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-003037-32/ES",
        "title": "A two-arm, randomized, double-blind, control group-compared, multicenter, phase IIIb study with monthly MRI and biomarker assessments to evaluate the efficacy, safety, and tolerability of Rebif® Ne... - ES",
        "timestamp": "2007-09-11"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-003037-32/results",
        "title": "A two-arm, randomized, double-blind, control group-compared, multicenter, phase IIIb study with monthly MRI and biomarker assessments to evaluate the efficacy, safety, and tolerability of Rebif® Ne... - View results",
        "timestamp": "2007-09-11"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-005083-28/ES",
        "title": "Estudio de fase II, aleatorizado, abierto, multicéntrico, para evaluar la eficacia de sorafenib solo y sorafenib en combinación con interferón alfa-2a a dosis bajas como tratamiento de segunda líne... - ES",
        "timestamp": "2008-02-27"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-005083-28/GB",
        "title": "Estudio de fase II, aleatorizado, abierto, multicéntrico, para evaluar la eficacia de sorafenib solo y sorafenib en combinación con interferón alfa-2a a dosis bajas como tratamiento de segunda líne... - GB",
        "timestamp": "2008-02-27"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-005083-28/FR",
        "title": "Estudio de fase II, aleatorizado, abierto, multicéntrico, para evaluar la eficacia de sorafenib solo y sorafenib en combinación con interferón alfa-2a a dosis bajas como tratamiento de segunda líne... - FR",
        "timestamp": "2008-02-27"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-005083-28/IT",
        "title": "Estudio de fase II, aleatorizado, abierto, multicéntrico, para evaluar la eficacia de sorafenib solo y sorafenib en combinación con interferón alfa-2a a dosis bajas como tratamiento de segunda líne... - IT",
        "timestamp": "2008-02-27"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-005083-28/IE",
        "title": "Estudio de fase II, aleatorizado, abierto, multicéntrico, para evaluar la eficacia de sorafenib solo y sorafenib en combinación con interferón alfa-2a a dosis bajas como tratamiento de segunda líne... - IE",
        "timestamp": "2008-02-27"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-005083-28/AT",
        "title": "Estudio de fase II, aleatorizado, abierto, multicéntrico, para evaluar la eficacia de sorafenib solo y sorafenib en combinación con interferón alfa-2a a dosis bajas como tratamiento de segunda líne... - AT",
        "timestamp": "2008-02-27"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-005083-28/PL",
        "title": "Estudio de fase II, aleatorizado, abierto, multicéntrico, para evaluar la eficacia de sorafenib solo y sorafenib en combinación con interferón alfa-2a a dosis bajas como tratamiento de segunda líne... - PL",
        "timestamp": "2008-02-27"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-005083-28/results",
        "title": "Estudio de fase II, aleatorizado, abierto, multicéntrico, para evaluar la eficacia de sorafenib solo y sorafenib en combinación con interferón alfa-2a a dosis bajas como tratamiento de segunda líne... - View results",
        "timestamp": "2008-02-27"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-005753-23/IT",
        "title": "A multicentre study for the long-term follow-up of HLH patients who received treatment with NI-0501, an anti-interferon gamma monoclonal antibody. - IT",
        "timestamp": "2013-06-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-005753-23/CZ",
        "title": "A multicentre study for the long-term follow-up of HLH patients who received treatment with NI-0501, an anti-interferon gamma monoclonal antibody. - CZ",
        "timestamp": "2013-06-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-005753-23/DE",
        "title": "A multicentre study for the long-term follow-up of HLH patients who received treatment with NI-0501, an anti-interferon gamma monoclonal antibody. - DE",
        "timestamp": "2013-06-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-005753-23/ES",
        "title": "A multicentre study for the long-term follow-up of HLH patients who received treatment with NI-0501, an anti-interferon gamma monoclonal antibody. - ES",
        "timestamp": "2013-06-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-005753-23/AT",
        "title": "A multicentre study for the long-term follow-up of HLH patients who received treatment with NI-0501, an anti-interferon gamma monoclonal antibody. - AT",
        "timestamp": "2013-06-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-005753-23/SE",
        "title": "A multicentre study for the long-term follow-up of HLH patients who received treatment with NI-0501, an anti-interferon gamma monoclonal antibody. - SE",
        "timestamp": "2013-06-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-005753-23/GB",
        "title": "A multicentre study for the long-term follow-up of HLH patients who received treatment with NI-0501, an anti-interferon gamma monoclonal antibody. - GB",
        "timestamp": "2013-06-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-005753-23/FR",
        "title": "A multicentre study for the long-term follow-up of HLH patients who received treatment with NI-0501, an anti-interferon gamma monoclonal antibody. - FR",
        "timestamp": "2013-06-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-005753-23/NL",
        "title": "A multicentre study for the long-term follow-up of HLH patients who received treatment with NI-0501, an anti-interferon gamma monoclonal antibody. - NL",
        "timestamp": "2013-06-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-002212-13/GB",
        "title": "A Phase II Study of GW786034 Using a Randomized Discontinuation Design in Subjects with Locally Recurrent or Metastatic Clear-Cell Renal Cell Carcinoma - GB",
        "timestamp": "2006-08-08"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-002212-13/CZ",
        "title": "A Phase II Study of GW786034 Using a Randomized Discontinuation Design in Subjects with Locally Recurrent or Metastatic Clear-Cell Renal Cell Carcinoma - CZ",
        "timestamp": "2006-08-08"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-002212-13/BE",
        "title": "A Phase II Study of GW786034 Using a Randomized Discontinuation Design in Subjects with Locally Recurrent or Metastatic Clear-Cell Renal Cell Carcinoma - BE",
        "timestamp": "2006-08-08"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-002212-13/results",
        "title": "A Phase II Study of GW786034 Using a Randomized Discontinuation Design in Subjects with Locally Recurrent or Metastatic Clear-Cell Renal Cell Carcinoma - View results",
        "timestamp": "2006-08-08"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-001469-16/GB",
        "title": "A double-blind, randomized, placebo-controlled, multi-centre, dose-ranging, parallel group, phase II study to assess efficacy, safety/tolerability, and pharmacokinetics of a thrombopoietin receptor... - GB",
        "timestamp": "2005-10-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-001469-16/DE",
        "title": "A double-blind, randomized, placebo-controlled, multi-centre, dose-ranging, parallel group, phase II study to assess efficacy, safety/tolerability, and pharmacokinetics of a thrombopoietin receptor... - DE",
        "timestamp": "2005-10-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-001469-16/ES",
        "title": "A double-blind, randomized, placebo-controlled, multi-centre, dose-ranging, parallel group, phase II study to assess efficacy, safety/tolerability, and pharmacokinetics of a thrombopoietin receptor... - ES",
        "timestamp": "2005-10-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-001469-16/results",
        "title": "A double-blind, randomized, placebo-controlled, multi-centre, dose-ranging, parallel group, phase II study to assess efficacy, safety/tolerability, and pharmacokinetics of a thrombopoietin receptor... - View results",
        "timestamp": "2005-10-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020387-38/DE",
        "title": "LIRA-B - Dose-Ranging Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Pegylated Interferon Lambda (BMS-914143) Monotherapy in Interferon-Naive Patients with Chronic Hepatitis B Virus... - DE",
        "timestamp": "2010-12-17"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020387-38/IT",
        "title": "LIRA-B - Dose-Ranging Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Pegylated Interferon Lambda (BMS-914143) Monotherapy in Interferon-Naive Patients with Chronic Hepatitis B Virus... - IT",
        "timestamp": "2010-12-17"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020387-38/NL",
        "title": "LIRA-B - Dose-Ranging Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Pegylated Interferon Lambda (BMS-914143) Monotherapy in Interferon-Naive Patients with Chronic Hepatitis B Virus... - NL",
        "timestamp": "2010-12-17"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020387-38/results",
        "title": "LIRA-B - Dose-Ranging Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Pegylated Interferon Lambda (BMS-914143) Monotherapy in Interferon-Naive Patients with Chronic Hepatitis B Virus... - View results",
        "timestamp": "2010-12-17"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-004693-29/IT",
        "title": "Pegylated interferon alfa-2a USE FOR CONTROLLING virological rebound after suspension of antiretroviral treatment  IN PATIENTS WITH CHRONIC HIV INFECTION - IT",
        "timestamp": "2011-11-15"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-011182-86/BG",
        "title": "480 Study: Phase 2b Open-label, Randomized Study in Treatment Naïve Subjects with HCV Genotype 1 to Compare the Efficacy, Safety, and Tolerability of  the 480 µg  Dose of Locteron™  Plus Ribavirin ... - BG",
        "timestamp": "2009-07-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-004237-14/DE",
        "title": "A Phase 3 Evaluation of BMS-790052 (Daclatasvir) Compared with Telaprevir in Combination with Peg-Interferon Alfa-2a and Ribavirin in Treatment-Naive Patients with Chronic Hepatitis-C\r\nRevised Prot... - DE",
        "timestamp": "2012-02-09"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-004237-14/AT",
        "title": "A Phase 3 Evaluation of BMS-790052 (Daclatasvir) Compared with Telaprevir in Combination with Peg-Interferon Alfa-2a and Ribavirin in Treatment-Naive Patients with Chronic Hepatitis-C\r\nRevised Prot... - AT",
        "timestamp": "2012-02-09"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-004237-14/ES",
        "title": "A Phase 3 Evaluation of BMS-790052 (Daclatasvir) Compared with Telaprevir in Combination with Peg-Interferon Alfa-2a and Ribavirin in Treatment-Naive Patients with Chronic Hepatitis-C\r\nRevised Prot... - ES",
        "timestamp": "2012-02-09"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-004237-14/GB",
        "title": "A Phase 3 Evaluation of BMS-790052 (Daclatasvir) Compared with Telaprevir in Combination with Peg-Interferon Alfa-2a and Ribavirin in Treatment-Naive Patients with Chronic Hepatitis-C\r\nRevised Prot... - GB",
        "timestamp": "2012-02-09"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-004237-14/IT",
        "title": "A Phase 3 Evaluation of BMS-790052 (Daclatasvir) Compared with Telaprevir in Combination with Peg-Interferon Alfa-2a and Ribavirin in Treatment-Naive Patients with Chronic Hepatitis-C\r\nRevised Prot... - IT",
        "timestamp": "2012-02-09"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-004237-14/DK",
        "title": "A Phase 3 Evaluation of BMS-790052 (Daclatasvir) Compared with Telaprevir in Combination with Peg-Interferon Alfa-2a and Ribavirin in Treatment-Naive Patients with Chronic Hepatitis-C\r\nRevised Prot... - DK",
        "timestamp": "2012-02-09"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-004237-14/results",
        "title": "A Phase 3 Evaluation of BMS-790052 (Daclatasvir) Compared with Telaprevir in Combination with Peg-Interferon Alfa-2a and Ribavirin in Treatment-Naive Patients with Chronic Hepatitis-C\r\nRevised Prot... - View results",
        "timestamp": "2012-02-09"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-002446-23/GB",
        "title": "A Phase 2, Open-Label, Multicenter, Multi-cohort Study to Investigate the Safety and Efficacy of Sofosbuvir/Velpatasvir in Adolescents and Children with Chronic HCV Infection - GB",
        "timestamp": "2017-01-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-002446-23/BE",
        "title": "A Phase 2, Open-Label, Multicenter, Multi-cohort Study to Investigate the Safety and Efficacy of Sofosbuvir/Velpatasvir in Adolescents and Children with Chronic HCV Infection - BE",
        "timestamp": "2017-01-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-002446-23/3rd",
        "title": "A Phase 2, Open-Label, Multicenter, Multi-cohort Study to Investigate the Safety and Efficacy of Sofosbuvir/Velpatasvir in Adolescents and Children with Chronic HCV Infection - Outside EU/EEA",
        "timestamp": "2017-01-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-002446-23/IT",
        "title": "A Phase 2, Open-Label, Multicenter, Multi-cohort Study to Investigate the Safety and Efficacy of Sofosbuvir/Velpatasvir in Adolescents and Children with Chronic HCV Infection - IT",
        "timestamp": "2017-01-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-000881-10/LT",
        "title": "International, multicenter, randomised, open-labeled, 2-arm - Phase III Study comparing Imatinib (STI571, Glivec®) Standard Dose (400 mg/day) with Imatinib High Dose Induction (800 mg/day) followed... - LT",
        "timestamp": "2005-03-08"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-000417-18/GB",
        "title": "A phase III, randomised, mulicentre dose escalation, efficacy and safety study examining the effects of treatment with peginterferon alfa-2a in patients with Child's A or B cirrhosis in chronic hep... - GB",
        "timestamp": "2008-05-10"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-001030-29/SE",
        "title": "A Phase III, Double-blind, Lot-to-Lot Consistency Clinical Trial to Evaluate the Safety, Tolerability and Immunogenicity of V212 in Healthy Adults - SE",
        "timestamp": "2014-05-27"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-001030-29/results",
        "title": "A Phase III, Double-blind, Lot-to-Lot Consistency Clinical Trial to Evaluate the Safety, Tolerability and Immunogenicity of V212 in Healthy Adults - View results",
        "timestamp": "2014-05-27"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-002138-13/GB",
        "title": "A placebo controlled, parallel group, randomised withdrawal study of subjects with symptoms of spasticity due to multiple sclerosis who are receiving long-term GW-1000-02 (Sativex®). - GB",
        "timestamp": "2007-09-13"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-002138-13/results",
        "title": "A placebo controlled, parallel group, randomised withdrawal study of subjects with symptoms of spasticity due to multiple sclerosis who are receiving long-term GW-1000-02 (Sativex®). - View results",
        "timestamp": "2007-09-13"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-004761-26/IT",
        "title": "PILOT MULTICENTER OPEN STUDY TO EVALUATE EFFICACY AND TOLERABILITY OF PEG-INTERFERON ALFA-2A IN PATIENTS WITH ANTI-HBE POSITIVE CHRONIC HEPATITIS B WHO PRESENT RESIDUAL VIREMIA OR VIROLOGICAL REBOU... - IT",
        "timestamp": "2009-03-26"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-004268-31/DK",
        "title": "Adalimumab (Humira) in the treatment of chronic pouchitis - DK",
        "timestamp": "2011-12-13"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-004613-24/NL",
        "title": "Hit hard and early. The effect of high dose methylprednisolon on nailfold capillary changes and biomarkers in early SSc: a 12-week randomized double-blind placebo-controlled trial. - NL",
        "timestamp": "2016-05-30"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005636-26/NL",
        "title": "Effect of Telaprevir in triple therapy for chronic hepatitis C patients on Intrahepatic immunological Mechanisms - NL",
        "timestamp": "2012-04-13"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-002641-11/GB",
        "title": "A Phase 3B Randomized, Open-Label, Multi-Center Trial Assessing Sofosbuvir + Ribavirin for 16 or 24 Weeks and Sofosbuvir + Pegylated Interferon + Ribavirin for 12 Weeks in Subjects with Genotype 2 ... - GB",
        "timestamp": "2013-10-07"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-002641-11/results",
        "title": "A Phase 3B Randomized, Open-Label, Multi-Center Trial Assessing Sofosbuvir + Ribavirin for 16 or 24 Weeks and Sofosbuvir + Pegylated Interferon + Ribavirin for 12 Weeks in Subjects with Genotype 2 ... - View results",
        "timestamp": "2013-10-07"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-003403-19/SE",
        "title": "Study of T- and B-cell immunity after vaccination with a virosomebased influenza vaccine (Inflexal V) in patients who have undergone hematopoietic allogeneic stem cell transplantation. - SE",
        "timestamp": "2013-09-25"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-002159-89/NL",
        "title": "Brimonidine Tartrate for the Treatment of Injection Related Erythema Associated with Sub-cutaneous Administration of Peginterferon beta-1a - NL",
        "timestamp": "2015-11-05"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-006323-39/DE",
        "title": "Sunphenon (Epigallocatechin-Gallate) in relapsing-remitting multiple sclerosis - DE",
        "timestamp": "2007-06-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-000149-72/ES",
        "title": "A Phase II Randomized, Placebo-Controlled Study to Evaluate the Safety and Efficacy of MK-7009 Administered Concomitantly With Pegylated-Interferon and Ribavirin for 28 Days in Treatment-Naïve Pati... - ES",
        "timestamp": "2008-08-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-000149-72/FR",
        "title": "A Phase II Randomized, Placebo-Controlled Study to Evaluate the Safety and Efficacy of MK-7009 Administered Concomitantly With Pegylated-Interferon and Ribavirin for 28 Days in Treatment-Naïve Pati... - FR",
        "timestamp": "2008-08-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-000149-72/DE",
        "title": "A Phase II Randomized, Placebo-Controlled Study to Evaluate the Safety and Efficacy of MK-7009 Administered Concomitantly With Pegylated-Interferon and Ribavirin for 28 Days in Treatment-Naïve Pati... - DE",
        "timestamp": "2008-08-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-000149-72/AT",
        "title": "A Phase II Randomized, Placebo-Controlled Study to Evaluate the Safety and Efficacy of MK-7009 Administered Concomitantly With Pegylated-Interferon and Ribavirin for 28 Days in Treatment-Naïve Pati... - AT",
        "timestamp": "2008-08-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-000149-72/DK",
        "title": "A Phase II Randomized, Placebo-Controlled Study to Evaluate the Safety and Efficacy of MK-7009 Administered Concomitantly With Pegylated-Interferon and Ribavirin for 28 Days in Treatment-Naïve Pati... - DK",
        "timestamp": "2008-08-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-000149-72/CZ",
        "title": "A Phase II Randomized, Placebo-Controlled Study to Evaluate the Safety and Efficacy of MK-7009 Administered Concomitantly With Pegylated-Interferon and Ribavirin for 28 Days in Treatment-Naïve Pati... - CZ",
        "timestamp": "2008-08-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-000149-72/results",
        "title": "A Phase II Randomized, Placebo-Controlled Study to Evaluate the Safety and Efficacy of MK-7009 Administered Concomitantly With Pegylated-Interferon and Ribavirin for 28 Days in Treatment-Naïve Pati... - View results",
        "timestamp": "2008-08-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-002504-15/FI",
        "title": "A RANDOMIZED PHASE II STUDY COMPARING IMATINIB AND THE COMBINATION OF IMATINIB AND PEGYLATED INTERFERON ALPHA-2B IN NEWLY DIAGNOSED NON-HIGH RISK CHRONIC MYELOID LEUKEMIA PATIENTS IN COMPLETE HEMAT... - FI",
        "timestamp": "2004-12-01"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020664-38/GR",
        "title": "Efficacy and safety of Bevacizumab/Temsirolimus combination after first-line Bevacizumab/IFN combination in advanced renal cell carcinoma - GR",
        "timestamp": "2010-09-28"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-019057-17/NL",
        "title": "A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Ascending Multiple-Dose Study to Assess Safety, Tolerability, Pharmacokinetics and Antiviral Activity of SPC3649 (miravirsen) Administered ... - NL",
        "timestamp": "2010-07-13"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-019057-17/DE",
        "title": "A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Ascending Multiple-Dose Study to Assess Safety, Tolerability, Pharmacokinetics and Antiviral Activity of SPC3649 (miravirsen) Administered ... - DE",
        "timestamp": "2010-07-13"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-019057-17/SK",
        "title": "A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Ascending Multiple-Dose Study to Assess Safety, Tolerability, Pharmacokinetics and Antiviral Activity of SPC3649 (miravirsen) Administered ... - SK",
        "timestamp": "2010-07-13"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-019057-17/PL",
        "title": "A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Ascending Multiple-Dose Study to Assess Safety, Tolerability, Pharmacokinetics and Antiviral Activity of SPC3649 (miravirsen) Administered ... - PL",
        "timestamp": "2010-07-13"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-005871-92/SE",
        "title": "En fas 1 studie av effekt av Tysabri (natalizumab), en IgG4 humaniserad monoklonal antikropp specifik mot VLA-4 (integrin alfa-4), administrerad som infusion  1 gång/månad under 3 månader hos patie... - SE",
        "timestamp": "2009-02-05"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-005849-19/GB",
        "title": "Finite duration treatment in pre-cirrhotic chronic hepatitis B virus (HBV) infection: Phase IV study of Lamivudine priming of Pegasys treatment in HBeAg positive patients - GB",
        "timestamp": "2006-07-06"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-001397-92/GB",
        "title": "An extension to a phase II study to determine the efficacy and safety of STI571 in patients with chronic myeloid leukemia who are refractory to or intolerant of interferon-alpha - GB",
        "timestamp": None
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-001397-92/results",
        "title": "An extension to a phase II study to determine the efficacy and safety of STI571 in patients with chronic myeloid leukemia who are refractory to or intolerant of interferon-alpha - View results",
        "timestamp": None
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-007649-30/DE",
        "title": "SELECT-2: Phase 2B, Partially Blinded, Randomized Study In Treatment Naïve Subjects With HCV Genotype 1 To Compare The Efficacy, Safety, And Tolerability Of Three Doses of Locteron™ Plus Ribavirin ... - DE",
        "timestamp": "2009-06-25"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-007649-30/BG",
        "title": "SELECT-2: Phase 2B, Partially Blinded, Randomized Study In Treatment Naïve Subjects With HCV Genotype 1 To Compare The Efficacy, Safety, And Tolerability Of Three Doses of Locteron™ Plus Ribavirin ... - BG",
        "timestamp": "2009-06-25"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-007649-30/FR",
        "title": "SELECT-2: Phase 2B, Partially Blinded, Randomized Study In Treatment Naïve Subjects With HCV Genotype 1 To Compare The Efficacy, Safety, And Tolerability Of Three Doses of Locteron™ Plus Ribavirin ... - FR",
        "timestamp": "2009-06-25"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-000955-90/IT",
        "title": "Randomized, single-blind, clinical and MRI study  for evaluation of safety and efficacy of N-Acetyl Cysteine (NAC) associated with high-dose beta-Interferon in Relapsing-Remitting (RR) multiple scl... - IT",
        "timestamp": "2007-04-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-002991-42/NL",
        "title": "Effect of ASV and DCV therapy on the quality of immune status in chronic HCV patients\r\n\r\nInvestigator initiated research proposal nr. AI447-108 - NL",
        "timestamp": "2013-12-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-003704-35/GB",
        "title": "A Randomized, Double-Blind Evaluation of the Antiviral Efficacy, Safety, and Tolerability of Tenofovir Disoproxil Fumarate Versus Placebo in Adolescents with Chronic Hepatitis B Infection - GB",
        "timestamp": "2008-12-11"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-003704-35/BE",
        "title": "A Randomized, Double-Blind Evaluation of the Antiviral Efficacy, Safety, and Tolerability of Tenofovir Disoproxil Fumarate Versus Placebo in Adolescents with Chronic Hepatitis B Infection - BE",
        "timestamp": "2008-12-11"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-003704-35/FR",
        "title": "A Randomized, Double-Blind Evaluation of the Antiviral Efficacy, Safety, and Tolerability of Tenofovir Disoproxil Fumarate Versus Placebo in Adolescents with Chronic Hepatitis B Infection - FR",
        "timestamp": "2008-12-11"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-003704-35/ES",
        "title": "A Randomized, Double-Blind Evaluation of the Antiviral Efficacy, Safety, and Tolerability of Tenofovir Disoproxil Fumarate Versus Placebo in Adolescents with Chronic Hepatitis B Infection - ES",
        "timestamp": "2008-12-11"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-003704-35/BG",
        "title": "A Randomized, Double-Blind Evaluation of the Antiviral Efficacy, Safety, and Tolerability of Tenofovir Disoproxil Fumarate Versus Placebo in Adolescents with Chronic Hepatitis B Infection - BG",
        "timestamp": "2008-12-11"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-003704-35/DE",
        "title": "A Randomized, Double-Blind Evaluation of the Antiviral Efficacy, Safety, and Tolerability of Tenofovir Disoproxil Fumarate Versus Placebo in Adolescents with Chronic Hepatitis B Infection - DE",
        "timestamp": "2008-12-11"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-003704-35/GR",
        "title": "A Randomized, Double-Blind Evaluation of the Antiviral Efficacy, Safety, and Tolerability of Tenofovir Disoproxil Fumarate Versus Placebo in Adolescents with Chronic Hepatitis B Infection - GR",
        "timestamp": "2008-12-11"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-003704-35/3rd",
        "title": "A Randomized, Double-Blind Evaluation of the Antiviral Efficacy, Safety, and Tolerability of Tenofovir Disoproxil Fumarate Versus Placebo in Adolescents with Chronic Hepatitis B Infection - Outside EU/EEA",
        "timestamp": "2008-12-11"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-003704-35/results",
        "title": "A Randomized, Double-Blind Evaluation of the Antiviral Efficacy, Safety, and Tolerability of Tenofovir Disoproxil Fumarate Versus Placebo in Adolescents with Chronic Hepatitis B Infection - View results",
        "timestamp": "2008-12-11"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-004761-42/ES",
        "title": "First line treatment with Rituximab asociated to CVP plus Interferon in Follicular Lymphoma. Phase II study.\nAsociación de Rituximab al esquema CVP + Interferón en el tratamiento de primera línea d... - ES",
        "timestamp": "2006-02-06"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-003749-42/ES",
        "title": "ESTUDIO DE LOS CAMBIOS EN EL RECUENTO DE LINFOCITOS CD4 TRAS LA SUSTITUCIÓN DE TENOFOVIR POR ABACAVIR EN PACIENTES CON UNA PAUTA HAART QUE INCLUYA DDI + TENOFOVIR Y CON SUPRESIÓN VIRAL - ES",
        "timestamp": "2005-02-01"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-014724-32/DE",
        "title": "SAFETY, TOLERABILITY AND MECHANISM OF ACTION OF BOSWELLIC ACIDS (BA) IN MULTIPLE SCLEROSIS (MS) AND CLINICALLY ISOLATED SYNDROME (CIS):\nA MRI-CONTROLLED, MULTICENTER, BASELINE-TO-TREATMENT, 32-WEEK... - DE",
        "timestamp": None
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-005262-35/BE",
        "title": "BENEFIT 11 a long-term, follow-up study (16401) of the BENEFIT (304747), BENEFIT Follow-up (305207) Studies and BENEFIT Extension (311129) Study to further evaluate the progress of patients with fi... - BE",
        "timestamp": "2013-07-08"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-005262-35/SE",
        "title": "BENEFIT 11 a long-term, follow-up study (16401) of the BENEFIT (304747), BENEFIT Follow-up (305207) Studies and BENEFIT Extension (311129) Study to further evaluate the progress of patients with fi... - SE",
        "timestamp": "2013-07-08"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-005262-35/PT",
        "title": "BENEFIT 11 a long-term, follow-up study (16401) of the BENEFIT (304747), BENEFIT Follow-up (305207) Studies and BENEFIT Extension (311129) Study to further evaluate the progress of patients with fi... - PT",
        "timestamp": "2013-07-08"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-005262-35/HU",
        "title": "BENEFIT 11 a long-term, follow-up study (16401) of the BENEFIT (304747), BENEFIT Follow-up (305207) Studies and BENEFIT Extension (311129) Study to further evaluate the progress of patients with fi... - HU",
        "timestamp": "2013-07-08"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-005262-35/CZ",
        "title": "BENEFIT 11 a long-term, follow-up study (16401) of the BENEFIT (304747), BENEFIT Follow-up (305207) Studies and BENEFIT Extension (311129) Study to further evaluate the progress of patients with fi... - CZ",
        "timestamp": "2013-07-08"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-005262-35/NO",
        "title": "BENEFIT 11 a long-term, follow-up study (16401) of the BENEFIT (304747), BENEFIT Follow-up (305207) Studies and BENEFIT Extension (311129) Study to further evaluate the progress of patients with fi... - NO",
        "timestamp": "2013-07-08"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-005262-35/AT",
        "title": "BENEFIT 11 a long-term, follow-up study (16401) of the BENEFIT (304747), BENEFIT Follow-up (305207) Studies and BENEFIT Extension (311129) Study to further evaluate the progress of patients with fi... - AT",
        "timestamp": "2013-07-08"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-005262-35/FI",
        "title": "BENEFIT 11 a long-term, follow-up study (16401) of the BENEFIT (304747), BENEFIT Follow-up (305207) Studies and BENEFIT Extension (311129) Study to further evaluate the progress of patients with fi... - FI",
        "timestamp": "2013-07-08"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-005262-35/DK",
        "title": "BENEFIT 11 a long-term, follow-up study (16401) of the BENEFIT (304747), BENEFIT Follow-up (305207) Studies and BENEFIT Extension (311129) Study to further evaluate the progress of patients with fi... - DK",
        "timestamp": "2013-07-08"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-005262-35/GB",
        "title": "BENEFIT 11 a long-term, follow-up study (16401) of the BENEFIT (304747), BENEFIT Follow-up (305207) Studies and BENEFIT Extension (311129) Study to further evaluate the progress of patients with fi... - GB",
        "timestamp": "2013-07-08"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-005262-35/ES",
        "title": "BENEFIT 11 a long-term, follow-up study (16401) of the BENEFIT (304747), BENEFIT Follow-up (305207) Studies and BENEFIT Extension (311129) Study to further evaluate the progress of patients with fi... - ES",
        "timestamp": "2013-07-08"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-005262-35/IT",
        "title": "BENEFIT 11 a long-term, follow-up study (16401) of the BENEFIT (304747), BENEFIT Follow-up (305207) Studies and BENEFIT Extension (311129) Study to further evaluate the progress of patients with fi... - IT",
        "timestamp": "2013-07-08"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-005262-35/SI",
        "title": "BENEFIT 11 a long-term, follow-up study (16401) of the BENEFIT (304747), BENEFIT Follow-up (305207) Studies and BENEFIT Extension (311129) Study to further evaluate the progress of patients with fi... - SI",
        "timestamp": "2013-07-08"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-005262-35/PL",
        "title": "BENEFIT 11 a long-term, follow-up study (16401) of the BENEFIT (304747), BENEFIT Follow-up (305207) Studies and BENEFIT Extension (311129) Study to further evaluate the progress of patients with fi... - PL",
        "timestamp": "2013-07-08"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-005262-35/results",
        "title": "BENEFIT 11 a long-term, follow-up study (16401) of the BENEFIT (304747), BENEFIT Follow-up (305207) Studies and BENEFIT Extension (311129) Study to further evaluate the progress of patients with fi... - View results",
        "timestamp": "2013-07-08"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-005260-15/DE",
        "title": "A Phase III Double-blind, Randomised, Parallel Group Comparison of the Efficacy and Safety of FP-1201-lyo (Recombinant Human Interferon Beta-1a) and Placebo in the Treatment of Patients with Modera... - DE",
        "timestamp": "2016-02-10"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-005260-15/FI",
        "title": "A Phase III Double-blind, Randomised, Parallel Group Comparison of the Efficacy and Safety of FP-1201-lyo (Recombinant Human Interferon Beta-1a) and Placebo in the Treatment of Patients with Modera... - FI",
        "timestamp": "2016-02-10"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-005260-15/BE",
        "title": "A Phase III Double-blind, Randomised, Parallel Group Comparison of the Efficacy and Safety of FP-1201-lyo (Recombinant Human Interferon Beta-1a) and Placebo in the Treatment of Patients with Modera... - BE",
        "timestamp": "2016-02-10"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-005260-15/ES",
        "title": "A Phase III Double-blind, Randomised, Parallel Group Comparison of the Efficacy and Safety of FP-1201-lyo (Recombinant Human Interferon Beta-1a) and Placebo in the Treatment of Patients with Modera... - ES",
        "timestamp": "2016-02-10"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-005260-15/CZ",
        "title": "A Phase III Double-blind, Randomised, Parallel Group Comparison of the Efficacy and Safety of FP-1201-lyo (Recombinant Human Interferon Beta-1a) and Placebo in the Treatment of Patients with Modera... - CZ",
        "timestamp": "2016-02-10"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-005260-15/results",
        "title": "A Phase III Double-blind, Randomised, Parallel Group Comparison of the Efficacy and Safety of FP-1201-lyo (Recombinant Human Interferon Beta-1a) and Placebo in the Treatment of Patients with Modera... - View results",
        "timestamp": "2016-02-10"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-004003-18/GB",
        "title": "A randomized, open-label, controlled, mutli-center two-year study comparing efficacy and safety of telbivudine 600mg PO in combination with peg alpha-2a 180 µg with peg alpha-2a montherapy, and wit... - GB",
        "timestamp": "2006-11-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-004003-18/FR",
        "title": "A randomized, open-label, controlled, mutli-center two-year study comparing efficacy and safety of telbivudine 600mg PO in combination with peg alpha-2a 180 µg with peg alpha-2a montherapy, and wit... - FR",
        "timestamp": "2006-11-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-004003-18/IT",
        "title": "A randomized, open-label, controlled, mutli-center two-year study comparing efficacy and safety of telbivudine 600mg PO in combination with peg alpha-2a 180 µg with peg alpha-2a montherapy, and wit... - IT",
        "timestamp": "2006-11-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-004003-18/DE",
        "title": "A randomized, open-label, controlled, mutli-center two-year study comparing efficacy and safety of telbivudine 600mg PO in combination with peg alpha-2a 180 µg with peg alpha-2a montherapy, and wit... - DE",
        "timestamp": "2006-11-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-004003-18/BE",
        "title": "A randomized, open-label, controlled, mutli-center two-year study comparing efficacy and safety of telbivudine 600mg PO in combination with peg alpha-2a 180 µg with peg alpha-2a montherapy, and wit... - BE",
        "timestamp": "2006-11-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-004003-18/NL",
        "title": "A randomized, open-label, controlled, mutli-center two-year study comparing efficacy and safety of telbivudine 600mg PO in combination with peg alpha-2a 180 µg with peg alpha-2a montherapy, and wit... - NL",
        "timestamp": "2006-11-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-004003-18/results",
        "title": "A randomized, open-label, controlled, mutli-center two-year study comparing efficacy and safety of telbivudine 600mg PO in combination with peg alpha-2a 180 µg with peg alpha-2a montherapy, and wit... - View results",
        "timestamp": "2006-11-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-000242-20/FI",
        "title": "A randomised trial of the European and American Osteosarcoma Study group to optimize treatment strategies for resectable osteosarcoma based on histological response to pre-operative chemotherapy - FI",
        "timestamp": "2005-04-05"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-000242-20/NO",
        "title": "A randomised trial of the European and American Osteosarcoma Study group to optimize treatment strategies for resectable osteosarcoma based on histological response to pre-operative chemotherapy - NO",
        "timestamp": "2005-04-05"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-000242-20/BE",
        "title": "A randomised trial of the European and American Osteosarcoma Study group to optimize treatment strategies for resectable osteosarcoma based on histological response to pre-operative chemotherapy - BE",
        "timestamp": "2005-04-05"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-000242-20/IE",
        "title": "A randomised trial of the European and American Osteosarcoma Study group to optimize treatment strategies for resectable osteosarcoma based on histological response to pre-operative chemotherapy - IE",
        "timestamp": "2005-04-05"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-000242-20/AT",
        "title": "A randomised trial of the European and American Osteosarcoma Study group to optimize treatment strategies for resectable osteosarcoma based on histological response to pre-operative chemotherapy - AT",
        "timestamp": "2005-04-05"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-000242-20/CZ",
        "title": "A randomised trial of the European and American Osteosarcoma Study group to optimize treatment strategies for resectable osteosarcoma based on histological response to pre-operative chemotherapy - CZ",
        "timestamp": "2005-04-05"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-000242-20/GB",
        "title": "A randomised trial of the European and American Osteosarcoma Study group to optimize treatment strategies for resectable osteosarcoma based on histological response to pre-operative chemotherapy - GB",
        "timestamp": "2005-04-05"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-007162-32/IT",
        "title": "ADVANCED MRI STUDY ON INFLAMMATORY AND DEGENRATIVE DAMAGE IN MULTIPLE SCLEROSIS - IT",
        "timestamp": "2007-10-30"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-001566-21/DK",
        "title": "Effect of Low-dose Interferon-alfa2a on post-operative immune suppression - a randomized trial - DK",
        "timestamp": "2018-01-29"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-017480-42/GB",
        "title": "A randomised, double-blind, placebo-controlled Phase II study, comparing the efficacy and safety of inhaled SNG001 to placebo administered to asthmatic subjects after the onset of a respiratory vir... - GB",
        "timestamp": "2010-03-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-014732-38/ES",
        "title": "Ensayo clínico fase IV.II para el análisis de los factores moleculares de pronóstico de respuesta y beneficio clínico en pacientes con cáncer renal metastásico o avanzado, tratados con bevacizumab ... - ES",
        "timestamp": "2010-03-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-005344-25/NL",
        "title": "High-dose versus standard-dose weight-based ribavirin in combination with peginterferon alfa-2a for patients infected with hepatitis C virus genotype 1 or 4 - NL",
        "timestamp": "2008-03-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-003484-30/ES",
        "title": "A multi-centre, open-label, non-randomised, parallel group clinical trial to assess the efficacy of fingolimod in naïve patients versus fingolimod in patients previously treated with interferons or... - ES",
        "timestamp": "2011-10-26"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-003484-30/results",
        "title": "A multi-centre, open-label, non-randomised, parallel group clinical trial to assess the efficacy of fingolimod in naïve patients versus fingolimod in patients previously treated with interferons or... - View results",
        "timestamp": "2011-10-26"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-002845-46/GB",
        "title": "A Phase 2a, Open-Label Study to Evaluate the Safety, Pharmacokinetics and Efficacy of the Combination of AL-335 and Odalasvir, with or without Simeprevir, in Treatment-Naïve Subjects with Genotype ... - GB",
        "timestamp": "2017-02-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-002845-46/results",
        "title": "A Phase 2a, Open-Label Study to Evaluate the Safety, Pharmacokinetics and Efficacy of the Combination of AL-335 and Odalasvir, with or without Simeprevir, in Treatment-Naïve Subjects with Genotype ... - View results",
        "timestamp": "2017-02-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-012500-11/IE",
        "title": "Multicenter, Double-blind, Randomized, Parallel-group, Monotherapy, Active-control Study to Determine the Efficacy and Safety of Daclizumab High Yield Process (DAC HYP) versus Avonex® (Interferon β... - IE",
        "timestamp": "2010-04-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-012500-11/FR",
        "title": "Multicenter, Double-blind, Randomized, Parallel-group, Monotherapy, Active-control Study to Determine the Efficacy and Safety of Daclizumab High Yield Process (DAC HYP) versus Avonex® (Interferon β... - FR",
        "timestamp": "2010-04-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-012500-11/DE",
        "title": "Multicenter, Double-blind, Randomized, Parallel-group, Monotherapy, Active-control Study to Determine the Efficacy and Safety of Daclizumab High Yield Process (DAC HYP) versus Avonex® (Interferon β... - DE",
        "timestamp": "2010-04-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-012500-11/CZ",
        "title": "Multicenter, Double-blind, Randomized, Parallel-group, Monotherapy, Active-control Study to Determine the Efficacy and Safety of Daclizumab High Yield Process (DAC HYP) versus Avonex® (Interferon β... - CZ",
        "timestamp": "2010-04-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-012500-11/HU",
        "title": "Multicenter, Double-blind, Randomized, Parallel-group, Monotherapy, Active-control Study to Determine the Efficacy and Safety of Daclizumab High Yield Process (DAC HYP) versus Avonex® (Interferon β... - HU",
        "timestamp": "2010-04-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-012500-11/FI",
        "title": "Multicenter, Double-blind, Randomized, Parallel-group, Monotherapy, Active-control Study to Determine the Efficacy and Safety of Daclizumab High Yield Process (DAC HYP) versus Avonex® (Interferon β... - FI",
        "timestamp": "2010-04-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-012500-11/SE",
        "title": "Multicenter, Double-blind, Randomized, Parallel-group, Monotherapy, Active-control Study to Determine the Efficacy and Safety of Daclizumab High Yield Process (DAC HYP) versus Avonex® (Interferon β... - SE",
        "timestamp": "2010-04-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-012500-11/ES",
        "title": "Multicenter, Double-blind, Randomized, Parallel-group, Monotherapy, Active-control Study to Determine the Efficacy and Safety of Daclizumab High Yield Process (DAC HYP) versus Avonex® (Interferon β... - ES",
        "timestamp": "2010-04-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-012500-11/GB",
        "title": "Multicenter, Double-blind, Randomized, Parallel-group, Monotherapy, Active-control Study to Determine the Efficacy and Safety of Daclizumab High Yield Process (DAC HYP) versus Avonex® (Interferon β... - GB",
        "timestamp": "2010-04-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-012500-11/GR",
        "title": "Multicenter, Double-blind, Randomized, Parallel-group, Monotherapy, Active-control Study to Determine the Efficacy and Safety of Daclizumab High Yield Process (DAC HYP) versus Avonex® (Interferon β... - GR",
        "timestamp": "2010-04-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-012500-11/IT",
        "title": "Multicenter, Double-blind, Randomized, Parallel-group, Monotherapy, Active-control Study to Determine the Efficacy and Safety of Daclizumab High Yield Process (DAC HYP) versus Avonex® (Interferon β... - IT",
        "timestamp": "2010-04-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-012500-11/DK",
        "title": "Multicenter, Double-blind, Randomized, Parallel-group, Monotherapy, Active-control Study to Determine the Efficacy and Safety of Daclizumab High Yield Process (DAC HYP) versus Avonex® (Interferon β... - DK",
        "timestamp": "2010-04-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-012500-11/SI",
        "title": "Multicenter, Double-blind, Randomized, Parallel-group, Monotherapy, Active-control Study to Determine the Efficacy and Safety of Daclizumab High Yield Process (DAC HYP) versus Avonex® (Interferon β... - SI",
        "timestamp": "2010-04-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-012500-11/results",
        "title": "Multicenter, Double-blind, Randomized, Parallel-group, Monotherapy, Active-control Study to Determine the Efficacy and Safety of Daclizumab High Yield Process (DAC HYP) versus Avonex® (Interferon β... - View results",
        "timestamp": "2010-04-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-023560-40/SE",
        "title": "Haematopoetic Stem Cell Therapy for Patients with Inflammatory Multiple Sclerosis Failing Alternate Approved Therapy: A Randomized Study - SE",
        "timestamp": "2011-03-23"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-002275-40/SE",
        "title": "Prospective study of patients treated with pegylated interferon-alpha 2b (PegIntron) for metastasizing ileal/coecal carcinoids - SE",
        "timestamp": "2007-01-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-002275-40/DK",
        "title": "Prospective study of patients treated with pegylated interferon-alpha 2b (PegIntron) for metastasizing ileal/coecal carcinoids - DK",
        "timestamp": "2007-01-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-002911-27/IT",
        "title": "Effect of boceprevir therapy on HCV-specific T cell responses: perspectives of immune monitoring and immune therapy - IT",
        "timestamp": "2011-09-30"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-000928-71/IT",
        "title": "TWIST. RANDOMIZED PROSPECTIVE PHASE II STUDY OF TEMSIROLIMUS WITH OR WITHOUT LOW-DOSE INTERFERON ALPHA IN METASTATIC NON-CLEAR RENAL CELL CARCINOMA: GOIRC STUDY 02/2008 - IT",
        "timestamp": "2008-11-14"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-001026-89/DE",
        "title": "Phase IV, multicenter, open label, randomized study of Rebif® 44 mcg administered three times per week by subcutaneous injection compared with no treatment in the therapy of relapsing multiple scle... - DE",
        "timestamp": "2005-07-14"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-001026-89/results",
        "title": "Phase IV, multicenter, open label, randomized study of Rebif® 44 mcg administered three times per week by subcutaneous injection compared with no treatment in the therapy of relapsing multiple scle... - View results",
        "timestamp": "2005-07-14"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-000728-97/NL",
        "title": "Regulation of the stress-axis by vitamin D3 in subjects with multiple sclerosis; a double-blinded, randomized, placebo-controlled study - NL",
        "timestamp": None
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-003147-19/GR",
        "title": "Novel Oral Nutraceutical Intervention NEUROASPIS PLP10® for the Treatment of Relapsing-Remitting Multiple Sclerosis: A Multicenter, Parallel-group, Phase III, Double-blind, Randomized, Placebo-Cont... - GR",
        "timestamp": "2016-07-18"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-018768-18/AT",
        "title": "An open-label, prospective, multicentre, phase I/II dose escalation study to determine the maximum tolerated dose and to assess the safety and efficacy of P1101, PEG-Proline-Interferon alpha-2b for... - AT",
        "timestamp": "2010-07-02"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-018768-18/results",
        "title": "An open-label, prospective, multicentre, phase I/II dose escalation study to determine the maximum tolerated dose and to assess the safety and efficacy of P1101, PEG-Proline-Interferon alpha-2b for... - View results",
        "timestamp": "2010-07-02"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-001840-23/3rd",
        "title": "An exploratory study of the biologic effects of Nivolumab and Ipilimumab Monotherapy and Nivolumab in Combination with Ipilimumab Treatment in Subjects with Advanced melanoma (Unresectable or metas... - Outside EU/EEA",
        "timestamp": "2019-07-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-006239-11/NL",
        "title": "Augmenting response to entecavir using a temporary peginterferon alpha-2a add-on strategy for the treatment of HBeAg-positive chronic hepatitis B (ARES study) - NL",
        "timestamp": "2009-05-15"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-024017-31/IT",
        "title": "A 6-month, Randomized, Active Comparator, Open-label, Multi-Center Study to Evaluate Patient OutComes, Safety and Tolerability of Fingolimod (FTY720) 0.5 mg/day in Patients with Relapsing Remitting... - IT",
        "timestamp": "2011-03-15"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-024017-31/results",
        "title": "A 6-month, Randomized, Active Comparator, Open-label, Multi-Center Study to Evaluate Patient OutComes, Safety and Tolerability of Fingolimod (FTY720) 0.5 mg/day in Patients with Relapsing Remitting... - View results",
        "timestamp": "2011-03-15"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-003192-22/BE",
        "title": "A Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Glecaprevir (GLE)/Pibrentasvir (PIB) in Adults with Chronic Hepatitis C Virus (HCV) Genotype 5 or 6 Infection. - BE",
        "timestamp": "2017-03-08"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-003192-22/results",
        "title": "A Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Glecaprevir (GLE)/Pibrentasvir (PIB) in Adults with Chronic Hepatitis C Virus (HCV) Genotype 5 or 6 Infection. - View results",
        "timestamp": "2017-03-08"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-002874-30/GB",
        "title": "AN OPEN LABEL RANDOMISED PHASE II STUDY COMPARING AZD2014 VERSUS EVEROLIMUS IN PATIENTS WITH ADVANCED METASTATIC RENAL CANCER AND PROGRESSION ON VEGF TARGETED THERAPY - GB",
        "timestamp": "2012-12-10"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-002874-30/results",
        "title": "AN OPEN LABEL RANDOMISED PHASE II STUDY COMPARING AZD2014 VERSUS EVEROLIMUS IN PATIENTS WITH ADVANCED METASTATIC RENAL CANCER AND PROGRESSION ON VEGF TARGETED THERAPY - View results",
        "timestamp": "2012-12-10"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-009503-19/BE",
        "title": "A prospective, open label, non-randomised, clinical trial to determine if natalizumab (Tysabri) improves ambulatory measures in relapsing remitting multiple sclerosis (RRMS) patients. - BE",
        "timestamp": "2010-07-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-009503-19/results",
        "title": "A prospective, open label, non-randomised, clinical trial to determine if natalizumab (Tysabri) improves ambulatory measures in relapsing remitting multiple sclerosis (RRMS) patients. - View results",
        "timestamp": "2010-07-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020435-40/BE",
        "title": "Phase I/II study of peptide vaccination associated with tumoral immunomodulation with proinflammatory cytokines and imiquimod in patients with advanced metastatic melanoma - BE",
        "timestamp": "2010-06-23"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-003924-34/ES",
        "title": "A phase II trial to assess the activity and safety of Palbociclib in patients with well- and moderately-differentiated metastatic pancreatic neuroendocrine tumors (pNET). - ES",
        "timestamp": "2015-02-13"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-004613-93/3rd",
        "title": "Open label study to evaluate the effect, safety and tolerability of 250µg (8 MIU) interferon beta 1b (Betaferon) given subcutaneously every other day (for 24 weeks) in patients of Chinese origin wi... - Outside EU/EEA",
        "timestamp": "2015-01-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-004613-93/results",
        "title": "Open label study to evaluate the effect, safety and tolerability of 250µg (8 MIU) interferon beta 1b (Betaferon) given subcutaneously every other day (for 24 weeks) in patients of Chinese origin wi... - View results",
        "timestamp": "2015-01-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-003894-41/IT",
        "title": "Effect of a Peg-interferon alfa 2A pulse on HBV-specific T cell responses in chronic hepatitis HBeAg negative patients under long-term nucleos(t)ide treatment - IT",
        "timestamp": "2014-11-21"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-005500-14/DE",
        "title": "A Randomized, Open-label, Multicenter, Efficacy and Safety Study Examining the Effects on Viral Kinetics of All-trans Retinoic Acid  (Tretinoin) (VESANOID®)in Combination with PEG-IFN alfa 2a (PEGA... - DE",
        "timestamp": "2007-09-05"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-004501-24/GB",
        "title": "Phase II study to evaluate the safety, tolerability and efficacy of CT-011 administered intravenously to patients with metastatic\r\nmelanoma - GB",
        "timestamp": "2012-03-06"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-018523-26/IT",
        "title": "Immediate versus delayed treatment with Entecavir in patients with active chronic hepatitis B (CHB): impact on liver fibrosis. - IT",
        "timestamp": "2010-03-17"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-022092-65/DE",
        "title": "A phase IIa, randomized, double-blind (subject and investigator blind, sponsor open) placebo-controlled trial to evaluate the safety, tolerability and antiviral activity of oral ACH-0141625 in comb... - DE",
        "timestamp": "2011-10-13"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-022092-65/BE",
        "title": "A phase IIa, randomized, double-blind (subject and investigator blind, sponsor open) placebo-controlled trial to evaluate the safety, tolerability and antiviral activity of oral ACH-0141625 in comb... - BE",
        "timestamp": "2011-10-13"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-022092-65/results",
        "title": "A phase IIa, randomized, double-blind (subject and investigator blind, sponsor open) placebo-controlled trial to evaluate the safety, tolerability and antiviral activity of oral ACH-0141625 in comb... - View results",
        "timestamp": "2011-10-13"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-003299-36/IT",
        "title": "A Randomized, Partially Double-Blind, Active-Controlled, Dose-Ranging  Estimation Study to Evaluate the Safety, Tolerability, and Efficacy of  Different Regimens of MK-5172 When Administered Concom... - IT",
        "timestamp": "2011-11-09"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-003299-36/results",
        "title": "A Randomized, Partially Double-Blind, Active-Controlled, Dose-Ranging  Estimation Study to Evaluate the Safety, Tolerability, and Efficacy of  Different Regimens of MK-5172 When Administered Concom... - View results",
        "timestamp": "2011-11-09"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-003114-10/DE",
        "title": "An Open-label, Single Arm, Multicenter Study to Broaden Access to Emapalumab, an Anti-Interferon Gamma (Anti-IFNγ) Monoclonal Antibody, and to Assess its Efficacy, Safety, Impact on Quality of Life... - DE",
        "timestamp": "2018-09-06"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-003114-10/ES",
        "title": "An Open-label, Single Arm, Multicenter Study to Broaden Access to Emapalumab, an Anti-Interferon Gamma (Anti-IFNγ) Monoclonal Antibody, and to Assess its Efficacy, Safety, Impact on Quality of Life... - ES",
        "timestamp": "2018-09-06"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-003114-10/GB",
        "title": "An Open-label, Single Arm, Multicenter Study to Broaden Access to Emapalumab, an Anti-Interferon Gamma (Anti-IFNγ) Monoclonal Antibody, and to Assess its Efficacy, Safety, Impact on Quality of Life... - GB",
        "timestamp": "2018-09-06"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-003114-10/IT",
        "title": "An Open-label, Single Arm, Multicenter Study to Broaden Access to Emapalumab, an Anti-Interferon Gamma (Anti-IFNγ) Monoclonal Antibody, and to Assess its Efficacy, Safety, Impact on Quality of Life... - IT",
        "timestamp": "2018-09-06"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-001382-33/IT",
        "title": "An extension to a phase II study to determine the efficacy and the safety of STI571 in patients with chronic myeloid leukemia who are refractory to or intolerant of interferon-alpha - IT",
        "timestamp": "2005-04-15"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-001382-33/results",
        "title": "An extension to a phase II study to determine the efficacy and the safety of STI571 in patients with chronic myeloid leukemia who are refractory to or intolerant of interferon-alpha - View results",
        "timestamp": "2005-04-15"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-003169-82/GB",
        "title": "A Phase III, Open Label, Randomized, Parallel Group Study to Evaluate the Efficacy and Safety of Intrapleural Administration of Adenovirus-Delivered Interferon Alpha-2b (rAd-IFN) in Combination wit... - GB",
        "timestamp": "2019-01-30"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-003169-82/DE",
        "title": "A Phase III, Open Label, Randomized, Parallel Group Study to Evaluate the Efficacy and Safety of Intrapleural Administration of Adenovirus-Delivered Interferon Alpha-2b (rAd-IFN) in Combination wit... - DE",
        "timestamp": "2019-01-30"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-003169-82/FR",
        "title": "A Phase III, Open Label, Randomized, Parallel Group Study to Evaluate the Efficacy and Safety of Intrapleural Administration of Adenovirus-Delivered Interferon Alpha-2b (rAd-IFN) in Combination wit... - FR",
        "timestamp": "2019-01-30"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-003169-82/PL",
        "title": "A Phase III, Open Label, Randomized, Parallel Group Study to Evaluate the Efficacy and Safety of Intrapleural Administration of Adenovirus-Delivered Interferon Alpha-2b (rAd-IFN) in Combination wit... - PL",
        "timestamp": "2019-01-30"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-005086-12/AT",
        "title": "Active-controlled phase IIIb study to investigate the ability of the HAP score to predict responders to Octagam 5% in patients with early relapsing multiple sclerosis. - AT",
        "timestamp": "2013-07-05"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-005086-12/HU",
        "title": "Active-controlled phase IIIb study to investigate the ability of the HAP score to predict responders to Octagam 5% in patients with early relapsing multiple sclerosis. - HU",
        "timestamp": "2013-07-05"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-005086-12/DE",
        "title": "Active-controlled phase IIIb study to investigate the ability of the HAP score to predict responders to Octagam 5% in patients with early relapsing multiple sclerosis. - DE",
        "timestamp": "2013-07-05"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-005086-12/BG",
        "title": "Active-controlled phase IIIb study to investigate the ability of the HAP score to predict responders to Octagam 5% in patients with early relapsing multiple sclerosis. - BG",
        "timestamp": "2013-07-05"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-005086-12/PL",
        "title": "Active-controlled phase IIIb study to investigate the ability of the HAP score to predict responders to Octagam 5% in patients with early relapsing multiple sclerosis. - PL",
        "timestamp": "2013-07-05"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-005086-12/results",
        "title": "Active-controlled phase IIIb study to investigate the ability of the HAP score to predict responders to Octagam 5% in patients with early relapsing multiple sclerosis. - View results",
        "timestamp": "2013-07-05"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003535-27/BE",
        "title": "A phase III randomised, partially double-blind and placebo-controlled study of  BI 207127 in combination with faldaprevir and ribavirin for chronic genotype 1 hepatitis C infection in an extended p... - BE",
        "timestamp": "2012-10-17"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003535-27/DE",
        "title": "A phase III randomised, partially double-blind and placebo-controlled study of  BI 207127 in combination with faldaprevir and ribavirin for chronic genotype 1 hepatitis C infection in an extended p... - DE",
        "timestamp": "2012-10-17"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003535-27/PT",
        "title": "A phase III randomised, partially double-blind and placebo-controlled study of  BI 207127 in combination with faldaprevir and ribavirin for chronic genotype 1 hepatitis C infection in an extended p... - PT",
        "timestamp": "2012-10-17"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003535-27/GB",
        "title": "A phase III randomised, partially double-blind and placebo-controlled study of  BI 207127 in combination with faldaprevir and ribavirin for chronic genotype 1 hepatitis C infection in an extended p... - GB",
        "timestamp": "2012-10-17"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003535-27/ES",
        "title": "A phase III randomised, partially double-blind and placebo-controlled study of  BI 207127 in combination with faldaprevir and ribavirin for chronic genotype 1 hepatitis C infection in an extended p... - ES",
        "timestamp": "2012-10-17"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003535-27/GR",
        "title": "A phase III randomised, partially double-blind and placebo-controlled study of  BI 207127 in combination with faldaprevir and ribavirin for chronic genotype 1 hepatitis C infection in an extended p... - GR",
        "timestamp": "2012-10-17"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003535-27/IT",
        "title": "A phase III randomised, partially double-blind and placebo-controlled study of  BI 207127 in combination with faldaprevir and ribavirin for chronic genotype 1 hepatitis C infection in an extended p... - IT",
        "timestamp": "2012-10-17"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003535-27/results",
        "title": "A phase III randomised, partially double-blind and placebo-controlled study of  BI 207127 in combination with faldaprevir and ribavirin for chronic genotype 1 hepatitis C infection in an extended p... - View results",
        "timestamp": "2012-10-17"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-001718-15/IT",
        "title": "An open-label, multicenter protocol providing pegylated interferon alfa 2-a  PEGASYS as monotherapy or in combination with ribavirin  COPEGUS  for patients with chronic hepatitis C who have parteci... - IT",
        "timestamp": "2004-12-27"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-001718-15/DE",
        "title": "An open-label, multicenter protocol providing pegylated interferon alfa 2-a  PEGASYS as monotherapy or in combination with ribavirin  COPEGUS  for patients with chronic hepatitis C who have parteci... - DE",
        "timestamp": "2004-12-27"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-001718-15/AT",
        "title": "An open-label, multicenter protocol providing pegylated interferon alfa 2-a  PEGASYS as monotherapy or in combination with ribavirin  COPEGUS  for patients with chronic hepatitis C who have parteci... - AT",
        "timestamp": "2004-12-27"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-002715-28/GB",
        "title": "A PHASE II, RANDOMIZED, DOUBLE-BLIND, MULTICENTER, PARALLEL\r\nGROUP STUDY TO EVALUATE THE SUSTAINED VIROLOGIC RESPONSE\r\nOF THE HCV POLYMERASE INHIBITOR PRODRUG RO5024048 IN\r\nCOMBINATION WITH TELAPRE... - GB",
        "timestamp": "2011-12-09"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-002715-28/DE",
        "title": "A PHASE II, RANDOMIZED, DOUBLE-BLIND, MULTICENTER, PARALLEL\r\nGROUP STUDY TO EVALUATE THE SUSTAINED VIROLOGIC RESPONSE\r\nOF THE HCV POLYMERASE INHIBITOR PRODRUG RO5024048 IN\r\nCOMBINATION WITH TELAPRE... - DE",
        "timestamp": "2011-12-09"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-002715-28/ES",
        "title": "A PHASE II, RANDOMIZED, DOUBLE-BLIND, MULTICENTER, PARALLEL\r\nGROUP STUDY TO EVALUATE THE SUSTAINED VIROLOGIC RESPONSE\r\nOF THE HCV POLYMERASE INHIBITOR PRODRUG RO5024048 IN\r\nCOMBINATION WITH TELAPRE... - ES",
        "timestamp": "2011-12-09"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-002715-28/IT",
        "title": "A PHASE II, RANDOMIZED, DOUBLE-BLIND, MULTICENTER, PARALLEL\r\nGROUP STUDY TO EVALUATE THE SUSTAINED VIROLOGIC RESPONSE\r\nOF THE HCV POLYMERASE INHIBITOR PRODRUG RO5024048 IN\r\nCOMBINATION WITH TELAPRE... - IT",
        "timestamp": "2011-12-09"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-002715-28/results",
        "title": "A PHASE II, RANDOMIZED, DOUBLE-BLIND, MULTICENTER, PARALLEL\r\nGROUP STUDY TO EVALUATE THE SUSTAINED VIROLOGIC RESPONSE\r\nOF THE HCV POLYMERASE INHIBITOR PRODRUG RO5024048 IN\r\nCOMBINATION WITH TELAPRE... - View results",
        "timestamp": "2011-12-09"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-003067-30/DE",
        "title": "A Phase 3, Open Label Study of Safety and Efficacy with BMS-790052 plus Peg-Interferon Alfa 2a and Ribavirin in Previously Untreated HCV Patients Coinfected with Human Immunodeficiency Virus (HIV) ... - DE",
        "timestamp": "2012-01-11"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-003067-30/ES",
        "title": "A Phase 3, Open Label Study of Safety and Efficacy with BMS-790052 plus Peg-Interferon Alfa 2a and Ribavirin in Previously Untreated HCV Patients Coinfected with Human Immunodeficiency Virus (HIV) ... - ES",
        "timestamp": "2012-01-11"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-003067-30/GB",
        "title": "A Phase 3, Open Label Study of Safety and Efficacy with BMS-790052 plus Peg-Interferon Alfa 2a and Ribavirin in Previously Untreated HCV Patients Coinfected with Human Immunodeficiency Virus (HIV) ... - GB",
        "timestamp": "2012-01-11"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-003067-30/BE",
        "title": "A Phase 3, Open Label Study of Safety and Efficacy with BMS-790052 plus Peg-Interferon Alfa 2a and Ribavirin in Previously Untreated HCV Patients Coinfected with Human Immunodeficiency Virus (HIV) ... - BE",
        "timestamp": "2012-01-11"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-003067-30/IT",
        "title": "A Phase 3, Open Label Study of Safety and Efficacy with BMS-790052 plus Peg-Interferon Alfa 2a and Ribavirin in Previously Untreated HCV Patients Coinfected with Human Immunodeficiency Virus (HIV) ... - IT",
        "timestamp": "2012-01-11"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-003067-30/results",
        "title": "A Phase 3, Open Label Study of Safety and Efficacy with BMS-790052 plus Peg-Interferon Alfa 2a and Ribavirin in Previously Untreated HCV Patients Coinfected with Human Immunodeficiency Virus (HIV) ... - View results",
        "timestamp": "2012-01-11"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-018295-24/SE",
        "title": "A Phase 2b Study of BMS-790052 in Combination with Peg-Interferon\r\nAlfa-2a and Ribavirin in Treatment Naive Subjects with Chronic Hepatitis\r\nC Genotype 1 and 4 Infection\r\n\r\nRevised Protocol Number ... - SE",
        "timestamp": "2010-07-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-018295-24/DE",
        "title": "A Phase 2b Study of BMS-790052 in Combination with Peg-Interferon\r\nAlfa-2a and Ribavirin in Treatment Naive Subjects with Chronic Hepatitis\r\nC Genotype 1 and 4 Infection\r\n\r\nRevised Protocol Number ... - DE",
        "timestamp": "2010-07-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-018295-24/FR",
        "title": "A Phase 2b Study of BMS-790052 in Combination with Peg-Interferon\r\nAlfa-2a and Ribavirin in Treatment Naive Subjects with Chronic Hepatitis\r\nC Genotype 1 and 4 Infection\r\n\r\nRevised Protocol Number ... - FR",
        "timestamp": "2010-07-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-018295-24/IT",
        "title": "A Phase 2b Study of BMS-790052 in Combination with Peg-Interferon\r\nAlfa-2a and Ribavirin in Treatment Naive Subjects with Chronic Hepatitis\r\nC Genotype 1 and 4 Infection\r\n\r\nRevised Protocol Number ... - IT",
        "timestamp": "2010-07-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-018295-24/DK",
        "title": "A Phase 2b Study of BMS-790052 in Combination with Peg-Interferon\r\nAlfa-2a and Ribavirin in Treatment Naive Subjects with Chronic Hepatitis\r\nC Genotype 1 and 4 Infection\r\n\r\nRevised Protocol Number ... - DK",
        "timestamp": "2010-07-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-018295-24/results",
        "title": "A Phase 2b Study of BMS-790052 in Combination with Peg-Interferon\r\nAlfa-2a and Ribavirin in Treatment Naive Subjects with Chronic Hepatitis\r\nC Genotype 1 and 4 Infection\r\n\r\nRevised Protocol Number ... - View results",
        "timestamp": "2010-07-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-002714-40/IT",
        "title": "A PHASE 2/3, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED (PART A) AND DOUBLE-BLIND, DOUBLE-DUMMY, ACTIVE CONTROLLED (PART B), PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY... - IT",
        "timestamp": "2013-05-09"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-002714-40/BE",
        "title": "A PHASE 2/3, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED (PART A) AND DOUBLE-BLIND, DOUBLE-DUMMY, ACTIVE CONTROLLED (PART B), PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY... - BE",
        "timestamp": "2013-05-09"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-002714-40/ES",
        "title": "A PHASE 2/3, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED (PART A) AND DOUBLE-BLIND, DOUBLE-DUMMY, ACTIVE CONTROLLED (PART B), PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY... - ES",
        "timestamp": "2013-05-09"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-002714-40/HU",
        "title": "A PHASE 2/3, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED (PART A) AND DOUBLE-BLIND, DOUBLE-DUMMY, ACTIVE CONTROLLED (PART B), PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY... - HU",
        "timestamp": "2013-05-09"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-002714-40/BG",
        "title": "A PHASE 2/3, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED (PART A) AND DOUBLE-BLIND, DOUBLE-DUMMY, ACTIVE CONTROLLED (PART B), PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY... - BG",
        "timestamp": "2013-05-09"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-002714-40/GR",
        "title": "A PHASE 2/3, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED (PART A) AND DOUBLE-BLIND, DOUBLE-DUMMY, ACTIVE CONTROLLED (PART B), PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY... - GR",
        "timestamp": "2013-05-09"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-002714-40/GB",
        "title": "A PHASE 2/3, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED (PART A) AND DOUBLE-BLIND, DOUBLE-DUMMY, ACTIVE CONTROLLED (PART B), PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY... - GB",
        "timestamp": "2013-05-09"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-002714-40/SK",
        "title": "A PHASE 2/3, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED (PART A) AND DOUBLE-BLIND, DOUBLE-DUMMY, ACTIVE CONTROLLED (PART B), PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY... - SK",
        "timestamp": "2013-05-09"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-002714-40/HR",
        "title": "A PHASE 2/3, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED (PART A) AND DOUBLE-BLIND, DOUBLE-DUMMY, ACTIVE CONTROLLED (PART B), PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY... - HR",
        "timestamp": "2013-05-09"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-002714-40/results",
        "title": "A PHASE 2/3, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED (PART A) AND DOUBLE-BLIND, DOUBLE-DUMMY, ACTIVE CONTROLLED (PART B), PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY... - View results",
        "timestamp": "2013-05-09"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003533-41/DE",
        "title": "A Phase III, Randomised, Partially Double-Blind and Placebo-Controlled Study of BI 207127 in Combination with Faldaprevir and Ribavirin in Treatment-Naïve Patients with Chronic Genotype 1 HCV Infec... - DE",
        "timestamp": "2012-12-04"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003533-41/PT",
        "title": "A Phase III, Randomised, Partially Double-Blind and Placebo-Controlled Study of BI 207127 in Combination with Faldaprevir and Ribavirin in Treatment-Naïve Patients with Chronic Genotype 1 HCV Infec... - PT",
        "timestamp": "2012-12-04"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003533-41/GB",
        "title": "A Phase III, Randomised, Partially Double-Blind and Placebo-Controlled Study of BI 207127 in Combination with Faldaprevir and Ribavirin in Treatment-Naïve Patients with Chronic Genotype 1 HCV Infec... - GB",
        "timestamp": "2012-12-04"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003533-41/ES",
        "title": "A Phase III, Randomised, Partially Double-Blind and Placebo-Controlled Study of BI 207127 in Combination with Faldaprevir and Ribavirin in Treatment-Naïve Patients with Chronic Genotype 1 HCV Infec... - ES",
        "timestamp": "2012-12-04"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003533-41/IE",
        "title": "A Phase III, Randomised, Partially Double-Blind and Placebo-Controlled Study of BI 207127 in Combination with Faldaprevir and Ribavirin in Treatment-Naïve Patients with Chronic Genotype 1 HCV Infec... - IE",
        "timestamp": "2012-12-04"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003533-41/IT",
        "title": "A Phase III, Randomised, Partially Double-Blind and Placebo-Controlled Study of BI 207127 in Combination with Faldaprevir and Ribavirin in Treatment-Naïve Patients with Chronic Genotype 1 HCV Infec... - IT",
        "timestamp": "2012-12-04"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003533-41/NL",
        "title": "A Phase III, Randomised, Partially Double-Blind and Placebo-Controlled Study of BI 207127 in Combination with Faldaprevir and Ribavirin in Treatment-Naïve Patients with Chronic Genotype 1 HCV Infec... - NL",
        "timestamp": "2012-12-04"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003533-41/HU",
        "title": "A Phase III, Randomised, Partially Double-Blind and Placebo-Controlled Study of BI 207127 in Combination with Faldaprevir and Ribavirin in Treatment-Naïve Patients with Chronic Genotype 1 HCV Infec... - HU",
        "timestamp": "2012-12-04"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003533-41/AT",
        "title": "A Phase III, Randomised, Partially Double-Blind and Placebo-Controlled Study of BI 207127 in Combination with Faldaprevir and Ribavirin in Treatment-Naïve Patients with Chronic Genotype 1 HCV Infec... - AT",
        "timestamp": "2012-12-04"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003533-41/results",
        "title": "A Phase III, Randomised, Partially Double-Blind and Placebo-Controlled Study of BI 207127 in Combination with Faldaprevir and Ribavirin in Treatment-Naïve Patients with Chronic Genotype 1 HCV Infec... - View results",
        "timestamp": "2012-12-04"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-000759-18/DE",
        "title": "A Randomized, Active-Controlled Dose-Ranging Estimation Study to Evaluate the Safety, Tolerability, and Efficacy of Different Regimens of MK-5172 When Administered Concomitantly with Peginterferon ... - DE",
        "timestamp": "2011-07-13"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-000759-18/BE",
        "title": "A Randomized, Active-Controlled Dose-Ranging Estimation Study to Evaluate the Safety, Tolerability, and Efficacy of Different Regimens of MK-5172 When Administered Concomitantly with Peginterferon ... - BE",
        "timestamp": "2011-07-13"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-000759-18/IT",
        "title": "A Randomized, Active-Controlled Dose-Ranging Estimation Study to Evaluate the Safety, Tolerability, and Efficacy of Different Regimens of MK-5172 When Administered Concomitantly with Peginterferon ... - IT",
        "timestamp": "2011-07-13"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-000759-18/results",
        "title": "A Randomized, Active-Controlled Dose-Ranging Estimation Study to Evaluate the Safety, Tolerability, and Efficacy of Different Regimens of MK-5172 When Administered Concomitantly with Peginterferon ... - View results",
        "timestamp": "2011-07-13"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-002982-38/BE",
        "title": "A phase III, randomized, double-blind, placebo-controlled, multicenter clinical trial of Rebif New Formulation (44 mcg tiw and 44 mcg ow) in subjects at high risk of converting to Multiple Sclerosis - BE",
        "timestamp": "2006-11-29"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-002982-38/CZ",
        "title": "A phase III, randomized, double-blind, placebo-controlled, multicenter clinical trial of Rebif New Formulation (44 mcg tiw and 44 mcg ow) in subjects at high risk of converting to Multiple Sclerosis - CZ",
        "timestamp": "2006-11-29"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-002982-38/AT",
        "title": "A phase III, randomized, double-blind, placebo-controlled, multicenter clinical trial of Rebif New Formulation (44 mcg tiw and 44 mcg ow) in subjects at high risk of converting to Multiple Sclerosis - AT",
        "timestamp": "2006-11-29"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-002982-38/LT",
        "title": "A phase III, randomized, double-blind, placebo-controlled, multicenter clinical trial of Rebif New Formulation (44 mcg tiw and 44 mcg ow) in subjects at high risk of converting to Multiple Sclerosis - LT",
        "timestamp": "2006-11-29"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-002982-38/SK",
        "title": "A phase III, randomized, double-blind, placebo-controlled, multicenter clinical trial of Rebif New Formulation (44 mcg tiw and 44 mcg ow) in subjects at high risk of converting to Multiple Sclerosis - SK",
        "timestamp": "2006-11-29"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-002982-38/DE",
        "title": "A phase III, randomized, double-blind, placebo-controlled, multicenter clinical trial of Rebif New Formulation (44 mcg tiw and 44 mcg ow) in subjects at high risk of converting to Multiple Sclerosis - DE",
        "timestamp": "2006-11-29"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-002982-38/FI",
        "title": "A phase III, randomized, double-blind, placebo-controlled, multicenter clinical trial of Rebif New Formulation (44 mcg tiw and 44 mcg ow) in subjects at high risk of converting to Multiple Sclerosis - FI",
        "timestamp": "2006-11-29"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-002982-38/FR",
        "title": "A phase III, randomized, double-blind, placebo-controlled, multicenter clinical trial of Rebif New Formulation (44 mcg tiw and 44 mcg ow) in subjects at high risk of converting to Multiple Sclerosis - FR",
        "timestamp": "2006-11-29"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-002982-38/EE",
        "title": "A phase III, randomized, double-blind, placebo-controlled, multicenter clinical trial of Rebif New Formulation (44 mcg tiw and 44 mcg ow) in subjects at high risk of converting to Multiple Sclerosis - EE",
        "timestamp": "2006-11-29"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-002982-38/DK",
        "title": "A phase III, randomized, double-blind, placebo-controlled, multicenter clinical trial of Rebif New Formulation (44 mcg tiw and 44 mcg ow) in subjects at high risk of converting to Multiple Sclerosis - DK",
        "timestamp": "2006-11-29"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-002982-38/IT",
        "title": "A phase III, randomized, double-blind, placebo-controlled, multicenter clinical trial of Rebif New Formulation (44 mcg tiw and 44 mcg ow) in subjects at high risk of converting to Multiple Sclerosis - IT",
        "timestamp": "2006-11-29"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-002982-38/GR",
        "title": "A phase III, randomized, double-blind, placebo-controlled, multicenter clinical trial of Rebif New Formulation (44 mcg tiw and 44 mcg ow) in subjects at high risk of converting to Multiple Sclerosis - GR",
        "timestamp": "2006-11-29"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-002982-38/PT",
        "title": "A phase III, randomized, double-blind, placebo-controlled, multicenter clinical trial of Rebif New Formulation (44 mcg tiw and 44 mcg ow) in subjects at high risk of converting to Multiple Sclerosis - PT",
        "timestamp": "2006-11-29"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-002982-38/ES",
        "title": "A phase III, randomized, double-blind, placebo-controlled, multicenter clinical trial of Rebif New Formulation (44 mcg tiw and 44 mcg ow) in subjects at high risk of converting to Multiple Sclerosis - ES",
        "timestamp": "2006-11-29"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-002982-38/results",
        "title": "A phase III, randomized, double-blind, placebo-controlled, multicenter clinical trial of Rebif New Formulation (44 mcg tiw and 44 mcg ow) in subjects at high risk of converting to Multiple Sclerosis - View results",
        "timestamp": "2006-11-29"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-002714-37/DE",
        "title": "A PHASE II, RANDOMIZED, DOUBLE-BLIND, MULTICENTER, PARALLEL GROUP STUDY TO EVALUATE THE SUSTAINED VIROLOGIC RESPONSE OF THE HCV POLYMERASE INHIBITOR PRODRUG RO5024048 IN COMBINATION WITH BOCEPREVIR... - DE",
        "timestamp": "2011-11-07"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-002714-37/ES",
        "title": "A PHASE II, RANDOMIZED, DOUBLE-BLIND, MULTICENTER, PARALLEL GROUP STUDY TO EVALUATE THE SUSTAINED VIROLOGIC RESPONSE OF THE HCV POLYMERASE INHIBITOR PRODRUG RO5024048 IN COMBINATION WITH BOCEPREVIR... - ES",
        "timestamp": "2011-11-07"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-002714-37/IT",
        "title": "A PHASE II, RANDOMIZED, DOUBLE-BLIND, MULTICENTER, PARALLEL GROUP STUDY TO EVALUATE THE SUSTAINED VIROLOGIC RESPONSE OF THE HCV POLYMERASE INHIBITOR PRODRUG RO5024048 IN COMBINATION WITH BOCEPREVIR... - IT",
        "timestamp": "2011-11-07"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-002714-37/results",
        "title": "A PHASE II, RANDOMIZED, DOUBLE-BLIND, MULTICENTER, PARALLEL GROUP STUDY TO EVALUATE THE SUSTAINED VIROLOGIC RESPONSE OF THE HCV POLYMERASE INHIBITOR PRODRUG RO5024048 IN COMBINATION WITH BOCEPREVIR... - View results",
        "timestamp": "2011-11-07"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005409-65/ES",
        "title": "A Phase 3 Evaluation of Daclatasvir in Combination with Peginterferon Lambda-1a and Ribavirin (RBV) or Telaprevir in Combination with Peginterferon Alfa-2a and RBV in Patients with Chronic Hepatiti... - ES",
        "timestamp": "2013-01-18"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005409-65/IT",
        "title": "A Phase 3 Evaluation of Daclatasvir in Combination with Peginterferon Lambda-1a and Ribavirin (RBV) or Telaprevir in Combination with Peginterferon Alfa-2a and RBV in Patients with Chronic Hepatiti... - IT",
        "timestamp": "2013-01-18"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005409-65/DE",
        "title": "A Phase 3 Evaluation of Daclatasvir in Combination with Peginterferon Lambda-1a and Ribavirin (RBV) or Telaprevir in Combination with Peginterferon Alfa-2a and RBV in Patients with Chronic Hepatiti... - DE",
        "timestamp": "2013-01-18"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005409-65/PL",
        "title": "A Phase 3 Evaluation of Daclatasvir in Combination with Peginterferon Lambda-1a and Ribavirin (RBV) or Telaprevir in Combination with Peginterferon Alfa-2a and RBV in Patients with Chronic Hepatiti... - PL",
        "timestamp": "2013-01-18"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005409-65/GB",
        "title": "A Phase 3 Evaluation of Daclatasvir in Combination with Peginterferon Lambda-1a and Ribavirin (RBV) or Telaprevir in Combination with Peginterferon Alfa-2a and RBV in Patients with Chronic Hepatiti... - GB",
        "timestamp": "2013-01-18"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005409-65/results",
        "title": "A Phase 3 Evaluation of Daclatasvir in Combination with Peginterferon Lambda-1a and Ribavirin (RBV) or Telaprevir in Combination with Peginterferon Alfa-2a and RBV in Patients with Chronic Hepatiti... - View results",
        "timestamp": "2013-01-18"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-017003-28/IT",
        "title": "Relationship between IL-6 and TNF-α polymorphism and flu-like syndrome development in multiple sclerosis patients treated with Interferon-beta 1a i.m.  Open label multicentre study - IT",
        "timestamp": "2010-04-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-017003-28/results",
        "title": "Relationship between IL-6 and TNF-α polymorphism and flu-like syndrome development in multiple sclerosis patients treated with Interferon-beta 1a i.m.  Open label multicentre study - View results",
        "timestamp": "2010-04-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-003876-39/BE",
        "title": "A Randomized, Open-label, Multi-center, Phase 3, 2-arm Study Evaluating the Efficacy and Safety of Peg interferon Alfa-2b Low-dose Maintenance Monotherapy Versus Standard Supportive Care in Patient... - BE",
        "timestamp": "2006-09-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-003876-39/results",
        "title": "A Randomized, Open-label, Multi-center, Phase 3, 2-arm Study Evaluating the Efficacy and Safety of Peg interferon Alfa-2b Low-dose Maintenance Monotherapy Versus Standard Supportive Care in Patient... - View results",
        "timestamp": "2006-09-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-005370-49/EE",
        "title": "Baltic Post-marketing Program of PEGASYS® (Peg interferon alpha-2a 40KD) in Patients with HBeAg-positive Chronic Hepatitis B - EE",
        "timestamp": "2006-12-13"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-005370-49/LT",
        "title": "Baltic Post-marketing Program of PEGASYS® (Peg interferon alpha-2a 40KD) in Patients with HBeAg-positive Chronic Hepatitis B - LT",
        "timestamp": "2006-12-13"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-005370-49/LV",
        "title": "Baltic Post-marketing Program of PEGASYS® (Peg interferon alpha-2a 40KD) in Patients with HBeAg-positive Chronic Hepatitis B - LV",
        "timestamp": "2006-12-13"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-005370-49/results",
        "title": "Baltic Post-marketing Program of PEGASYS® (Peg interferon alpha-2a 40KD) in Patients with HBeAg-positive Chronic Hepatitis B - View results",
        "timestamp": "2006-12-13"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003632-23/GB",
        "title": "A Phase 2/3, Open-label, Single Arm, Multicentre Study to Assess Safety, Tolerability, Pharmacokinetics and Efficacy of Intravenous Multiple Administrations of NI-0501, an Anti-interferon Gamma (An... - GB",
        "timestamp": "2016-02-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003632-23/IT",
        "title": "A Phase 2/3, Open-label, Single Arm, Multicentre Study to Assess Safety, Tolerability, Pharmacokinetics and Efficacy of Intravenous Multiple Administrations of NI-0501, an Anti-interferon Gamma (An... - IT",
        "timestamp": "2016-02-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003632-23/AT",
        "title": "A Phase 2/3, Open-label, Single Arm, Multicentre Study to Assess Safety, Tolerability, Pharmacokinetics and Efficacy of Intravenous Multiple Administrations of NI-0501, an Anti-interferon Gamma (An... - AT",
        "timestamp": "2016-02-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003632-23/CZ",
        "title": "A Phase 2/3, Open-label, Single Arm, Multicentre Study to Assess Safety, Tolerability, Pharmacokinetics and Efficacy of Intravenous Multiple Administrations of NI-0501, an Anti-interferon Gamma (An... - CZ",
        "timestamp": "2016-02-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003632-23/DE",
        "title": "A Phase 2/3, Open-label, Single Arm, Multicentre Study to Assess Safety, Tolerability, Pharmacokinetics and Efficacy of Intravenous Multiple Administrations of NI-0501, an Anti-interferon Gamma (An... - DE",
        "timestamp": "2016-02-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003632-23/ES",
        "title": "A Phase 2/3, Open-label, Single Arm, Multicentre Study to Assess Safety, Tolerability, Pharmacokinetics and Efficacy of Intravenous Multiple Administrations of NI-0501, an Anti-interferon Gamma (An... - ES",
        "timestamp": "2016-02-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003632-23/SE",
        "title": "A Phase 2/3, Open-label, Single Arm, Multicentre Study to Assess Safety, Tolerability, Pharmacokinetics and Efficacy of Intravenous Multiple Administrations of NI-0501, an Anti-interferon Gamma (An... - SE",
        "timestamp": "2016-02-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-004724-35/DE",
        "title": "Open-Label, Phase 3b Study To Determine Efficacy and Safety of Telaprevir, Pegylated-Interferon-alfa-2a and Ribavirin in Hepatitis C Genotype 1 Infected, Stable Liver Transplant Subjects - DE",
        "timestamp": None
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-004724-35/ES",
        "title": "Open-Label, Phase 3b Study To Determine Efficacy and Safety of Telaprevir, Pegylated-Interferon-alfa-2a and Ribavirin in Hepatitis C Genotype 1 Infected, Stable Liver Transplant Subjects - ES",
        "timestamp": None
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-004724-35/GB",
        "title": "Open-Label, Phase 3b Study To Determine Efficacy and Safety of Telaprevir, Pegylated-Interferon-alfa-2a and Ribavirin in Hepatitis C Genotype 1 Infected, Stable Liver Transplant Subjects - GB",
        "timestamp": None
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-004724-35/IT",
        "title": "Open-Label, Phase 3b Study To Determine Efficacy and Safety of Telaprevir, Pegylated-Interferon-alfa-2a and Ribavirin in Hepatitis C Genotype 1 Infected, Stable Liver Transplant Subjects - IT",
        "timestamp": None
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-004724-35/AT",
        "title": "Open-Label, Phase 3b Study To Determine Efficacy and Safety of Telaprevir, Pegylated-Interferon-alfa-2a and Ribavirin in Hepatitis C Genotype 1 Infected, Stable Liver Transplant Subjects - AT",
        "timestamp": None
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-004724-35/BE",
        "title": "Open-Label, Phase 3b Study To Determine Efficacy and Safety of Telaprevir, Pegylated-Interferon-alfa-2a and Ribavirin in Hepatitis C Genotype 1 Infected, Stable Liver Transplant Subjects - BE",
        "timestamp": None
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-004724-35/results",
        "title": "Open-Label, Phase 3b Study To Determine Efficacy and Safety of Telaprevir, Pegylated-Interferon-alfa-2a and Ribavirin in Hepatitis C Genotype 1 Infected, Stable Liver Transplant Subjects - View results",
        "timestamp": None
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-002732-70/GB",
        "title": "A Phase IIIb Parallel Group, Open Label Study of Pegylated Interferon alfa-2a Monotherapy (PEG-IFN, Ro 25-8310) Compared to Untreated Control in Children with HBeAg Positive Chronic Hepatitis B in ... - GB",
        "timestamp": "2012-02-09"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-002732-70/BE",
        "title": "A Phase IIIb Parallel Group, Open Label Study of Pegylated Interferon alfa-2a Monotherapy (PEG-IFN, Ro 25-8310) Compared to Untreated Control in Children with HBeAg Positive Chronic Hepatitis B in ... - BE",
        "timestamp": "2012-02-09"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-002732-70/DE",
        "title": "A Phase IIIb Parallel Group, Open Label Study of Pegylated Interferon alfa-2a Monotherapy (PEG-IFN, Ro 25-8310) Compared to Untreated Control in Children with HBeAg Positive Chronic Hepatitis B in ... - DE",
        "timestamp": "2012-02-09"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-002732-70/PL",
        "title": "A Phase IIIb Parallel Group, Open Label Study of Pegylated Interferon alfa-2a Monotherapy (PEG-IFN, Ro 25-8310) Compared to Untreated Control in Children with HBeAg Positive Chronic Hepatitis B in ... - PL",
        "timestamp": "2012-02-09"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-002732-70/IT",
        "title": "A Phase IIIb Parallel Group, Open Label Study of Pegylated Interferon alfa-2a Monotherapy (PEG-IFN, Ro 25-8310) Compared to Untreated Control in Children with HBeAg Positive Chronic Hepatitis B in ... - IT",
        "timestamp": "2012-02-09"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-002732-70/BG",
        "title": "A Phase IIIb Parallel Group, Open Label Study of Pegylated Interferon alfa-2a Monotherapy (PEG-IFN, Ro 25-8310) Compared to Untreated Control in Children with HBeAg Positive Chronic Hepatitis B in ... - BG",
        "timestamp": "2012-02-09"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-002732-70/results",
        "title": "A Phase IIIb Parallel Group, Open Label Study of Pegylated Interferon alfa-2a Monotherapy (PEG-IFN, Ro 25-8310) Compared to Untreated Control in Children with HBeAg Positive Chronic Hepatitis B in ... - View results",
        "timestamp": "2012-02-09"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-021715-17/GB",
        "title": "A phase III, randomised, double-blind and placebo controlled study of once daily BI 201335, 240 mg for 12 or 24 weeks in combination with pegylated interferon-α and ribavirin in patients with genot... - GB",
        "timestamp": "2011-07-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-021715-17/PT",
        "title": "A phase III, randomised, double-blind and placebo controlled study of once daily BI 201335, 240 mg for 12 or 24 weeks in combination with pegylated interferon-α and ribavirin in patients with genot... - PT",
        "timestamp": "2011-07-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-021715-17/BE",
        "title": "A phase III, randomised, double-blind and placebo controlled study of once daily BI 201335, 240 mg for 12 or 24 weeks in combination with pegylated interferon-α and ribavirin in patients with genot... - BE",
        "timestamp": "2011-07-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-021715-17/DE",
        "title": "A phase III, randomised, double-blind and placebo controlled study of once daily BI 201335, 240 mg for 12 or 24 weeks in combination with pegylated interferon-α and ribavirin in patients with genot... - DE",
        "timestamp": "2011-07-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-021715-17/AT",
        "title": "A phase III, randomised, double-blind and placebo controlled study of once daily BI 201335, 240 mg for 12 or 24 weeks in combination with pegylated interferon-α and ribavirin in patients with genot... - AT",
        "timestamp": "2011-07-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-021715-17/ES",
        "title": "A phase III, randomised, double-blind and placebo controlled study of once daily BI 201335, 240 mg for 12 or 24 weeks in combination with pegylated interferon-α and ribavirin in patients with genot... - ES",
        "timestamp": "2011-07-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-021715-17/results",
        "title": "A phase III, randomised, double-blind and placebo controlled study of once daily BI 201335, 240 mg for 12 or 24 weeks in combination with pegylated interferon-α and ribavirin in patients with genot... - View results",
        "timestamp": "2011-07-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-000602-23/PT",
        "title": "A randomized double blind, placebo controlled study to evaluate the efficacy and security of immunotherapy with a depigmented and polymerized allergen extract of Dermatophagoides pteronyssinus in p... - PT",
        "timestamp": "2007-09-17"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-007075-16/NL",
        "title": "The effect of peroxisome proliferator activator receptor γ agonist pre-treatment on pegylated interferon-α2a and ribavirin efficacy in hepatitis C patients, previously resistant to treatment with p... - NL",
        "timestamp": "2008-12-01"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020659-30/IT",
        "title": "COMBINED THERAPY WITH PEG-INTERFERON-α, RIBAVIRIN AND RITUXIMAB OF HEPATITIS C VIRUS-RELATED   MIXED CRYOGLOBULINEMIA - IT",
        "timestamp": "2009-10-26"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-018279-99/DE",
        "title": "Skin Topoproteome under Adalimumab (Humira®) Treatment\nin Patients with Moderate to Severe Psoriasis - DE",
        "timestamp": "2010-05-05"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-004511-21/GB",
        "title": "Upfront Sunitinib (SU011248)® therapy followed by surgery in patients with metastatic renal cancer: a pilot Phase II study [SuMR] - GB",
        "timestamp": "2007-08-01"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-004511-21/results",
        "title": "Upfront Sunitinib (SU011248)® therapy followed by surgery in patients with metastatic renal cancer: a pilot Phase II study [SuMR] - View results",
        "timestamp": "2007-08-01"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-000994-30/AT",
        "title": "A randomized, double‐blind, placebo controlled trial to evaluate the effects of vitamin D supplementation on metabolic and fertility parameters in PCOS women - AT",
        "timestamp": "2013-02-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-007100-42/FI",
        "title": "Viral Inception of Asthma: Prospective study from infancy to early school-age. - FI",
        "timestamp": "2007-01-29"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-004822-97/GB",
        "title": "A Phase I / II Trial to Evaluate the Combination of Infliximab and Sorafenib in the Treatment of Renal Cell Carcinoma - GB",
        "timestamp": "2007-01-09"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-004822-97/results",
        "title": "A Phase I / II Trial to Evaluate the Combination of Infliximab and Sorafenib in the Treatment of Renal Cell Carcinoma - View results",
        "timestamp": "2007-01-09"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-005332-83/IT",
        "title": "Combined therapy with Adefovir and Interferon-Pegylated alfa 2a vs Adefovir alone, in patients affected by chronic hepatitis B, HbeAg negative (The PAC (Peg Adefovir Combination) Study). - IT",
        "timestamp": "2007-03-22"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-005473-35/ES",
        "title": "PILOT STUDY TO ASSESS THE ROLE OF IMMUNE ACTIVATION AND APOPTOSIS AS A MARKER FOR TREATMENT INTENSIFICATION WITH RALTEGRAVIR IN HIV-INFECTED PATIENTS ON ANTIRETROVIRAL THERAPY WITH LONG-TERM VIRAL ... - ES",
        "timestamp": "2008-11-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-005473-35/results",
        "title": "PILOT STUDY TO ASSESS THE ROLE OF IMMUNE ACTIVATION AND APOPTOSIS AS A MARKER FOR TREATMENT INTENSIFICATION WITH RALTEGRAVIR IN HIV-INFECTED PATIENTS ON ANTIRETROVIRAL THERAPY WITH LONG-TERM VIRAL ... - View results",
        "timestamp": "2008-11-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-022248-19/SE",
        "title": "An open, phase II long term extension study to evaluate the immune responses to and safety of GSK Biologicals’ candidate herpes zoster vaccine, (gE/AS01B), at Months 48, 60 and 72 post-vaccination ... - SE",
        "timestamp": "2011-01-25"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-022248-19/DE",
        "title": "An open, phase II long term extension study to evaluate the immune responses to and safety of GSK Biologicals’ candidate herpes zoster vaccine, (gE/AS01B), at Months 48, 60 and 72 post-vaccination ... - DE",
        "timestamp": "2011-01-25"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-022248-19/NL",
        "title": "An open, phase II long term extension study to evaluate the immune responses to and safety of GSK Biologicals’ candidate herpes zoster vaccine, (gE/AS01B), at Months 48, 60 and 72 post-vaccination ... - NL",
        "timestamp": "2011-01-25"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-022248-19/CZ",
        "title": "An open, phase II long term extension study to evaluate the immune responses to and safety of GSK Biologicals’ candidate herpes zoster vaccine, (gE/AS01B), at Months 48, 60 and 72 post-vaccination ... - CZ",
        "timestamp": "2011-01-25"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-022248-19/results",
        "title": "An open, phase II long term extension study to evaluate the immune responses to and safety of GSK Biologicals’ candidate herpes zoster vaccine, (gE/AS01B), at Months 48, 60 and 72 post-vaccination ... - View results",
        "timestamp": "2011-01-25"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-002491-14/NL",
        "title": "The effects of interferon-gamma on sepsis-induced immunoparalysis, a randomised double-blind placebo-controlled pilot (Phase IIIb) study - NL",
        "timestamp": "2012-11-08"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-002808-25/NL",
        "title": "Immune phenotyping in chronic hepatitis C patients treated with Sofosbuvir and Daclatasvir combination with or without Ribavirin for 12 or 24 weeks -SODA study - NL",
        "timestamp": "2015-04-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-004786-80/DE",
        "title": "A phase IIa, randomized, placebo-controlled, double-blind, cross-over study to evaluate safety and efficacy of subcutanous administration of anakinra in patients with cystic fibrosis. - DE",
        "timestamp": None
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-000336-25/IT",
        "title": "Longitudinal analysis of HBV-specific T cell responses in patients with HBeAg-negative chronic hepatitis B (CHB) treated with pegylated interferon alfa-2a (40 KD) (PEGASYS, Ro 25-8310).      Immuno... - IT",
        "timestamp": "2005-04-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-000336-25/results",
        "title": "Longitudinal analysis of HBV-specific T cell responses in patients with HBeAg-negative chronic hepatitis B (CHB) treated with pegylated interferon alfa-2a (40 KD) (PEGASYS, Ro 25-8310).      Immuno... - View results",
        "timestamp": "2005-04-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-005996-17/IT",
        "title": "A pilot, open label, multicenter, randomized clinical trial on Lopinavir/ritonavir-monotherapy vs Lopinavir/ritonavir plus selected Nucs, in HIV/HCV ARV-naive coinfected patients with chronic hepat... - IT",
        "timestamp": "2007-02-02"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-018014-20/GB",
        "title": "A Randomised Phase II Study Evaluating Cediranib vs. Cediranib and Saracatanib in patients with relapsed metastatic clear cell renal cancer - GB",
        "timestamp": "2010-04-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-018014-20/results",
        "title": "A Randomised Phase II Study Evaluating Cediranib vs. Cediranib and Saracatanib in patients with relapsed metastatic clear cell renal cancer - View results",
        "timestamp": "2010-04-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-002010-37/NL",
        "title": "A Multi-center, Randomized, Open-label study for Induction of HBsAg decline using an add-on treatment of peginterferon alfa-2a in HBeAg-negative chronic hepatitis B patients treated with nucleos(t)... - NL",
        "timestamp": "2012-02-17"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-000328-85/FI",
        "title": "Randomized comparative trial between abrupt and tapered mode of discontinuation of longterm hormone therapy: Impact on endothelial function, recurrence of vasomotor symptoms and quality of life - FI",
        "timestamp": "2017-05-18"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-000334-12/DE",
        "title": "A RANDOMIZED, PLACEBO CONTROLLED, DOUBLE-BLIND, CROSS-OVER, MONOCENTER STUDY TO EVALUATE THE EFFECT OF A 7-DAY MONTELUKAST TREATMENT ON AIRWAY INFLAMMATION AND FUNCTION BY MEANS OF BRONCHOPROVOCATI... - DE",
        "timestamp": "2006-03-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-000334-12/results",
        "title": "A RANDOMIZED, PLACEBO CONTROLLED, DOUBLE-BLIND, CROSS-OVER, MONOCENTER STUDY TO EVALUATE THE EFFECT OF A 7-DAY MONTELUKAST TREATMENT ON AIRWAY INFLAMMATION AND FUNCTION BY MEANS OF BRONCHOPROVOCATI... - View results",
        "timestamp": "2006-03-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-006366-29/IT",
        "title": "IMMUNOTHERAPY OF MAINTENANCE IN THE PATIENTS WITH METASTATIC MELANOMA, CLINICAL BENEFIT AFTER CHEMOTHERAPY - IT",
        "timestamp": "2009-04-07"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-004848-45/AT",
        "title": "HCV/HIV Coinfection- STUDY: \nMULTICENTER STUDY TO EVALUATE THE EFFICACY OF 48 WEEKS  COMBINATION-THERAPY WITH PEGYLATED INTERFERON ALFA 2A (PEG-IFN ALFA 2A) AND DIFFERENT DOSES OF RIBAVIRIN IN PATI... - AT",
        "timestamp": "2005-03-02"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-002985-39/IT",
        "title": "A multicenter, randomized, controlled study comparing the efficacy and safety of 48 weeks of 40kD branched pegylated interferon alfa-2a (PEGASYS, Ro 25-8310) versus 96 weeks of PEGASYS, alone or in... - IT",
        "timestamp": "2004-12-13"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-002985-39/results",
        "title": "A multicenter, randomized, controlled study comparing the efficacy and safety of 48 weeks of 40kD branched pegylated interferon alfa-2a (PEGASYS, Ro 25-8310) versus 96 weeks of PEGASYS, alone or in... - View results",
        "timestamp": "2004-12-13"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-000834-36/NL",
        "title": "Simvastatin addition to improve symptoms, cognition and metabolic syndrome in patients with recent-onset schizophrenia. - NL",
        "timestamp": "2013-09-26"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-002541-37/BE",
        "title": "A Phase II, open label, mono-centric study to evaluate the kinetics of mRNA expression after two doses of GSK Biologicals’ candidate tuberculosis (TB) vaccine GSK 692342 in healthy BCG-primed, HIV-... - BE",
        "timestamp": "2012-08-14"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-002541-37/results",
        "title": "A Phase II, open label, mono-centric study to evaluate the kinetics of mRNA expression after two doses of GSK Biologicals’ candidate tuberculosis (TB) vaccine GSK 692342 in healthy BCG-primed, HIV-... - View results",
        "timestamp": "2012-08-14"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-002743-24/GB",
        "title": "Study to evaluate different duration of treatment regimes of 40kD pegylated interferon alfa 2a (Pegasys) plus ribavirin on sustained virological responses (SVR) in Genotype 3 HCV infected cirrhotic... - GB",
        "timestamp": "2007-08-22"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-002743-24/results",
        "title": "Study to evaluate different duration of treatment regimes of 40kD pegylated interferon alfa 2a (Pegasys) plus ribavirin on sustained virological responses (SVR) in Genotype 3 HCV infected cirrhotic... - View results",
        "timestamp": "2007-08-22"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-006042-33/IT",
        "title": "A pilot, open label, multicenter, randomized clinical trial on Lopinavir/Ritonavir-monotherapy vs Lopinavir/Ritonavir plus selected Nucs, in HIV/HCV  coinfected patients with chronic hepatitis C or... - IT",
        "timestamp": "2007-02-01"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003151-11/IT",
        "title": "An open-label, single-arm, phase II, prospective, pilot study of tocilizumab in patients with Erdheim-Chester disease. - IT",
        "timestamp": "2012-09-27"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-000638-21/DE",
        "title": "A Randomized, Open-Label, Multicenter Study of the Safety, Efficacy, and Tolerability of Combination Treatment of Setrobuvir, Danoprevir, Ritonavir, and Copegus® with or without Mericitabine in Tre... - DE",
        "timestamp": "2012-07-06"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-000638-21/PL",
        "title": "A Randomized, Open-Label, Multicenter Study of the Safety, Efficacy, and Tolerability of Combination Treatment of Setrobuvir, Danoprevir, Ritonavir, and Copegus® with or without Mericitabine in Tre... - PL",
        "timestamp": "2012-07-06"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-004988-32/NL",
        "title": "Rotterdam Observational Study in CIDP of Pharmacokinetics of Intravenous γ-globulin - NL",
        "timestamp": "2014-01-22"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005607-32/NL",
        "title": "LOWERING VIRAL LOAD WITH NUCLEOS(T)IDE ANALOGUES PRIOR TO PEGINTERFERON ALFA-2B TREATMENT TO INCREASE SUSTAINED RESPONSE IN HBEAG-POSITIVE CHRONIC HEPATITIS B (PEGON-STUDY) - NL",
        "timestamp": "2012-02-15"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-001406-42/DK",
        "title": "Statin- and bisphosphonate treatment in patients with the Philadelphia-negative chronic myeloproliferative neoplasms -  essential thrombocytosis, polycythemia vera and hypercellular myelofibrosis. - DK",
        "timestamp": "2016-12-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-001958-99/FI",
        "title": "Collecalciferol as an Add-on Treatment to Subcutaneously-Administred Interferon-beta-1b for Treatment MS - FI",
        "timestamp": "2007-12-18"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-000728-14/NL",
        "title": "A Phase 2a, Randomized, Open-Label Study in Patients with Chronic Hepatitis C Viral Infection to Assess the Safety, Tolerability, Pharmacodynamics, and Antiviral Activity of ANA773 Tosylate Adminis... - NL",
        "timestamp": "2011-05-10"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-001071-40/AT",
        "title": "A Phase IIa Safety study of oral administration of anti-CD3 monoclonal antibody in non-responder genotype-I chronic Hepatitis C subjects, a single-blind, randomized, controlled multi-center study - AT",
        "timestamp": "2011-08-11"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-001071-40/PL",
        "title": "A Phase IIa Safety study of oral administration of anti-CD3 monoclonal antibody in non-responder genotype-I chronic Hepatitis C subjects, a single-blind, randomized, controlled multi-center study - PL",
        "timestamp": "2011-08-11"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-006227-31/DE",
        "title": "Inflammatory Topoproteome of Psoriasis under Etanercept Treatment - DE",
        "timestamp": "2009-01-09"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-001176-31/HU",
        "title": "BENEFIT 15 long-term follow-up study of the BENEFIT and BENEFIT follow-up studies - HU",
        "timestamp": "2017-09-22"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-001176-31/ES",
        "title": "BENEFIT 15 long-term follow-up study of the BENEFIT and BENEFIT follow-up studies - ES",
        "timestamp": "2017-09-22"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-001176-31/SE",
        "title": "BENEFIT 15 long-term follow-up study of the BENEFIT and BENEFIT follow-up studies - SE",
        "timestamp": "2017-09-22"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-001176-31/GB",
        "title": "BENEFIT 15 long-term follow-up study of the BENEFIT and BENEFIT follow-up studies - GB",
        "timestamp": "2017-09-22"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-001176-31/AT",
        "title": "BENEFIT 15 long-term follow-up study of the BENEFIT and BENEFIT follow-up studies - AT",
        "timestamp": "2017-09-22"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-001176-31/CZ",
        "title": "BENEFIT 15 long-term follow-up study of the BENEFIT and BENEFIT follow-up studies - CZ",
        "timestamp": "2017-09-22"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-001176-31/FI",
        "title": "BENEFIT 15 long-term follow-up study of the BENEFIT and BENEFIT follow-up studies - FI",
        "timestamp": "2017-09-22"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-001176-31/DK",
        "title": "BENEFIT 15 long-term follow-up study of the BENEFIT and BENEFIT follow-up studies - DK",
        "timestamp": "2017-09-22"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-001176-31/BE",
        "title": "BENEFIT 15 long-term follow-up study of the BENEFIT and BENEFIT follow-up studies - BE",
        "timestamp": "2017-09-22"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-001176-31/FR",
        "title": "BENEFIT 15 long-term follow-up study of the BENEFIT and BENEFIT follow-up studies - FR",
        "timestamp": "2017-09-22"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-001176-31/PT",
        "title": "BENEFIT 15 long-term follow-up study of the BENEFIT and BENEFIT follow-up studies - PT",
        "timestamp": "2017-09-22"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-001176-31/results",
        "title": "BENEFIT 15 long-term follow-up study of the BENEFIT and BENEFIT follow-up studies - View results",
        "timestamp": "2017-09-22"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005477-24/GB",
        "title": "A Phase I/IIa Sporozoite Challenge Study to Assess the Protective Efficacy of Two Prime-boost Malaria Vaccine Candidates: ChAd63 and MVA encoding ME-TRAP and the same Viral Vectors encoding CS - GB",
        "timestamp": "2012-02-28"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005477-24/results",
        "title": "A Phase I/IIa Sporozoite Challenge Study to Assess the Protective Efficacy of Two Prime-boost Malaria Vaccine Candidates: ChAd63 and MVA encoding ME-TRAP and the same Viral Vectors encoding CS - View results",
        "timestamp": "2012-02-28"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-005129-10/FI",
        "title": "Multiple Sclerosis and Menopause: the effect of hormone replacement therapy on clinical picture and immunology of multiple sclerosis - FI",
        "timestamp": "2015-01-27"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-000328-16/ES",
        "title": "Efecto del tratamiento con dosis altas de Ribavirina frente a dosis estándar en pacientes infectados con el virus de la Hepatitis C Crónica genotipo 3 y carga viral alta sin respuesta en semana 4. - ES",
        "timestamp": "2008-06-10"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-022408-28/IT",
        "title": "A Phase 2B Pilot Study of Short-Term Treatment of BMS-790052 in Combination with Peg-Interferon Alfa-2a and Ribavirin in Treatment Naive Subjects with Chronic Hepatitis C Genotype 2 or 3 Infection. - IT",
        "timestamp": "2010-12-10"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-022408-28/DK",
        "title": "A Phase 2B Pilot Study of Short-Term Treatment of BMS-790052 in Combination with Peg-Interferon Alfa-2a and Ribavirin in Treatment Naive Subjects with Chronic Hepatitis C Genotype 2 or 3 Infection. - DK",
        "timestamp": "2010-12-10"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-022408-28/results",
        "title": "A Phase 2B Pilot Study of Short-Term Treatment of BMS-790052 in Combination with Peg-Interferon Alfa-2a and Ribavirin in Treatment Naive Subjects with Chronic Hepatitis C Genotype 2 or 3 Infection. - View results",
        "timestamp": "2010-12-10"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-011099-31/HU",
        "title": "A Multi-center, Randomized, Double-blind, Comparator-controlled, Dose-escalation Safety Assessment Study of Combination Treatment with IMO-2125 and Ribavirin in Naïve Hepatitis C-infected, Genotype... - HU",
        "timestamp": "2010-06-11"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-004165-41/GB",
        "title": "Hematopoietic Stem Cell Therapy for Patients with Inflammatory Multiple Sclerosis Failing Alternate Approved Therapy: A Randomized Study - GB",
        "timestamp": "2013-11-04"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-003934-28/GB",
        "title": "Enhanced Epidermal Antigen Specific Immunotherapy trial -1 (EE-ASI-1): A Phase 1a study of gold nanoparticles administered intradermally by microneedles to deliver immunotherapy with a proinsulin d... - GB",
        "timestamp": "2016-03-04"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-003934-28/SE",
        "title": "Enhanced Epidermal Antigen Specific Immunotherapy trial -1 (EE-ASI-1): A Phase 1a study of gold nanoparticles administered intradermally by microneedles to deliver immunotherapy with a proinsulin d... - SE",
        "timestamp": "2016-03-04"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-013053-15/SE",
        "title": "A Phase II Open Label Study of MK-7009 Administered Concomitantly with Pegylated Interferon Alfa and Ribavirin to Patients with Chronic Hepatitis C Infection After Participation in Other MK-7009 Cl... - SE",
        "timestamp": "2010-05-31"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-013053-15/FR",
        "title": "A Phase II Open Label Study of MK-7009 Administered Concomitantly with Pegylated Interferon Alfa and Ribavirin to Patients with Chronic Hepatitis C Infection After Participation in Other MK-7009 Cl... - FR",
        "timestamp": "2010-05-31"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-013053-15/BE",
        "title": "A Phase II Open Label Study of MK-7009 Administered Concomitantly with Pegylated Interferon Alfa and Ribavirin to Patients with Chronic Hepatitis C Infection After Participation in Other MK-7009 Cl... - BE",
        "timestamp": "2010-05-31"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-013053-15/DE",
        "title": "A Phase II Open Label Study of MK-7009 Administered Concomitantly with Pegylated Interferon Alfa and Ribavirin to Patients with Chronic Hepatitis C Infection After Participation in Other MK-7009 Cl... - DE",
        "timestamp": "2010-05-31"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-013053-15/AT",
        "title": "A Phase II Open Label Study of MK-7009 Administered Concomitantly with Pegylated Interferon Alfa and Ribavirin to Patients with Chronic Hepatitis C Infection After Participation in Other MK-7009 Cl... - AT",
        "timestamp": "2010-05-31"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-013053-15/GB",
        "title": "A Phase II Open Label Study of MK-7009 Administered Concomitantly with Pegylated Interferon Alfa and Ribavirin to Patients with Chronic Hepatitis C Infection After Participation in Other MK-7009 Cl... - GB",
        "timestamp": "2010-05-31"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-013053-15/LT",
        "title": "A Phase II Open Label Study of MK-7009 Administered Concomitantly with Pegylated Interferon Alfa and Ribavirin to Patients with Chronic Hepatitis C Infection After Participation in Other MK-7009 Cl... - LT",
        "timestamp": "2010-05-31"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-013053-15/PL",
        "title": "A Phase II Open Label Study of MK-7009 Administered Concomitantly with Pegylated Interferon Alfa and Ribavirin to Patients with Chronic Hepatitis C Infection After Participation in Other MK-7009 Cl... - PL",
        "timestamp": "2010-05-31"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-013053-15/ES",
        "title": "A Phase II Open Label Study of MK-7009 Administered Concomitantly with Pegylated Interferon Alfa and Ribavirin to Patients with Chronic Hepatitis C Infection After Participation in Other MK-7009 Cl... - ES",
        "timestamp": "2010-05-31"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-013053-15/CZ",
        "title": "A Phase II Open Label Study of MK-7009 Administered Concomitantly with Pegylated Interferon Alfa and Ribavirin to Patients with Chronic Hepatitis C Infection After Participation in Other MK-7009 Cl... - CZ",
        "timestamp": "2010-05-31"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-013053-15/results",
        "title": "A Phase II Open Label Study of MK-7009 Administered Concomitantly with Pegylated Interferon Alfa and Ribavirin to Patients with Chronic Hepatitis C Infection After Participation in Other MK-7009 Cl... - View results",
        "timestamp": "2010-05-31"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-001103-31/GB",
        "title": "A Phase 2a, Randomized, Double-blind, Placebo-controlled Assessment of the Safety and Protective Efficacy of FF-3 Dry Powder Administered by Nasal Inhalation for 5 Days to Healthy Adult Subjects wh... - GB",
        "timestamp": "2015-07-10"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-001103-31/results",
        "title": "A Phase 2a, Randomized, Double-blind, Placebo-controlled Assessment of the Safety and Protective Efficacy of FF-3 Dry Powder Administered by Nasal Inhalation for 5 Days to Healthy Adult Subjects wh... - View results",
        "timestamp": "2015-07-10"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-000870-63/FR",
        "title": "A phase IV, 2x2 factorial, double blind study of 24 versus 48 weeks and 90 versus 180 mcg doses of pegylated interferon alfa 2a 40KD (PEG IFN, Ro 25-8310) in adult patients with HBeAg positive chro... - FR",
        "timestamp": "2007-03-01"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-000870-63/DE",
        "title": "A phase IV, 2x2 factorial, double blind study of 24 versus 48 weeks and 90 versus 180 mcg doses of pegylated interferon alfa 2a 40KD (PEG IFN, Ro 25-8310) in adult patients with HBeAg positive chro... - DE",
        "timestamp": "2007-03-01"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-000870-63/results",
        "title": "A phase IV, 2x2 factorial, double blind study of 24 versus 48 weeks and 90 versus 180 mcg doses of pegylated interferon alfa 2a 40KD (PEG IFN, Ro 25-8310) in adult patients with HBeAg positive chro... - View results",
        "timestamp": "2007-03-01"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-006644-19/IT",
        "title": "Evaluation of inflammatory immune parameters predicting cardiovascular risk in HIV-1-infected antiretroviral therapy naive patients treated with atazanavir/ritonavir versus lopinavir/ritonavir base... - IT",
        "timestamp": "2009-01-29"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-001601-10/IT",
        "title": "MULTICENTTRIC, NATIONAL, SINGLE BLIND,CONTROLLED IN PARALLEL GROUP TO EVALUATE THE SAFETY AND EFFICACY OF THE SEQUENTIAL COMBINATION OF MITOXANTRONE AND BETA INTERFERON  REBIF 44 mcg X 3 TIMES WEEK... - IT",
        "timestamp": "2004-11-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-001601-10/FR",
        "title": "MULTICENTTRIC, NATIONAL, SINGLE BLIND,CONTROLLED IN PARALLEL GROUP TO EVALUATE THE SAFETY AND EFFICACY OF THE SEQUENTIAL COMBINATION OF MITOXANTRONE AND BETA INTERFERON  REBIF 44 mcg X 3 TIMES WEEK... - FR",
        "timestamp": "2004-11-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-006157-24/DE",
        "title": "A multicenter open label phase II study to assess the efficacy and safety of APO866 in the treatment of patients with refractory or relapsed cutaneous T-cell lymphoma - DE",
        "timestamp": "2007-01-31"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-006157-24/AT",
        "title": "A multicenter open label phase II study to assess the efficacy and safety of APO866 in the treatment of patients with refractory or relapsed cutaneous T-cell lymphoma - AT",
        "timestamp": "2007-01-31"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-002508-26/IT",
        "title": "Outcome-related factors in patients with metastatic renal cell carcinoma treated with everolimus after failure of a first-line treatment with VEGF inhibitor - IT",
        "timestamp": "2015-02-10"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-003436-13/HU",
        "title": "A RANDOMIZED PHASE 2 TRIAL OF AXITINIB AND TRC105 VERSUS AXITINIB ALONE  (INCLUDING A LEAD-IN PHASE 1B DOSE-ESCALATION PORTION) IN PATIENTS WITH ADVANCED OR METASTATIC RENAL CELL CARCINOMA - HU",
        "timestamp": "2016-05-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-003436-13/GB",
        "title": "A RANDOMIZED PHASE 2 TRIAL OF AXITINIB AND TRC105 VERSUS AXITINIB ALONE  (INCLUDING A LEAD-IN PHASE 1B DOSE-ESCALATION PORTION) IN PATIENTS WITH ADVANCED OR METASTATIC RENAL CELL CARCINOMA - GB",
        "timestamp": "2016-05-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-003436-13/PL",
        "title": "A RANDOMIZED PHASE 2 TRIAL OF AXITINIB AND TRC105 VERSUS AXITINIB ALONE  (INCLUDING A LEAD-IN PHASE 1B DOSE-ESCALATION PORTION) IN PATIENTS WITH ADVANCED OR METASTATIC RENAL CELL CARCINOMA - PL",
        "timestamp": "2016-05-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-003436-13/CZ",
        "title": "A RANDOMIZED PHASE 2 TRIAL OF AXITINIB AND TRC105 VERSUS AXITINIB ALONE  (INCLUDING A LEAD-IN PHASE 1B DOSE-ESCALATION PORTION) IN PATIENTS WITH ADVANCED OR METASTATIC RENAL CELL CARCINOMA - CZ",
        "timestamp": "2016-05-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-001956-31/DK",
        "title": "Direct acting antiviral therapy of hepatitis C in Denmark: treatment response, adverse events and resistance associated variants - DK",
        "timestamp": "2015-06-09"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-001956-31/results",
        "title": "Direct acting antiviral therapy of hepatitis C in Denmark: treatment response, adverse events and resistance associated variants - View results",
        "timestamp": "2015-06-09"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-009214-40/HU",
        "title": "A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF FILIBUVIR PLUS PEGYLATED INTERFERON ALFA-2A AND RIBAVIRIN IN TREATMENT NAÏVE, HCV GENOTYPE 1 INF... - HU",
        "timestamp": "2009-07-08"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-009214-40/FR",
        "title": "A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF FILIBUVIR PLUS PEGYLATED INTERFERON ALFA-2A AND RIBAVIRIN IN TREATMENT NAÏVE, HCV GENOTYPE 1 INF... - FR",
        "timestamp": "2009-07-08"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-009214-40/ES",
        "title": "A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF FILIBUVIR PLUS PEGYLATED INTERFERON ALFA-2A AND RIBAVIRIN IN TREATMENT NAÏVE, HCV GENOTYPE 1 INF... - ES",
        "timestamp": "2009-07-08"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-009214-40/BE",
        "title": "A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF FILIBUVIR PLUS PEGYLATED INTERFERON ALFA-2A AND RIBAVIRIN IN TREATMENT NAÏVE, HCV GENOTYPE 1 INF... - BE",
        "timestamp": "2009-07-08"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-009214-40/DE",
        "title": "A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF FILIBUVIR PLUS PEGYLATED INTERFERON ALFA-2A AND RIBAVIRIN IN TREATMENT NAÏVE, HCV GENOTYPE 1 INF... - DE",
        "timestamp": "2009-07-08"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-009214-40/results",
        "title": "A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF FILIBUVIR PLUS PEGYLATED INTERFERON ALFA-2A AND RIBAVIRIN IN TREATMENT NAÏVE, HCV GENOTYPE 1 INF... - View results",
        "timestamp": "2009-07-08"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-015121-37/FR",
        "title": "Etude multicentrique randomisée ouverte comparant la réduction virale et la tolérance\nde l’association IFN alpha-2b XL + ribavirine versus IFN peg alpha-2b + ribavirine chez des\npatients atteints d... - FR",
        "timestamp": "2009-12-10"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-001081-42/DE",
        "title": "Interferon-free Treatment of Acute Genotype 1 Hepatitis C Virus Infection with Ledipasvir/Sofosbuvir Fixed-Dose Combination - The HepNet Acute HCV IV Study - DE",
        "timestamp": "2014-10-21"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-024152-29/DE",
        "title": "Canakinumab for Behçet`s Disease Resistant to Standard Treatment\r\n(CanBeDisT) - DE",
        "timestamp": "2011-09-02"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-000955-15/IT",
        "title": "A phase IIa open-label, single arm, multi-center trial evaluating the safety of standard antiviral therapy (pegylated interferon and ribavirin) plus deferasirox in thalassemia patients with transfu... - IT",
        "timestamp": "2012-10-02"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-004408-29/DE",
        "title": "ESTABLISH TOLERANCE IN MS WITH PEPTIDE-PULSED, PERIPHERAL BLOOD MONONUCLEAR CELLS - A MRI-CONTROLLED, SINGLE CENTER, BASELINE-TO-TREATMENT CROSS-OVER, PHASE I/IIA TRIAL IN RELAPSING-REMITTING MS PA... - DE",
        "timestamp": "2009-11-27"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-004408-29/results",
        "title": "ESTABLISH TOLERANCE IN MS WITH PEPTIDE-PULSED, PERIPHERAL BLOOD MONONUCLEAR CELLS - A MRI-CONTROLLED, SINGLE CENTER, BASELINE-TO-TREATMENT CROSS-OVER, PHASE I/IIA TRIAL IN RELAPSING-REMITTING MS PA... - View results",
        "timestamp": "2009-11-27"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-015502-19/FI",
        "title": "A multinational, multicenter, single visit, exploratory pharmacogenetic trial and long-term follow-up of the PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Mu... - FI",
        "timestamp": "2009-12-14"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-015502-19/SE",
        "title": "A multinational, multicenter, single visit, exploratory pharmacogenetic trial and long-term follow-up of the PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Mu... - SE",
        "timestamp": "2009-12-14"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-015502-19/DE",
        "title": "A multinational, multicenter, single visit, exploratory pharmacogenetic trial and long-term follow-up of the PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Mu... - DE",
        "timestamp": "2009-12-14"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-015502-19/BE",
        "title": "A multinational, multicenter, single visit, exploratory pharmacogenetic trial and long-term follow-up of the PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Mu... - BE",
        "timestamp": "2009-12-14"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-015502-19/GB",
        "title": "A multinational, multicenter, single visit, exploratory pharmacogenetic trial and long-term follow-up of the PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Mu... - GB",
        "timestamp": "2009-12-14"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-015502-19/results",
        "title": "A multinational, multicenter, single visit, exploratory pharmacogenetic trial and long-term follow-up of the PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Mu... - View results",
        "timestamp": "2009-12-14"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-003578-17/3rd",
        "title": "A Phase 2, Open-Label, Multicenter, Multi-cohort Study to Investigate the Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination in Adolescents and Children with Chronic HCV-Infection - Outside EU/EEA",
        "timestamp": "2015-01-28"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-003578-17/GB",
        "title": "A Phase 2, Open-Label, Multicenter, Multi-cohort Study to Investigate the Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination in Adolescents and Children with Chronic HCV-Infection - GB",
        "timestamp": "2015-01-28"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-003578-17/results",
        "title": "A Phase 2, Open-Label, Multicenter, Multi-cohort Study to Investigate the Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination in Adolescents and Children with Chronic HCV-Infection - View results",
        "timestamp": "2015-01-28"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-001249-26/DE",
        "title": "A Registry for Subjects with Cirrhosis Who Achieve a Sustained Virologic Response Following Treatment with a Sofosbuvir-Based Regimen without Interferon for Chronic Hepatitis C Infection in Gilead-... - DE",
        "timestamp": "2016-02-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-001249-26/ES",
        "title": "A Registry for Subjects with Cirrhosis Who Achieve a Sustained Virologic Response Following Treatment with a Sofosbuvir-Based Regimen without Interferon for Chronic Hepatitis C Infection in Gilead-... - ES",
        "timestamp": "2016-02-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-001249-26/GB",
        "title": "A Registry for Subjects with Cirrhosis Who Achieve a Sustained Virologic Response Following Treatment with a Sofosbuvir-Based Regimen without Interferon for Chronic Hepatitis C Infection in Gilead-... - GB",
        "timestamp": "2016-02-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-011121-13/DE",
        "title": "A phase II randomized, multicenter, open-label study of TG4040 (MVA-HCV) in combination with pegylated interferon alfa-2a and ribavirin versus pegylated interferon alfa-2a and ribavirin in treatmen... - DE",
        "timestamp": "2010-07-27"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-011121-13/ES",
        "title": "A phase II randomized, multicenter, open-label study of TG4040 (MVA-HCV) in combination with pegylated interferon alfa-2a and ribavirin versus pegylated interferon alfa-2a and ribavirin in treatmen... - ES",
        "timestamp": "2010-07-27"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-011121-13/PL",
        "title": "A phase II randomized, multicenter, open-label study of TG4040 (MVA-HCV) in combination with pegylated interferon alfa-2a and ribavirin versus pegylated interferon alfa-2a and ribavirin in treatmen... - PL",
        "timestamp": "2010-07-27"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-011121-13/results",
        "title": "A phase II randomized, multicenter, open-label study of TG4040 (MVA-HCV) in combination with pegylated interferon alfa-2a and ribavirin versus pegylated interferon alfa-2a and ribavirin in treatmen... - View results",
        "timestamp": "2010-07-27"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-000586-20/PL",
        "title": "A Randomized, Double-Blind Evaluation of the Antiviral\nEfficacy, Safety, and Tolerability of Tenofovir Disoproxil\nFumarate Versus Placebo in Pediatric Patients with Chronic Hepatitis B Infection - PL",
        "timestamp": "2013-01-23"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-000586-20/BG",
        "title": "A Randomized, Double-Blind Evaluation of the Antiviral\nEfficacy, Safety, and Tolerability of Tenofovir Disoproxil\nFumarate Versus Placebo in Pediatric Patients with Chronic Hepatitis B Infection - BG",
        "timestamp": "2013-01-23"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-000586-20/3rd",
        "title": "A Randomized, Double-Blind Evaluation of the Antiviral\nEfficacy, Safety, and Tolerability of Tenofovir Disoproxil\nFumarate Versus Placebo in Pediatric Patients with Chronic Hepatitis B Infection - Outside EU/EEA",
        "timestamp": "2013-01-23"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-004223-23/IT",
        "title": "A pilot, open-label, single arm, multicenter study to evaluate safety, tolerability, pharmacokinetics and efficacy of intravenous administrations of NI-0501, an anti-interferon gamma (anti-IFNγ) mo... - IT",
        "timestamp": "2017-04-14"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-004223-23/FR",
        "title": "A pilot, open-label, single arm, multicenter study to evaluate safety, tolerability, pharmacokinetics and efficacy of intravenous administrations of NI-0501, an anti-interferon gamma (anti-IFNγ) mo... - FR",
        "timestamp": "2017-04-14"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-004223-23/GB",
        "title": "A pilot, open-label, single arm, multicenter study to evaluate safety, tolerability, pharmacokinetics and efficacy of intravenous administrations of NI-0501, an anti-interferon gamma (anti-IFNγ) mo... - GB",
        "timestamp": "2017-04-14"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-004223-23/ES",
        "title": "A pilot, open-label, single arm, multicenter study to evaluate safety, tolerability, pharmacokinetics and efficacy of intravenous administrations of NI-0501, an anti-interferon gamma (anti-IFNγ) mo... - ES",
        "timestamp": "2017-04-14"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-004223-23/NL",
        "title": "A pilot, open-label, single arm, multicenter study to evaluate safety, tolerability, pharmacokinetics and efficacy of intravenous administrations of NI-0501, an anti-interferon gamma (anti-IFNγ) mo... - NL",
        "timestamp": "2017-04-14"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-000533-22/BE",
        "title": "A randomized, double-blind, placebo-controlled, Phase III trial of 2 regimens of telaprevir (with and without delayed start) combined with pegylated interferon alfa-2a (Pegasys®) and ribavirin (Cop... - BE",
        "timestamp": "2008-11-14"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-000533-22/DE",
        "title": "A randomized, double-blind, placebo-controlled, Phase III trial of 2 regimens of telaprevir (with and without delayed start) combined with pegylated interferon alfa-2a (Pegasys®) and ribavirin (Cop... - DE",
        "timestamp": "2008-11-14"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-000533-22/SE",
        "title": "A randomized, double-blind, placebo-controlled, Phase III trial of 2 regimens of telaprevir (with and without delayed start) combined with pegylated interferon alfa-2a (Pegasys®) and ribavirin (Cop... - SE",
        "timestamp": "2008-11-14"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-000533-22/FR",
        "title": "A randomized, double-blind, placebo-controlled, Phase III trial of 2 regimens of telaprevir (with and without delayed start) combined with pegylated interferon alfa-2a (Pegasys®) and ribavirin (Cop... - FR",
        "timestamp": "2008-11-14"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-000533-22/AT",
        "title": "A randomized, double-blind, placebo-controlled, Phase III trial of 2 regimens of telaprevir (with and without delayed start) combined with pegylated interferon alfa-2a (Pegasys®) and ribavirin (Cop... - AT",
        "timestamp": "2008-11-14"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-000533-22/IT",
        "title": "A randomized, double-blind, placebo-controlled, Phase III trial of 2 regimens of telaprevir (with and without delayed start) combined with pegylated interferon alfa-2a (Pegasys®) and ribavirin (Cop... - IT",
        "timestamp": "2008-11-14"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-000533-22/GB",
        "title": "A randomized, double-blind, placebo-controlled, Phase III trial of 2 regimens of telaprevir (with and without delayed start) combined with pegylated interferon alfa-2a (Pegasys®) and ribavirin (Cop... - GB",
        "timestamp": "2008-11-14"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-000533-22/ES",
        "title": "A randomized, double-blind, placebo-controlled, Phase III trial of 2 regimens of telaprevir (with and without delayed start) combined with pegylated interferon alfa-2a (Pegasys®) and ribavirin (Cop... - ES",
        "timestamp": "2008-11-14"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-000533-22/NL",
        "title": "A randomized, double-blind, placebo-controlled, Phase III trial of 2 regimens of telaprevir (with and without delayed start) combined with pegylated interferon alfa-2a (Pegasys®) and ribavirin (Cop... - NL",
        "timestamp": "2008-11-14"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-000533-22/results",
        "title": "A randomized, double-blind, placebo-controlled, Phase III trial of 2 regimens of telaprevir (with and without delayed start) combined with pegylated interferon alfa-2a (Pegasys®) and ribavirin (Cop... - View results",
        "timestamp": "2008-11-14"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-000824-12/DK",
        "title": "A Phase III Randomized Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172/MK-8742 in Subjects who have Failed Prior Treatment with Pegylated Interferon and Ribavi... - DK",
        "timestamp": "2014-06-06"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-000824-12/ES",
        "title": "A Phase III Randomized Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172/MK-8742 in Subjects who have Failed Prior Treatment with Pegylated Interferon and Ribavi... - ES",
        "timestamp": "2014-06-06"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-000824-12/FI",
        "title": "A Phase III Randomized Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172/MK-8742 in Subjects who have Failed Prior Treatment with Pegylated Interferon and Ribavi... - FI",
        "timestamp": "2014-06-06"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-000824-12/PL",
        "title": "A Phase III Randomized Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172/MK-8742 in Subjects who have Failed Prior Treatment with Pegylated Interferon and Ribavi... - PL",
        "timestamp": "2014-06-06"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-000824-12/NL",
        "title": "A Phase III Randomized Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172/MK-8742 in Subjects who have Failed Prior Treatment with Pegylated Interferon and Ribavi... - NL",
        "timestamp": "2014-06-06"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-000824-12/results",
        "title": "A Phase III Randomized Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172/MK-8742 in Subjects who have Failed Prior Treatment with Pegylated Interferon and Ribavi... - View results",
        "timestamp": "2014-06-06"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-004078-25/GB",
        "title": "A Randomized, Double-blind, Placebo-controlled, Multi-center Phase III Study to Evaluate the Efficacy and Safety of Pazopanib (GW786034) Compared to Placebo in Patients with Locally Advanced and/or... - GB",
        "timestamp": "2006-03-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-004078-25/IE",
        "title": "A Randomized, Double-blind, Placebo-controlled, Multi-center Phase III Study to Evaluate the Efficacy and Safety of Pazopanib (GW786034) Compared to Placebo in Patients with Locally Advanced and/or... - IE",
        "timestamp": "2006-03-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-004078-25/SK",
        "title": "A Randomized, Double-blind, Placebo-controlled, Multi-center Phase III Study to Evaluate the Efficacy and Safety of Pazopanib (GW786034) Compared to Placebo in Patients with Locally Advanced and/or... - SK",
        "timestamp": "2006-03-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-004078-25/LT",
        "title": "A Randomized, Double-blind, Placebo-controlled, Multi-center Phase III Study to Evaluate the Efficacy and Safety of Pazopanib (GW786034) Compared to Placebo in Patients with Locally Advanced and/or... - LT",
        "timestamp": "2006-03-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-004078-25/EE",
        "title": "A Randomized, Double-blind, Placebo-controlled, Multi-center Phase III Study to Evaluate the Efficacy and Safety of Pazopanib (GW786034) Compared to Placebo in Patients with Locally Advanced and/or... - EE",
        "timestamp": "2006-03-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-004078-25/AT",
        "title": "A Randomized, Double-blind, Placebo-controlled, Multi-center Phase III Study to Evaluate the Efficacy and Safety of Pazopanib (GW786034) Compared to Placebo in Patients with Locally Advanced and/or... - AT",
        "timestamp": "2006-03-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-004078-25/CZ",
        "title": "A Randomized, Double-blind, Placebo-controlled, Multi-center Phase III Study to Evaluate the Efficacy and Safety of Pazopanib (GW786034) Compared to Placebo in Patients with Locally Advanced and/or... - CZ",
        "timestamp": "2006-03-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-004078-25/IT",
        "title": "A Randomized, Double-blind, Placebo-controlled, Multi-center Phase III Study to Evaluate the Efficacy and Safety of Pazopanib (GW786034) Compared to Placebo in Patients with Locally Advanced and/or... - IT",
        "timestamp": "2006-03-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-004078-25/GR",
        "title": "A Randomized, Double-blind, Placebo-controlled, Multi-center Phase III Study to Evaluate the Efficacy and Safety of Pazopanib (GW786034) Compared to Placebo in Patients with Locally Advanced and/or... - GR",
        "timestamp": "2006-03-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-004078-25/HU",
        "title": "A Randomized, Double-blind, Placebo-controlled, Multi-center Phase III Study to Evaluate the Efficacy and Safety of Pazopanib (GW786034) Compared to Placebo in Patients with Locally Advanced and/or... - HU",
        "timestamp": "2006-03-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-004078-25/LV",
        "title": "A Randomized, Double-blind, Placebo-controlled, Multi-center Phase III Study to Evaluate the Efficacy and Safety of Pazopanib (GW786034) Compared to Placebo in Patients with Locally Advanced and/or... - LV",
        "timestamp": "2006-03-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-004078-25/results",
        "title": "A Randomized, Double-blind, Placebo-controlled, Multi-center Phase III Study to Evaluate the Efficacy and Safety of Pazopanib (GW786034) Compared to Placebo in Patients with Locally Advanced and/or... - View results",
        "timestamp": "2006-03-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-000150-12/LT",
        "title": "A Phase II Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability  and  Efficacy of 4 Different Regimens of MK-7009 When Administered Concomitantly With Pegylated Interferon and ... - LT",
        "timestamp": "2009-09-07"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-000150-12/SE",
        "title": "A Phase II Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability  and  Efficacy of 4 Different Regimens of MK-7009 When Administered Concomitantly With Pegylated Interferon and ... - SE",
        "timestamp": "2009-09-07"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-000150-12/DE",
        "title": "A Phase II Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability  and  Efficacy of 4 Different Regimens of MK-7009 When Administered Concomitantly With Pegylated Interferon and ... - DE",
        "timestamp": "2009-09-07"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-000150-12/BE",
        "title": "A Phase II Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability  and  Efficacy of 4 Different Regimens of MK-7009 When Administered Concomitantly With Pegylated Interferon and ... - BE",
        "timestamp": "2009-09-07"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-000150-12/GB",
        "title": "A Phase II Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability  and  Efficacy of 4 Different Regimens of MK-7009 When Administered Concomitantly With Pegylated Interferon and ... - GB",
        "timestamp": "2009-09-07"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-000150-12/CZ",
        "title": "A Phase II Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability  and  Efficacy of 4 Different Regimens of MK-7009 When Administered Concomitantly With Pegylated Interferon and ... - CZ",
        "timestamp": "2009-09-07"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-000150-12/AT",
        "title": "A Phase II Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability  and  Efficacy of 4 Different Regimens of MK-7009 When Administered Concomitantly With Pegylated Interferon and ... - AT",
        "timestamp": "2009-09-07"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-000150-12/FR",
        "title": "A Phase II Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability  and  Efficacy of 4 Different Regimens of MK-7009 When Administered Concomitantly With Pegylated Interferon and ... - FR",
        "timestamp": "2009-09-07"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-000150-12/results",
        "title": "A Phase II Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability  and  Efficacy of 4 Different Regimens of MK-7009 When Administered Concomitantly With Pegylated Interferon and ... - View results",
        "timestamp": "2009-09-07"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-003706-33/CZ",
        "title": "A Phase III, randomized, double-blind, placebo-controlled, multicenter clinical trial of oral cladribine in subjects with a first clinical event at high risk of converting to MS - CZ",
        "timestamp": "2009-03-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-003706-33/FI",
        "title": "A Phase III, randomized, double-blind, placebo-controlled, multicenter clinical trial of oral cladribine in subjects with a first clinical event at high risk of converting to MS - FI",
        "timestamp": "2009-03-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-003706-33/EE",
        "title": "A Phase III, randomized, double-blind, placebo-controlled, multicenter clinical trial of oral cladribine in subjects with a first clinical event at high risk of converting to MS - EE",
        "timestamp": "2009-03-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-003706-33/AT",
        "title": "A Phase III, randomized, double-blind, placebo-controlled, multicenter clinical trial of oral cladribine in subjects with a first clinical event at high risk of converting to MS - AT",
        "timestamp": "2009-03-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-003706-33/GB",
        "title": "A Phase III, randomized, double-blind, placebo-controlled, multicenter clinical trial of oral cladribine in subjects with a first clinical event at high risk of converting to MS - GB",
        "timestamp": "2009-03-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-003706-33/DE",
        "title": "A Phase III, randomized, double-blind, placebo-controlled, multicenter clinical trial of oral cladribine in subjects with a first clinical event at high risk of converting to MS - DE",
        "timestamp": "2009-03-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-003706-33/ES",
        "title": "A Phase III, randomized, double-blind, placebo-controlled, multicenter clinical trial of oral cladribine in subjects with a first clinical event at high risk of converting to MS - ES",
        "timestamp": "2009-03-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-003706-33/NO",
        "title": "A Phase III, randomized, double-blind, placebo-controlled, multicenter clinical trial of oral cladribine in subjects with a first clinical event at high risk of converting to MS - NO",
        "timestamp": "2009-03-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-003706-33/BE",
        "title": "A Phase III, randomized, double-blind, placebo-controlled, multicenter clinical trial of oral cladribine in subjects with a first clinical event at high risk of converting to MS - BE",
        "timestamp": "2009-03-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-003706-33/PT",
        "title": "A Phase III, randomized, double-blind, placebo-controlled, multicenter clinical trial of oral cladribine in subjects with a first clinical event at high risk of converting to MS - PT",
        "timestamp": "2009-03-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-003706-33/IT",
        "title": "A Phase III, randomized, double-blind, placebo-controlled, multicenter clinical trial of oral cladribine in subjects with a first clinical event at high risk of converting to MS - IT",
        "timestamp": "2009-03-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-003706-33/GR",
        "title": "A Phase III, randomized, double-blind, placebo-controlled, multicenter clinical trial of oral cladribine in subjects with a first clinical event at high risk of converting to MS - GR",
        "timestamp": "2009-03-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-003706-33/FR",
        "title": "A Phase III, randomized, double-blind, placebo-controlled, multicenter clinical trial of oral cladribine in subjects with a first clinical event at high risk of converting to MS - FR",
        "timestamp": "2009-03-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-003706-33/SE",
        "title": "A Phase III, randomized, double-blind, placebo-controlled, multicenter clinical trial of oral cladribine in subjects with a first clinical event at high risk of converting to MS - SE",
        "timestamp": "2009-03-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-003706-33/BG",
        "title": "A Phase III, randomized, double-blind, placebo-controlled, multicenter clinical trial of oral cladribine in subjects with a first clinical event at high risk of converting to MS - BG",
        "timestamp": "2009-03-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-003706-33/results",
        "title": "A Phase III, randomized, double-blind, placebo-controlled, multicenter clinical trial of oral cladribine in subjects with a first clinical event at high risk of converting to MS - View results",
        "timestamp": "2009-03-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-012613-21/NL",
        "title": "An open-label, single-arm, roll-over trial of telaprevir in combination with pegylated interferon alfa-2a (Pegasys®) and ribavirin (Copegus®) for subjects from the control group of the VX-950-TiDP2... - NL",
        "timestamp": "2010-06-02"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-012613-21/BE",
        "title": "An open-label, single-arm, roll-over trial of telaprevir in combination with pegylated interferon alfa-2a (Pegasys®) and ribavirin (Copegus®) for subjects from the control group of the VX-950-TiDP2... - BE",
        "timestamp": "2010-06-02"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-012613-21/DE",
        "title": "An open-label, single-arm, roll-over trial of telaprevir in combination with pegylated interferon alfa-2a (Pegasys®) and ribavirin (Copegus®) for subjects from the control group of the VX-950-TiDP2... - DE",
        "timestamp": "2010-06-02"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-012613-21/FR",
        "title": "An open-label, single-arm, roll-over trial of telaprevir in combination with pegylated interferon alfa-2a (Pegasys®) and ribavirin (Copegus®) for subjects from the control group of the VX-950-TiDP2... - FR",
        "timestamp": "2010-06-02"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-012613-21/SE",
        "title": "An open-label, single-arm, roll-over trial of telaprevir in combination with pegylated interferon alfa-2a (Pegasys®) and ribavirin (Copegus®) for subjects from the control group of the VX-950-TiDP2... - SE",
        "timestamp": "2010-06-02"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-012613-21/PL",
        "title": "An open-label, single-arm, roll-over trial of telaprevir in combination with pegylated interferon alfa-2a (Pegasys®) and ribavirin (Copegus®) for subjects from the control group of the VX-950-TiDP2... - PL",
        "timestamp": "2010-06-02"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-012613-21/ES",
        "title": "An open-label, single-arm, roll-over trial of telaprevir in combination with pegylated interferon alfa-2a (Pegasys®) and ribavirin (Copegus®) for subjects from the control group of the VX-950-TiDP2... - ES",
        "timestamp": "2010-06-02"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-012613-21/AT",
        "title": "An open-label, single-arm, roll-over trial of telaprevir in combination with pegylated interferon alfa-2a (Pegasys®) and ribavirin (Copegus®) for subjects from the control group of the VX-950-TiDP2... - AT",
        "timestamp": "2010-06-02"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-012613-21/GB",
        "title": "An open-label, single-arm, roll-over trial of telaprevir in combination with pegylated interferon alfa-2a (Pegasys®) and ribavirin (Copegus®) for subjects from the control group of the VX-950-TiDP2... - GB",
        "timestamp": "2010-06-02"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-012613-21/IT",
        "title": "An open-label, single-arm, roll-over trial of telaprevir in combination with pegylated interferon alfa-2a (Pegasys®) and ribavirin (Copegus®) for subjects from the control group of the VX-950-TiDP2... - IT",
        "timestamp": "2010-06-02"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-012613-21/results",
        "title": "An open-label, single-arm, roll-over trial of telaprevir in combination with pegylated interferon alfa-2a (Pegasys®) and ribavirin (Copegus®) for subjects from the control group of the VX-950-TiDP2... - View results",
        "timestamp": "2010-06-02"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-003100-30/ES",
        "title": "A Multi-center, Open-label, Single-arm, Before and After Switch Study to Evaluate the Efficacy, Safety and Tolerability of Alemtuzumab in Pediatric Patients with Relapsing Remitting Multiple Sclero... - ES",
        "timestamp": "2017-04-04"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-003100-30/DE",
        "title": "A Multi-center, Open-label, Single-arm, Before and After Switch Study to Evaluate the Efficacy, Safety and Tolerability of Alemtuzumab in Pediatric Patients with Relapsing Remitting Multiple Sclero... - DE",
        "timestamp": "2017-04-04"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-003100-30/GB",
        "title": "A Multi-center, Open-label, Single-arm, Before and After Switch Study to Evaluate the Efficacy, Safety and Tolerability of Alemtuzumab in Pediatric Patients with Relapsing Remitting Multiple Sclero... - GB",
        "timestamp": "2017-04-04"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-003100-30/NO",
        "title": "A Multi-center, Open-label, Single-arm, Before and After Switch Study to Evaluate the Efficacy, Safety and Tolerability of Alemtuzumab in Pediatric Patients with Relapsing Remitting Multiple Sclero... - NO",
        "timestamp": "2017-04-04"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-003100-30/GR",
        "title": "A Multi-center, Open-label, Single-arm, Before and After Switch Study to Evaluate the Efficacy, Safety and Tolerability of Alemtuzumab in Pediatric Patients with Relapsing Remitting Multiple Sclero... - GR",
        "timestamp": "2017-04-04"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-003100-30/PT",
        "title": "A Multi-center, Open-label, Single-arm, Before and After Switch Study to Evaluate the Efficacy, Safety and Tolerability of Alemtuzumab in Pediatric Patients with Relapsing Remitting Multiple Sclero... - PT",
        "timestamp": "2017-04-04"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-003100-30/NL",
        "title": "A Multi-center, Open-label, Single-arm, Before and After Switch Study to Evaluate the Efficacy, Safety and Tolerability of Alemtuzumab in Pediatric Patients with Relapsing Remitting Multiple Sclero... - NL",
        "timestamp": "2017-04-04"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-003100-30/BE",
        "title": "A Multi-center, Open-label, Single-arm, Before and After Switch Study to Evaluate the Efficacy, Safety and Tolerability of Alemtuzumab in Pediatric Patients with Relapsing Remitting Multiple Sclero... - BE",
        "timestamp": "2017-04-04"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-003100-30/BG",
        "title": "A Multi-center, Open-label, Single-arm, Before and After Switch Study to Evaluate the Efficacy, Safety and Tolerability of Alemtuzumab in Pediatric Patients with Relapsing Remitting Multiple Sclero... - BG",
        "timestamp": "2017-04-04"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-003100-30/3rd",
        "title": "A Multi-center, Open-label, Single-arm, Before and After Switch Study to Evaluate the Efficacy, Safety and Tolerability of Alemtuzumab in Pediatric Patients with Relapsing Remitting Multiple Sclero... - Outside EU/EEA",
        "timestamp": "2017-04-04"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-003100-30/FR",
        "title": "A Multi-center, Open-label, Single-arm, Before and After Switch Study to Evaluate the Efficacy, Safety and Tolerability of Alemtuzumab in Pediatric Patients with Relapsing Remitting Multiple Sclero... - FR",
        "timestamp": "2017-04-04"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-003100-30/PL",
        "title": "A Multi-center, Open-label, Single-arm, Before and After Switch Study to Evaluate the Efficacy, Safety and Tolerability of Alemtuzumab in Pediatric Patients with Relapsing Remitting Multiple Sclero... - PL",
        "timestamp": "2017-04-04"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-003100-30/AT",
        "title": "A Multi-center, Open-label, Single-arm, Before and After Switch Study to Evaluate the Efficacy, Safety and Tolerability of Alemtuzumab in Pediatric Patients with Relapsing Remitting Multiple Sclero... - AT",
        "timestamp": "2017-04-04"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-003100-30/IT",
        "title": "A Multi-center, Open-label, Single-arm, Before and After Switch Study to Evaluate the Efficacy, Safety and Tolerability of Alemtuzumab in Pediatric Patients with Relapsing Remitting Multiple Sclero... - IT",
        "timestamp": "2017-04-04"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-000880-27/FI",
        "title": "A Phase II Study Of Oral LBH589 In Adult Patients With Refractory Cutaneous T-Cell Lymphoma - FI",
        "timestamp": "2007-02-01"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-000880-27/HU",
        "title": "A Phase II Study Of Oral LBH589 In Adult Patients With Refractory Cutaneous T-Cell Lymphoma - HU",
        "timestamp": "2007-02-01"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-000880-27/BE",
        "title": "A Phase II Study Of Oral LBH589 In Adult Patients With Refractory Cutaneous T-Cell Lymphoma - BE",
        "timestamp": "2007-02-01"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-000880-27/DE",
        "title": "A Phase II Study Of Oral LBH589 In Adult Patients With Refractory Cutaneous T-Cell Lymphoma - DE",
        "timestamp": "2007-02-01"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-000880-27/FR",
        "title": "A Phase II Study Of Oral LBH589 In Adult Patients With Refractory Cutaneous T-Cell Lymphoma - FR",
        "timestamp": "2007-02-01"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-000880-27/IT",
        "title": "A Phase II Study Of Oral LBH589 In Adult Patients With Refractory Cutaneous T-Cell Lymphoma - IT",
        "timestamp": "2007-02-01"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-000880-27/ES",
        "title": "A Phase II Study Of Oral LBH589 In Adult Patients With Refractory Cutaneous T-Cell Lymphoma - ES",
        "timestamp": "2007-02-01"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-000880-27/results",
        "title": "A Phase II Study Of Oral LBH589 In Adult Patients With Refractory Cutaneous T-Cell Lymphoma - View results",
        "timestamp": "2007-02-01"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-021113-23/ES",
        "title": "\"\"Estudio en fase III, aleatorizado, doble ciego y controlado con placebo para investigar la eficacia, la seguridad y la tolerabilidad de TMC435 frente a placebo como parte de una pauta con peginte... - ES",
        "timestamp": "2010-12-23"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-021113-23/DE",
        "title": "\"\"Estudio en fase III, aleatorizado, doble ciego y controlado con placebo para investigar la eficacia, la seguridad y la tolerabilidad de TMC435 frente a placebo como parte de una pauta con peginte... - DE",
        "timestamp": "2010-12-23"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-021113-23/BE",
        "title": "\"\"Estudio en fase III, aleatorizado, doble ciego y controlado con placebo para investigar la eficacia, la seguridad y la tolerabilidad de TMC435 frente a placebo como parte de una pauta con peginte... - BE",
        "timestamp": "2010-12-23"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-021113-23/GB",
        "title": "\"\"Estudio en fase III, aleatorizado, doble ciego y controlado con placebo para investigar la eficacia, la seguridad y la tolerabilidad de TMC435 frente a placebo como parte de una pauta con peginte... - GB",
        "timestamp": "2010-12-23"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-021113-23/AT",
        "title": "\"\"Estudio en fase III, aleatorizado, doble ciego y controlado con placebo para investigar la eficacia, la seguridad y la tolerabilidad de TMC435 frente a placebo como parte de una pauta con peginte... - AT",
        "timestamp": "2010-12-23"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-021113-23/PL",
        "title": "\"\"Estudio en fase III, aleatorizado, doble ciego y controlado con placebo para investigar la eficacia, la seguridad y la tolerabilidad de TMC435 frente a placebo como parte de una pauta con peginte... - PL",
        "timestamp": "2010-12-23"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-021113-23/IT",
        "title": "\"\"Estudio en fase III, aleatorizado, doble ciego y controlado con placebo para investigar la eficacia, la seguridad y la tolerabilidad de TMC435 frente a placebo como parte de una pauta con peginte... - IT",
        "timestamp": "2010-12-23"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-021113-23/results",
        "title": "\"\"Estudio en fase III, aleatorizado, doble ciego y controlado con placebo para investigar la eficacia, la seguridad y la tolerabilidad de TMC435 frente a placebo como parte de una pauta con peginte... - View results",
        "timestamp": "2010-12-23"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-002887-26/BE",
        "title": "A randomized, double-blind, multicenter, Phase III study of everolimus (RAD001) plus best supportive care versus placebo plus best supportive care in the treatment of patients with advanced NET of ... - BE",
        "timestamp": "2012-04-26"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-002887-26/AT",
        "title": "A randomized, double-blind, multicenter, Phase III study of everolimus (RAD001) plus best supportive care versus placebo plus best supportive care in the treatment of patients with advanced NET of ... - AT",
        "timestamp": "2012-04-26"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-002887-26/DE",
        "title": "A randomized, double-blind, multicenter, Phase III study of everolimus (RAD001) plus best supportive care versus placebo plus best supportive care in the treatment of patients with advanced NET of ... - DE",
        "timestamp": "2012-04-26"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-002887-26/CZ",
        "title": "A randomized, double-blind, multicenter, Phase III study of everolimus (RAD001) plus best supportive care versus placebo plus best supportive care in the treatment of patients with advanced NET of ... - CZ",
        "timestamp": "2012-04-26"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-002887-26/HU",
        "title": "A randomized, double-blind, multicenter, Phase III study of everolimus (RAD001) plus best supportive care versus placebo plus best supportive care in the treatment of patients with advanced NET of ... - HU",
        "timestamp": "2012-04-26"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-002887-26/ES",
        "title": "A randomized, double-blind, multicenter, Phase III study of everolimus (RAD001) plus best supportive care versus placebo plus best supportive care in the treatment of patients with advanced NET of ... - ES",
        "timestamp": "2012-04-26"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-002887-26/GB",
        "title": "A randomized, double-blind, multicenter, Phase III study of everolimus (RAD001) plus best supportive care versus placebo plus best supportive care in the treatment of patients with advanced NET of ... - GB",
        "timestamp": "2012-04-26"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-002887-26/IT",
        "title": "A randomized, double-blind, multicenter, Phase III study of everolimus (RAD001) plus best supportive care versus placebo plus best supportive care in the treatment of patients with advanced NET of ... - IT",
        "timestamp": "2012-04-26"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-002887-26/NO",
        "title": "A randomized, double-blind, multicenter, Phase III study of everolimus (RAD001) plus best supportive care versus placebo plus best supportive care in the treatment of patients with advanced NET of ... - NO",
        "timestamp": "2012-04-26"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-002887-26/NL",
        "title": "A randomized, double-blind, multicenter, Phase III study of everolimus (RAD001) plus best supportive care versus placebo plus best supportive care in the treatment of patients with advanced NET of ... - NL",
        "timestamp": "2012-04-26"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-002887-26/GR",
        "title": "A randomized, double-blind, multicenter, Phase III study of everolimus (RAD001) plus best supportive care versus placebo plus best supportive care in the treatment of patients with advanced NET of ... - GR",
        "timestamp": "2012-04-26"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-002887-26/SK",
        "title": "A randomized, double-blind, multicenter, Phase III study of everolimus (RAD001) plus best supportive care versus placebo plus best supportive care in the treatment of patients with advanced NET of ... - SK",
        "timestamp": "2012-04-26"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-002887-26/PL",
        "title": "A randomized, double-blind, multicenter, Phase III study of everolimus (RAD001) plus best supportive care versus placebo plus best supportive care in the treatment of patients with advanced NET of ... - PL",
        "timestamp": "2012-04-26"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-005460-28/ES",
        "title": "Estudio multicéntrico, abierto, de acceso expandido de RAD001, en pacientes con carcinoma renal metastásico que han progresado a pesar de la terapia con  inhibidor de tirosina quinasas del receptor... - ES",
        "timestamp": "2008-07-18"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-005460-28/DE",
        "title": "Estudio multicéntrico, abierto, de acceso expandido de RAD001, en pacientes con carcinoma renal metastásico que han progresado a pesar de la terapia con  inhibidor de tirosina quinasas del receptor... - DE",
        "timestamp": "2008-07-18"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-005460-28/AT",
        "title": "Estudio multicéntrico, abierto, de acceso expandido de RAD001, en pacientes con carcinoma renal metastásico que han progresado a pesar de la terapia con  inhibidor de tirosina quinasas del receptor... - AT",
        "timestamp": "2008-07-18"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-005460-28/SK",
        "title": "Estudio multicéntrico, abierto, de acceso expandido de RAD001, en pacientes con carcinoma renal metastásico que han progresado a pesar de la terapia con  inhibidor de tirosina quinasas del receptor... - SK",
        "timestamp": "2008-07-18"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-005460-28/CZ",
        "title": "Estudio multicéntrico, abierto, de acceso expandido de RAD001, en pacientes con carcinoma renal metastásico que han progresado a pesar de la terapia con  inhibidor de tirosina quinasas del receptor... - CZ",
        "timestamp": "2008-07-18"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-005460-28/FI",
        "title": "Estudio multicéntrico, abierto, de acceso expandido de RAD001, en pacientes con carcinoma renal metastásico que han progresado a pesar de la terapia con  inhibidor de tirosina quinasas del receptor... - FI",
        "timestamp": "2008-07-18"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-005460-28/SE",
        "title": "Estudio multicéntrico, abierto, de acceso expandido de RAD001, en pacientes con carcinoma renal metastásico que han progresado a pesar de la terapia con  inhibidor de tirosina quinasas del receptor... - SE",
        "timestamp": "2008-07-18"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-005460-28/HU",
        "title": "Estudio multicéntrico, abierto, de acceso expandido de RAD001, en pacientes con carcinoma renal metastásico que han progresado a pesar de la terapia con  inhibidor de tirosina quinasas del receptor... - HU",
        "timestamp": "2008-07-18"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-005460-28/GB",
        "title": "Estudio multicéntrico, abierto, de acceso expandido de RAD001, en pacientes con carcinoma renal metastásico que han progresado a pesar de la terapia con  inhibidor de tirosina quinasas del receptor... - GB",
        "timestamp": "2008-07-18"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-005460-28/BE",
        "title": "Estudio multicéntrico, abierto, de acceso expandido de RAD001, en pacientes con carcinoma renal metastásico que han progresado a pesar de la terapia con  inhibidor de tirosina quinasas del receptor... - BE",
        "timestamp": "2008-07-18"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-005460-28/GR",
        "title": "Estudio multicéntrico, abierto, de acceso expandido de RAD001, en pacientes con carcinoma renal metastásico que han progresado a pesar de la terapia con  inhibidor de tirosina quinasas del receptor... - GR",
        "timestamp": "2008-07-18"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-005460-28/IT",
        "title": "Estudio multicéntrico, abierto, de acceso expandido de RAD001, en pacientes con carcinoma renal metastásico que han progresado a pesar de la terapia con  inhibidor de tirosina quinasas del receptor... - IT",
        "timestamp": "2008-07-18"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-005460-28/NL",
        "title": "Estudio multicéntrico, abierto, de acceso expandido de RAD001, en pacientes con carcinoma renal metastásico que han progresado a pesar de la terapia con  inhibidor de tirosina quinasas del receptor... - NL",
        "timestamp": "2008-07-18"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-005460-28/results",
        "title": "Estudio multicéntrico, abierto, de acceso expandido de RAD001, en pacientes con carcinoma renal metastásico que han progresado a pesar de la terapia con  inhibidor de tirosina quinasas del receptor... - View results",
        "timestamp": "2008-07-18"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-001357-17/HU",
        "title": "An open-label, multicenter, phase IIIb study assessing the long-term efficacy and safety of AOP2014 and standard first line treatment (BAT) in patients with Polycythemia Vera who previously partici... - HU",
        "timestamp": "2014-11-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-001357-17/AT",
        "title": "An open-label, multicenter, phase IIIb study assessing the long-term efficacy and safety of AOP2014 and standard first line treatment (BAT) in patients with Polycythemia Vera who previously partici... - AT",
        "timestamp": "2014-11-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-001357-17/CZ",
        "title": "An open-label, multicenter, phase IIIb study assessing the long-term efficacy and safety of AOP2014 and standard first line treatment (BAT) in patients with Polycythemia Vera who previously partici... - CZ",
        "timestamp": "2014-11-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-001357-17/PL",
        "title": "An open-label, multicenter, phase IIIb study assessing the long-term efficacy and safety of AOP2014 and standard first line treatment (BAT) in patients with Polycythemia Vera who previously partici... - PL",
        "timestamp": "2014-11-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-001357-17/SK",
        "title": "An open-label, multicenter, phase IIIb study assessing the long-term efficacy and safety of AOP2014 and standard first line treatment (BAT) in patients with Polycythemia Vera who previously partici... - SK",
        "timestamp": "2014-11-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-001357-17/BG",
        "title": "An open-label, multicenter, phase IIIb study assessing the long-term efficacy and safety of AOP2014 and standard first line treatment (BAT) in patients with Polycythemia Vera who previously partici... - BG",
        "timestamp": "2014-11-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-001357-17/ES",
        "title": "An open-label, multicenter, phase IIIb study assessing the long-term efficacy and safety of AOP2014 and standard first line treatment (BAT) in patients with Polycythemia Vera who previously partici... - ES",
        "timestamp": "2014-11-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-001357-17/DE",
        "title": "An open-label, multicenter, phase IIIb study assessing the long-term efficacy and safety of AOP2014 and standard first line treatment (BAT) in patients with Polycythemia Vera who previously partici... - DE",
        "timestamp": "2014-11-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005293-31/DE",
        "title": "A Long-Term Follow-Up Study of Subjects Who Participated in a Clinical Trial in which Peginterferon Lambda-1a (BMS-914143) was Administered for the Treatment of Chronic Hepatitis C\r\n\r\nRevised Proto... - DE",
        "timestamp": "2012-06-01"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005293-31/AT",
        "title": "A Long-Term Follow-Up Study of Subjects Who Participated in a Clinical Trial in which Peginterferon Lambda-1a (BMS-914143) was Administered for the Treatment of Chronic Hepatitis C\r\n\r\nRevised Proto... - AT",
        "timestamp": "2012-06-01"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005293-31/ES",
        "title": "A Long-Term Follow-Up Study of Subjects Who Participated in a Clinical Trial in which Peginterferon Lambda-1a (BMS-914143) was Administered for the Treatment of Chronic Hepatitis C\r\n\r\nRevised Proto... - ES",
        "timestamp": "2012-06-01"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005293-31/PL",
        "title": "A Long-Term Follow-Up Study of Subjects Who Participated in a Clinical Trial in which Peginterferon Lambda-1a (BMS-914143) was Administered for the Treatment of Chronic Hepatitis C\r\n\r\nRevised Proto... - PL",
        "timestamp": "2012-06-01"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005293-31/IT",
        "title": "A Long-Term Follow-Up Study of Subjects Who Participated in a Clinical Trial in which Peginterferon Lambda-1a (BMS-914143) was Administered for the Treatment of Chronic Hepatitis C\r\n\r\nRevised Proto... - IT",
        "timestamp": "2012-06-01"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005293-31/GR",
        "title": "A Long-Term Follow-Up Study of Subjects Who Participated in a Clinical Trial in which Peginterferon Lambda-1a (BMS-914143) was Administered for the Treatment of Chronic Hepatitis C\r\n\r\nRevised Proto... - GR",
        "timestamp": "2012-06-01"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005293-31/FI",
        "title": "A Long-Term Follow-Up Study of Subjects Who Participated in a Clinical Trial in which Peginterferon Lambda-1a (BMS-914143) was Administered for the Treatment of Chronic Hepatitis C\r\n\r\nRevised Proto... - FI",
        "timestamp": "2012-06-01"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005293-31/BE",
        "title": "A Long-Term Follow-Up Study of Subjects Who Participated in a Clinical Trial in which Peginterferon Lambda-1a (BMS-914143) was Administered for the Treatment of Chronic Hepatitis C\r\n\r\nRevised Proto... - BE",
        "timestamp": "2012-06-01"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005293-31/NL",
        "title": "A Long-Term Follow-Up Study of Subjects Who Participated in a Clinical Trial in which Peginterferon Lambda-1a (BMS-914143) was Administered for the Treatment of Chronic Hepatitis C\r\n\r\nRevised Proto... - NL",
        "timestamp": "2012-06-01"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005293-31/results",
        "title": "A Long-Term Follow-Up Study of Subjects Who Participated in a Clinical Trial in which Peginterferon Lambda-1a (BMS-914143) was Administered for the Treatment of Chronic Hepatitis C\r\n\r\nRevised Proto... - View results",
        "timestamp": "2012-06-01"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-004400-30/SE",
        "title": "A phase IIIB, open, long term extension study to evaluate the persistence of immune responses and the safety of GSK Biologicals’ Herpes Zoster subunit (HZ/su) vaccine 1437173A, at Months 108 and 12... - SE",
        "timestamp": "2016-02-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-004400-30/DE",
        "title": "A phase IIIB, open, long term extension study to evaluate the persistence of immune responses and the safety of GSK Biologicals’ Herpes Zoster subunit (HZ/su) vaccine 1437173A, at Months 108 and 12... - DE",
        "timestamp": "2016-02-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-004400-30/CZ",
        "title": "A phase IIIB, open, long term extension study to evaluate the persistence of immune responses and the safety of GSK Biologicals’ Herpes Zoster subunit (HZ/su) vaccine 1437173A, at Months 108 and 12... - CZ",
        "timestamp": "2016-02-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-004400-30/results",
        "title": "A phase IIIB, open, long term extension study to evaluate the persistence of immune responses and the safety of GSK Biologicals’ Herpes Zoster subunit (HZ/su) vaccine 1437173A, at Months 108 and 12... - View results",
        "timestamp": "2016-02-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020034-26/DE",
        "title": "A multicenter, randomized, open label, parallel-group phase IIB study on the efficacy and safety of oral regimens of DEB025 alone or in combination with ribavirin versus Standard of Care (peg-IFN a... - DE",
        "timestamp": "2010-11-18"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020034-26/PL",
        "title": "A multicenter, randomized, open label, parallel-group phase IIB study on the efficacy and safety of oral regimens of DEB025 alone or in combination with ribavirin versus Standard of Care (peg-IFN a... - PL",
        "timestamp": "2010-11-18"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020034-26/GB",
        "title": "A multicenter, randomized, open label, parallel-group phase IIB study on the efficacy and safety of oral regimens of DEB025 alone or in combination with ribavirin versus Standard of Care (peg-IFN a... - GB",
        "timestamp": "2010-11-18"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020034-26/BE",
        "title": "A multicenter, randomized, open label, parallel-group phase IIB study on the efficacy and safety of oral regimens of DEB025 alone or in combination with ribavirin versus Standard of Care (peg-IFN a... - BE",
        "timestamp": "2010-11-18"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020034-26/IT",
        "title": "A multicenter, randomized, open label, parallel-group phase IIB study on the efficacy and safety of oral regimens of DEB025 alone or in combination with ribavirin versus Standard of Care (peg-IFN a... - IT",
        "timestamp": "2010-11-18"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020034-26/results",
        "title": "A multicenter, randomized, open label, parallel-group phase IIB study on the efficacy and safety of oral regimens of DEB025 alone or in combination with ribavirin versus Standard of Care (peg-IFN a... - View results",
        "timestamp": "2010-11-18"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-002070-21/DE",
        "title": "A randomized, double-blind, placebo-controlled, multicenter phase III study to compare the safety and efficacy of RAD001 plus Best Supportive Care (BSC) versus BSC plus Placebo in patients with met... - DE",
        "timestamp": "2006-10-17"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-002070-21/NL",
        "title": "A randomized, double-blind, placebo-controlled, multicenter phase III study to compare the safety and efficacy of RAD001 plus Best Supportive Care (BSC) versus BSC plus Placebo in patients with met... - NL",
        "timestamp": "2006-10-17"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-002070-21/AT",
        "title": "A randomized, double-blind, placebo-controlled, multicenter phase III study to compare the safety and efficacy of RAD001 plus Best Supportive Care (BSC) versus BSC plus Placebo in patients with met... - AT",
        "timestamp": "2006-10-17"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-002070-21/FR",
        "title": "A randomized, double-blind, placebo-controlled, multicenter phase III study to compare the safety and efficacy of RAD001 plus Best Supportive Care (BSC) versus BSC plus Placebo in patients with met... - FR",
        "timestamp": "2006-10-17"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-002070-21/IT",
        "title": "A randomized, double-blind, placebo-controlled, multicenter phase III study to compare the safety and efficacy of RAD001 plus Best Supportive Care (BSC) versus BSC plus Placebo in patients with met... - IT",
        "timestamp": "2006-10-17"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-002070-21/results",
        "title": "A randomized, double-blind, placebo-controlled, multicenter phase III study to compare the safety and efficacy of RAD001 plus Best Supportive Care (BSC) versus BSC plus Placebo in patients with met... - View results",
        "timestamp": "2006-10-17"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-004928-35/SE",
        "title": "Open-Label, Phase 3b Study to Determine Efficacy and Safety of Telaprevir, Pegylated-Interferon-alfa-2a and Ribavirin in Hepatitis C Virus Treatment-Naïve and Treatment-Experienced Subjects with Ge... - SE",
        "timestamp": "2012-02-29"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-004928-35/GB",
        "title": "Open-Label, Phase 3b Study to Determine Efficacy and Safety of Telaprevir, Pegylated-Interferon-alfa-2a and Ribavirin in Hepatitis C Virus Treatment-Naïve and Treatment-Experienced Subjects with Ge... - GB",
        "timestamp": "2012-02-29"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-004928-35/ES",
        "title": "Open-Label, Phase 3b Study to Determine Efficacy and Safety of Telaprevir, Pegylated-Interferon-alfa-2a and Ribavirin in Hepatitis C Virus Treatment-Naïve and Treatment-Experienced Subjects with Ge... - ES",
        "timestamp": "2012-02-29"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-004928-35/PL",
        "title": "Open-Label, Phase 3b Study to Determine Efficacy and Safety of Telaprevir, Pegylated-Interferon-alfa-2a and Ribavirin in Hepatitis C Virus Treatment-Naïve and Treatment-Experienced Subjects with Ge... - PL",
        "timestamp": "2012-02-29"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-004928-35/results",
        "title": "Open-Label, Phase 3b Study to Determine Efficacy and Safety of Telaprevir, Pegylated-Interferon-alfa-2a and Ribavirin in Hepatitis C Virus Treatment-Naïve and Treatment-Experienced Subjects with Ge... - View results",
        "timestamp": "2012-02-29"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-004876-23/GB",
        "title": "A Single Arm, Open Label, Multicenter Study to Evaluate the Efficacy and Safety of Glecaprevir(GLE)/Pibrentasvir(PIB) in Treatment Naïve Adults with Chronic Hepatitis C Virus (HCV) Genotypes 1 – 6 ... - GB",
        "timestamp": "2017-09-13"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-004876-23/ES",
        "title": "A Single Arm, Open Label, Multicenter Study to Evaluate the Efficacy and Safety of Glecaprevir(GLE)/Pibrentasvir(PIB) in Treatment Naïve Adults with Chronic Hepatitis C Virus (HCV) Genotypes 1 – 6 ... - ES",
        "timestamp": "2017-09-13"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-004876-23/DE",
        "title": "A Single Arm, Open Label, Multicenter Study to Evaluate the Efficacy and Safety of Glecaprevir(GLE)/Pibrentasvir(PIB) in Treatment Naïve Adults with Chronic Hepatitis C Virus (HCV) Genotypes 1 – 6 ... - DE",
        "timestamp": "2017-09-13"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-004876-23/BG",
        "title": "A Single Arm, Open Label, Multicenter Study to Evaluate the Efficacy and Safety of Glecaprevir(GLE)/Pibrentasvir(PIB) in Treatment Naïve Adults with Chronic Hepatitis C Virus (HCV) Genotypes 1 – 6 ... - BG",
        "timestamp": "2017-09-13"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-004876-23/PL",
        "title": "A Single Arm, Open Label, Multicenter Study to Evaluate the Efficacy and Safety of Glecaprevir(GLE)/Pibrentasvir(PIB) in Treatment Naïve Adults with Chronic Hepatitis C Virus (HCV) Genotypes 1 – 6 ... - PL",
        "timestamp": "2017-09-13"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-004876-23/results",
        "title": "A Single Arm, Open Label, Multicenter Study to Evaluate the Efficacy and Safety of Glecaprevir(GLE)/Pibrentasvir(PIB) in Treatment Naïve Adults with Chronic Hepatitis C Virus (HCV) Genotypes 1 – 6 ... - View results",
        "timestamp": "2017-09-13"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-000185-22/SE",
        "title": "A Phase 1b/2, Multicenter, Open-label Trial of Talimogene Laherparepvec in Combination With MK-3475 for Treatment of Previously Untreated, Unresected, Stage IIIB to IVM1c Melanoma - SE",
        "timestamp": "2014-12-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-000185-22/ES",
        "title": "A Phase 1b/2, Multicenter, Open-label Trial of Talimogene Laherparepvec in Combination With MK-3475 for Treatment of Previously Untreated, Unresected, Stage IIIB to IVM1c Melanoma - ES",
        "timestamp": "2014-12-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-000185-22/BE",
        "title": "A Phase 1b/2, Multicenter, Open-label Trial of Talimogene Laherparepvec in Combination With MK-3475 for Treatment of Previously Untreated, Unresected, Stage IIIB to IVM1c Melanoma - BE",
        "timestamp": "2014-12-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-000185-22/DE",
        "title": "A Phase 1b/2, Multicenter, Open-label Trial of Talimogene Laherparepvec in Combination With MK-3475 for Treatment of Previously Untreated, Unresected, Stage IIIB to IVM1c Melanoma - DE",
        "timestamp": "2014-12-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-000185-22/AT",
        "title": "A Phase 1b/2, Multicenter, Open-label Trial of Talimogene Laherparepvec in Combination With MK-3475 for Treatment of Previously Untreated, Unresected, Stage IIIB to IVM1c Melanoma - AT",
        "timestamp": "2014-12-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-000185-22/GR",
        "title": "A Phase 1b/2, Multicenter, Open-label Trial of Talimogene Laherparepvec in Combination With MK-3475 for Treatment of Previously Untreated, Unresected, Stage IIIB to IVM1c Melanoma - GR",
        "timestamp": "2014-12-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-000185-22/IT",
        "title": "A Phase 1b/2, Multicenter, Open-label Trial of Talimogene Laherparepvec in Combination With MK-3475 for Treatment of Previously Untreated, Unresected, Stage IIIB to IVM1c Melanoma - IT",
        "timestamp": "2014-12-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-000185-22/FI",
        "title": "A Phase 1b/2, Multicenter, Open-label Trial of Talimogene Laherparepvec in Combination With MK-3475 for Treatment of Previously Untreated, Unresected, Stage IIIB to IVM1c Melanoma - FI",
        "timestamp": "2014-12-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-000185-22/CZ",
        "title": "A Phase 1b/2, Multicenter, Open-label Trial of Talimogene Laherparepvec in Combination With MK-3475 for Treatment of Previously Untreated, Unresected, Stage IIIB to IVM1c Melanoma - CZ",
        "timestamp": "2014-12-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-000185-22/PT",
        "title": "A Phase 1b/2, Multicenter, Open-label Trial of Talimogene Laherparepvec in Combination With MK-3475 for Treatment of Previously Untreated, Unresected, Stage IIIB to IVM1c Melanoma - PT",
        "timestamp": "2014-12-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-000185-22/HU",
        "title": "A Phase 1b/2, Multicenter, Open-label Trial of Talimogene Laherparepvec in Combination With MK-3475 for Treatment of Previously Untreated, Unresected, Stage IIIB to IVM1c Melanoma - HU",
        "timestamp": "2014-12-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-012000-10/BE",
        "title": "A Phase II Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of Different Regimens of MK-7009 When Administered Concomitantly with Pegylated Interferon and Rib... - BE",
        "timestamp": "2009-07-13"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-012000-10/DE",
        "title": "A Phase II Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of Different Regimens of MK-7009 When Administered Concomitantly with Pegylated Interferon and Rib... - DE",
        "timestamp": "2009-07-13"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-012000-10/GB",
        "title": "A Phase II Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of Different Regimens of MK-7009 When Administered Concomitantly with Pegylated Interferon and Rib... - GB",
        "timestamp": "2009-07-13"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-012000-10/AT",
        "title": "A Phase II Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of Different Regimens of MK-7009 When Administered Concomitantly with Pegylated Interferon and Rib... - AT",
        "timestamp": "2009-07-13"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-012000-10/ES",
        "title": "A Phase II Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of Different Regimens of MK-7009 When Administered Concomitantly with Pegylated Interferon and Rib... - ES",
        "timestamp": "2009-07-13"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-012000-10/results",
        "title": "A Phase II Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of Different Regimens of MK-7009 When Administered Concomitantly with Pegylated Interferon and Rib... - View results",
        "timestamp": "2009-07-13"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-006338-32/FR",
        "title": "Phase II, multicenter, randomized, parallel-group, partially blinded, placebo and Avonex controlled dose finding study to evaluate the efficacy, as measured by brain MRI lesions, and safety of 2 do... - FR",
        "timestamp": "2008-05-06"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-006338-32/GB",
        "title": "Phase II, multicenter, randomized, parallel-group, partially blinded, placebo and Avonex controlled dose finding study to evaluate the efficacy, as measured by brain MRI lesions, and safety of 2 do... - GB",
        "timestamp": "2008-05-06"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-006338-32/DE",
        "title": "Phase II, multicenter, randomized, parallel-group, partially blinded, placebo and Avonex controlled dose finding study to evaluate the efficacy, as measured by brain MRI lesions, and safety of 2 do... - DE",
        "timestamp": "2008-05-06"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-006338-32/ES",
        "title": "Phase II, multicenter, randomized, parallel-group, partially blinded, placebo and Avonex controlled dose finding study to evaluate the efficacy, as measured by brain MRI lesions, and safety of 2 do... - ES",
        "timestamp": "2008-05-06"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-006338-32/CZ",
        "title": "Phase II, multicenter, randomized, parallel-group, partially blinded, placebo and Avonex controlled dose finding study to evaluate the efficacy, as measured by brain MRI lesions, and safety of 2 do... - CZ",
        "timestamp": "2008-05-06"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-006338-32/SK",
        "title": "Phase II, multicenter, randomized, parallel-group, partially blinded, placebo and Avonex controlled dose finding study to evaluate the efficacy, as measured by brain MRI lesions, and safety of 2 do... - SK",
        "timestamp": "2008-05-06"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-006338-32/DK",
        "title": "Phase II, multicenter, randomized, parallel-group, partially blinded, placebo and Avonex controlled dose finding study to evaluate the efficacy, as measured by brain MRI lesions, and safety of 2 do... - DK",
        "timestamp": "2008-05-06"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-006338-32/BE",
        "title": "Phase II, multicenter, randomized, parallel-group, partially blinded, placebo and Avonex controlled dose finding study to evaluate the efficacy, as measured by brain MRI lesions, and safety of 2 do... - BE",
        "timestamp": "2008-05-06"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-006338-32/NL",
        "title": "Phase II, multicenter, randomized, parallel-group, partially blinded, placebo and Avonex controlled dose finding study to evaluate the efficacy, as measured by brain MRI lesions, and safety of 2 do... - NL",
        "timestamp": "2008-05-06"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-006338-32/FI",
        "title": "Phase II, multicenter, randomized, parallel-group, partially blinded, placebo and Avonex controlled dose finding study to evaluate the efficacy, as measured by brain MRI lesions, and safety of 2 do... - FI",
        "timestamp": "2008-05-06"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-006338-32/BG",
        "title": "Phase II, multicenter, randomized, parallel-group, partially blinded, placebo and Avonex controlled dose finding study to evaluate the efficacy, as measured by brain MRI lesions, and safety of 2 do... - BG",
        "timestamp": "2008-05-06"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-006338-32/IT",
        "title": "Phase II, multicenter, randomized, parallel-group, partially blinded, placebo and Avonex controlled dose finding study to evaluate the efficacy, as measured by brain MRI lesions, and safety of 2 do... - IT",
        "timestamp": "2008-05-06"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-006338-32/results",
        "title": "Phase II, multicenter, randomized, parallel-group, partially blinded, placebo and Avonex controlled dose finding study to evaluate the efficacy, as measured by brain MRI lesions, and safety of 2 do... - View results",
        "timestamp": "2008-05-06"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-000977-31/GB",
        "title": "PHASE IIIB, RANDOMIZED, OPEN LABEL STUDY OF PEGYLATED INTERFERON ALFA-2A IN COMBINATION WITH LAMIVUDINE OR ENTECAVIR COMPARED WITH UNTREATED CONTROL PATIENTS IN CHILDREN WITH HBEAG POSITIVE CHRONIC... - GB",
        "timestamp": "2006-05-05"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-000977-31/DE",
        "title": "PHASE IIIB, RANDOMIZED, OPEN LABEL STUDY OF PEGYLATED INTERFERON ALFA-2A IN COMBINATION WITH LAMIVUDINE OR ENTECAVIR COMPARED WITH UNTREATED CONTROL PATIENTS IN CHILDREN WITH HBEAG POSITIVE CHRONIC... - DE",
        "timestamp": "2006-05-05"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-000977-31/BE",
        "title": "PHASE IIIB, RANDOMIZED, OPEN LABEL STUDY OF PEGYLATED INTERFERON ALFA-2A IN COMBINATION WITH LAMIVUDINE OR ENTECAVIR COMPARED WITH UNTREATED CONTROL PATIENTS IN CHILDREN WITH HBEAG POSITIVE CHRONIC... - BE",
        "timestamp": "2006-05-05"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-017490-38/DE",
        "title": "Randomized Treatment Interruption of Natalizumab - DE",
        "timestamp": "2010-05-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-017490-38/ES",
        "title": "Randomized Treatment Interruption of Natalizumab - ES",
        "timestamp": "2010-05-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-017490-38/results",
        "title": "Randomized Treatment Interruption of Natalizumab - View results",
        "timestamp": "2010-05-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-005428-99/GB",
        "title": "A randomised controlled phase III trial comparing hyperthermia plus mitomycin to a second course of bacillus Calmette-Guerin or standard therapy in patients with recurrence of non-muscle invasive b... - GB",
        "timestamp": "2009-10-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-005428-99/results",
        "title": "A randomised controlled phase III trial comparing hyperthermia plus mitomycin to a second course of bacillus Calmette-Guerin or standard therapy in patients with recurrence of non-muscle invasive b... - View results",
        "timestamp": "2009-10-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005036-26/GB",
        "title": "An Exploratory Phase IIa Study to Investigate the Biological Activity of Oral FX125L in Adult Patients with Chronic Inflammatory Disease - GB",
        "timestamp": "2011-11-29"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-001012-32/DE",
        "title": "A single agent Phase II study of depsipeptide (FK228) in the treatment of Cutaneous T-cell lymphoma - DE",
        "timestamp": "2005-03-31"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-001012-32/GB",
        "title": "A single agent Phase II study of depsipeptide (FK228) in the treatment of Cutaneous T-cell lymphoma - GB",
        "timestamp": "2005-03-31"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-001012-32/AT",
        "title": "A single agent Phase II study of depsipeptide (FK228) in the treatment of Cutaneous T-cell lymphoma - AT",
        "timestamp": "2005-03-31"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-001012-32/results",
        "title": "A single agent Phase II study of depsipeptide (FK228) in the treatment of Cutaneous T-cell lymphoma - View results",
        "timestamp": "2005-03-31"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-004905-29/BE",
        "title": "A Phase 3, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of TMC435 plus Pegylated Interferon alfa-2a and Ribavirin Administered for 12 Weeks in Treatment-Naïve Subjects with Chro... - BE",
        "timestamp": "2013-08-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-004905-29/GB",
        "title": "A Phase 3, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of TMC435 plus Pegylated Interferon alfa-2a and Ribavirin Administered for 12 Weeks in Treatment-Naïve Subjects with Chro... - GB",
        "timestamp": "2013-08-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-004905-29/AT",
        "title": "A Phase 3, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of TMC435 plus Pegylated Interferon alfa-2a and Ribavirin Administered for 12 Weeks in Treatment-Naïve Subjects with Chro... - AT",
        "timestamp": "2013-08-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-004905-29/IT",
        "title": "A Phase 3, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of TMC435 plus Pegylated Interferon alfa-2a and Ribavirin Administered for 12 Weeks in Treatment-Naïve Subjects with Chro... - IT",
        "timestamp": "2013-08-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-004905-29/ES",
        "title": "A Phase 3, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of TMC435 plus Pegylated Interferon alfa-2a and Ribavirin Administered for 12 Weeks in Treatment-Naïve Subjects with Chro... - ES",
        "timestamp": "2013-08-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-004905-29/DE",
        "title": "A Phase 3, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of TMC435 plus Pegylated Interferon alfa-2a and Ribavirin Administered for 12 Weeks in Treatment-Naïve Subjects with Chro... - DE",
        "timestamp": "2013-08-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-004905-29/results",
        "title": "A Phase 3, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of TMC435 plus Pegylated Interferon alfa-2a and Ribavirin Administered for 12 Weeks in Treatment-Naïve Subjects with Chro... - View results",
        "timestamp": "2013-08-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-004939-39/BE",
        "title": "Pharmacoepidemiology study to define the long-term safety profile of tenofovir disoproxil fumarate (Tenofovir DF, Viread®) and describe the management of Tenofovir DF-associated renal and bone toxi... - BE",
        "timestamp": "2015-05-26"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-004939-39/GB",
        "title": "Pharmacoepidemiology study to define the long-term safety profile of tenofovir disoproxil fumarate (Tenofovir DF, Viread®) and describe the management of Tenofovir DF-associated renal and bone toxi... - GB",
        "timestamp": "2015-05-26"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-004939-39/ES",
        "title": "Pharmacoepidemiology study to define the long-term safety profile of tenofovir disoproxil fumarate (Tenofovir DF, Viread®) and describe the management of Tenofovir DF-associated renal and bone toxi... - ES",
        "timestamp": "2015-05-26"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-004939-39/BG",
        "title": "Pharmacoepidemiology study to define the long-term safety profile of tenofovir disoproxil fumarate (Tenofovir DF, Viread®) and describe the management of Tenofovir DF-associated renal and bone toxi... - BG",
        "timestamp": "2015-05-26"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-004939-39/GR",
        "title": "Pharmacoepidemiology study to define the long-term safety profile of tenofovir disoproxil fumarate (Tenofovir DF, Viread®) and describe the management of Tenofovir DF-associated renal and bone toxi... - GR",
        "timestamp": "2015-05-26"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-004939-39/FR",
        "title": "Pharmacoepidemiology study to define the long-term safety profile of tenofovir disoproxil fumarate (Tenofovir DF, Viread®) and describe the management of Tenofovir DF-associated renal and bone toxi... - FR",
        "timestamp": "2015-05-26"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-004939-39/results",
        "title": "Pharmacoepidemiology study to define the long-term safety profile of tenofovir disoproxil fumarate (Tenofovir DF, Viread®) and describe the management of Tenofovir DF-associated renal and bone toxi... - View results",
        "timestamp": "2015-05-26"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-019584-10/ES",
        "title": "Estudio aleatorizado, abierto, multicéntrico, de búsqueda de dosis y duración del tratamiento para evaluar la respuesta virológica mantenida del inhibidor de proteasa VHC Danoprevir (RO5190591) ref... - ES",
        "timestamp": "2010-12-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-019584-10/DE",
        "title": "Estudio aleatorizado, abierto, multicéntrico, de búsqueda de dosis y duración del tratamiento para evaluar la respuesta virológica mantenida del inhibidor de proteasa VHC Danoprevir (RO5190591) ref... - DE",
        "timestamp": "2010-12-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-019584-10/GB",
        "title": "Estudio aleatorizado, abierto, multicéntrico, de búsqueda de dosis y duración del tratamiento para evaluar la respuesta virológica mantenida del inhibidor de proteasa VHC Danoprevir (RO5190591) ref... - GB",
        "timestamp": "2010-12-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-019584-10/AT",
        "title": "Estudio aleatorizado, abierto, multicéntrico, de búsqueda de dosis y duración del tratamiento para evaluar la respuesta virológica mantenida del inhibidor de proteasa VHC Danoprevir (RO5190591) ref... - AT",
        "timestamp": "2010-12-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-019584-10/FR",
        "title": "Estudio aleatorizado, abierto, multicéntrico, de búsqueda de dosis y duración del tratamiento para evaluar la respuesta virológica mantenida del inhibidor de proteasa VHC Danoprevir (RO5190591) ref... - FR",
        "timestamp": "2010-12-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-019584-10/IT",
        "title": "Estudio aleatorizado, abierto, multicéntrico, de búsqueda de dosis y duración del tratamiento para evaluar la respuesta virológica mantenida del inhibidor de proteasa VHC Danoprevir (RO5190591) ref... - IT",
        "timestamp": "2010-12-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-004097-32/GB",
        "title": "An Open-Label, Multicenter, Phase III Trial of ABI-007 vs Dacarbazine in Previously Untreated Patients with Metastatic Malignant Melanoma - GB",
        "timestamp": "2009-07-30"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-004097-32/DE",
        "title": "An Open-Label, Multicenter, Phase III Trial of ABI-007 vs Dacarbazine in Previously Untreated Patients with Metastatic Malignant Melanoma - DE",
        "timestamp": "2009-07-30"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-004097-32/NL",
        "title": "An Open-Label, Multicenter, Phase III Trial of ABI-007 vs Dacarbazine in Previously Untreated Patients with Metastatic Malignant Melanoma - NL",
        "timestamp": "2009-07-30"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-004097-32/FR",
        "title": "An Open-Label, Multicenter, Phase III Trial of ABI-007 vs Dacarbazine in Previously Untreated Patients with Metastatic Malignant Melanoma - FR",
        "timestamp": "2009-07-30"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-004097-32/ES",
        "title": "An Open-Label, Multicenter, Phase III Trial of ABI-007 vs Dacarbazine in Previously Untreated Patients with Metastatic Malignant Melanoma - ES",
        "timestamp": "2009-07-30"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-004097-32/IT",
        "title": "An Open-Label, Multicenter, Phase III Trial of ABI-007 vs Dacarbazine in Previously Untreated Patients with Metastatic Malignant Melanoma - IT",
        "timestamp": "2009-07-30"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-004097-32/results",
        "title": "An Open-Label, Multicenter, Phase III Trial of ABI-007 vs Dacarbazine in Previously Untreated Patients with Metastatic Malignant Melanoma - View results",
        "timestamp": "2009-07-30"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-002133-22/ES",
        "title": "A Phase 2, Open-label Study to Evaluate the Efficacy and Safety of Single-Agent MLN0128 and the Combination of MLN0128+MLN1117 Compared With Everolimus in the Treatment of Adult Patients With Advan... - ES",
        "timestamp": "2016-05-29"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-002133-22/FR",
        "title": "A Phase 2, Open-label Study to Evaluate the Efficacy and Safety of Single-Agent MLN0128 and the Combination of MLN0128+MLN1117 Compared With Everolimus in the Treatment of Adult Patients With Advan... - FR",
        "timestamp": "2016-05-29"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-002133-22/PL",
        "title": "A Phase 2, Open-label Study to Evaluate the Efficacy and Safety of Single-Agent MLN0128 and the Combination of MLN0128+MLN1117 Compared With Everolimus in the Treatment of Adult Patients With Advan... - PL",
        "timestamp": "2016-05-29"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-009995-11/DE",
        "title": "A randomized, adaptive-design dose finding study to assess the antiviral efficacy and\nsafety of NIM811 administered in combination with Standard of Care (SOC) for 12 weeks in relapsed HCV-1 infecte... - DE",
        "timestamp": "2009-07-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-009995-11/ES",
        "title": "A randomized, adaptive-design dose finding study to assess the antiviral efficacy and\nsafety of NIM811 administered in combination with Standard of Care (SOC) for 12 weeks in relapsed HCV-1 infecte... - ES",
        "timestamp": "2009-07-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-009995-11/IT",
        "title": "A randomized, adaptive-design dose finding study to assess the antiviral efficacy and\nsafety of NIM811 administered in combination with Standard of Care (SOC) for 12 weeks in relapsed HCV-1 infecte... - IT",
        "timestamp": "2009-07-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-009995-11/BE",
        "title": "A randomized, adaptive-design dose finding study to assess the antiviral efficacy and\nsafety of NIM811 administered in combination with Standard of Care (SOC) for 12 weeks in relapsed HCV-1 infecte... - BE",
        "timestamp": "2009-07-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-009995-11/NL",
        "title": "A randomized, adaptive-design dose finding study to assess the antiviral efficacy and\nsafety of NIM811 administered in combination with Standard of Care (SOC) for 12 weeks in relapsed HCV-1 infecte... - NL",
        "timestamp": "2009-07-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-009995-11/results",
        "title": "A randomized, adaptive-design dose finding study to assess the antiviral efficacy and\nsafety of NIM811 administered in combination with Standard of Care (SOC) for 12 weeks in relapsed HCV-1 infecte... - View results",
        "timestamp": "2009-07-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-021337-31/GB",
        "title": "A Phase III open-label study to evaluate the safety, tolerability and efficacy of TMC435 plus PegIFNα-2a (Pegasys) and ribavirin (Copegus) triple therapy in chronic hepatitis C genotype-1 infected ... - GB",
        "timestamp": "2011-11-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-021337-31/ES",
        "title": "A Phase III open-label study to evaluate the safety, tolerability and efficacy of TMC435 plus PegIFNα-2a (Pegasys) and ribavirin (Copegus) triple therapy in chronic hepatitis C genotype-1 infected ... - ES",
        "timestamp": "2011-11-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-021337-31/PT",
        "title": "A Phase III open-label study to evaluate the safety, tolerability and efficacy of TMC435 plus PegIFNα-2a (Pegasys) and ribavirin (Copegus) triple therapy in chronic hepatitis C genotype-1 infected ... - PT",
        "timestamp": "2011-11-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-021337-31/results",
        "title": "A Phase III open-label study to evaluate the safety, tolerability and efficacy of TMC435 plus PegIFNα-2a (Pegasys) and ribavirin (Copegus) triple therapy in chronic hepatitis C genotype-1 infected ... - View results",
        "timestamp": "2011-11-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020150-34/DE",
        "title": "A Phase III, Double-Blind, Randomized, Placebo-Controlled, Multicenter Clinical Trial to Study the Safety, Tolerability, Efficacy, and Immunogenicity of V212 in Recipients of Autologous Hematopoiet... - DE",
        "timestamp": "2010-10-28"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020150-34/NL",
        "title": "A Phase III, Double-Blind, Randomized, Placebo-Controlled, Multicenter Clinical Trial to Study the Safety, Tolerability, Efficacy, and Immunogenicity of V212 in Recipients of Autologous Hematopoiet... - NL",
        "timestamp": "2010-10-28"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020150-34/ES",
        "title": "A Phase III, Double-Blind, Randomized, Placebo-Controlled, Multicenter Clinical Trial to Study the Safety, Tolerability, Efficacy, and Immunogenicity of V212 in Recipients of Autologous Hematopoiet... - ES",
        "timestamp": "2010-10-28"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020150-34/SE",
        "title": "A Phase III, Double-Blind, Randomized, Placebo-Controlled, Multicenter Clinical Trial to Study the Safety, Tolerability, Efficacy, and Immunogenicity of V212 in Recipients of Autologous Hematopoiet... - SE",
        "timestamp": "2010-10-28"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020150-34/CZ",
        "title": "A Phase III, Double-Blind, Randomized, Placebo-Controlled, Multicenter Clinical Trial to Study the Safety, Tolerability, Efficacy, and Immunogenicity of V212 in Recipients of Autologous Hematopoiet... - CZ",
        "timestamp": "2010-10-28"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020150-34/GB",
        "title": "A Phase III, Double-Blind, Randomized, Placebo-Controlled, Multicenter Clinical Trial to Study the Safety, Tolerability, Efficacy, and Immunogenicity of V212 in Recipients of Autologous Hematopoiet... - GB",
        "timestamp": "2010-10-28"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020150-34/LT",
        "title": "A Phase III, Double-Blind, Randomized, Placebo-Controlled, Multicenter Clinical Trial to Study the Safety, Tolerability, Efficacy, and Immunogenicity of V212 in Recipients of Autologous Hematopoiet... - LT",
        "timestamp": "2010-10-28"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020150-34/IT",
        "title": "A Phase III, Double-Blind, Randomized, Placebo-Controlled, Multicenter Clinical Trial to Study the Safety, Tolerability, Efficacy, and Immunogenicity of V212 in Recipients of Autologous Hematopoiet... - IT",
        "timestamp": "2010-10-28"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020150-34/BE",
        "title": "A Phase III, Double-Blind, Randomized, Placebo-Controlled, Multicenter Clinical Trial to Study the Safety, Tolerability, Efficacy, and Immunogenicity of V212 in Recipients of Autologous Hematopoiet... - BE",
        "timestamp": "2010-10-28"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020150-34/PT",
        "title": "A Phase III, Double-Blind, Randomized, Placebo-Controlled, Multicenter Clinical Trial to Study the Safety, Tolerability, Efficacy, and Immunogenicity of V212 in Recipients of Autologous Hematopoiet... - PT",
        "timestamp": "2010-10-28"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020150-34/results",
        "title": "A Phase III, Double-Blind, Randomized, Placebo-Controlled, Multicenter Clinical Trial to Study the Safety, Tolerability, Efficacy, and Immunogenicity of V212 in Recipients of Autologous Hematopoiet... - View results",
        "timestamp": "2010-10-28"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-001550-29/ES",
        "title": "A Phase II randomized double-blind study of Santostatin LAR in combination with Axitinib versus Placebo in patients with progressive advanced well-differentiated neuroendocrine carcinomas of non-pa... - ES",
        "timestamp": "2011-08-11"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-001550-29/DE",
        "title": "A Phase II randomized double-blind study of Santostatin LAR in combination with Axitinib versus Placebo in patients with progressive advanced well-differentiated neuroendocrine carcinomas of non-pa... - DE",
        "timestamp": "2011-08-11"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-004497-10/BE",
        "title": "A Randomized, Double-Blind, Parallel-Group, Phase 3 Study to Demonstrate Noninferiority in Efficacy and to Assess the Safety of CT-P13 Compared to Remicade in Patients With Active Crohn’s Disease - BE",
        "timestamp": "2014-07-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-004497-10/HU",
        "title": "A Randomized, Double-Blind, Parallel-Group, Phase 3 Study to Demonstrate Noninferiority in Efficacy and to Assess the Safety of CT-P13 Compared to Remicade in Patients With Active Crohn’s Disease - HU",
        "timestamp": "2014-07-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-004497-10/GB",
        "title": "A Randomized, Double-Blind, Parallel-Group, Phase 3 Study to Demonstrate Noninferiority in Efficacy and to Assess the Safety of CT-P13 Compared to Remicade in Patients With Active Crohn’s Disease - GB",
        "timestamp": "2014-07-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-004497-10/IT",
        "title": "A Randomized, Double-Blind, Parallel-Group, Phase 3 Study to Demonstrate Noninferiority in Efficacy and to Assess the Safety of CT-P13 Compared to Remicade in Patients With Active Crohn’s Disease - IT",
        "timestamp": "2014-07-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-004497-10/ES",
        "title": "A Randomized, Double-Blind, Parallel-Group, Phase 3 Study to Demonstrate Noninferiority in Efficacy and to Assess the Safety of CT-P13 Compared to Remicade in Patients With Active Crohn’s Disease - ES",
        "timestamp": "2014-07-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-004497-10/RO",
        "title": "A Randomized, Double-Blind, Parallel-Group, Phase 3 Study to Demonstrate Noninferiority in Efficacy and to Assess the Safety of CT-P13 Compared to Remicade in Patients With Active Crohn’s Disease - RO",
        "timestamp": "2014-07-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-004497-10/DK",
        "title": "A Randomized, Double-Blind, Parallel-Group, Phase 3 Study to Demonstrate Noninferiority in Efficacy and to Assess the Safety of CT-P13 Compared to Remicade in Patients With Active Crohn’s Disease - DK",
        "timestamp": "2014-07-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-004497-10/NL",
        "title": "A Randomized, Double-Blind, Parallel-Group, Phase 3 Study to Demonstrate Noninferiority in Efficacy and to Assess the Safety of CT-P13 Compared to Remicade in Patients With Active Crohn’s Disease - NL",
        "timestamp": "2014-07-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-004497-10/results",
        "title": "A Randomized, Double-Blind, Parallel-Group, Phase 3 Study to Demonstrate Noninferiority in Efficacy and to Assess the Safety of CT-P13 Compared to Remicade in Patients With Active Crohn’s Disease - View results",
        "timestamp": "2014-07-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-005259-18/HU",
        "title": "A randomized, open-label, multicenter, controlled, parallel arm, phase III study assessing the efficacy and safety of AOP2014 vs. Hydroxyurea in patients with Polycythemia Vera - HU",
        "timestamp": "2013-08-15"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-005259-18/CZ",
        "title": "A randomized, open-label, multicenter, controlled, parallel arm, phase III study assessing the efficacy and safety of AOP2014 vs. Hydroxyurea in patients with Polycythemia Vera - CZ",
        "timestamp": "2013-08-15"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-005259-18/IT",
        "title": "A randomized, open-label, multicenter, controlled, parallel arm, phase III study assessing the efficacy and safety of AOP2014 vs. Hydroxyurea in patients with Polycythemia Vera - IT",
        "timestamp": "2013-08-15"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-005259-18/SK",
        "title": "A randomized, open-label, multicenter, controlled, parallel arm, phase III study assessing the efficacy and safety of AOP2014 vs. Hydroxyurea in patients with Polycythemia Vera - SK",
        "timestamp": "2013-08-15"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-005259-18/AT",
        "title": "A randomized, open-label, multicenter, controlled, parallel arm, phase III study assessing the efficacy and safety of AOP2014 vs. Hydroxyurea in patients with Polycythemia Vera - AT",
        "timestamp": "2013-08-15"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-005259-18/BG",
        "title": "A randomized, open-label, multicenter, controlled, parallel arm, phase III study assessing the efficacy and safety of AOP2014 vs. Hydroxyurea in patients with Polycythemia Vera - BG",
        "timestamp": "2013-08-15"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-005259-18/DE",
        "title": "A randomized, open-label, multicenter, controlled, parallel arm, phase III study assessing the efficacy and safety of AOP2014 vs. Hydroxyurea in patients with Polycythemia Vera - DE",
        "timestamp": "2013-08-15"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-005259-18/PL",
        "title": "A randomized, open-label, multicenter, controlled, parallel arm, phase III study assessing the efficacy and safety of AOP2014 vs. Hydroxyurea in patients with Polycythemia Vera - PL",
        "timestamp": "2013-08-15"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-005259-18/ES",
        "title": "A randomized, open-label, multicenter, controlled, parallel arm, phase III study assessing the efficacy and safety of AOP2014 vs. Hydroxyurea in patients with Polycythemia Vera - ES",
        "timestamp": "2013-08-15"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-005259-18/BE",
        "title": "A randomized, open-label, multicenter, controlled, parallel arm, phase III study assessing the efficacy and safety of AOP2014 vs. Hydroxyurea in patients with Polycythemia Vera - BE",
        "timestamp": "2013-08-15"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-005259-18/results",
        "title": "A randomized, open-label, multicenter, controlled, parallel arm, phase III study assessing the efficacy and safety of AOP2014 vs. Hydroxyurea in patients with Polycythemia Vera - View results",
        "timestamp": "2013-08-15"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-000944-43/DE",
        "title": "A Phase 2 Randomized, Open-Label Study of GS-5885 Administered Concomitantly with GS-9451, Tegobuvir and Ribavirin (RBV) to Treatment-Naive Subjects with Chronic Genotype 1 HCV Infection - DE",
        "timestamp": "2011-08-09"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-000944-43/results",
        "title": "A Phase 2 Randomized, Open-Label Study of GS-5885 Administered Concomitantly with GS-9451, Tegobuvir and Ribavirin (RBV) to Treatment-Naive Subjects with Chronic Genotype 1 HCV Infection - View results",
        "timestamp": "2011-08-09"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-002591-40/FR",
        "title": "Evaluation of bronchial remodeling during mepolizumab treatment in severe eosinophilic asthma - FR",
        "timestamp": "2018-11-26"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-003084-37/CZ",
        "title": "A phase I/II study to evaluate safety and efficacy of DCVAC/LuCa added to standard first line chemotherapy with carboplatin and paclitaxel +/- immune enhancers (interferon-α and hydroxychloroquine)... - CZ",
        "timestamp": "2014-10-15"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-003084-37/SK",
        "title": "A phase I/II study to evaluate safety and efficacy of DCVAC/LuCa added to standard first line chemotherapy with carboplatin and paclitaxel +/- immune enhancers (interferon-α and hydroxychloroquine)... - SK",
        "timestamp": "2014-10-15"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-000807-99/GB",
        "title": "A multicentre, double blind, randomised, placebo controlled, Phase II trial to evaluate Resminostat for maintenance treatment of patients with advanced stage (Stage IIB-IVB) mycosis fungoides (MF) ... - GB",
        "timestamp": "2016-09-15"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-000807-99/DE",
        "title": "A multicentre, double blind, randomised, placebo controlled, Phase II trial to evaluate Resminostat for maintenance treatment of patients with advanced stage (Stage IIB-IVB) mycosis fungoides (MF) ... - DE",
        "timestamp": "2016-09-15"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-000807-99/NL",
        "title": "A multicentre, double blind, randomised, placebo controlled, Phase II trial to evaluate Resminostat for maintenance treatment of patients with advanced stage (Stage IIB-IVB) mycosis fungoides (MF) ... - NL",
        "timestamp": "2016-09-15"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-000807-99/ES",
        "title": "A multicentre, double blind, randomised, placebo controlled, Phase II trial to evaluate Resminostat for maintenance treatment of patients with advanced stage (Stage IIB-IVB) mycosis fungoides (MF) ... - ES",
        "timestamp": "2016-09-15"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-000807-99/AT",
        "title": "A multicentre, double blind, randomised, placebo controlled, Phase II trial to evaluate Resminostat for maintenance treatment of patients with advanced stage (Stage IIB-IVB) mycosis fungoides (MF) ... - AT",
        "timestamp": "2016-09-15"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-000807-99/BE",
        "title": "A multicentre, double blind, randomised, placebo controlled, Phase II trial to evaluate Resminostat for maintenance treatment of patients with advanced stage (Stage IIB-IVB) mycosis fungoides (MF) ... - BE",
        "timestamp": "2016-09-15"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-000807-99/PL",
        "title": "A multicentre, double blind, randomised, placebo controlled, Phase II trial to evaluate Resminostat for maintenance treatment of patients with advanced stage (Stage IIB-IVB) mycosis fungoides (MF) ... - PL",
        "timestamp": "2016-09-15"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-000807-99/GR",
        "title": "A multicentre, double blind, randomised, placebo controlled, Phase II trial to evaluate Resminostat for maintenance treatment of patients with advanced stage (Stage IIB-IVB) mycosis fungoides (MF) ... - GR",
        "timestamp": "2016-09-15"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-000381-20/FI",
        "title": "A Phase IIIb, Double-Blind, Placebo-Controlled, Multicenter, Parallel Group, Extension Trial to Evaluate the Safety and Tolerability of Oral Cladribine in Subjects with Relapsing-Remitting Multiple... - FI",
        "timestamp": "2007-11-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-000381-20/FR",
        "title": "A Phase IIIb, Double-Blind, Placebo-Controlled, Multicenter, Parallel Group, Extension Trial to Evaluate the Safety and Tolerability of Oral Cladribine in Subjects with Relapsing-Remitting Multiple... - FR",
        "timestamp": "2007-11-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-000381-20/GB",
        "title": "A Phase IIIb, Double-Blind, Placebo-Controlled, Multicenter, Parallel Group, Extension Trial to Evaluate the Safety and Tolerability of Oral Cladribine in Subjects with Relapsing-Remitting Multiple... - GB",
        "timestamp": "2007-11-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-000381-20/CZ",
        "title": "A Phase IIIb, Double-Blind, Placebo-Controlled, Multicenter, Parallel Group, Extension Trial to Evaluate the Safety and Tolerability of Oral Cladribine in Subjects with Relapsing-Remitting Multiple... - CZ",
        "timestamp": "2007-11-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-000381-20/BE",
        "title": "A Phase IIIb, Double-Blind, Placebo-Controlled, Multicenter, Parallel Group, Extension Trial to Evaluate the Safety and Tolerability of Oral Cladribine in Subjects with Relapsing-Remitting Multiple... - BE",
        "timestamp": "2007-11-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-000381-20/EE",
        "title": "A Phase IIIb, Double-Blind, Placebo-Controlled, Multicenter, Parallel Group, Extension Trial to Evaluate the Safety and Tolerability of Oral Cladribine in Subjects with Relapsing-Remitting Multiple... - EE",
        "timestamp": "2007-11-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-000381-20/AT",
        "title": "A Phase IIIb, Double-Blind, Placebo-Controlled, Multicenter, Parallel Group, Extension Trial to Evaluate the Safety and Tolerability of Oral Cladribine in Subjects with Relapsing-Remitting Multiple... - AT",
        "timestamp": "2007-11-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-000381-20/PT",
        "title": "A Phase IIIb, Double-Blind, Placebo-Controlled, Multicenter, Parallel Group, Extension Trial to Evaluate the Safety and Tolerability of Oral Cladribine in Subjects with Relapsing-Remitting Multiple... - PT",
        "timestamp": "2007-11-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-000381-20/NL",
        "title": "A Phase IIIb, Double-Blind, Placebo-Controlled, Multicenter, Parallel Group, Extension Trial to Evaluate the Safety and Tolerability of Oral Cladribine in Subjects with Relapsing-Remitting Multiple... - NL",
        "timestamp": "2007-11-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-000381-20/DE",
        "title": "A Phase IIIb, Double-Blind, Placebo-Controlled, Multicenter, Parallel Group, Extension Trial to Evaluate the Safety and Tolerability of Oral Cladribine in Subjects with Relapsing-Remitting Multiple... - DE",
        "timestamp": "2007-11-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-000381-20/DK",
        "title": "A Phase IIIb, Double-Blind, Placebo-Controlled, Multicenter, Parallel Group, Extension Trial to Evaluate the Safety and Tolerability of Oral Cladribine in Subjects with Relapsing-Remitting Multiple... - DK",
        "timestamp": "2007-11-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-000381-20/IT",
        "title": "A Phase IIIb, Double-Blind, Placebo-Controlled, Multicenter, Parallel Group, Extension Trial to Evaluate the Safety and Tolerability of Oral Cladribine in Subjects with Relapsing-Remitting Multiple... - IT",
        "timestamp": "2007-11-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-000381-20/GR",
        "title": "A Phase IIIb, Double-Blind, Placebo-Controlled, Multicenter, Parallel Group, Extension Trial to Evaluate the Safety and Tolerability of Oral Cladribine in Subjects with Relapsing-Remitting Multiple... - GR",
        "timestamp": "2007-11-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-000381-20/LV",
        "title": "A Phase IIIb, Double-Blind, Placebo-Controlled, Multicenter, Parallel Group, Extension Trial to Evaluate the Safety and Tolerability of Oral Cladribine in Subjects with Relapsing-Remitting Multiple... - LV",
        "timestamp": "2007-11-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-000381-20/LT",
        "title": "A Phase IIIb, Double-Blind, Placebo-Controlled, Multicenter, Parallel Group, Extension Trial to Evaluate the Safety and Tolerability of Oral Cladribine in Subjects with Relapsing-Remitting Multiple... - LT",
        "timestamp": "2007-11-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-000381-20/BG",
        "title": "A Phase IIIb, Double-Blind, Placebo-Controlled, Multicenter, Parallel Group, Extension Trial to Evaluate the Safety and Tolerability of Oral Cladribine in Subjects with Relapsing-Remitting Multiple... - BG",
        "timestamp": "2007-11-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-000381-20/results",
        "title": "A Phase IIIb, Double-Blind, Placebo-Controlled, Multicenter, Parallel Group, Extension Trial to Evaluate the Safety and Tolerability of Oral Cladribine in Subjects with Relapsing-Remitting Multiple... - View results",
        "timestamp": "2007-11-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-000141-20/GB",
        "title": "A phase III, open-label study of once daily BI 201335 240 mg for 24 weeks in combination with pegylated interferon-α (PegIFN) and ribavirin (RBV) in patients with genotype 1 chronic hepatitis C inf... - GB",
        "timestamp": "2011-07-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-000141-20/PT",
        "title": "A phase III, open-label study of once daily BI 201335 240 mg for 24 weeks in combination with pegylated interferon-α (PegIFN) and ribavirin (RBV) in patients with genotype 1 chronic hepatitis C inf... - PT",
        "timestamp": "2011-07-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-000141-20/DE",
        "title": "A phase III, open-label study of once daily BI 201335 240 mg for 24 weeks in combination with pegylated interferon-α (PegIFN) and ribavirin (RBV) in patients with genotype 1 chronic hepatitis C inf... - DE",
        "timestamp": "2011-07-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-000141-20/AT",
        "title": "A phase III, open-label study of once daily BI 201335 240 mg for 24 weeks in combination with pegylated interferon-α (PegIFN) and ribavirin (RBV) in patients with genotype 1 chronic hepatitis C inf... - AT",
        "timestamp": "2011-07-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-000141-20/BE",
        "title": "A phase III, open-label study of once daily BI 201335 240 mg for 24 weeks in combination with pegylated interferon-α (PegIFN) and ribavirin (RBV) in patients with genotype 1 chronic hepatitis C inf... - BE",
        "timestamp": "2011-07-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-000141-20/ES",
        "title": "A phase III, open-label study of once daily BI 201335 240 mg for 24 weeks in combination with pegylated interferon-α (PegIFN) and ribavirin (RBV) in patients with genotype 1 chronic hepatitis C inf... - ES",
        "timestamp": "2011-07-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-000141-20/results",
        "title": "A phase III, open-label study of once daily BI 201335 240 mg for 24 weeks in combination with pegylated interferon-α (PegIFN) and ribavirin (RBV) in patients with genotype 1 chronic hepatitis C inf... - View results",
        "timestamp": "2011-07-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020328-23/FI",
        "title": "A three-arm, randomized, double-blind, placebo controlled, multicenter,\r\nphase II study to evaluate the efficacy of Vigantol® oil as add-on\r\ntherapy in subjects with Relapsing-Remitting Multiple Sc... - FI",
        "timestamp": "2010-10-21"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020328-23/NL",
        "title": "A three-arm, randomized, double-blind, placebo controlled, multicenter,\r\nphase II study to evaluate the efficacy of Vigantol® oil as add-on\r\ntherapy in subjects with Relapsing-Remitting Multiple Sc... - NL",
        "timestamp": "2010-10-21"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020328-23/DE",
        "title": "A three-arm, randomized, double-blind, placebo controlled, multicenter,\r\nphase II study to evaluate the efficacy of Vigantol® oil as add-on\r\ntherapy in subjects with Relapsing-Remitting Multiple Sc... - DE",
        "timestamp": "2010-10-21"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020328-23/DK",
        "title": "A three-arm, randomized, double-blind, placebo controlled, multicenter,\r\nphase II study to evaluate the efficacy of Vigantol® oil as add-on\r\ntherapy in subjects with Relapsing-Remitting Multiple Sc... - DK",
        "timestamp": "2010-10-21"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020328-23/BE",
        "title": "A three-arm, randomized, double-blind, placebo controlled, multicenter,\r\nphase II study to evaluate the efficacy of Vigantol® oil as add-on\r\ntherapy in subjects with Relapsing-Remitting Multiple Sc... - BE",
        "timestamp": "2010-10-21"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020328-23/IT",
        "title": "A three-arm, randomized, double-blind, placebo controlled, multicenter,\r\nphase II study to evaluate the efficacy of Vigantol® oil as add-on\r\ntherapy in subjects with Relapsing-Remitting Multiple Sc... - IT",
        "timestamp": "2010-10-21"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020328-23/LT",
        "title": "A three-arm, randomized, double-blind, placebo controlled, multicenter,\r\nphase II study to evaluate the efficacy of Vigantol® oil as add-on\r\ntherapy in subjects with Relapsing-Remitting Multiple Sc... - LT",
        "timestamp": "2010-10-21"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020328-23/EE",
        "title": "A three-arm, randomized, double-blind, placebo controlled, multicenter,\r\nphase II study to evaluate the efficacy of Vigantol® oil as add-on\r\ntherapy in subjects with Relapsing-Remitting Multiple Sc... - EE",
        "timestamp": "2010-10-21"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020328-23/LV",
        "title": "A three-arm, randomized, double-blind, placebo controlled, multicenter,\r\nphase II study to evaluate the efficacy of Vigantol® oil as add-on\r\ntherapy in subjects with Relapsing-Remitting Multiple Sc... - LV",
        "timestamp": "2010-10-21"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020328-23/AT",
        "title": "A three-arm, randomized, double-blind, placebo controlled, multicenter,\r\nphase II study to evaluate the efficacy of Vigantol® oil as add-on\r\ntherapy in subjects with Relapsing-Remitting Multiple Sc... - AT",
        "timestamp": "2010-10-21"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020328-23/PT",
        "title": "A three-arm, randomized, double-blind, placebo controlled, multicenter,\r\nphase II study to evaluate the efficacy of Vigantol® oil as add-on\r\ntherapy in subjects with Relapsing-Remitting Multiple Sc... - PT",
        "timestamp": "2010-10-21"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020328-23/results",
        "title": "A three-arm, randomized, double-blind, placebo controlled, multicenter,\r\nphase II study to evaluate the efficacy of Vigantol® oil as add-on\r\ntherapy in subjects with Relapsing-Remitting Multiple Sc... - View results",
        "timestamp": "2010-10-21"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-004061-41/GB",
        "title": "An Open-label, Multicenter, Extension Study to Evaluate the Safety and Tolerability of Natalizumab Following Re-Initiation of Dosing in Multiple Sclerosis Subjects Who Have Completed Study C-1801 o... - GB",
        "timestamp": "2006-06-01"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-004061-41/BE",
        "title": "An Open-label, Multicenter, Extension Study to Evaluate the Safety and Tolerability of Natalizumab Following Re-Initiation of Dosing in Multiple Sclerosis Subjects Who Have Completed Study C-1801 o... - BE",
        "timestamp": "2006-06-01"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-004061-41/FI",
        "title": "An Open-label, Multicenter, Extension Study to Evaluate the Safety and Tolerability of Natalizumab Following Re-Initiation of Dosing in Multiple Sclerosis Subjects Who Have Completed Study C-1801 o... - FI",
        "timestamp": "2006-06-01"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-004061-41/IE",
        "title": "An Open-label, Multicenter, Extension Study to Evaluate the Safety and Tolerability of Natalizumab Following Re-Initiation of Dosing in Multiple Sclerosis Subjects Who Have Completed Study C-1801 o... - IE",
        "timestamp": "2006-06-01"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-004061-41/DE",
        "title": "An Open-label, Multicenter, Extension Study to Evaluate the Safety and Tolerability of Natalizumab Following Re-Initiation of Dosing in Multiple Sclerosis Subjects Who Have Completed Study C-1801 o... - DE",
        "timestamp": "2006-06-01"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-004061-41/AT",
        "title": "An Open-label, Multicenter, Extension Study to Evaluate the Safety and Tolerability of Natalizumab Following Re-Initiation of Dosing in Multiple Sclerosis Subjects Who Have Completed Study C-1801 o... - AT",
        "timestamp": "2006-06-01"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-004061-41/SE",
        "title": "An Open-label, Multicenter, Extension Study to Evaluate the Safety and Tolerability of Natalizumab Following Re-Initiation of Dosing in Multiple Sclerosis Subjects Who Have Completed Study C-1801 o... - SE",
        "timestamp": "2006-06-01"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-004061-41/HU",
        "title": "An Open-label, Multicenter, Extension Study to Evaluate the Safety and Tolerability of Natalizumab Following Re-Initiation of Dosing in Multiple Sclerosis Subjects Who Have Completed Study C-1801 o... - HU",
        "timestamp": "2006-06-01"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-004061-41/DK",
        "title": "An Open-label, Multicenter, Extension Study to Evaluate the Safety and Tolerability of Natalizumab Following Re-Initiation of Dosing in Multiple Sclerosis Subjects Who Have Completed Study C-1801 o... - DK",
        "timestamp": "2006-06-01"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-004061-41/CZ",
        "title": "An Open-label, Multicenter, Extension Study to Evaluate the Safety and Tolerability of Natalizumab Following Re-Initiation of Dosing in Multiple Sclerosis Subjects Who Have Completed Study C-1801 o... - CZ",
        "timestamp": "2006-06-01"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-004061-41/ES",
        "title": "An Open-label, Multicenter, Extension Study to Evaluate the Safety and Tolerability of Natalizumab Following Re-Initiation of Dosing in Multiple Sclerosis Subjects Who Have Completed Study C-1801 o... - ES",
        "timestamp": "2006-06-01"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-004061-41/IT",
        "title": "An Open-label, Multicenter, Extension Study to Evaluate the Safety and Tolerability of Natalizumab Following Re-Initiation of Dosing in Multiple Sclerosis Subjects Who Have Completed Study C-1801 o... - IT",
        "timestamp": "2006-06-01"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-004061-41/GR",
        "title": "An Open-label, Multicenter, Extension Study to Evaluate the Safety and Tolerability of Natalizumab Following Re-Initiation of Dosing in Multiple Sclerosis Subjects Who Have Completed Study C-1801 o... - GR",
        "timestamp": "2006-06-01"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-004061-41/results",
        "title": "An Open-label, Multicenter, Extension Study to Evaluate the Safety and Tolerability of Natalizumab Following Re-Initiation of Dosing in Multiple Sclerosis Subjects Who Have Completed Study C-1801 o... - View results",
        "timestamp": "2006-06-01"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-005151-42/FR",
        "title": "A Phase 3 Safety and Efficacy Study of Boceprevir in Subjects With Chronic Hepatitis C Genotype 1 Who Failed Prior Treatment With Peginterferon/Ribavirin - FR",
        "timestamp": "2008-08-28"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-005151-42/PT",
        "title": "A Phase 3 Safety and Efficacy Study of Boceprevir in Subjects With Chronic Hepatitis C Genotype 1 Who Failed Prior Treatment With Peginterferon/Ribavirin - PT",
        "timestamp": "2008-08-28"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-005151-42/ES",
        "title": "A Phase 3 Safety and Efficacy Study of Boceprevir in Subjects With Chronic Hepatitis C Genotype 1 Who Failed Prior Treatment With Peginterferon/Ribavirin - ES",
        "timestamp": "2008-08-28"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-005151-42/IT",
        "title": "A Phase 3 Safety and Efficacy Study of Boceprevir in Subjects With Chronic Hepatitis C Genotype 1 Who Failed Prior Treatment With Peginterferon/Ribavirin - IT",
        "timestamp": "2008-08-28"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-005151-42/BE",
        "title": "A Phase 3 Safety and Efficacy Study of Boceprevir in Subjects With Chronic Hepatitis C Genotype 1 Who Failed Prior Treatment With Peginterferon/Ribavirin - BE",
        "timestamp": "2008-08-28"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-005151-42/DE",
        "title": "A Phase 3 Safety and Efficacy Study of Boceprevir in Subjects With Chronic Hepatitis C Genotype 1 Who Failed Prior Treatment With Peginterferon/Ribavirin - DE",
        "timestamp": "2008-08-28"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-005151-42/GB",
        "title": "A Phase 3 Safety and Efficacy Study of Boceprevir in Subjects With Chronic Hepatitis C Genotype 1 Who Failed Prior Treatment With Peginterferon/Ribavirin - GB",
        "timestamp": "2008-08-28"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-005151-42/results",
        "title": "A Phase 3 Safety and Efficacy Study of Boceprevir in Subjects With Chronic Hepatitis C Genotype 1 Who Failed Prior Treatment With Peginterferon/Ribavirin - View results",
        "timestamp": "2008-08-28"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-002318-11/SE",
        "title": "Open-Label, Randomized, Multicenter, Multiple-Dose, Active Controlled, Parallel-Group, Efficacy and Safety Study of BG00012 in Children From 10 to Less Than 18 Years of Age With Relapsing-Remitting... - SE",
        "timestamp": "2014-06-05"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-002318-11/BE",
        "title": "Open-Label, Randomized, Multicenter, Multiple-Dose, Active Controlled, Parallel-Group, Efficacy and Safety Study of BG00012 in Children From 10 to Less Than 18 Years of Age With Relapsing-Remitting... - BE",
        "timestamp": "2014-06-05"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-002318-11/IT",
        "title": "Open-Label, Randomized, Multicenter, Multiple-Dose, Active Controlled, Parallel-Group, Efficacy and Safety Study of BG00012 in Children From 10 to Less Than 18 Years of Age With Relapsing-Remitting... - IT",
        "timestamp": "2014-06-05"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-002318-11/HU",
        "title": "Open-Label, Randomized, Multicenter, Multiple-Dose, Active Controlled, Parallel-Group, Efficacy and Safety Study of BG00012 in Children From 10 to Less Than 18 Years of Age With Relapsing-Remitting... - HU",
        "timestamp": "2014-06-05"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-002318-11/DK",
        "title": "Open-Label, Randomized, Multicenter, Multiple-Dose, Active Controlled, Parallel-Group, Efficacy and Safety Study of BG00012 in Children From 10 to Less Than 18 Years of Age With Relapsing-Remitting... - DK",
        "timestamp": "2014-06-05"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-002318-11/CZ",
        "title": "Open-Label, Randomized, Multicenter, Multiple-Dose, Active Controlled, Parallel-Group, Efficacy and Safety Study of BG00012 in Children From 10 to Less Than 18 Years of Age With Relapsing-Remitting... - CZ",
        "timestamp": "2014-06-05"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-002318-11/PL",
        "title": "Open-Label, Randomized, Multicenter, Multiple-Dose, Active Controlled, Parallel-Group, Efficacy and Safety Study of BG00012 in Children From 10 to Less Than 18 Years of Age With Relapsing-Remitting... - PL",
        "timestamp": "2014-06-05"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-002318-11/GB",
        "title": "Open-Label, Randomized, Multicenter, Multiple-Dose, Active Controlled, Parallel-Group, Efficacy and Safety Study of BG00012 in Children From 10 to Less Than 18 Years of Age With Relapsing-Remitting... - GB",
        "timestamp": "2014-06-05"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-002318-11/ES",
        "title": "Open-Label, Randomized, Multicenter, Multiple-Dose, Active Controlled, Parallel-Group, Efficacy and Safety Study of BG00012 in Children From 10 to Less Than 18 Years of Age With Relapsing-Remitting... - ES",
        "timestamp": "2014-06-05"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-002318-11/FR",
        "title": "Open-Label, Randomized, Multicenter, Multiple-Dose, Active Controlled, Parallel-Group, Efficacy and Safety Study of BG00012 in Children From 10 to Less Than 18 Years of Age With Relapsing-Remitting... - FR",
        "timestamp": "2014-06-05"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-002318-11/DE",
        "title": "Open-Label, Randomized, Multicenter, Multiple-Dose, Active Controlled, Parallel-Group, Efficacy and Safety Study of BG00012 in Children From 10 to Less Than 18 Years of Age With Relapsing-Remitting... - DE",
        "timestamp": "2014-06-05"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-000853-23/CZ",
        "title": "Prospektivní, otevřená, randomizovaná multicentrická studie hodnotící účinnost a bezpečnost pegylovaného interferonu alfa 2a (Pegasys) v adjuvantní léčbě rizikového primárního kožního melanomu - CZ",
        "timestamp": "2006-07-27"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-001096-39/SK",
        "title": "An International, Multi-Center Study Evaluating the Correlation of IL28B Genotypes with Chronic Hepatitis C Disease Characteristics and Patient Demographics - SK",
        "timestamp": "2012-07-10"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-006673-24/FR",
        "title": "Etude pilote multicentrique de phase IV, en ouvert, randomisée, en groupe parallèles destinée à évaluer l'éfficacité d'un protocole de rééducation fonctionnelle des patients atteints d'une forme ré... - FR",
        "timestamp": "2008-03-17"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-006673-24/results",
        "title": "Etude pilote multicentrique de phase IV, en ouvert, randomisée, en groupe parallèles destinée à évaluer l'éfficacité d'un protocole de rééducation fonctionnelle des patients atteints d'une forme ré... - View results",
        "timestamp": "2008-03-17"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-001645-41/DE",
        "title": "An adaptive Phase II study to evaluate the efficacy, pharmacodynamics, safety and tolerability of GSK2586184 in patients with active systemic lupus erythematosus. - DE",
        "timestamp": "2013-02-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-001645-41/HU",
        "title": "An adaptive Phase II study to evaluate the efficacy, pharmacodynamics, safety and tolerability of GSK2586184 in patients with active systemic lupus erythematosus. - HU",
        "timestamp": "2013-02-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-001645-41/SE",
        "title": "An adaptive Phase II study to evaluate the efficacy, pharmacodynamics, safety and tolerability of GSK2586184 in patients with active systemic lupus erythematosus. - SE",
        "timestamp": "2013-02-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-001645-41/ES",
        "title": "An adaptive Phase II study to evaluate the efficacy, pharmacodynamics, safety and tolerability of GSK2586184 in patients with active systemic lupus erythematosus. - ES",
        "timestamp": "2013-02-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-001645-41/GR",
        "title": "An adaptive Phase II study to evaluate the efficacy, pharmacodynamics, safety and tolerability of GSK2586184 in patients with active systemic lupus erythematosus. - GR",
        "timestamp": "2013-02-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-001645-41/EE",
        "title": "An adaptive Phase II study to evaluate the efficacy, pharmacodynamics, safety and tolerability of GSK2586184 in patients with active systemic lupus erythematosus. - EE",
        "timestamp": "2013-02-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-001645-41/CZ",
        "title": "An adaptive Phase II study to evaluate the efficacy, pharmacodynamics, safety and tolerability of GSK2586184 in patients with active systemic lupus erythematosus. - CZ",
        "timestamp": "2013-02-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-001645-41/PL",
        "title": "An adaptive Phase II study to evaluate the efficacy, pharmacodynamics, safety and tolerability of GSK2586184 in patients with active systemic lupus erythematosus. - PL",
        "timestamp": "2013-02-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-001645-41/results",
        "title": "An adaptive Phase II study to evaluate the efficacy, pharmacodynamics, safety and tolerability of GSK2586184 in patients with active systemic lupus erythematosus. - View results",
        "timestamp": "2013-02-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-004416-66/GB",
        "title": "A Phase I/IIa Sporozoite Challenge Study to Assess the Efficacy of Candidate Combination Malaria Vaccine Approaches using the ChAd63 and MVA vectors encoding the antigens ME-TRAP, CS and AMA1. - GB",
        "timestamp": "2012-11-26"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-004416-66/results",
        "title": "A Phase I/IIa Sporozoite Challenge Study to Assess the Efficacy of Candidate Combination Malaria Vaccine Approaches using the ChAd63 and MVA vectors encoding the antigens ME-TRAP, CS and AMA1. - View results",
        "timestamp": "2012-11-26"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005939-78/DE",
        "title": "A prospective, open-label, multicenter, randomized phase II trial: \r\nSequential therapy with BEvacizumab, RAd001 (everolimus) and AxiTinib in metastatic renal cell carcinoma (mRCC) (BERAT study) - DE",
        "timestamp": "2012-06-25"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-001929-40/NL",
        "title": "A prospective, randomized pilot study of the immunomodulatory effects of azithromycin in adults with pulmonary tuberculosis - NL",
        "timestamp": "2017-11-21"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-002132-25/DE",
        "title": "RUXOlitinib versus BEst Available Therapy in patients with high-risk polycythemia vera or high-risk essential thrombocythemia – The RUXO-BEAT Trial - DE",
        "timestamp": "2015-06-29"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-002696-40/DE",
        "title": "A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Investigate the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of Multiple Doses of ACH-0137171 in Subjects w... - DE",
        "timestamp": "2006-10-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-018517-29/DE",
        "title": "Topoproteome-Analysis of Psoriasis under Fumarate-Treatment. - DE",
        "timestamp": "2010-02-22"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-011888-37/DE",
        "title": "A 1-year, multicenter, double-blind, randomized, placebo-controlled, parallel group study to evaluate the efficacy of zoledronic acid 5 mg (Aclasta®) on bone mineral density in patients with multip... - DE",
        "timestamp": "2010-07-23"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-011888-37/results",
        "title": "A 1-year, multicenter, double-blind, randomized, placebo-controlled, parallel group study to evaluate the efficacy of zoledronic acid 5 mg (Aclasta®) on bone mineral density in patients with multip... - View results",
        "timestamp": "2010-07-23"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-024515-13/NL",
        "title": "Phase 1-2 study of everolimus and low-dose oral cyclophosphamide in patients with metastatic renal cell cancer. - NL",
        "timestamp": "2011-03-22"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-002378-26/SE",
        "title": "Switch To RItuXimab in MS extension\nAn extension study of STRIX-MS - a phase 2 open label study of Rituximab in MS patients previously treated with self-injectibles using a target based therapy app... - SE",
        "timestamp": "2014-11-13"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-002378-26/results",
        "title": "Switch To RItuXimab in MS extension\nAn extension study of STRIX-MS - a phase 2 open label study of Rituximab in MS patients previously treated with self-injectibles using a target based therapy app... - View results",
        "timestamp": "2014-11-13"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-023602-12/IT",
        "title": "A FEASIBILITY STUDY EVALUATING THE EFFICACY AND SAFETY OF SORAFENIB IN PATIENTS WITH ADVANCED HEPATOCELLULAR (HCC) CARCINOMA AND HIV INFECTION TREATED WITH HAART REGIMENS - IT",
        "timestamp": "2011-03-25"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-001789-41/FR",
        "title": "Trial Of Imatinib After Ponatinib Induction (Tipi) - A multicentre, open label phase II trial evaluating the safety and efficacy of ponatinib induction followed by imatinib maintenance in adult pat... - FR",
        "timestamp": "2019-07-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-003804-21/DE",
        "title": "Multi-centre, Randomized, Double-blind, Placebo-Controlled Pilot Safety and Efficacy Study of 8 Weeks of Treatment with DFD-07 for Actinic Keratosis of the Face and Scalp - DE",
        "timestamp": "2015-11-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-004709-24/NL",
        "title": "Mycophenolate sodium (Myfortic®) in the Treatment of Uveitis: a Pilot Study. - NL",
        "timestamp": "2007-03-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-018339-16/DE",
        "title": "CRESCENDO (Compliance: Role Emerges for Success in CML: Evaluation aND Optimisation): A prospective, multi-center, phase IV study to assess the compliance in patients with Philadelphia chromosome-p... - DE",
        "timestamp": "2010-07-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-018339-16/results",
        "title": "CRESCENDO (Compliance: Role Emerges for Success in CML: Evaluation aND Optimisation): A prospective, multi-center, phase IV study to assess the compliance in patients with Philadelphia chromosome-p... - View results",
        "timestamp": "2010-07-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003754-84/HU",
        "title": "A Randomized, Open-Label Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT-267 and ABT-333 Co-administered with and without Ribavirin Compared to Telaprevir Co-administered with Pe... - HU",
        "timestamp": "2013-04-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003754-84/FI",
        "title": "A Randomized, Open-Label Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT-267 and ABT-333 Co-administered with and without Ribavirin Compared to Telaprevir Co-administered with Pe... - FI",
        "timestamp": "2013-04-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003754-84/SK",
        "title": "A Randomized, Open-Label Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT-267 and ABT-333 Co-administered with and without Ribavirin Compared to Telaprevir Co-administered with Pe... - SK",
        "timestamp": "2013-04-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003754-84/PL",
        "title": "A Randomized, Open-Label Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT-267 and ABT-333 Co-administered with and without Ribavirin Compared to Telaprevir Co-administered with Pe... - PL",
        "timestamp": "2013-04-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003754-84/results",
        "title": "A Randomized, Open-Label Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT-267 and ABT-333 Co-administered with and without Ribavirin Compared to Telaprevir Co-administered with Pe... - View results",
        "timestamp": "2013-04-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-000393-30/GB",
        "title": "A Phase I/IIa Sporozoite Challenge Study to Assess the Safety and Protective Efficacy of the Combination Malaria Vaccine Candidate Regimen of RTS,S/AS01B + ChAd63 and MVA encoding ME-TRAP and also ... - GB",
        "timestamp": "2013-05-22"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-000393-30/results",
        "title": "A Phase I/IIa Sporozoite Challenge Study to Assess the Safety and Protective Efficacy of the Combination Malaria Vaccine Candidate Regimen of RTS,S/AS01B + ChAd63 and MVA encoding ME-TRAP and also ... - View results",
        "timestamp": "2013-05-22"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-004810-41/AT",
        "title": "An international, multicenter, open-label study evaluating sustained virological response and safety with Boceprevir in triple combination therapy with Peginterferon alfa-2a (40KD) and Ribavirin in... - AT",
        "timestamp": "2012-04-18"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-004810-41/HU",
        "title": "An international, multicenter, open-label study evaluating sustained virological response and safety with Boceprevir in triple combination therapy with Peginterferon alfa-2a (40KD) and Ribavirin in... - HU",
        "timestamp": "2012-04-18"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-004810-41/ES",
        "title": "An international, multicenter, open-label study evaluating sustained virological response and safety with Boceprevir in triple combination therapy with Peginterferon alfa-2a (40KD) and Ribavirin in... - ES",
        "timestamp": "2012-04-18"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-004810-41/PL",
        "title": "An international, multicenter, open-label study evaluating sustained virological response and safety with Boceprevir in triple combination therapy with Peginterferon alfa-2a (40KD) and Ribavirin in... - PL",
        "timestamp": "2012-04-18"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-004810-41/DE",
        "title": "An international, multicenter, open-label study evaluating sustained virological response and safety with Boceprevir in triple combination therapy with Peginterferon alfa-2a (40KD) and Ribavirin in... - DE",
        "timestamp": "2012-04-18"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-004810-41/results",
        "title": "An international, multicenter, open-label study evaluating sustained virological response and safety with Boceprevir in triple combination therapy with Peginterferon alfa-2a (40KD) and Ribavirin in... - View results",
        "timestamp": "2012-04-18"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-004213-41/ES",
        "title": "A Phase II Clinical Trial to Study the Efficacy and Safety of the combination regimen of MK-5172 + MK-8742 + Ribavirin (R) in Subjects with Chronic Hepatitis C Virus Infection who failed prior Dire... - ES",
        "timestamp": "2014-05-30"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-004213-41/AT",
        "title": "A Phase II Clinical Trial to Study the Efficacy and Safety of the combination regimen of MK-5172 + MK-8742 + Ribavirin (R) in Subjects with Chronic Hepatitis C Virus Infection who failed prior Dire... - AT",
        "timestamp": "2014-05-30"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-004213-41/results",
        "title": "A Phase II Clinical Trial to Study the Efficacy and Safety of the combination regimen of MK-5172 + MK-8742 + Ribavirin (R) in Subjects with Chronic Hepatitis C Virus Infection who failed prior Dire... - View results",
        "timestamp": "2014-05-30"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-001804-12/DE",
        "title": "A multicenter, open label Phase I/II study to determine the safety and immune modulating effects of the therapeutic Human Papilloma Virus Type 16 (HPV16) E6/E7 Synthetic Long Peptides Vaccine (ISA1... - DE",
        "timestamp": "2016-12-01"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-001804-12/NL",
        "title": "A multicenter, open label Phase I/II study to determine the safety and immune modulating effects of the therapeutic Human Papilloma Virus Type 16 (HPV16) E6/E7 Synthetic Long Peptides Vaccine (ISA1... - NL",
        "timestamp": "2016-12-01"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-001804-12/BE",
        "title": "A multicenter, open label Phase I/II study to determine the safety and immune modulating effects of the therapeutic Human Papilloma Virus Type 16 (HPV16) E6/E7 Synthetic Long Peptides Vaccine (ISA1... - BE",
        "timestamp": "2016-12-01"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-001804-12/results",
        "title": "A multicenter, open label Phase I/II study to determine the safety and immune modulating effects of the therapeutic Human Papilloma Virus Type 16 (HPV16) E6/E7 Synthetic Long Peptides Vaccine (ISA1... - View results",
        "timestamp": "2016-12-01"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-003527-57/3rd",
        "title": "An Open-label, Exploratory Study to Establish the Safety and Efficacy of 3 Months Treatment With Canakinumab in Patients With Colchicine Resistant Familial Mediterranean Fever - Outside EU/EEA",
        "timestamp": "2016-04-14"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-003527-57/results",
        "title": "An Open-label, Exploratory Study to Establish the Safety and Efficacy of 3 Months Treatment With Canakinumab in Patients With Colchicine Resistant Familial Mediterranean Fever - View results",
        "timestamp": "2016-04-14"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-001301-40/GB",
        "title": "A Phase I/IIa Sporozoite Challenge Study to Assess the Safety and Protective Efficacy of Concomitant Administration of the Combination Malaria Vaccine Candidate Regimen of RTS,S/AS01¬B + ChAd63 and... - GB",
        "timestamp": "2014-07-31"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-001301-40/results",
        "title": "A Phase I/IIa Sporozoite Challenge Study to Assess the Safety and Protective Efficacy of Concomitant Administration of the Combination Malaria Vaccine Candidate Regimen of RTS,S/AS01¬B + ChAd63 and... - View results",
        "timestamp": "2014-07-31"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-004954-34/CZ",
        "title": "Double-blind extension of the study 27025 (REFLEX) to obtain long-term follow-up data in patients with clinically definite MS and patients with a first demyelinating event at high risk of convertin... - CZ",
        "timestamp": "2008-12-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-004954-34/AT",
        "title": "Double-blind extension of the study 27025 (REFLEX) to obtain long-term follow-up data in patients with clinically definite MS and patients with a first demyelinating event at high risk of convertin... - AT",
        "timestamp": "2008-12-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-004954-34/FI",
        "title": "Double-blind extension of the study 27025 (REFLEX) to obtain long-term follow-up data in patients with clinically definite MS and patients with a first demyelinating event at high risk of convertin... - FI",
        "timestamp": "2008-12-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-004954-34/ES",
        "title": "Double-blind extension of the study 27025 (REFLEX) to obtain long-term follow-up data in patients with clinically definite MS and patients with a first demyelinating event at high risk of convertin... - ES",
        "timestamp": "2008-12-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-004954-34/PT",
        "title": "Double-blind extension of the study 27025 (REFLEX) to obtain long-term follow-up data in patients with clinically definite MS and patients with a first demyelinating event at high risk of convertin... - PT",
        "timestamp": "2008-12-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-004954-34/EE",
        "title": "Double-blind extension of the study 27025 (REFLEX) to obtain long-term follow-up data in patients with clinically definite MS and patients with a first demyelinating event at high risk of convertin... - EE",
        "timestamp": "2008-12-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-004954-34/DE",
        "title": "Double-blind extension of the study 27025 (REFLEX) to obtain long-term follow-up data in patients with clinically definite MS and patients with a first demyelinating event at high risk of convertin... - DE",
        "timestamp": "2008-12-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-004954-34/BE",
        "title": "Double-blind extension of the study 27025 (REFLEX) to obtain long-term follow-up data in patients with clinically definite MS and patients with a first demyelinating event at high risk of convertin... - BE",
        "timestamp": "2008-12-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-004954-34/LV",
        "title": "Double-blind extension of the study 27025 (REFLEX) to obtain long-term follow-up data in patients with clinically definite MS and patients with a first demyelinating event at high risk of convertin... - LV",
        "timestamp": "2008-12-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-004954-34/GR",
        "title": "Double-blind extension of the study 27025 (REFLEX) to obtain long-term follow-up data in patients with clinically definite MS and patients with a first demyelinating event at high risk of convertin... - GR",
        "timestamp": "2008-12-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-004954-34/IT",
        "title": "Double-blind extension of the study 27025 (REFLEX) to obtain long-term follow-up data in patients with clinically definite MS and patients with a first demyelinating event at high risk of convertin... - IT",
        "timestamp": "2008-12-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-004954-34/FR",
        "title": "Double-blind extension of the study 27025 (REFLEX) to obtain long-term follow-up data in patients with clinically definite MS and patients with a first demyelinating event at high risk of convertin... - FR",
        "timestamp": "2008-12-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-004954-34/BG",
        "title": "Double-blind extension of the study 27025 (REFLEX) to obtain long-term follow-up data in patients with clinically definite MS and patients with a first demyelinating event at high risk of convertin... - BG",
        "timestamp": "2008-12-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-004954-34/PL",
        "title": "Double-blind extension of the study 27025 (REFLEX) to obtain long-term follow-up data in patients with clinically definite MS and patients with a first demyelinating event at high risk of convertin... - PL",
        "timestamp": "2008-12-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-004954-34/SK",
        "title": "Double-blind extension of the study 27025 (REFLEX) to obtain long-term follow-up data in patients with clinically definite MS and patients with a first demyelinating event at high risk of convertin... - SK",
        "timestamp": "2008-12-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-004954-34/results",
        "title": "Double-blind extension of the study 27025 (REFLEX) to obtain long-term follow-up data in patients with clinically definite MS and patients with a first demyelinating event at high risk of convertin... - View results",
        "timestamp": "2008-12-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-001220-20/AT",
        "title": "Efficacy and Safety of PEG-Intron plus Rebetol  in Subjects with Chronic Hepatitis C Genotype 1 Non Responder to Pegasys - AT",
        "timestamp": "2005-01-25"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-001220-20/GB",
        "title": "Efficacy and Safety of PEG-Intron plus Rebetol  in Subjects with Chronic Hepatitis C Genotype 1 Non Responder to Pegasys - GB",
        "timestamp": "2005-01-25"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-001220-20/DE",
        "title": "Efficacy and Safety of PEG-Intron plus Rebetol  in Subjects with Chronic Hepatitis C Genotype 1 Non Responder to Pegasys - DE",
        "timestamp": "2005-01-25"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-001220-20/ES",
        "title": "Efficacy and Safety of PEG-Intron plus Rebetol  in Subjects with Chronic Hepatitis C Genotype 1 Non Responder to Pegasys - ES",
        "timestamp": "2005-01-25"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-001220-20/IT",
        "title": "Efficacy and Safety of PEG-Intron plus Rebetol  in Subjects with Chronic Hepatitis C Genotype 1 Non Responder to Pegasys - IT",
        "timestamp": "2005-01-25"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-001220-20/results",
        "title": "Efficacy and Safety of PEG-Intron plus Rebetol  in Subjects with Chronic Hepatitis C Genotype 1 Non Responder to Pegasys - View results",
        "timestamp": "2005-01-25"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-007015-32/DE",
        "title": "A 16-week, multicenter, double-blind, randomized, placebo-controlled, parallel group study to evaluate the efficacy of rivastigmine (Exelon® patch 10 cm2) on cognitive deficits in patients with mul... - DE",
        "timestamp": None
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-007015-32/results",
        "title": "A 16-week, multicenter, double-blind, randomized, placebo-controlled, parallel group study to evaluate the efficacy of rivastigmine (Exelon® patch 10 cm2) on cognitive deficits in patients with mul... - View results",
        "timestamp": None
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-006182-88/SE",
        "title": "A single arm, multicenter, single-stage phase II trial of RAD001 in Advanced and Metastatic Silent neuro-Endocrine Tumours in Europe - SE",
        "timestamp": "2009-03-31"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-006182-88/DE",
        "title": "A single arm, multicenter, single-stage phase II trial of RAD001 in Advanced and Metastatic Silent neuro-Endocrine Tumours in Europe - DE",
        "timestamp": "2009-03-31"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-006182-88/GB",
        "title": "A single arm, multicenter, single-stage phase II trial of RAD001 in Advanced and Metastatic Silent neuro-Endocrine Tumours in Europe - GB",
        "timestamp": "2009-03-31"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-006182-88/ES",
        "title": "A single arm, multicenter, single-stage phase II trial of RAD001 in Advanced and Metastatic Silent neuro-Endocrine Tumours in Europe - ES",
        "timestamp": "2009-03-31"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-006182-88/NL",
        "title": "A single arm, multicenter, single-stage phase II trial of RAD001 in Advanced and Metastatic Silent neuro-Endocrine Tumours in Europe - NL",
        "timestamp": "2009-03-31"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-006182-88/IT",
        "title": "A single arm, multicenter, single-stage phase II trial of RAD001 in Advanced and Metastatic Silent neuro-Endocrine Tumours in Europe - IT",
        "timestamp": "2009-03-31"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-006182-88/results",
        "title": "A single arm, multicenter, single-stage phase II trial of RAD001 in Advanced and Metastatic Silent neuro-Endocrine Tumours in Europe - View results",
        "timestamp": "2009-03-31"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-001283-37/IT",
        "title": "Chronic hepatitis C in illicit drug users and the role of antiviral therapy: the ARNICA project (Antiviral tReatment for chroNic\nhepatItis C in Active substance users) - IT",
        "timestamp": "2007-09-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-000591-33/GB",
        "title": "A Phase II study of Gemcitabine and Bexarotene (GemBex) in the treatment of cutaneous T-cell lymphoma - GB",
        "timestamp": "2006-05-10"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-000591-33/results",
        "title": "A Phase II study of Gemcitabine and Bexarotene (GemBex) in the treatment of cutaneous T-cell lymphoma - View results",
        "timestamp": "2006-05-10"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-023901-36/DE",
        "title": "Psoriasis-topoproteome under ustekinumab treatment (PIROUETTE-Study)\n- as an interventional observation study (phase IV) within approved label and indication and with minimal invasive taking of ski... - DE",
        "timestamp": "2011-04-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-002178-22/ES",
        "title": "A Phase 2, Double-blind, Randomized, Placebo-controlled, Four-arm, Multicenter, Dose-finding Study to Assess the Safety and Efficacy of Three Dose Levels of AVP-923 (Dextromethorphan/Quinidine) in ... - ES",
        "timestamp": "2011-12-26"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-002178-22/CZ",
        "title": "A Phase 2, Double-blind, Randomized, Placebo-controlled, Four-arm, Multicenter, Dose-finding Study to Assess the Safety and Efficacy of Three Dose Levels of AVP-923 (Dextromethorphan/Quinidine) in ... - CZ",
        "timestamp": "2011-12-26"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-002178-22/PL",
        "title": "A Phase 2, Double-blind, Randomized, Placebo-controlled, Four-arm, Multicenter, Dose-finding Study to Assess the Safety and Efficacy of Three Dose Levels of AVP-923 (Dextromethorphan/Quinidine) in ... - PL",
        "timestamp": "2011-12-26"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-002178-22/GB",
        "title": "A Phase 2, Double-blind, Randomized, Placebo-controlled, Four-arm, Multicenter, Dose-finding Study to Assess the Safety and Efficacy of Three Dose Levels of AVP-923 (Dextromethorphan/Quinidine) in ... - GB",
        "timestamp": "2011-12-26"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-022302-41/ES",
        "title": "Ensayo clínico prospectivo, aleatorizado, comparativo de la eficacia y seguridad del levofloxacino versus isoniazida en el tratamiento de la infección latente tuberculosa del trasplante hepático - ES",
        "timestamp": "2011-03-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-002183-27/GB",
        "title": "Can netazepide eradicate the inflammatory response of the gastric mucosa to H. pylori infection? - GB",
        "timestamp": "2013-04-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-004043-23/BE",
        "title": "A Phase I/IIa Study Assessing Single and Multiple Doses of IDX21437 in Healthy and HCV-Infected Subjects - BE",
        "timestamp": "2013-11-13"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-004043-23/results",
        "title": "A Phase I/IIa Study Assessing Single and Multiple Doses of IDX21437 in Healthy and HCV-Infected Subjects - View results",
        "timestamp": "2013-11-13"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-004830-25/NO",
        "title": "Kidney Cancer Integrated Therapy (KIT) - Personalized integrated therapy for patients with advanced kidney cancer - NO",
        "timestamp": "2015-09-01"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-003753-13/FR",
        "title": "Multicentre, randomized, prospective trial comparing the efficacy and safety of Infliximab to tocilizumab in refractory or relapsing Takayasu arteritis - FR",
        "timestamp": "2019-03-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-006071-12/IT",
        "title": "Evaluation of efficacy, safety and tolerability of an ADd-on therapy with Cianocabalamine  Vitamin B12  plus Calcium levofolinate in relapsing-remitting multiple sclerosis patients Already in treat... - IT",
        "timestamp": "2005-08-31"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-013333-24/IT",
        "title": "Multicenter, open-label, 12 weeks Phase IV study to  assess adherence to treatment in relapsing multiple  sclerosis (RMS) subjects switching from other  injectable DMDs using ReBiSmart to self-inje... - IT",
        "timestamp": "2009-08-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-013333-24/results",
        "title": "Multicenter, open-label, 12 weeks Phase IV study to  assess adherence to treatment in relapsing multiple  sclerosis (RMS) subjects switching from other  injectable DMDs using ReBiSmart to self-inje... - View results",
        "timestamp": "2009-08-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-000499-25/DE",
        "title": "International, multicenter, single-arm, open-label, 12-week phase IIIb study to evaluate RebiSmartTM suitability for self-injection of Rebif New Formulation (RNF) in  multidose cartridges in patien... - DE",
        "timestamp": None
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-000499-25/SE",
        "title": "International, multicenter, single-arm, open-label, 12-week phase IIIb study to evaluate RebiSmartTM suitability for self-injection of Rebif New Formulation (RNF) in  multidose cartridges in patien... - SE",
        "timestamp": None
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-000499-25/ES",
        "title": "International, multicenter, single-arm, open-label, 12-week phase IIIb study to evaluate RebiSmartTM suitability for self-injection of Rebif New Formulation (RNF) in  multidose cartridges in patien... - ES",
        "timestamp": None
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-000499-25/IT",
        "title": "International, multicenter, single-arm, open-label, 12-week phase IIIb study to evaluate RebiSmartTM suitability for self-injection of Rebif New Formulation (RNF) in  multidose cartridges in patien... - IT",
        "timestamp": None
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-000499-25/results",
        "title": "International, multicenter, single-arm, open-label, 12-week phase IIIb study to evaluate RebiSmartTM suitability for self-injection of Rebif New Formulation (RNF) in  multidose cartridges in patien... - View results",
        "timestamp": None
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-002683-24/ES",
        "title": "A phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel group study to evaluate the safety and efficacy of NU100 in patients with relapsing forms of multiple sclerosis - ES",
        "timestamp": "2012-01-30"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-002683-24/HU",
        "title": "A phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel group study to evaluate the safety and efficacy of NU100 in patients with relapsing forms of multiple sclerosis - HU",
        "timestamp": "2012-01-30"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-002683-24/IT",
        "title": "A phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel group study to evaluate the safety and efficacy of NU100 in patients with relapsing forms of multiple sclerosis - IT",
        "timestamp": "2012-01-30"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-002683-24/BG",
        "title": "A phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel group study to evaluate the safety and efficacy of NU100 in patients with relapsing forms of multiple sclerosis - BG",
        "timestamp": "2012-01-30"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003738-18/HU",
        "title": "A Randomized, Open-Labeled Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT-267 and ABT-333 Co-administered with Ribavirin Compared to Telaprevir Co-administered with Pegylated In... - HU",
        "timestamp": "2013-04-26"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003738-18/FI",
        "title": "A Randomized, Open-Labeled Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT-267 and ABT-333 Co-administered with Ribavirin Compared to Telaprevir Co-administered with Pegylated In... - FI",
        "timestamp": "2013-04-26"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003738-18/SK",
        "title": "A Randomized, Open-Labeled Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT-267 and ABT-333 Co-administered with Ribavirin Compared to Telaprevir Co-administered with Pegylated In... - SK",
        "timestamp": "2013-04-26"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003738-18/PL",
        "title": "A Randomized, Open-Labeled Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT-267 and ABT-333 Co-administered with Ribavirin Compared to Telaprevir Co-administered with Pegylated In... - PL",
        "timestamp": "2013-04-26"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003738-18/results",
        "title": "A Randomized, Open-Labeled Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT-267 and ABT-333 Co-administered with Ribavirin Compared to Telaprevir Co-administered with Pegylated In... - View results",
        "timestamp": "2013-04-26"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-001020-35/NO",
        "title": "A randomized phase II trial comparing bevacizumab monotherapy with dacarbazine (DTIC) in treatment of malignant melanoma, focusing on angiogenic markers and prevention of hypertension. - NO",
        "timestamp": "2012-12-05"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-001717-92/AT",
        "title": "A randomised, double-blind, placebo-controlled Phase II study to target the type I IFN receptor by administrating Anifrolumab in RA patients with a high IFN signature (TarIFNiRA) - AT",
        "timestamp": "2017-12-11"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-001081-99/BE",
        "title": "A clinical trial to document safety and radiological disease activity in patients with relapsing-remitting multiple sclerosis treated with autologous CD4+ cells, stimulated and expanded ex vivo by ... - BE",
        "timestamp": "2014-12-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-000359-26/ES",
        "title": "Phase I/II safety, tolerability and initial efficacy study of adeno-associated viral vector serotype 9 containing human sulfamidase gene after intracerebroventricular administration to patients wit... - ES",
        "timestamp": "2016-04-29"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-000925-38/GB",
        "title": "GO-8: Gene therapy for haemophilia A using a novel serotype 8 capsid pseudotyped adeno-associated viral vector encoding Factor VIII-V3 - GB",
        "timestamp": "2017-01-04"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-001861-25/SE",
        "title": "A Phase IIb, 2-Arm, Randomized, Double-blind, Placebo-Controlled, Multicentre Study to Optimize Diamyd® Therapy Administered into Lymph Nodes Combined with Oral Vitamin D to Investigate the Impact ... - SE",
        "timestamp": "2017-06-22"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-001861-25/CZ",
        "title": "A Phase IIb, 2-Arm, Randomized, Double-blind, Placebo-Controlled, Multicentre Study to Optimize Diamyd® Therapy Administered into Lymph Nodes Combined with Oral Vitamin D to Investigate the Impact ... - CZ",
        "timestamp": "2017-06-22"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-001861-25/ES",
        "title": "A Phase IIb, 2-Arm, Randomized, Double-blind, Placebo-Controlled, Multicentre Study to Optimize Diamyd® Therapy Administered into Lymph Nodes Combined with Oral Vitamin D to Investigate the Impact ... - ES",
        "timestamp": "2017-06-22"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-001861-25/NL",
        "title": "A Phase IIb, 2-Arm, Randomized, Double-blind, Placebo-Controlled, Multicentre Study to Optimize Diamyd® Therapy Administered into Lymph Nodes Combined with Oral Vitamin D to Investigate the Impact ... - NL",
        "timestamp": "2017-06-22"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-003250-41/GB",
        "title": "Protection induced by Live Attenuated Influenza Vaccine (LAIV or Fluenz Tetra) - applied epidemiological study - GB",
        "timestamp": "2015-09-15"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-003250-41/results",
        "title": "Protection induced by Live Attenuated Influenza Vaccine (LAIV or Fluenz Tetra) - applied epidemiological study - View results",
        "timestamp": "2015-09-15"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-004547-35/DE",
        "title": "Phase IV study to investigate neutrophil downregulation of Thy-1 by Raptiva® (Efalizumab) as a potential responder predictor in patients with moderate to severe plaque psoriasis - DE",
        "timestamp": "2007-01-10"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-004547-35/results",
        "title": "Phase IV study to investigate neutrophil downregulation of Thy-1 by Raptiva® (Efalizumab) as a potential responder predictor in patients with moderate to severe plaque psoriasis - View results",
        "timestamp": "2007-01-10"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-004699-38/DE",
        "title": "A prospective phase I/II, one-arm, multi-center, open label study of \npioglitazone in combination with sorafenib and low dose IFN alpha\nin metastatic, non-resectable renal clear cell carcinoma - DE",
        "timestamp": None
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-004602-97/ES",
        "title": "?Vitamin D as add-on treatment for relapsing-remitting multiple sclerosis: an unicentric, randomized, double-blinded, placebo-controlled clinical trial? - ES",
        "timestamp": "2013-01-11"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-004626-28/FI",
        "title": "Does targeting of S1P receptors reduce microglial activation in multiple sclerosis? - FI",
        "timestamp": "2013-12-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-003575-11/AT",
        "title": "A randomized, double-blind, placebo controlled trial to evaluate the effects of vitamin D supplementation on androgen levels in hypogonadal men - AT",
        "timestamp": "2013-03-05"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-002458-66/FR",
        "title": "A Phase 3 Evaluation of a daclatasvir/asunaprevir/BMS-791325 Fixed Dose Combination in Subjects with Genotype 1 Chronic Hepatitis C and Compensated Cirrhosis - FR",
        "timestamp": "2013-12-13"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-002458-66/results",
        "title": "A Phase 3 Evaluation of a daclatasvir/asunaprevir/BMS-791325 Fixed Dose Combination in Subjects with Genotype 1 Chronic Hepatitis C and Compensated Cirrhosis - View results",
        "timestamp": "2013-12-13"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-004347-12/FR",
        "title": "Exploratory Study of Inecalcitol in Imatinib-Treated\nResidual Chronic Myeloid Leukaemia: INIM Study - FR",
        "timestamp": "2016-03-05"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-003653-16/BE",
        "title": "Abatacept in patients with Birdshot HLA A29 uveitis: A Phase II\nProspective 0pen Label Interventional Proof-of-Concept Study - BE",
        "timestamp": "2019-03-21"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-001679-36/CZ",
        "title": "Prospektivní, otevřená, randomizovaná multicentrická studie hodnotící účinnost a bezpečnost kombinace isotretinoinu (Roaccutane® tobolky) a interferonu alfa 2a oproti samotnému interferonu alfa 2a ... - CZ",
        "timestamp": "2005-06-14"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-002104-18/FR",
        "title": "Evaluation of the Cellular, Humoral and Mucosal Immune Response in Adults and Elderly Subjects Vaccinated either with an Inactivated Influenza Vaccine Administered via the Intradermal Route or an I... - FR",
        "timestamp": "2007-08-27"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-002104-18/results",
        "title": "Evaluation of the Cellular, Humoral and Mucosal Immune Response in Adults and Elderly Subjects Vaccinated either with an Inactivated Influenza Vaccine Administered via the Intradermal Route or an I... - View results",
        "timestamp": "2007-08-27"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-022589-29/GB",
        "title": "Investigation of pathways regulating cell survival and early antiangiogenic response to single agent Everolimus or Rapamycin in renal cancer - GB",
        "timestamp": "2011-03-22"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-019367-11/FR",
        "title": "ANRS HB 06 PEGAN\nEssai de phase III, randomisé, multicentrique, sans insu, évaluant à S96 la perte de l’Ag HBs suite à un traitement de 48 semaines par l’interféron pégylé alpha 2a chez des patient... - FR",
        "timestamp": "2010-08-30"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-001725-26/DE",
        "title": "A Phase I/II Gene Therapy trial for X-CGD with a SIN gamma retroviral vector - DE",
        "timestamp": "2013-03-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-013695-46/FR",
        "title": "ETUDE MULTICENTRIQUE, RANDOMISEE EN DOUBLE AVEUGLE VERSUS PLACEBO EVALUANT L’EFFICACITE D’UN TRAITEMENT ADDITIONNEL PAR CHOLECALCIFEROL (VITAMINE D3) CHEZ DES PATIENTS ATTEINTS DE SCLEROSE EN PLAQU... - FR",
        "timestamp": "2009-10-22"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-013695-46/results",
        "title": "ETUDE MULTICENTRIQUE, RANDOMISEE EN DOUBLE AVEUGLE VERSUS PLACEBO EVALUANT L’EFFICACITE D’UN TRAITEMENT ADDITIONNEL PAR CHOLECALCIFEROL (VITAMINE D3) CHEZ DES PATIENTS ATTEINTS DE SCLEROSE EN PLAQU... - View results",
        "timestamp": "2009-10-22"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-003662-87/DK",
        "title": "Pseudomonas Aeruginosa - Inhalation treatment, biomarkers and quality of life - DK",
        "timestamp": "2015-11-13"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-003150-16/AT",
        "title": "Copanlisib and Rituximab in Marginal Zone Lymphoma Patients - AT",
        "timestamp": "2019-09-04"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005989-38/NO",
        "title": "A SAFETY AND EFFICACY STUDY OF ADDING LOW DOSE PEGYLATED IFN-ΑLPHA 2B TO STANDARD DOSE DASATINIB IN PATIENTS WITH NEWLY DIAGNOSED CHRONIC PHASE CHRONIC MYELOID LEUKEMIA - NO",
        "timestamp": "2012-11-01"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005989-38/FI",
        "title": "A SAFETY AND EFFICACY STUDY OF ADDING LOW DOSE PEGYLATED IFN-ΑLPHA 2B TO STANDARD DOSE DASATINIB IN PATIENTS WITH NEWLY DIAGNOSED CHRONIC PHASE CHRONIC MYELOID LEUKEMIA - FI",
        "timestamp": "2012-11-01"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005989-38/SE",
        "title": "A SAFETY AND EFFICACY STUDY OF ADDING LOW DOSE PEGYLATED IFN-ΑLPHA 2B TO STANDARD DOSE DASATINIB IN PATIENTS WITH NEWLY DIAGNOSED CHRONIC PHASE CHRONIC MYELOID LEUKEMIA - SE",
        "timestamp": "2012-11-01"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005989-38/DK",
        "title": "A SAFETY AND EFFICACY STUDY OF ADDING LOW DOSE PEGYLATED IFN-ΑLPHA 2B TO STANDARD DOSE DASATINIB IN PATIENTS WITH NEWLY DIAGNOSED CHRONIC PHASE CHRONIC MYELOID LEUKEMIA - DK",
        "timestamp": "2012-11-01"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005475-16/GB",
        "title": "A Phase 1/2 Randomized, Dose-finding Study of MEDI-551 in Subjects with Relapsing-Remitting Multiple Sclerosis - GB",
        "timestamp": "2012-07-25"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005475-16/results",
        "title": "A Phase 1/2 Randomized, Dose-finding Study of MEDI-551 in Subjects with Relapsing-Remitting Multiple Sclerosis - View results",
        "timestamp": "2012-07-25"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-004116-38/SE",
        "title": "RItuximab versus FUmarate in Newly Diagnosed Multiple Sclerosis – RIFUND-MS\nA randomized phase 3 study comparing Rituximab with Dimethyl Fumarate in early Relapsing-Remitting Multiple Sclerosis\n\nOb... - SE",
        "timestamp": "2015-12-18"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-002468-20/FR",
        "title": "A Phase 3 Evaluation of a daclatasvir/asunaprevir/BMS-791325 Fixed Dose Combination in Non-cirrhotic Subjects with Genotype 1 Chronic Hepatitis C - FR",
        "timestamp": "2013-12-13"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-002468-20/results",
        "title": "A Phase 3 Evaluation of a daclatasvir/asunaprevir/BMS-791325 Fixed Dose Combination in Non-cirrhotic Subjects with Genotype 1 Chronic Hepatitis C - View results",
        "timestamp": "2013-12-13"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-003149-56/DE",
        "title": "OBINUTUZUMAB in MARGINAL ZONE LYMPHOMA - DE",
        "timestamp": "2018-05-14"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-001625-16/GB",
        "title": "A Phase 2, Single-Arm, Open-Label Study to Evaluate the Safety and Tolerability of PBI-4050 and of its Effects on the Inflammatory, Fibrosis,Diabetes and Obesity Biomarkers in Subjects with Alström... - GB",
        "timestamp": "2015-10-29"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-002291-41/IT",
        "title": "A Randomized, Open Label, Multi-Center Phase 2 Study of nab-Paclitaxel versus Epigenetic Modifying Therapy of CC-486 with nab-Paclitaxel in Subjects with Chemotherapy Naïve Metastatic Melanoma - IT",
        "timestamp": "2014-01-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-002251-14/GB",
        "title": "Localized on site testing and treatment of hepatitis C in homeless persons in London: a pilot non-randomised phase 4 interventional clinical trial of grazoprevir and elbasvir ± ribavirin in partici... - GB",
        "timestamp": "2019-01-02"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-002562-19/IT",
        "title": "Immunoablation with Cyclophosphamide at high dosage and Rabbit antithymoglobulin followed by autologous hematopoietic stem cell transplantation in severe multiple sclerosis - IT",
        "timestamp": "2006-04-21"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-008211-26/IT",
        "title": "Peptide-based vaccine in combination or not with chemotherapy in melanoma patients: a phase II randomized clinical study. - IT",
        "timestamp": "2009-05-25"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-000750-21/GB",
        "title": "The HALT-LTBI study: Phase IV, multi-site, unblinded, randomised trial of prophylactic daily  rifampicin/isoniazid vs. weekly rifapentine/isoniazid  for latent tuberculosis infection (LTBI) - GB",
        "timestamp": "2013-12-18"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-000750-21/results",
        "title": "The HALT-LTBI study: Phase IV, multi-site, unblinded, randomised trial of prophylactic daily  rifampicin/isoniazid vs. weekly rifapentine/isoniazid  for latent tuberculosis infection (LTBI) - View results",
        "timestamp": "2013-12-18"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-018585-23/BG",
        "title": "AG-013736 (axitinib) for the treatment of metastatic renal cell cancer (mRCC) - BG",
        "timestamp": "2010-12-21"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-006588-21/IT",
        "title": "Fluvastatin as adjuvant therapy to alfa-interferon and ribavirin in the treatment of chronic hepatitis C in patients with HIV-1 coinfection - IT",
        "timestamp": "2007-05-10"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-003922-70/DE",
        "title": "Uncontrolled, open Phase IIa study to investigate efficacy and safety of efalizumab in patients with moderate to severe palmoplantar pustular psoriasis (PPP) - DE",
        "timestamp": "2007-11-28"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-004610-26/GB",
        "title": "Evaluating the Long Term Immunogenicity of adenoviral and MVA vectored Ebola vaccine schedules and response to late boosting with AD26.ZEBOV vaccine: an open-label clinical trial - GB",
        "timestamp": "2018-11-28"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-004072-30/ES",
        "title": "A phase II trial to assess the activity and safety of TH-302 in combination with sunitinib in patients with well- and moderately-differentiated metastatic pancreatic neuroendocrine tumors (pNET) pr... - ES",
        "timestamp": "2015-01-22"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001254-22/BE",
        "title": "A prospective, randomized, open-label, interventional study to investigate the efficacy of sargramostim (Leukine®) in improving oxygenation and short- and long-term outcome of COVID-19 patients wit... - BE",
        "timestamp": "2020-03-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-006262-40/CZ",
        "title": "A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Subjects with Relapsing Forms of ... - CZ",
        "timestamp": "2013-06-18"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-006262-40/IT",
        "title": "A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Subjects with Relapsing Forms of ... - IT",
        "timestamp": "2013-06-18"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-006262-40/NL",
        "title": "A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Subjects with Relapsing Forms of ... - NL",
        "timestamp": "2013-06-18"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-006262-40/HU",
        "title": "A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Subjects with Relapsing Forms of ... - HU",
        "timestamp": "2013-06-18"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-006262-40/ES",
        "title": "A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Subjects with Relapsing Forms of ... - ES",
        "timestamp": "2013-06-18"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-006262-40/GB",
        "title": "A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Subjects with Relapsing Forms of ... - GB",
        "timestamp": "2013-06-18"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-006262-40/results",
        "title": "A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Subjects with Relapsing Forms of ... - View results",
        "timestamp": "2013-06-18"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-004114-17/GB",
        "title": "REVEAL 2: A Prospective, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of VGX-3100 Delivered Intramuscularly Followed by Electroporation with CELLECTRA™ 5PSP for the Treatment of HPV-1... - GB",
        "timestamp": None
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-004114-17/LT",
        "title": "REVEAL 2: A Prospective, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of VGX-3100 Delivered Intramuscularly Followed by Electroporation with CELLECTRA™ 5PSP for the Treatment of HPV-1... - LT",
        "timestamp": None
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-004114-17/EE",
        "title": "REVEAL 2: A Prospective, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of VGX-3100 Delivered Intramuscularly Followed by Electroporation with CELLECTRA™ 5PSP for the Treatment of HPV-1... - EE",
        "timestamp": None
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-004114-17/ES",
        "title": "REVEAL 2: A Prospective, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of VGX-3100 Delivered Intramuscularly Followed by Electroporation with CELLECTRA™ 5PSP for the Treatment of HPV-1... - ES",
        "timestamp": None
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-004114-17/BE",
        "title": "REVEAL 2: A Prospective, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of VGX-3100 Delivered Intramuscularly Followed by Electroporation with CELLECTRA™ 5PSP for the Treatment of HPV-1... - BE",
        "timestamp": None
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-004114-17/PL",
        "title": "REVEAL 2: A Prospective, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of VGX-3100 Delivered Intramuscularly Followed by Electroporation with CELLECTRA™ 5PSP for the Treatment of HPV-1... - PL",
        "timestamp": None
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-004114-17/FI",
        "title": "REVEAL 2: A Prospective, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of VGX-3100 Delivered Intramuscularly Followed by Electroporation with CELLECTRA™ 5PSP for the Treatment of HPV-1... - FI",
        "timestamp": None
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-013219-37/HU",
        "title": "A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib (AV-951) to Sorafenib in Subjects With Advanced Renal Cell Carcinoma - HU",
        "timestamp": "2010-02-02"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-013219-37/FR",
        "title": "A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib (AV-951) to Sorafenib in Subjects With Advanced Renal Cell Carcinoma - FR",
        "timestamp": "2010-02-02"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-013219-37/PL",
        "title": "A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib (AV-951) to Sorafenib in Subjects With Advanced Renal Cell Carcinoma - PL",
        "timestamp": "2010-02-02"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-013219-37/CZ",
        "title": "A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib (AV-951) to Sorafenib in Subjects With Advanced Renal Cell Carcinoma - CZ",
        "timestamp": "2010-02-02"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-013219-37/IT",
        "title": "A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib (AV-951) to Sorafenib in Subjects With Advanced Renal Cell Carcinoma - IT",
        "timestamp": "2010-02-02"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-013219-37/BG",
        "title": "A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib (AV-951) to Sorafenib in Subjects With Advanced Renal Cell Carcinoma - BG",
        "timestamp": "2010-02-02"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-013219-37/GB",
        "title": "A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib (AV-951) to Sorafenib in Subjects With Advanced Renal Cell Carcinoma - GB",
        "timestamp": "2010-02-02"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-003167-54/GB",
        "title": "A Phase 3, Matrix Design, Partially Double-Blind, Randomized Study of the Efficacy and Safety of 50 mg Lonafarnib/100 mg Ritonavir BID with and without 180 mcg PEG IFN-alfa-2a for 48 Weeks Compared... - GB",
        "timestamp": "2019-05-09"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-003167-54/FR",
        "title": "A Phase 3, Matrix Design, Partially Double-Blind, Randomized Study of the Efficacy and Safety of 50 mg Lonafarnib/100 mg Ritonavir BID with and without 180 mcg PEG IFN-alfa-2a for 48 Weeks Compared... - FR",
        "timestamp": "2019-05-09"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-003167-54/BG",
        "title": "A Phase 3, Matrix Design, Partially Double-Blind, Randomized Study of the Efficacy and Safety of 50 mg Lonafarnib/100 mg Ritonavir BID with and without 180 mcg PEG IFN-alfa-2a for 48 Weeks Compared... - BG",
        "timestamp": "2019-05-09"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-003167-54/GR",
        "title": "A Phase 3, Matrix Design, Partially Double-Blind, Randomized Study of the Efficacy and Safety of 50 mg Lonafarnib/100 mg Ritonavir BID with and without 180 mcg PEG IFN-alfa-2a for 48 Weeks Compared... - GR",
        "timestamp": "2019-05-09"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-003167-54/ES",
        "title": "A Phase 3, Matrix Design, Partially Double-Blind, Randomized Study of the Efficacy and Safety of 50 mg Lonafarnib/100 mg Ritonavir BID with and without 180 mcg PEG IFN-alfa-2a for 48 Weeks Compared... - ES",
        "timestamp": "2019-05-09"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-003167-54/SE",
        "title": "A Phase 3, Matrix Design, Partially Double-Blind, Randomized Study of the Efficacy and Safety of 50 mg Lonafarnib/100 mg Ritonavir BID with and without 180 mcg PEG IFN-alfa-2a for 48 Weeks Compared... - SE",
        "timestamp": "2019-05-09"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-023156-89/ES",
        "title": "Ensayo clínico en fase III, aleatorizado y controlado con placebo para estudiar la seguridad y la eficacia de V212 en pacientes adultos con tumor sólido o neoplasia hematológica.\n\nA Phase III Rando... - ES",
        "timestamp": "2011-02-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-023156-89/DE",
        "title": "Ensayo clínico en fase III, aleatorizado y controlado con placebo para estudiar la seguridad y la eficacia de V212 en pacientes adultos con tumor sólido o neoplasia hematológica.\n\nA Phase III Rando... - DE",
        "timestamp": "2011-02-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-023156-89/CZ",
        "title": "Ensayo clínico en fase III, aleatorizado y controlado con placebo para estudiar la seguridad y la eficacia de V212 en pacientes adultos con tumor sólido o neoplasia hematológica.\n\nA Phase III Rando... - CZ",
        "timestamp": "2011-02-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-023156-89/GB",
        "title": "Ensayo clínico en fase III, aleatorizado y controlado con placebo para estudiar la seguridad y la eficacia de V212 en pacientes adultos con tumor sólido o neoplasia hematológica.\n\nA Phase III Rando... - GB",
        "timestamp": "2011-02-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-023156-89/SK",
        "title": "Ensayo clínico en fase III, aleatorizado y controlado con placebo para estudiar la seguridad y la eficacia de V212 en pacientes adultos con tumor sólido o neoplasia hematológica.\n\nA Phase III Rando... - SK",
        "timestamp": "2011-02-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-023156-89/AT",
        "title": "Ensayo clínico en fase III, aleatorizado y controlado con placebo para estudiar la seguridad y la eficacia de V212 en pacientes adultos con tumor sólido o neoplasia hematológica.\n\nA Phase III Rando... - AT",
        "timestamp": "2011-02-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-023156-89/BE",
        "title": "Ensayo clínico en fase III, aleatorizado y controlado con placebo para estudiar la seguridad y la eficacia de V212 en pacientes adultos con tumor sólido o neoplasia hematológica.\n\nA Phase III Rando... - BE",
        "timestamp": "2011-02-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-023156-89/EE",
        "title": "Ensayo clínico en fase III, aleatorizado y controlado con placebo para estudiar la seguridad y la eficacia de V212 en pacientes adultos con tumor sólido o neoplasia hematológica.\n\nA Phase III Rando... - EE",
        "timestamp": "2011-02-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-023156-89/LT",
        "title": "Ensayo clínico en fase III, aleatorizado y controlado con placebo para estudiar la seguridad y la eficacia de V212 en pacientes adultos con tumor sólido o neoplasia hematológica.\n\nA Phase III Rando... - LT",
        "timestamp": "2011-02-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-023156-89/GR",
        "title": "Ensayo clínico en fase III, aleatorizado y controlado con placebo para estudiar la seguridad y la eficacia de V212 en pacientes adultos con tumor sólido o neoplasia hematológica.\n\nA Phase III Rando... - GR",
        "timestamp": "2011-02-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-023156-89/BG",
        "title": "Ensayo clínico en fase III, aleatorizado y controlado con placebo para estudiar la seguridad y la eficacia de V212 en pacientes adultos con tumor sólido o neoplasia hematológica.\n\nA Phase III Rando... - BG",
        "timestamp": "2011-02-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-023156-89/IT",
        "title": "Ensayo clínico en fase III, aleatorizado y controlado con placebo para estudiar la seguridad y la eficacia de V212 en pacientes adultos con tumor sólido o neoplasia hematológica.\n\nA Phase III Rando... - IT",
        "timestamp": "2011-02-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-023156-89/results",
        "title": "Ensayo clínico en fase III, aleatorizado y controlado con placebo para estudiar la seguridad y la eficacia de V212 en pacientes adultos con tumor sólido o neoplasia hematológica.\n\nA Phase III Rando... - View results",
        "timestamp": "2011-02-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-004760-39/DE",
        "title": "A phase 3 safety and efficacy study of boceprevir in combination with peginterferon alfa-2a and ribavirin in subjects with chronic hepatitis C genotype 1 who failed prior treatment with peginterfer... - DE",
        "timestamp": "2009-04-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-004760-39/BE",
        "title": "A phase 3 safety and efficacy study of boceprevir in combination with peginterferon alfa-2a and ribavirin in subjects with chronic hepatitis C genotype 1 who failed prior treatment with peginterfer... - BE",
        "timestamp": "2009-04-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-004760-39/IT",
        "title": "A phase 3 safety and efficacy study of boceprevir in combination with peginterferon alfa-2a and ribavirin in subjects with chronic hepatitis C genotype 1 who failed prior treatment with peginterfer... - IT",
        "timestamp": "2009-04-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-004760-39/FR",
        "title": "A phase 3 safety and efficacy study of boceprevir in combination with peginterferon alfa-2a and ribavirin in subjects with chronic hepatitis C genotype 1 who failed prior treatment with peginterfer... - FR",
        "timestamp": "2009-04-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-004760-39/results",
        "title": "A phase 3 safety and efficacy study of boceprevir in combination with peginterferon alfa-2a and ribavirin in subjects with chronic hepatitis C genotype 1 who failed prior treatment with peginterfer... - View results",
        "timestamp": "2009-04-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-001683-35/DE",
        "title": "A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of\r\nSofosbuvir/GS-5816 Fixed Dose Combination for 12 Weeks in Subjects with Chronic... - DE",
        "timestamp": "2014-10-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-001683-35/GB",
        "title": "A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of\r\nSofosbuvir/GS-5816 Fixed Dose Combination for 12 Weeks in Subjects with Chronic... - GB",
        "timestamp": "2014-10-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-001683-35/IT",
        "title": "A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of\r\nSofosbuvir/GS-5816 Fixed Dose Combination for 12 Weeks in Subjects with Chronic... - IT",
        "timestamp": "2014-10-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-001683-35/BE",
        "title": "A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of\r\nSofosbuvir/GS-5816 Fixed Dose Combination for 12 Weeks in Subjects with Chronic... - BE",
        "timestamp": "2014-10-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-001683-35/FR",
        "title": "A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of\r\nSofosbuvir/GS-5816 Fixed Dose Combination for 12 Weeks in Subjects with Chronic... - FR",
        "timestamp": "2014-10-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-001683-35/results",
        "title": "A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of\r\nSofosbuvir/GS-5816 Fixed Dose Combination for 12 Weeks in Subjects with Chronic... - View results",
        "timestamp": "2014-10-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005055-14/SE",
        "title": "A Phase 3, Multicenter, Randomized, Active-Controlled Study to Investigate the Safety and Efficacy of PSI-7977 and Ribavirin for 12 Weeks Compared to Pegylated Interferon and Ribavirin for 24 Weeks... - SE",
        "timestamp": "2012-03-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005055-14/EE",
        "title": "A Phase 3, Multicenter, Randomized, Active-Controlled Study to Investigate the Safety and Efficacy of PSI-7977 and Ribavirin for 12 Weeks Compared to Pegylated Interferon and Ribavirin for 24 Weeks... - EE",
        "timestamp": "2012-03-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005055-14/IT",
        "title": "A Phase 3, Multicenter, Randomized, Active-Controlled Study to Investigate the Safety and Efficacy of PSI-7977 and Ribavirin for 12 Weeks Compared to Pegylated Interferon and Ribavirin for 24 Weeks... - IT",
        "timestamp": "2012-03-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005055-14/ES",
        "title": "A Phase 3, Multicenter, Randomized, Active-Controlled Study to Investigate the Safety and Efficacy of PSI-7977 and Ribavirin for 12 Weeks Compared to Pegylated Interferon and Ribavirin for 24 Weeks... - ES",
        "timestamp": "2012-03-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005055-14/NL",
        "title": "A Phase 3, Multicenter, Randomized, Active-Controlled Study to Investigate the Safety and Efficacy of PSI-7977 and Ribavirin for 12 Weeks Compared to Pegylated Interferon and Ribavirin for 24 Weeks... - NL",
        "timestamp": "2012-03-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005055-14/results",
        "title": "A Phase 3, Multicenter, Randomized, Active-Controlled Study to Investigate the Safety and Efficacy of PSI-7977 and Ribavirin for 12 Weeks Compared to Pegylated Interferon and Ribavirin for 24 Weeks... - View results",
        "timestamp": "2012-03-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-002520-16/SE",
        "title": "A Phase 3 Randomized, Placebo-controlled Trial to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) and Lenvatinib (E7080/MK-7902) Versus Pembrolizumab Alone as First-line Intervention in... - SE",
        "timestamp": "2018-11-28"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-002520-16/DE",
        "title": "A Phase 3 Randomized, Placebo-controlled Trial to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) and Lenvatinib (E7080/MK-7902) Versus Pembrolizumab Alone as First-line Intervention in... - DE",
        "timestamp": "2018-11-28"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-002520-16/ES",
        "title": "A Phase 3 Randomized, Placebo-controlled Trial to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) and Lenvatinib (E7080/MK-7902) Versus Pembrolizumab Alone as First-line Intervention in... - ES",
        "timestamp": "2018-11-28"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-002520-16/FR",
        "title": "A Phase 3 Randomized, Placebo-controlled Trial to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) and Lenvatinib (E7080/MK-7902) Versus Pembrolizumab Alone as First-line Intervention in... - FR",
        "timestamp": "2018-11-28"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-002520-16/GB",
        "title": "A Phase 3 Randomized, Placebo-controlled Trial to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) and Lenvatinib (E7080/MK-7902) Versus Pembrolizumab Alone as First-line Intervention in... - GB",
        "timestamp": "2018-11-28"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-006604-11/AT",
        "title": "A Phase II, Randomized, Double-Blinded, Multicenter, Dose Finding Study Evaluating the Efficacy and Safety of the HCV Polymerase Inhibitor Prodrug (RO4588161) when given in combination with Pegasys... - AT",
        "timestamp": "2007-12-06"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-006604-11/DE",
        "title": "A Phase II, Randomized, Double-Blinded, Multicenter, Dose Finding Study Evaluating the Efficacy and Safety of the HCV Polymerase Inhibitor Prodrug (RO4588161) when given in combination with Pegasys... - DE",
        "timestamp": "2007-12-06"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-006604-11/FR",
        "title": "A Phase II, Randomized, Double-Blinded, Multicenter, Dose Finding Study Evaluating the Efficacy and Safety of the HCV Polymerase Inhibitor Prodrug (RO4588161) when given in combination with Pegasys... - FR",
        "timestamp": "2007-12-06"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-006604-11/ES",
        "title": "A Phase II, Randomized, Double-Blinded, Multicenter, Dose Finding Study Evaluating the Efficacy and Safety of the HCV Polymerase Inhibitor Prodrug (RO4588161) when given in combination with Pegasys... - ES",
        "timestamp": "2007-12-06"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-006604-11/IT",
        "title": "A Phase II, Randomized, Double-Blinded, Multicenter, Dose Finding Study Evaluating the Efficacy and Safety of the HCV Polymerase Inhibitor Prodrug (RO4588161) when given in combination with Pegasys... - IT",
        "timestamp": "2007-12-06"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-006604-11/results",
        "title": "A Phase II, Randomized, Double-Blinded, Multicenter, Dose Finding Study Evaluating the Efficacy and Safety of the HCV Polymerase Inhibitor Prodrug (RO4588161) when given in combination with Pegasys... - View results",
        "timestamp": "2007-12-06"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-000626-63/IT",
        "title": "A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Tenofovir Alafenamide (TAF) 25 mg QD versus Tenofovir Disoproxil Fumarate (TDF) 300 mg QD for the Treatment of HBeAg... - IT",
        "timestamp": "2013-11-21"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-000626-63/GB",
        "title": "A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Tenofovir Alafenamide (TAF) 25 mg QD versus Tenofovir Disoproxil Fumarate (TDF) 300 mg QD for the Treatment of HBeAg... - GB",
        "timestamp": "2013-11-21"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-000626-63/DE",
        "title": "A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Tenofovir Alafenamide (TAF) 25 mg QD versus Tenofovir Disoproxil Fumarate (TDF) 300 mg QD for the Treatment of HBeAg... - DE",
        "timestamp": "2013-11-21"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-000626-63/ES",
        "title": "A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Tenofovir Alafenamide (TAF) 25 mg QD versus Tenofovir Disoproxil Fumarate (TDF) 300 mg QD for the Treatment of HBeAg... - ES",
        "timestamp": "2013-11-21"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-000626-63/PL",
        "title": "A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Tenofovir Alafenamide (TAF) 25 mg QD versus Tenofovir Disoproxil Fumarate (TDF) 300 mg QD for the Treatment of HBeAg... - PL",
        "timestamp": "2013-11-21"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-000836-27/IE",
        "title": "An Open-Label Re-treatment Study with Peg-Interferon Alfa-2a, Ribavirin and BMS-790052 With or Without BMS-650032 for Subjects With Chronic Hepatitis C\r\nRevised Protocol Number 05; Incorporates Ame... - IE",
        "timestamp": "2011-09-30"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-000836-27/GB",
        "title": "An Open-Label Re-treatment Study with Peg-Interferon Alfa-2a, Ribavirin and BMS-790052 With or Without BMS-650032 for Subjects With Chronic Hepatitis C\r\nRevised Protocol Number 05; Incorporates Ame... - GB",
        "timestamp": "2011-09-30"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-000836-27/ES",
        "title": "An Open-Label Re-treatment Study with Peg-Interferon Alfa-2a, Ribavirin and BMS-790052 With or Without BMS-650032 for Subjects With Chronic Hepatitis C\r\nRevised Protocol Number 05; Incorporates Ame... - ES",
        "timestamp": "2011-09-30"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-000836-27/SE",
        "title": "An Open-Label Re-treatment Study with Peg-Interferon Alfa-2a, Ribavirin and BMS-790052 With or Without BMS-650032 for Subjects With Chronic Hepatitis C\r\nRevised Protocol Number 05; Incorporates Ame... - SE",
        "timestamp": "2011-09-30"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-000836-27/DK",
        "title": "An Open-Label Re-treatment Study with Peg-Interferon Alfa-2a, Ribavirin and BMS-790052 With or Without BMS-650032 for Subjects With Chronic Hepatitis C\r\nRevised Protocol Number 05; Incorporates Ame... - DK",
        "timestamp": "2011-09-30"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-000836-27/IT",
        "title": "An Open-Label Re-treatment Study with Peg-Interferon Alfa-2a, Ribavirin and BMS-790052 With or Without BMS-650032 for Subjects With Chronic Hepatitis C\r\nRevised Protocol Number 05; Incorporates Ame... - IT",
        "timestamp": "2011-09-30"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-000836-27/AT",
        "title": "An Open-Label Re-treatment Study with Peg-Interferon Alfa-2a, Ribavirin and BMS-790052 With or Without BMS-650032 for Subjects With Chronic Hepatitis C\r\nRevised Protocol Number 05; Incorporates Ame... - AT",
        "timestamp": "2011-09-30"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-000836-27/NL",
        "title": "An Open-Label Re-treatment Study with Peg-Interferon Alfa-2a, Ribavirin and BMS-790052 With or Without BMS-650032 for Subjects With Chronic Hepatitis C\r\nRevised Protocol Number 05; Incorporates Ame... - NL",
        "timestamp": "2011-09-30"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-000836-27/GR",
        "title": "An Open-Label Re-treatment Study with Peg-Interferon Alfa-2a, Ribavirin and BMS-790052 With or Without BMS-650032 for Subjects With Chronic Hepatitis C\r\nRevised Protocol Number 05; Incorporates Ame... - GR",
        "timestamp": "2011-09-30"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-000836-27/results",
        "title": "An Open-Label Re-treatment Study with Peg-Interferon Alfa-2a, Ribavirin and BMS-790052 With or Without BMS-650032 for Subjects With Chronic Hepatitis C\r\nRevised Protocol Number 05; Incorporates Ame... - View results",
        "timestamp": "2011-09-30"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-010806-12/ES",
        "title": "Estudio multicéntrico, aleatorizado, abierto, controlado para comparar la Respuesta Virológica Sostenida durante el tratamiento con Sandimmun Neoral® o tacrolimus en el mantenimiento de receptores ... - ES",
        "timestamp": "2009-07-22"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-010806-12/BE",
        "title": "Estudio multicéntrico, aleatorizado, abierto, controlado para comparar la Respuesta Virológica Sostenida durante el tratamiento con Sandimmun Neoral® o tacrolimus en el mantenimiento de receptores ... - BE",
        "timestamp": "2009-07-22"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-010806-12/IT",
        "title": "Estudio multicéntrico, aleatorizado, abierto, controlado para comparar la Respuesta Virológica Sostenida durante el tratamiento con Sandimmun Neoral® o tacrolimus en el mantenimiento de receptores ... - IT",
        "timestamp": "2009-07-22"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-010806-12/HU",
        "title": "Estudio multicéntrico, aleatorizado, abierto, controlado para comparar la Respuesta Virológica Sostenida durante el tratamiento con Sandimmun Neoral® o tacrolimus en el mantenimiento de receptores ... - HU",
        "timestamp": "2009-07-22"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-010806-12/FR",
        "title": "Estudio multicéntrico, aleatorizado, abierto, controlado para comparar la Respuesta Virológica Sostenida durante el tratamiento con Sandimmun Neoral® o tacrolimus en el mantenimiento de receptores ... - FR",
        "timestamp": "2009-07-22"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-010806-12/DE",
        "title": "Estudio multicéntrico, aleatorizado, abierto, controlado para comparar la Respuesta Virológica Sostenida durante el tratamiento con Sandimmun Neoral® o tacrolimus en el mantenimiento de receptores ... - DE",
        "timestamp": "2009-07-22"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-010806-12/AT",
        "title": "Estudio multicéntrico, aleatorizado, abierto, controlado para comparar la Respuesta Virológica Sostenida durante el tratamiento con Sandimmun Neoral® o tacrolimus en el mantenimiento de receptores ... - AT",
        "timestamp": "2009-07-22"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-010806-12/GB",
        "title": "Estudio multicéntrico, aleatorizado, abierto, controlado para comparar la Respuesta Virológica Sostenida durante el tratamiento con Sandimmun Neoral® o tacrolimus en el mantenimiento de receptores ... - GB",
        "timestamp": "2009-07-22"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-010806-12/results",
        "title": "Estudio multicéntrico, aleatorizado, abierto, controlado para comparar la Respuesta Virológica Sostenida durante el tratamiento con Sandimmun Neoral® o tacrolimus en el mantenimiento de receptores ... - View results",
        "timestamp": "2009-07-22"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-010273-20/BE",
        "title": "Adjuvant peginterferon alfa-2b for 2 years vs Observation in patients with an ulcerated primary cutaneous melanoma with T(2-4)bN0M0: a randomized phase III trial of the EORTC Melanoma Group. - BE",
        "timestamp": "2012-11-28"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-010273-20/GB",
        "title": "Adjuvant peginterferon alfa-2b for 2 years vs Observation in patients with an ulcerated primary cutaneous melanoma with T(2-4)bN0M0: a randomized phase III trial of the EORTC Melanoma Group. - GB",
        "timestamp": "2012-11-28"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-010273-20/DE",
        "title": "Adjuvant peginterferon alfa-2b for 2 years vs Observation in patients with an ulcerated primary cutaneous melanoma with T(2-4)bN0M0: a randomized phase III trial of the EORTC Melanoma Group. - DE",
        "timestamp": "2012-11-28"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-010273-20/AT",
        "title": "Adjuvant peginterferon alfa-2b for 2 years vs Observation in patients with an ulcerated primary cutaneous melanoma with T(2-4)bN0M0: a randomized phase III trial of the EORTC Melanoma Group. - AT",
        "timestamp": "2012-11-28"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-010273-20/IT",
        "title": "Adjuvant peginterferon alfa-2b for 2 years vs Observation in patients with an ulcerated primary cutaneous melanoma with T(2-4)bN0M0: a randomized phase III trial of the EORTC Melanoma Group. - IT",
        "timestamp": "2012-11-28"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-010273-20/DK",
        "title": "Adjuvant peginterferon alfa-2b for 2 years vs Observation in patients with an ulcerated primary cutaneous melanoma with T(2-4)bN0M0: a randomized phase III trial of the EORTC Melanoma Group. - DK",
        "timestamp": "2012-11-28"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-010273-20/ES",
        "title": "Adjuvant peginterferon alfa-2b for 2 years vs Observation in patients with an ulcerated primary cutaneous melanoma with T(2-4)bN0M0: a randomized phase III trial of the EORTC Melanoma Group. - ES",
        "timestamp": "2012-11-28"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-010273-20/NL",
        "title": "Adjuvant peginterferon alfa-2b for 2 years vs Observation in patients with an ulcerated primary cutaneous melanoma with T(2-4)bN0M0: a randomized phase III trial of the EORTC Melanoma Group. - NL",
        "timestamp": "2012-11-28"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-010273-20/PT",
        "title": "Adjuvant peginterferon alfa-2b for 2 years vs Observation in patients with an ulcerated primary cutaneous melanoma with T(2-4)bN0M0: a randomized phase III trial of the EORTC Melanoma Group. - PT",
        "timestamp": "2012-11-28"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-010273-20/PL",
        "title": "Adjuvant peginterferon alfa-2b for 2 years vs Observation in patients with an ulcerated primary cutaneous melanoma with T(2-4)bN0M0: a randomized phase III trial of the EORTC Melanoma Group. - PL",
        "timestamp": "2012-11-28"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-010273-20/results",
        "title": "Adjuvant peginterferon alfa-2b for 2 years vs Observation in patients with an ulcerated primary cutaneous melanoma with T(2-4)bN0M0: a randomized phase III trial of the EORTC Melanoma Group. - View results",
        "timestamp": "2012-11-28"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-001356-31/HU",
        "title": "An open-label, single arm, Phase III study to assess the self-administration of AOP2014 using a pre-filled pen, developed for the treatment of Polycythemia Vera patients - HU",
        "timestamp": "2015-05-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-001356-31/SK",
        "title": "An open-label, single arm, Phase III study to assess the self-administration of AOP2014 using a pre-filled pen, developed for the treatment of Polycythemia Vera patients - SK",
        "timestamp": "2015-05-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-001356-31/AT",
        "title": "An open-label, single arm, Phase III study to assess the self-administration of AOP2014 using a pre-filled pen, developed for the treatment of Polycythemia Vera patients - AT",
        "timestamp": "2015-05-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-001356-31/CZ",
        "title": "An open-label, single arm, Phase III study to assess the self-administration of AOP2014 using a pre-filled pen, developed for the treatment of Polycythemia Vera patients - CZ",
        "timestamp": "2015-05-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-001356-31/BG",
        "title": "An open-label, single arm, Phase III study to assess the self-administration of AOP2014 using a pre-filled pen, developed for the treatment of Polycythemia Vera patients - BG",
        "timestamp": "2015-05-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-001356-31/PL",
        "title": "An open-label, single arm, Phase III study to assess the self-administration of AOP2014 using a pre-filled pen, developed for the treatment of Polycythemia Vera patients - PL",
        "timestamp": "2015-05-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-001356-31/results",
        "title": "An open-label, single arm, Phase III study to assess the self-administration of AOP2014 using a pre-filled pen, developed for the treatment of Polycythemia Vera patients - View results",
        "timestamp": "2015-05-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-001682-27/GB",
        "title": "A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Sofosbuvir/GS-5816 Fixed\nDose Combination for 12 Weeks with Sofosbuvir and Ribavirin for 24 Weeks in Subje... - GB",
        "timestamp": "2014-08-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-001682-27/IT",
        "title": "A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Sofosbuvir/GS-5816 Fixed\nDose Combination for 12 Weeks with Sofosbuvir and Ribavirin for 24 Weeks in Subje... - IT",
        "timestamp": "2014-08-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-001682-27/FR",
        "title": "A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Sofosbuvir/GS-5816 Fixed\nDose Combination for 12 Weeks with Sofosbuvir and Ribavirin for 24 Weeks in Subje... - FR",
        "timestamp": "2014-08-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-001682-27/results",
        "title": "A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Sofosbuvir/GS-5816 Fixed\nDose Combination for 12 Weeks with Sofosbuvir and Ribavirin for 24 Weeks in Subje... - View results",
        "timestamp": "2014-08-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003627-38/SE",
        "title": "Proof of Mechanism Study to Assess the Potential of GSK239512 to Remyelinate Lesions in Subjects with Relapsing Remitting Multiple Sclerosis - SE",
        "timestamp": "2013-01-30"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003627-38/DE",
        "title": "Proof of Mechanism Study to Assess the Potential of GSK239512 to Remyelinate Lesions in Subjects with Relapsing Remitting Multiple Sclerosis - DE",
        "timestamp": "2013-01-30"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003627-38/ES",
        "title": "Proof of Mechanism Study to Assess the Potential of GSK239512 to Remyelinate Lesions in Subjects with Relapsing Remitting Multiple Sclerosis - ES",
        "timestamp": "2013-01-30"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003627-38/CZ",
        "title": "Proof of Mechanism Study to Assess the Potential of GSK239512 to Remyelinate Lesions in Subjects with Relapsing Remitting Multiple Sclerosis - CZ",
        "timestamp": "2013-01-30"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003627-38/BG",
        "title": "Proof of Mechanism Study to Assess the Potential of GSK239512 to Remyelinate Lesions in Subjects with Relapsing Remitting Multiple Sclerosis - BG",
        "timestamp": "2013-01-30"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003627-38/GB",
        "title": "Proof of Mechanism Study to Assess the Potential of GSK239512 to Remyelinate Lesions in Subjects with Relapsing Remitting Multiple Sclerosis - GB",
        "timestamp": "2013-01-30"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003627-38/results",
        "title": "Proof of Mechanism Study to Assess the Potential of GSK239512 to Remyelinate Lesions in Subjects with Relapsing Remitting Multiple Sclerosis - View results",
        "timestamp": "2013-01-30"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-023498-20/GB",
        "title": "Assessment of the Pharmacokinetics of Boceprevir in Pediatric Subjects with Chronic Hepatitis C Genotype 1 (Phase 1b) - GB",
        "timestamp": "2011-11-14"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-023498-20/PL",
        "title": "Assessment of the Pharmacokinetics of Boceprevir in Pediatric Subjects with Chronic Hepatitis C Genotype 1 (Phase 1b) - PL",
        "timestamp": "2011-11-14"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-023498-20/ES",
        "title": "Assessment of the Pharmacokinetics of Boceprevir in Pediatric Subjects with Chronic Hepatitis C Genotype 1 (Phase 1b) - ES",
        "timestamp": "2011-11-14"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-023498-20/DE",
        "title": "Assessment of the Pharmacokinetics of Boceprevir in Pediatric Subjects with Chronic Hepatitis C Genotype 1 (Phase 1b) - DE",
        "timestamp": "2011-11-14"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-023498-20/3rd",
        "title": "Assessment of the Pharmacokinetics of Boceprevir in Pediatric Subjects with Chronic Hepatitis C Genotype 1 (Phase 1b) - Outside EU/EEA",
        "timestamp": "2011-11-14"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-023498-20/results",
        "title": "Assessment of the Pharmacokinetics of Boceprevir in Pediatric Subjects with Chronic Hepatitis C Genotype 1 (Phase 1b) - View results",
        "timestamp": "2011-11-14"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-000636-10/IT",
        "title": "A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Tenofovir Alafenamide (TAF) 25 mg QD versus Tenofovir Disoproxil Fumarate (TDF) 300 mg QD for the Treatment of HBeAg... - IT",
        "timestamp": "2013-11-21"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-000636-10/GB",
        "title": "A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Tenofovir Alafenamide (TAF) 25 mg QD versus Tenofovir Disoproxil Fumarate (TDF) 300 mg QD for the Treatment of HBeAg... - GB",
        "timestamp": "2013-11-21"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-000636-10/DE",
        "title": "A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Tenofovir Alafenamide (TAF) 25 mg QD versus Tenofovir Disoproxil Fumarate (TDF) 300 mg QD for the Treatment of HBeAg... - DE",
        "timestamp": "2013-11-21"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-000636-10/ES",
        "title": "A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Tenofovir Alafenamide (TAF) 25 mg QD versus Tenofovir Disoproxil Fumarate (TDF) 300 mg QD for the Treatment of HBeAg... - ES",
        "timestamp": "2013-11-21"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-000636-10/PL",
        "title": "A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Tenofovir Alafenamide (TAF) 25 mg QD versus Tenofovir Disoproxil Fumarate (TDF) 300 mg QD for the Treatment of HBeAg... - PL",
        "timestamp": "2013-11-21"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-000636-10/BG",
        "title": "A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Tenofovir Alafenamide (TAF) 25 mg QD versus Tenofovir Disoproxil Fumarate (TDF) 300 mg QD for the Treatment of HBeAg... - BG",
        "timestamp": "2013-11-21"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-000636-10/results",
        "title": "A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Tenofovir Alafenamide (TAF) 25 mg QD versus Tenofovir Disoproxil Fumarate (TDF) 300 mg QD for the Treatment of HBeAg... - View results",
        "timestamp": "2013-11-21"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-004766-17/IT",
        "title": "Open-Label, Multi-Center, Randomized Study of Anti-CCR4 Monoclonal Antibody KW 0761 (mogamulizumab) Versus Vorinostat in Subjects with Previously Treated Cutaneous T-Cell Lymphoma (CTCL) - IT",
        "timestamp": "2013-07-23"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-004766-17/ES",
        "title": "Open-Label, Multi-Center, Randomized Study of Anti-CCR4 Monoclonal Antibody KW 0761 (mogamulizumab) Versus Vorinostat in Subjects with Previously Treated Cutaneous T-Cell Lymphoma (CTCL) - ES",
        "timestamp": "2013-07-23"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-004766-17/NL",
        "title": "Open-Label, Multi-Center, Randomized Study of Anti-CCR4 Monoclonal Antibody KW 0761 (mogamulizumab) Versus Vorinostat in Subjects with Previously Treated Cutaneous T-Cell Lymphoma (CTCL) - NL",
        "timestamp": "2013-07-23"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-004766-17/DK",
        "title": "Open-Label, Multi-Center, Randomized Study of Anti-CCR4 Monoclonal Antibody KW 0761 (mogamulizumab) Versus Vorinostat in Subjects with Previously Treated Cutaneous T-Cell Lymphoma (CTCL) - DK",
        "timestamp": "2013-07-23"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-004766-17/GB",
        "title": "Open-Label, Multi-Center, Randomized Study of Anti-CCR4 Monoclonal Antibody KW 0761 (mogamulizumab) Versus Vorinostat in Subjects with Previously Treated Cutaneous T-Cell Lymphoma (CTCL) - GB",
        "timestamp": "2013-07-23"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-004766-17/DE",
        "title": "Open-Label, Multi-Center, Randomized Study of Anti-CCR4 Monoclonal Antibody KW 0761 (mogamulizumab) Versus Vorinostat in Subjects with Previously Treated Cutaneous T-Cell Lymphoma (CTCL) - DE",
        "timestamp": "2013-07-23"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003176-39/DE",
        "title": "A Multicenter, Open-Label, Extension Study to Evaluate the Long Term Safety and Efficacy of BIIB019, Daclizumab High Yield Process (DAC HYP), Monotherapy in Subjects With Multiple Sclerosis Who Hav... - DE",
        "timestamp": "2013-05-31"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003176-39/IT",
        "title": "A Multicenter, Open-Label, Extension Study to Evaluate the Long Term Safety and Efficacy of BIIB019, Daclizumab High Yield Process (DAC HYP), Monotherapy in Subjects With Multiple Sclerosis Who Hav... - IT",
        "timestamp": "2013-05-31"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003176-39/CZ",
        "title": "A Multicenter, Open-Label, Extension Study to Evaluate the Long Term Safety and Efficacy of BIIB019, Daclizumab High Yield Process (DAC HYP), Monotherapy in Subjects With Multiple Sclerosis Who Hav... - CZ",
        "timestamp": "2013-05-31"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003176-39/HU",
        "title": "A Multicenter, Open-Label, Extension Study to Evaluate the Long Term Safety and Efficacy of BIIB019, Daclizumab High Yield Process (DAC HYP), Monotherapy in Subjects With Multiple Sclerosis Who Hav... - HU",
        "timestamp": "2013-05-31"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003176-39/PL",
        "title": "A Multicenter, Open-Label, Extension Study to Evaluate the Long Term Safety and Efficacy of BIIB019, Daclizumab High Yield Process (DAC HYP), Monotherapy in Subjects With Multiple Sclerosis Who Hav... - PL",
        "timestamp": "2013-05-31"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003176-39/SE",
        "title": "A Multicenter, Open-Label, Extension Study to Evaluate the Long Term Safety and Efficacy of BIIB019, Daclizumab High Yield Process (DAC HYP), Monotherapy in Subjects With Multiple Sclerosis Who Hav... - SE",
        "timestamp": "2013-05-31"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003176-39/ES",
        "title": "A Multicenter, Open-Label, Extension Study to Evaluate the Long Term Safety and Efficacy of BIIB019, Daclizumab High Yield Process (DAC HYP), Monotherapy in Subjects With Multiple Sclerosis Who Hav... - ES",
        "timestamp": "2013-05-31"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003176-39/IE",
        "title": "A Multicenter, Open-Label, Extension Study to Evaluate the Long Term Safety and Efficacy of BIIB019, Daclizumab High Yield Process (DAC HYP), Monotherapy in Subjects With Multiple Sclerosis Who Hav... - IE",
        "timestamp": "2013-05-31"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003176-39/GB",
        "title": "A Multicenter, Open-Label, Extension Study to Evaluate the Long Term Safety and Efficacy of BIIB019, Daclizumab High Yield Process (DAC HYP), Monotherapy in Subjects With Multiple Sclerosis Who Hav... - GB",
        "timestamp": "2013-05-31"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003176-39/FI",
        "title": "A Multicenter, Open-Label, Extension Study to Evaluate the Long Term Safety and Efficacy of BIIB019, Daclizumab High Yield Process (DAC HYP), Monotherapy in Subjects With Multiple Sclerosis Who Hav... - FI",
        "timestamp": "2013-05-31"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003176-39/GR",
        "title": "A Multicenter, Open-Label, Extension Study to Evaluate the Long Term Safety and Efficacy of BIIB019, Daclizumab High Yield Process (DAC HYP), Monotherapy in Subjects With Multiple Sclerosis Who Hav... - GR",
        "timestamp": "2013-05-31"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003176-39/FR",
        "title": "A Multicenter, Open-Label, Extension Study to Evaluate the Long Term Safety and Efficacy of BIIB019, Daclizumab High Yield Process (DAC HYP), Monotherapy in Subjects With Multiple Sclerosis Who Hav... - FR",
        "timestamp": "2013-05-31"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003176-39/DK",
        "title": "A Multicenter, Open-Label, Extension Study to Evaluate the Long Term Safety and Efficacy of BIIB019, Daclizumab High Yield Process (DAC HYP), Monotherapy in Subjects With Multiple Sclerosis Who Hav... - DK",
        "timestamp": "2013-05-31"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003176-39/results",
        "title": "A Multicenter, Open-Label, Extension Study to Evaluate the Long Term Safety and Efficacy of BIIB019, Daclizumab High Yield Process (DAC HYP), Monotherapy in Subjects With Multiple Sclerosis Who Hav... - View results",
        "timestamp": "2013-05-31"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-001601-16/NL",
        "title": "A Phase IIa, Double-blind, Randomised, Placebo-Controlled Dose Escalation Study to Evalulate the Safety, Tolerability, Pharmacokinetics and Activity of GS-9450, a Caspase Inhibitor, in Subjects wit... - NL",
        "timestamp": "2007-04-13"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-001601-16/DE",
        "title": "A Phase IIa, Double-blind, Randomised, Placebo-Controlled Dose Escalation Study to Evalulate the Safety, Tolerability, Pharmacokinetics and Activity of GS-9450, a Caspase Inhibitor, in Subjects wit... - DE",
        "timestamp": "2007-04-13"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-001601-16/FR",
        "title": "A Phase IIa, Double-blind, Randomised, Placebo-Controlled Dose Escalation Study to Evalulate the Safety, Tolerability, Pharmacokinetics and Activity of GS-9450, a Caspase Inhibitor, in Subjects wit... - FR",
        "timestamp": "2007-04-13"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-001601-16/results",
        "title": "A Phase IIa, Double-blind, Randomised, Placebo-Controlled Dose Escalation Study to Evalulate the Safety, Tolerability, Pharmacokinetics and Activity of GS-9450, a Caspase Inhibitor, in Subjects wit... - View results",
        "timestamp": "2007-04-13"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-001467-39/ES",
        "title": "A phase II study to evaluate the safety and efficacy of lenvatinib in patients with advanced grade 1/2 neuroendocrine neoplasmas of pancreatic and extrapancreatic origin. - ES",
        "timestamp": "2015-07-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-001467-39/AT",
        "title": "A phase II study to evaluate the safety and efficacy of lenvatinib in patients with advanced grade 1/2 neuroendocrine neoplasmas of pancreatic and extrapancreatic origin. - AT",
        "timestamp": "2015-07-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-001044-54/FI",
        "title": "A STUDY OF EFFICACY AND SAFETY OF LONG-ACTING LOW DOSE ROPEGINTERFERON IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA TREATED WITH BOSUTINIB FROM DIAGNOSIS: \r\nA RANDOMIZED PROSPECTIVE TRIAL - FI",
        "timestamp": "2019-06-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-001044-54/DK",
        "title": "A STUDY OF EFFICACY AND SAFETY OF LONG-ACTING LOW DOSE ROPEGINTERFERON IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA TREATED WITH BOSUTINIB FROM DIAGNOSIS: \r\nA RANDOMIZED PROSPECTIVE TRIAL - DK",
        "timestamp": "2019-06-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-000224-41/DE",
        "title": "A\ndouble-blind, multicentre, parallel group, randomised, controlled trial\nto evaluate the possible benefit of isoniazid dose adjustment according\nto the genotype for NAT2 (arylamine N-acetyltransfe... - DE",
        "timestamp": "2008-08-26"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-000224-41/BG",
        "title": "A\ndouble-blind, multicentre, parallel group, randomised, controlled trial\nto evaluate the possible benefit of isoniazid dose adjustment according\nto the genotype for NAT2 (arylamine N-acetyltransfe... - BG",
        "timestamp": "2008-08-26"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-001362-25/DK",
        "title": "Randomized autologous hematopoietic stem cell transplantation versus alemtuzumab, cladribine or ocrelizumab for patients with relapsing remitting Multiple Sclerosis - DK",
        "timestamp": "2018-06-27"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-001362-25/NL",
        "title": "Randomized autologous hematopoietic stem cell transplantation versus alemtuzumab, cladribine or ocrelizumab for patients with relapsing remitting Multiple Sclerosis - NL",
        "timestamp": "2018-06-27"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-002041-36/GB",
        "title": "A Randomized, Double-Blind, Multi-Center Phase 3 Study of ADI-PEG\r\n20 Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in\r\nSubjects With Advanced Hepatocellular Carcinoma (HCC) Who Have\r\nFai... - GB",
        "timestamp": "2011-11-15"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-002041-36/IT",
        "title": "A Randomized, Double-Blind, Multi-Center Phase 3 Study of ADI-PEG\r\n20 Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in\r\nSubjects With Advanced Hepatocellular Carcinoma (HCC) Who Have\r\nFai... - IT",
        "timestamp": "2011-11-15"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-000785-37/3rd",
        "title": "A Randomized, Double-Blind Evaluation of the Pharmacokinetics, Safety, and Antiviral Efficacy of Tenofovir Alafenamide (TAF) in Adolescents with Chronic Hepatitis B Virus Infection - Outside EU/EEA",
        "timestamp": "2016-08-26"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-000785-37/BE",
        "title": "A Randomized, Double-Blind Evaluation of the Pharmacokinetics, Safety, and Antiviral Efficacy of Tenofovir Alafenamide (TAF) in Adolescents with Chronic Hepatitis B Virus Infection - BE",
        "timestamp": "2016-08-26"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-002522-36/SE",
        "title": "An open label phase II study to evaluate the efficacy and safety of PDR001 in patients with advanced or metastatic, well-differentiated, non-functional neuroendocrine tumors of pancreatic, gastroin... - SE",
        "timestamp": "2016-12-29"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-002522-36/GB",
        "title": "An open label phase II study to evaluate the efficacy and safety of PDR001 in patients with advanced or metastatic, well-differentiated, non-functional neuroendocrine tumors of pancreatic, gastroin... - GB",
        "timestamp": "2016-12-29"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-002522-36/DE",
        "title": "An open label phase II study to evaluate the efficacy and safety of PDR001 in patients with advanced or metastatic, well-differentiated, non-functional neuroendocrine tumors of pancreatic, gastroin... - DE",
        "timestamp": "2016-12-29"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-002522-36/ES",
        "title": "An open label phase II study to evaluate the efficacy and safety of PDR001 in patients with advanced or metastatic, well-differentiated, non-functional neuroendocrine tumors of pancreatic, gastroin... - ES",
        "timestamp": "2016-12-29"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-002522-36/AT",
        "title": "An open label phase II study to evaluate the efficacy and safety of PDR001 in patients with advanced or metastatic, well-differentiated, non-functional neuroendocrine tumors of pancreatic, gastroin... - AT",
        "timestamp": "2016-12-29"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-002522-36/NL",
        "title": "An open label phase II study to evaluate the efficacy and safety of PDR001 in patients with advanced or metastatic, well-differentiated, non-functional neuroendocrine tumors of pancreatic, gastroin... - NL",
        "timestamp": "2016-12-29"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-002522-36/BE",
        "title": "An open label phase II study to evaluate the efficacy and safety of PDR001 in patients with advanced or metastatic, well-differentiated, non-functional neuroendocrine tumors of pancreatic, gastroin... - BE",
        "timestamp": "2016-12-29"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-002522-36/FR",
        "title": "An open label phase II study to evaluate the efficacy and safety of PDR001 in patients with advanced or metastatic, well-differentiated, non-functional neuroendocrine tumors of pancreatic, gastroin... - FR",
        "timestamp": "2016-12-29"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-000533-12/DE",
        "title": "A Phase II, Open-label, Multicentre, Randomised Study of the Pharmacokinetics, Pharmacodynamics, Efficacy, and Safety of CAM2029 in Two Patient Groups with Acromegaly and Neuroendocrine Tumours (NE... - DE",
        "timestamp": "2014-07-02"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-000533-12/IT",
        "title": "A Phase II, Open-label, Multicentre, Randomised Study of the Pharmacokinetics, Pharmacodynamics, Efficacy, and Safety of CAM2029 in Two Patient Groups with Acromegaly and Neuroendocrine Tumours (NE... - IT",
        "timestamp": "2014-07-02"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-000533-12/results",
        "title": "A Phase II, Open-label, Multicentre, Randomised Study of the Pharmacokinetics, Pharmacodynamics, Efficacy, and Safety of CAM2029 in Two Patient Groups with Acromegaly and Neuroendocrine Tumours (NE... - View results",
        "timestamp": "2014-07-02"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-004468-31/GB",
        "title": "An Open-Label, Single-Arm, Extension Study to Demonstrate Long-Term Efficacy and Safety of CT-P13 When Co-administered With Methotrexate in Patients With Rheumatoid Arthritis Who Were Treated With ... - GB",
        "timestamp": "2012-01-06"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-004468-31/AT",
        "title": "An Open-Label, Single-Arm, Extension Study to Demonstrate Long-Term Efficacy and Safety of CT-P13 When Co-administered With Methotrexate in Patients With Rheumatoid Arthritis Who Were Treated With ... - AT",
        "timestamp": "2012-01-06"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-004468-31/ES",
        "title": "An Open-Label, Single-Arm, Extension Study to Demonstrate Long-Term Efficacy and Safety of CT-P13 When Co-administered With Methotrexate in Patients With Rheumatoid Arthritis Who Were Treated With ... - ES",
        "timestamp": "2012-01-06"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-004468-31/LV",
        "title": "An Open-Label, Single-Arm, Extension Study to Demonstrate Long-Term Efficacy and Safety of CT-P13 When Co-administered With Methotrexate in Patients With Rheumatoid Arthritis Who Were Treated With ... - LV",
        "timestamp": "2012-01-06"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-004468-31/SK",
        "title": "An Open-Label, Single-Arm, Extension Study to Demonstrate Long-Term Efficacy and Safety of CT-P13 When Co-administered With Methotrexate in Patients With Rheumatoid Arthritis Who Were Treated With ... - SK",
        "timestamp": "2012-01-06"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-004468-31/LT",
        "title": "An Open-Label, Single-Arm, Extension Study to Demonstrate Long-Term Efficacy and Safety of CT-P13 When Co-administered With Methotrexate in Patients With Rheumatoid Arthritis Who Were Treated With ... - LT",
        "timestamp": "2012-01-06"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-004468-31/PL",
        "title": "An Open-Label, Single-Arm, Extension Study to Demonstrate Long-Term Efficacy and Safety of CT-P13 When Co-administered With Methotrexate in Patients With Rheumatoid Arthritis Who Were Treated With ... - PL",
        "timestamp": "2012-01-06"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-004468-31/IT",
        "title": "An Open-Label, Single-Arm, Extension Study to Demonstrate Long-Term Efficacy and Safety of CT-P13 When Co-administered With Methotrexate in Patients With Rheumatoid Arthritis Who Were Treated With ... - IT",
        "timestamp": "2012-01-06"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-004468-31/results",
        "title": "An Open-Label, Single-Arm, Extension Study to Demonstrate Long-Term Efficacy and Safety of CT-P13 When Co-administered With Methotrexate in Patients With Rheumatoid Arthritis Who Were Treated With ... - View results",
        "timestamp": "2012-01-06"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-002279-16/DE",
        "title": "A MulticenteR, Open-Label, First-in-Human, PhaSe Ib/IIa Trial of EO2401, a Novel Multipeptide Therapeutic VAccine, with and without PD-1 Check Point Inhibitor, FoLlowing Standard Treatment in PatIe... - DE",
        "timestamp": "2020-01-02"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-002279-16/ES",
        "title": "A MulticenteR, Open-Label, First-in-Human, PhaSe Ib/IIa Trial of EO2401, a Novel Multipeptide Therapeutic VAccine, with and without PD-1 Check Point Inhibitor, FoLlowing Standard Treatment in PatIe... - ES",
        "timestamp": "2020-01-02"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-002713-19/GB",
        "title": "A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Proof of Concept Study to Evaluate the Efficacy and Safety of VIB4920 in subjects with Sjögren’s Syndrome (SS) - GB",
        "timestamp": "2020-01-15"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-002713-19/PL",
        "title": "A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Proof of Concept Study to Evaluate the Efficacy and Safety of VIB4920 in subjects with Sjögren’s Syndrome (SS) - PL",
        "timestamp": "2020-01-15"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-002264-41/FR",
        "title": "Etude randomisée multicentrique évaluant l’efficacité et la tolérance de l’infliximab comparativement au Cyclophosphamide dans les formes sévères de maladie de Behçet\n\" Multicenter, randomized, pro... - FR",
        "timestamp": None
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-001968-78/GB",
        "title": "A Phase II, Randomised, Double-Blind, Placebo-Controlled Pilot Efficacy Study of ADC4022 (Theophylline Solution for Inhalation) on Markers of Pulmonary Inflammation in Subjects with Moderate to Sev... - GB",
        "timestamp": "2007-07-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-001968-78/results",
        "title": "A Phase II, Randomised, Double-Blind, Placebo-Controlled Pilot Efficacy Study of ADC4022 (Theophylline Solution for Inhalation) on Markers of Pulmonary Inflammation in Subjects with Moderate to Sev... - View results",
        "timestamp": "2007-07-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-005555-80/ES",
        "title": "Efficacy and safety of Hemangiol solution in the treatment of high risk infantile hemangioma. A Multinational Single Arm Study - ES",
        "timestamp": "2015-05-21"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-005555-80/results",
        "title": "Efficacy and safety of Hemangiol solution in the treatment of high risk infantile hemangioma. A Multinational Single Arm Study - View results",
        "timestamp": "2015-05-21"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-004974-82/FR",
        "title": "PETALS study : PEgylated interferon-alpha2a and TAsigna® for first Line therapy of Philadelphia chromosome-positive chronic phase CML patientS - FR",
        "timestamp": "2014-04-04"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-018361-33/SK",
        "title": "A Randomised, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Determine the Efficacy, Safety and Tolerability of AZD7295 in Combination with Pegylated Interferon alpha-2a and Ribavirin in P... - SK",
        "timestamp": "2010-09-10"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-018361-33/HU",
        "title": "A Randomised, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Determine the Efficacy, Safety and Tolerability of AZD7295 in Combination with Pegylated Interferon alpha-2a and Ribavirin in P... - HU",
        "timestamp": "2010-09-10"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-002515-25/ES",
        "title": "Pharmacokinetic interactions  between Telaprevir and not powered Atazanavir with ritonavir in co-infected patients with HIV and HCV genotype 1 in treatment for chronic liver disease by HCV - ES",
        "timestamp": "2012-09-10"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-003634-93/GB",
        "title": "A Phase 2/3 (Adaptive Design) Study of the Concomitant Administration of Indoximod or Placebo plus Pembrolizumab or Nivolumab in Adult Patients with Unresectable Stage III or Stage IV Malignant Mel... - GB",
        "timestamp": "2018-02-28"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-004112-19/GB",
        "title": "Phase 1-2 Study of ADI-PEG 20 plus FOLFOX in Subjects with\nAdvanced Gastrointestinal Malignancies Focusing on Hepatocellular Carcinoma - GB",
        "timestamp": "2018-07-10"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-001292-21/FR",
        "title": "Disease modifying therapies withdrawal in inactive Secondary Progressive Multiple Sclerosis patients older than 50 years - FR",
        "timestamp": "2018-07-27"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-000307-32/DE",
        "title": "A Phase 1b/2, Multicenter, Open-label Trial to Evaluate the Safety and Efficacy of Talimogene Laherparepvec and Ipilimumab Compared to Ipilimumab Alone in Subjects With Unresected, Stage IIIB-IV Me... - DE",
        "timestamp": "2014-11-18"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-003701-24/IT",
        "title": "A RANDOMISED, OPEN-LABEL PHASE III TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF BEXAROTENE (TARGRETIN) CAPSULES COMBINED WITH PUVA, COMPARED TO PUVA TREATMENT ALONE IN PATIENTS WITH MYCOSIS FUNGOIDES. - IT",
        "timestamp": "2004-12-10"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-003701-24/DK",
        "title": "A RANDOMISED, OPEN-LABEL PHASE III TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF BEXAROTENE (TARGRETIN) CAPSULES COMBINED WITH PUVA, COMPARED TO PUVA TREATMENT ALONE IN PATIENTS WITH MYCOSIS FUNGOIDES. - DK",
        "timestamp": "2004-12-10"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-003701-24/results",
        "title": "A RANDOMISED, OPEN-LABEL PHASE III TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF BEXAROTENE (TARGRETIN) CAPSULES COMBINED WITH PUVA, COMPARED TO PUVA TREATMENT ALONE IN PATIENTS WITH MYCOSIS FUNGOIDES. - View results",
        "timestamp": "2004-12-10"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-004980-39/GB",
        "title": "A double blind randomised controlled trial on neuroprotection of amiloride in optic neuritis - GB",
        "timestamp": "2013-01-21"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-003410-41/AT",
        "title": "A phase III randomized, multicenter, double-blind, active controlled study to compare the efficacy and safety of two different anagrelide formulations in patients with Essential Thrombocythemia (TE... - AT",
        "timestamp": "2014-01-13"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-003410-41/LT",
        "title": "A phase III randomized, multicenter, double-blind, active controlled study to compare the efficacy and safety of two different anagrelide formulations in patients with Essential Thrombocythemia (TE... - LT",
        "timestamp": "2014-01-13"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-003410-41/BG",
        "title": "A phase III randomized, multicenter, double-blind, active controlled study to compare the efficacy and safety of two different anagrelide formulations in patients with Essential Thrombocythemia (TE... - BG",
        "timestamp": "2014-01-13"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-003410-41/PL",
        "title": "A phase III randomized, multicenter, double-blind, active controlled study to compare the efficacy and safety of two different anagrelide formulations in patients with Essential Thrombocythemia (TE... - PL",
        "timestamp": "2014-01-13"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-003410-41/results",
        "title": "A phase III randomized, multicenter, double-blind, active controlled study to compare the efficacy and safety of two different anagrelide formulations in patients with Essential Thrombocythemia (TE... - View results",
        "timestamp": "2014-01-13"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-003481-25/DE",
        "title": "A 24-week, multicenter, exploratory, two arm study to assess the effect of Dimethyl fumarate on Immune-Modulatory Action on T cells in patients with relapsing remitting Multiple Sclerosis - DE",
        "timestamp": "2015-05-13"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-003481-25/results",
        "title": "A 24-week, multicenter, exploratory, two arm study to assess the effect of Dimethyl fumarate on Immune-Modulatory Action on T cells in patients with relapsing remitting Multiple Sclerosis - View results",
        "timestamp": "2015-05-13"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-003006-16/DE",
        "title": "A Phase IIb Clinical Study to Assess the Pharmacokinetics, Safety, and Efficacy of the Combination Regimen of Elbasvir (EBR)/Grazoprevir (GZR) in Participants Aged 3 to less than 18 Years with Chro... - DE",
        "timestamp": "2017-12-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-003006-16/SE",
        "title": "A Phase IIb Clinical Study to Assess the Pharmacokinetics, Safety, and Efficacy of the Combination Regimen of Elbasvir (EBR)/Grazoprevir (GZR) in Participants Aged 3 to less than 18 Years with Chro... - SE",
        "timestamp": "2017-12-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-003006-16/PL",
        "title": "A Phase IIb Clinical Study to Assess the Pharmacokinetics, Safety, and Efficacy of the Combination Regimen of Elbasvir (EBR)/Grazoprevir (GZR) in Participants Aged 3 to less than 18 Years with Chro... - PL",
        "timestamp": "2017-12-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-003006-16/3rd",
        "title": "A Phase IIb Clinical Study to Assess the Pharmacokinetics, Safety, and Efficacy of the Combination Regimen of Elbasvir (EBR)/Grazoprevir (GZR) in Participants Aged 3 to less than 18 Years with Chro... - Outside EU/EEA",
        "timestamp": "2017-12-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-006803-35/IT",
        "title": "An open-label, randomized, multicenter, active-controlled,\ndose-ranging study to evaluate the safety and efficacy of\nalbinterferon alfa-2b administered every 4 weeks plus\nribavirin in interferon al... - IT",
        "timestamp": "2008-02-21"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-006803-35/results",
        "title": "An open-label, randomized, multicenter, active-controlled,\ndose-ranging study to evaluate the safety and efficacy of\nalbinterferon alfa-2b administered every 4 weeks plus\nribavirin in interferon al... - View results",
        "timestamp": "2008-02-21"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-005591-33/AT",
        "title": "Response-guided triple therapy using boceprevir in combination with PEGIFN/RBV in HIV/HCV coinfected patients - AT",
        "timestamp": "2013-07-29"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-005591-33/results",
        "title": "Response-guided triple therapy using boceprevir in combination with PEGIFN/RBV in HIV/HCV coinfected patients - View results",
        "timestamp": "2013-07-29"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-003187-37/GB",
        "title": "A Phase II, Randomized, Open-Label Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of Elbasvir/Grazoprevir (EBR/GZR) and Sofosbuvir (SOF) with and without Ribavirin (RBV)... - GB",
        "timestamp": "2016-01-25"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-003187-37/results",
        "title": "A Phase II, Randomized, Open-Label Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of Elbasvir/Grazoprevir (EBR/GZR) and Sofosbuvir (SOF) with and without Ribavirin (RBV)... - View results",
        "timestamp": "2016-01-25"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-005497-38/GB",
        "title": "Effects of TAMoxifen on the Mutant Allele Burden and Disease Course in Patients with MyeloprolifeRatIve Neoplasms - GB",
        "timestamp": "2016-05-25"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-003255-54/CZ",
        "title": "A Double-blind, Randomised, Comparative Pharmacokinetic, Pharmacodynamic, Efficacy and Safety Evaluation of RGB-03 and MabThera® Combined with Methotrexate in Rheumatoid Arthritis Patients - CZ",
        "timestamp": "2015-01-21"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-005306-49/DK",
        "title": "A Phase II Study of Vorinostat in Patients with Polycythaemia Vera and Essential Thrombocythaemia - DK",
        "timestamp": "2008-09-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-005306-49/SE",
        "title": "A Phase II Study of Vorinostat in Patients with Polycythaemia Vera and Essential Thrombocythaemia - SE",
        "timestamp": "2008-09-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-005306-49/NL",
        "title": "A Phase II Study of Vorinostat in Patients with Polycythaemia Vera and Essential Thrombocythaemia - NL",
        "timestamp": "2008-09-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-005306-49/GB",
        "title": "A Phase II Study of Vorinostat in Patients with Polycythaemia Vera and Essential Thrombocythaemia - GB",
        "timestamp": "2008-09-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-001410-41/IT",
        "title": "Vaccination with autologous dendritic cells loaded with autologous tumor lysate or homogenate combined with immunomodulating radiotherapy and/or preleukapheresis IFN-alfa in patients with metastati... - IT",
        "timestamp": "2013-05-30"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-002858-20/ES",
        "title": "A phase II study of durvalumab (MEDI4736) plus tremelimumab for the treatment of patients with advanced neuroendocrine neoplasms of gastroenteropancreatic or lung origin (the DUNE trial). - ES",
        "timestamp": "2017-03-02"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-003475-11/GB",
        "title": "A phase II double-blind, randomised, placebo-controlled trial of neuroprotection with phenytoin in acute optic neuritis - GB",
        "timestamp": "2011-11-15"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-003475-11/results",
        "title": "A phase II double-blind, randomised, placebo-controlled trial of neuroprotection with phenytoin in acute optic neuritis - View results",
        "timestamp": "2011-11-15"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-001130-13/SE",
        "title": "Hepatitis C in a cohort of patients with maintenance  therapy for opiate dependence - prevalence, severity and outcome of antiviral therapy - SE",
        "timestamp": "2007-12-05"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-023245-30/IT",
        "title": "Treatment with Peg-interferon alfa-2a and ribavirin in patients with hepatitis HCV-related, with or without HIV co-infection, and end stage renal disease on dialysis - IT",
        "timestamp": "2011-02-02"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-002695-17/IT",
        "title": "A multi-centre, randomised, double-blind, placebo-controlled escalating dose ranging phase II study on the efficacy of DEBIO-025 to reduce HCV viral load in combination with PEGASYS  180  g/week  i... - IT",
        "timestamp": "2006-09-21"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-002695-17/results",
        "title": "A multi-centre, randomised, double-blind, placebo-controlled escalating dose ranging phase II study on the efficacy of DEBIO-025 to reduce HCV viral load in combination with PEGASYS  180  g/week  i... - View results",
        "timestamp": "2006-09-21"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-000309-21/ES",
        "title": "An Open-Label, Multi-Center Trial of INO-5401 + INO-9012 in Combination with Atezolizumab in Subjects with Locally Advanced Unresectable or Metastatic/Recurrent Urothelial Carcinoma - ES",
        "timestamp": "2018-10-31"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-001672-38/CZ",
        "title": "A Two-Part, Randomized, Open-label, Multicenter, Phase 2a/2b Study of the Efficacy, Safety, and Pharmacokinetics of KRT-232 Compared to Ruxolitinib in Patients with Phlebotomy-Dependent Polycythemi... - CZ",
        "timestamp": "2018-12-10"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-001672-38/HU",
        "title": "A Two-Part, Randomized, Open-label, Multicenter, Phase 2a/2b Study of the Efficacy, Safety, and Pharmacokinetics of KRT-232 Compared to Ruxolitinib in Patients with Phlebotomy-Dependent Polycythemi... - HU",
        "timestamp": "2018-12-10"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-001672-38/ES",
        "title": "A Two-Part, Randomized, Open-label, Multicenter, Phase 2a/2b Study of the Efficacy, Safety, and Pharmacokinetics of KRT-232 Compared to Ruxolitinib in Patients with Phlebotomy-Dependent Polycythemi... - ES",
        "timestamp": "2018-12-10"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-001672-38/BG",
        "title": "A Two-Part, Randomized, Open-label, Multicenter, Phase 2a/2b Study of the Efficacy, Safety, and Pharmacokinetics of KRT-232 Compared to Ruxolitinib in Patients with Phlebotomy-Dependent Polycythemi... - BG",
        "timestamp": "2018-12-10"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-003811-23/DE",
        "title": "A Multi-Center, Open Label Study to Assess the Safety, Steady­ State Pharmacokinetics and Pharmacodynamics of IMG-7289 in Patients with Myelofibrosis - DE",
        "timestamp": "2019-12-11"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-003707-19/FR",
        "title": "A Phase II, Multicenter, Open label Study to Investigate the Clinical Efficacy of M7824 Monotherapy in Participants With Locally Advanced or Metastatic Biliary Tract Cancer Who Fail or are Intolera... - FR",
        "timestamp": "2019-04-15"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-003707-19/DE",
        "title": "A Phase II, Multicenter, Open label Study to Investigate the Clinical Efficacy of M7824 Monotherapy in Participants With Locally Advanced or Metastatic Biliary Tract Cancer Who Fail or are Intolera... - DE",
        "timestamp": "2019-04-15"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-003707-19/GB",
        "title": "A Phase II, Multicenter, Open label Study to Investigate the Clinical Efficacy of M7824 Monotherapy in Participants With Locally Advanced or Metastatic Biliary Tract Cancer Who Fail or are Intolera... - GB",
        "timestamp": "2019-04-15"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-003707-19/ES",
        "title": "A Phase II, Multicenter, Open label Study to Investigate the Clinical Efficacy of M7824 Monotherapy in Participants With Locally Advanced or Metastatic Biliary Tract Cancer Who Fail or are Intolera... - ES",
        "timestamp": "2019-04-15"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-001992-35/ES",
        "title": "A Phase II/III, Multicenter, Randomized, Placebo-controlled Study of Gemcitabine Plus Cisplatin With or Without M7824 (bintrafusp alfa) as First-line Treatment of Biliary Tract Cancer - ES",
        "timestamp": "2020-01-09"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-001286-28/BE",
        "title": "A Single-Arm, Open-Label, Multicenter Clinical Trial with Nivolumab (BMS-936558) for Subjects with Histologically Confirmed Stage III (unresectable) or Stage IV Melanoma Progressing After Prior Tre... - BE",
        "timestamp": "2014-09-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-001286-28/IT",
        "title": "A Single-Arm, Open-Label, Multicenter Clinical Trial with Nivolumab (BMS-936558) for Subjects with Histologically Confirmed Stage III (unresectable) or Stage IV Melanoma Progressing After Prior Tre... - IT",
        "timestamp": "2014-09-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-001286-28/DE",
        "title": "A Single-Arm, Open-Label, Multicenter Clinical Trial with Nivolumab (BMS-936558) for Subjects with Histologically Confirmed Stage III (unresectable) or Stage IV Melanoma Progressing After Prior Tre... - DE",
        "timestamp": "2014-09-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-001286-28/GB",
        "title": "A Single-Arm, Open-Label, Multicenter Clinical Trial with Nivolumab (BMS-936558) for Subjects with Histologically Confirmed Stage III (unresectable) or Stage IV Melanoma Progressing After Prior Tre... - GB",
        "timestamp": "2014-09-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-001286-28/ES",
        "title": "A Single-Arm, Open-Label, Multicenter Clinical Trial with Nivolumab (BMS-936558) for Subjects with Histologically Confirmed Stage III (unresectable) or Stage IV Melanoma Progressing After Prior Tre... - ES",
        "timestamp": "2014-09-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-001286-28/NL",
        "title": "A Single-Arm, Open-Label, Multicenter Clinical Trial with Nivolumab (BMS-936558) for Subjects with Histologically Confirmed Stage III (unresectable) or Stage IV Melanoma Progressing After Prior Tre... - NL",
        "timestamp": "2014-09-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-001286-28/AT",
        "title": "A Single-Arm, Open-Label, Multicenter Clinical Trial with Nivolumab (BMS-936558) for Subjects with Histologically Confirmed Stage III (unresectable) or Stage IV Melanoma Progressing After Prior Tre... - AT",
        "timestamp": "2014-09-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-001286-28/DK",
        "title": "A Single-Arm, Open-Label, Multicenter Clinical Trial with Nivolumab (BMS-936558) for Subjects with Histologically Confirmed Stage III (unresectable) or Stage IV Melanoma Progressing After Prior Tre... - DK",
        "timestamp": "2014-09-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-001286-28/PT",
        "title": "A Single-Arm, Open-Label, Multicenter Clinical Trial with Nivolumab (BMS-936558) for Subjects with Histologically Confirmed Stage III (unresectable) or Stage IV Melanoma Progressing After Prior Tre... - PT",
        "timestamp": "2014-09-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-001286-28/IE",
        "title": "A Single-Arm, Open-Label, Multicenter Clinical Trial with Nivolumab (BMS-936558) for Subjects with Histologically Confirmed Stage III (unresectable) or Stage IV Melanoma Progressing After Prior Tre... - IE",
        "timestamp": "2014-09-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-001286-28/SE",
        "title": "A Single-Arm, Open-Label, Multicenter Clinical Trial with Nivolumab (BMS-936558) for Subjects with Histologically Confirmed Stage III (unresectable) or Stage IV Melanoma Progressing After Prior Tre... - SE",
        "timestamp": "2014-09-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-001286-28/FI",
        "title": "A Single-Arm, Open-Label, Multicenter Clinical Trial with Nivolumab (BMS-936558) for Subjects with Histologically Confirmed Stage III (unresectable) or Stage IV Melanoma Progressing After Prior Tre... - FI",
        "timestamp": "2014-09-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-001286-28/HU",
        "title": "A Single-Arm, Open-Label, Multicenter Clinical Trial with Nivolumab (BMS-936558) for Subjects with Histologically Confirmed Stage III (unresectable) or Stage IV Melanoma Progressing After Prior Tre... - HU",
        "timestamp": "2014-09-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-001286-28/CZ",
        "title": "A Single-Arm, Open-Label, Multicenter Clinical Trial with Nivolumab (BMS-936558) for Subjects with Histologically Confirmed Stage III (unresectable) or Stage IV Melanoma Progressing After Prior Tre... - CZ",
        "timestamp": "2014-09-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-001286-28/GR",
        "title": "A Single-Arm, Open-Label, Multicenter Clinical Trial with Nivolumab (BMS-936558) for Subjects with Histologically Confirmed Stage III (unresectable) or Stage IV Melanoma Progressing After Prior Tre... - GR",
        "timestamp": "2014-09-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-001286-28/PL",
        "title": "A Single-Arm, Open-Label, Multicenter Clinical Trial with Nivolumab (BMS-936558) for Subjects with Histologically Confirmed Stage III (unresectable) or Stage IV Melanoma Progressing After Prior Tre... - PL",
        "timestamp": "2014-09-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-001286-28/results",
        "title": "A Single-Arm, Open-Label, Multicenter Clinical Trial with Nivolumab (BMS-936558) for Subjects with Histologically Confirmed Stage III (unresectable) or Stage IV Melanoma Progressing After Prior Tre... - View results",
        "timestamp": "2014-09-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-001314-42/SE",
        "title": "Evaluation of the Benefits and Risks in Maintenance Renal Transplant Recipients Following Conversion\r\nto Nulojix® (belatacept)-based Immunosuppression - SE",
        "timestamp": "2013-09-11"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-001314-42/AT",
        "title": "Evaluation of the Benefits and Risks in Maintenance Renal Transplant Recipients Following Conversion\r\nto Nulojix® (belatacept)-based Immunosuppression - AT",
        "timestamp": "2013-09-11"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-001314-42/DE",
        "title": "Evaluation of the Benefits and Risks in Maintenance Renal Transplant Recipients Following Conversion\r\nto Nulojix® (belatacept)-based Immunosuppression - DE",
        "timestamp": "2013-09-11"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-001314-42/FR",
        "title": "Evaluation of the Benefits and Risks in Maintenance Renal Transplant Recipients Following Conversion\r\nto Nulojix® (belatacept)-based Immunosuppression - FR",
        "timestamp": "2013-09-11"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-002077-21/GB",
        "title": "PHOENIX Trial: A pre-surgical window of opportunity and post-surgical adjuvant biomarker study of DNA damage response inhibition and/or anti-PD-L1 immunotherapy in patients with neoadjuvant chemoth... - GB",
        "timestamp": "2019-04-18"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-004391-39/FR",
        "title": "A Phase I/II multi-center, open label study  of TKI258 administered orally on an intermittent schedule in adult patients with advanced or metastatic Renal Cell Cancer (RCC) - FR",
        "timestamp": "2008-04-15"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-004391-39/NL",
        "title": "A Phase I/II multi-center, open label study  of TKI258 administered orally on an intermittent schedule in adult patients with advanced or metastatic Renal Cell Cancer (RCC) - NL",
        "timestamp": "2008-04-15"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-004391-39/DE",
        "title": "A Phase I/II multi-center, open label study  of TKI258 administered orally on an intermittent schedule in adult patients with advanced or metastatic Renal Cell Cancer (RCC) - DE",
        "timestamp": "2008-04-15"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-004391-39/results",
        "title": "A Phase I/II multi-center, open label study  of TKI258 administered orally on an intermittent schedule in adult patients with advanced or metastatic Renal Cell Cancer (RCC) - View results",
        "timestamp": "2008-04-15"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-013442-86/BE",
        "title": "A Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial of 48 Weeks of GS-9190 in Combination with Peginterferon Alfa 2a (Pegasys®) and Ribavirin (Copegus®) in Previously Untreated Subjects w... - BE",
        "timestamp": "2009-10-02"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-013442-86/IE",
        "title": "A Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial of 48 Weeks of GS-9190 in Combination with Peginterferon Alfa 2a (Pegasys®) and Ribavirin (Copegus®) in Previously Untreated Subjects w... - IE",
        "timestamp": "2009-10-02"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-013442-86/AT",
        "title": "A Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial of 48 Weeks of GS-9190 in Combination with Peginterferon Alfa 2a (Pegasys®) and Ribavirin (Copegus®) in Previously Untreated Subjects w... - AT",
        "timestamp": "2009-10-02"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-013442-86/results",
        "title": "A Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial of 48 Weeks of GS-9190 in Combination with Peginterferon Alfa 2a (Pegasys®) and Ribavirin (Copegus®) in Previously Untreated Subjects w... - View results",
        "timestamp": "2009-10-02"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-002326-75/GB",
        "title": "A multicentre, open label, early stopping design, proof of concept study with tasquinimod in treating patients with advanced or metastatic hepatocellular, ovarian, renal cell and gastric carcinomas. - GB",
        "timestamp": "2012-09-27"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-002326-75/BE",
        "title": "A multicentre, open label, early stopping design, proof of concept study with tasquinimod in treating patients with advanced or metastatic hepatocellular, ovarian, renal cell and gastric carcinomas. - BE",
        "timestamp": "2012-09-27"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-002326-75/ES",
        "title": "A multicentre, open label, early stopping design, proof of concept study with tasquinimod in treating patients with advanced or metastatic hepatocellular, ovarian, renal cell and gastric carcinomas. - ES",
        "timestamp": "2012-09-27"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-002326-75/results",
        "title": "A multicentre, open label, early stopping design, proof of concept study with tasquinimod in treating patients with advanced or metastatic hepatocellular, ovarian, renal cell and gastric carcinomas. - View results",
        "timestamp": "2012-09-27"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-004702-42/HU",
        "title": "A Multi-Center, Parallel Group, Open-Label, Phase 2 Study to Evaluate the Efficacy and Safety of a Single Subcutaneous Injection of RG-101 Combined with Oral GSK2878175 Taken Once Daily for 6, 9, o... - HU",
        "timestamp": "2016-01-15"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-004702-42/GR",
        "title": "A Multi-Center, Parallel Group, Open-Label, Phase 2 Study to Evaluate the Efficacy and Safety of a Single Subcutaneous Injection of RG-101 Combined with Oral GSK2878175 Taken Once Daily for 6, 9, o... - GR",
        "timestamp": "2016-01-15"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-004702-42/ES",
        "title": "A Multi-Center, Parallel Group, Open-Label, Phase 2 Study to Evaluate the Efficacy and Safety of a Single Subcutaneous Injection of RG-101 Combined with Oral GSK2878175 Taken Once Daily for 6, 9, o... - ES",
        "timestamp": "2016-01-15"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-004396-36/DE",
        "title": "Phase III randomized sequential open-label study to evaluate the efficacy and safety of sorafenib followed by pazopanib versus pazopanib followed by sorafenib in the treatment of advanced / metasta... - DE",
        "timestamp": "2012-03-23"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-004396-36/AT",
        "title": "Phase III randomized sequential open-label study to evaluate the efficacy and safety of sorafenib followed by pazopanib versus pazopanib followed by sorafenib in the treatment of advanced / metasta... - AT",
        "timestamp": "2012-03-23"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-004396-36/NL",
        "title": "Phase III randomized sequential open-label study to evaluate the efficacy and safety of sorafenib followed by pazopanib versus pazopanib followed by sorafenib in the treatment of advanced / metasta... - NL",
        "timestamp": "2012-03-23"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-004396-36/results",
        "title": "Phase III randomized sequential open-label study to evaluate the efficacy and safety of sorafenib followed by pazopanib versus pazopanib followed by sorafenib in the treatment of advanced / metasta... - View results",
        "timestamp": "2012-03-23"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-009608-38/DE",
        "title": "A Randomized, Partially-blind Study to Evaluate the Safety, Tolerability and Effect on Virological Response of Treatment with the HCV Protease Inhibitor RO5190591 in combination with Pegasys and Co... - DE",
        "timestamp": "2010-06-14"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-009608-38/AT",
        "title": "A Randomized, Partially-blind Study to Evaluate the Safety, Tolerability and Effect on Virological Response of Treatment with the HCV Protease Inhibitor RO5190591 in combination with Pegasys and Co... - AT",
        "timestamp": "2010-06-14"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-009608-38/IT",
        "title": "A Randomized, Partially-blind Study to Evaluate the Safety, Tolerability and Effect on Virological Response of Treatment with the HCV Protease Inhibitor RO5190591 in combination with Pegasys and Co... - IT",
        "timestamp": "2010-06-14"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-009608-38/FR",
        "title": "A Randomized, Partially-blind Study to Evaluate the Safety, Tolerability and Effect on Virological Response of Treatment with the HCV Protease Inhibitor RO5190591 in combination with Pegasys and Co... - FR",
        "timestamp": "2010-06-14"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-009608-38/results",
        "title": "A Randomized, Partially-blind Study to Evaluate the Safety, Tolerability and Effect on Virological Response of Treatment with the HCV Protease Inhibitor RO5190591 in combination with Pegasys and Co... - View results",
        "timestamp": "2010-06-14"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-024557-36/GB",
        "title": "A phase IV open-label multicentre, international trial of response guided treatment with directly observed pegylated interferon alfa 2b and self-administered ribavirin for patients with chronic HCV... - GB",
        "timestamp": "2012-05-29"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-024557-36/BE",
        "title": "A phase IV open-label multicentre, international trial of response guided treatment with directly observed pegylated interferon alfa 2b and self-administered ribavirin for patients with chronic HCV... - BE",
        "timestamp": "2012-05-29"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-024557-36/DE",
        "title": "A phase IV open-label multicentre, international trial of response guided treatment with directly observed pegylated interferon alfa 2b and self-administered ribavirin for patients with chronic HCV... - DE",
        "timestamp": "2012-05-29"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-024557-36/results",
        "title": "A phase IV open-label multicentre, international trial of response guided treatment with directly observed pegylated interferon alfa 2b and self-administered ribavirin for patients with chronic HCV... - View results",
        "timestamp": "2012-05-29"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-016087-37/ES",
        "title": "Estudio farmacogenético exploratorio, multinacional, multicéntrico y con una sola toma de muestras de sangre del ensayo REGARD (REbif vs Glatiramer Acetate in Relapsing MS Disease).\n \nA multination... - ES",
        "timestamp": "2009-12-18"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-016087-37/IE",
        "title": "Estudio farmacogenético exploratorio, multinacional, multicéntrico y con una sola toma de muestras de sangre del ensayo REGARD (REbif vs Glatiramer Acetate in Relapsing MS Disease).\n \nA multination... - IE",
        "timestamp": "2009-12-18"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-016087-37/FR",
        "title": "Estudio farmacogenético exploratorio, multinacional, multicéntrico y con una sola toma de muestras de sangre del ensayo REGARD (REbif vs Glatiramer Acetate in Relapsing MS Disease).\n \nA multination... - FR",
        "timestamp": "2009-12-18"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-016087-37/GB",
        "title": "Estudio farmacogenético exploratorio, multinacional, multicéntrico y con una sola toma de muestras de sangre del ensayo REGARD (REbif vs Glatiramer Acetate in Relapsing MS Disease).\n \nA multination... - GB",
        "timestamp": "2009-12-18"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-016087-37/IT",
        "title": "Estudio farmacogenético exploratorio, multinacional, multicéntrico y con una sola toma de muestras de sangre del ensayo REGARD (REbif vs Glatiramer Acetate in Relapsing MS Disease).\n \nA multination... - IT",
        "timestamp": "2009-12-18"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-016087-37/results",
        "title": "Estudio farmacogenético exploratorio, multinacional, multicéntrico y con una sola toma de muestras de sangre del ensayo REGARD (REbif vs Glatiramer Acetate in Relapsing MS Disease).\n \nA multination... - View results",
        "timestamp": "2009-12-18"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-002826-70/GB",
        "title": "A Phase 2, open label, single arm study to evaluate the efficacy, safety, tolerability and pharmacokinetics of ticilimumab in patients with advanced refractory and/or relapsed melanoma - GB",
        "timestamp": "2005-11-28"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-002826-70/ES",
        "title": "A Phase 2, open label, single arm study to evaluate the efficacy, safety, tolerability and pharmacokinetics of ticilimumab in patients with advanced refractory and/or relapsed melanoma - ES",
        "timestamp": "2005-11-28"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-002826-70/DE",
        "title": "A Phase 2, open label, single arm study to evaluate the efficacy, safety, tolerability and pharmacokinetics of ticilimumab in patients with advanced refractory and/or relapsed melanoma - DE",
        "timestamp": "2005-11-28"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-002826-70/IT",
        "title": "A Phase 2, open label, single arm study to evaluate the efficacy, safety, tolerability and pharmacokinetics of ticilimumab in patients with advanced refractory and/or relapsed melanoma - IT",
        "timestamp": "2005-11-28"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-002826-70/results",
        "title": "A Phase 2, open label, single arm study to evaluate the efficacy, safety, tolerability and pharmacokinetics of ticilimumab in patients with advanced refractory and/or relapsed melanoma - View results",
        "timestamp": "2005-11-28"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-014249-10/FI",
        "title": "A randomised double-blind cross-over patient preference study of pazopanib versus sunitinib in treatment naïve locally advanced or metastatic renal cell carcinoma. - FI",
        "timestamp": "2010-04-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-014249-10/DE",
        "title": "A randomised double-blind cross-over patient preference study of pazopanib versus sunitinib in treatment naïve locally advanced or metastatic renal cell carcinoma. - DE",
        "timestamp": "2010-04-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-014249-10/IT",
        "title": "A randomised double-blind cross-over patient preference study of pazopanib versus sunitinib in treatment naïve locally advanced or metastatic renal cell carcinoma. - IT",
        "timestamp": "2010-04-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-014249-10/GB",
        "title": "A randomised double-blind cross-over patient preference study of pazopanib versus sunitinib in treatment naïve locally advanced or metastatic renal cell carcinoma. - GB",
        "timestamp": "2010-04-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-014249-10/results",
        "title": "A randomised double-blind cross-over patient preference study of pazopanib versus sunitinib in treatment naïve locally advanced or metastatic renal cell carcinoma. - View results",
        "timestamp": "2010-04-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-004993-15/AT",
        "title": "A Randomized, Open-Label,  Multicenter Study Examining the Effects of 24 Versus 48 Weeks of Combination Therapy with  PEGASYS® (Peginterferon alfa-2a 40KD) plus COPEGUS® (Ribavirin) on Sustained Vi... - AT",
        "timestamp": "2008-03-07"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-004993-15/BE",
        "title": "A Randomized, Open-Label,  Multicenter Study Examining the Effects of 24 Versus 48 Weeks of Combination Therapy with  PEGASYS® (Peginterferon alfa-2a 40KD) plus COPEGUS® (Ribavirin) on Sustained Vi... - BE",
        "timestamp": "2008-03-07"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-004993-15/DE",
        "title": "A Randomized, Open-Label,  Multicenter Study Examining the Effects of 24 Versus 48 Weeks of Combination Therapy with  PEGASYS® (Peginterferon alfa-2a 40KD) plus COPEGUS® (Ribavirin) on Sustained Vi... - DE",
        "timestamp": "2008-03-07"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-004993-15/results",
        "title": "A Randomized, Open-Label,  Multicenter Study Examining the Effects of 24 Versus 48 Weeks of Combination Therapy with  PEGASYS® (Peginterferon alfa-2a 40KD) plus COPEGUS® (Ribavirin) on Sustained Vi... - View results",
        "timestamp": "2008-03-07"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-002761-63/GB",
        "title": "A PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY OF VGX-3100 DELIVERED INTRAMUSCULARLY FOLLOWED BY ELECTROPORATION WITH CELLECTRA™ 5PSP FOR THE TREATMENT OF HPV-16 AND/OR H... - GB",
        "timestamp": "2018-04-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-002761-63/LT",
        "title": "A PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY OF VGX-3100 DELIVERED INTRAMUSCULARLY FOLLOWED BY ELECTROPORATION WITH CELLECTRA™ 5PSP FOR THE TREATMENT OF HPV-16 AND/OR H... - LT",
        "timestamp": "2018-04-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-002761-63/FI",
        "title": "A PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY OF VGX-3100 DELIVERED INTRAMUSCULARLY FOLLOWED BY ELECTROPORATION WITH CELLECTRA™ 5PSP FOR THE TREATMENT OF HPV-16 AND/OR H... - FI",
        "timestamp": "2018-04-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-002761-63/DE",
        "title": "A PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY OF VGX-3100 DELIVERED INTRAMUSCULARLY FOLLOWED BY ELECTROPORATION WITH CELLECTRA™ 5PSP FOR THE TREATMENT OF HPV-16 AND/OR H... - DE",
        "timestamp": "2018-04-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-002761-63/CZ",
        "title": "A PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY OF VGX-3100 DELIVERED INTRAMUSCULARLY FOLLOWED BY ELECTROPORATION WITH CELLECTRA™ 5PSP FOR THE TREATMENT OF HPV-16 AND/OR H... - CZ",
        "timestamp": "2018-04-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-002761-63/ES",
        "title": "A PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY OF VGX-3100 DELIVERED INTRAMUSCULARLY FOLLOWED BY ELECTROPORATION WITH CELLECTRA™ 5PSP FOR THE TREATMENT OF HPV-16 AND/OR H... - ES",
        "timestamp": "2018-04-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-002761-63/PT",
        "title": "A PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY OF VGX-3100 DELIVERED INTRAMUSCULARLY FOLLOWED BY ELECTROPORATION WITH CELLECTRA™ 5PSP FOR THE TREATMENT OF HPV-16 AND/OR H... - PT",
        "timestamp": "2018-04-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-002761-63/PL",
        "title": "A PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY OF VGX-3100 DELIVERED INTRAMUSCULARLY FOLLOWED BY ELECTROPORATION WITH CELLECTRA™ 5PSP FOR THE TREATMENT OF HPV-16 AND/OR H... - PL",
        "timestamp": "2018-04-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-002761-63/SK",
        "title": "A PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY OF VGX-3100 DELIVERED INTRAMUSCULARLY FOLLOWED BY ELECTROPORATION WITH CELLECTRA™ 5PSP FOR THE TREATMENT OF HPV-16 AND/OR H... - SK",
        "timestamp": "2018-04-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-002761-63/BE",
        "title": "A PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY OF VGX-3100 DELIVERED INTRAMUSCULARLY FOLLOWED BY ELECTROPORATION WITH CELLECTRA™ 5PSP FOR THE TREATMENT OF HPV-16 AND/OR H... - BE",
        "timestamp": "2018-04-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-002761-63/NL",
        "title": "A PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY OF VGX-3100 DELIVERED INTRAMUSCULARLY FOLLOWED BY ELECTROPORATION WITH CELLECTRA™ 5PSP FOR THE TREATMENT OF HPV-16 AND/OR H... - NL",
        "timestamp": "2018-04-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-002761-63/EE",
        "title": "A PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY OF VGX-3100 DELIVERED INTRAMUSCULARLY FOLLOWED BY ELECTROPORATION WITH CELLECTRA™ 5PSP FOR THE TREATMENT OF HPV-16 AND/OR H... - EE",
        "timestamp": "2018-04-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-001203-79/HU",
        "title": "A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of BMS-986165 in Subjects with Systemic Lupus Erythematosus - HU",
        "timestamp": "2017-12-04"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-001203-79/PL",
        "title": "A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of BMS-986165 in Subjects with Systemic Lupus Erythematosus - PL",
        "timestamp": "2017-12-04"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-001203-79/ES",
        "title": "A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of BMS-986165 in Subjects with Systemic Lupus Erythematosus - ES",
        "timestamp": "2017-12-04"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-001247-64/SE",
        "title": "An open label, stratified, single-arm phase II study of RAD001 in patients with advanced pancreatic neuroendocrine tumor (NET) after failure of cytotoxic chemotherapy - SE",
        "timestamp": "2006-06-27"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-001247-64/ES",
        "title": "An open label, stratified, single-arm phase II study of RAD001 in patients with advanced pancreatic neuroendocrine tumor (NET) after failure of cytotoxic chemotherapy - ES",
        "timestamp": "2006-06-27"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-001247-64/DE",
        "title": "An open label, stratified, single-arm phase II study of RAD001 in patients with advanced pancreatic neuroendocrine tumor (NET) after failure of cytotoxic chemotherapy - DE",
        "timestamp": "2006-06-27"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-001247-64/NL",
        "title": "An open label, stratified, single-arm phase II study of RAD001 in patients with advanced pancreatic neuroendocrine tumor (NET) after failure of cytotoxic chemotherapy - NL",
        "timestamp": "2006-06-27"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-001247-64/BE",
        "title": "An open label, stratified, single-arm phase II study of RAD001 in patients with advanced pancreatic neuroendocrine tumor (NET) after failure of cytotoxic chemotherapy - BE",
        "timestamp": "2006-06-27"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-001247-64/IT",
        "title": "An open label, stratified, single-arm phase II study of RAD001 in patients with advanced pancreatic neuroendocrine tumor (NET) after failure of cytotoxic chemotherapy - IT",
        "timestamp": "2006-06-27"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-001247-64/results",
        "title": "An open label, stratified, single-arm phase II study of RAD001 in patients with advanced pancreatic neuroendocrine tumor (NET) after failure of cytotoxic chemotherapy - View results",
        "timestamp": "2006-06-27"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-008258-21/AT",
        "title": "A Randomized, Double-blinded, Multicenter, Dose and Duration Finding Study to Evaluate the Sustained Virologic Response of the HCV Polymerase Inhibitor Prodrug (RO5024048) in Combination with Pegas... - AT",
        "timestamp": "2009-03-30"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-008258-21/DE",
        "title": "A Randomized, Double-blinded, Multicenter, Dose and Duration Finding Study to Evaluate the Sustained Virologic Response of the HCV Polymerase Inhibitor Prodrug (RO5024048) in Combination with Pegas... - DE",
        "timestamp": "2009-03-30"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-008258-21/ES",
        "title": "A Randomized, Double-blinded, Multicenter, Dose and Duration Finding Study to Evaluate the Sustained Virologic Response of the HCV Polymerase Inhibitor Prodrug (RO5024048) in Combination with Pegas... - ES",
        "timestamp": "2009-03-30"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-008258-21/FR",
        "title": "A Randomized, Double-blinded, Multicenter, Dose and Duration Finding Study to Evaluate the Sustained Virologic Response of the HCV Polymerase Inhibitor Prodrug (RO5024048) in Combination with Pegas... - FR",
        "timestamp": "2009-03-30"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-008258-21/GB",
        "title": "A Randomized, Double-blinded, Multicenter, Dose and Duration Finding Study to Evaluate the Sustained Virologic Response of the HCV Polymerase Inhibitor Prodrug (RO5024048) in Combination with Pegas... - GB",
        "timestamp": "2009-03-30"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-008258-21/IT",
        "title": "A Randomized, Double-blinded, Multicenter, Dose and Duration Finding Study to Evaluate the Sustained Virologic Response of the HCV Polymerase Inhibitor Prodrug (RO5024048) in Combination with Pegas... - IT",
        "timestamp": "2009-03-30"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-000880-34/GB",
        "title": "A Phase IIB, randomised, observer-blind, placebo-controlled, multi-centre study to evaluate the efficacy, safety, reactogenicity and immunogenicity of the GSK Biologicals’ investigational vaccine G... - GB",
        "timestamp": "2017-10-10"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-000880-34/BE",
        "title": "A Phase IIB, randomised, observer-blind, placebo-controlled, multi-centre study to evaluate the efficacy, safety, reactogenicity and immunogenicity of the GSK Biologicals’ investigational vaccine G... - BE",
        "timestamp": "2017-10-10"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-000880-34/ES",
        "title": "A Phase IIB, randomised, observer-blind, placebo-controlled, multi-centre study to evaluate the efficacy, safety, reactogenicity and immunogenicity of the GSK Biologicals’ investigational vaccine G... - ES",
        "timestamp": "2017-10-10"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-000880-34/DE",
        "title": "A Phase IIB, randomised, observer-blind, placebo-controlled, multi-centre study to evaluate the efficacy, safety, reactogenicity and immunogenicity of the GSK Biologicals’ investigational vaccine G... - DE",
        "timestamp": "2017-10-10"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-000880-34/FR",
        "title": "A Phase IIB, randomised, observer-blind, placebo-controlled, multi-centre study to evaluate the efficacy, safety, reactogenicity and immunogenicity of the GSK Biologicals’ investigational vaccine G... - FR",
        "timestamp": "2017-10-10"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-004022-87/NL",
        "title": "A PHASE III RANDOMIZED, DOUBLE-BLIND STUDY OF SUNITINIB (SU011248, SUTENT®) VERSUS PLACEBO IN PATIENTS WITH PROGRESSIVE ADVANCED/METASTATIC WELL-DIFFERENTIATED PANCREATIC ISLET CELL TUMORS - NL",
        "timestamp": "2007-04-05"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-004022-87/ES",
        "title": "A PHASE III RANDOMIZED, DOUBLE-BLIND STUDY OF SUNITINIB (SU011248, SUTENT®) VERSUS PLACEBO IN PATIENTS WITH PROGRESSIVE ADVANCED/METASTATIC WELL-DIFFERENTIATED PANCREATIC ISLET CELL TUMORS - ES",
        "timestamp": "2007-04-05"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-004022-87/DK",
        "title": "A PHASE III RANDOMIZED, DOUBLE-BLIND STUDY OF SUNITINIB (SU011248, SUTENT®) VERSUS PLACEBO IN PATIENTS WITH PROGRESSIVE ADVANCED/METASTATIC WELL-DIFFERENTIATED PANCREATIC ISLET CELL TUMORS - DK",
        "timestamp": "2007-04-05"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-004022-87/BE",
        "title": "A PHASE III RANDOMIZED, DOUBLE-BLIND STUDY OF SUNITINIB (SU011248, SUTENT®) VERSUS PLACEBO IN PATIENTS WITH PROGRESSIVE ADVANCED/METASTATIC WELL-DIFFERENTIATED PANCREATIC ISLET CELL TUMORS - BE",
        "timestamp": "2007-04-05"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-004022-87/FR",
        "title": "A PHASE III RANDOMIZED, DOUBLE-BLIND STUDY OF SUNITINIB (SU011248, SUTENT®) VERSUS PLACEBO IN PATIENTS WITH PROGRESSIVE ADVANCED/METASTATIC WELL-DIFFERENTIATED PANCREATIC ISLET CELL TUMORS - FR",
        "timestamp": "2007-04-05"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-004022-87/DE",
        "title": "A PHASE III RANDOMIZED, DOUBLE-BLIND STUDY OF SUNITINIB (SU011248, SUTENT®) VERSUS PLACEBO IN PATIENTS WITH PROGRESSIVE ADVANCED/METASTATIC WELL-DIFFERENTIATED PANCREATIC ISLET CELL TUMORS - DE",
        "timestamp": "2007-04-05"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-004022-87/IT",
        "title": "A PHASE III RANDOMIZED, DOUBLE-BLIND STUDY OF SUNITINIB (SU011248, SUTENT®) VERSUS PLACEBO IN PATIENTS WITH PROGRESSIVE ADVANCED/METASTATIC WELL-DIFFERENTIATED PANCREATIC ISLET CELL TUMORS - IT",
        "timestamp": "2007-04-05"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-004022-87/GB",
        "title": "A PHASE III RANDOMIZED, DOUBLE-BLIND STUDY OF SUNITINIB (SU011248, SUTENT®) VERSUS PLACEBO IN PATIENTS WITH PROGRESSIVE ADVANCED/METASTATIC WELL-DIFFERENTIATED PANCREATIC ISLET CELL TUMORS - GB",
        "timestamp": "2007-04-05"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-004022-87/results",
        "title": "A PHASE III RANDOMIZED, DOUBLE-BLIND STUDY OF SUNITINIB (SU011248, SUTENT®) VERSUS PLACEBO IN PATIENTS WITH PROGRESSIVE ADVANCED/METASTATIC WELL-DIFFERENTIATED PANCREATIC ISLET CELL TUMORS - View results",
        "timestamp": "2007-04-05"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-003836-38/CZ",
        "title": "A Phase III, Open-Label Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172/MK-8742 versus Sofosbuvir/Pegylated Interferon/Ribavirin (PR) in Treatment-Naïve and PR... - CZ",
        "timestamp": "2015-02-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-003836-38/LT",
        "title": "A Phase III, Open-Label Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172/MK-8742 versus Sofosbuvir/Pegylated Interferon/Ribavirin (PR) in Treatment-Naïve and PR... - LT",
        "timestamp": "2015-02-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-003836-38/ES",
        "title": "A Phase III, Open-Label Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172/MK-8742 versus Sofosbuvir/Pegylated Interferon/Ribavirin (PR) in Treatment-Naïve and PR... - ES",
        "timestamp": "2015-02-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-003836-38/NO",
        "title": "A Phase III, Open-Label Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172/MK-8742 versus Sofosbuvir/Pegylated Interferon/Ribavirin (PR) in Treatment-Naïve and PR... - NO",
        "timestamp": "2015-02-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-003836-38/HU",
        "title": "A Phase III, Open-Label Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172/MK-8742 versus Sofosbuvir/Pegylated Interferon/Ribavirin (PR) in Treatment-Naïve and PR... - HU",
        "timestamp": "2015-02-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-003836-38/DK",
        "title": "A Phase III, Open-Label Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172/MK-8742 versus Sofosbuvir/Pegylated Interferon/Ribavirin (PR) in Treatment-Naïve and PR... - DK",
        "timestamp": "2015-02-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-003836-38/PL",
        "title": "A Phase III, Open-Label Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172/MK-8742 versus Sofosbuvir/Pegylated Interferon/Ribavirin (PR) in Treatment-Naïve and PR... - PL",
        "timestamp": "2015-02-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-003836-38/results",
        "title": "A Phase III, Open-Label Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172/MK-8742 versus Sofosbuvir/Pegylated Interferon/Ribavirin (PR) in Treatment-Naïve and PR... - View results",
        "timestamp": "2015-02-16"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-000881-35/DK",
        "title": "A phase II, multicentre study of oral LBH589 in patients with chronic phase chronic myeloid leukemia with resistant disease following treatment with at least two BCR-ABL tyrosine kinase inhibitors - DK",
        "timestamp": "2007-01-11"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-000881-35/BE",
        "title": "A phase II, multicentre study of oral LBH589 in patients with chronic phase chronic myeloid leukemia with resistant disease following treatment with at least two BCR-ABL tyrosine kinase inhibitors - BE",
        "timestamp": "2007-01-11"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-000881-35/NL",
        "title": "A phase II, multicentre study of oral LBH589 in patients with chronic phase chronic myeloid leukemia with resistant disease following treatment with at least two BCR-ABL tyrosine kinase inhibitors - NL",
        "timestamp": "2007-01-11"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-000881-35/FR",
        "title": "A phase II, multicentre study of oral LBH589 in patients with chronic phase chronic myeloid leukemia with resistant disease following treatment with at least two BCR-ABL tyrosine kinase inhibitors - FR",
        "timestamp": "2007-01-11"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-000881-35/GB",
        "title": "A phase II, multicentre study of oral LBH589 in patients with chronic phase chronic myeloid leukemia with resistant disease following treatment with at least two BCR-ABL tyrosine kinase inhibitors - GB",
        "timestamp": "2007-01-11"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-000881-35/DE",
        "title": "A phase II, multicentre study of oral LBH589 in patients with chronic phase chronic myeloid leukemia with resistant disease following treatment with at least two BCR-ABL tyrosine kinase inhibitors - DE",
        "timestamp": "2007-01-11"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-000881-35/IT",
        "title": "A phase II, multicentre study of oral LBH589 in patients with chronic phase chronic myeloid leukemia with resistant disease following treatment with at least two BCR-ABL tyrosine kinase inhibitors - IT",
        "timestamp": "2007-01-11"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-000881-35/results",
        "title": "A phase II, multicentre study of oral LBH589 in patients with chronic phase chronic myeloid leukemia with resistant disease following treatment with at least two BCR-ABL tyrosine kinase inhibitors - View results",
        "timestamp": "2007-01-11"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-004946-17/ES",
        "title": "Estudio multicéntrico aleatorizado, controlado con placebo, para evaluar la eficacia y la seguridad de eltrombopag en sujetos trombocitopénicos infectados por el virus de la hepatitis C (VHC) que, ... - ES",
        "timestamp": "2007-11-02"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-004946-17/FR",
        "title": "Estudio multicéntrico aleatorizado, controlado con placebo, para evaluar la eficacia y la seguridad de eltrombopag en sujetos trombocitopénicos infectados por el virus de la hepatitis C (VHC) que, ... - FR",
        "timestamp": "2007-11-02"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-004946-17/BE",
        "title": "Estudio multicéntrico aleatorizado, controlado con placebo, para evaluar la eficacia y la seguridad de eltrombopag en sujetos trombocitopénicos infectados por el virus de la hepatitis C (VHC) que, ... - BE",
        "timestamp": "2007-11-02"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-004946-17/NL",
        "title": "Estudio multicéntrico aleatorizado, controlado con placebo, para evaluar la eficacia y la seguridad de eltrombopag en sujetos trombocitopénicos infectados por el virus de la hepatitis C (VHC) que, ... - NL",
        "timestamp": "2007-11-02"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-004946-17/IT",
        "title": "Estudio multicéntrico aleatorizado, controlado con placebo, para evaluar la eficacia y la seguridad de eltrombopag en sujetos trombocitopénicos infectados por el virus de la hepatitis C (VHC) que, ... - IT",
        "timestamp": "2007-11-02"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-004946-17/CZ",
        "title": "Estudio multicéntrico aleatorizado, controlado con placebo, para evaluar la eficacia y la seguridad de eltrombopag en sujetos trombocitopénicos infectados por el virus de la hepatitis C (VHC) que, ... - CZ",
        "timestamp": "2007-11-02"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-004946-17/GB",
        "title": "Estudio multicéntrico aleatorizado, controlado con placebo, para evaluar la eficacia y la seguridad de eltrombopag en sujetos trombocitopénicos infectados por el virus de la hepatitis C (VHC) que, ... - GB",
        "timestamp": "2007-11-02"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-004946-17/SK",
        "title": "Estudio multicéntrico aleatorizado, controlado con placebo, para evaluar la eficacia y la seguridad de eltrombopag en sujetos trombocitopénicos infectados por el virus de la hepatitis C (VHC) que, ... - SK",
        "timestamp": "2007-11-02"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-004946-17/DE",
        "title": "Estudio multicéntrico aleatorizado, controlado con placebo, para evaluar la eficacia y la seguridad de eltrombopag en sujetos trombocitopénicos infectados por el virus de la hepatitis C (VHC) que, ... - DE",
        "timestamp": "2007-11-02"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-004946-17/results",
        "title": "Estudio multicéntrico aleatorizado, controlado con placebo, para evaluar la eficacia y la seguridad de eltrombopag en sujetos trombocitopénicos infectados por el virus de la hepatitis C (VHC) que, ... - View results",
        "timestamp": "2007-11-02"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-024260-17/DE",
        "title": "A Phase 3 Study to Assess the Efficacy and Safety of Boceprevir in Combination with Peginterferon alfa-2b Plus Ribavirin in Pediatric Subjects With Chronic Hepatitis C Genotype 1 - DE",
        "timestamp": "2012-11-08"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-024260-17/AT",
        "title": "A Phase 3 Study to Assess the Efficacy and Safety of Boceprevir in Combination with Peginterferon alfa-2b Plus Ribavirin in Pediatric Subjects With Chronic Hepatitis C Genotype 1 - AT",
        "timestamp": "2012-11-08"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-024260-17/BE",
        "title": "A Phase 3 Study to Assess the Efficacy and Safety of Boceprevir in Combination with Peginterferon alfa-2b Plus Ribavirin in Pediatric Subjects With Chronic Hepatitis C Genotype 1 - BE",
        "timestamp": "2012-11-08"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-024260-17/PT",
        "title": "A Phase 3 Study to Assess the Efficacy and Safety of Boceprevir in Combination with Peginterferon alfa-2b Plus Ribavirin in Pediatric Subjects With Chronic Hepatitis C Genotype 1 - PT",
        "timestamp": "2012-11-08"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-024260-17/CZ",
        "title": "A Phase 3 Study to Assess the Efficacy and Safety of Boceprevir in Combination with Peginterferon alfa-2b Plus Ribavirin in Pediatric Subjects With Chronic Hepatitis C Genotype 1 - CZ",
        "timestamp": "2012-11-08"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-024260-17/ES",
        "title": "A Phase 3 Study to Assess the Efficacy and Safety of Boceprevir in Combination with Peginterferon alfa-2b Plus Ribavirin in Pediatric Subjects With Chronic Hepatitis C Genotype 1 - ES",
        "timestamp": "2012-11-08"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-024260-17/IT",
        "title": "A Phase 3 Study to Assess the Efficacy and Safety of Boceprevir in Combination with Peginterferon alfa-2b Plus Ribavirin in Pediatric Subjects With Chronic Hepatitis C Genotype 1 - IT",
        "timestamp": "2012-11-08"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-024260-17/PL",
        "title": "A Phase 3 Study to Assess the Efficacy and Safety of Boceprevir in Combination with Peginterferon alfa-2b Plus Ribavirin in Pediatric Subjects With Chronic Hepatitis C Genotype 1 - PL",
        "timestamp": "2012-11-08"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-024260-17/NO",
        "title": "A Phase 3 Study to Assess the Efficacy and Safety of Boceprevir in Combination with Peginterferon alfa-2b Plus Ribavirin in Pediatric Subjects With Chronic Hepatitis C Genotype 1 - NO",
        "timestamp": "2012-11-08"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-024260-17/GB",
        "title": "A Phase 3 Study to Assess the Efficacy and Safety of Boceprevir in Combination with Peginterferon alfa-2b Plus Ribavirin in Pediatric Subjects With Chronic Hepatitis C Genotype 1 - GB",
        "timestamp": "2012-11-08"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-001010-14/HU",
        "title": "A Phase 3, Randomized, Controlled Study of Cabozantinib (XL184) vs Everolimus in Subjects with Metastatic Renal Cell Carcinoma that has Progressed after Prior VEGFR Tyrosine Kinase Inhibitor Therapy - HU",
        "timestamp": "2013-08-15"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-001010-14/AT",
        "title": "A Phase 3, Randomized, Controlled Study of Cabozantinib (XL184) vs Everolimus in Subjects with Metastatic Renal Cell Carcinoma that has Progressed after Prior VEGFR Tyrosine Kinase Inhibitor Therapy - AT",
        "timestamp": "2013-08-15"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-001010-14/SE",
        "title": "A Phase 3, Randomized, Controlled Study of Cabozantinib (XL184) vs Everolimus in Subjects with Metastatic Renal Cell Carcinoma that has Progressed after Prior VEGFR Tyrosine Kinase Inhibitor Therapy - SE",
        "timestamp": "2013-08-15"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-001010-14/BE",
        "title": "A Phase 3, Randomized, Controlled Study of Cabozantinib (XL184) vs Everolimus in Subjects with Metastatic Renal Cell Carcinoma that has Progressed after Prior VEGFR Tyrosine Kinase Inhibitor Therapy - BE",
        "timestamp": "2013-08-15"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-001010-14/CZ",
        "title": "A Phase 3, Randomized, Controlled Study of Cabozantinib (XL184) vs Everolimus in Subjects with Metastatic Renal Cell Carcinoma that has Progressed after Prior VEGFR Tyrosine Kinase Inhibitor Therapy - CZ",
        "timestamp": "2013-08-15"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-001010-14/PT",
        "title": "A Phase 3, Randomized, Controlled Study of Cabozantinib (XL184) vs Everolimus in Subjects with Metastatic Renal Cell Carcinoma that has Progressed after Prior VEGFR Tyrosine Kinase Inhibitor Therapy - PT",
        "timestamp": "2013-08-15"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-001010-14/IE",
        "title": "A Phase 3, Randomized, Controlled Study of Cabozantinib (XL184) vs Everolimus in Subjects with Metastatic Renal Cell Carcinoma that has Progressed after Prior VEGFR Tyrosine Kinase Inhibitor Therapy - IE",
        "timestamp": "2013-08-15"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-001010-14/IT",
        "title": "A Phase 3, Randomized, Controlled Study of Cabozantinib (XL184) vs Everolimus in Subjects with Metastatic Renal Cell Carcinoma that has Progressed after Prior VEGFR Tyrosine Kinase Inhibitor Therapy - IT",
        "timestamp": "2013-08-15"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-001010-14/NL",
        "title": "A Phase 3, Randomized, Controlled Study of Cabozantinib (XL184) vs Everolimus in Subjects with Metastatic Renal Cell Carcinoma that has Progressed after Prior VEGFR Tyrosine Kinase Inhibitor Therapy - NL",
        "timestamp": "2013-08-15"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-001010-14/SK",
        "title": "A Phase 3, Randomized, Controlled Study of Cabozantinib (XL184) vs Everolimus in Subjects with Metastatic Renal Cell Carcinoma that has Progressed after Prior VEGFR Tyrosine Kinase Inhibitor Therapy - SK",
        "timestamp": "2013-08-15"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-001010-14/GB",
        "title": "A Phase 3, Randomized, Controlled Study of Cabozantinib (XL184) vs Everolimus in Subjects with Metastatic Renal Cell Carcinoma that has Progressed after Prior VEGFR Tyrosine Kinase Inhibitor Therapy - GB",
        "timestamp": "2013-08-15"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-001010-14/ES",
        "title": "A Phase 3, Randomized, Controlled Study of Cabozantinib (XL184) vs Everolimus in Subjects with Metastatic Renal Cell Carcinoma that has Progressed after Prior VEGFR Tyrosine Kinase Inhibitor Therapy - ES",
        "timestamp": "2013-08-15"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-001010-14/DE",
        "title": "A Phase 3, Randomized, Controlled Study of Cabozantinib (XL184) vs Everolimus in Subjects with Metastatic Renal Cell Carcinoma that has Progressed after Prior VEGFR Tyrosine Kinase Inhibitor Therapy - DE",
        "timestamp": "2013-08-15"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-001010-14/DK",
        "title": "A Phase 3, Randomized, Controlled Study of Cabozantinib (XL184) vs Everolimus in Subjects with Metastatic Renal Cell Carcinoma that has Progressed after Prior VEGFR Tyrosine Kinase Inhibitor Therapy - DK",
        "timestamp": "2013-08-15"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-001010-14/FI",
        "title": "A Phase 3, Randomized, Controlled Study of Cabozantinib (XL184) vs Everolimus in Subjects with Metastatic Renal Cell Carcinoma that has Progressed after Prior VEGFR Tyrosine Kinase Inhibitor Therapy - FI",
        "timestamp": "2013-08-15"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-001010-14/PL",
        "title": "A Phase 3, Randomized, Controlled Study of Cabozantinib (XL184) vs Everolimus in Subjects with Metastatic Renal Cell Carcinoma that has Progressed after Prior VEGFR Tyrosine Kinase Inhibitor Therapy - PL",
        "timestamp": "2013-08-15"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-000660-17/SK",
        "title": "TPL108392:  An open-label, multi-centre rollover study to assess the safety and efficacy of eltrombopag in thrombocytopenic subjects with hepatitis C virus (HCV) infection who are otherwise eligibl... - SK",
        "timestamp": "2009-07-29"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-000660-17/DE",
        "title": "TPL108392:  An open-label, multi-centre rollover study to assess the safety and efficacy of eltrombopag in thrombocytopenic subjects with hepatitis C virus (HCV) infection who are otherwise eligibl... - DE",
        "timestamp": "2009-07-29"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-000660-17/ES",
        "title": "TPL108392:  An open-label, multi-centre rollover study to assess the safety and efficacy of eltrombopag in thrombocytopenic subjects with hepatitis C virus (HCV) infection who are otherwise eligibl... - ES",
        "timestamp": "2009-07-29"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-000660-17/FR",
        "title": "TPL108392:  An open-label, multi-centre rollover study to assess the safety and efficacy of eltrombopag in thrombocytopenic subjects with hepatitis C virus (HCV) infection who are otherwise eligibl... - FR",
        "timestamp": "2009-07-29"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-000660-17/IT",
        "title": "TPL108392:  An open-label, multi-centre rollover study to assess the safety and efficacy of eltrombopag in thrombocytopenic subjects with hepatitis C virus (HCV) infection who are otherwise eligibl... - IT",
        "timestamp": "2009-07-29"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-000660-17/GR",
        "title": "TPL108392:  An open-label, multi-centre rollover study to assess the safety and efficacy of eltrombopag in thrombocytopenic subjects with hepatitis C virus (HCV) infection who are otherwise eligibl... - GR",
        "timestamp": "2009-07-29"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-000660-17/GB",
        "title": "TPL108392:  An open-label, multi-centre rollover study to assess the safety and efficacy of eltrombopag in thrombocytopenic subjects with hepatitis C virus (HCV) infection who are otherwise eligibl... - GB",
        "timestamp": "2009-07-29"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-000660-17/results",
        "title": "TPL108392:  An open-label, multi-centre rollover study to assess the safety and efficacy of eltrombopag in thrombocytopenic subjects with hepatitis C virus (HCV) infection who are otherwise eligibl... - View results",
        "timestamp": "2009-07-29"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-001778-17/FI",
        "title": "A phase IIIb, open-label, multi-country, multi-centre, long-term follow-up study (ZOE-LTFU) of studies 110390 and 113077 (ZOSTER-006/022) to assess the prophylactic efficacy, safety, and immunogeni... - FI",
        "timestamp": "2016-03-17"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-001778-17/EE",
        "title": "A phase IIIb, open-label, multi-country, multi-centre, long-term follow-up study (ZOE-LTFU) of studies 110390 and 113077 (ZOSTER-006/022) to assess the prophylactic efficacy, safety, and immunogeni... - EE",
        "timestamp": "2016-03-17"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-001778-17/CZ",
        "title": "A phase IIIb, open-label, multi-country, multi-centre, long-term follow-up study (ZOE-LTFU) of studies 110390 and 113077 (ZOSTER-006/022) to assess the prophylactic efficacy, safety, and immunogeni... - CZ",
        "timestamp": "2016-03-17"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-001778-17/GB",
        "title": "A phase IIIb, open-label, multi-country, multi-centre, long-term follow-up study (ZOE-LTFU) of studies 110390 and 113077 (ZOSTER-006/022) to assess the prophylactic efficacy, safety, and immunogeni... - GB",
        "timestamp": "2016-03-17"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-001778-17/DE",
        "title": "A phase IIIb, open-label, multi-country, multi-centre, long-term follow-up study (ZOE-LTFU) of studies 110390 and 113077 (ZOSTER-006/022) to assess the prophylactic efficacy, safety, and immunogeni... - DE",
        "timestamp": "2016-03-17"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-001778-17/ES",
        "title": "A phase IIIb, open-label, multi-country, multi-centre, long-term follow-up study (ZOE-LTFU) of studies 110390 and 113077 (ZOSTER-006/022) to assess the prophylactic efficacy, safety, and immunogeni... - ES",
        "timestamp": "2016-03-17"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-002125-11/LV",
        "title": "A Randomized, Parallel-Group, Phase I/III Study to Evaluate Efficacy, Pharmacokinetics and Safety between Subcutaneous CT-P13 and Intravenous CT-P13 in Patients with Active Rheumatoid Arthritis - LV",
        "timestamp": "2016-08-23"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-002125-11/EE",
        "title": "A Randomized, Parallel-Group, Phase I/III Study to Evaluate Efficacy, Pharmacokinetics and Safety between Subcutaneous CT-P13 and Intravenous CT-P13 in Patients with Active Rheumatoid Arthritis - EE",
        "timestamp": "2016-08-23"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-002125-11/HU",
        "title": "A Randomized, Parallel-Group, Phase I/III Study to Evaluate Efficacy, Pharmacokinetics and Safety between Subcutaneous CT-P13 and Intravenous CT-P13 in Patients with Active Rheumatoid Arthritis - HU",
        "timestamp": "2016-08-23"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-002125-11/CZ",
        "title": "A Randomized, Parallel-Group, Phase I/III Study to Evaluate Efficacy, Pharmacokinetics and Safety between Subcutaneous CT-P13 and Intravenous CT-P13 in Patients with Active Rheumatoid Arthritis - CZ",
        "timestamp": "2016-08-23"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-002125-11/BG",
        "title": "A Randomized, Parallel-Group, Phase I/III Study to Evaluate Efficacy, Pharmacokinetics and Safety between Subcutaneous CT-P13 and Intravenous CT-P13 in Patients with Active Rheumatoid Arthritis - BG",
        "timestamp": "2016-08-23"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-002125-11/ES",
        "title": "A Randomized, Parallel-Group, Phase I/III Study to Evaluate Efficacy, Pharmacokinetics and Safety between Subcutaneous CT-P13 and Intravenous CT-P13 in Patients with Active Rheumatoid Arthritis - ES",
        "timestamp": "2016-08-23"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-002125-11/results",
        "title": "A Randomized, Parallel-Group, Phase I/III Study to Evaluate Efficacy, Pharmacokinetics and Safety between Subcutaneous CT-P13 and Intravenous CT-P13 in Patients with Active Rheumatoid Arthritis - View results",
        "timestamp": "2016-08-23"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005287-21/DE",
        "title": "A Long-Term Follow-up Study of Subjects Who Participated in a Clinical Trial in Which Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052) Was Administered for the Treatment of Chronic Hepatiti... - DE",
        "timestamp": "2012-02-09"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005287-21/IE",
        "title": "A Long-Term Follow-up Study of Subjects Who Participated in a Clinical Trial in Which Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052) Was Administered for the Treatment of Chronic Hepatiti... - IE",
        "timestamp": "2012-02-09"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005287-21/SE",
        "title": "A Long-Term Follow-up Study of Subjects Who Participated in a Clinical Trial in Which Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052) Was Administered for the Treatment of Chronic Hepatiti... - SE",
        "timestamp": "2012-02-09"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005287-21/IT",
        "title": "A Long-Term Follow-up Study of Subjects Who Participated in a Clinical Trial in Which Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052) Was Administered for the Treatment of Chronic Hepatiti... - IT",
        "timestamp": "2012-02-09"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005287-21/GB",
        "title": "A Long-Term Follow-up Study of Subjects Who Participated in a Clinical Trial in Which Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052) Was Administered for the Treatment of Chronic Hepatiti... - GB",
        "timestamp": "2012-02-09"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005287-21/DK",
        "title": "A Long-Term Follow-up Study of Subjects Who Participated in a Clinical Trial in Which Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052) Was Administered for the Treatment of Chronic Hepatiti... - DK",
        "timestamp": "2012-02-09"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005287-21/ES",
        "title": "A Long-Term Follow-up Study of Subjects Who Participated in a Clinical Trial in Which Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052) Was Administered for the Treatment of Chronic Hepatiti... - ES",
        "timestamp": "2012-02-09"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-002977-24/ES",
        "title": "A Phase IIA, open-label study to evaluate the immunogenicity and safety of sequential use of GSK's investigational vaccine GSK3277511A when administered to healthy smokers and ex-smokers aged 50 to... - ES",
        "timestamp": "2019-04-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-002977-24/FI",
        "title": "A Phase IIA, open-label study to evaluate the immunogenicity and safety of sequential use of GSK's investigational vaccine GSK3277511A when administered to healthy smokers and ex-smokers aged 50 to... - FI",
        "timestamp": "2019-04-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-002977-24/FR",
        "title": "A Phase IIA, open-label study to evaluate the immunogenicity and safety of sequential use of GSK's investigational vaccine GSK3277511A when administered to healthy smokers and ex-smokers aged 50 to... - FR",
        "timestamp": "2019-04-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-000706-34/GB",
        "title": "A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 STUDY TO ASSESS THE IMMUNE RESPONSE FOLLOWING ADMINISTRATION OF ZOSTER VACCINE TO SUBJECTS WITH RHEUMATOID ARTHRITIS RECEIVING TOFACITINIB (C... - GB",
        "timestamp": "2014-10-06"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-000706-34/results",
        "title": "A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 STUDY TO ASSESS THE IMMUNE RESPONSE FOLLOWING ADMINISTRATION OF ZOSTER VACCINE TO SUBJECTS WITH RHEUMATOID ARTHRITIS RECEIVING TOFACITINIB (C... - View results",
        "timestamp": "2014-10-06"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-002748-28/DE",
        "title": "A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of GS-5885, GS-9451, Tegobuvir and Ribavirin (RBV) Compared with GS-5885, GS-9451 with Tegobuvir or RBV in Treatment-Experienced Subject... - DE",
        "timestamp": "2011-11-30"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-002748-28/results",
        "title": "A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of GS-5885, GS-9451, Tegobuvir and Ribavirin (RBV) Compared with GS-5885, GS-9451 with Tegobuvir or RBV in Treatment-Experienced Subject... - View results",
        "timestamp": "2011-11-30"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-000408-41/GB",
        "title": "RANDOMIZED, DOUBLE–BLIND, MULTICENTER STUDY TO COMPARE THE SAFETY AND EFFICACY OF VIRAMIDINE TO RIBAVIRIN IN TREATMENT–NAïVE PATIENTS WITH CHRONIC HEPATITIS C - GB",
        "timestamp": "2004-10-07"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-000408-41/IT",
        "title": "RANDOMIZED, DOUBLE–BLIND, MULTICENTER STUDY TO COMPARE THE SAFETY AND EFFICACY OF VIRAMIDINE TO RIBAVIRIN IN TREATMENT–NAïVE PATIENTS WITH CHRONIC HEPATITIS C - IT",
        "timestamp": "2004-10-07"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-005473-29/DE",
        "title": "Randomisierte Phase III-Studie zur Primärtherapie von fortgeschrittenen follikulären Lymphomen bei älteren Patienten (>65 J.) und jüngeren Patienten, die nicht für eine Hochdosistherapie mit autolo... - DE",
        "timestamp": "2007-03-28"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-001012-56/DE",
        "title": "A Phase 2 Study of LY2784544 in Patients with Myeloproliferative Neoplasms - DE",
        "timestamp": "2012-08-30"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-001012-56/ES",
        "title": "A Phase 2 Study of LY2784544 in Patients with Myeloproliferative Neoplasms - ES",
        "timestamp": "2012-08-30"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-001012-56/SE",
        "title": "A Phase 2 Study of LY2784544 in Patients with Myeloproliferative Neoplasms - SE",
        "timestamp": "2012-08-30"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-001012-56/AT",
        "title": "A Phase 2 Study of LY2784544 in Patients with Myeloproliferative Neoplasms - AT",
        "timestamp": "2012-08-30"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-001012-56/IT",
        "title": "A Phase 2 Study of LY2784544 in Patients with Myeloproliferative Neoplasms - IT",
        "timestamp": "2012-08-30"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-004250-34/ES",
        "title": "A Phase 2, Open-label, Single-arm Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of 12 Weeks Treatment With Simeprevir and Daclatasvir in Subjects With Chronic Hepatit... - ES",
        "timestamp": "2015-05-11"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-000880-28/IT",
        "title": "Bendamustine and Rituximab for the treatment of Splenic Marginal Zone Lymphoma.  The IELSG-36 phase II prospective study. - IT",
        "timestamp": "2012-10-25"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-001191-38/ES",
        "title": "Multicentric, randomized, open-label, controlled study, of 12 months of follow-up to assess the effect in renal function of a immunosuppressive treatment based on  tacrolimus minimization in combin... - ES",
        "timestamp": "2013-08-21"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-001191-38/results",
        "title": "Multicentric, randomized, open-label, controlled study, of 12 months of follow-up to assess the effect in renal function of a immunosuppressive treatment based on  tacrolimus minimization in combin... - View results",
        "timestamp": "2013-08-21"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-005671-14/GB",
        "title": "A phase III, randomised, open-label, multicentre clinical trial to assess the safety and immunogenicity of GSK Biologicals’ HZ/su candidate vaccine when administered subcutaneously as compared to i... - GB",
        "timestamp": "2013-09-30"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-005671-14/results",
        "title": "A phase III, randomised, open-label, multicentre clinical trial to assess the safety and immunogenicity of GSK Biologicals’ HZ/su candidate vaccine when administered subcutaneously as compared to i... - View results",
        "timestamp": "2013-09-30"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-005506-23/ES",
        "title": "Estudio de fase IV, multicéntrico, aleatorizado y doble ciego para comparar la seguridad y eficacia de 180 µg de Pegasys® más 1000 ó 1200 mg de Copegus® con la combinación actualmente aprobada de 1... - ES",
        "timestamp": "2006-04-28"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-005506-23/PT",
        "title": "Estudio de fase IV, multicéntrico, aleatorizado y doble ciego para comparar la seguridad y eficacia de 180 µg de Pegasys® más 1000 ó 1200 mg de Copegus® con la combinación actualmente aprobada de 1... - PT",
        "timestamp": "2006-04-28"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-005506-23/results",
        "title": "Estudio de fase IV, multicéntrico, aleatorizado y doble ciego para comparar la seguridad y eficacia de 180 µg de Pegasys® más 1000 ó 1200 mg de Copegus® con la combinación actualmente aprobada de 1... - View results",
        "timestamp": "2006-04-28"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005912-27/DE",
        "title": "A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED,\r\nMULTICENTER PHASE II STUDY EVALUATING THE EFFICACY\r\nAND SAFETY OF ONARTUZUMAB IN COMBINATION WITH\r\nBEVACIZUMAB OR ONARTUZUMAB MONOTHERAPY IN\r\nPATIEN... - DE",
        "timestamp": "2012-08-17"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005912-27/ES",
        "title": "A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED,\r\nMULTICENTER PHASE II STUDY EVALUATING THE EFFICACY\r\nAND SAFETY OF ONARTUZUMAB IN COMBINATION WITH\r\nBEVACIZUMAB OR ONARTUZUMAB MONOTHERAPY IN\r\nPATIEN... - ES",
        "timestamp": "2012-08-17"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005912-27/GB",
        "title": "A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED,\r\nMULTICENTER PHASE II STUDY EVALUATING THE EFFICACY\r\nAND SAFETY OF ONARTUZUMAB IN COMBINATION WITH\r\nBEVACIZUMAB OR ONARTUZUMAB MONOTHERAPY IN\r\nPATIEN... - GB",
        "timestamp": "2012-08-17"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005912-27/IT",
        "title": "A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED,\r\nMULTICENTER PHASE II STUDY EVALUATING THE EFFICACY\r\nAND SAFETY OF ONARTUZUMAB IN COMBINATION WITH\r\nBEVACIZUMAB OR ONARTUZUMAB MONOTHERAPY IN\r\nPATIEN... - IT",
        "timestamp": "2012-08-17"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005912-27/results",
        "title": "A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED,\r\nMULTICENTER PHASE II STUDY EVALUATING THE EFFICACY\r\nAND SAFETY OF ONARTUZUMAB IN COMBINATION WITH\r\nBEVACIZUMAB OR ONARTUZUMAB MONOTHERAPY IN\r\nPATIEN... - View results",
        "timestamp": "2012-08-17"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-003741-42/3rd",
        "title": "A Phase 2, Open-label Study to Investigate the Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed Dose Combination in the Treatment of Hepatitis C Virus (HCV) Infection in Pediatric Subjects Underg... - Outside EU/EEA",
        "timestamp": "2018-10-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-003741-42/results",
        "title": "A Phase 2, Open-label Study to Investigate the Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed Dose Combination in the Treatment of Hepatitis C Virus (HCV) Infection in Pediatric Subjects Underg... - View results",
        "timestamp": "2018-10-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003389-42/FR",
        "title": "A phase II study to assess the efficacy and safety of frontline combination of dasatinib (SPRYCEL®) and pegylated-interferon alpha 2b (Peg-IFNα2b) therapy in patients newly diagnosed with chronic p... - FR",
        "timestamp": "2013-06-26"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-003625-42/GB",
        "title": "A Phase 2, Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Sofosbuvir/Velpatasvir for 12 Weeks in Subjects with Chronic HCV Infection Who are on Dialysis for End Stage Renal Di... - GB",
        "timestamp": "2017-03-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-003625-42/ES",
        "title": "A Phase 2, Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Sofosbuvir/Velpatasvir for 12 Weeks in Subjects with Chronic HCV Infection Who are on Dialysis for End Stage Renal Di... - ES",
        "timestamp": "2017-03-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-003625-42/results",
        "title": "A Phase 2, Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Sofosbuvir/Velpatasvir for 12 Weeks in Subjects with Chronic HCV Infection Who are on Dialysis for End Stage Renal Di... - View results",
        "timestamp": "2017-03-24"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-000292-42/DE",
        "title": "ENABLE 2 (Eltrombopag to INitiate and Maintain Interferon Antiviral Treatment to Benefit Subjects with Hepatitis C related Liver DiseasE)\nRandomised, placebo-controlled, multi-centre study to asses... - DE",
        "timestamp": "2007-12-06"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-000292-42/FR",
        "title": "ENABLE 2 (Eltrombopag to INitiate and Maintain Interferon Antiviral Treatment to Benefit Subjects with Hepatitis C related Liver DiseasE)\nRandomised, placebo-controlled, multi-centre study to asses... - FR",
        "timestamp": "2007-12-06"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-000292-42/GR",
        "title": "ENABLE 2 (Eltrombopag to INitiate and Maintain Interferon Antiviral Treatment to Benefit Subjects with Hepatitis C related Liver DiseasE)\nRandomised, placebo-controlled, multi-centre study to asses... - GR",
        "timestamp": "2007-12-06"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-000292-42/BE",
        "title": "ENABLE 2 (Eltrombopag to INitiate and Maintain Interferon Antiviral Treatment to Benefit Subjects with Hepatitis C related Liver DiseasE)\nRandomised, placebo-controlled, multi-centre study to asses... - BE",
        "timestamp": "2007-12-06"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-000292-42/ES",
        "title": "ENABLE 2 (Eltrombopag to INitiate and Maintain Interferon Antiviral Treatment to Benefit Subjects with Hepatitis C related Liver DiseasE)\nRandomised, placebo-controlled, multi-centre study to asses... - ES",
        "timestamp": "2007-12-06"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-000292-42/IT",
        "title": "ENABLE 2 (Eltrombopag to INitiate and Maintain Interferon Antiviral Treatment to Benefit Subjects with Hepatitis C related Liver DiseasE)\nRandomised, placebo-controlled, multi-centre study to asses... - IT",
        "timestamp": "2007-12-06"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-000292-42/CZ",
        "title": "ENABLE 2 (Eltrombopag to INitiate and Maintain Interferon Antiviral Treatment to Benefit Subjects with Hepatitis C related Liver DiseasE)\nRandomised, placebo-controlled, multi-centre study to asses... - CZ",
        "timestamp": "2007-12-06"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-000292-42/SK",
        "title": "ENABLE 2 (Eltrombopag to INitiate and Maintain Interferon Antiviral Treatment to Benefit Subjects with Hepatitis C related Liver DiseasE)\nRandomised, placebo-controlled, multi-centre study to asses... - SK",
        "timestamp": "2007-12-06"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-000292-42/NL",
        "title": "ENABLE 2 (Eltrombopag to INitiate and Maintain Interferon Antiviral Treatment to Benefit Subjects with Hepatitis C related Liver DiseasE)\nRandomised, placebo-controlled, multi-centre study to asses... - NL",
        "timestamp": "2007-12-06"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-000292-42/results",
        "title": "ENABLE 2 (Eltrombopag to INitiate and Maintain Interferon Antiviral Treatment to Benefit Subjects with Hepatitis C related Liver DiseasE)\nRandomised, placebo-controlled, multi-centre study to asses... - View results",
        "timestamp": "2007-12-06"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-007612-29/DE",
        "title": "Immunotherapy with CD19ζ chimeric antigen receptor gene-modified EBV-specific CTLs after stem cell transplant in children with high-risk acute lymphoblastic leukaemia - DE",
        "timestamp": "2013-02-26"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-007612-29/GB",
        "title": "Immunotherapy with CD19ζ chimeric antigen receptor gene-modified EBV-specific CTLs after stem cell transplant in children with high-risk acute lymphoblastic leukaemia - GB",
        "timestamp": "2013-02-26"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-007612-29/results",
        "title": "Immunotherapy with CD19ζ chimeric antigen receptor gene-modified EBV-specific CTLs after stem cell transplant in children with high-risk acute lymphoblastic leukaemia - View results",
        "timestamp": "2013-02-26"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-016560-36/DE",
        "title": "A long-term monitoring study to evaluate the persistence of direct acting antiviral (DAA) treatment-resistant mutations or the durability of sustained virological response (SVR) in patients treated... - DE",
        "timestamp": "2010-07-27"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-016560-36/IT",
        "title": "A long-term monitoring study to evaluate the persistence of direct acting antiviral (DAA) treatment-resistant mutations or the durability of sustained virological response (SVR) in patients treated... - IT",
        "timestamp": "2010-07-27"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-016560-36/AT",
        "title": "A long-term monitoring study to evaluate the persistence of direct acting antiviral (DAA) treatment-resistant mutations or the durability of sustained virological response (SVR) in patients treated... - AT",
        "timestamp": "2010-07-27"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-016560-36/ES",
        "title": "A long-term monitoring study to evaluate the persistence of direct acting antiviral (DAA) treatment-resistant mutations or the durability of sustained virological response (SVR) in patients treated... - ES",
        "timestamp": "2010-07-27"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-016560-36/PL",
        "title": "A long-term monitoring study to evaluate the persistence of direct acting antiviral (DAA) treatment-resistant mutations or the durability of sustained virological response (SVR) in patients treated... - PL",
        "timestamp": "2010-07-27"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-016560-36/SK",
        "title": "A long-term monitoring study to evaluate the persistence of direct acting antiviral (DAA) treatment-resistant mutations or the durability of sustained virological response (SVR) in patients treated... - SK",
        "timestamp": "2010-07-27"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-004665-33/DE",
        "title": "A Phase 2 Study of Telaprevir (VX-950) in Combination with Peginterferon Alfa-2a (Pegasys®), and Ribavirin (Copegus®) in Subjects with Genotype 1 Hepatitis C Who Have Not Achieved Sustained Viral R... - DE",
        "timestamp": "2007-04-04"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-004665-33/NL",
        "title": "A Phase 2 Study of Telaprevir (VX-950) in Combination with Peginterferon Alfa-2a (Pegasys®), and Ribavirin (Copegus®) in Subjects with Genotype 1 Hepatitis C Who Have Not Achieved Sustained Viral R... - NL",
        "timestamp": "2007-04-04"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-004665-33/results",
        "title": "A Phase 2 Study of Telaprevir (VX-950) in Combination with Peginterferon Alfa-2a (Pegasys®), and Ribavirin (Copegus®) in Subjects with Genotype 1 Hepatitis C Who Have Not Achieved Sustained Viral R... - View results",
        "timestamp": "2007-04-04"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-004243-39/NL",
        "title": "A randomised study of interferon-free treatment for recently acquired hepatitis C in people who inject drugs and people with HIV coinfection. - NL",
        "timestamp": "2016-11-17"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-004243-39/GB",
        "title": "A randomised study of interferon-free treatment for recently acquired hepatitis C in people who inject drugs and people with HIV coinfection. - GB",
        "timestamp": "2016-11-17"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-004991-31/SE",
        "title": "A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of Pembrolizumab (MK-3475) in Combination With Epacadostat or Placebo in Subjects with Unresectable or Metastatic Melanoma (Keynote-252 ... - SE",
        "timestamp": "2016-05-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-004991-31/NL",
        "title": "A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of Pembrolizumab (MK-3475) in Combination With Epacadostat or Placebo in Subjects with Unresectable or Metastatic Melanoma (Keynote-252 ... - NL",
        "timestamp": "2016-05-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-004991-31/DK",
        "title": "A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of Pembrolizumab (MK-3475) in Combination With Epacadostat or Placebo in Subjects with Unresectable or Metastatic Melanoma (Keynote-252 ... - DK",
        "timestamp": "2016-05-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-004991-31/IE",
        "title": "A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of Pembrolizumab (MK-3475) in Combination With Epacadostat or Placebo in Subjects with Unresectable or Metastatic Melanoma (Keynote-252 ... - IE",
        "timestamp": "2016-05-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-004991-31/ES",
        "title": "A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of Pembrolizumab (MK-3475) in Combination With Epacadostat or Placebo in Subjects with Unresectable or Metastatic Melanoma (Keynote-252 ... - ES",
        "timestamp": "2016-05-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-004991-31/PL",
        "title": "A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of Pembrolizumab (MK-3475) in Combination With Epacadostat or Placebo in Subjects with Unresectable or Metastatic Melanoma (Keynote-252 ... - PL",
        "timestamp": "2016-05-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-004991-31/FR",
        "title": "A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of Pembrolizumab (MK-3475) in Combination With Epacadostat or Placebo in Subjects with Unresectable or Metastatic Melanoma (Keynote-252 ... - FR",
        "timestamp": "2016-05-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-004991-31/BE",
        "title": "A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of Pembrolizumab (MK-3475) in Combination With Epacadostat or Placebo in Subjects with Unresectable or Metastatic Melanoma (Keynote-252 ... - BE",
        "timestamp": "2016-05-03"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-001341-86/DE",
        "title": "A Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Neutralization of the Interferon Gene Signature and the Clinical Efficacy of IFNα-Kinoid in Adult Subjects with Syste... - DE",
        "timestamp": "2015-11-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-001341-86/BE",
        "title": "A Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Neutralization of the Interferon Gene Signature and the Clinical Efficacy of IFNα-Kinoid in Adult Subjects with Syste... - BE",
        "timestamp": "2015-11-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-001341-86/HR",
        "title": "A Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Neutralization of the Interferon Gene Signature and the Clinical Efficacy of IFNα-Kinoid in Adult Subjects with Syste... - HR",
        "timestamp": "2015-11-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-001341-86/ES",
        "title": "A Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Neutralization of the Interferon Gene Signature and the Clinical Efficacy of IFNα-Kinoid in Adult Subjects with Syste... - ES",
        "timestamp": "2015-11-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-001341-86/BG",
        "title": "A Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Neutralization of the Interferon Gene Signature and the Clinical Efficacy of IFNα-Kinoid in Adult Subjects with Syste... - BG",
        "timestamp": "2015-11-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-001341-86/results",
        "title": "A Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Neutralization of the Interferon Gene Signature and the Clinical Efficacy of IFNα-Kinoid in Adult Subjects with Syste... - View results",
        "timestamp": "2015-11-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-005047-32/DK",
        "title": "A Randomized, Placebo-Controlled, Phase 2 Study of HB-101, a Bivalent Cytomegalovirus (CMV) Vaccine, in CMV-Seronegative Recipient (R-) Patients Awaiting Kidney Transplantation from Living CMV-Sero... - DK",
        "timestamp": "2018-09-27"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-005047-32/BE",
        "title": "A Randomized, Placebo-Controlled, Phase 2 Study of HB-101, a Bivalent Cytomegalovirus (CMV) Vaccine, in CMV-Seronegative Recipient (R-) Patients Awaiting Kidney Transplantation from Living CMV-Sero... - BE",
        "timestamp": "2018-09-27"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-005047-32/FR",
        "title": "A Randomized, Placebo-Controlled, Phase 2 Study of HB-101, a Bivalent Cytomegalovirus (CMV) Vaccine, in CMV-Seronegative Recipient (R-) Patients Awaiting Kidney Transplantation from Living CMV-Sero... - FR",
        "timestamp": "2018-09-27"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-005047-32/AT",
        "title": "A Randomized, Placebo-Controlled, Phase 2 Study of HB-101, a Bivalent Cytomegalovirus (CMV) Vaccine, in CMV-Seronegative Recipient (R-) Patients Awaiting Kidney Transplantation from Living CMV-Sero... - AT",
        "timestamp": "2018-09-27"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-005047-32/DE",
        "title": "A Randomized, Placebo-Controlled, Phase 2 Study of HB-101, a Bivalent Cytomegalovirus (CMV) Vaccine, in CMV-Seronegative Recipient (R-) Patients Awaiting Kidney Transplantation from Living CMV-Sero... - DE",
        "timestamp": "2018-09-27"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-005047-32/NL",
        "title": "A Randomized, Placebo-Controlled, Phase 2 Study of HB-101, a Bivalent Cytomegalovirus (CMV) Vaccine, in CMV-Seronegative Recipient (R-) Patients Awaiting Kidney Transplantation from Living CMV-Sero... - NL",
        "timestamp": "2018-09-27"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-001546-34/DE",
        "title": "Neoadjuvant treatment with the combination of Vemurafenib, Cobimetinib and Atezolizumab in limited metastasis of malignant melanoma (AJCC stage IIIC/IV) and integrated biomarker study: A single arm... - DE",
        "timestamp": "2014-10-02"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-001546-34/AT",
        "title": "Neoadjuvant treatment with the combination of Vemurafenib, Cobimetinib and Atezolizumab in limited metastasis of malignant melanoma (AJCC stage IIIC/IV) and integrated biomarker study: A single arm... - AT",
        "timestamp": "2014-10-02"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-001264-31/IT",
        "title": "Peg-Intron/Rebetol vs Peg-Intron / SCH 503034 with and without Ribavirin in Chronic Hepatitis C HCV 1 Peginterferon alfa/Ribavirin Nonresponders: A SCH 503034 dose finding Phase 2 Study. - IT",
        "timestamp": "2005-07-06"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-001264-31/DE",
        "title": "Peg-Intron/Rebetol vs Peg-Intron / SCH 503034 with and without Ribavirin in Chronic Hepatitis C HCV 1 Peginterferon alfa/Ribavirin Nonresponders: A SCH 503034 dose finding Phase 2 Study. - DE",
        "timestamp": "2005-07-06"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-001264-31/results",
        "title": "Peg-Intron/Rebetol vs Peg-Intron / SCH 503034 with and without Ribavirin in Chronic Hepatitis C HCV 1 Peginterferon alfa/Ribavirin Nonresponders: A SCH 503034 dose finding Phase 2 Study. - View results",
        "timestamp": "2005-07-06"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-005859-16/DE",
        "title": "Prospective randomized Multicenter study \r\nin first-line treatment\r\nof Advanced progredIeNT follicular And other IndoleNt  \r\nand mantle cell lymphomas - DE",
        "timestamp": "2009-02-27"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-005859-16/AT",
        "title": "Prospective randomized Multicenter study \r\nin first-line treatment\r\nof Advanced progredIeNT follicular And other IndoleNt  \r\nand mantle cell lymphomas - AT",
        "timestamp": "2009-02-27"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005606-30/GB",
        "title": "Keratinocyte Growth Factor - promoting thymic reconstitution and preventing autoimmunity after alemtuzumab (Campath-1H) treatment of multiple sclerosis. CAM-THY - GB",
        "timestamp": "2012-04-25"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005606-30/results",
        "title": "Keratinocyte Growth Factor - promoting thymic reconstitution and preventing autoimmunity after alemtuzumab (Campath-1H) treatment of multiple sclerosis. CAM-THY - View results",
        "timestamp": "2012-04-25"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-003489-25/BE",
        "title": "A Phase 2, Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Ledipasvir/Sofosbuvir in Subjects with Genotype 1, 4, 5 and 6 Chronic HCV Infection Who are on Dialysis for End Stage... - BE",
        "timestamp": "2017-03-27"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-003489-25/results",
        "title": "A Phase 2, Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Ledipasvir/Sofosbuvir in Subjects with Genotype 1, 4, 5 and 6 Chronic HCV Infection Who are on Dialysis for End Stage... - View results",
        "timestamp": "2017-03-27"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-000194-12/IT",
        "title": "Isoquercetin as an adjunct therapy in patients with kidney cancer receiving first-line sunitinib: a phase I/II trial - IT",
        "timestamp": "2016-06-27"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-003366-33/IT",
        "title": "A phase II, multicenter, randomized, double-blind, placebo-controlled, safety, tolerability and efficacy study of add-on Cladribine tablet therapy with Rebif New Formulation in Multiple Scleroris S... - IT",
        "timestamp": "2008-10-30"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-003366-33/ES",
        "title": "A phase II, multicenter, randomized, double-blind, placebo-controlled, safety, tolerability and efficacy study of add-on Cladribine tablet therapy with Rebif New Formulation in Multiple Scleroris S... - ES",
        "timestamp": "2008-10-30"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-003366-33/results",
        "title": "A phase II, multicenter, randomized, double-blind, placebo-controlled, safety, tolerability and efficacy study of add-on Cladribine tablet therapy with Rebif New Formulation in Multiple Scleroris S... - View results",
        "timestamp": "2008-10-30"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-002043-16/ES",
        "title": "Estudio fase IV, abierto, aleatorizado, controlado, para evaluar el efecto sobre el perfil lipídico del cambio de un régimen TARGA estable de dosis fija de abacavir/lamivudina (Kivexa) más lopinavi... - ES",
        "timestamp": "2008-09-02"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-002043-16/DE",
        "title": "Estudio fase IV, abierto, aleatorizado, controlado, para evaluar el efecto sobre el perfil lipídico del cambio de un régimen TARGA estable de dosis fija de abacavir/lamivudina (Kivexa) más lopinavi... - DE",
        "timestamp": "2008-09-02"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-002043-16/AT",
        "title": "Estudio fase IV, abierto, aleatorizado, controlado, para evaluar el efecto sobre el perfil lipídico del cambio de un régimen TARGA estable de dosis fija de abacavir/lamivudina (Kivexa) más lopinavi... - AT",
        "timestamp": "2008-09-02"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-002043-16/IT",
        "title": "Estudio fase IV, abierto, aleatorizado, controlado, para evaluar el efecto sobre el perfil lipídico del cambio de un régimen TARGA estable de dosis fija de abacavir/lamivudina (Kivexa) más lopinavi... - IT",
        "timestamp": "2008-09-02"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-002043-16/results",
        "title": "Estudio fase IV, abierto, aleatorizado, controlado, para evaluar el efecto sobre el perfil lipídico del cambio de un régimen TARGA estable de dosis fija de abacavir/lamivudina (Kivexa) más lopinavi... - View results",
        "timestamp": "2008-09-02"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-003347-35/DK",
        "title": "A Phase II, Randomized, Open-Label Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172 and MK-3682 with Either MK-8742 or MK-8408 in Subjects with Chronic HCV GT3,... - DK",
        "timestamp": "2014-10-30"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-003347-35/GB",
        "title": "A Phase II, Randomized, Open-Label Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172 and MK-3682 with Either MK-8742 or MK-8408 in Subjects with Chronic HCV GT3,... - GB",
        "timestamp": "2014-10-30"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-003347-35/DE",
        "title": "A Phase II, Randomized, Open-Label Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172 and MK-3682 with Either MK-8742 or MK-8408 in Subjects with Chronic HCV GT3,... - DE",
        "timestamp": "2014-10-30"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-003347-35/IT",
        "title": "A Phase II, Randomized, Open-Label Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172 and MK-3682 with Either MK-8742 or MK-8408 in Subjects with Chronic HCV GT3,... - IT",
        "timestamp": "2014-10-30"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-003347-35/results",
        "title": "A Phase II, Randomized, Open-Label Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172 and MK-3682 with Either MK-8742 or MK-8408 in Subjects with Chronic HCV GT3,... - View results",
        "timestamp": "2014-10-30"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-000372-95/CZ",
        "title": "A Phase II Multicenter, Randomized, Double-blind, Placebo controlled, Dose-range Finding Study to Evaluate the Safety and Efficacy of ALX 0061 Administered Subcutaneously in Subjects with Moderate ... - CZ",
        "timestamp": "2015-08-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-000372-95/DE",
        "title": "A Phase II Multicenter, Randomized, Double-blind, Placebo controlled, Dose-range Finding Study to Evaluate the Safety and Efficacy of ALX 0061 Administered Subcutaneously in Subjects with Moderate ... - DE",
        "timestamp": "2015-08-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-000372-95/PT",
        "title": "A Phase II Multicenter, Randomized, Double-blind, Placebo controlled, Dose-range Finding Study to Evaluate the Safety and Efficacy of ALX 0061 Administered Subcutaneously in Subjects with Moderate ... - PT",
        "timestamp": "2015-08-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-000372-95/HU",
        "title": "A Phase II Multicenter, Randomized, Double-blind, Placebo controlled, Dose-range Finding Study to Evaluate the Safety and Efficacy of ALX 0061 Administered Subcutaneously in Subjects with Moderate ... - HU",
        "timestamp": "2015-08-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-000372-95/ES",
        "title": "A Phase II Multicenter, Randomized, Double-blind, Placebo controlled, Dose-range Finding Study to Evaluate the Safety and Efficacy of ALX 0061 Administered Subcutaneously in Subjects with Moderate ... - ES",
        "timestamp": "2015-08-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-000372-95/results",
        "title": "A Phase II Multicenter, Randomized, Double-blind, Placebo controlled, Dose-range Finding Study to Evaluate the Safety and Efficacy of ALX 0061 Administered Subcutaneously in Subjects with Moderate ... - View results",
        "timestamp": "2015-08-20"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-001044-44/BE",
        "title": "A Phase IIa randomized, open-label study of telaprevir (VX-950) administered every 12 or every 8 hours in combination with either Peg-IFN alfa2a (Pegasys®) and ribavirin (Copegus®) or Peg-IFN alfa2... - BE",
        "timestamp": "2007-08-01"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-001044-44/DE",
        "title": "A Phase IIa randomized, open-label study of telaprevir (VX-950) administered every 12 or every 8 hours in combination with either Peg-IFN alfa2a (Pegasys®) and ribavirin (Copegus®) or Peg-IFN alfa2... - DE",
        "timestamp": "2007-08-01"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-001044-44/ES",
        "title": "A Phase IIa randomized, open-label study of telaprevir (VX-950) administered every 12 or every 8 hours in combination with either Peg-IFN alfa2a (Pegasys®) and ribavirin (Copegus®) or Peg-IFN alfa2... - ES",
        "timestamp": "2007-08-01"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-001044-44/FR",
        "title": "A Phase IIa randomized, open-label study of telaprevir (VX-950) administered every 12 or every 8 hours in combination with either Peg-IFN alfa2a (Pegasys®) and ribavirin (Copegus®) or Peg-IFN alfa2... - FR",
        "timestamp": "2007-08-01"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-001044-44/IT",
        "title": "A Phase IIa randomized, open-label study of telaprevir (VX-950) administered every 12 or every 8 hours in combination with either Peg-IFN alfa2a (Pegasys®) and ribavirin (Copegus®) or Peg-IFN alfa2... - IT",
        "timestamp": "2007-08-01"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-001044-44/AT",
        "title": "A Phase IIa randomized, open-label study of telaprevir (VX-950) administered every 12 or every 8 hours in combination with either Peg-IFN alfa2a (Pegasys®) and ribavirin (Copegus®) or Peg-IFN alfa2... - AT",
        "timestamp": "2007-08-01"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-001044-44/results",
        "title": "A Phase IIa randomized, open-label study of telaprevir (VX-950) administered every 12 or every 8 hours in combination with either Peg-IFN alfa2a (Pegasys®) and ribavirin (Copegus®) or Peg-IFN alfa2... - View results",
        "timestamp": "2007-08-01"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-005507-41/HU",
        "title": "Randomized, Multicenter, Double-Blinded, Phase IV Study Evaluating the Efficacy (as measured by Sustained Virological Response) and Safety of 360 µg Induction Dosing of Pegasys in Combination with ... - HU",
        "timestamp": "2007-01-28"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-005507-41/NL",
        "title": "Randomized, Multicenter, Double-Blinded, Phase IV Study Evaluating the Efficacy (as measured by Sustained Virological Response) and Safety of 360 µg Induction Dosing of Pegasys in Combination with ... - NL",
        "timestamp": "2007-01-28"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-005507-41/SE",
        "title": "Randomized, Multicenter, Double-Blinded, Phase IV Study Evaluating the Efficacy (as measured by Sustained Virological Response) and Safety of 360 µg Induction Dosing of Pegasys in Combination with ... - SE",
        "timestamp": "2007-01-28"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-005507-41/DE",
        "title": "Randomized, Multicenter, Double-Blinded, Phase IV Study Evaluating the Efficacy (as measured by Sustained Virological Response) and Safety of 360 µg Induction Dosing of Pegasys in Combination with ... - DE",
        "timestamp": "2007-01-28"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-005507-41/BE",
        "title": "Randomized, Multicenter, Double-Blinded, Phase IV Study Evaluating the Efficacy (as measured by Sustained Virological Response) and Safety of 360 µg Induction Dosing of Pegasys in Combination with ... - BE",
        "timestamp": "2007-01-28"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-005507-41/DK",
        "title": "Randomized, Multicenter, Double-Blinded, Phase IV Study Evaluating the Efficacy (as measured by Sustained Virological Response) and Safety of 360 µg Induction Dosing of Pegasys in Combination with ... - DK",
        "timestamp": "2007-01-28"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-005507-41/FR",
        "title": "Randomized, Multicenter, Double-Blinded, Phase IV Study Evaluating the Efficacy (as measured by Sustained Virological Response) and Safety of 360 µg Induction Dosing of Pegasys in Combination with ... - FR",
        "timestamp": "2007-01-28"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-005507-41/GB",
        "title": "Randomized, Multicenter, Double-Blinded, Phase IV Study Evaluating the Efficacy (as measured by Sustained Virological Response) and Safety of 360 µg Induction Dosing of Pegasys in Combination with ... - GB",
        "timestamp": "2007-01-28"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-005507-41/results",
        "title": "Randomized, Multicenter, Double-Blinded, Phase IV Study Evaluating the Efficacy (as measured by Sustained Virological Response) and Safety of 360 µg Induction Dosing of Pegasys in Combination with ... - View results",
        "timestamp": "2007-01-28"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-001141-14/AT",
        "title": "A PHASE 4, BLOOD SAMPLE COLLECTION STUDY FOR EXPLORATORY EVALUATION OF THE ASSOCIATION OF SINGLE NUCLEOTIDE\r\nPOLYMORPHISMS WITH TREATMENT RESPONSES FROM SUBJECTS WITH HBEANTIGEN POSITIVE OR NEGATIV... - AT",
        "timestamp": "2013-10-01"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-001141-14/DE",
        "title": "A PHASE 4, BLOOD SAMPLE COLLECTION STUDY FOR EXPLORATORY EVALUATION OF THE ASSOCIATION OF SINGLE NUCLEOTIDE\r\nPOLYMORPHISMS WITH TREATMENT RESPONSES FROM SUBJECTS WITH HBEANTIGEN POSITIVE OR NEGATIV... - DE",
        "timestamp": "2013-10-01"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-001141-14/BG",
        "title": "A PHASE 4, BLOOD SAMPLE COLLECTION STUDY FOR EXPLORATORY EVALUATION OF THE ASSOCIATION OF SINGLE NUCLEOTIDE\r\nPOLYMORPHISMS WITH TREATMENT RESPONSES FROM SUBJECTS WITH HBEANTIGEN POSITIVE OR NEGATIV... - BG",
        "timestamp": "2013-10-01"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-001141-14/IT",
        "title": "A PHASE 4, BLOOD SAMPLE COLLECTION STUDY FOR EXPLORATORY EVALUATION OF THE ASSOCIATION OF SINGLE NUCLEOTIDE\r\nPOLYMORPHISMS WITH TREATMENT RESPONSES FROM SUBJECTS WITH HBEANTIGEN POSITIVE OR NEGATIV... - IT",
        "timestamp": "2013-10-01"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-001141-14/GR",
        "title": "A PHASE 4, BLOOD SAMPLE COLLECTION STUDY FOR EXPLORATORY EVALUATION OF THE ASSOCIATION OF SINGLE NUCLEOTIDE\r\nPOLYMORPHISMS WITH TREATMENT RESPONSES FROM SUBJECTS WITH HBEANTIGEN POSITIVE OR NEGATIV... - GR",
        "timestamp": "2013-10-01"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-001141-14/FR",
        "title": "A PHASE 4, BLOOD SAMPLE COLLECTION STUDY FOR EXPLORATORY EVALUATION OF THE ASSOCIATION OF SINGLE NUCLEOTIDE\r\nPOLYMORPHISMS WITH TREATMENT RESPONSES FROM SUBJECTS WITH HBEANTIGEN POSITIVE OR NEGATIV... - FR",
        "timestamp": "2013-10-01"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-000117-76/ES",
        "title": "A Phase 1/2, randomized, observer-blind, controlled, multi-center, dose-escalation study to evaluate safety, reactogenicity and immunogenicity of GSK Biologicals’ respiratory syncytial virus (RSV) ... - ES",
        "timestamp": "2016-09-27"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-000117-76/PL",
        "title": "A Phase 1/2, randomized, observer-blind, controlled, multi-center, dose-escalation study to evaluate safety, reactogenicity and immunogenicity of GSK Biologicals’ respiratory syncytial virus (RSV) ... - PL",
        "timestamp": "2016-09-27"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-004653-31/DE",
        "title": "A multicenter, single-arm trial evaluating the safety and efficacy of DEB025/Alisporivir in combination with pegylated interferon-α2a and ribavirin (peg-IFNα2a/RBV) in protease inhibitor treatment ... - DE",
        "timestamp": "2012-02-22"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-004653-31/ES",
        "title": "A multicenter, single-arm trial evaluating the safety and efficacy of DEB025/Alisporivir in combination with pegylated interferon-α2a and ribavirin (peg-IFNα2a/RBV) in protease inhibitor treatment ... - ES",
        "timestamp": "2012-02-22"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-004653-31/GB",
        "title": "A multicenter, single-arm trial evaluating the safety and efficacy of DEB025/Alisporivir in combination with pegylated interferon-α2a and ribavirin (peg-IFNα2a/RBV) in protease inhibitor treatment ... - GB",
        "timestamp": "2012-02-22"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-004653-31/IT",
        "title": "A multicenter, single-arm trial evaluating the safety and efficacy of DEB025/Alisporivir in combination with pegylated interferon-α2a and ribavirin (peg-IFNα2a/RBV) in protease inhibitor treatment ... - IT",
        "timestamp": "2012-02-22"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-004653-31/results",
        "title": "A multicenter, single-arm trial evaluating the safety and efficacy of DEB025/Alisporivir in combination with pegylated interferon-α2a and ribavirin (peg-IFNα2a/RBV) in protease inhibitor treatment ... - View results",
        "timestamp": "2012-02-22"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-004150-26/DE",
        "title": "A Multicenter, Open-Label, Phase 2b Pilot Study to Evaluate the Efficacy and Safety of Quadruple Therapy (VX-222, Telaprevir, Peginterferon-Alfa-2 and Ribavirin) in Subjects With Genotype 1 Chronic... - DE",
        "timestamp": "2012-03-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-004150-26/GB",
        "title": "A Multicenter, Open-Label, Phase 2b Pilot Study to Evaluate the Efficacy and Safety of Quadruple Therapy (VX-222, Telaprevir, Peginterferon-Alfa-2 and Ribavirin) in Subjects With Genotype 1 Chronic... - GB",
        "timestamp": "2012-03-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-004150-26/PL",
        "title": "A Multicenter, Open-Label, Phase 2b Pilot Study to Evaluate the Efficacy and Safety of Quadruple Therapy (VX-222, Telaprevir, Peginterferon-Alfa-2 and Ribavirin) in Subjects With Genotype 1 Chronic... - PL",
        "timestamp": "2012-03-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-004150-26/results",
        "title": "A Multicenter, Open-Label, Phase 2b Pilot Study to Evaluate the Efficacy and Safety of Quadruple Therapy (VX-222, Telaprevir, Peginterferon-Alfa-2 and Ribavirin) in Subjects With Genotype 1 Chronic... - View results",
        "timestamp": "2012-03-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-005341-44/AT",
        "title": "Molecular-biological tumor profiling for drug treatment selection in patients with advanced and refractory carcinoma - AT",
        "timestamp": "2015-05-04"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-004435-22/CZ",
        "title": "INCIDENCE OF INHIBITORS IN PREVIOUSLY UNTREATED PATIENTS WITH SEVERE HEAMOPHILIA A TREATED WITH OCTANATE - CZ",
        "timestamp": "2005-12-13"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-004435-22/FR",
        "title": "INCIDENCE OF INHIBITORS IN PREVIOUSLY UNTREATED PATIENTS WITH SEVERE HEAMOPHILIA A TREATED WITH OCTANATE - FR",
        "timestamp": "2005-12-13"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-004435-22/results",
        "title": "INCIDENCE OF INHIBITORS IN PREVIOUSLY UNTREATED PATIENTS WITH SEVERE HEAMOPHILIA A TREATED WITH OCTANATE - View results",
        "timestamp": "2005-12-13"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-003452-21/ES",
        "title": "BRF117277: A Phase II, Open-Label, Multicentre Study of Dabrafenib plus Trametinib in Subjects with BRAF Mutation-Positive Melanoma that has Metastasized to the Brain. - ES",
        "timestamp": "2014-01-27"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-003452-21/DE",
        "title": "BRF117277: A Phase II, Open-Label, Multicentre Study of Dabrafenib plus Trametinib in Subjects with BRAF Mutation-Positive Melanoma that has Metastasized to the Brain. - DE",
        "timestamp": "2014-01-27"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-003452-21/IT",
        "title": "BRF117277: A Phase II, Open-Label, Multicentre Study of Dabrafenib plus Trametinib in Subjects with BRAF Mutation-Positive Melanoma that has Metastasized to the Brain. - IT",
        "timestamp": "2014-01-27"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-003452-21/results",
        "title": "BRF117277: A Phase II, Open-Label, Multicentre Study of Dabrafenib plus Trametinib in Subjects with BRAF Mutation-Positive Melanoma that has Metastasized to the Brain. - View results",
        "timestamp": "2014-01-27"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-000945-19/DE",
        "title": "A Long Term Follow-up Registry for Subjects Who Achieve a Sustained Virologic Response to Treatment in Gilead Sponsored Trials in Subjects with Chronic Hepatitis C Infection - DE",
        "timestamp": "2011-11-21"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-000945-19/GB",
        "title": "A Long Term Follow-up Registry for Subjects Who Achieve a Sustained Virologic Response to Treatment in Gilead Sponsored Trials in Subjects with Chronic Hepatitis C Infection - GB",
        "timestamp": "2011-11-21"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-000945-19/FR",
        "title": "A Long Term Follow-up Registry for Subjects Who Achieve a Sustained Virologic Response to Treatment in Gilead Sponsored Trials in Subjects with Chronic Hepatitis C Infection - FR",
        "timestamp": "2011-11-21"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-000945-19/CZ",
        "title": "A Long Term Follow-up Registry for Subjects Who Achieve a Sustained Virologic Response to Treatment in Gilead Sponsored Trials in Subjects with Chronic Hepatitis C Infection - CZ",
        "timestamp": "2011-11-21"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-000945-19/HU",
        "title": "A Long Term Follow-up Registry for Subjects Who Achieve a Sustained Virologic Response to Treatment in Gilead Sponsored Trials in Subjects with Chronic Hepatitis C Infection - HU",
        "timestamp": "2011-11-21"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-000945-19/PL",
        "title": "A Long Term Follow-up Registry for Subjects Who Achieve a Sustained Virologic Response to Treatment in Gilead Sponsored Trials in Subjects with Chronic Hepatitis C Infection - PL",
        "timestamp": "2011-11-21"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-000945-19/IT",
        "title": "A Long Term Follow-up Registry for Subjects Who Achieve a Sustained Virologic Response to Treatment in Gilead Sponsored Trials in Subjects with Chronic Hepatitis C Infection - IT",
        "timestamp": "2011-11-21"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-000945-19/AT",
        "title": "A Long Term Follow-up Registry for Subjects Who Achieve a Sustained Virologic Response to Treatment in Gilead Sponsored Trials in Subjects with Chronic Hepatitis C Infection - AT",
        "timestamp": "2011-11-21"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-000945-19/SE",
        "title": "A Long Term Follow-up Registry for Subjects Who Achieve a Sustained Virologic Response to Treatment in Gilead Sponsored Trials in Subjects with Chronic Hepatitis C Infection - SE",
        "timestamp": "2011-11-21"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-000945-19/ES",
        "title": "A Long Term Follow-up Registry for Subjects Who Achieve a Sustained Virologic Response to Treatment in Gilead Sponsored Trials in Subjects with Chronic Hepatitis C Infection - ES",
        "timestamp": "2011-11-21"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-000945-19/EE",
        "title": "A Long Term Follow-up Registry for Subjects Who Achieve a Sustained Virologic Response to Treatment in Gilead Sponsored Trials in Subjects with Chronic Hepatitis C Infection - EE",
        "timestamp": "2011-11-21"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-000945-19/NL",
        "title": "A Long Term Follow-up Registry for Subjects Who Achieve a Sustained Virologic Response to Treatment in Gilead Sponsored Trials in Subjects with Chronic Hepatitis C Infection - NL",
        "timestamp": "2011-11-21"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-000945-19/BE",
        "title": "A Long Term Follow-up Registry for Subjects Who Achieve a Sustained Virologic Response to Treatment in Gilead Sponsored Trials in Subjects with Chronic Hepatitis C Infection - BE",
        "timestamp": "2011-11-21"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-000945-19/results",
        "title": "A Long Term Follow-up Registry for Subjects Who Achieve a Sustained Virologic Response to Treatment in Gilead Sponsored Trials in Subjects with Chronic Hepatitis C Infection - View results",
        "timestamp": "2011-11-21"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-000946-39/DE",
        "title": "A Long Term Follow-up Registry Study of Subjects Who Did Not Achieve Sustained Virologic Response in Gilead Sponsored Trials in Subjects with Chronic Hepatitis C Infection - DE",
        "timestamp": "2011-11-21"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-000946-39/GB",
        "title": "A Long Term Follow-up Registry Study of Subjects Who Did Not Achieve Sustained Virologic Response in Gilead Sponsored Trials in Subjects with Chronic Hepatitis C Infection - GB",
        "timestamp": "2011-11-21"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-000946-39/FR",
        "title": "A Long Term Follow-up Registry Study of Subjects Who Did Not Achieve Sustained Virologic Response in Gilead Sponsored Trials in Subjects with Chronic Hepatitis C Infection - FR",
        "timestamp": "2011-11-21"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-000946-39/CZ",
        "title": "A Long Term Follow-up Registry Study of Subjects Who Did Not Achieve Sustained Virologic Response in Gilead Sponsored Trials in Subjects with Chronic Hepatitis C Infection - CZ",
        "timestamp": "2011-11-21"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-000946-39/HU",
        "title": "A Long Term Follow-up Registry Study of Subjects Who Did Not Achieve Sustained Virologic Response in Gilead Sponsored Trials in Subjects with Chronic Hepatitis C Infection - HU",
        "timestamp": "2011-11-21"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-000946-39/PL",
        "title": "A Long Term Follow-up Registry Study of Subjects Who Did Not Achieve Sustained Virologic Response in Gilead Sponsored Trials in Subjects with Chronic Hepatitis C Infection - PL",
        "timestamp": "2011-11-21"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-000946-39/AT",
        "title": "A Long Term Follow-up Registry Study of Subjects Who Did Not Achieve Sustained Virologic Response in Gilead Sponsored Trials in Subjects with Chronic Hepatitis C Infection - AT",
        "timestamp": "2011-11-21"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-000946-39/SE",
        "title": "A Long Term Follow-up Registry Study of Subjects Who Did Not Achieve Sustained Virologic Response in Gilead Sponsored Trials in Subjects with Chronic Hepatitis C Infection - SE",
        "timestamp": "2011-11-21"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-000946-39/ES",
        "title": "A Long Term Follow-up Registry Study of Subjects Who Did Not Achieve Sustained Virologic Response in Gilead Sponsored Trials in Subjects with Chronic Hepatitis C Infection - ES",
        "timestamp": "2011-11-21"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-000946-39/EE",
        "title": "A Long Term Follow-up Registry Study of Subjects Who Did Not Achieve Sustained Virologic Response in Gilead Sponsored Trials in Subjects with Chronic Hepatitis C Infection - EE",
        "timestamp": "2011-11-21"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-000946-39/NL",
        "title": "A Long Term Follow-up Registry Study of Subjects Who Did Not Achieve Sustained Virologic Response in Gilead Sponsored Trials in Subjects with Chronic Hepatitis C Infection - NL",
        "timestamp": "2011-11-21"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-000946-39/BE",
        "title": "A Long Term Follow-up Registry Study of Subjects Who Did Not Achieve Sustained Virologic Response in Gilead Sponsored Trials in Subjects with Chronic Hepatitis C Infection - BE",
        "timestamp": "2011-11-21"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-000946-39/results",
        "title": "A Long Term Follow-up Registry Study of Subjects Who Did Not Achieve Sustained Virologic Response in Gilead Sponsored Trials in Subjects with Chronic Hepatitis C Infection - View results",
        "timestamp": "2011-11-21"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020807-57/BE",
        "title": "Randomized, open label, multicenter phase III study of Efficacy and Safety in Polycythemia vera subjects who are resistant to or intolerant of hydroxyurea: JAK iNhibitor INC424 tablets verSus bEst ... - BE",
        "timestamp": "2011-02-08"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020807-57/DE",
        "title": "Randomized, open label, multicenter phase III study of Efficacy and Safety in Polycythemia vera subjects who are resistant to or intolerant of hydroxyurea: JAK iNhibitor INC424 tablets verSus bEst ... - DE",
        "timestamp": "2011-02-08"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020807-57/ES",
        "title": "Randomized, open label, multicenter phase III study of Efficacy and Safety in Polycythemia vera subjects who are resistant to or intolerant of hydroxyurea: JAK iNhibitor INC424 tablets verSus bEst ... - ES",
        "timestamp": "2011-02-08"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020807-57/GB",
        "title": "Randomized, open label, multicenter phase III study of Efficacy and Safety in Polycythemia vera subjects who are resistant to or intolerant of hydroxyurea: JAK iNhibitor INC424 tablets verSus bEst ... - GB",
        "timestamp": "2011-02-08"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020807-57/IT",
        "title": "Randomized, open label, multicenter phase III study of Efficacy and Safety in Polycythemia vera subjects who are resistant to or intolerant of hydroxyurea: JAK iNhibitor INC424 tablets verSus bEst ... - IT",
        "timestamp": "2011-02-08"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020807-57/NL",
        "title": "Randomized, open label, multicenter phase III study of Efficacy and Safety in Polycythemia vera subjects who are resistant to or intolerant of hydroxyurea: JAK iNhibitor INC424 tablets verSus bEst ... - NL",
        "timestamp": "2011-02-08"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020807-57/HU",
        "title": "Randomized, open label, multicenter phase III study of Efficacy and Safety in Polycythemia vera subjects who are resistant to or intolerant of hydroxyurea: JAK iNhibitor INC424 tablets verSus bEst ... - HU",
        "timestamp": "2011-02-08"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020807-57/results",
        "title": "Randomized, open label, multicenter phase III study of Efficacy and Safety in Polycythemia vera subjects who are resistant to or intolerant of hydroxyurea: JAK iNhibitor INC424 tablets verSus bEst ... - View results",
        "timestamp": "2011-02-08"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-002827-15/GB",
        "title": "Phase 3, open label, randomized, comparative study of ticilimumab and either dacarbazine or temozolomide in patients with advanced melanoma - GB",
        "timestamp": "2006-01-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-002827-15/ES",
        "title": "Phase 3, open label, randomized, comparative study of ticilimumab and either dacarbazine or temozolomide in patients with advanced melanoma - ES",
        "timestamp": "2006-01-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-002827-15/DE",
        "title": "Phase 3, open label, randomized, comparative study of ticilimumab and either dacarbazine or temozolomide in patients with advanced melanoma - DE",
        "timestamp": "2006-01-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-002827-15/AT",
        "title": "Phase 3, open label, randomized, comparative study of ticilimumab and either dacarbazine or temozolomide in patients with advanced melanoma - AT",
        "timestamp": "2006-01-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-002827-15/BE",
        "title": "Phase 3, open label, randomized, comparative study of ticilimumab and either dacarbazine or temozolomide in patients with advanced melanoma - BE",
        "timestamp": "2006-01-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-002827-15/SE",
        "title": "Phase 3, open label, randomized, comparative study of ticilimumab and either dacarbazine or temozolomide in patients with advanced melanoma - SE",
        "timestamp": "2006-01-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-002827-15/GR",
        "title": "Phase 3, open label, randomized, comparative study of ticilimumab and either dacarbazine or temozolomide in patients with advanced melanoma - GR",
        "timestamp": "2006-01-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-002827-15/CZ",
        "title": "Phase 3, open label, randomized, comparative study of ticilimumab and either dacarbazine or temozolomide in patients with advanced melanoma - CZ",
        "timestamp": "2006-01-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-002827-15/SK",
        "title": "Phase 3, open label, randomized, comparative study of ticilimumab and either dacarbazine or temozolomide in patients with advanced melanoma - SK",
        "timestamp": "2006-01-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-002827-15/IT",
        "title": "Phase 3, open label, randomized, comparative study of ticilimumab and either dacarbazine or temozolomide in patients with advanced melanoma - IT",
        "timestamp": "2006-01-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-002827-15/results",
        "title": "Phase 3, open label, randomized, comparative study of ticilimumab and either dacarbazine or temozolomide in patients with advanced melanoma - View results",
        "timestamp": "2006-01-19"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-004842-92/IT",
        "title": "A three arms prospective, randomized phase II study to evaluate the best sequential approach with combo immunotherapy (ipilimumab/nivolumab) and combo target therapy (LGX818/MEK162) in patients wit... - IT",
        "timestamp": "2016-06-30"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-004842-92/ES",
        "title": "A three arms prospective, randomized phase II study to evaluate the best sequential approach with combo immunotherapy (ipilimumab/nivolumab) and combo target therapy (LGX818/MEK162) in patients wit... - ES",
        "timestamp": "2016-06-30"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-004842-92/DE",
        "title": "A three arms prospective, randomized phase II study to evaluate the best sequential approach with combo immunotherapy (ipilimumab/nivolumab) and combo target therapy (LGX818/MEK162) in patients wit... - DE",
        "timestamp": "2016-06-30"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-004842-92/GR",
        "title": "A three arms prospective, randomized phase II study to evaluate the best sequential approach with combo immunotherapy (ipilimumab/nivolumab) and combo target therapy (LGX818/MEK162) in patients wit... - GR",
        "timestamp": "2016-06-30"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-004842-92/AT",
        "title": "A three arms prospective, randomized phase II study to evaluate the best sequential approach with combo immunotherapy (ipilimumab/nivolumab) and combo target therapy (LGX818/MEK162) in patients wit... - AT",
        "timestamp": "2016-06-30"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-004842-92/GB",
        "title": "A three arms prospective, randomized phase II study to evaluate the best sequential approach with combo immunotherapy (ipilimumab/nivolumab) and combo target therapy (LGX818/MEK162) in patients wit... - GB",
        "timestamp": "2016-06-30"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-004842-92/SE",
        "title": "A three arms prospective, randomized phase II study to evaluate the best sequential approach with combo immunotherapy (ipilimumab/nivolumab) and combo target therapy (LGX818/MEK162) in patients wit... - SE",
        "timestamp": "2016-06-30"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-004842-92/PL",
        "title": "A three arms prospective, randomized phase II study to evaluate the best sequential approach with combo immunotherapy (ipilimumab/nivolumab) and combo target therapy (LGX818/MEK162) in patients wit... - PL",
        "timestamp": "2016-06-30"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-019585-90/AT",
        "title": "A Randomized, Open-label, Multicenter Study to Evaluate the Sustained Virologic Response of the HCV Protease Inhibitor Danoprevir Boosted with Low Dose Ritonavir (Danoprevir/r) and Copegus®, in Com... - AT",
        "timestamp": "2011-05-05"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-019585-90/DE",
        "title": "A Randomized, Open-label, Multicenter Study to Evaluate the Sustained Virologic Response of the HCV Protease Inhibitor Danoprevir Boosted with Low Dose Ritonavir (Danoprevir/r) and Copegus®, in Com... - DE",
        "timestamp": "2011-05-05"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-019585-90/GB",
        "title": "A Randomized, Open-label, Multicenter Study to Evaluate the Sustained Virologic Response of the HCV Protease Inhibitor Danoprevir Boosted with Low Dose Ritonavir (Danoprevir/r) and Copegus®, in Com... - GB",
        "timestamp": "2011-05-05"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-019585-90/IT",
        "title": "A Randomized, Open-label, Multicenter Study to Evaluate the Sustained Virologic Response of the HCV Protease Inhibitor Danoprevir Boosted with Low Dose Ritonavir (Danoprevir/r) and Copegus®, in Com... - IT",
        "timestamp": "2011-05-05"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-019585-90/ES",
        "title": "A Randomized, Open-label, Multicenter Study to Evaluate the Sustained Virologic Response of the HCV Protease Inhibitor Danoprevir Boosted with Low Dose Ritonavir (Danoprevir/r) and Copegus®, in Com... - ES",
        "timestamp": "2011-05-05"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-004527-31/IE",
        "title": "A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Trial Comparing 24 or 48 Weeks of GS-9190, in Combination with Peginterferon Alfa 2a and Ribavirin, to 48 Weeks of Peginterferon Alfa 2a and... - IE",
        "timestamp": "2008-12-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-004527-31/GB",
        "title": "A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Trial Comparing 24 or 48 Weeks of GS-9190, in Combination with Peginterferon Alfa 2a and Ribavirin, to 48 Weeks of Peginterferon Alfa 2a and... - GB",
        "timestamp": "2008-12-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-004527-31/DE",
        "title": "A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Trial Comparing 24 or 48 Weeks of GS-9190, in Combination with Peginterferon Alfa 2a and Ribavirin, to 48 Weeks of Peginterferon Alfa 2a and... - DE",
        "timestamp": "2008-12-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-004527-31/BE",
        "title": "A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Trial Comparing 24 or 48 Weeks of GS-9190, in Combination with Peginterferon Alfa 2a and Ribavirin, to 48 Weeks of Peginterferon Alfa 2a and... - BE",
        "timestamp": "2008-12-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-004527-31/results",
        "title": "A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Trial Comparing 24 or 48 Weeks of GS-9190, in Combination with Peginterferon Alfa 2a and Ribavirin, to 48 Weeks of Peginterferon Alfa 2a and... - View results",
        "timestamp": "2008-12-12"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-004510-28/SE",
        "title": "An open-label, randomized, controlled, multicenter, phase II study evaluating safety and efficacy of intratumorally administered Intuvax pre-nephrectomy followed by Sunitinib post-nephrectomy, comp... - SE",
        "timestamp": "2015-03-05"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-004510-28/CZ",
        "title": "An open-label, randomized, controlled, multicenter, phase II study evaluating safety and efficacy of intratumorally administered Intuvax pre-nephrectomy followed by Sunitinib post-nephrectomy, comp... - CZ",
        "timestamp": "2015-03-05"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-004510-28/HU",
        "title": "An open-label, randomized, controlled, multicenter, phase II study evaluating safety and efficacy of intratumorally administered Intuvax pre-nephrectomy followed by Sunitinib post-nephrectomy, comp... - HU",
        "timestamp": "2015-03-05"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-004510-28/LV",
        "title": "An open-label, randomized, controlled, multicenter, phase II study evaluating safety and efficacy of intratumorally administered Intuvax pre-nephrectomy followed by Sunitinib post-nephrectomy, comp... - LV",
        "timestamp": "2015-03-05"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-004510-28/GB",
        "title": "An open-label, randomized, controlled, multicenter, phase II study evaluating safety and efficacy of intratumorally administered Intuvax pre-nephrectomy followed by Sunitinib post-nephrectomy, comp... - GB",
        "timestamp": "2015-03-05"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-004510-28/ES",
        "title": "An open-label, randomized, controlled, multicenter, phase II study evaluating safety and efficacy of intratumorally administered Intuvax pre-nephrectomy followed by Sunitinib post-nephrectomy, comp... - ES",
        "timestamp": "2015-03-05"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-005120-41/GB",
        "title": "A Randomized, Double-Blind, Controlled Evaluation of Tenofovir DF versus Adefovir Dipivoxil  for the Treatment of HBeAg Positive Chronic Hepatitis B. - GB",
        "timestamp": "2005-07-21"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-005120-41/DE",
        "title": "A Randomized, Double-Blind, Controlled Evaluation of Tenofovir DF versus Adefovir Dipivoxil  for the Treatment of HBeAg Positive Chronic Hepatitis B. - DE",
        "timestamp": "2005-07-21"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-005120-41/CZ",
        "title": "A Randomized, Double-Blind, Controlled Evaluation of Tenofovir DF versus Adefovir Dipivoxil  for the Treatment of HBeAg Positive Chronic Hepatitis B. - CZ",
        "timestamp": "2005-07-21"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-005120-41/ES",
        "title": "A Randomized, Double-Blind, Controlled Evaluation of Tenofovir DF versus Adefovir Dipivoxil  for the Treatment of HBeAg Positive Chronic Hepatitis B. - ES",
        "timestamp": "2005-07-21"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-005120-41/IT",
        "title": "A Randomized, Double-Blind, Controlled Evaluation of Tenofovir DF versus Adefovir Dipivoxil  for the Treatment of HBeAg Positive Chronic Hepatitis B. - IT",
        "timestamp": "2005-07-21"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-005120-41/results",
        "title": "A Randomized, Double-Blind, Controlled Evaluation of Tenofovir DF versus Adefovir Dipivoxil  for the Treatment of HBeAg Positive Chronic Hepatitis B. - View results",
        "timestamp": "2005-07-21"
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-004605-34/DE",
        "title": "A multicentre, randomised, double-blind, placebo-controlled, parallel-group phase II study on the efficacy and safety of Debio 025 combined with peg-IFNα2a and ribavirin in treatment naïve chronic ... - DE",
        "timestamp": None
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-004605-34/FR",
        "title": "A multicentre, randomised, double-blind, placebo-controlled, parallel-group phase II study on the efficacy and safety of Debio 025 combined with peg-IFNα2a and ribavirin in treatment naïve chronic ... - FR",
        "timestamp": None
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-004605-34/BE",
        "title": "A multicentre, randomised, double-blind, placebo-controlled, parallel-group phase II study on the efficacy and safety of Debio 025 combined with peg-IFNα2a and ribavirin in treatment naïve chronic ... - BE",
        "timestamp": None
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-004605-34/ES",
        "title": "A multicentre, randomised, double-blind, placebo-controlled, parallel-group phase II study on the efficacy and safety of Debio 025 combined with peg-IFNα2a and ribavirin in treatment naïve chronic ... - ES",
        "timestamp": None
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-004605-34/PL",
        "title": "A multicentre, randomised, double-blind, placebo-controlled, parallel-group phase II study on the efficacy and safety of Debio 025 combined with peg-IFNα2a and ribavirin in treatment naïve chronic ... - PL",
        "timestamp": None
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-004605-34/IT",
        "title": "A multicentre, randomised, double-blind, placebo-controlled, parallel-group phase II study on the efficacy and safety of Debio 025 combined with peg-IFNα2a and ribavirin in treatment naïve chronic ... - IT",
        "timestamp": None
    },
    {
        "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-004605-34/results",
        "title": "A multicentre, randomised, double-blind, placebo-controlled, parallel-group phase II study on the efficacy and safety of Debio 025 combined with peg-IFNα2a and ribavirin in treatment naïve chronic ... - View results",
        "timestamp": None
    }
]
